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New aspects of emerging Clostridium difﬁcile
infections (CDI)
S2 Pros and cons of molecular ﬁngerprinting for Clostridium
difﬁcile infections
E.J. Kuijper ° (Leiden, NL)
Since the 1980s the epidemiology of Clostridium difﬁcile infection (CDI)
has been investigated by the application of many different typing or
ﬁngerprinting methods. To study the epidemiology of CDI, a typing
method with a high discriminatory power, typeability, stability, power,
reproducibility and epidemiological concordance is required. It should
also have technical advantages, such as ease of performance, relative low
cost, and high throughput. A growing number of molecular methods
have been applied to C. difﬁcile. For the early and rapid detection
of outbreak situations, methods such as restriction enzyme analysis,
arbitrary primed polymerase chain reaction (PCR), pulsed-ﬁeld gel
electrophoresis, and PCR ribotyping are commonly used. For long-term
epidemiology, multilocus sequence typing, multilocus variable number
of tandem repeats analysis (MLVA), and ampliﬁed fragment length
polymorphism are of interest.
Currently, the PCR-ribotyping method and the library of PCR ribotypes
in Cardiff are the benchmarks to which most typing studies around the
world are compared. Conventional agarose gel-based PCR ribotyping
is easy to use and relatively cheap, but analysis of fragment lengths is
hampered by poor resolution. Recently, a capillary gel electrophoresis-
based PCR ribotyping assay has been developed that signiﬁcantly reduces
the hands-on time required for C. difﬁcile PCR ribotyping. The results
were highly reproducible, independent of reagent batches or brands used
and allows inter-laboratory comparisons of typing results.
The analysis of the sequenced C. difﬁcile genome revealed a high
percentage of DNA that consisted of a variable number of tandem repeats
(VNTR). Recently, a new MLVA method was developed using smal short
tandem repeats (2−9 bp) to facilitate automated fragment analysis with
multicoloured capillary electrophoresis instead of sequencing. In a study
using isolates from laboratories in Canada, the Netherlands, the United
Kingdom, and the United States, seven C. difﬁcile typing techniques were
compared, but only REA and MLVA showed sufﬁcient discrimination to
distinguish strains from different outbreaks. MLVA has also been applied
to study local outbreaks of C. difﬁcile PCR ribotype 027 strains. MLVA
is currently the most discriminative typing method and will contribute
signiﬁcantly to our understanding of the epidemiology of C. difﬁcile.
S3 New treatment aspects of CDI
M. Wilcox ° (Leeds, UK)
The need for new therapeutic alternatives in CDI is clear. Current
recurrence rates are unacceptably high. The optimal treatment of severe
CDI, infection caused by strains associated with poor outcome (e.g.
C. difﬁcile ribotype 027), and multiple recurrences is unclear. There
are several potentially promising new CDI treatment approaches under
investigation, including antibiotic, anti-toxin and bacterial interference
options. Probiotic therapy remains of unproven beneﬁt. As new options
become available, prognostic data will be needed to guide on the most
approriate therapeutic choices.
S4 Emerging community-acquired CDI in North America and
Europe
S. Dial ° (Montreal, CA)
Clostridium difﬁcile has long been recognised as important cause
of antibiotic associated diarrhoea in hospitalised patients. Although
community associated disease has been described in the 80’s, it is only
in this decade that it has been recognised as an important cause of
infectious diarrhoea in patients in the community.
As C. difﬁcile was mostly recognised as a nosocomial pathogen, the
majority of studies of clinical C. difﬁcile infections (CDI) have been
conducted in acute care hospitals, and many have been performed
during outbreak situations. The hospital environment has very speciﬁc
characteristics which are likely to be important determinants of infectious
disease occurrence and transmission, such as clustering of susceptible
hosts, increased possibility of environmental contamination, physical
proximity and multiple person to person contacts. Similarly, the
demographics of hospitalized patients population also differ signiﬁcantly
from that of the community. In hospitals, the prevalence of antibiotic use
is very high, and highly correlated with many other factors which could
be important in the expression of CDI. Until recently antibiotics were
believed to be a prerequisite for the development of CDI but studies
of community acquired disease are consistently describing disease
occurring in a high proportion of patients who have no such exposure.
This has lead to research examining other risk factors.
CDI appears to be increasing in the community especially in the
elderly, but also in the pediatric population. As up to 50% of CDI
in the community may not be precceded by recent antibiotic exposure
particularly in patients without a recent hospitalization, many of the
recommended diarrhea testing alogarithms will result in this diagnosis
being missed or delayed. This could have important implications for
patient care and control of outbreaks. Well designed studies of C. difﬁcile
in the community could improve our understanding of this disease and
improve the ability to explore other risk factors and where antibiotic
exposure maybe less confounded.
Presentation of International Sepsis Forum
Award
S5 Genetic analysis of pattern recognition receptors links a
functional polymorphism in the gene for CD14 to susceptibility
for meningococcal septic shock
T. Sprong °, M. Emonts, R. Rossau, E. de Meester, M. van Thielen,
M.G. Netea, C. Neeleman, I. Klasen, R. de Groot, J.A. Hazelzet, J. van der
Meer, J. Drenth, M. van Deuren (Nijmegen, Rotterdam, NL; Ghent, BE)
Objectives: Contact with, and colonization by, pathogenic meningococci
occurs rather often. Still, only a limited number of individuals develop
invasive disease, most often within a few days after acquisition of
a new meningococcal strain. Thus, it can be assumed that disease
develops because of defects in the early innate defense. We hypothesized
that polymorphisms in Pattern Recognition Receptors (PRRs) inﬂuence
susceptibility to meningococcal disease or alter disease severity.
Methods: 73 different single-nucleotide polymorphisms (SNPs) in 21
genes encoding PRRs and related molecules of the innate immune
system were investigated using a research prototype of a line-probe
assay (INNO-LiPA, Innogenetics). We performed a three-stage approach.
First (stage 1) we performed a case-parent study in subjects with
meningcococcal disease admitted to the intensive care unit (ICU)
(n = 118). Second (stage 2), we performed a case–control study in an
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extended cohort (n = 147). Finally (stage 3), the observed associations
were tested for replication in an independent case–control study
(n = 146).
Results: In stage 1, we found SNPs in the genes for MASP2, CD14,
LBP and TLR6 to be associated with increased susceptibility to
meningococcal disease. For the rs2563298 SNP in CD14 this was
replicated in the case control study (stage 2; OR 1.65, 95%CI 1.17–2.31)
and in the separate replication study with the independent (conﬁrmatory)
cohort (Stage 3; OR 1.44, 95%CI 1.02–2.04). Subgroup analysis showed
that the CD14 SNP conferred increased risk only in shock patients
(OR 1.99, 95%CI 1.28–3.08). This CD14 SNP is functional and leads
to decreased IL-10 and IL-12 production in a whole blood model of
meningococcal sepsis.
Conclusions: In conclusion, we identiﬁed a functional SNP in CD14
that is associated with an increased risk for meningococcal septic shock.
Possible other SNPs associated with increased risk for meningococcal
disease were in MASP2, LBP and TLR6.
S6 Histones in sepsis
T. Roger ° (Lausanne, CH)
Chromatin is made-up of DNA, histones and non-histones proteins.
Covalent modiﬁcations of histones through acetylation at Lysine residues
strongly inﬂuence the structure and the function of the chromatin.
Whereas acetylation of histones results in a relaxed chromatin structure
that is associated with active transcription, de-acetylation of histones
results in a compacted chromatin structure associated with repressed
transcription. Global histone acetylation is regulated by the opposing
actions of histone acetyltransferases (HATs) and histone deacetylases
(HDACs). Beside histones, non histones proteins are modiﬁed by
reversible acetylation, among which a-tubulin, HSP90 and transcription
regulators. Therefore, HDACs impact on many biological functions,
primarily cell differentiation, growth and survival. HDAC inhibitors
(HDIs) were originally developed for their powerful anti-cancer
activity. Yet, recent preclinical studies suggest that HDIs possess anti-
inﬂammatory activity. Based on these observations, we postulated that
HDIs could impact on innate immune response to microbial infection.
Here we will discuss the results from our studies on the effect of
HDIs on the innate immune system. We ﬁrst performed genome-wide
gene expression analyses to have a global view of the impact of
HDIs on the transcriptome of resting and microbial product-stimulated
primary macrophages. We then studied the inﬂuence of HDIs on key
parameters (activation of the intracellular signal transduction pathways,
production of cytokines and chemokines, expression of co-stimulatory
and chemokine receptors..) of macrophages, dendritic cells and whole
blood activated by a broad range of microbial products. Finally, we
analyzed the impact of HDIs in preclinical models of non-severe bacterial
and fungal infections, toxic shock and severe sepsis.
Overall, these studies demonstrate that HDIs are powerful anti-
inﬂammatory and immunosuppressive drugs that impair innate immune
responses to microbial infections in vitro and in vivo. While the results
suggest that HDIs may represent attractive adjunctive therapies to
treat pathological situations characterized by dysregulated inﬂammatory
responses such as autoimmune diseases and severe sepsis, they also warn
that HDIs may increase the risk of developing opportunistic infections
and sepsis, especially in immunocompromised cancer patients.
Latest trends from the molecular laboratory
for studying fungal pathogens and invasive
fungal infections
S14 Diagnostic PCR for IFI. Does it really work?
M. Cuenca-Estrella ° (Majadahonda, ES)
Invasive aspergillosis (IA) continues to have high mortality, partly as
a consequence of the difﬁculties of early diagnosis and also due to
therapeutic limitations. Nowadays IA diagnosis is based on extensive use
of galactomannan (GM) and high-resolution chest tomography (HRCT).
Despite the fact positive GM has prompted an earlier treatment of IA,
mortality is still high in this population showing that other diagnostic
approaches should be taken into account. Detection of nucleic acids,
PCR-based methods mainly, appears to be an option to assess although
to date there are many doubts as to the proﬁtability of this type of
methods.
Diagnostic PCR must be considered an additional test that is being
developed and that is used in some reference laboratories. Its lack
of standardization should be stressed, since different laboratories use
different approaches in terms of extraction, probes, primers, PCR
conditions, and measurement. Furthermore the beneﬁt of detecting DNA
of Aspergillus fumigatus depends on the clinical sample used. PCR
techniques have shown high diagnostic reliability in tissue biopsies and
respiratory samples with high negative predictive values and discreet
positive predictive values, but lower diagnostic reliability has been
obtained in blood samples. Those high negative predictive values could
be useful to rule out the presence of infection.
Newer approaches such as serial determinations of Aspergillus DNA in
serum or blood, and detection of fungal DNA in higher volumes of blood
have shown a greater diagnostic applicability, which increases when
combined with GM quantiﬁcation and high-resolution chest tomography.
Those approaches have had higher rates of both sensitivity and speciﬁcity
and improved the early diagnosis of aspergillosis.
Fewer data are available for other mycoses. PCR methods have been
developed to detect Candida, endemic mycosis and emerging pathogens
but more data are needed and reliable conclusions should not be drawn.
S16 Clinically relevant novel fungal taxa from old species complexes
T. Boekhout °, F. Hagen, B. Theelen, K. Khayhan, C. Klaassen, J. Meis
(Utrecht, Nijmegen, NL)
Our understanding of causative agents of fungal diseases has changed
considerably during recent years. This is mainly due to the large scale
introduction of molecular studies, in which one or more stretches of DNA
are compared across a wide range of fungi, including human and animal
pathogens. One of the most striking discoveries was the recognition of
Pneumocystis as a fungus, as this organism was considered previously
to belong to the parasites. In many cases traditional ‘species’ turned
out to represent species complexes and many of the newly recognized
clinically relevant species may differ in the susceptibility to commonly
used antifungals. Therefore, correct identiﬁcation of these new pathogens
is important for proper patient management.
A brief overview will be presented of these developments in fungal
taxonomy and their implications for the clinical practice. Examples
will be given from the main lineages of the fungal kingdom, namely
Zygomycetes, Ascomycetes (Aspergillus, Fusarium, and Candida spp.)
and Basidiomycetes (Malassezia, Trichosporon and Cryptococcus spp.).
Due to our own experience with the basidiomycetous yeasts we will give
more in depth information on these fungi. The number of recognized
species is rapidly increasing due to the application of molecular
systematics and the availability of a large database of ribosomal DNA
(rDNA) sequences, most notable the D1/D2 domains of the LSU rDNA
and the ITS 1 and 2 regions. Only a few species are generally recognized
as important pathogens for humans and animals, including Cryptococcus
neoformans and Cr. gattii, several Trichosporon species and Malassezia
spp. However, several non-conventional basidiomycetous yeast species
can cause infection or are otherwise involved in health problems, such
as hypersensitivity pneumonitis. We will present data on the involvement
of these emerging basidiomycetous species, such as C. adeliensis,
C. difﬂuens, C. ﬂavescens and C. laurentii in human diseases. Emphasis
will be on the Cr. neoformans-Cr. gattii and Malassezia species
complexes, especially the role of the newly recognized species in disease,
virulence, and susceptibility to antifungals.
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S17 Is molecular subtyping a clinical tool?
S. Bretagne ° (Cre´teil, FR)
The main application of genotyping is for the investigation of epidemics
or tracking routes of contamination. Several molecular typing techniques
have been developed for fungi. Ideally, typing results should be
accurate, reproducible, and easy to interpret. Importantly, methods
should be transferable to other settings. Many typing methods such
as randomly ampliﬁed polymorphic DNA, restriction fragment length
polymorphism, single-strand conformation polymorphism analysis, and
ampliﬁed fragment length polymorphism yield ﬁngerprint proﬁles that
are difﬁcult to reproduce in different settings. In contrast, two methods
have emerged for clinical applications as providing reliable, portable and
easy to obtain data: microsatellite markers and Multi Locus Sequence
Typing (MLST).
Microsatellites, or short tandem repeats, are deﬁned as tandemly
repetitive stretches of two to ﬁve nucleotides. After ampliﬁcation,
PCR products are analyzed based on amplicon length. The present
limitation of microsatellite typing is transferability. A straightforward
and universally applicable method to achieve such a calibration is
through the use of allelic ladders. MLST is based on sequencing several
housekeeping genes. Active MLST schemes are publicly available
(http://www.mlst.net/) for yeasts. The main advantage of MLST is the
ability to provide indisputable data based on sequencing. However,
MLST is laborious, based on the quality of the sequences, has a long
turn-around time and is associated with signiﬁcant costs.
The nosocomial acquisition of invasive infections has been investi-
gated. The conclusion are disappointing for invasive aspergillosis but
unambiguous for invasive candidiasis. However, genotyping itself is not
sufﬁcient. Sampling, collection of clinical and epidemiological data are
compulsory to reach a meaningful conclusion. Another interesting point
is the propagation of a given clone with a resistant phenotype. This
has already been investigated for Aspergillus fumigatus and Candida
tropicalis.
Getting more and more pieces of information on the genome of each
microorganism will probably be part of the future routine laboratories.
The current trend towards mass sequencing creates such opportunities.
This technology might lead to several modiﬁcations in the way we
identify a species or characterize an isolate.
Pulmonary hypertension and infectious
diseases
S19 Pulmonary arterial hypertension related to HIV: update on
diagnosis and treatment
N. Petrosillo ° (Rome, IT)
The introduction of the highly active antiretroviral therapy (HAART)
has profoundly inﬂuenced the course of HIV infection, improving
the survival of HIV infected patients and reducing HIV-associated
opportunistic infections. Nevertheless, long-term outcomes secondary
to HIV infection are now serious concerns, like non-infectious cardio-
vascular complications including cardiomegaly, pericarditis, myocarditis
and pulmonary arterial hypertension.
The lung is the most frequent target organ for disorders associated
with HIV infection, and the cardiopulmonary vascular system can be
sometimes involved; indeed, HIV-related pulmonary arterial hyperten-
sion (HRPAH) affects more HIV-infected individuals (i.e. 0.5%) than
uninfected (i.e., 1 to 2 cases per million people).
The average age of HRPAH patients is 33 years, although the range
can span from infancy to old age. There is no trend between HRPAH
and HIV viral loads or CD4+ T cell counts but is more severe in
AIDS patients. Shortness of breath is the most common symptom, and
a clinical, cardiological, radiological work up is required for diagnosis.
Cardiac catheterisation is the gold standard for the ﬁnal diagnosis, and
is mandatory to characterize the disease and exclude secondary causes.
There is no deﬁnitive evidence of HIV as a causal agent for HRPAH.
However, viral proteins and its interactions with molecular partners in
the infected host are strong candidates for cause-effect relationships
because they may promote apoptosis, growth and proliferation. At least
three of the HIV proteins are implicated in the pathology of PAH: the
HIV envelope glycoprotein-120 (Env), the HIV protein Tat and HIV Nef
(negative factor). Nef impairs vasomotor functions in pulmonary artery
cells, decreases the expression of endothelial nitric oxide synthase and
increases oxidative stress, suggesting a strong role in the formation of
plexiform lesions in the lung vasculature.
The role of antiretroviral therapy (ART) in HRPAH is still debated. From
a literature review, survival rates are 69% and 38% among patients
treated or not with ART and speciﬁc therapy for PAH, respectively
(p = 0.02), thus suggesting that speciﬁc therapy for pulmonary arterial
hypertension should be strongly recommended in these patients. The
role of the combination treatment with antiretrovirals in inﬂuencing the
outcome of HRPAH is controversial, even if some evidences seem to
indicate a beneﬁcial effect in the clinical course of the disease.
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O22 Comparison of different bacterial DNA isolation methods
to accelerate differentiation of Staphylococcus aureus from
coagulase negative staphylococci from blood culture material
A. Loonen °, W. Hansen, A. Jansz, H. Kreeftenberg, C.A. Bruggeman,
P. Wolffs, A. van den Brule (Veldhoven, Maastricht, Eindhoven, NL)
Objectives: This study aims to compare 6 different DNA extraction
methods from 2 commonly used blood culture materials, BACTEC (BD)
and Bact/ALERT (Biomerieux), to accelerate differentiation between
S. aureus and Coagulase Negative Staphylococci (CNS).
Methods: Two fast real-time PCR duplex assays, targeting the Tuf
gene, to differentiate S. aureus from CNS, were developed in order to
select the most sensitive one. This Tuf RT-PCR was used to compare
6 different DNA isolation protocols on two different blood culture
systems. Negative blood culture material was spiked with S. aureus;
bacterial DNA was isolated with: automated extractor EasyMAG by
using 3 different protocols (Biomerieux), automated extractor MagNA
Pure (Roche), a manual kit MolYsis Plus (MolZyme), and a combination
between MolYsis Plus and the EasyMAG. The most optimal isolation
method was used to evaluate the possibility of reduced bacterial culture
times.
Results: Approximately 160 positive blood cultures containing Gram-
positive cocci in clusters were tested in the Tuf RT-PCR and all were
identiﬁed correctly. Bacterial DNA isolation, from spiked blood culture
material, with the MolYsis Plus kit in combination with the EasyMAG
showed the highest analytical performance, with a detection limit of 10
CFU/ml in Bact/ALERT material, whereas using BACTEC resulted in
a detection limit of 100 CFU/ml. With this sensitive bacterial DNA
isolation method 1 CFU/ml S. aureus in Bact/ALERT material was
detected after a 5 hour pre-culture step in the Bact/ALERT3D.
Conclusions: A sensitive RT-PCR was developed for detection and
differentiation of S. aureus versus CNS. Bacterial DNA isolation with the
MolYsis Plus kit in combination with the EasyMAG resulted in the most
sensitive detection of S. aureus, with a detection limit of 10 CFU/ml,
in Bact/ALERT material. An initial S. aureus load of 1 CFU/ml can
be detected after 5 hours incubation in Bact/ALERT3D by usage of the
TUF test.
O23 Comparison of MRSA detection by Xpert MRSA test, Xpert
MRSA/SA nasal test and culture
N.P. Brenwald °, B. Walker, K. Chana, M. Parsons, R. Fleming,
B. Oppenheim (Birmingham, UK)
Objectives: PCR based tests are increasingly being used to screen
patients for MRSA carriage. Most commercially available tests use the
SCCmec / orfX junction as one of the main targets for ampliﬁcation.
However, false positive MRSA results have been described due to
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the presence of incomplete SCCmec cassettes in meticillin sensitive
S. aureus (MSSA). Recently, PCR tests have been developed that detect
targets, in addition to SCCmec, to overcome the problems of associated
with partial SSCmec. Our study compares the detection of MRSA by
the Xpert MRSA test (single target) with the Xpert MRSA/SA nasal test
(multiple targets) and a sensitive enrichment culture method.
Methods: Nasal samples were collected with double-headed swabs from
patients admitted to the Sandwell and West Birmingham Hospitals NHS
Trust. Swabs were tested for MRSA using the Xpert MRSA/SA nasal
test and the Xpert MRSA test (Cepheid Europe) run on the Cepheid
GeneXpert system. All samples were also cultured for MRSA and MSSA
using 2.5% NaCl broth and sub-cultured onto chromogenic MRSA agar
and non-selective blood agar.
Results: 304 nasal swabs were included in the study (189 Xpert MRSA
positive; 115 Xpert MRSA negative). MRSA was cultured from 92/304
(30.3%) of the swabs. The Xpert MRSA /SA nasal test versus MRSA
culture showed a sensitivity, speciﬁcity, PPV and NPV of 84.8, 91.0,
80.4 and 93.2, respectively. 23/48 MSSA (so far analysed) isolated from
nasal swabs testing PCR positive, but culture negative were identiﬁed as
presumptive SCCmec mutants (SCCmec/chromosome junction positive;
mecA negative). All 23 isolates were positive by the Xpert MRSA test
whilst only 6/23 isolates were MRSA positive by the Xpert MRSA/SA
nasal test.
Conclusion: Both the Xpert MRSA and MRSA/SA nasal tests showed
high NPVs compared with MRSA culture making them useful as
screening tests for MRSA. However, the beneﬁt of detecting multiple
targets (SCCmec/orfX, mecA, spa) by the Xpert MRSA/SA nasal test
compared with only SCCmec/orfX by the Xpert MRSA test was reﬂected
in the reduced number of false positives reported using the Xpert
MRSA/SA nasal test. Our sample group was skewed to contain large
numbers of PCR positive samples to increase to likelihood of detecting
false positives. In a normal sample population, false positive results
would only constitute a very small proportion of the overall results.
O24 Rapid detection of MRSA in screening specimens during a
hospital outbreak
D.S. Blanc °, I. Nahimana Tessemo, K. Jaton-Ogay, G. Zanetti
(Lausanne, CH)
Objectives: To compare the results of rapid PCR screening for MRSA
using the GeneXpert system with those of cultures in an outbreak setting.
Methods: GeneXpert was used for screening MRSA in nose, throat,
groin, and other clinical samples during a 6-month period. Samples were
performed using a double-swab transystem. When >1 sample was found
positive in a screening set, all second swabs of the set were analysed by
culture.
Results: From June to October 2009, 7568 rapid tests were performed,
among which 432 (5.7%) were positive (nose: 149/2090, 7.1%; throat:
98/2078, 4.7%; groin: 152/2080, 7.3%; urine: 14/1090, 1.3%; wounds:
18/150, 12%; and others:1/27, 3.7%), and 84 (1.1%) were invalid. A
total of 1517 samples were analyzed by both rapid PCR and culture.
Rapid tests had a sensitivity of 0.896 compared to cultures, a speciﬁcity
of 0.769, a PPV of 0.763, and a NPV of 0.899. The rapid test was found
to be less sensitive in throat samples (0.81) than in nose or inguinal
samples (0.93 for both). In 32/192 (16%) patients a positive rapid PCR
result was not conﬁrmed by culture, despite several subsequent screening
samples in some patients. Cycle threshold (Ct) for SCCmec of these PCR
positive reactions were all >30.
Conclusions: GeneXpert MRSA was found to be suitable for the rapid
detection in nose, inguinal, and throat samples, however with a lower
sensitivity in the later. Negative cultures in 16% of our PCR-positive
patients raised the question of false positivity or higher sensitivity of
GeneXpert. Further work is needed to investigate these cases.
O25 Performance of the novel NucliSens EasyQ® MRSA assay
with a diverse selection of clonal complexes from a low
prevalence country
M. Mølvadgaard ° (Aalborg, DK)
Objectives: Several commercial assays have been developed for the rapid
detection of MRSA colonization directly from nasal swabs, but genetic
variations within the SCCmec cassette poses a constant challenge in the
primer design. Another pitfall is the sharing of the SCCmec cassette
among S. aureus and coagulase-negative staphylococci. NucliSENS
EasyQ® MRSA (bioMe´rieux) is a novel test which simultaneous
detects both the mecA gene and a speciﬁc cassette junction conﬁrming
the presence of the SCCmec cassette integrated in the S. aureus
chromosome. The objective is to evaluate the performance of the assay
with a collection of community-acquired MRSA strains from a low
prevalence country.
Method: MRSA isolates were obtained from residents in North Jutland,
Denmark and were characterized genetically by spa typing and clustered
into spa clonal complex (CC) groups (www.ridom.de) as part of the
Danish national surveillance program maintained by Statens Serum
Institut. Cultures of MRSA strains were processed according to the
manufacturer’s guidelines for positive controls and analysed on the
EasyQ instrument, a NASBA based platform.
Results: The study comprised 15 MRSA strains representing 10 different
clonal complexes [number in brackets]: CC1 [1], 5 [3], 8 [1], 22 [2],
30 [1], 59 [1], 72 [1], 88 [3], 97 [1], 398 [1]). Eleven were reported to
be MRSA whereas 4 were found MRSA negative (CC5 [1], CC59 [1],
CC97 [1], CC398 [1]). The mecA gene was reported for all 15 strains,
however both genes have to be present before denoted MRSA and the
4 cases of a negative test result were due to failure in detection of the
SCCmec cassette junction.
Conclusion: A very rapid test (<3 hours) and easy to perform. The
sequence targeted at the junction of the SCCmec cassette serves to ensure
the S. aureus diagnosis and is a safeguard against false positive results.
However, the current results raise the question whether genetic variation
in the junction area reduces the sensitivity of the test. This study will be
extended to a larger and more diverse collection of MRSA strains and
patient swabs.
O26 Multicentre evaluation of laboratory work time and cost for
real-time PCR tests for methicillin-resistant Staphylococcus
aureus compared to microbiological culture
L. Peterson °, C.W. Woods, S. Allen, D. Pombo, A. Onderdonk,
O. Liesenfeld (Evanston, Durham, Indianapolis, Murray, Boston,
Pleasanton, US)
Objectives: MRSA continues to increase globally. Rapid detection
of MRSA colonization followed by appropriate isolation can reduce
transmission and infection in healthcare settings (Ann Int Med 148:409–
418, 2008). A concern raised is the cost of molecular assays plus the
personnel time to perform this testing compared to culture. The BD
GeneOhmTM MRSA (BD) test is a FDA cleared diagnostic assay for
rapid detection of MRSA. Our objective was to compare personnel
work time and cost needed for this assay and the LightCycler® MRSA
Advanced test (Roche) to culture.
Methods: Double headed swabs were used to collect anterior nasal
specimens from each subject. For the BD test, one swab was broken off in
sample buffer tube, DNA was extracted and rt-PCR performed according
to package insert. For the Roche test, DNA was extracted and rt-PCR
performed according to proposed package insert. For culture, one swab
was plated directly to CHROMagarTM as well as to an enrichment broth
that was subsequently plated to CHROMagarTM. Colonies resembling
Staphylococcus species were conﬁrmed as MRSA by standard methods.
Processing time and cost of supplies were compared for these tests.
Results: Total hands-on technologist processing time for an average of
25 specimens was 75.4 min for the BD test (N = 263 runs) and 41 min
for the Roche assay (N= 435 runs). The ampliﬁcation and detection time
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was 61.8 and 77.6 min, respectively. Hands on time for enriched culture
processing of 25 specimens is estimated at 63 min (AJCP 131:532−9,
2009). Potential reporting time for a ﬁnal result was <2 hours for the
rt-PCR tests and 48.7 hours for enriched culture. The reagent cost for
culture, including or excluding broth enrichment, is somewhat lower
(8−10 Euro) than the rt-PCR tests from BD and Roche; costs of rt-PCR
tests are comparable between these two suppliers. New rt-PCR methods
have a comparable time of processing and cost of materials, but offer
potentially much faster reporting time than does culture. The hands on
time for the Roche assay was 1.8 min/test on average compared to 3 min
with the BD assay and 2.5 min/test for culture.
Conclusion: The Roche and BD tests had little difference in overall
time to result. With respect to resource utilization, hands-on time for
the Roche assay was lower than BD and culture; the cost per test is
comparable for both PCR assays. Molecular assays are able to report
results more rapidly compared to culture with comparable resource
utilization.
O27 A novel multiplex PCR identiﬁes 7 staphylococcal species and
mecA gene directly from blood cultures
K.S. Chatzigeorgiou °, N. Siafakas, A. Tarpatzi, E. Petinaki, L. Zerva
(Chaidari, Athens, Larisa, Greece, GR)
Objectives: Besides the well-established pathogenic potential of Staphy-
lococcus. aureus, coagulase negative species virulence is increasingly
being appreciated. The aim of the present report was to describe a
multiplex PCR assay suitable for the identiﬁcation of 7 staphylococcal
species and the detection of the methicillin resistance determinant mecA.
Methods: Eight different primer pairs targeting femA (for S. aureus,
Staphylococcus hominis and Staphylococcus saprophyticus), sodA
(for Staphylococcus haemolyticus and Staphylococcus capitis), fbl
(for Staphylococcus lugdunensis), a gene of unknown function (for
Staphylococcus epidermidis) and mecA, were used for the optimization
of the multiplex PCR protocol. The assay was tested on DNA extracted
from solid cultures of 213 isolates belonging to 12 staphylococcal and
17 non-staphylococcal species (6 Gram-positive and 11 Gram-negative).
RFLP analysis of the tuf gene was used as a reference method for
speciation of 196 staphylococcal isolates, whereas the presence of mecA
gene was assayed by a uniplex PCR. The 17 non-staphylococcal strains
were speciated by Phoenix System (Becton Dickinson, BD). The assay
was also tested on DNA extracted directly from 21 blood culture broths
(Aerobic/F, Anaerobic/F, BD), spiked with isolates previously assigned to
the staphylococcal 7 species (one reference strain and two clinical from
each species) included in the multiplex protocol. An organic extraction
protocol using benzyl alcohol was optimized for DNA extraction from
the blood culture broths.
Results: The new method identiﬁed correctly 67 strains as S. aureus,
64 as S. epidermidis, 18 as S. lugdunensis, 16 as S. haemolyticus,
10 as S. hominis, 6 as S. saprophyticus and 4 as S. capitis. No
ampliﬁcation products were recorded for the remaining staphylococcal
species and genera. In accordance with the uniplex mecA PCR,
61 methicillin resistant staphylococci were detected by the multiplex
protocol. Application of the protocol on DNA extracted directly from
spiked blood bottles produced the expected results in all cases within
6−8 hours.
Conclusion: The newly developed multiplex PCR assay speciﬁcally
discriminates the 7 most commonly encountered staphylococcal species
and concurrently determines their resistance towards methicillin. Its
application on positive blood cultures is expected to reduce signiﬁcantly
the turn-around time and reliable identiﬁcation and susceptibility results.
O28 Exotoxin-proﬁling of Panton-Valentine leukocidin positive
MSSA versus MRSA
H. Lagler °, K. Krziwanek, I. Elbau, K. Stich, R. Gattringer,
W. Graninger, S. Knapp (Vienna, Linz, AT)
Objective: The pathogenicity of S. aureus depends on the synergistic
interaction of bacterial virulence factors. Accordingly, the emergence of
virulent strains is frequently associated with the acquisition of genes
encoding diverse virulence factors. As such, the recent spread of CA-
MRSA was found associated with the presence of Panton Valentine
(PVL) toxin. However, the exotoxin proﬁle of PVL-positive MRSA
versus MSSA is not known.
Methods: We analyzed a collection of 79 clinical isolates of PVL-
positive MRSA and MSSA for the presence of genes encoding 22
exotoxins, including enterotoxins (ET) (sea-see, seg-ser, seu), toxic shock
syndrome toxin (TSST)-1 (tst), exfoliative toxins (EF) (eta, etb) and
hemolysines (HL) (hla) using PCR. Furthermore, MRSA genes (mecA,
SCCmec) and agr-locus were investigated by PCR.
Results: In total we studied 61 MRSA and 18 MSSA strains. More than
90% of mecA positive MRSA harboured the SCCmec cassette SCCmec
IV (71%) and 21% SCCmec V (21%), indicating the high incidence
of CA-MRSA in the investigated collection. While agr3 was present
in most MRSA and MSSA altogether (52%), agr4 was surprisingly
only found in MSSA (56% of MSSA). Overall, MRSA harboured
signiﬁcantly fewer toxin genes as compared to MSSA. This holds true
for enterotoxins, among which the genes for seg, sei, sem, sen, seo, and
seu (= enterotoxin gene cluster egc) were the most prevalent ones (on
average 30% of MRSA and 95% of MSSA tested positive for respective
genes). Rather surprising, and in contrast to published studies from PVL-
negative MRSA, we only discovered 12% of PVL-positive MRSA to
express enterotoxin A (sea).
Conclusions: This exotoxin-proﬁling study revealed that the majority
of PVL-positive S. aureus are CA-MRSA. Furthermore, the absolute
number of expressed exotoxin genes was higher in PVL-positive
MSSA versus MRSA, while ‘common’ MRSA-associated toxins such
as enterotoxin A, were found in relative low frequency in PVL-positive
MRSA.
O29 Different PVL encoding phages insert into the same chromoso-
mal locus in distinct lineages of MRSA in England and Wales
E. Boakes °, A.M. Kearns, R. Hill, M.J. Ellington (London, UK)
Objectives: To date, six Panton-Valentine Leukocidin (PVL) encoding
phages (phiPVL, phiSLT, phiSa2mw, phi108PVL, phiSa2USA and
phiSa2958) have been reported in PVL positive MRSA (PVL-MRSA).
We sought to detect and analyse the DNA sequence of the chromosomal
insertion site(s) of lysogenised PVL-phages amongst diverse PVL-
MRSA clones found in England and Wales.
Methods: PCRs differentiated the lysogenised PVL-encoding phage
present in PVL-MRSAs representing MLST Clonal Complexes (CCs)
1 (n = 11), 5 (n = 9), 59 (n = 3), 88 (n = 5) and ST93 (Queensland clone)
(n = 11) as well as CC8 (USA300; n = 12) and CC80 (European clone;
n = 7). Additional PCRs spanning the proximal and distal junctions of
the phage / chromosome DNA were designed to detect the insertion
site of the six known PVL phages and resultant DNA amplicons were
sequenced on both strands.
Results: PCR and DNA sequence data indicated different PVL phages
integrated at the same chromosomal locus in isolates of different
lineages of PVL-MRSA. Lineage speciﬁc sequence polymorphisms in
the chromosomal insertion site surrounding the PVL phage sequence
occurred in isolates of CC 59 (SNPs = 8), 93 (SNPs = 5) and 5 (SNP= 1).
By contrast, in CC1 and CC8 the insertion site sequence was identical to
the USA300 genome. The PVL encoding phage was consistent within the
lineage for: CC8 (phiSa2USA); CC80 (phiSa2MW); CC88 (Unknown
Elongated Phage) and ST93 (phiSa2USA). Conversely, different PVL
phages were identiﬁed within the same lineage for CCs; 1, 5 and 59.
Polymorphisms in both ends of the phage genomes were detected and
in most cases SNPs correlated with the identity of the PVL encoding
phage. However, in some lineages the same SNPs occurred in apparently
variant phages; in CC1 the same SNPs were identiﬁed in three different
phages; phiSa2USA (n = 7) and phiSa2MW (n = 3) and unknown PVL
phage (n = 1); whilst in CC5 a single SNP occurred at the 5′ end of
either phiSa2USA (n = 7) or an unknown variant phage(s) (n = 2).
Conclusion: Amongst genetically diverse UK PVL-MRSA different
PVL phages integrated at the same chromosomal locus. In some lineages
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the DNA sequence at the phage insertion locus was speciﬁc to the PVL-
MRSA lineage, we also detected SNPs in the extremities of the genomes
of the lysogenised PVL phages. Together with MLST CC and SCCmec,
these data suggest hitherto unidentiﬁed variance in lysogenised phages
and suggests that lineages of PVL-MRSA have evolved on multiple
occasions.
O30 Kinetics of bacterial DNA in blood during endovascular
infections with Staphylococcus aureus
W. Rozemeijer °, R.P. Peters, J. Kluytmans, P. Savelkoul, R.P. Schade
(Amsterdam, NL)
Objectives: Endovascular infection with Staphylococcus aureus is a
serious infection that requires rapid and adequate treatment to minimize
the risk of metastatic foci. Currently there are no effective tools to
monitor response to therapy. Sensitivity of blood cultures signiﬁcantly
decreases after initiation of antimicrobial therapy and other laboratory
parameters such as C-reactive protein lack speciﬁcity. Measurement of
bacterial DNA load (BDL) is not inﬂuenced by the use of antibiotics and
has been shown to have a good correlation with severity of infection. To
understand the kinetics of this parameter and to investigate its possible
usefulness in guiding clinical management, we have prospectively
determined the sequential BDL in patients with S. aureus endovascular
infections.
Methods: Whole blood samples were collected from patients with
culture proven S. aureus bacteraemia at several time points over a 2 week
period. BDL was determined in 44 sequential samples from 8 patients
with endovascular infection. We studied 4 severe endovascular infections
(endocarditis and/or other intravascular foci) requiring more than 2 weeks
of therapy, and 4 non-severe endovascular infections (phlebitis) requiring
a maximum of 14 days of therapy. Quantiﬁcation of S. aureus speciﬁc
DNA was performed by real time PCR on DNA extracted from 200ul
of blood.
Results: The S. aureus speciﬁc BDL was above the cut-off (5 cfu/ml) in 4
of 6 available samples taken within 24 hours after the ﬁrst positive blood
culture. Median BDL was 28 cfu/ml (range: 11–664). In all ﬁve patients
who had detectable BDL levels during treatment, the load decreased
signiﬁcantly in the ﬁrst days after treatment. In patients with non-severe
infections, the BDL decreased below the detection limit within 4 days. In
contrast, in patients with severe infections, the load remained detectable
during the ﬁrst 7 days. CRP measurements showed no correlation with
disease severity.
Conclusion: We present the ﬁrst description of kinetics of BDL in
blood from patients with S. aureus endovascular infections. The results
indicate that severe infections are characterized by prolonged presence
of detectable BDL. These results provide new insights and suggest that
BDL measurement has the potential to be used for monitoring treatment
response.
O31 External quality assessment of molecular diagnostics of
methicillin-resistant Staphylococcus aureus
R. te Witt °, A. van Belkum, W. MacKay, P. Wallace, W. van Leeuwen
(Rotterdam, NL; Glasgow, UK)
Background: This external quality assessment study determines the
performance of molecular diagnostics for meticillin-resistant Staphy-
lococcus aureus (MRSA) in the participating laboratories and was
organised by Quality Control for Molecular Diagnostics (QCMD)
(www.qcmd.org).
Methods: Eleven samples containing various concentrations of in-
activated cells of MRSA, meticillin-susceptible S. aureus (MSSA),
meticillin-resistant coagulase-negative staphylococci (MRCoNS) and
Escherichia coli were distributed to 80 laboratories in August 2009.
Results: Out of the 80 participants, 68 (85%) responded. Samples
containing 102 or 103 MRSA cells were correctly detected in only 16%
and 46% of the datasets returned, respectively. Two MSSA panel strains
contained a SCCmec cassette lacking the mecA gene. Only 12% of the
datasets generated using commercial PCR kits, reported correct results
for these two MSSA strains, which is a marked difference compared to
the MSSA strain lacking the SCCmec cassette (89% correct results). The
MRCoNS sample was correctly reported as negative in 89% of datasets
generated using commercial tests used and by 70% of in-house assays.
The E. coli sample was correctly reported as negative in 89% of datasets.
Discussion: In this EQA study on molecular diagnostics for the detection
of MRSA, we conclude that the detection of MRSA by using samples
with high CFU counts is reliable, which can and has been implemented
in the laboratory setting with conﬁdence. Pre-enrichment of clinical
samples leads to concentrations of MRSA exceeding 109 CFU/ml, but
also reduces one of the major improvements offered by NAAT, namely
more rapid diagnosis.
This year, two MSSA samples harbouring a SCCmec cassette, but
lacking the mecA gene, were included. The high percentages of incorrect
results for commercial PCR underscore the need for improved speciﬁcity
of these MRSA tests and therefore positive results should always be
conﬁrmed by a culture method or a second molecular test.
Performance in 2009 shows no signiﬁcant changes since our ﬁrst EQA
in 2006. Major diagnostic performance discrepancies still exist between
diagnostic microbiology laboratories.
In conclusion, the quality of molecular diagnostic MRSA tests still needs
improvement. Programme expansion is required and regular quality
control and international standardisation for MRSA diagnostics should
be mandatory for the years to come.
Drugs and combinations for difﬁcult-to-treat
S. aureus infections
O32 A novel approach to identify antimicrobial synergy against
methicillin-resistant Staphylococcus aureus
S.M. Garonzik °, A. Forrest, W. Wisniewski, B. Tsuji (Buffalo, US)
The increasing occurrence of vancomycin (V) resistance among
methicillin-resistant Staphylococcus aureus (MRSA) represents a serious
therapeutic problem. Proposed empiric approaches to combination
therapy have been based on little evidence.
Objectives: 1) To examine the pharmacodynamics (PD) of V paired
with several antibiotics. 2) To identify synergistic combinations. 3) To
develop better approaches to describe PD drug interactions.
Methods: Two MRSA strains Mu50 VISA and USA300 heteroresistant-
VISA (USA300 hVISA) were used. MICs were completed as per CLSI.
Time kill experiments were performed for V at 0, 0.5, 1, 2, 4, 8, 16,
32, 64, 128 & 256mg/L vs. each strain in log phase growth at two
initial inocula: 106 & 108 CFU/mL. To accommodate the study of
multiple antimicrobials a previously unexploited screening method was
used employing the maximal effect (Emax) concentrations (guided by
highest clinically achievable conc.) vs. two initial initial inocula for
6 pairs of antibiotics: V 128mg/L + gentamicin (G), ciproﬂoxacin,
TMP/SMX, caftazidime, tetracycline and linezolid. Combinations that
demonstrated activity at screening were studied at 9 combinations for
the same two drugs with concentrations ranging from low to Emax of
each drug. PD analysis was performed by integrated area approach for
reduction in area under the CFU vs. time curves, which were ﬁt to 2-D or
3-D Hill-type PD models. We developed a new PD model which adheres
to Loewe additivity and an interaction index (AFA index).
Results: Maximal bacterial reductions for V vs. 108 CFU/mL were
−2.91 (−1.97) and −3.04 (−1.42) for Mu50 and USA300 hVISA at
48 h (24 h). For USA300 hVISA V+G was synergistic against 108
CFU/mL with max reductions of −7.85 (−7.85) at 48 h (24 h). 48 h log re-
ductions for were: V32(−2.91) + G0.5(+1.4) = −3.28, V32 + G8(+1.58) =
−6.45, V32 + G64(+1.64) = −7.84, V128(−3.03) +G0.5 = −6.26,
V128 + G8 = −6.70, V128 + G64 = −7.85. AUC based PD parameters
for V at 48 h/24 h/8 h were H= 4.60/3.57/3.68; Emax = 1.48/1.05/0.558;
EC50 = 18/14.07/9.13; R2 = 0.998/0.994/0.992. The same parameters for
G at 8 h were H= 1.67, Emax = 1.51, EC50 = 3.55, R2 = 0.996. Per the
AFA index all V+G combinations studied for V> 1mg/L demonstrate
activity 400–500 fold greater than additivity (see ﬁg. 1).
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Conclusion: MRSA hVISA represents a therapeutic challenge with few
alternatives. This study may have implications for optimal therapy of
difﬁcult to treat MRSA infections to preserve the usefulness of V if
combined with other drugs.
Figure 1. PD interaction surface analysis: vancomycin & gentamicin
departures from additivity.
O33 Telavancin pharmacokinetics and pharmacodynamics in
patients with complicated skin and skin structure infections
with varying degrees of renal function
T. Lodise, N. Patel, S. Hegde, J. Shaw, S. Barriere ° (Albany, San
Francisco, US)
Objectives: Telavancin is a lipoglycopeptide approved in the US and
Canada for complicated skin and skin structure infections (cSSSI) due
to Gram-positive bacteria, including MRSA. The objectives were to (1)
simulate telavancin plasma concentration-time proﬁles in cSSSI patients
with varying degrees of renal function and (2) evaluate the percentage of
subjects with AUC/MIC ratios greater than the pharmacodynamic target
of 219.
Methods: Data from 513 patients from telavancin phase 2−3 cSSSI
clinical trials were used to perform the analysis. Individual concentration-
time proﬁles were simulated for 10260 subjects (NONMEM VI,
Icon, Elliot City, MD) using a previously described population two-
compartment model, with a combined additive and proportional residual
error model. The structural model was parameterized on clearance
(CL), volume of the central compartment (V1), intercompartment
clearance (Q), and volume of the peripheral compartment (V2).
Distributions of body weight and creatinine clearance of the 513
patients were used to simulate body weight and creatinine clearance
values for 10260 subjects in Matlab R2006a (Mathworks, Natick,
MA). Telavancin dosing regimens simulated were 10mg/kg Q24H for
creatinine clearance (CrCl)> 50mL/min, 7.5mg/kg Q24H for CrCl
30−50mL/min and 10mg/kg Q48H for CrCl< 30mL/min. AUC under
one dosing interval (AUCtau) was computed as dose/CL. The number of
subjects achieving an AUCtau/MIC ratio of 219 or greater was evaluated
separately in subjects with mild renal impairment to normal renal
function (CrCl> 50mL/min), moderate renal impairment (CrCl between
30−50mL/min), and severe renal impairment (CrCl< 30mL/min), using
MIC values of 0.5, 1, and 2mg/L.
Results: Summary statistics of AUCtau values of subjects with varying
degrees of renal function are provided in the table. Using the 3 dosing
regimens, AUCtau values were similar across the renal function groups.
More than 90% of the simulated subjects achieved an AUCtau/MIC ratio
of 219 or greater, assuming an MIC of 0.5, 1 or 2mg/L (targeting 2×
and 4× the MRSA MIC90 of 0.5mg/L).
Conclusion: Using the three dosing regimens, AUCtau were similar
across the different renal function groups, indicating that the dose
adjustments employed in the phase 3 cSSSI trials were appropriate.
All proposed telavancin dosing regimens are expected to provide an
AUCtau/MIC ratio of 219 or greater in at least 90% of the population,
for organisms with an MIC of 2mg/L or less.
Simulated AUCt and the AUCt/MIC ratio in subjects with various
degrees of renal function
Parameter CrCl (mL/min)
<30† 30−50# >50‡
AUCt (mean±SD, mg.h/L) 1058±316 762±238 776±264
AUCt range (min, max, mg.h/L) (466, 2071) (318, 1974) (203, 2820)
Percentage of population with
AUCt/MIC219
MIC= 0.5 100% 100% 100%
MIC= 1 100% 100% 100%
MIC= 2 98.6% 95.0% 93.8%
†Based on 140 simulated proﬁles; #based on 480 simulated proﬁles; ‡based on
9640 simulated proﬁles.
O34 Biphasic killing of levoﬂoxacin against Staphylococcus aureus:
modelling bacterial response to drug-selective pressures
V.H. Tam °, P. Bhagunde, K.R. Ledesma, K.T. Chang, R. Singh,
M. Nikolaou (Houston, US)
Objective: We have previously developed a mathematical model
predicting the response of P. aeruginosa to levoﬂoxacin (LEV) (Ann
Biomed Eng 07). However, the applicability of the model to other
pathogens is unknown. We extended our model to predict the effect
of various ﬂuctuating LEV exposures on Staphylococcus aureus (SA),
a bacterium commonly associated with nosocomial bloodstream and
surgical site infections.
Methods: Time-kill studies (TKS) with 107 CFU/ml of SA ATCC 29213
at baseline were performed in duplicate. LEV at 0–16mg/l was used
for 24 h (MIC = 0.25mg/l). The experimental data were used to derive
estimates of the best-ﬁt model parameters, and SA response (resistance
development or suppression) to various LEV exposures was predicted via
a 3-dimensional response surface. The computer model predictions were
subsequently validated using an in vitro hollow ﬁber infection model
(HFIM); LEV proﬁles (t1/2 = 7 h) corresponding to different daily doses
(given every 12 h or 24 h) were investigated over 120 h.
Results: In contrast to the anticipated concentration-dependent killing,
LEV exhibited a biphasic killing proﬁle in TKS. The data could only be
satisfactorily captured by a modiﬁed mathematical model (r2 = 0.977).
Dosing frequency was predicted not to have signiﬁcant impact on
bacterial response, as long as the daily doses were kept constant. A
daily dose of <300mg was predicted to facilitate resistance development,
while >500mg was expected to suppress resistance. These predictions
correlated well with our experimental data in HFIM.
Conclusions: The modiﬁed mathematical model was reasonable in
predicting extended SA response to various ﬂuctuating LEV exposures
qualitatively, based on limited input data from TKS. In view of its
robustness and efﬁciency, our mathematical modeling approach could
be used as a decision-support tool for dosing regimen selection in
antimicrobial (pre)-clinical development.
O35 Penetration of daptomycin in serum and bradytroph tissues
of patients undergoing orthopaedic surgery
D. Maier-Lenz °, A. Ko¨nig, U. Frank (Freiburg i.Br., DE)
Objective: To investigate the serum and tissue concentrations of
daptomycin in patients undergoing orthopaedic surgery.
Methods: A total of 18 patients received 350mg of daptomycin in
a short intravenous bolus infusion. Three groups of six patients each
received the drug prior to hip- or knee replacement surgery, i.e. between
1−1.5 h (Group I), between 1.5−2.5 h (Group II) and between 2.5−3.5 h
(Group III) before intra-operative sampling of serum and tissue, i.e. bone,
cartilage, muscle, fat, was performed.
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Results: Daptomycin serum concentrations showed a mean of 62.5
[mg/ml] in group I, 45.2 [mg/ml] in group II and 31.9 [mg/ml] in group III.
In bone a mean of 5.3 [mg/g] in group I, 4.5 [mg/ml] in group II and
4.5 [mg/ml] in group III was found. Cartilage showed a mean of 1.9
[mg/g] in group I, 2.0[mg/ml] in group II and 1.7 [mg/ml] in group III.
Muscle revealed a mean of 4.0 [mg/g] in group I, 2.3 [mg/ml] in group II
(for 5 patients) and 2.6 [mg/ml] in group III. In fat only a few samples
could be successfully analysed. These showed a mean of 6.0 [mg/g] in
group I (evaluable samples only for two patients), a mean of 1.9 [mg/ml]
in group II (evaluable samples only for three patients); for group III the
samples of all six patients were below the detection limit of the analytical
method. In a linear regression analysis the decrease of serum daptomycin
concentration per minute was estimated as −0.230, 95% conﬁdence
interval (CI) [−0.347, −0.112], p = 0.0008. For bone concentrations the
decrease was −0.0078, 95%-CI [−0.0247, 0.0092], p = 0.35) including all
18 patients, and −0.012, 95%CI [−0.024, −0.0005], p = 0.042) excluding
one single patient with an extraordinary high value. For cartilage, muscle
and fat, no decrease over time was shown. However, for serum, bone,
cartilage, muscle and fat the daptomycin concentrations were clearly
above the MIC values for staphlococci (<1.0mg/ml).
Conclusions: Daptomycin concentrations in serum showed a slow
decrease and the drug concentrations measured in both serum and
bradytoph tissues remained clearly above the MICs for staphylococci
for up to 3.5 hours. Within the postoperative observational period of
one week, no postoperative wound infection occurred. The application
of daptomycin was well tolerated without any adverse effects.
O36 Vancomycin serum trough levels and outcomes in patients
with hospital-acquired pneumonia due to Staphylococcus
aureus: the ATTAIN study
M. Stryjewski, G.R. Corey, S. Barriere °, F.C. Genter, E. Rubinstein
on behalf of the ATTAIN study group
Objectives: Higher vancomycin (VAN) serum trough levels (STL) have
been recommended when MRSA HAP is suspected. However, the
correlation between VAN STL and clinical outcomes and safety is still
poorly understood.
Methods: ATTAIN 1 and 2 were randomized, methodologically
identical, double-blind, phase 3, clinical trials in patients with hospital-
acquired pneumonia (HAP). We analyzed baseline characteristics and
outcomes from patients with S. aureus (SA) randomized to VAN (1 g
IV q12 h; 7 to 21 days) as a function of median VAN STL. VAN could be
adjusted for renal function and/or institutional policies. The all-treated
(AT) population included randomized patients who received 1 dose of
study medication. This analysis was limited to the subset of SA-infected
patients with VAN STL.
Results: 98 VAN AT patients with S aureus had STL (Table).
Median VAN Trough Level (mg/ml)
<10 (n = 30) 10 to <15
(n = 33)
15 (n = 35) p-value [1]
Number of trough values per patient
(median, range)
1 (1 to 5) 2 (1 to 8) 2 (1 to 14) −
Age (mean±SD) (yr) 60±19.6 69±12.7 69±13.6 0.139 (KW)
ICU at baseline 20 (67%) 24 (73%) 28 (80%) 0.485 (chi)
APACHE (mean±SD) 16±5.6 17±6.6 18±6.0 0.452 (KW)
VAP 13 (43%) 13 (39%) 14 (40%) 0.934 (chi)
Organism
MRSA 20 (67%) 26 (79%) 30 (86%) 0.186 (chi)
MSSA 10 (33%) 7 (21%) 5 (14%)
MRSA MIC [3]
0.5mg/mL 1/18 (6%) 3/22 (14%) 5/23 (22%) 0.354 (chi)
1.0mg/mL 17/18 (94%) 19/22 (86%) 17/23 (74%) [2]
>1.0mg/mL 0/18 (0%) 0/22 (0%) 1/23 (4%)
MSSA MIC [4]
0.5mg/mL 2/9 (22%) 1/6 (17%) 1/4 (25%) 1.000 (chi)
1.0mg/mL 7/9 (78%) 5/6 (83%) 3/4 (75%)
Clinical response of “cure” 21 (70%) 18 (55%) 17 (49%) 0.104 (CA)
Any serious TEAE 4 (13%) 8 (24%) 13 (37%) 0.033 (CA)
Renal TEAE 0 (0%) 1 (3%) 6 (17%) 0.006 (CA)
Deaths 3 (10%) 5 (15%) 7 (20%) 0.306 (CA)
ICU, intensive care unit; SD, standard deviation; TEAE, treatment-emergent adverse event; [1] 2-sided p-value from
the Kruskal-Wallis test (“KW”), an exact Pearson chi-square test (“chi”), or an exact Cochran-Armitage trend test
(“CA”); [2] Test of 0.5mcg/mL vs. 1.0mg/mL.
Conclusions: Patients in whom higher VAN STL were achieved had
poorer outcomes; and were more likely to experience renal adverse events
than patients with lower VAN STL.
O37 Combination therapy with cefoxitin and b-lactams is syner-
gistic against community-associated but not hospital-acquired
methicillin-resistant Staphylococcus aureus strains in vitro
M.G. Fernandez °, R. Banerjee, S.M. Schmidt, K.E. Piper,
J. Steckelberg, R. Patel (Rochester, US)
Objective: There is an urgent need for strategies to treat community-
associated methicillin-resistant Staphylococcus aureus (CA-MRSA)
infections. Preliminary in vitro studies demonstrate that nafcillin minimal
inhibitory concentrations (MICs) for USA300 and USA400 strains
decrease in the presence of subinhibitory concentrations of cefoxitin.
The aim of this study was to characterize the in vitro antimicrobial
activity of cefoxitin and several anti-staphylococcal b-lactams alone and
together against MRSA isolates using MICs and time kill assays.
Methods: MICs and time kill assays were performed using standard
methods with the following strains: ATCC29213 (control strain),
USA300 and USA400 (CA-MRSA strains), N315 and COLn [hospital-
acquired (HA) MRSA strains]. Time kill assays were performed with a
starting inoculum of 5.5 to 6.5 log10 CFU/ml and quantitative cultures
performed at 0, 6 and 24 h.
Results: The MICs of nafcillin, cefazolin, cefuroxime, ceftriaxone and
cefotaxime decreased in the presence of 10 ug/ml cefoxitin to a greater
extent for CA- than HA-MRSA strains (see table). In triplicate time kill
assays, cefoxitin (10 ug/ml) combined with either nafcillin (4 mg/ml) or
cefazolin (16 mg/ml) displayed synergy against CA- but not HA-MRSA
strains. Compared to nafcillin alone, nafcillin plus cefoxitin showed a
log10 CFU/ml reduction ranging from 0.8 to 2.1 for USA300 and 1.5 to
2.1 for USA400. Compared to cefazolin alone, cefazolin plus cefoxitin
showed a log10 CFU/ml reduction ranging from 2.8 to 2.9 for USA300
and 2.9 to 4.7 for USA400. Overall, cefazolin plus cefoxitin caused a
log10 CFU/ml reduction of the initial inoculum at 24 h ranging from 0.8
to 1.2 for USA 300 and 1.6 to 3.1 for USA400. The activity of cefazolin
combined with cefoxitin was superior to that of clindamycin (8 mg/ml)
alone but inferior to that of vancomycin (16 mg/ml) alone for USA300
and USA400.
Conclusion: Cefoxitin combined with a variety of b-lactams enhanced
their activity against CA-MRSA strains in vitro. Cefoxitin synergy was
greater with cefazolin than with nafcillin. Combination b-lactam therapy
for CA-MRSA deserves further study.
Minimal inhibitory concentration (microg/ml)*
Strain Cefoxitin Nafcillin Cefazolin Cefuroxime Ceftriaxone Cefotaxime Vancomycin
USA300 32 4/0.5 16/0.5 64/2 128/16 32/8 1/1
USA400 32 4/0.5 4/0.5 >128/2 128/8 32/2 1/1
N315 32 16/8 64/1 >128/>128 >128/32 128/8 0.5/1
COLn >128 128/>128 >/128/>128 >128/>128 >128/>128 >128/>128 0.5/1
*Antibiotic/Antibiotic plus 10microg/ml cefoxitin.
O38 Evaluation of vancomycin and oxacillin combination against
mecA positive vancomycin-intermediate Staphylococcus
aureus (VISA) and heterogenous VISA with varying oxacillin
susceptibility
C. Vidaillac °, K. Murray, M. Rybak (Detroit, US)
Objectives: S. aureus with reduced susceptibility to vancomycin (VAN)
currently represents a serious clinical dilemma given the limited
availability of alternative treatments. The VAN intermediate-type of
resistance in S. aureus (VISA) has been previously reported to result
in cell wall remodeling and antimicrobial susceptibility changes in favor
of b-lactam activity. We evaluated the activity of VAN, oxacillin (OXA)
and cefoxitin (CFX) and the potential for synergy of the combination of
VAN+OXA against a collection of clinical heterogenous VISA (hVISA)
and VISA strains.
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Methods: 60 VISA and 93 hVISA isolates carrying the mecA genes
were selected from the Anti-Infective Research Laboratory collection.
VAN, OXA and CFX MICs were determined in duplicate by broth
microdilution according to CLSI guidelines. Pearson’s rank correlation
coefﬁcient test was used to assess the association between VAN and
OXA or CFX MICs. Eight VISA and hVISA strains were selected on
the basis of their OXA MIC to be evaluated by time kill curves (TK)
against VAN and OXA alone or in combination at 0.5 and 0.25× MIC
in presence of 50% human serum. Synergy (S) was deﬁned as 2 log
kill compared to the most efﬁcient drug alone.
Results: MIC distribution is reported in Table1. Of interest, 23% and
10% of the VISA strains were susceptible to OXA and CFX, respectively.
A signiﬁcant inverse correlation was found between the MICs of VAN
and OXA (P = 0.003), and VAN and CFX (P = 0.001). Considering the
subpopulation with the highest VAN MIC for each hVISA strain, 36%
displayed a 2−8 x decrease in the OXA MIC compared to the overall
population. In contrast, 41% had a 2−16× increase in OXA MIC.
Isolates performed in TK exhibited a MIC range of 2−8mg/L and 0.5–
512mg/L for VAN and OXA, respectively. In TK, S was observed with
the combination of VAN+OXA at 0.5 x MIC against all VISA and hVISA
isolates, except 1 VISA strain resistant to OXA and 1 hVISA exhibiting
a decreased OXA MIC in the population with the highest VAN MIC.
Combination of VAN+OXA at 0.25 x MIC did not demonstrate S against
any tested isolates.
Conclusions: We conﬁrmed susceptibility changes in favor of b-lactam
activity in the VISA collection. Further in vitro and in vivo experiments
are now warranted to determine if the potentially synergistic combination
of VAN+OXA would be useful to treat patients with infections caused
by MRSA, in order to eradicate the infection and/or prevent emergence
of VAN intermediate resistance.
Table 1. MICs distribution of 93 hVISA and 60 VISA isolates.
Species Percent of isolates
VAN MIC (mg/L) OXA MIC (mg/L) CFX MIC (mg/L)
0.5 1 2 4−8 4 8−32 64–>512 16 32−64 128–>512
hVISA (n= 93) 4 66 30 0 0 13 87 1 26 73
VISA (n= 60) 0 0 0 100 23 25 52 10 48 42
O39 In vitro synergism between ceftobiprole and vancomycin
against methicillin-resistant and glycopeptide-intermediate
Staphylococcus aureus
J.M. Entenza °, J. Vouillamoz, A. Bizzini, M. Giddey, J. Bille,
P. Moreillon (Lausanne, CH)
Objective: Several studies have reported synergy in vitro between
b-lactams and vancomycin (VAN) in their activity against methicillin-
resistant S. aureus (MRSA) and glycopeptide-intermediate S. aureus
(GISA) isolates. Nevertheless, attempts to use such combinations against
GISA in animal infection models yielded conﬂicting results. This was
probably due to the fact that the b-lactams used (e.g., cloxacillin and
nafcillin) had weak afﬁnity for penicillin-binding protein 2A (PBP2A),
the major determinant of methicillin resistance in MRSA and GISA.
Ceftobiprole (BPR) is a novel cephalosporin with improved afﬁnity for
PBP2A, and enhanced in vitro activity against MRSA and GISA. Here
we tested the potential for synergy between BPR and VAN against both
MRSA and GISA in vitro.
Methods: Three GISA clinical isolates (Mu50, PC3 and 1092, a human
isolate from Switzerland) were tested. One VAN-susceptible MRSA
(COL) and one VAN-susceptible methicillin-susceptible S. aureus
(MSSA 1112) were used as controls. The interaction of BPR with VAN
was determined by applying BPR or VAN Etest strips to inoculated
(0.5 McFarland) BHI agar plates with the partner drug incorporated
into the agar at 0, 0.25× and 0.5× the MIC for each strain. The time-
kill assay was used to test for BPR and VAN synergy using antibiotic
concentrations of 0.25× to 1× the MIC.
Results: MICs of BPR were 1−2mg/L for GISA, 1mg/L for MRSA,
and 0.12mg/L for MSSA. MICs of VAN were 4−8mg/L for GISA,
and 2mg/L for both MSSA and MRSA. Subinhibitory concentrations of
VAN added to the agar medium caused 2- to 4-fold decreases in BPR
MICs for GISA and 4-fold for MRSA. The GISA and MRSA isolates
showed corresponding 4- to 8-fold decrease in VAN MIC in the presence
of subinhibitory levels of BPR. In time-kill curves, combinations of
BPR and VAN displayed synergism (deﬁned by a decrease of 2log10
CFU/ml at 24 h compared with the single most active agent and with
the starting inoculum) for all GISA and MRSA strains. For MSSA, the
combination was indifferent by both Etest and time-kill methods.
Conclusions: In vitro, BPR and VAN were synergistic against GISA
and MRSA. An indifferent effect was noted against MSSA. Assessment
of BPR plus VAN for the therapy of GISA in an experimental animal
model of infection (experimental endocarditis) is currently in progress
to assess the potential clinical therapeutic beneﬁt of this combination.
O40 Comparative in vitro activity of torezolid and linezolid against
Staphylococcus and Enterococcus isolates
N. Bourgeois-Nicolaos, G. Defrance, E. Jacouton, C. Marguerite,
E. Jouy, A. Perrin-Guyomard, F. Doucet-Populaire ° (Clamart, Paris,
Ploufragan, Fouge`res, FR)
Objective: Torezolid is a new oxazolidinone with in vitro and in vivo
efﬁcacy against several Gram-positive species. The aim of our study
was (i) to determine Linezolid (LZ) MICs against 104 French isolates
of Staphylococcus and Enterococcus (ii) to characterize LZ resistance
mechanisms for the strains with a LZ MIC >2mg/L (iii) to compare the
in vitro activity of Torezolid with LZ.
Methods: A total of 104 French isolates of animal and clinical origin
resistant to chloramphenicol were studied including 38 Staphylococcus
strains and 66 Enterococcus strains. MICs of LZ and Torezolid were
determined using the Mueller Hinton agar dilution method according to
CLSI guidelines. 23s rRNA target mutations and cfr genes were detected
by PCR and sequencing.
Results: For all 104 strains, MICs of LZ were 0.5−64mg/L (geom. mean
MIC 7.3mg/L). MIC of LZ was >2mg/L for 23 strains: 6 S. aureus
isolates and 17 Enterococcus isolates (12 E. faecalis and 5 E. faecium),
all of clinical origin. All S. aureus isolates resistant to linezolid harbored
a G2576T mutation in rrl gene. Enterococcus isolates harbored either
G2447T (n = 4), G2505A (n = 3) or G2576T (n = 10), No strains whatever
their susceptibility to LZ harbored cfr gene.
For all 104 strains, MICs of Torezolid were <0.5−8mg/L (mean MIC
1mg/L. MICs of Torezolid were <0.5−1mg/L vs. 0.5−2mg/L LZ for LZ-
susceptible staphylococci (n = 32) irrespective of species and methicillin
resistance. Against linezolid susceptible Enterococcus of animal origin
(n = 34) and clinical origin (n = 15), MICs of Torezolid were 0.5−1mg/L
vs. 2mg/L LZ. MICs of Torezolid for LZ-resistant Enterococcus isolates
were 1−8mg/l vs. 4−64mg/L LZ.
Conclusion: No cfr genes were found in French chloramphenicol-
resistant Staphylococcus and Enterococcus isolates of human or animal
origin. Torezolid was 4 to 8 fold more active than Linezolid against LZ-
susceptible strains and LZ-resistant Staphylococcus and Enterococcus
isolates with G2576T, G2505A or G2447T mutations.
O41 In vitro evaluation of the bactericidal activities of MRSA
active antibiotics in four different peritoneal dialyses ﬂuids
S. Tobudic °, W. Po¨ppl, C. Kratzer, W. Graninger, H. Burgmann
(Vienna, AT)
Objectives: Continuous ambulatory peritoneal dialysis used in the
treatment of patients with end-stage renal failure is often complicated
by peritonitis. Staphylococcus aureus peritonitis is associated with
severe peritonitis, particularly if caused by methicilin resistant strain
(MRSA). The intraperitoneal administration (IP) of drugs for peritonitis
is preferable to intravenous or oral administration because of the resulting
higher local antibiotic concentrations. Peritoneal dialyses ﬂuids (PDFs)
affect bacteriostatic, which may compromise the effectivity of antibiotics.
Therefore, it is important that prescribed antibiotics are compatible
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with PDFs. The purpose of this study was to investigate in vitro the
bactericidal effectiveness of for MRSA infections appropriated antibiotic
in diverse PDFs.
Methods: Against MRSA the bactericidal activities of vancomycin
(VAN), teicoplanin (TEI), daptomycin (DAP), linezolid (LIN), cefto-
biprole (CEF) and tigecycline (TIG) in different PDFs: Dianeal
PD4 Glucose 1.36%; Physioneal 40 Glucose 1.36%; Extraneal 7.5%
Icodextrin, and Nutrineal PD4 1.1% amino acid were proved. Cation-
adjusted Mueller-Hinton Broth. (CAMHB) was used as a control broth.
Ten milliliter of diverse PDFs and CAMHB containing bacteria inoculum
of approximately 106 CFU/ml was incubated for 2 h at 37ºC. Following
incubation, the antibiotics at concentrations: 1×MIC, 4×MIC, 8×MIC
were added. Additionally, the bactericidal concentration at clinical used
concentration: VAN 50 mg/ml, TEI 20 mg/ml, DAP 60 mg/ml, CEF 30
mg/ml, LIN 32 mg/ml, TIG 50mg/ml was tested. Samples were taken at 2,
4, 6, 8 and 24 h and the number of CFU/ml was determined. To stimulate
in vivo conditions human serum albumin at 2 g/l was added. Control
experiments with bacteria and no antibiotics in PDFs and CAMHB were
run.
Results: All antibiotics showed concentration- and time-dependent
bactericidal activities, but the reduction of CFU/ml in diverse PDFs
differed considerably. All tested antibiotics showed signiﬁcantly higher
bactericidal activity in Extraneal 7.5% Icodextrin, and Nutrineal PD4
1.1% amino acid than in Dianeal PD4 Glucose 1.36% and Physioneal
40 Glucose 1.36% (p< 0.05). The highest decrease in CFU/ml attained in
Extraneal 7.5% Icodextrin, and Nutrineal PD4 1.1% amino acid showed
DAP and VAN.
Conclusion: Based on these in vitro data, we conclude that the choice
of PDFs used for IP administration is not trivial and could be crucial for
therapy outcome.
Imported infections: tropical and travel
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O42 Investigation of molecular diagnostic assays for the detection
of Trypanosoma cruzi DNA in blood
M.J. Alvarez-Martinez °, D. Nolder, P. Chiodini (London, UK)
Objectives: Chagas disease, caused by Trypanosoma cruzi, is endemic to
Latin America, and of emerging importance in non-endemic countries
because of migration of people infected with T. cruzi. The majority
of patients diagnosed in non-endemic settings are in the indeterminate
or chronic phases. However, acute cases may be seen in congenitally-
infected infants and in people receiving blood products or organs from
infected donors. Molecular diagnostic assays needed to be standardized
to diagnose and monitor congenital infection, aid serological diagnosis
in expatriate travellers and migrants from Latin America, and monitor
infection in known cases of Chagas Disease.
Methods: Two molecular assays for the diagnosis of T. cruzi infection
were investigated, a SYBR green real-time PCR targeting nuclear
satellite DNA, and a hotstart PCR targeting kinetoplast DNA (kDNA).
One hundred and eighty PCR controls and 180 blood-simulated
specimens prepared from cultures of T. cruzi strains of lineages TcI,
TcIIb and TcIIe were evaluated. Samples for DNA were prepared from
the specimens using 3 lysis methods (Qiagen (Q), Guanidine-EDTA
(GE) and GE+boiling (GEB). DNA extraction after lysis was carried
out using silica-membrane technology. Ten-fold serial dilutions were
prepared. Statistical analysis was performed by SPSS v15, Chicago IL.
Results: The sensitivity of the real-time PCR assay was calculated by
PROBIT analysis with 12 replicates of 8-fold serial dilutions of the
DNA from culture of TcIIb extracted by Qiagen. The 95% and 50%
positive hit rates were 0.8 parasites/ml (95% IC: 0.41–1.53) and 0.2
parasites/ ml (95% IC: 0.08–0.32), respectively. The assay showed a
speciﬁcity of 100%. More consistent results were found for all lineages
and types of samples when DNA was extracted by the Qiagen method. A
higher detection limit was found in lineage TcI (p< 0.01). Lineage TcIIb
showed statistically better results in controls and simulated specimens,
than the other two lineages (p< 0.01). The kDNA assay was performed
in simulated specimens from the three lineages, and it gave better results
using Q and GEB methods on low concentration samples, although not
statistically signiﬁcant (p = 0.08).
Conclusions: Molecular assays are very promising in the diagnosis of
T. cruzi infection and have applications where serological assays are not
of use. Further work should be done to standardize the methods.
O43 Congenital transmission of Chagas’ disease in Latin American
immigrants in a health department of Valencia, Spain
M.J. Gimenez °, M.D. Gomez-Ruiz, E. Calabuig, A. Perez-Tamarit,
M.C. Otero, L. Fernandez-Silveira, J. Lopez-Aldeguer, M. Gobernado
(Valencia, ES)
Objective: To describe congenital transmission of Chagas disease in
Latin American immigrants in our Health Department 07-La Fe, in
Valencia (Spain).
Methods: We collected sera from pregnant women from Latin America
who attended our hospital between June 2007 and October 2009.
The samples were tested for anti-Trypanosoma cruzi antibodies (IgG)
using 2 differents enzyme-linked immunosorbent assays (ELISA) and
a particle gel immuno assay. Positive sera were then conﬁrmed with
an immunoﬂuorescent assay (IFA). Total blood from infected patients
was sent to Carlos III Health Institute (Madrid) in order to perform a
polymerase chain reaction (PCR) study. Newborns’ sera and umbilical
cord blood from infected mothers were tested for anti-T. cruzi antibodies
and blood microscopic examination, microhematocrit concentration
technique and PCR, respectively, at birth, at 1−6-12 months old. Infected
children, considering 2 positive PCR and/or positive parasitological
examination for diagnosis, were treated with a 60-day course of
benznidazol (3.5−7mg/kg/day).
Results: Out of 574 pregnant women sera, 35 (6.1%) were positive
for T. cruzi serology and gave birth at our hospital. Their mean age
was 29.1 years old; All of them were from Bolivia, mainly from Santa
Cruz (39.3%) and Cochabamba (28.6%) departments, except one from
Argentina. 12 pregnant women PCR were positive, but none of them
was symptomatic for Chagas disease. 2 newborns had two positive PCR
along the ﬁrst 6 months and 1 newborn had positive blood examination
also. Two of them were born from positive PCR women and the other
is unknown. Only one of the babies had symptoms at birth (dilated
cardiomyopathy and a neuroblastoma). Benznidazol treatment was well
tolerated by all babies.
Conclusions:
1. Although we have not documented any congenital transmission in
newborns from negative PCR mothers, we cannot consider yet that
positive PCR is a predictor factor for T. cruzi infection transmission.
2. Positive PCR results at birth allows us to initiate an early treatment in
infected newborns, which has been demonstrated as the most effective
treatment.
3. Benznidazol has been well tolerated by newborns with no side effects.
4. It is really important to follow-up seropositive children at least during
one year with serology tests. Negative PCR blood from newborns only
can be conﬁrmed as non-infected patients when T. cruzi antibodies
desapear along the ﬁrst year.
O44 Paediatric drug formulations of artemisinin combination
therapies: is there evidence for improvement of patient
management in the treatment of children suffering from
malaria? A systematic review and meta-analysis
M. Ramharter °, P. Kremsner (Vienna, AT; Tuebingen, DE)
Objectives: Artemisinin combination therapy (ACT) is the mainstay
of antimalarial treatment with high efﬁcacy, good tolerability, and
a reduced risk for resistance selection. However, conventional ﬁxed
dose ACTs are inadequate for the treatment of young children −
the most important target population − due to difﬁculties in drug
administration of tablets. Recently, a number of ACTs with paediatric
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drug formulations have been developed. However to date there is no
objective evidence from individual controlled trials for an improvement
of patient management by their use when compared to conventional
tablet formulations. We therefore aimed to collate all available evidence
from individual controlled trials in order to investigate whether objective
evidence supports the development of these paediatric antimalarials.
Methods: We performed a systematic review and meta-analysis of
controlled clinical trials evaluating paediatric artemisinin combination
therapies compared to tablet drug formulations. Outcome parameters
were efﬁcacy, safety, tolerability, and tolerability of drug administration.
Results: Out of 667 potentially relevant publication, seven studies
met the predeﬁned inclusion criteria. Meta-analysis of 2515 chil-
dren was performed evaluating paediatric drug formulations of the
following ACTs: artesunate-meﬂoquine, artemether-lumefantrine, and
pyronaridine-artesunate. Per protocol and intention to treat analysis
of efﬁcacy were comparable between paediatric and tablet drug
formulations. Overall tolerability, deﬁned as the total number of
adverse events experienced by patients was also similar between
groups. However, the tolerability of drug administration evaluated by
the number of drug related adverse events (RR: 0.79, 95%CI: 0.64–
0.96), drug related vomiting (RR: 0.77, 95%CI: 0.61–0.99), and drug
related gastrointestinal disorders (RR: 0.34; 95%CI: 0.15–0.80) was
considerably improved for paediatric drug formulations.
Conclusion: Data of this meta-analysis show for the ﬁrst time objective
evidence of an improved tolerability of drug administration by paediatric
ACTs compared to tablet ACTs. To our knowledge this is the ﬁrst
evidence for an improvement in patient management by paediatric drug
formulations in any indication. Therefore paediatric ACTs should be
considered in international recommendations for the treatment of malaria
in young children.
O45 Is benign tertian malaria actually benign?
A. Gogia °, A. Kakar, S. Byotra (New Delhi, IN)
Objective: This retrospective study was conducted to determine the
incidence of various complications of Plasmodium vivax malaria based
on review of case records in a tertiary care hospital, New Delhi, India.
Methods: The case records of all conﬁrmed cases of malaria over
the period of one year (September 2008-August 2009) were studied.
Complete blood count, peripheral blood ﬁndings, liver and kidney
functions were reviewed. The results of rapid diagnostic test for malaria
(OptiMAL test, Diamed AG, Switzerland) were correlated with the
peripheral blood smear ﬁndings in the patients in whom it was requested.
All abnormal results like a positive direct Coomb’s test were noted.
Findings were clinically correlated.
Results: There were 165 conﬁrmed cases by peripheral blood
examination. Of these 121 were due to Plasmodium vivax and 42 due
to P. falciparum. Two cases had mixed infection. The peak incidence of
malaria was seen in September 2008 and July 2009. The complications
in P. vivax were thrombocytopenia, biochemical evidence of hepatic
dysfunction, renal damage, positive DCT and death due to ARDS.
Thrombocytopenia was seen in 113 patients with counts <20×103/microl
in 43 patients. Fifteen patients had serum bilirubin >3mg/dl with normal
liver enzymes. Liver enzymes were elevated in 55 patients with twelve
patients showing liver enzymes level, three times the normal. Renal
dysfunction was seen in 21 patients with serum creatinine ranging from
1.3–10.65mg/dl. There were three deaths due to ARDS.
Conclusion: This paper is presented to highlight that P. vivax malaria
though considered to be a benign entity can also have a severe and
complicated course which is usually associated with P. falciparum
malaria.
O46 Incidence of inﬂuenza, dengue and Japanese encephalitis in
Australian travellers visiting South and south-eastern Asia
I. Ratnam °, J. Black, K. Leder, B. Biggs, M. Richards, L. Pollissard,
C. Luxemburger, E. Matchett, A. Padaglione, I. Woolley, P. Schlagenhauf,
T. Gherardin, J. Torresi (Melbourne, AU; Lyon, FR; Zurich, CH)
Objective: To estimate the incidence density of inﬂuenza, dengue and
Japanese encephalitis (JE) in Australian travellers to Asia.
Methods: Prospective cohort study of Australian travellers to South
and South East Asia over a 2 year period. Travellers 16 years of age
were recruited from 3 travel clinics, completed validated questionnaires
and provided pre and post-travel blood samples for serological testing.
Demographic data, destinations and travel patterns, vaccination details
and history of ﬂavivirus infection were obtained. Serological testing for
dengue IgG by ELISA (Pan-Bio assay), Inﬂuenza A and B (complement
ﬁxation antibody) and JE (In-house indirect ﬂuorescence antibody) was
performed.
Results: Among 450 travellers enrolled, 345 have returned for follow-
up, 53 (11.7%) have been lost to follow-up and paired sera have been
tested for 324 travellers; 58% were female, median age was 32 years and
24% were born overseas. 72% were short term travellers (<30 days) and
main traveller types were vacation/holiday goers (69%) and business
travellers (16%). 76% reported prior travel to Asia and 10.8% and
54% had received the JE and inﬂuenza vaccines respectively. Dengue
sero-prevalence: Acute seroconversion for dengue virus infection was
demonstrated in 4/324 (1.2%) of travellers tested. This translates to
an incidence of 4.17 dengue virus infections per 10,000 days of travel
(95%CI 1.7–10.7). A further 13 travellers (4%) were positive for dengue
IgG prior to travel indicating past exposure. Travellers with acute dengue
infection had travelled to China (n = 2) India (n = 1) and Thailand (n = 1),
and two of these travellers had received the JE vaccine. Inﬂuenza sero-
prevalence: 4/324 (1.2%) had evidence of recent inﬂuenza infection.
The incidence of inﬂuenza virus infections is 4.17 per 10,000 days of
travel (95%CI 1.7–10.7). JE sero-prevalence: There was no acute JE
seroconversion in this cohort.
Conclusion: To our knowledge, this is the largest prospective study
estimating the incidence of both respiratory and arboviral infections
in travellers. For travellers to Asia, the risk of acquiring dengue in
an inter-epidemic period is low (incidence density 4.17 infections per
10,000 days of travel). The risk of acquiring inﬂuenza in this well
vaccinated cohort was equally as low and no JE infections were observed.
These ﬁndings have important implications for practitioners advising
prospective travellers.
O47 Genetic diversity of intestinal protists: the implication for
PCR-based diagnostic assays
C.R. Stensvold °, M. Lebbad (Copenhagen, DK; Solna, SE)
Objective: Diagnosis of intestinal protists by PCR is being employed
more and more by diagnostic and research laboratories. Data from
molecular characterisation of intestinal protists is the raw material for our
current and future efforts to develop improved diagnostic PCRs. Apart
from our ability to sample correctly and extract DNA from parasites
directly from faeces, important issues include primer speciﬁcity and
sensitivity, which have impact on predictive values of the diagnostic
assays. Thus, it is important to be aware of the genetic diversity among
these parasites. Extensive data from the molecular characterisation of
intestinal protists are necessary if PCR-based diagnosis is to detect all
genetic variants of intestinal parasites especially if the eventual aim is
for it to substitute for morphology-based methods. Diagnostic PCRs are
very often based on ampliﬁcation of the Small Subunit (SSU) rRNA
gene, partly due to the fact that this gene is present in a high-copy
number. However, data from very few strains are currently available for
the SSU rRNA gene of most intestinal parasites. Often only one or two
sequences are available in the Genbank database.
Methods and Results: We are in the process of collecting data from the
genetic characterisation of protozoa such as Iodamoeba, Entamoeba coli,
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Entamoeba hartmanni and Entamoeba polecki-like organisms isolated
from clinical samples. Knowing the amount of diversity displayed among
clinical isolates of these (and other) parasites will help us generate
speciﬁc and sensitive primers that can be used in cases where a deﬁnitive
diagnosis cannot be established on the basis of microscopy. Preliminary
results show that the genetic diversity within Entamoeba coli is extensive,
and that no less than four genetic subtypes of uninucleate amoebic cysts
can be isolated from human faeces. We have also obtained genetic data
from protozoan genera that have not been sequenced before.
Conclusion: If future platforms for the diagnosis of intestinal protists
are to rely on PCR, comprehensive data from molecular characterisation
of these organisms are needed to design, evaluate, validate and optimise
PCR protocols.
O48 Synthesis and evaluation of 4-ﬂuoro-amodiaquine a novel
antimalarial drug against sensitive and resistant strains of
Plasmodium falciparum
E. Asadollahy, P. O’Neill ° (Ilam, IR; Liverpool, UK)
Objectives: Resistance to chloroquine (CQ) in Plasmodium falciparum
malaria has become a major health concern of the developing world.
This resistance has prompted a re-examination of the pharmacology of
alternative antimalarials that may be effective against resistant strains.
Amodiaquine (AQ) is a 4-aminoquinoline antimalarial which is effective
against many chloroquine-resistant strains of P. falciparum. However,
clinical use of AQ has been severely restricted because of associations
with hepatotoxicity and agranulocytosis. Based on a knowledge of the
metabolic basis of amodiaquine toxicity, the aim of this study was to
examine the effects of replacing the 4′OH function of amodiaquine with
ﬂuorine.
Materials and Methods: A successful four-step synthesis of a
new series of 4′-ﬂuoro analogues has been designed and applied to
the synthesis of an array of 10 analogues. Malaria parasites were
maintained in continuous culture using the method of Jensen and
Trager. Antimalarial activity was assessed with an adaption of the
48-h sensitivity assay of Desjardins et al.. using [3H]-hypoxanthine
incorporation as an assessment of parasite growth.
Results: The chemistry in the 4′ﬂuoro series provided the target
compounds in higher overall yields. Initial testing on both series of
analogues was carried out on a chloroquine sensitive (3D7) and resistant
strains TM6, K1, TM4, V1S and J164 at the Liverpool School of
Tropical. It is apparent that several analogues have potent antimalarial
activity against sensitive 3D7 strain of the parasite. The data indicates
that 6 h is superior to the pyrollidino analogue 6b against all of the
strains examined. It is also clear that N-tert butyl analogue 6b is potent
against chloroquine resistant strains, though it is not quite as active
as amodiaquine (AQ) against both chloroquine senstitive and resistant
parasites.
Conclusion: In summary, work conducted in this study has identiﬁed
several potent back-up compounds to the clinical candidate. It is
clear that the 4′ﬂuoro series has several members with potent activity
compared to amodiaquine. It has been shown that (6 h) has is slightly
less potent than amodiaquine, chloroquine and the clinical candidate
(4b). Further studies on the metabolism and pharmacokinetics of 6 h are
necessary.
O49 Antimicrobial resistance in Salmonella infections associated
with foreign travel
M. Al-Mashhadani, R. Hewson °, R. Vivancos, A. Keenan, N. Beeching,
J. Wain, C. Parry (Liverpool, Colindale, London, UK)
Objectives: Non-typhoidal Salmonella (NTS) causes gastroenteritis and
can lead to serious invasive illness and death. Many cases of NTS go
untreated as they cause a mild illness. In more serious cases treatment is
required and the ﬂuoroquinolones are often the drug of choice. Isolates
with decreased susceptibility to ciproﬂoxacin (DCS), which is usually
associated with resistance to nalidixic acid (NA), are on the increase. It
has been suggested that foreign travel is a risk factor for the acquisition
of Salmonella enterica isolates with NA resistance and DCS. This study
aims to investigate the link between foreign travel and NA resistant/DCS
isolates in Liverpool.
Methods: NTS strains from 2003 onwards were characterised for
resistance to NA and DCS. A database containing all Salmonella strains
detected by the Microbiology Service at a Liverpool Teaching Hospital
from 2003 was merged with statutory notiﬁcation of diseases data that
contains the travel history (validated through an enhanced questionnaire)
to investigate the link between NA resistance, DCS and foreign travel.
Results: 433 unique NTS strains were isolated. NA susceptibility DCS
information was available for 371 (85.6%) and 364 (84.1%) of cases
respectively. NA resistance was found in 82 (22.1%) and DCS in 84/364
(23.1%) of the isolates. Approximately one ﬁfth of cases of salmonellosis
had travelled abroad during the incubation period. Signiﬁcantly higher
levels of NA resistance (travel 38.4% vs no travel 18.1%; RR 2.12,
95%CI 1.45–3.09) and DCS (travel 37.5% vs no travel 19.5%; RR 1.92,
95%CI 1.32–2.81) were found in isolates associated with foreign travel.
Conclusions: Foreign travel is a signiﬁcant risk factor for the acquisition
of Salmonella isolates with NA resistance and DCS. Antibiotic resistance
can lead to delays in effective treatment and result in complications.
Public health authorities need to engage with the travel industry in order
to improve surveillance and prevention of travel related gastrointestinal
infections.
Therapy of multi-drug resistant
Gram-negatives
S57 Carbapenem-resistant Acinetobacter: a study of class D
b-lactamases
R.A. Bonomo ° (Cleveland, US)
Carbapenem resistant Acinetobacter represent a major threat to our
antibiotic armamentarium. In general, Class B and D b-lactamases
form the basis for this phenotype. Class D b-lactamases are serine
enzymes that are either monomers or dimers that possess unique
structural motifs. By utilizing a carbamylated Lysine, a distinctive
complex hydrogen-bonding network is created to ﬁx the b-lactam in the
substrate-binding pocket and assist in binding, acylation and deacylation.
As a result of substitutions accelerated by b-lactam use, many class D
enzymes emerged that possess functional and structural properties which
confer a selective advantage to the bacterium housing the carbapenem
hydrolyzing b-lactamase. Important carbapenemases in Acinetobacter
include: blaOXA-23, blaOXA-24/40, blaOXA-48, blaOXA-58, blaOXA-66. With
these notions in mind, our purpose will be to i) review the molecular
epidemiology and genetics of the major class D serine carbapenemases
that are present in Acinetobacter spp; ii) analyze how amino acid
changes have altered substrate speciﬁcity by using select examples;
and iii) highlight changes in the expression of efﬂux pumps and outer
membrane proteins in the ampliﬁcation of carbapenem resistance. The
crystal structures of important class D enzymes will be reviewed and
analyzed.
S58 Multidrug-resistant Pseudomonas aeruginosa
N. Petrosillo ° (Rome, IT)
In recent decades Pseudomonas aeruginosa has emerged as a major
threat as a result of the signiﬁcant mortality associated with pneumonia
and bacteraemia, and the evolving resistance exhibited by the pathogen
to numerous antibacterials.
Since a timely and appropriate therapy is needed for severe P aeruginosa
infections, clinicians should be aware of the risk factors associated with
this pathogen and with multidrug resistance. There is still debate if a
combination or a monotherapy should be instituted for Ps. aeruginosa
infections.
The use of combination therapies for Ps. aeruginosa pneumonia has
been a long-advocated practice, but the potential increased value of
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combination therapy over monotherapy remains controversial. However,
empirical combination therapy maximizes the chances of bacterial
coverage, especially in severe infections, and likely exerts a lower
resistance selection pressure.
Upon conﬁrmation of Ps. aeruginosa infection, treatment should
be given according to the site of infection, the pathophysiology
of the patient, the pharmacokinetic/pharmacodynamic proﬁle of the
antimicrobials, and the antimicrobial susceptibility pattern, including the
MIC values.
For strains that are resistant to all antimicrobials but colistin, this
antimicrobial is advocated as the choice option either in mono- or in
combination therapy. Indeed, since there are no novel antibiotics in
the drug development pipeline for multidrug-resistant Ps. aeruginosa,
old antibiotics, such as the polymyxins (ie, colistin, also known as
polymyxin E and polymyxin B), have re-emerged as the last resort
therapy. However, current clinical use of colistin is largely informed
by inadequate and, in some cases inaccurate, pharmacokinetic and
pharmacodynamic data.
Rifampin, sulbactam, carbapenems, fosfomycin are all possible options
for combination treatment, due to their in vitro synergistic effect.
Among carbapenems, doripenem seems to possess a lower potential
for resistance selection and a more favourable pharmacokinetic proﬁle.
Newer anti-pseudomonal antibacterials are expected to be available in the
near future. Among them, experimental polypeptides (i.e. the anti-PcrV
immunoglobulin G antibody) may provide a new therapeutic approach.
S59 ESBL-producing enterobacteria beyond carbapenems
J. Rodrı´guez-Ban˜o ° (Seville, ES)
Carbapenems are considered the drugs of choice for the treatment of
serious infections caused by ESBL-producing enterobacteria. However,
alternatives are needed because carbapenem-resistance due to carbapene-
mases and other mechanisms are increasing worldwide. For the treatment
of uncomplicated cystitis due to ESBL producers, observational
studies showed high cure rates with oral fosfomycin, nitrofurantoine,
and amoxicillin–clavulatane when a susceptible isolate was involved.
Mecillinam, which is stable against ESBLs, is also a potential option.
For patients with other types of infections including complicated urinary
tract infections, the options are more limited. Some isolates may show
low MIC to speciﬁc cephalosporins depending on the type of ESBL
produced; PK/PD data suggest that these infections can be treated with
these cephalosporins (particularly cefepime) using appropriate doses, but
this practice is not recommended for empirical therapy because the MIC
cannot be predicted. Adding an aminoglycoside to a standard regimen
is a reasonable option for selected patients at low risk of renal toxicity
in areas where prevalence of aminoglycoside resistance among ESBL-
producers is low. The efﬁcacy of combinations of cephalosporins with
b-lactamase inhibitors (as cefoperazone-sulbactam, or as the combination
of a cephalosporin and amoxicillin/clavulatane) and temocillin are to
be studied in different clinical settings. However, the worldwide spread
of the multi-drug resistant clones of E. coli and K. pneumoniae
further reduce the therapeutic options, for which only carbapenems,
tigecycline and colistin might be active. While older drugs, such
as fosfomycin (probably in combination), merit being investigated in
systemic infections, new drugs active against these organisms are clearly
needed. The increasing prevalence of ESBL producing Enterobacteria
in the community and hospital is not just a threat anymore but a real
everyday problem.
S60 Carbapenemase-producing enterobacteria
H. Giamarellou ° (Athens, GR)
Resistance to carbapenems due to the production of metallo-b-lactamases
(MBL) or KPC enzymes in Enterobacteriaceae is an increasing
international public health problem. An MDR or even an PDR phenotype
is associated with carbapenem resistance in Enterobacteriaceae, because
these strains usually harbor mechanisms of resistance to aminoglycosides
and quinolones, as well. Nevertheless, some of these strains often
exhibit low-level resistance to carbapenems with MICs remaining in
the susceptible range rendering the therapeutic role of carbapenems
questionable.
The armamentarium against PDR Gram-negative microorganisms has
almost been exhausted. The only options left are colistin, an antibiotic
introduced in the 1950s, and tigecycline, a modiﬁed minocycline.
Monotherapy or combination therapy with colistin is most often used
but recently, the emergence of colistin-resistant strains of Klebsiella
pneumoniae has limited our therapeutic options even further. There is
accumulated evidence on the in vivo activity of tigecycline against MDR
Enterobacteriaceae but the low levels of the drug achieved in blood
indicate the necessity of a higher dose in case of bacteraemia. Some of
the MBL or KPC producing Enterobacteriae are in vitro susceptible to
fosfomycin. Clinical experience in the setting of serious infections by
carbapenemase-producing bacteria is still limited. Finally, combination
regimens have very often been used empirically in clinical practice
although scientiﬁc evidence on the advantages of combinations is usually
scarce with the exception of carbapenem-susceptible K. pneumoniae,
for which clinical data suggest that the combination of meropenem
and gentamicin could be active in vivo, in the case of meropenem
MIC 2mg/ml.
The emergence of carbapenemase-producing Enterobacteriaceae high-
lights the “end of antibiotics”. Concentrated efforts are needed to
preserve and wisely use the few options available. In the meantime,
intensiﬁed infection control measures may protect our hospitalized
patients from these difﬁcult to treat pathogens.
New horizons in the diagnosis of bacterial
sepsis
S62 Biomarkers for the diagnosis of sepsis: do they provide added
value?
B. Mu¨ller ° (Aarau, CH)
The ambiguities of clinical signs and the limitations of current microbial
techniques for the diagnosis of bacterial infections − and to grade
their severity − are well known. The use of biomarkers provides a
novel, complementary approach to diagnose infection, and to estimate
treatment response and the outcome of patients. A plethora of proteins
has been speculated to be “promising markers” in observational studies
including c-reactive protein, various interleukins and chemokines and
procalctionin, amongh others. Unfortunately, in most infections including
sepsis, a true “gold standard” for diagnosis does not exist. Thus, the true
“added value” of a biomarker in clinical use can only be assessed in
interventions studies, where the endpoints are safety and antibiotic use.
In the hospital setting, this has only been shown for procalcitonin (PCT)
in multiple randomized controlled interenvetion studies from several
independent groups. With a similar outcome antibiotic exposure could be
reduced from by 50 to 75%. For prognostic assessment, other biomarkers
(e.g. adrenomedullin) have demonstrated high predictive potential to
estimate the risk for mortality in the short and long term, and other
adverse outcomes. A critical appraisal of the advantages and limitations
of biomarkers in different clinical situations is mandatory. We discuss the
current data on the use of PCT and other biomarkers for the diagnosis,
treatment guidance, and prognostic assessment of bacterial infections,
and their potential role in the overall assessment of patients with sepsis
and respiratory tract infection as its most important precursor.
S63 Rapid detection of pathogens in sepsis: molecular techniques
versus culture
C. Vandenbroucke-Grauls ° (Amsterdam, NL)
Molecular techniques are gaining more and more interest for rapid
diagnosis of severe bacterial infections. DNA-hybridisation probes and
PCR-based detection are used for rapid identiﬁcation of bacteria after
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the ﬁrst signal of growth in conventional blood cultures. PCR-assays can
also be used for direct detection of pathogens in blood. Such PCRs can
be aimed at speciﬁc pathogens, or be more broad-range, in which case
the PCR is followed by sequencing of the PCR product for identiﬁcation.
PCR can also be used for quantiﬁcation of the amount of bacterial DNA
in blood; several studies point to the value of the bacterial DNA load
(BDL) in blood as a marker of severity of infection. This has been
shown for pneumococci and meningococci in particular, and there is
anecdotal evidence that BDL also correlates with severity of infection
in staphylococcal infections. Interpretation of the results of PCR applied
directly on blood samples needs further study, however, because several
aspects of the kinetics of the presence of bacterial DNA in blood during
infection are still unknown. In particular, we must be aware that it is
difﬁcult to deﬁne the best gold standard for bacteraemia, that PCR
detects DNA, rather than living pathogens, that there is always a risk of
contamination, and that little is known yet about background bacterial
DNA in blood.
S64 Signiﬁcance of DNAemia in sepsis
K.P. Hunfeld ° (Frankfurt/M., DE)
Sepsis is associated with mortality rates ranging from 20% to 50%
and represents the second leading cause of death in the non-coronary
intensive care unit. Early diagnosis of sepsis followed by prompt
appropriate treatment improves the prognosis of septic patients. It has
been suggested that nucleic-acid-based technology such as PCR is more
sensitive and can also shorten the time to result when compared with
conventional blood culture techniques. To date, however, little is known
about the kinetics and the clinical and therapeutic relevance of bacterial
DNA present in the blood of patients with sepsis over time in the
course of an invasive blood stream infection. The recent introduction of
more standardized new PCR-based diagnostic assays including tests that
provide a more exact quantitative measurement of DNA, therefore, may
open a window of opportunity for a better understanding of the kinetics
and clinical signiﬁcance of microbial DNA circulating in the blood of
patients during a blood stream infection. In fact, the potential inﬂuence of
bacterial DNA on the severity and outcome of blood stream infections
is underlined by the ﬁndings of recent clinical and laboratory studies
suggesting that procalcitonin plasma levels and SOFA scores were
signiﬁcantly higher, length of ICU and hospital stay were longer, and
survival was clearly decreased in subgroups of septic patients revealing
positive ﬁndings in both PCR testing and blood culture. Whether a
better insight into the clinical signiﬁcance of DNAemia will indeed
contribute to more rapid initiation of better-tailored therapy and improved
management of septic patients in conjunction with other laboratory
markers, however, awaits further evaluation of in laboratory studies and
interventional clinical trials. The present lecture will summarise what is
known from recent studies on the diagnostic and clinical signiﬁcance of
DNAemia in patients with sepsis.
Diagnostic dilemmas − things that look like
infections but aren’t
S65 Non-infectious causes of fever in the critical-care unit
M. Skalweit ° (Cleveland, US)
“Fever” is a common symptom in critically ill patients and often sets
into play a series of investigations by health care providers to establish
an etiology. Recent practice guidelines for the evaluation of fever in
the ICU patient recognize that “knee-jerk” responses to this syndrome,
in the absence of careful clinical evaluation, lead to increased costs
and morbidity for patients. In addition, many diagnostic studies are
uninformative. Nevertheless, non-infectious causes of fever are often
diagnoses of exclusion; a balance between expensive and invasive
investigations, and “old fashioned” clinical acumen needs to be applied
to evaluate fever in the ICU. In this session, common non-infectious
etiologies of fever will be discussed with illustrative case examples, e.g.
gout, drug fever, vasculitis, etc. In addition the role of molecular tests
that are used to assist in determining the infectious etiologies of fever
(PCR methods and biomarkers such procalcitonin and 1,3-b-glucan) will
be reviewed.
S67 When are arthritis real infections?
M.A. Muniain ° (Seville, ES)
Joint diseases may present as acute, chronic and at the same time
as monarticular or polyarticular arthritis. Most of the aetiological
agents who have been identiﬁed in monarticular infections may also
cause polyarticular infections. Similarly, most of the polyarticular
non infectious arthritis may appear as monarticular. In many clinical
situations extra-articular manifestations may differentiate infectious from
non infectious arthritis.
The recent development of new technology for culture and molecular
biology has permitted to recognise virus or bacteria into the joints of
degenerative, inﬂammatory and of course, in infectious arthritis. Reactive
arthritis (ReA) is the conceptual ground somewhere between septic
arthritis and autoimmune diseases such as rheumatoid arthritis. The fact
that some arthritis (Whipple, SAPHO etc) now have been recognised as
infectious arthritis and may respond to antibiotic treatment, as prompted
to treat a number of patients with arthritis of “unknown aetiology” with
antimicrobials.
Form a practical point of view the answer to the question “When
are arthritis real infections?” may be “When we can treat and
cure the infection”. Three aetiologies are involved in most or
the patients with acute monarticular arthritis; mechanical, infections
and microcrystallines. Inﬂammatory arthritis may also present as
monarticular arthritis. But besides that, more than 20 different non
infectious diseases can produce acute arthritis (“pseudoseptic” arthritis”).
The tools for the diagnosis of arthritis are limited. As a matter of fact in
Rheumatology the “pattern” of the disease is particularly important; what
joints are involved, what is the sequence, the accompanying symptoms
or even the duration of the disease. There are no deﬁnitive laboratory
markers (except crystals and cultures in the synovial ﬂuid). Biochemical
and cytology values in synovial ﬂuid permit to classiﬁed arthritis as
mechanical, inﬂammatory or septic, but in a particular patient they have
only a marginal value. In critical reviews for cytology in the synovial,
ﬂuid the evidence is mainly anecdotal and there are no reports of
speciﬁty, sensitivity and reliability.
In this topic as in many other, medical history, epidemiological
investigation and clinical examination are the main stone for the
diagnosis. Detailed history and physical examinations may raise the
possibility of some initially unsuspected systemic or localized non
infectious disease.
S68 Autoimmunity and infection: a bidirectional relationship
R. Cervera ° (Barcelona, ES)
The hypothesis of an infectious origin for autoimmune diseases has
received great attention during the recent years. Microbial agents or
viruses can induce autoimmune diseases by a variety of mechanisms.
For example, proteins of certain infectious agents can act as polyclonal
activators on unique lymphocyte subsets. Viruses can preferentially
infect/destroy a particular T cell subset, leading to an imbalance in the
immune response. In other instances, infectious agents can up-regulate
Th1 cytokines, thereby increasing selected expression of molecules such
as major histocompatibility complex (MHC) glycoproteins, as well as
activation of costimulatory molecules. Several microbial agents have
been found to encode superantigens that can selectively activate subsets
of T cells. Microbes can also direct the release of cytokines and
chemokines, which can act as growth, differentiation, or chemotactic
factors for different Th populations and regulate expression of MHC
class I and class II molecules.
On the other hand, the healthy immune system is tolerant to the
molecules of which the body is composed of. However, one can ﬁnd
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that among the major antigens recognized during a wide variety of
bacterial viral and parasitic diseases, many belong to conserved protein
families, sharing extensive sequence identity or conformational ﬁts, with
host’s molecules, namely molecular mimicry. Antigenic similarity of
either molecules’ linear amino-acid sequences or their conformational
structure between antigens of infectious agents and host tissues might
trigger an immune response against the shared determinant. As a result,
the tolerance to autoantigens breaks down, and the pathogen-speciﬁc
immune response that is generated cross-react with host structures to
cause tissue damage and disease.
In this presentation, the cases of Sjo¨gren’s syndrome, systemic lupus
erythematosus and the antiphospholipid syndrome, among others, will be
reviewed as clear examples of autoimmune diseases where an infectious
origin is postulated.
Pneumococcal infection: insights into
pathogenesis and therapeutic potential
S69 The interface between innate and adaptive immune responses
D.H. Dockrell ° (Shefﬁeld, UK)
Nasopharyngal colonisation with pneumococci is frequent but in contrast
pneumococcal pneumonia and invasive pneumococcal disease are
comparatively infrequent events. This reﬂects the success of both innate
and adaptive host responses to pneumococci. The presence of a variety
of virulence factors including polysaccharide capsule and pneumolysin
challenges the host response. Epithelial cells sense microbial products
and release cytokines in response to pneumococci in the lower respiratory
tract. Soluble factors, including complement factors, activated through
both the classical and alternative pathway, play an important contribution
to host defence in the lung. Alveolar macrophages play a critical role as
the resident phagocytes in the lung clearing bacteria from the lung and
orchestrating the inﬂammatory response. Once resident defence becomes
compromised an inﬂammatory response including the recruitment of
neutrophils becomes essential to microbial control but comes at the
potential cost of compromising lung homeostasis. The regulation of
this process also requires macrophage competence to ensure a limited
inﬂammatory response which results in bacterial clearance but without
lung injury. During the evolution of pulmonary infection a number
of critical transition points occur when speciﬁc molecules and host
responses are critical in determining how the infection evolves and what
the outcome of infection will be. The infectious inoculum, the virulence
of the pathogen and host susceptibility determines the position of these
transitions and the relative role of key host defence strategies. There
is increasing recognition of the role of T-cells, B-cells and dendritic
cells in the pulmonary response to pneumococci. The integration of
these various host responses to pneumococci, in most cases, represents
a paradigm which provides a template for successful host responses to
pathogenic pulmonary bacteria.
S71 Bacterial evolution in the face of immunological pressure
C. Donati °, A. Muzzi, A. Covacci, R. Rappuoli, V. Masignani,
M. Barocchi (Siena, IT)
S. pneumoniae is part of the normal upper respiratory tract ﬂora but it
can become pathogenic causing a variety of diseases, which range from
otitis media and sinusitis to pneumonia, septicemia, and meningitis. Due
to its intimate relationship with the human host, S. pneumoniae has
evolved a series of strategies to vary its genetic repertoire to evade the
host immune response. Using their ability to recombine DNA acquired
from the environment, S. pneumoniae strains are able to renew their
dispensable genome (i.e. those regions of the genome that are not shared
by all isolates). Dispensable genes are frequently acquired and lost,
causing a loss of correlation between the phylogenetic history of strains
and the presence of genes encoding proteins with antigenic properties. As
a consequence these organisms have access to a genetic repertoire − the
pan-genome − that is larger than the genome of any component strain. At
the species level the pan-genome of S. pneumoniae grows as the number
of sequenced strains increases due to the inﬂux of genetic material
from closely related species, and the mode of this growth positions the
pneumococcal species on the edge between open and closed pan-genome.
A second strategy for antigenic variation is shown by the evolution of
pili, long ﬁlamentous appendages involved in adhesion to host cells.
Pili are encoded in the rlrA islet, a 12 kb genomic region, that consists
of the rlrA transcriptional regulator, rrgA, rrgB and rrgC, coding for
LPXTG proteins forming the structure of the pilus, and srtB, srtC and
srtD, coding for sortase enzymes catalyzing the pilus polymerization
reaction. Due to their exposure to the host immune response, rrgA and
rrgB are under positive selection that causes an increased rate of ﬁxation
of new alleles, and exist in three distinct clades that correlate with
the MLST designation of the strains. Instead the rrgC, srtB, srtC and
srtD genes, coding for proteins not directly exposed to the host immune
system, are not under positive selection. In the region containing these
genes, there is evidence of homologous recombination, and 4 major
recombination hotspots can be identiﬁed. Due to the homogenizing
effect of recombination these genes, differently from the major structural
components of the pilus, are well conserved at the sequence level. In
addition, piliated strains of Pneumococcus have been associated with
multi-drug resistance cassets that may provide S. pneumoniae added
ﬁtness.
S72 Pneumococcal vaccination
D. Bogaert ° (Utrecht, NL)
Streptococcus pneumoniae is worldwide a leading cause of morbidity
and mortality due to respiratory and invasive diseases. WHO estimates
that annually at least one million children under 5 years of age die
of infections caused by this pathogen. The more than 90 different
capsular serotypes make it difﬁcult to design a preventive strategy with
universal pneumococcal coverage. In 1983, a 23-valent polysaccharide
vaccine was marketed, being effective against invasive pneumococcal
bloodstream infections in adults. Unfortunately, this vaccine proved low
immunogenic in children due to it’s T-cell independent type of immune-
protection. In 2000, a new 7-valent conjugate vaccine (PCV7) was
licensed in the USA, protecting very well against invasive pneumococcal
diseases (IPD) caused by vaccine serotypes, also in infants and young
children. However, within the years following implementation of PCV7,
in addition to a serious drop in vaccine serotype diseases, a signiﬁcant
increase in IPD caused by non-vaccine serotypes was observed. The
impact of this so called ‘replacement’ disease on the total incidence of
IPD seems to vary by population and country. Recently, two extended
pneumococcal conjugate vaccines have been approved for use in children
and adults, covering most of the currently ‘emerging serotypes’.
In this presentation, the following topics will be addressed; What most
likely causes ‘replacement’ disease: vaccine pressure, ‘unmasking’ of
non-vaccine serotypes, secular trends or a combination of those? Do
we expect the new extended conjugate vaccines to solve the issue of
‘replacement’ disease? Do we expect in addition to shifts within IPD
causing serotypes also shifts in diseases caused by other respiratory
bacteria? What are potential new vaccine candidates, and what do we
expect of those vaccines with respect to impact on pneumococcal and
non-pneumococcal diseases?
Nosocomial infections in critical-care
patients
S73 Ventilator-associated tracheobronchitis
S. Nseir ° (Lille, FR)
Ventilator-associated tracheobronchitis (VAT) is an intermediate process
between colonization of lower respiratory tract and ventilator-associated
pneumonia (VAP). Postmortem studies showed a continuum between
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bronchitis and pneumonia in mechanically ventilated ICU patients. The
progression from colonization to VAT, and in some cases to VAP depends
on quantity and virulence of the bacterial pathogen, and host lung
defenses.
VAT is common in mechanically ventilated patients. Its incidence ranges
from 3−10% of ICU patients. Deﬁnition of VAT is matter of debate. Our
group deﬁned VAT using all the following criteria: fever (>38ºC) with no
other recognizable cause, purulent sputum production, positive culture
of respiratory specimen at signiﬁcant threshold, and no radiographic
signs of new pneumonia. Portable chest radiograph is inaccurate in
diagnosing new inﬁltrates in mechanically ventilated patients. Therefore,
differentiating VAT from VAP could be a difﬁcult task in ICU patients.
VAT is frequently caused by Gram-negative bacilli, especially Pseudo-
monas aeruginosa. Although several studies investigated risk factors for
VAP, few have evaluated risk factors for VAT. However, risk factors
for these infections appear to be similar. Age >60 years, COPD, prior
antimicrobial treatment and surgery were identiﬁed as risk factors for
VAT.
Tracheobronchitis is characterized by lower respiratory tract in-
ﬂammation and increased sputum production. These factors may
generate weaning difﬁculties, resulting in longer duration of mechanical
ventilation. In a large cohort of mechanically ventilated patients,
VAT was signiﬁcantly associated with longer duration of mechanical
ventilation and ICU stay.
Beneﬁcial effects of antimicrobial therapy were recently reported in VAT
patients. In a randomized blinded placebo-controlled trial, aerosolized
antibiotics signiﬁcantly reduced the incidence of subsequent VAP.
Further, aerosolized antibiotics increased weaning from mechanical
ventilation, reduced usage of systemic antibiotics and antibiotic
resistance. The impact of systemic antibiotics on outcomes of VAT
patients was evaluated in a randomized unblinded controlled study.
Antibiotic treatment increased mechanical ventilation free days, and
reduced the incidence of subsequent VAP and ICU-mortality. Future
studies should conﬁrm these promising results, and determine the best
duration of antimicrobial therapy in VAT patients.
S74 CMV and HSV in critical-care patients: pathogens or
bystanders?
C. Linssen ° (Maastricht, NL)
Cytomegalovirus (CMV) and human herpes simplex virus (HSV) belong
to the family of Herpesviridae. Both CMV and HSV are highly
prevalent and ubiquitously distributed. In the immunocompetent adult
host CMV and HSV infections usually have a benign course. As
is the case with other herpesviruses, the initial infection is followed
by a lifelong latent infection from which reactivation can occur. In
immunocompetent individuals, asymptomatic viral shedding may be
detectable in respiratory materials such as saliva or sputum in case
of both HSV and CMV and also in urine in case of CMV. This
viral shedding in patients without active viral disease makes it difﬁcult
to diagnose active disease in patients, especially since the symptoms
of CMV and HSV infection (excluding typical skin lesions) are
often non-speciﬁc. In immunocompromised patients CMV can lead to
severe disease varying from retinitis and pneumonitis to generalized
CMV disease. Occasionally, HSV may cause pneumonia as a result
of immunosuppression, with a high mortality. However, critically ill
patients admitted to the intensive care unit (ICU) are considered
immunocompetent. Studies performed in ICU patients have shown these
patients to be at risk for severe infections with CMV and HSV. In
case of CMV, results from previously conducted studies point towards
reactivation from latency as the most likely explanation rather than
primary infection in ICU patients. Recent studies suggest that active
CMV infection is quite common in ICU patients, with a prevalence up
to 35%, depending on the sub-group of patients studied. Furthermore,
an association between the presence of a CMV infection and increased
mortality in critically ill patients was found. In recent years, the interest
in HSV as a causative micro-organism in ICU patients has increased,
especially as a cause of pulmonary infection. Recent reports detected
HSV-1 in respiratory samples from ICU patients not considered to be
primarily immunocompromised. In all studies a signiﬁcant adverse effect
of HSV-1 shedding in the respiratory tract on clinical outcome was
established. Two studies showed an association between a high load of
HSV present in the respiratory tract and increased mortality. At this
moment it is not clear whether the association of both CMV and HSV
with increased mortality is due to the micro-organism itself or that it is
just an indication of the deteriorating physical condition of the patients
leading to reactivation of the virus.
S75 The concept of clinical sepsis − when all cultures are negative
in a “septic” patient
P. Eggimann ° (Lausanne, CH)
Despite all attempts to prevent them, nosocomial infection (NI) may
complicate the stay of up to one third of patients requiring ICU
management and the development of a sepsis of any severity should
be considered as a potential NI. Prompt initiation of broad-spectrum
antibiotics and source control are key factor for favorable outcome. A
majority of them are device-related and a systematic workshop should
be performed to identify them. Documentation of the source of infection
may then allow to more speciﬁc measures, such as abscess drainage or
catheter removal. Guidelines nowadays also include recommendations
for systematic periodical revaluation of the evolution in order to
adapt antibiotics and other therapeutic measures. In the absence of
positive cultures, combination of clinical evolution and some biological
parameters may contribute to safe de-escalation strategy.
Bacterial pathogenesis
O77 Role of biotic interactions in microbial adaptation
M. Miskinyte °, S. Magalhaes, I. Gordo (Oeiras, PT)
During millions of years “arms-race” shaped evolution not only between
the species across the planet but also inside the human body. Innate
immune system is constantly evolving different strategies to detect and
destroy intrusive microbes, while microbes evolving herewith. What are
the strategies that microbes can develop to avoid and circumvent immune
recognition?
We study the evolution of the model organism Escherichia coli under the
selective pressure of bacterial killing cells, the macrophages (cell line
RAW 264.7), which form an important component of the innate immune
system.
In approximately 100 generations all bacterial lines, evolved in the
presence of the macrophages, showed a remarkable polymorphism,
which did not occur in the controls. The relative abundance of the
new morphs ﬂuctuated stochastically over time, exhibiting a mixture of
local peaks and short periods of apparent stable frequency. The distinct
genotypes are marked by morphological differences clearly seen in the
E. coli forming colonies and in FACs measurements. Furthermore, the
ﬁrst observed morphs that persist better inside the macrophages because
of the slow growth rate and deﬁciency in metabolism have the same
characteristics as SCVs (small colony variants) sampled from patients
with various recurrent and persistent infections. Other morphs became
resistant to engulfment and possibly killing by phagocytes and showed
mucoid phenotype.
Investigating the long-term consequences of biotic interactions is
clearly an emerging ﬁeld of research because has implications on
applied biomedicine furthermore it will be able to generate predictions
concerning the nature of adaptations of microorganisms to multiple
infections and to the immune system.
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O78 Intracellular lifestyle of Streptococcus pyogenes in human
macrophages: survival strategies, replication, egress and
re-infection
E. Hertze´n °, L. Johansson, M. Mo¨rgelin, R. Wallin, A. Norrby-Teglund
(Stockholm, Lund, SE)
Objectives: Our recent studies using tissue biopsies from patients
suffering from sepsis, necrotising faciitis and toxic shock demonstrated
that S. pyogenes survive intracellularly in macrophages and contributes
to bacterial persistence during acute deep tissue infections. This study
aimed to elucidate the mechanisms by which S. pyogenes enters and
survives in macrophages during severe streptococcal infections.
Methods: Primary human monocyte-derived macrophages were infected
in kinetic experiments with a clinical M1T1 S. pyogenes isolate
expressing green ﬂuorescent protein (GFP), or an isogenic mutant
deﬁcient in M1 protein. Viability of bacteria was assessed by GFP-
expression and conﬁrmed by use of a bacterial viability staining kit or
viable counts. Uptake, intracellular trafﬁcking, and egress were analysed
using ﬂow cytometry, confocal and electron microscopy (EM). Re-
infection was assessed by co-culture with FarRed labelled cells.
Results: S. pyogenes are taken up by large pseudopod loops in an actin-
dependent manner, after which they reside within membrane surrounded
vesicles. In kinetic studies, transient co-localisation is seen with early
endosomal marker (EEA-1), whereas no association is noted with the
late endosomes/lysosomes (LAMP-1 and lysotracker stain). In contrast,
infection with the M1 mutant results in fusion with vesicles and signif-
icantly reduced bacterial counts intracellularly, as compared to the wild
type strain (p = 0.03). Moreover, EM-studies demonstrated that the bac-
teria replicate intracellularly, and that after 6−10 h the bacteria migrate
out of the cells. This is an active process as ﬁxed bacteria used in control
experiments remains intracellularly. Lactate dehydrogenase (LDH)-
release experiments indicate that the egress is associated with cell death.
Conclusions: The ﬁndings demonstrate that M1 protein is crucial for
intracellular survival of S. pyogenes in macrophages. Survival seems
to be associated with impaired fusion with the lysosomes. Subsequent
intracellular bacterial replication and egress of the bacteria is followed
by re-infection of surrounding cells. This is likely an important event
for dissemination and progression of severe streptococcal infections.
O79 Inhibition of the inﬂammasome is a component of
immunoparalysis in Gram-negative sepsis
E.J. Giamarellos-Bourboulis °, F.L. van de Veerdonk, M. Mouktaroudi,
M. Raftogiannis, A. Antonopoulou, M. Georgitsi, J. van der Meer,
M.G. Netea (Athens, GR; Nijmegen, NL)
Objective: Immunoparalysis in sepsis is characterized by impairment
of cytokine production by monocytes. Interleukin (IL)-1b to be
produced requires cleavage of its pro-form that is mediated through the
inﬂammasome. The function of inﬂammasome in sepsis was assessed.
Methods: Peripheral blood mononuclear cells (PBMCs) were isolated
from 34 healthy volunteers and from 92 patients with sepsis (49
uncomplicated sepsis; 26 severe sepsis; and 16 with septic shock deﬁned
by ACCP/SCCM 1992 criteria) caused by Gram-negative bacteria.
PBMCs were stimulated with a variety of stimuli in the absence and
presence of caspase-1 inhibitor and of crystals of monosodium urate
(MSU) that is an agonist of NALP3 inﬂammasome. IL-1b was estimated
by an enzyme immunoassay. Gene transcripts of IL-1b were estimated
by RT-PCR.
Results: Release of IL-1b from PBMCs of septic patients was
signiﬁcantly reduced after stimulation with LPS and heat-inactivated
isolates (Figure 1a, asterisks denote signiﬁcant differences with controls).
Gene transcripts of IL-1b were lower compared with healthy controls
but this difference was not signiﬁcant. Effect of caspase-1 inhibitor
on release of IL-1b is shown in Figure 1b (asterisk denotes signiﬁcant
differences in the absence of inhibitor). Stimulation with MSU yielded
signiﬁcant releases of IL-1b from PBMCs of healthy controls but not of
patients with sepsis (Figure 1c). LPS and MSU acted in synergy for the
production of IL-1b by PBMCs of healthy volunteers but not of patients
with sepsis (Figure 1d; asterisk denotes signiﬁcant difference by the LPS
and MSU compared with single LPS).
Conclusions: Inhibition of the inﬂammasome is a considerable
component of the phenomenon of immunoparalysis presented among
patients with Gram-negative sepsis.
Figure 1.
O80 Fluoroquinolone-resistant Salmonella Typhimurium has
decreased intracellular survival in macrophages
A. Dehn Lunn °, A. Fa`brega, J. Vila, R. Read (Shefﬁeld, UK;
Barcelona, ES)
Objectives: Previous studies have suggested that ﬂuoroquinolone
resistance may be associated with attenuated virulence, and this may be
the reason for the low levels of ﬂuoroquinolone resistance compared with
nalidixic acid resistance in Salmonella clinical isolates. We compared
the intracellular survival of wild-type (ciproﬂoxacin MIC: 0.012 ug
ml-1), ﬂuoroquinolone-resistant (ciproﬂoxacin MIC: 64 ug ml-1) and
reverted (ciproﬂoxacin MIC: 1.5 ug ml-1) S. Typhimurium in murine
macrophages.
Methods: The ﬂuoroquinolone-resistant S. Typhimurium was obtained
in vitro by serial passage of the wild-type strain in increasing
concentrations of ciproﬂoxacin, whereas the reverted strain was obtained
from passage of the ﬂuoroquinolone-resistant strain on antibiotic-free
media. J774.2 macrophages were seeded at 2×105 cells per well and left
to adhere for 24 hours. Control wells were ﬁxed with paraformaldehyde.
Prior to infection, wells were blocked with BSA for 30 minutes.
Bacterial cultures were grown to log phase and then diluted to infect
the macrophages with an MOI of 100. A gentamicin protection assay
was performed, with viable counts performed at 0, 1, 4 and 24 hours.
Results: Fluoroquinolone-resistant S. Typhimurium showed signiﬁcantly
decreased overall survival in comparison to wild-type (median area
under the curve (AUC) of 1.49×106 versus 1.43×105, statistically
signiﬁcant at the 1% level). In most experiments, there was a log
difference in bacterial concentration (cfu ml-1) between the wild-type
and resistant strains at all timepoints. There was not a signiﬁcant
difference between the wild-type and reverted strains or between the
reverted and ﬂuoroquinolone-resistant strains. To determine whether
there was a difference in intracellular replication, data were analysed as a
percentage of the bacterial concentration at t = 0 (that is, 90 minutes after
infection). There was not a statistically signiﬁcant difference between
groups (p = 0.96).
Conclusions: Fluoroquinolone-resistant S. Typhimurium showed de-
creased survival in murine macrophages. Further work is needed to
identify the genes responsible for this change, since the mutants were
not isogenic.
S18 20th ECCMID, Oral presentations
O81 Binding and activation of plasminogen on Fusobacterium
necrophorum
P. Kuusela °, N. Friberg, H. Jarva, P. Mattila, R. Soliymani,
M. Baumann (Helsinki, FI)
Objective: Many bacteria have plasminogen (Plg) receptors (PlgR) on
their surface. Binding to PlgRs enhances activation of the bound Plg
to active enzyme plasmin and leads to protection of surface-associated
plasmin against physiological plasmin inhibitors. Surface-associated
plasmin is thought to play a pathogenetic role in various infections. In
this work we have studied Plg binding and activation on Fusobacterium
necrophorum (Fnec), an important Gram-negative rod-shaped anaerobe
causing Lemierre’s syndrome characterized by sepsis and internal jugular
vein thrombosis preceded by an oropharyngeal infection.
Methods: Plg binding was monitored by incubating bacteria isolated
from clinical samples with I125 Plg alone or in various combinations
with lysine analog epsilon-amino-caproic acid (EACA), tissue-type
plasminogen activator (tPA) and alfa2-antiplasmin (alfa2AP), the
physiological plasmin inhibitor, followed by counting of the bound
radioactivity or by analyzing the bound Plg with SDS-PAGE and
autoradiography. Plg activation was recorded by following the breakdown
of the chromogenic substrate S-2251 in various reagent combinations.
Tentative fusobacterial PlgRs were identiﬁed by means of ligand blotting
of bacterial outer membrane proteins with Plg and by subsequent
MALDI-Tof analysis.
Results: Fnec (n = 11) bound signiﬁcantly better iodinated Plg than
F. nucleatum (n = 14). Binding was inhibited by EACA and lead to
enhanced activation by tPA. Formed plasmin was protected against
inhibition by alfa2AP. Additionally, SDS-PAGE analysis of the bound
plasmin revealed trimming of the formed Glu-plasmin to a slightly
shorter Lys-form of the enzyme. Ligand blotting/MALDI-Tof analyses
revealed that acyl-CoA dehydrogenase was a predominant Plg binder
among the fusobacterial outer membrane proteins.
Conclusions: The present results show that Fnec has a much stronger
capacity to bind Plg than F. nucleatum. Inhibition of binding by EACA
indicates that lysine binding sites in the N-terminal portion of Plg are
involved in the binding. Inability of alfa2AP to inhibit formed plasmin
activity emphasizes the receptor association of plasmin. Trimming of the
surface-associated Glu-plasmin into the Lys-form speaks for an increased
afﬁnity between plasmin and PlgRs. Acyl-CoA dehydrogenase is a strong
tentative PlgR on Fnec. The data indicate that formation of surface
associated plasmin on Fnec may play an important role in tissue invasion
and in escape from thrombi.
O82 Characterization of the Klebsiella oxytoca cytotoxin
G. Schneditz °, M.M. Joainig, C. Ho¨genauer, E.L. Zechner (Graz, AT)
Objectives: Klebsiella oxytoca has been shown to be the causative agent
for Antibiotic Associated Hemorrhagic colitis (AAHC). The disease
occurs during medical treatment with penicillin and results in a sudden
onset of bloody diarrhoea and abdominal cramps. Pathological features
are mucosal haemorrhage and mucosal oedema that affect the ascending
colon and cecum. The histological features of the AAHC resemble toxin-
induced colitis and a cytotoxic substance is found in conditioned (cell-
free) medium of bacterial cultures.
We aim to identify genes involved in cytotoxin production and
secretion. The identiﬁcation of cytotoxicity related genes will allow the
biochemical description of the toxin and should provide insights into the
effects on the host cells.
Methods: A human epithelial Hep2 cell line is used to measure
cytotoxicity of the Klebsiella product qualitatively and quantitatively via
the MTT viability assay. A random miniTn5 transposon mutagenesis
created a library of randomly inserted knock out mutants in an AAHC
patient isolate of K. oxytoca. The mutant library was screened for
loss of cytotoxicity. The transposon insertion sites of toxin negative
mutants were identiﬁed through isolation of adjacent chromosomal DNA
via a plasposon rescue protocol followed by DNA sequencing. Finally,
speciﬁc deletion mutants of the identiﬁed genes were generated and
complementation of the cytotoxin negative phenotype was performed.
Structure and regulation of cytotoxin production genes and the
cytotoxin’s chemical nature are under investigation. Cytotoxin positive
and -negative K. oxytoca strains will be screened furthermore for
distribution of those genes.
Results: So far screening the mutant library revealed two toxin negative
mutants. The insertion sites cluster in the same region, indicating an
operon. Three functionally related putative genes could be identiﬁed: a
non-ribosomal peptide synthase, a DAHP synthase and a Xaa proline
amino peptidase. The genes are involved in the non-ribosomal peptide
biosynthesis and are not conserved in other Klebsiella species.
Conclusion: The clustering of mutations leading to a cytotoxin negative
phenotype suggests that the non-ribosomal biosynthesis pathway is
essential for cytotoxin production. The substance family known to be
synthesized through that pathway in other organisms includes numerous
fungal and bacterial effector substances, including antibiotics, cytostatics
and siderophores.
O83 Infrequent deletion of the chromosomal genes speB and speF
in GAS clinical isolates
A. Friaes °, C. Silva-Costa, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objectives: The chromosomal genes speB and speF do not encode true
exotoxins (SpeB is a cysteine protease and SpeF a mitogenic factor),
but are commonly included in the exotoxin gene proﬁling of Group A
Streptococci (GAS) and have both been implicated in virulence. The
aim of the present work was to conﬁrm the presence of these genes
in all GAS isolates and to characterise in detail any putative genomic
deletions.
Methods: The genes speA, speB, speC, speF, speH, and ssa were PCR-
screened in a total of 724 GAS isolates (160 from invasive infections
and 564 from pharyngitis). PCR-negative results for speB and speF were
conﬁrmed by Southern blot hybridization with probes speciﬁc for each
gene. Long-range PCR with primers speciﬁc for the regions ﬂanking
the putative deletions was performed, and the exact deletion breakpoints
were determined by sequencing.
Results: The absence of speB was detected in four isolates, one of
which was also the only isolate negative for speF. The latter was
an emm28/ST52 strain isolated from blood. Sequencing conﬁrmed a
deletion of 4933 bp by comparison with the published genome sequence
of the emm28 strain MGAS6180, between nucleotides 2463 and 7395
(GenBank NC007296). The other speB-negative isolates belonged to
emm types 4, 11, and 13, and were all isolated from pharyngitis cases.
Conclusion: The presence of the speB and speF genes is a characteristic
of GAS recovered from human infections. Still, four isolates (0.6%)
were speB-negative and one (0.1%) was speF-negative. The speB− speF−
isolate was apparently highly virulent, in spite of the 4933 bp
deletion encompassing several genes encoding proteins recognized to be
important for virulence, such as SpeB, SpeF, the transcriptional regulator
Rgg, the glycerol dehydrogenase, as well as four ORFs of unidentiﬁed
function.
O84 Lipocalin 2 is detrimental during murine pneumococcal
pneumonia
J. Warszawska °, O. Sharif, B. Doninger, I. Mesteri, K. Stich, S. Knapp
(Vienna, AT)
Objectives: Lipocalin 2 (Lcn2) is an antibacterial protein, known to
interfere with bacterial siderophore-dependent iron acquisition. Thus,
Lcn2−/− mice are highly susceptible to infections with siderophore-
dependent pathogens such as E. coli and mycobacteria. Although no
siderophores have been detected in Streptococcus pneumoniae, infection
with this bacterium induces tremendously elevated levels of Lcn2 − and
the biological role of this ﬁnding remains elusive. We therefore attempted
to investigate the role of Lcn2 during pneumococcal pneumonia.
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Methods: Age- and sex-matched C57BL/6 and Lcn2−/− mice were
inoculated intranasally with Streptococcus pneumoniae and sacriﬁced
6 or 48 hours after infection or monitored for survival. Lungs were
homogenized and plated on agar plates for bacterial counts and cytokine
detection or embedded in parafﬁn for histological analysis.
Results: We observed signiﬁcantly more KC and IL-6 in the
bronchoalveolar lavage of Lcn2−/− mice 6 hours after infection. This
resulted in signiﬁcantly increased neutrophil inﬂux after 6 hours leading
to improved bacterial clearance after 48 hours. Consistent with this
observation we found decreased cytokine levels and reduced lung
inﬂammation in Lcn2−/− mice at later time-points after infection. Finally,
Lcn2KO mice displayed a signiﬁcant survival advantage over wild type
animals.
Conclusion: Lcn2 is detrimental during murine pneumococcal pneu-
monia. We postulate that Lipocalin 2 prevents the early induction of
inﬂammation upon S. pneumoniae infection and thus impairs clearance
of bacteria and survival.
O85 Apoptosis of neurogenic cells in an in vitro model of bacterial
meningitis
S. Hofer, D. Grandgirard, T. Trachsel, S.L. Leib ° (Berne, CH)
Background: Bacterial meningitis (BM) leads to learning deﬁcits in up
to 50% of survivors. The histomorphologic correlates of the deﬁcits
include apoptosis of neurogenic cells in the hippocampus, a brain
structure involved in learning.
Objective: To use an in vitro system of hippocampal neuronal
differentiation to (i) identify triggers and molecular mechanism of
apoptosis and, (ii) to investigate whether the differentiation stage during
neurogenesis determines the vulnerability for apoptosis.
Methods: Stem- and neuronal progenitor-cells were isolated from
postnatal (P4−6) rat hippocampus. Dissociated cells were driven into
neuronal differentiation by the addition of BDNF for 21d. Cells were
challenged with different stimuli characteristic for BM: Growth factor
deprivation (GFD) by omission of BDNF, EGF and FGF for 24 h,
application of TNF-a (20ng/ml) for 24 h and exposure to live bacteria
(Streptococcus pneumoniae), together with penicillin and streptomycin
(10ng/ml) to cause bacteriolysis, for 2 h. Differentiation stage was
documented by immunoassaying for nestin (stem cells), doublecortin
(immature neurons) and MAP2 (neurons). Neuronal differentiation
in vitro was documented by a shift in the predominant staining pattern
from nestin at 1d, doublecortin at 7−14d and MAP2 at 21d (Figure 1A).
Caspase dependent and independent apoptosis was immunoassayed by
active caspase-3 and annexin-V, respectively.
Figure 1.
Results: Caspase-3 dependent apoptosis was observed after GFD
(27±7% of cells) and TNF-a (29±3%) but less after bacteria (5±3%)
in mixed cell population at 7d. In contrast, apoptosis identiﬁed by
annexin-V staining was induced by bacteria (25±6%) and to a lesser
extent by GFD (16±7%) and TNF-a (17±3%). Vulnerability to
apoptosis peaked at 7d when stem cells and immature neurons were
speciﬁcally susceptible for caspase-3 dependent apoptosis induced by
GFD 10±11% and 17±12% and by TNF-a 13±17% and 28±12%
respectively (Figure 1B).
Conclusions: In a novel in vitro system of hippocampal neuronal
differentiation, GFD and TNF-a induced caspase dependent apoptosis
while bacteria induced caspase independent apoptosis. Stem cells and
immature neurons are speciﬁcally vulnerable to undergo apoptosis in
paradigms of BM. These results suggest that hippocampal injury in BM
includes apoptosis of stem cells. The compromised regenerative potential
of the hippocampus may contribute to the persistence of neurological
deﬁcits after BM.
O86 Streptococcus suis, an emerging zoonotic agent of meningitis,
triggers different inﬂammatory signalling pathways by
murine microglia
M.C. Dominguez Punaro °, M. Segura, I. Contreras, N. Fittipaldi,
M.P. Lecours, M. Olivier, M. Gottschalk on behalf of the Centre
de Recherche en Infectiologie Porcine (CRIP) and the Groupe de
Recherche sur les Maladies Infectieuses du Porc (GREMIP)
Objective: Streptococcus suis type 2 is an important swine and human
pathogen responsible for septicaemia and meningitis. We demonstrated
that in the brain of infected mice with S. suis, microglia expressed
increased levels of different pro-inﬂammatory genes. To expand our
knowledge of the interactions between S. suis and microglia, we
evaluated the signalling pathways underlying S. suis-induced pro-
inﬂammatory events.
Methods: Mouse microglia line BV-2 was infected with a virulent
wild type (WT) strain of S. suis or a panel of mutants altered at the
capsule (CPS-mutant) or cell wall levels. Phagocytosis was quantiﬁed by
an antibiotic protection assay. Cell supernatants were used to measure
pro-inﬂammatory cytokines by ELISA and nitric oxide (NO) by the
Griess reaction. Analysis from cell lysates, to evaluate inﬂammation-
associated intracellular signalization pathways, was carried out by
western blot using speciﬁc antibodies against iNOS, p-PKC, p-Tyr and
mitogen-activated proteine kinase (MAPK) members p-JNK, p-ERK
1/2 and p-p38. Speciﬁc inhibitors of MAPK were used to conﬁrm
their participation in cytokine production. The involvement of the
inﬂammatory transcription factor NF-kB was monitored by EMSA.
Results: Phagocytosis and cytokine studies showed that the CPS was
the only relevant virulence factor modulating bacterial interactions with
microglia. The CPS helped bacteria to resist phagocytosis and regulate
the inﬂammatory response as it hides pro-inﬂammatory components
from the bacterial cell wall. S. suis induced iNOS expression and further
NO production from microglia. Cells infected with the CPS-mutant
showed stronger phosphorylation proﬁles for PKC, Tyr and MAPK.
Likewise, pharmacologic inhibition of MAPK abrogated TNF-a and
MCP-1 production from infected cells. Finally, S. suis-induced NF-
kB translocation was faster for cells stimulated with the CPS-mutant,
suggesting that bacterial cell wall components are potent inducers of
NF-kB.
Conclusions: Our data help to better understand the mechanisms
underlying S. suis induction of inﬂammation in the brain, that in time
would be useful to design more efﬁcient anti-inﬂammatory strategies for
meningitis.
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O87 Antimicrobial stewardship programs in Spanish hospitals: a
nationwide survey
J.R. Pan˜o-Pardo °, M.P. Romero-Go´mez, J.M. Ortega-Go´mez,
A. Martı´n Quiro´s, M. Mora, A. Rico, J.P. Horcajada, B. Padilla,
J. Rodrı´guez-Ban˜o on behalf of GEIH (Spanish Study Group on
Hospital Acquired Infections), GEMARA, and GEIPC from SEIMC
(Spanish Society of Infectious Diseases and Clinical Microbiology)
Objectives: 1) To describe the number, distribution and main features of
antimicrobial stewardship programs (ASP) in Spanish hospitals. 2) To
describe the Spanish Infectious Diseases (ID) community perceptions
about antimicrobial (ABX) stewardship.
Methods: An online survey was designed. The link was distributed
through the e-mailing lists of several working groups of the Spanish
Clinical Microbiology and Infectious Diseases Society (SEIMC). The
survey was anonymously submitted.
Results: Between Sept 15 2009 and Nov 15 2009, 110 surveys
representing 76 hospitals were received from all over the country. 84
surveys were completely fulﬁlled (76%). Distribution of the replies
per hospital size is described in table 1. Most of the respondents
were either ID physicians (30%) or microbiologists (29%). 35/76
hospitals (41%) had an ongoing ASP. These programs were not
homogenously distributed along the country but concentrated in 4 of
the 17 Spanish Autonomous Communities, especially in Catalonia.
19/30 (63%) of the ASP were not limited to a speciﬁc clinical area
of the hospital and could be considered “hospitalwide” programs.
Most of these ASP (70%) have been working for more than 5
years. The most frequent principles of ABX stewardship implemented
in these programs were: 1) ABX streamlining or de-escalation and
2) intravenous to P.O. switch, both present in 23/30 of the surveys
followed by 3) monitoring of “strategic” ABX (22/30). 26/30 (86%)
of respondents stated that any physician could initially prescribe all
of the antimicrobials included in the formulary. The most frequently
activity carried out in the setting of Spanish ASP was 1) ABX restriction
80% followed by 2) conferences (74%) and 3) therapeutic audit and
feed-back TAFB (68%). Asked for the antimicrobials that should
be closely monitored, carbapenems (26/39), linezolid (11/30) and
ﬂuoroquinolones (11/30). A majority of respondents (72%) was highly
pleased with this task. The most efﬁcacious activity in the setting were
thought to be the TAFB (68% considered them highly efﬁcacious) and
automatic reminders of antimicrobial duration of therapy.
Conclusions: A minority (41%) of the surveyed hospitals in Spain has
an ongoing ASP and large geographical variations were observed. Few
of the ASP (30%) have been implemented in the last 5 years. TAFB
was perceived as the most useful intervention in the setting of ASP.
Carbapenems, linezolid and ﬂuoriquinolones were considered the ABX
most suitable to be monitored.
1000 beds 500–999 beds <500 beds
Responses (%) 23 (20.9%) 35 (31.81%) 52 (47.27%)
Hospitals 11 (14.4%) 28 (36.8%) 37 (48.68%)
O88 Antimicrobial stewardship improves appropriateness of
antimicrobial therapy prescription in a neurosurgical unit
L. Pagani °, N. Vernaz, R. Aschbacher, M. Falciani, P. Mian,
A. Schwarz (Bolzano, IT; Geneva, CH)
Objectives: To assess the impact of an Antimicrobial Stewardship
Program (ASP) on antimicrobial usage and consumption, and patients’
outcome in the neurosurgical setting of an Italian 850-bed tertiary
hospital.
Methods: Between January 2007 and December 2008, a multidisci-
plinary Antimicrobial Management Team (AMT) provided a two-phase
intervention in our 21-bed Division of Neurosurgery (NSU). In the ob-
servational period (2007), clinical, microbiological and pharmaceutical
data of the year were collected, and reviewed with the ward medical
staff thereafter. In the interventional period (2008), the AMT provided
antimicrobial recommendation prescription on a regular and on-call
basis, together with formulary restrictions and encouraged appropriate
prophylaxis or targeted therapy whenever indicated. Recommendations
were driven by updated speciﬁc pathogen resistance patterns and clinical
pharmacology parameters; pharmaceutical data analysis was performed
through the ESGAP ABC 3.1 program.
Results: The total number of admissions was 797 (bed-occupancy
index = 0.87) in 2007 and 761 (bed-occupancy index = 0.82) in 2008,
accounting for 6668.55 and 6302.52 bed-days, respectively. Among
antimicrobial drugs commonly used for prophylaxis, the deﬁned daily
doses/100 bed-days (DDD) decreased from 558.33 to 406 for cefazolin,
and from 363.66 to 239 for amoxicillin/clavulanate between 2007 and
2008. Among therapeutically used antimicrobials, vancomycin decreased
from 205.5 to 37, meropenem from 360 to 249.5, levoﬂoxacin from 804
to 564, and linezolid from 275.5 to 199, whereas ertapenem slightly
increased (from 17 to 30) because of few invasive infections caused
by ESBL-producing Enterobacteriaceae. However, mean length of stay
decreased from 9.29 days to 8.90 between the two years, and no patients
died in NSU due to infection-related causes during 2008. The grand
total of antimicrobial expenditures also decreased from Euros 88,787.94
to 60,584.34.
Conclusion: The interventional policy by an AMT, based on the
development of agreed upon prophylactic and therapeutic antimicrobial
regimens, regular educational activities and microbiological and pharma-
ceutical monitoring signiﬁcantly improved not only the appropriateness
of antimicrobial prescription in this high-risk setting, but also the
economical costs of antimicrobial acquisition.
O89 Efﬁcacy and efﬁciency of a restrictive antibiotic policy on
MRSA in the intensive care unit
N. Vernaz °, R. Aschbacher, B. Moser, S. Harbarth, P. Mian,
P. Bonnabry, L. Pagani (Geneva, CH; Bolzano, IT)
Objectives: To determine the efﬁcacy and the efﬁciency of a restrictive
antibiotic policy on the incidence of methicillin-resistant Staphylococcus
aureus (MRSA) in the 18-bed general Intensive Care Unit (ICU) of an
850-bed tertiary care hospital in Italy.
Methods: Based on updated microbiological reports and clinical
pharmacology parameters, the dedicated Antimicrobial Management
Team pursued a more appropriate approach to antimicrobial prophylaxis
and empirical therapy in ICU, either withdrawing ampicillin/sulbactam
(AS) prophylaxis, or targeting vancomycin (VAN) therapy whenever
indicated. Using an intervention time-series analysis, we ﬁrst evaluated
the efﬁcacy of AS and VAN restrictions on their consumption, then
combined this model with a transfer function model on use of other
antibiotics and ﬁnally assessed the efﬁciency on the incidence of clinical
isolates of MRSA from April 2004 to December 2007. The WHO
ATC/DDD classiﬁcation was used as reference normalized per 100
patient-days (PD).
Results: The intervention model demonstrated that the restrictive
antibiotic policy yielded a statistical signiﬁcant decrease of AS from 303
to 134 DDD/100 PD, and R2 was 64% in November 2003; six months
later, VAN decreased from 36 to 11 DDD/100 PD (R2 of 46%). Five
months after AS restriction, the MRSA incidence signiﬁcantly decreased
from 3.4 to 1.4 cases. The ﬁnal model explained 42% of the incidence of
MRSA over time, showing, conversely, that an increase of 1 DDD/100
PD of antibiotics increased the incidence of MRSA isolates from current
level, i.e. 0.043 for ceftriaxone (signiﬁcant impact at lag 2 and 3), and
0.012 for levoﬂoxacin, at the same time.
Conclusion: This study shows that modelling antibiotic use can either
drive a more appropriate empirical and targeted antimicrobial therapy, or
inform policy makers about negative adverse effects of certain antibiotic
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agents on selection of MRSA, and may ultimately control and prevent
the misuse of antimicrobials. Restriction of several broad-spectrum
antimicrobials might positively impact on MRSA, even if case-mix and
the huge inhomogeneity of patients in general ICU may negatively affect
the overall ﬁtness of the model.
O90 Modelling the impact of antibiotic use on antibiotic-resistant
Escherichia coli using population-based data from a large
hospital and its surrounding community
N. Vernaz °, B. Huttner, D. Muscionico, J. Salomon, P. Bonnabry,
J. Lo´pez-Lozano, J. Schrenzel, S. Harbarth (Geneva, CH; Alicante, ES)
Objectives: We determined the temporal relationship between antibiotic
use and the incidence of antibiotic-resistant Escherichia coli both in the
inpatient and outpatient setting of the Swiss canton of Geneva.
Methods: An observational time-series analysis was performed to
evaluate the incidence of non-duplicate clinical isolates of E. coli
resistant to ciproﬂoxacin, trimethoprim/sulfamethoxazole and cefepime
from January 2000 through December 2007. The resistance data were
combined with a transfer function model of aggregated data on antibiotic
use in both settings obtained from the hospital’s pharmacy and outpatient
billing ofﬁces.
Results: Ciproﬂoxacin resistance increased from 6% (2000) to 15.4%
(2007; P< 0.0001) and cefepime resistance from 0.9% to 3.2%
(P = 0.01). Trimethoprim/sulfamethoxazole resistance showed no trend
(23.7%-25.8%). Total antibiotic use increased in both settings, while
ﬂuoroquinolone use increased signiﬁcantly only among outpatients.
A temporal effect between resistance in community isolates and
outpatient use of ciproﬂoxacin (immediate and time lag, 1 month) and
moxiﬂoxacine (time lag 4 months) was observed, explaining 52% of the
variance over time. The incidence of cefepime resistance in E. coli, as
surrogate marker for ESBL, was correlated to ciproﬂoxacin use in the
inpatient (lag 1 month) and outpatient (lag 4 months) settings and to
the use of ceftriaxone (lag 0 months), piperacillin / tazobactam (lag 3
months) and cefepime (3 months) in the hospital (R2, 51%).
Conclusions: These results support efforts to reduce prescriptions
of selected antimicrobial drug classes such as ﬂuoroquinolones for
reduction of resistant E. coli including ESBL and show the added
value of time series analysis to better understand the interaction between
community and hospital antibiotic prescribing.
Table. Multivariate transfer function model of ﬂuoroquinolones use in the
inpatient and outpatient setting and temporal relation with the incidence
of non-duplicate clinical isolates of E. coli-resistance per 100 patient-
days to ciproﬂoxacin. University of Geneva Hospitals, January 2000 to
December 2007.










































Constant −3.54 (0.24) −14.76 0.0000 −3.34 (0.01) −42.86 0.0000
Ciproﬂoxacin, outpatient use 0 1.31 (0.49) 2.68 0.0089
1 1.01 (0.49) 2.08 0.0406 1 0.82 (0.30) 2.76 0.0069
Moxiﬂoxacin, outpatient use 4 0.44 (0.16) 2.72 0.0081
Autoregressive termc 1 0.31 (0.11) 2.89 0.0050 1 0.24 (0.10) 2.43 0.0170
Moving average termd 8 0.36 (0.11) 3.24 0.0017
CIP-R-CA: Community acquired ciproﬂoxacin resistant E. coli isolates, CIP-R-HA: hospital acquired ciproﬂoxacin
resistant E. coli isolates.
aDelay (months) necessary to observe the effect. bSize and direction of the effect. cThe autoregressive term
represents the past value of the resistance. dThe moving average term represents disturbances or abrupt changes of
resistance.
O91 Reduction in ciproﬂoxacin use in a university hospital
correlates with increased susceptibility to both quinolone and
b-lactam antibiotics in Gram-negative organisms
J. Troughton °, G. Millar, E. Smyth, R. McMullan (Belfast, UK)
Objectives: An antibiotic policy revision was implemented at our
institution, a university hospital in Belfast, in July 2008. Its purpose was
to substitute ceftriaxone and ciproﬂoxacin, with B-lactam antibiotics.
The aim of this study was to investigate whether, following the policy
change, there was a:
• change in usage of piperacillin–tazobactam (pip–tazo), aztreonam,
ceftriaxone, ciproﬂoxacin and meropenem, based on deﬁned daily
doses (DDD) prescribed;
• shift in the proportion of Gram-negative organisms susceptible to these
antibiotics;
• signiﬁcant relationship between susceptibility and usage of these
antibiotics.
Methods: The ﬁrst isolate of all Gram-negative organisms recovered
from blood cultures, sputum and urine of hospitalised adults, between
January 2008 and August 2009, were included. The proportion of isolates
reported susceptible, before and after the policy change, were compared
by c2 test; DDD before and after were compared using independent
t-test. The association between DDD prescription and susceptibility was
tested using Pearson correlation and linear regression.
Results: Ciproﬂoxacin use decreased (p< 0.001) and aztreonam use
increased (p = 0.03) following policy revision. There was no change
in meropenem, ceftriaxone or pip–tazo use. In all, 5445 isolates
were evaluated; the proportion susceptible to ciproﬂoxacin (p< 0.001),
aztreonam (p< 0.001), and pip–tazo (p = 0.049) increased. A signiﬁcant
inverse linear association between ciproﬂoxacin use and susceptibility
was detected (p< 0.001; correlation p< 0.001). Furthermore, pip–tazo,
aztreonam and meropenem susceptibility were inversely correlated with
ciproﬂoxacin use (univariate pip–tazo r = −0.39 p = 0.045; aztreonam
r = −0.69 p< 0.001; meropenem r = −0.53 p = 0.008), with a linear rela-
tionship apparent (pip–tazo p = 0.089; aztreonam p= 0.001; meropenem
p= 0.016). Surprisingly, there was a signiﬁcant positive linear association
between aztreonam use and susceptibility (r = 0.61 p = 0.004).
Conclusions: These data suggest that an antibiotic policy revision,
successfully reducing ciproﬂoxacin use, correlated with an increase in
ciproﬂoxacin susceptibility among Gram-negative organisms. Further-
more, this was also associated with an increase in susceptibility to
B-lactam antibiotics, in spite of increased use of aztreonam. Therefore,
reducing quinolone exposure within a population appears to exert a
favourable effect on both quinolone and B-lactam susceptibility of Gram-
negative organisms.
Figure. Correlation of ciproﬂoxacin DDD with ciproﬂoxacin and
b-lactam.
O92 Life without ciproﬂoxacin: implementation and consequences
of a ﬂuoroquinolone ban for a tertiary referral hospital
K. Burns °, S. Foley, M. Morris-Downes, F. Fitzpatrick, H. Humphreys,
E. Smyth (Dublin, IE)
Objectives: An outbreak of Clostridium difﬁcile infection (CDI) due
to PCR ribotype 027 affecting 42 patients occurred in our hospital
between July 2008 and March 2009. The reported association between
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ﬂuoroquinolone use and C. difﬁcile colitis and evidence that C. difﬁcile
027 isolates tend to be ﬂuoroquinolone-resistant, prompted the outbreak
control team to recommend a complete ban on the prescription of
ﬂuoroquinolone antimicrobials as one component of the multifactorial
outbreak management programme, effective September 2008. This report
describes the practicalities of introducing a ﬂuoroquinolone ban, the
efforts to maintain the ban and some of the observed consequences of
the ban.
Methods: The hospital’s clinical microbiology team, surveillance
scientist and antimicrobial pharmacist collected data regarding the
impact of this ban on rates of inpatient C. difﬁcile infection,
ﬂuoroquinolone resistance in E. coli bacteraemia isolates and the use
of other antimicrobial agents.
Results: At the peak of the outbreak of CDI, there were on average
16 new cases diagnosed per month. Following closure of the outbreak,
the number of new cases of CDI has declined to an average of 7.8
per month. Compared with 2007, ﬂuoroquinolone use for inpatients
during 2008 declined by 59% (19.07 DDD/100BD to 7.82 DDD/100BD).
However, for the same period, meropenem use increased by 43% (1.34
DDD/100BD to 1.92 DDD/100BD). The proportion of ﬂuoroquinolone
resistance in E. coli isolates from bloodstream infections in our hospital
has decreased from 25% in 2008 to 5% for quarters 1 & 2 2009.
Conclusions: Implementation of a ﬂuoroquinolone ban has proved
challenging, but has rewarded with a reduction in cases of CDI and
ﬂuoroquinolone resistance in E. coli. Such an intervention may be a
useful adjunctive measure in the management of outbreaks of infection
due to Clostridium difﬁcile ribotype 027. Of concern, is the increased use
of broad spectrum agents such as meropenem. Further effort is required
to limit the use of such agents, particularly in the context of the recent
emergence of carbapenemase producing Enterobacteriaceae and the lack
of new anti-Gram-negative agents.
O93 An audit of ﬂuoroquinolone prescription in a paediatric
hospital
Z.T. Yang °, J-R. Zahar, F. Mechai, M. Postaire, S. Blanot,
S. Balfagon-Viel, M. Lecuit, X. Nassif, O. Lortholary (Paris, FR)
Objectives: To evaluate the prescription of ﬂuoroquinolones (FQ) for
pediatric infections.
Methods: An audit of FQ prescription was conducted between 1st
December 2007 and 30th June 2008 in Necker-Enfants Malades
University hospital in Paris. Children admitted and receiving systemic
FQ were included in the study. Descriptive data concerning patients’
characteristics (immune status, cystic ﬁbrosis), the present FQ regimen
(drug, indication and bacteriologic ﬁndings, justiﬁcation for use,
concomitant drugs) were evaluated by 3 experts of infectious disease and
1 pharmacist. Statistical analysis was performed using Epi info version
6, CDC Atlanta.
Results: 52 oral (53.1%) and 46 (46.9%) intravenous FQ prescriptions
were collected. Prescriptions mainly originated from general pediatric
wards (25.4%), immuno-hematology department (20.4%), intensive care
units (12.2%) and cardiac surgery unit (11.2%).
Among these 98 children, median age was 10 years. 45 (45.9%) had
an underlying condition, CF (21.4%) and immune deﬁciency such as
neutropenia (12.2%), use of any immunosuppressive agent (12.2%).
The indications for FQ prescription to patients with CF (21) were
bronchopulmonary P. aeruginosa infection or prophylaxis (20/21).
Among 77 patients without CF, of which only 14 had P. aeruginosa
infection, the main infection sites were bronchopulmonary (25), post-
operative (10), urinary tract (8), gastrointestinal tract (6), septicemia (6),
bone or joint (4) and cerebral (4), endocarditis (2). 61 (62.2%) infections
were nosocomially aquired. 22 of the 35 community acquired were health
care associated. Bacteriological conﬁrmation was isolated in 60 (61.2%)
patients.
52 prescriptions were considered as adequate FQ use, of which 36
were mandatory, 16 as adequate indication based on clinical and/or
microbiologic ﬁndings. 35 of 46 inadequate prescriptions might have
had an alternative antibiotic to FQ, 11 were unnecessary. Median
ciproﬂoxacine dosage was 20mg/kg/24 h. 46 patients received an
excessive dose, while 7 had insufﬁcient treatment. 87.8% patients had a
concomitant drug use.
Appropriate prescription of FQ was associated with P. aeruginosa
infection in CF patients (p = 0.0001, OR= 12.67, 95%CI 2.52−86).
Conclusion: More than a half FQ prescription in pediatric patients was
adequate and mandatory. The problems of inadequate prescriptions focus
on the dosage and that FQ could be replaced by an alternative antibiotic.
Appropriated prescriptions were associated with P. aeruginosa infection
in CF patients.
O94 Do published studies provide accurate estimates of the
association between antibiotic exposure and acquisition of
antibiotic-resistant bacteria?
M.A. Cataldo, G. De Angelis, M. Cipriani, R. Cauda, E. Tacconelli °
(Rome, IT)
Objectives: Antibiotic stewardship is usually included in a multifaceted
approach to combat the spreading of antibiotic resistant bacteria (ARB)
into the healthcare setting. Numerous papers have demonstrated that
prior antimicrobial drug exposure is a strong risk factor for infection
due to ARB. However, the association between antibiotic therapy and the
acquisition of ARB is still unclear and it is often confounded by scarce
data on antibiotic usage. Our objectives were to deﬁne major limits of
the available evidence and to explore the sources of heterogeneity.
Methods: Two meta-analyses were performed to determine whether
antibiotic exposure is a risk factor for the isolation of ARB. Target
bacteria were: methicillin-resistant Staphylococcus aureus (MRSA) and
carbapenems-resistant Acinetobacter baumannii (CRAB). The I2 test
was calculated to assess whether results varied no more than might
have been expected by the play of chance. The subgroup analysis
was performed by stratifying sampling frame for inclusion, deﬁnition
of case subjects and controls, study design, geographic area of the
study, presence of adjustment of covariates and length of time in
which antibiotic exposure was detected. A signiﬁcant heterogeneity was
considered for I2> 50%.
Results: Seventy-eight studies (60 related to MRSA and 18 studies to
CRAB) were considered eligible for inclusion. All studies were cohort,
case–control or prevalence survey. Patients who had taken antibiotics
had a risk increased by 1.8 (95%CI, 1.7−1.9) and by 1.3 (95%CI,
1.2−1.4) fold of acquiring MRSA and CRAB, respectively. Signiﬁcantly
heterogeneity was detected for study design, deﬁnition of controls,
sampling frame for inclusion, endemic / epidemic setting, adjustment
for covariates. A regression analysis revealed that the heterogeneity was
linked to the length of time in which antibiotic exposure was detected
before isolation, selection of the control group, and sampling frame for
inclusion.
Conclusions: Our analysis conﬁrms that the quality of the evidence
available on the association between antibiotic therapy and the
acquisition of antibiotic-resistant bacteria is poor. Speciﬁc guidelines
focused on methodological issues to address the epidemiology of
antibiotic-resistant infections are urgently needed.
O95 Divergent intentions to use a local antibiotic guideline: a
theory of planned behaviour survey
P. Cortoos °, B. Schreurs, W. Peetermans, K. De Witte, G. Laekeman
(Leuven, Brussels, BE)
Background: In order to improve antimicrobial practice, correctly
identifying antibiotic guideline barriers, and assessing their relative
importance are important factors. The Theory of Planned Behaviour
(TPB) permits such assessment and has been used already for evaluating
antibiotic use (1). According this theory, the intention driving guideline
use, is fuelled by three factors: attitude; subjective norm (SN) (perceived
social pressure regarding guidelines); and perceived behavioural control
(PBC) over the guideline. Using a TBP-based questionnaire, we wanted
to study how guideline use is affected in our hospital.
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Methods: Based on earlier observations, a questionnaire was con-
structed, modiﬁed to account for habit strength (2). After pilot testing,
the survey was distributed among physicians in a major teaching hospital.
Results: Out of 393 contacted physicians, 195 completed questionnaires
were received (50.5% corrected response rate). Using multivariate
analysis, habit strength (b = 0.186; P = 0.022) and PBC (b= 0.171;
P = 0.036), were signiﬁcant determinants for overall intention. A
moderator effect of respondents’ position (staff member vs. resident)
was found with staff members’ intention inﬂuenced by habit strength
(b = 0.281; P = 0.038), and residents’ intention by PBC (b = 0.220;
P = 0.040) only. Other factors were not signiﬁcant. Looking for speciﬁc
issues, education on antibiotics and guidelines was rated unsatisfactory.
Conclusions: These divergent origins stipulate different approaches
for improvement. With staff members experiencing a high inﬂuence
of previous routine and habits, preferred interventions for this group
are education, focused on changes in prior antibiotic practice and
their causes, and reminders. Residents’ intention is guided mainly by
external inﬂuences and the amount of self-conﬁdence, making feedback,
convenient guideline formats and thorough guideline familiarization
more suitable.
Reference(s)
[1] Francis et al. Constructing questionnaires based on the theory
of planned behaviour. A manual for health services researchers.
http://www.rebeqi.org.
[2] Cortoos et al. Opposing expectations and suboptimal use of
a local antibiotic hospital guideline: a qualitative study. JAC
2008;62:189−95
O96 Temporal effects of a restrictive antibiotic policy on
hospital-acquired Clostridium difﬁcile, methicillin-resistant
Staphylococcus aureus and extended-spectrum b-lactamase
producing coliforms in a district general hospital
S. Dancer, P. Kirkpatrick, D. Corcoran °, F. Christison, D. Farmer
(Glasgow, UK)
Objectives: Following a persistent problem with cases of Clostridium
difﬁcile, a restrictive antibiotic policy was imposed on a 400-bedded
district general hospital. This policy banned the use of cephalosporin
and quinolone antibiotics unless released by the microbiologist. Hospital
pharmacists upheld the policy on the wards and stocks of restricted
agents were removed from all wards except intensive and emergency
care.
Methods: The policy was introduced following a brief educational
campaign aimed at all doctors. From six months before, until 14
months after the policy began, we calculated the monthly consumption
of all antibiotic classes in deﬁned daily doses (DDDs) per 1000
patient-occupied bed-days (1000 pt bds) for the whole hospital. In
addition, we determined each new case of hospital-acquired C. difﬁcile,
meticillin-resistant Staphylococcus aureus (MRSA) and extended-
spectrum b-lactamase-producing coliform (ESBLs) infection for the
whole 22-month period. These were calculated as the number of cases
per month per 1000 pt bds.
Results: During the six months before the policy was introduced, the
hospital experienced an average monthly rate of 1.009 MRSA cases/1000
pt bds; 2.398 C. difﬁcile cases/1000 pt bds; and 1.480 cases ESBLs/1000
pt bds. The average monthly consumption of ceftriaxone over the
same period was 46.213 DDDs/1000 pt bds and for ciproﬂoxacin was
109.804 DDDs/1000 pt bds. During the six month period at the end
of the study, ten months after the policy was introduced, infection
control identiﬁed a monthly average of 0.938 MRSA cases/1000 pt bds;
1.424 C. difﬁcile cases/1000 pt bds; and 1.134 cases ESBLs/1000 pt
bds. The average monthly consumption of ceftriaxone over the ﬁnal
six months had dropped by 95% to 2.113 DDDs/1000 pt bds and
for ciproﬂoxacin by 76% to 26.672 DDDs/1000 pt bds. There were
corresponding increases in consumption of amoxicillin and gentamicin,
no change in consumption of piperacillin–tazobactam, and a small
decrease in carbapenem antibiotics. We have submitted the data for time-
lag modelling.
Conclusion: A restrictive antibiotic policy had a profound effect on the
number of cases of hospital-acquired C. difﬁcile (reduction of 40%),
less effect on ESBLs (reduction of 23%) and little effect on MRSA (7%
reduction). Whilst it is important to reduce antibiotic consumption as far
as possible, it is clear that additional infection control interventions are
required for hospital-acquired infection, particularly MRSA.
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O97 Microarray analysis and antibiotic susceptibility patterns
among 131 Staphylococcus aureus causing infective
endocarditis in France in 2008
A. Tristan °, F. Laurent, M. Celard, O. Dumitrescu, M. Bes, P. Tattevin,
M.E. Reverdy, V. Le Moing, S. Monecke, H. Meugnier, G. Lina,
J. Etienne, F. Vandenesch for the French AEPEI Study Group on
infective endocarditis
Background: The changing epidemiology of staphylococci worldwide,
with the emergence of community-acquired MRSA called for a thorough
analysis of the S. aureus isolated during the French national survey on
infective endocarditis (IE) conducted in 2008.
Methods: We analyzed 131 non-duplicate staphylococcal isolates
collected during the 2008 IE French survey. Genomic identiﬁcation,
antibiotic susceptibility testing and search for mecA gene were
performed. MRSA strains were subjected to population analysis for
determination of glycopeptide heteroresistance. All S. aureus were spa-
typed and 114 MSSA were analyzed by a DNA microarray covering 185
distinct genes (300 alleles), including genes encoding virulence factors
and resistance genes.
Results: MRSA: 17 MRSA (13%) belonging to only 5 spa-types and
3 sequence-types (ST) were detected demonstrating a high clonality.
They were frequently resistant to levoﬂoxacin (88%), kanamycin and
tobramycin (47%), and to erythromycin (35%). Four of the MRSA were
categorized as hVISA by population analysis. No strain belongs to any
CA-MRSA clone.
MSSA: The 114 MSSA isolates were seldom resistant to erythromycin
(16/114, 1.4%) and almost fully susceptible to all other antibiotics.
Phenotypic results were highly correlated with genomic data from
microarray. All MSSA isolates were assigned to 19 ST. Their ST
diversity evaluated by the lamba modiﬁed Simpson was not different
when compared to a set of 114 S. aureus invasive isolates collected
throughout France during the EARSS study in 2006–2007 (88.31% vs
91.09%). Surprisingly we noticed that 8 isolates belonged to ST398.
Genomic DNA microarray comparison of the 114 MSSA IE isolates
with 152 MSSA nasal carriage isolates highlighted that several speciﬁc
determinants or gene alleles (e.g., bone sialoprotein, elastin binding
protein, modulins) were preferentially harbored by MSSA IE isolates.
Conclusions: The genetic diversity of S. aureus strains from IE suggests
that there is no speciﬁc background strain associated with IE; however
some virulence traits are highlighted; it remains to be determined
whether some speciﬁc genetic traits of the human host favor the
occurrence of S. aureus IE. MRSA, including CA-MRSA are infrequent.
O98 Improved discrmination of highly-clonal ST22-methicillin-
resistant Staphylococcus aureus (MRSA)-IV isolates achieved
by combining spa, dru and pulsed ﬁeld gel electrophoresis
typing data
A. Shore °, A. Rossney, P. Kinnevey, O. Brennan, O. Sherlock,
E. Creamer, D. Sullivan, R. Cunney, R. Goering, H. Humphreys,
D. Coleman (Dublin, IE; Omaha, Nebraska, US)
Objective: The pandemic ST22-methicillin resistant Staphylococcus
aureus (MRSA)-IV strain has been endemic in Irish hospitals since
2002, where it is designated as antibiogram-resistogram type-pulsed-
ﬁeld group (AR-PFG) 06−01 and is similar to the UK epidemic strain
EMRSA-15. Differentiating isolates of this strain is difﬁcult as they
exhibit a limited number of pulsed-ﬁeld gel electrophoresis (PFGE)
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patterns and spa types. This study investigated whether combining
PFGE and spa typing with DNA sequencing of the SCCmec-associated
direct repeat unit (dru typing) would signiﬁcantly improve isolate
discrimination.
Methods: One hundred and seventy-three MRSA isolates recovered in
one Irish hospital during 2007 and 2008 were investigated using AR,
PFGE, spa, dru and SCCmec typing. One isolate representative of each
of the spa types identiﬁed underwent multilocus sequence typing.
Results: Ninety-seven percent of isolates (168/173) exhibited AR-PFG
06−01 or closely related AR patterns and 163 of these harboured
SCCmec IVh. Isolates representative of the 17 PFG-01 spa types
were identiﬁed as ST22. Combining PFGE, spa and dru typing data
signiﬁcantly improved discrimination of the 168 PFG-01 isolates yielding
65 type combinations with a Simpson’s Index of Diversity (SID) of 96.53
compared to a) pairwise combinations which yielded 37, 44 and 43 type
combinations with SIDs of 90.84 for spa and dru, 91.00 for spa and
PFGE and 93.57 for dru and PFGE; respectively, or b) individual typing
methods which yielded 21, 17 and 17 types with SIDs of 66.9, 77.8 and
81.34 for spa, dru and PFGE, respectively. Analysis of epidemiological
information for a subset of PFG-01 isolates validated the relationships
inferred using combined PFGE, spa and dru typing data.
Conclusions: This study demonstrates that the combination of PFGE,
spa and dru typing improves discrimination and epidemiological tracking
of highly clonal ST22-MRSA-IV isolates.
O99 External quality assessment of genotyping techniques for
methicillin-resistant Staphylococcus aureus
R. te Witt °, A. van Belkum, W. MacKay, P. Wallace, W. van Leeuwen
(Rotterdam, NL; Glasgow, UK)
Background: After detection of meticillin resistant Staphylococcus
aureus (MRSA), genotyping may be necessary to proceed with infection-
preventive measures. This external quality assessment study determines
the performance of genotyping techniques for MRSA in participating
laboratories and was organised by Quality Control for Molecular
Diagnostics (QCMD) (www.qcmd.org).
Methods: The EQA panel for MRSA genotyping was distributed to 19
participants in 8 countries in August 2009 and consisted of 10 samples
(2 identical, 3 genetically related and 5 unique, as determined originally
with pulsed-ﬁeld gel electrophoresis [PFGE]) of viable MRSA strains
in Mu¨ller Hinton broth. A different letter signiﬁed the detection of a
different genotype, whereas a different number signiﬁed the detection of
a different subtype. All data were reported in relation to the reference
strain in panel sample MRSATP09−01.
Results: Out of the 19 potential participants, 14 (74%) responded. Four
of the non-responders withdrew ofﬁcially indicating ‘panel used for
research’ (n = 1) and ‘assay not offered’ (n = 3). The majority of datasets
were generated by PFGE (n = 11), with the remainder generated by AFLP
(n = 2) and spa typing (n = 2). Seventy-three percent of participants typed
all samples correctly, all with PFGE. Results obtained from spa-typing
and ampliﬁed fragment length polymorphism (AFLP) were found to be
less discriminative than those obtained with PFGE.
Discussion: We present the ﬁrst EQA programme for the genotyping
of MRSA. PFGE was implemented by most of the participating
laboratories. However, most protocols proved to be suboptimal, resulting
in inferior resolution in the higher or lower fragment regions. This
suggests that further assay optimisation is required. The lack of
resolution was most evident with the closely related MRSA strains
in the panel. Results generated using AFLP and spa-typing showed
less discriminatory power compared to PFGE. Participants reported a
range of criteria for determining genotype and subtype. The guidance
according to Tenover et al was the most prominent method. Future
EQA distributions will gather information on the cutoff values used
by participants. To improve the performance and quality of MRSA
genotyping and subtyping, both laboratories and manufacturers should
be encouraged to participate in EQAs. The availability of EQA panels
for detection and typing should also be developed for other important
(nosocomial) infectious agents.
O100 Usefulness of DiversiLab rep-PCR system for typing and
follow-up of Pseudomonas aeruginosa strains colonizing
cystic ﬁbrosis patients: comparison with PFGE and MLST
techniques
A. Fernandez-Olmos °, R. del Campo, A. Lamas, L. Ma´iz, F. Baquero,
R. Canto´n on behalf of the CIBERESP
Objective: rep-PCR typing method has been recently proposed as
alternative to the classical PFGE for Clinical Microbiology Laboratories.
This method demonstrated their utility in outbreaks typing whereas
non-experience in the follow-up of chronically colonized patients is
available. The aim of this work was to evaluate the ability of the rep-PCR
DiversiLab system (bioMe´rieux) to discriminate a well-typed collection
of clinical P. aeruginosa strains from cystic ﬁbrosis (CF) patients.
Material and Methods: A collection of 49 P. aeruginosa strains
recovered from sputum samples of 24 CF-patients (1994–2009) were
studied. Strains were classiﬁed as ﬁrst colonizer (n = 24), sporadic or
intermittent (n = 13), and persistent colonizers (n = 12). First colonizer
was deﬁned as the ﬁrst P. aeruginosa isolate detected from sputum
in each CF-patient. In four patients, ﬁrst colonizers were identical
to the follow-up isolates, so were also classiﬁed as persistent.
Genetic relationships were analyzed by PFGE-SpeI and MLST and
after compared with those obtained by DiversiLab, which generates
patterns by use of microﬂuidic chips. Follow-up of CF-patients include
comparison of the ﬁrst colonizer, sporadic and chronic isolates as well
as possible persistence and cross-colonization.
Results: Among the 24 ﬁrst colonizer strains, 22 PFGE patterns and 21
unrelated STs were detected. rep-PCR DiversiLab conﬁrmed these data
with discrepancies only in one strain. Two strains belonging to ST312
were classiﬁed by DiversiLab as unrelated, and another two strains
grouped in ST274 had different PFGE and DiversiLab patterns. The 13
sporadic strains were obtained from 7 CF-patients. Genetic relationship
was not detectable among them using either PFGE or MLST tools, and
DiversiLab conﬁrmed this pattern of heterogeneity except in one strain.
Chronic colonizers (12 + 4 ﬁrst colonizer strains) were obtained from 4
CF-patients (2−5 strains per patient). The three typing methods agreed
with the result that particular host-speciﬁc stable clones were detected
in different patients, with no genetic relation between them.
Conclusions: DiversiLab system based on rep-PCR technique is a
reliable method useful for Clinical Microbiological Laboratories in the
follow-up and colonization dynamic of CF-P. aeruginosa strains. This
technique is considerably less laborious than the classical PFGE and
MLST and genetic results for our ﬁrst colonizers, sporadic or persistent
strains are comparable.
O101 Sequence types of carbapenem-resistant Acinetobacter
baumannii strains in Greece during the last decade
S. Pournaras °, V. Gogou, E. Voulgari, A. Poulou, R. Zarrilli, A. Tsakris
(Larissa, Athens, Serres, Napoli, GR)
Objectives: During the last decade, carbapenem-resistant Acinetobacter
baumannii isolates are increasingly isolated; in the ICUs of many
regions worldwide such isolates currently represent the vast majority
of A. baumannii recovered from hospital infections. The aim of the
present study was to analyse the genetic relatedness of multidrug resistant
A. baumannii isolates recovered from ICU patients in different regions
in Greece.
Methods: One hundred A. baumannii isolates that were derived
from 2001 to 2009 from 10 hospitals located in four different
geographical regions in Greece were included in the study. Antimicrobial
susceptibilities to carbapenems were determined by the reference agar
dilution method. The isolates were tested by PFGE and sequence-based
typing (ST) using ompA, csuE and blaOXA-51-like sequences.
Results: Eighty-one (81%) of the isolates were carbapenem-resistant.
Eleven different ST-types were revealed. Thirty-four isolates (34%)
belonged to ST-group 2 (corresponding to EU clone I), 55 (55%) to
ST-group 1 (EU clone II) and the remaining 11 were sporadic isolates
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belonging to 10 unique ST-types. The latter ST-types were not assigned to
ST-groups, as not yet being epidemic. This is in accordance with previous
reports showing that the majority of A. baumannii strains circulating in
Europe belonged to ST-groups 1 and 2. Within the same institution,
isolates with the same PFGE-proﬁle belonged to the same ST-type,
although some isolates of the same ST-type exhibited different PFGE
proﬁles and isolates of different ST-types tended to have unrelated PFGE
proﬁles. Sporadic isolates that had unique ST-types had also unique
PFGE proﬁles. ST-groups 1 and 2 included isolates that were derived
from all geographical regions and comprised both carbapenem-resistant
and susceptible isolates. The majority of isolates recovered prior to 2003
belonged to ST-group 2, while those isolated after 2004 more commonly
belonged to ST-group 1.
Conclusions: The epidemic of multidrug and carbapenem-resistant
A. baumannii in Greece was sustained by the spread of distinct genotypes
belonging mainly to ST groups 1 and 2, which also included carbapenem-
susceptible isolates and in a lesser extent to other sporadic ST-types.
O102 Differentiation of Austrian Salmonella serotypes using
high-resolution melting curve analysis
J. Zeinzinger °, A. Stoeger, C. Kornschober, R. Mach, F. Allerberger,
W. Ruppitsch, A. Pietzka (Vienna, AT)
Objectives: Effective epidemiological surveillance requires the accurate
subtyping of strains. The standard method for differentiation of
Salmonella strains is serotyping. Despite the utility of serotyping, testing
with a complete set of sera is time consuming and requires a well
trained technician; problems associated with antiserum production and
occurrence of strains for which a serotype antigen cannot be detected
prompted reference laboratories to pursue molecular approaches for
serotyping.
The aim of this study was to assess the usefulness of high-resolution
melting (HRM) curve analysis on the LightCycler 480 PCR system as a
tool for accurate and fast molecular typing of Salmonella enterica subsp.
enterica strains.
Methods: A collection of Salmonella isolates representing diverse
serotypes was recently analysed using Ampliﬁed Fragment Length
Polymorphism (AFLP) (1). A phylogenetic cluster comprising the
serotypes Blockley, Virchow, Braenderup, Manhattan and Muenchen was
chosen to evaluate the potential of HRM analysis for molecular typing.
A 171 bp fragment of the gyrase B gene (gyrB) was ampliﬁed for HRM
curve analysis on a LightCycler 480 instrument (Roche Diagnostics,
Penzberg, Germany).
Results: HRM curve analysis of a 171 bp amplicon of the gyrB gene
resulted in ﬁve different melting curves (Figure 1), and thus allowed the
rapid and accurate discrimination of the investigated serotypes.
Figure 1. Melting curve proﬁles of the tested Salmonella serotypes.
Conclusion: HRM analysis is a new single-step closed-tube screening
method for fast mutation detection and can therefore be used to
discriminate even genetically closely related samples. HRM analysis
has the potential to complement the classical serotyping of Salmonella
isolates due to its discriminatory power and simplicity.
Reference(s)
[1] Pietzka A., Sto¨ger A., Kornschober C., Zeinzinger J., Ruppitsch
W., Franz Allerberger F. (2008) Ampliﬁed fragment length
polymorphism of diverse Salmonella enterica serovars for serotype
differentiation and identiﬁcation of serotype speciﬁc genetic
markers. Infection. 36(s1): 72−73.
O103 Direct high-resolution genotyping of Chlamydia trachomatis
positive swabs from women in Southampton using ompA
and three variable-number tandem repeats
Y. Wang, R. Skilton, E. Andrews, I. Clarke, P. Marsh ° (Southampton, UK)
Objectives: Genital chlamydial infection is the commonest diagnosed
sexually transmitted infection in the UK. Chlamydia trachomatis
infections are caused by strains which fall into two pathovars: ‘serovars’
of lymphogranuloma venereum (LGV) and the genitourinary ‘serovars’
D-K. Although these serovars can be discriminated by outer membrane
protein gene (ompA) sequencing (genotyping) or multi-locus sequence
typing (MLST), neither affords the high-resolution genetic typing
required for local epidemiology and accurate contact-tracing. Therefore
our objectives were to develop and apply a new high resolution
genetic typing technique to studying the molecular epidemiology of
C. trachomatis in positive swabs from our local genitourinary medicine
(GUM) clinic.
Methods: 162 endocervical swabs were taken at the Southampton
GUM clinic and tested by routine diagnostic PCR for the presence of
C. trachomatis. Positive samples were genotyped by use of a variable
number tandem repeat (VNTR)-ompA sequencing technique. Isolates
were cultured from the positives where possible.
Results: Of the 162 samples, 86 were fully typed by VNTR-ompA.
Only one mixed infection (E & F) in one sample was conﬁrmed. The
commonest genotypes were D, E & F, comprising 20%, 45% and 15%
of the genotyped positives respectively. Within each of these genovars
there were multiple VNTR sub-types. 69 of the swabs yielded culturable
isolates able to passage multiple times.
Conclusions: This is the ﬁrst comprehensive ﬁne molecular epidemiol-
ogy genetic typing survey of C. trachomatis in the UK. Amongst the
common genotypes, there are a signiﬁcant number of deﬁned sub-types,
which may reﬂect backgrounds of particular demographics relating to
age group, geography, high-risk sexual behaviour, and sexual networks.
O104 Comparison of Listeria monocytogenes strains from food and
human origin by ampliﬁed fragment length polymorphism
D.L. Hess °, P. Savelkoul, E. De Boer, A. Heuvelink, L. Spanjaard,
C.W. Ang (Amsterdam, Zutphen, NL)
Objectives: Listeria monocytogenes is a foodborne pathogen, respon-
sible for neurological, systemic and gastro-intestinal disease with a
mortality up to 30%. For the investigation of L. monocytogenes
epidemiology highly discriminatory typing methods are needed. The
aim of our study was to develop an Ampliﬁed Fragment Length
Polymorphism (AFLP) for L. monocytogenes, analyze isolates from
clinical human and food origin and determine the possibility of
differentiation between human and food isolates by AFLP.
Methods: Based on genome sequence analysis we selected restriction
enzyme combination HindIII-G and HPyCHIV4-C. With this com-
bination, a collection of 279 L. monocytogenes strains was typed,
consisting of 168 human clinical isolates from the Netherlands Reference
Laboratory for Bacterial Meningitis (RBM), 111 food isolates from
the Food and Consumer Product Safety Authority (VWA), 3 complete
genome sequenced strains (ATCC BAA-679 (=EGDe), F2365, HCC23)
and L. monocytogenes type strain ATCC 15313. As such, this
L. monocytogenes collection is one of the largest collections in the world
comparing both clinical and food isolates.
Results: AFLP patterns of the 279 L. monocytogenes isolates were
grouped in two major clusters and a few individual isolates. Cluster I
included 100 human isolates and 37 isolates of food origin. The human
S26 20th ECCMID, Oral presentations
cluster I isolates mainly consisted of the virulent serotype 4b (63/100,
63%) and serotype 1/2b (14/100, 14%). The cluster I isolates originating
from food consisted mainly of serotype 1/2b (15/37, 40.5%). These food
isolates formed a subcluster within cluster I. Cluster II included 68
human and 74 food isolates, mainly serotype 1/2a (69.1% and 35.1%,
respectively).
Conclusion: AFLP allows discrimination of L. monocytogenes in two
major clusters. The two clusters show segregation of the virulent 4b
serotype into AFLP cluster I, whereas serotype 1/2a predominates in
AFLP cluster II. Within cluster I, it is possible to differentiate most food
1/2b isolates from human isolates.
O105 Investigation of an outbreak of CTX-M-15-producing
Escherichia coli of sequence types 131 and 1441 in a
neonatal surgical ward: comparison of typing methods
N. Karami °, L. Helldal, M. Andersson, C. Unosson, L. Larsson,
C. Welinder-Olsson, C. Ahren, E. Moore (Gothenburg, SE)
Objectives: The spread of E. coli producing the CTX-M-15-type of
extended-spectrum b-lactamase (ESBL) was ongoing in a surgical ward
caring for newborns since, at least, September 2008 and was ﬁnally
recognised in late December. Various typing methods were applied and
compared with pulsed-ﬁeld gel electrophoresis (PFGE) to verify the
outbreak and to determine the number of affected children.
Methods: Subsequent to clinical sampling, 125 children hospitalised
September-December were screened for ESBL-bacteria in stool. January-
June 2009, newly admitted children were screened at admission and
twice weekly. 51 ESBL-E. coli isolates were detected in 26 children,
of which 6 later were found to carry isolates of several PFGE-types.
The 51 isolates were typed by PFGE, multiple-locus-variable number
tandem repeat analysis (MLVA), a “mini” multiple-locus-sequence typing
(mMLST) method (fumC, purA and dnaJ genes) and by Phene Plate
(PhP) biochemical ﬁngerprinting.
Results: When the outbreak was revealed, ﬁve children had developed
infections with ESBL-E. coli of two PFGE-types, A (ST 131) and B
(ST 1441), later determined to be the outbreak strains. One or both types
spread to a total of 21 children. Altogether, 38 isolates (20 children) were
of type A and 7 isolates (5 children) of type B. In addition six children
carried isolates of six distinct PFGE-types (C-H), only found in one child
each. MLVA generated the same strain differentiation proﬁle as PFGE.
mMLST accurately detected the same STs of PFGE-types as detected
by standard MLST (http://mlst.ucc.ie/mlst/dbs/Ecoli), although it did not
differentiate ST 131 isolates of different PFGE-types (A and C). PhP-
typing differentiated isolates such that little correlation was observed
with PFGE. By monitoring resistance patterns of isolates we could not
predict the identity of isolates.
Conclusion: If transmission is ongoing for an extended time period,
several types of ESBL-producing bacteria may be detected in an outbreak
and all isolates, including screened as well as repeat isolates, should
be typed to identify affected patients. Only genetic methods gave
satisfactory typing results in investigating this outbreak. MLVA generated
identical results as those of PFGE and is, thus, attractive, being faster,
less-costly and producing results that are easier to communicate. The
mMLST, although accurately detecting the STs, despite using only three
house-keeping genes, was less discriminatory than PFGE or MLVA.
O106 Deep sequencing for accurate and high-throughput HPV
genotyping in clinical samples
L. Barzon °, V. Militello, E. Peta, E. Lavezzo, S. Toppo, M. Trevisan,
L. Squarzon, E. Franchin, G. Palu` (Padua, IT)
Objectives: Human papillomavirus (HPV) typing is useful for studies
on HPV transmission, natural history, pathogenesis, and prevention and
for clinical management of HPV-related lesions. HPV typing methods
based on Sanger sequencing or reverse hybridization show poor accuracy
in multiple infections. Moreover, discordant results have been reported
when using different typing methods even in single infection. Aim of
the study was to develop an HPV typing method based on 454 Life-
Sciences ultradeep pyrosequencing in order to dissect the contribution
of each HPV type in multiple infections and to identify possible HPV
sequence variants.
Methods: A group of 50 HPV-DNA positive cervical samples, including
40 with multiple infections, were selected for deep pyrosequencing. For
each cervical sample, a library of amplicons targeting a conserved region
of HPV-L1 was generated and sequenced in multiplex reactions on a 454
Life-Sciences platform. Multiple alignment of sequences was performed
with Clustalw2, followed by clustering analysis based on sequence
identity (Jalview 2.4). A representative sequence was selected for each
cluster and aligned with the non redundant database of nucleotide
sequences, in order to identify either multiple infections or contaminant
genomic DNA. Results from deep sequencing were compared with
Sanger sequencing and with the Inno-LiPA HPV genotyping test.
Results: A mean coverage of 1228 (range, 234–3202) sequences was
obtained for each sample analyzed by deep sequencing. In 3 cases
classiﬁed as single infection by both Sanger sequencing and Inno-LiPA,
deep sequencing revealed the presence of multiple HPV types, while in
12 cases classiﬁed as multiple infection, Inno-LiPA and deep sequencing
gave discordant typing results. An overall analysis of results showed
the sensitivity of HPV deep sequencing was higher than other typing
methods, since it could detect HPV types representing less than 1% of
sequences in multiple infections, at variance with Sanger sequencing,
which failed in most cases of multiple infection, and the Inno-LiPA
assay, which could not detect HPV types representing less than 8% of
sequences in multiple infections nor those not included in the probe set.
Moreover, deep sequencing allowed identiﬁcation of unclassiﬁed HPV
types and detection of HPV sequence variants within types.
Conclusions: Deep sequencing may be a sensitive and accurate high-
throughput method for HPV genotyping in clinical samples.
Antifungal therapy under the microscope:
from fungus to mouse to man (Symposium
supported by Gilead)
S108 Do animal models help predict host responses to fungal
infections and antifungal treatments? Choosing therapy on
the basis of efﬁcacy not safety
J. Adler-Moore ° (Pomona, US)
Clinical outcomes from invasive fungal infections involve a complex
interplay between the infecting organism, antifungal treatment and the
host immune response. Factors such as the host’s neutropenic status are
well known to inﬂuence outcome and may be of particular relevance
if the antifungal treatment is fungistatic rather than fungicidal, but the
immune response involves far more than neutrophils alone. Cytokine
changes may correlate with both clinical response and clinical failure.
In this symposium the faculty will show how changes in vitro may
correlate with responses in vivo in animal models and therefore predict
the response in the human host.
MRSA: from molecular epidemiology to
molecular screening (Symposium supported
by Roche Molecular Diagnostics)
S111 Differentiation between human epidemic and animal asso-
ciated MRSA strains by LightCycler melting curve analysis
U. Reischl ° (Regensburg, DE)
Objectives: A number of real-time PCR assays for direct detection
of MRSA in clinical specimens are targeting the SCCmec-orfX
junction in the S. aureus genome. With respect to their implication as
screening tests performed at admission of a patient at risk for MRSA
infection, such assays should be as rapid and as sensitive as possible.
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Selection of efﬁcient primers and probes is complicated by the known
sequence diversity among the various types of SCCmec cassettes. As a
consequence, primer and probes are designed to cover the most common
SCCmec types encountered in clinical MRSA isolates. Considering the
enormous diversity of SCCmec sequences, rational primer selection can
only be a best compromise between the coverage of as many SCCmec
variants as possible and loosing analytical sensitivity due to primer
multiplexing problems. Therefore incusivity rates may differ among the
various PCR assay concepts.
Methods: Three commercial PCR tests targeting the SCCmec-orfX
junction were evaluated for analytical sensitivity, time-to-result and for
their performance to cover animal-associated MRSA strains of the clonal
complex CC398 next to human epidemic MRSA strains.
Results: With exception of MRSA strains harboring “uncommon”
SCCmec elements, all of the investigated human epidemic and animal-
associated MRSA strains were detected by the Roche LightCycler MRSA
Advanced Test, but the latter strains presented with a different Tm-value
in melting curve analysis. DNA sequencing revealed single-nucleotide
polymorphisms (SNPs) within the S. aureus orfX region characteristic
for MRSA CC398 strains, which are obviously covered by the proprietary
sensor hybridization probe of the assay. All MRSA strains covered by
the LightCycler MRSA Advanced Test also tested positive in the BD
GeneOhm MRSA and the Cepheid Xpert MRSA test, but either these
real-time PCR tests had no option to perform Tm-analysis or viewing
of melting curves.
Conclusions: As a practical application of the newly identiﬁed SNPs,
we present the use of this commercial real-time PCR test for the direct
detection and simultaneous identiﬁcation of animal-associated MRSA
strains. All of the investigated MRSA CC398 strains harbored at least
one of the novel SNPs in the SCCmec-orfX junction − represented by a
characteristic Tm of 55.5ºC in subsequent melting curve analysis. Since
such a Tm-shift was not observed with any non CC398 MRSA strains
yet, it may serve as a molecular marker for the presence of MRSA CC
398.
Antibacterial susceptibility testing and
implications for resistance surveillance and
treatment
S120 Problems with low level resistance against quinolones
L. Martı´nez-Martı´nez ° (Santander, ES)
Bacterial resistance to quinolones is related to decreased permeability,
active efﬂux, drug modiﬁcation, target modiﬁcation or target protection.
Recent studies indicate that certain genes (recA, recC, tolC, ﬁs, ruvC,
xseA, xseB) also contribute to the intrinsic resistance of E. coli to
quinolones. Microbiological and clinical aspects of low level quinolone
resistance have been more often studied in enterobacteria. In these
organisms, a single gyrA mutation causes resistance to nalidixic acid
and MICs of ﬂuoroquinolones as low as 0.125–0.25 mcg/ml (still
higher than MICs of <0.008–0.06 mcg/ml for wild-type isolates). This
mechanism favours the appearance of additional mutations in gyrA or
in other topoisomerase-encoding genes, ﬁnally resulting in high level
resistance. Target protection by Qnr proteins (often encoded by plasmid
genes), decreased permeability by porin modiﬁcations or active efﬂux
of chromosomal (particularly RND transporters) of plasmid (QepA
proteins, OqxAB) origin also determine low level quinolone resistance.
The Aac(6′)-Ib-cr enzyme modiﬁes quinolones with a piperazinyl
substituent. Both in vitro and in vivo data suggest that these additional
low-level mechanisms may also represent an initial step for acquisition of
increased resistance. Low level resistance mechanisms may be difﬁcult
to detect because they translate into MICs below current EUCAST or
CLSI breakpoints. Interestingly, plasmid-mediated mechanisms may not
sufﬁciently compromise the activity of nalidixic acid, which results
in decreased susceptibility or low-level ﬂuoroquinolone resistance in
the absence of nalidixic acid resistance, which is in contrast with the
usual consequences of mutations in topoisomerase genes. As quinolone
efﬁcacy is related to Cmax/CMI and AUC /CMI parameters, small
variations (of even only 2−4 dilutions) due to low-level resistance
mechanisms may contribute to therapeutic failure. Animal models and
clinical data suggest a poor outcome of patients with severe infections
caused by Salmonella, Klebsiella (and presumably other enterobacteria)
with low level ﬂuoroquinolone resistance. Because of these reasons, it
would be important to know actual MICs of quinolones for clinical
isolates, and to obtain additional information on quinolone resistance
mechanisms. This will allow a better knowledge of risk factors for
acquiring low level resistant strains, and a better deﬁnition of the actual
therapeutic relevance of these organisms.
S121 Problems with low level resistance against glycopeptides
A. Soriano ° (Barcelona, ES)
The emergence of methicillin-resistant Staphylococcus aureus (MRSA)
strains has complicated the treatment of S. aureus infections. Van-
comycin is currently a cornerstone in the treatment of bacteraemia and
infectious endocarditis (IE) due to this pathogen, but evidence linking
vancomycin minimum inhibitory concentration (MIC) of 4−8mg/ml
to a high failure rate of vancomycin has led to the susceptibility
breakpoint being considered when the MIC is 2mg/ml. However,
vancomycin treatment failure is not uncommon even when MRSA strains
are fully susceptible (MIC 2mg/ml), and studies have described a
reduction in vancomycin efﬁcacy against MRSA strains with high MIC
but within the susceptible range. The presentation will deal with the
different methods for determining the vancomycin MIC and discuss the
implications of understanding the relationship between vancomycin MIC
and vancomycin efﬁcacy.
Evolution and epidemiology of b-lactamases
in Enterobacteriaceae
O127 Rapid increase of antimicrobial-resistant Gram-negative
pathogens in Europe
B.M. Roede °, J. Monen, N. van de Sande-Bruinsma, M. de Kraker,
H. Grundmann on behalf of the EARSS Study Group
Objectives: E. coli is the most frequent cause of Gram-negative
blood stream infections, and one of the most important food-born
pathogens worldwide. K. pneumoniae has a central role in the
acquisition of novel resistance mechanisms and may precede subsequent
dissemination among other Enterobacteriaceae. Monitoring resistance in
these pathogens is therefore important. In this study we determined the
resistance proportions and the trends over time for invasive E. coli and
K. pneumoniae infections in Europe.
Methods: Since 1999, EARSS (European Antimicrobial Resistance
Surveillance System) has been collecting routine antimicrobial sus-
ceptibility testing data from seven major invasive pathogens. In 2008,
almost 900 laboratories in 33 countries collected data from over 700,000
isolates. Resistance proportions were calculated for each participating
country and trends in resistance over the past four years were calculated
using the Cochran Armitage test (two-sided p-value <0.05).
Results: In 2008, four out of 33 (12%) countries reported E. coli
ﬂuoroquinolone (FQ) resistance below 10%, 18 (55%) countries between
10% and 25%, and 10 (30%) countries reported rates between 25% and
50%, and Turkey above 50%. FQ resistance increased signiﬁcantly in
19 (58%) countries in the last four years. Although less then half of the
countries (15/33) reported less than 5% resistance against 3rd generation
cephalosporins (3GCs), resistance proportions have been increasing over
the last four years in 21 countries. Two east European countries reported
levels higher than 25%, Bulgaria (29%) and Turkey (42%). Combined
resistance in E. coli was signiﬁcantly increasing in 19 out of 33 (58%)
countries.
Carbapenem resistance in K. pneumoniae is still absent in 21/31
countries, but seven countries reported rates from 1% to 5%, while in
three countries this was much higher: Cyprus (10%), Israel (19%), and
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Greece (37%). For combined resistance, the most frequent pattern was
against all three classes of antibiotics (3GCs, FQ and aminoglycosides),
14%. The proportion of combined resistance from 9/31 (29%) countries
increased signiﬁcantly over the last four years.
Conclusion: The data gathered by EARSS over the years show an
increasing loss of effective antimicrobial therapy. Combined resistance
is the dominant threat imposed by invasive E. coli and K. pneumoniae
in Europe. Delivery of crucial health services in hospitals and in the
community is at stake.
O128 Emerging resistance mechanisms in ESBL-producing strains
I. Frasson °, C. Bergo, A. Cavallaro, G. Palu`, S. Richter (Padua, IT)
Objective: ESBL producing strains are increasingly reported to present
additional resistance mechanisms. These multidrug resistant strains
should be detected early to rationalize drug treatment and avoid increased
selection of resistance. The aim of this study was to detect the
presence of AmpC, carbapenemases and plasmid-mediated quinolone
resistance (PMQR) (qnr, aac(6′)-Ib-cr and qepA) mechanisms in ESBL-
producing strains by genotypic assays and compare their efﬁciency
versus phenotypic methods.
Methods: ESBL- and AmpC-producing strains were identiﬁed by
the double-disk test and double disk synergy test, respectively.
Carbapenemases were phenotypically detected by the Hodge test. MIC
of ﬂuoroquinolones was detected by Etest. AmpC, carbapenemase, qnr,
aac(6′)-Ib-cr and qepA genes were identiﬁed by multiplex PCR and
sequencing. Topoisomerase II mutations were detected by sequencing
of the quinolone-resistant determining region.
Results: In 2009, 200 ESBL-producing Enterobacteriaceae isolates
were collected at the Microbiology Unit of the Padua Hospital. ESBL
belonging to different classes (TEM, SHV, CTX-M and OXA) were
characterized by genotypic analysis. Qnr and aac(6′)-Ib-cr genes were
found in 26% and 8% isolates, respectively. Qnr was mostly present
in Klebsiella pneumoniae, while aac(6′)-Ib-cr was found exclusively
in Escherichia coli. QepA was not found. Both genes were localized
on plasmids and could be both transformed and trans-conjugated in
acceptor strains. MIC of ﬂuoroquinolones on these acceptor strains
indicated a 20–100 increased resistance due to the plasmid-mediated
mechanism. However, high-level resistance to ﬂuoroquinolone in the
wild-type strains was due to the additional presence of topoisomerase
mutations in strains presenting both ESBL and PMQR. AmpC were
detected on 5.5% isolates of Enterobacter spp. and Proteus mirabilis.
Carbapenemases were found in 3% isolates of E. aerogenes, E. coli
and K. pneumoniae. Carbapenemases were subsequently genotypically
characterized as IMP, VIM, OXA, KPC CMY or SME types.
Conclusions: Emerging resistance mechanisms were found in ESBL-
producing strains, with PMQR being the most frequent. While genotypic
assays implement phenotypic testing of AmpC and carbapenemases, they
are the only methods available up to date for detection of PMQR. Hence,
both phenotypic and genotypic methods should be employed to rationally
direct the pharmacological treatment.
O129 Emergence of Klebsiella pneumoniae ST11-producing KPC-3
carbapenemase at a Lisbon hospital
P. Machado °, A. Silva, L. Lito, J. Melo-Cristino, A. Duarte (Lisbon, PT)
Background: KPC-type carbapenemases are emerging resistance in
Klebsiella pneumoniae and other Gram-negative bacteria in several
geographical areas since 2001. KPC producers area increasingly
prevalent in USA, Israel and Greece, and have been recently detected in
Asia, Latin America and Europe.
Objective: The aim of this study was to investigate the resistance
mechanisms in a Klebsiella pneumoniae 2564FF clinical isolate resistant
to oxyiminocephalosporins, a-methoxycephalosporins and carbapenems.
Methods: Minimum Inhibitory Concentrations (MICs) were determined
by Etest technique and isolates were screened for extended-spectrum
b-lactamases (ESBLs), metallo-b-lactamases (MBLs) and class A
carbapenemase was detected by boronic acid assay. Polymerase Chain
Reaction (PCR) was performed with primers designed to amplify
blaSHV, blaTEM, blactx, blaKPC genes and respectively genetic
environment. Population analysis by multilocus sequence typing (MLST)
were screened by speciﬁc PCRs and sequencing analysis. M13
ﬁngerprint typing method was used to compare this isolate with others
K. pneumoniae isolates found in this hospital.
Results: K. pneumoniae 2564FF was isolated from a blood culture of
a patient with leukemia at Santa Maria Hospital, Lisbon. The MIC
for imipenem, aztreonam and to extended-spectrum cephalosporins was
32mg/L. The resistant phenotype was unchanged by EDTA but the
inhibition zones for imipenem, aztreonam and to extended-spectrum
cephalosporins were increased with boronic acid. K. pneumoniae 2564FF
produced a restrict b-lactamase SHV-1 and the carbapenemase KPC-3.
The blaKPC-3 gene is part of a plasmid and no ampliﬁcation was
observed after PCR for detection of transposase, resolvase, and putative
insertion sequences (IS) elements located upstream of blaKPC gene,
suggesting that the blaKPC gene in K. pneumoniae 2564FF was included
in a different genetic environment like Tn4401. M13 ﬁngerprinting
analysis revealed that this genotype had not been detected in the hospital
previously. Also the sequence type ST11 was not detected in others
K. pneumoniae KPC-producing strains described worldwide.
Conclusions: This is the ﬁrst report of K. pneumoniae KPC-3 clinical
isolate in Portugal. Our ﬁndings should alert medical authorities to
implement stringent methods for the detection and spread control of
emerging KPC carbapenemases.
O130 The changing epidemiology of carbapenem-resistant
Enterobacteriaceae carriage in hospitalized patients
H. Sprecher °, I. Oren, R. Finkelstein, I. Tavleva, Y. Geffen (Haifa, IL)
Objective: Klebsiella pneumoniae (KP) ranks second as cause of Gram-
negative sepsis at our medical center and forty ﬁve percent of the isolates
display an extended spectrum b-lactamase producer (ESBL) phenotype.
Starting in January 2006, the prevalence of carbapenem-resistant (CR)
KP isolates increased signiﬁcantly. Similar trends have been recorded
worldwide.
In April 2006, an extensive infection control program was started in our
medical center. In 2008 this program included surveillance to identify
potential carbapenem-resistant Enterobacteriaceae (CRE) carriers among
asymptomatic hospitalized patients being contacts of patients with KP-
CR clinical infection and all patients admitted to the general ICU and
to the hemato-oncology wards. The present study describes the results
of this program.
Methods: Rectal swabs were obtained weekly and plated on KPC
selective agar. Suspected colonies were identiﬁed by Vitek II system.
Susceptibility testing for imipenem, meropenem, and ertapenem was
performed using E-test (AB Biodisk) in accordance with the manu-
facturer’s instructions. The molecular mechanism underlying resistance
to carbapenems was assessed by PCR ampliﬁction of blaKPC and KP
speciﬁc genes directly from bacterial isolates.
Results: During a 22-month period we assessed 8650 samples from
3239 patients (1810 patients in 2008 and 1429 in 2009). Of the 105
CRE carriers identiﬁed in 2008 (5.8% of patients tested), 100 (95.2%)
were KP-CR carriers and 5 (4.8%) were CR Enterobacter sp. and/or
E. coli sp. carriers. As the carrier rate decreased in 2009 (40 of 1429
tested patients, 2.8%; p< 0.001) the proportion of CRE carriers other
than KP-CR increased signiﬁcantly (11 of 40 positive patients, 27%;
p< 0.001).
All of CRE isolates were found to carry blaKPC gene.
Conclusions: Our results show that during the present outbreak of
CR-KP, a large number of hospitalized patients considered at risk
are asymptomatic carriers and certainly constitute a major reservoir
for the nosocomial spread of the organism. The presence of multiple
CRE isolates suggests transfer of the genetic element encoding this
b-lactamase between Enterobacteriaceae species in the gastrointestinal
tract.
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O131 Impact of EUCAST breakpoints on susceptibility levels of
nosocomial Gram-negatives in Belgium
M. Ieven °, M. Delmee, P. De Mol, H. Goossens, Y. Glupczynski,
D. Pierard, M.J. Struelens, J. Verhaegen, G. Verschraegen, J. Van Eldere
(Edegem, Brussels, Lie`ge, Yvoir, Leuven, Ghent, BE; Stockholm, SE)
Objectives: The implementation of EUCAST breakpoints was simulated
on the susceptibility rates of isolates from 8 teaching hospitals in
Belgium, collected from 1998 to 2007 as part of the MYSTIC study,
against 5 antibiotics.
Materials and Methods: E-tests were used on 6993 unduplicated
Enterobacteriaceae (EB) and 2409 P. aeruginosa isolates collected over
a ten year surveillance study from patients admitted in ICU, hematology
and general wards. Results were analysed using both CLSI and the new
EUCAST breakpoints and compared.
Results: Among the EB (n = 6993), susceptibility rates according to
CLSI and EUCAST breakpoints did not signiﬁcantly decrease for
meropenem (MEM); 99.6% and 99.1% respectively. A signiﬁcant
decrease in susceptibility rates (P< 0.0001) was seen for ceftazidime
(CAZ): 83.8% to 75.5% (P< 0.0001), for cefepime (CPE): 96.9% to
88.0% (P< 0.0001), for pip/tazo (TAZO): 84.1% to 78.4% (P< 0.001)
and for ciproﬂoxacin (CIP): 83.1% to 80.2% (P< 0.0001).
Susceptibility rates for E. aerogenes isolates (n = 766), among which
TEM-24 and SHV-4 ESBL-producing isolates, decreased from 94.0%
to 77.4% for CPE (P< 0.0001) and from 54.1% to 32.4% for
TAZO (P< 0.0001) using CLSI and EUCAST criteria respectively;
susceptibility rates for MEM did not decrease signiﬁcantly and remained
high at 96.3% and 94.2% respectively.
After implementation of EUCAST breakpoints, susceptibility rates of
P. aeruginosa (n = 2409) for CAZ and CPE were not affected: 72.3%
and 61.2% respectively. MEM remained the most active agent against
P. aeruginosa though a decrease in susceptibility was observed from
81.6% to 75.2% (P< 0.0001). The activity of TAZO is affected the most
with a decrease in susceptibility from 80.4% to 69.3% (P< 0.0001).
Conclusions: When implementing EUCAST breakpoints carbapenem
activity against EB does not change whereas an important decrease
in CAZ and CPE susceptibility rates are observed. MEM remains the
most active agent against P. aeruginosa whereas the activity of TAZO is
markedly decreased.
O132 Characteristics of the multi-resistant bacteria that actually
diffuse in the Centre region, France, in and out of healthcare
institutions
N. van der Mee-Marquet °, A.S. Valentin-Domelier, T. Charbonnier,
M. Gras, L.A. Ligeon, N. Guichard, N. Girard, R. Quentin the RHC
Study Group (Tours, FR)
Objectives: Epidemiological study involving the teaching hospital, 20
general hospitals, 7 local hospitals, 16 private clinics, 12 rehabilitation-
care centers, 5 psychiatric clinics, 30 nursing homes (NHs) and 19 in
town-clinical laboratories (for outpatients), to document the diffusion of
multiresistant bacteria (MRB) into the region (2.8 millions unhabitants).
Methods: During 15 days, all MRB isolated from diagnostic clinical
samples were documented and strains were centralized. After identiﬁ-
cation control, antibiotic susceptibility testing was performed (standard
procedures). Genetic diversity of strains was studied (PFGE).
Results: The study involved 346,251 patient-days and 244,091 resident-
days. During the study, 43,379 diagnostic clinical samples were
performed: 7,564 blood cultures, 2,130 deep pus, 1,054 respiratory tract
samples, 17,768 urines, 606 intravenous devices, 12,889 superﬁcial pus.
From the 43,379 clinical samples, 281 MRB were obtained (0.6%):
56% from urine (1.5% of urine samples), 23% from superﬁcial pus
(0.6% of pus), 9% from respiratory tract (5% of respiratory tract
samples), 5% from deep pus, 4% from blood and one from intravenous
devices. MRB belonged to 14 species. S. aureus (36%) and E. coli
(31%) predominated, followed by E. cloacae (9%), P. aeruginosa (8%),
K. pneumoniae (5%) and A. baumannii (2%). Vancomycin-resistant
E. faecalis or E. faecium were not recovered. Diversity was the highest
in healthcare institutions (HCIs). By contrast, S. aureus predominated
in NHs, E. coli among outpatients. 70% of MRSA strains were non-
multiresistant (usually named CA-MRSA). 79% of ESBL-producing
E. coli strains were CTX-M. MRSA and ESBL-producing E. coli strains
were (1) mostly resistant to ﬂuoroquinolones (93 and 60% respectively),
(2) genetically diverse and distinct from clones classically spreading into
HCIs, (3) widely spread in HCIs, NHs and outpatients, (4) responsible
for rare outbreaks, but in NHs. E. cloacae, K. pneumoniae, P. mirabilis
and A. baumannii were the most involved in outbreaks into HCIs, and
were associated with a lower genetic diversity.
Conclusion: MRD are unfrequent, but their diffusion is large, especially
for recent MRSA and ESBL-producing E. coli clones.
Prevalence is the highest into HCIs, but MDR diffuse now out of HCIs,
and especially in NHs.
We suggest that an effective alert system to detect emerging and/or
epidemic phenomenon should involve MDR survey in HCIs, NHs and
in town-clinical laboratories.
O133 Antimicrobial susceptibilities of Gram negative bacteria
and antibiotic consumption in a Greek tertiary hospital,
2001–2008
S. Miyakis °, C. Moschopoulos, D. Alexiadou, M. Gatsiou,
S. Charalampidou, C. Trakatelli, V. Koulourida, M. Sion (Thessaloniki,
GR)
Objective: To examine differences in antibiotic susceptibility of Gram
negative bacteria and in antibiotic consumption in a Tertiary Hospital,
within 7 years of operation.
Methods: All clinical samples from inpatients. Identiﬁcation and
susceptibility testing, using the Wider® semi-automated system with
CLSI breakpoints. Antibiotic consumption expressed as Deﬁned Daily
Doses (DDD) per patient-day.
Results: 1550 and 706 isolates identiﬁed during 2008 and 2001,
respectively.
E. coli non-susceptibility rates were signiﬁcantly higher in 2008 for
Cefotaxime (12.5%; 69/551 isolates vs. 4.5%; 12/266 in 2001), Cefepime
(14.9% vs. 3.8%); Cotrimoxazole (31.2% vs. 18.4%); Gentamicin (9.6%
vs. 3.7%); and Ciproﬂoxacin (21.6% vs. 3.3%) (for all, p< 0.01).
K. pneumoniae non-susceptibility increased signiﬁcantly for Cefotaxime
(55.1%; 97/176 isolates in 2008 vs. 35.6%; 21/59 in 2001), Cefuroxime
(58.5% vs. 31.8%); Cotrimoxazole (51.1% vs. 18.6%); Cefepime (53.4%
vs. 5.1%); and Ciproﬂoxacin (51.7% vs. 13.2%) (for all, p< 0.01).
P. aeruginosa non-susceptibility increased for Gentamicin (26.5%;
61/230 in 2008 vs. 14.2%; 15/95 in 2001, p = 0.01), Amikacin (18.2%
vs. 13.1%), Pip/Tazo (15.2% vs. 10.9) and Cefepime (25.6% vs. 16.3%).
In 2008, non-susceptibility rates to anti-pseudomonal antibiotics ranged
from 18.2% (Meropenem) to 26.1% (Ciproﬂoxacin). A. baumannii non-
susceptibility increased signiﬁcantly for Pip/Tazo (82.2%; 180/219 vs.
37.8%; 17/45, p< 0.01). In 2008, non-susceptibility rates ranged from
52.1% (Cefepime) to 88.6% (Ciproﬂoxacin).
Pan-Drug Resistant (PDR − to B-lactams, Carbapenems, Amikacin,
Ciproﬂoxacin and Colistin) bacteria isolated in 2008: Klebsiella (12),
A. baumannii and P. aeruginosa (1 each). No PDR isolates were found
in 2001.
Consumption of antibiotics with activity against Gram negatives
increased by 30.3% (15.9 DDD/100 hospital-days in 2008 vs. 12.2
in 2001). Increase was more marked for Carbapenems (3.2 vs.
1.1; p< 0.03), Fluoroquinolones (6.4 vs. 4.3) and Colistin (0.05 vs.
0.03), whereas decreased was the consumption of 3rd Generation
Cephalosporins (2.1 in 2008 vs. 2.3 in 2001) and the anti-pseudomonal
penicillins (3.8 vs. 4.0).
Conclusion: Non-susceptibility rates of Gram negative bacteria
markedly increased within 7 years and PDR strains emerged. This
paralleled the increased consumption of wide-spectrum antibiotics
(mainly Carbapenems and Fluoroquinolones) and of antibiotics used as
last-resource (Colistin).
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O134 Recent epidemic emergence of blaNDM-1 metallo-
b-lactamase in enteric organisms from India is mostly linked
to A/C plasmids
M. Toleman °, K. Karthikeyan, M. Sharma, U. Chaudhary,
M. Thirunarayan, P. Krishnan, T. Walsh (Cardiff, UK; Chennai,
Rohtak, Haryana, IN)
Objective: Metallo-b-lactamases are powerful resistance mechanisms
that can generate insensitivity to virtually all b-lactam antibiotics.
The recent epidemic emergence of this resistance mechanism in
Klebsiella spp., E. coli, Enterobacter cloacae, Citrobacter freundii and
Providencia rettgeri in geographically distant areas of India and the UK
is a major cause for concern. This project was initiated to determine the
genetic vehicle(s) responsible for the rapid emergence and dissemination
of the blaNDM-1 MBL in enteric organisms.
Methods: Species identiﬁcation and antibiotic susceptibility proﬁle of
67 blaNDM-1 harbouring enteric isolates collected from Chenai (south
India) and Haryana (North India) was performed using the Phoenix
machine. Isolates were typed by pulsed ﬁeld Gel electrophoresis after
Xba1 digestion. Plasmids were visualized by ethidium bromide staining
following PFGE of S1 partially digested plugs. Plasmids carrying
blaNDM-1 were further identiﬁed by probing of the same gels using
a 32P labelled blaNDM-1 and A/C rep probes. Transconjugants were
selected following matting with J53 on MacConkey plates containing
azide and 0.5mg/L meropenem. Plasmid analysis on A subset of
transconjugants (20) was performed by replicant typing and S1 PFGE
and subsequent probing. A/C plasmid analysis was further performed
using a set of 12 primers designed to amplify sections of the backbone
of A/C plasmids and DNA probing with A/C probes.
Results: All isolates from the North of India were Klebsiella pneumoniae
and carried A/C plasmids of size 50kb (9), 80−90kb (2), or 118kb (11).
However, in the south of India isolates were of various enteric species and
gave numerous different pulsed ﬁeld gel restriction types. Furthermore
plasmids found in the isolates from the south were of many different
sizes ranging from 100kb to 375kb in size. Probing indicated that most
plasmids carrying blaNDM-1 were of rep A/C type (19/20) only 1/20
tested were found to be carried on the F plasmid. Transconjugants were
selected for all strains except the small plasmids from the North of India.
Transconjugants gave plasmids of mostly the same size but examples
were found of size changes following transconjugation including both
increasing and decreasing size. PCR on transconjugants and parents
indicated differences in the A/C plasmid backbone.
Conclusions: blaNDM-1 emergence in enteric organisms in India is
linked mostly to A/C plasmid types of varying sizes ranging from 50kb
to 375kb.
O135 Stabilization in prevalence of ESBLs and ciproﬂoxacin
non-susceptibility in Enterobacteriaceae from blood in the
United Kingdom and Ireland
R. Reynolds °, R. Hope on behalf of BSAC Working Party on Resistance
Surveillance
Objective: E. coli is the most frequent cause of bacteraemia in the
UK, and increasing antimicrobial resistance could severely compromise
current therapeutic approaches. The BSAC Bacteraemia Resistance
Surveillance Programme has monitored resistance in pathogens from
blood, including Enterobacteriaceae, since 2001.
Methods: Each year, 25 laboratories in the UK and Ireland sent up
to 10 isolates each of E. coli (20 in 2008), Enterobacter, Klebsiella,
Proteeae and other Gram-negative bacteria for central MIC testing by
BSAC methods. The presence of ESBLs was deduced phenotypically
from clavulanate synergy and blaCTX-M genes were sought by PCR.
Results: The prevalence of ESBL production in E. coli and Klebsiella,
and ciproﬂoxacin non-susceptibility in E. coli, rose markedly in the
early 2000s, but has not risen further since 2006. Segmented logistic
regression (assuming two periods) located change points near early
2006 for E. coli and early 2004 for Klebsiella, with no signiﬁcant
increase in ESBLs or ciproﬂoxacin non-susceptibility in the later period.
Prevalence of resistance, including AmpC and ESBLs, has changed
little in Enterobacter over this period, and ESBLs remain very rare
in Proteeae and Serratia. ESBL production increased with similar time
course in both infections acquired in hospital (>48 hours after admission)
and others, but was always more prevalent in hospital infections (twice
as prevalent for E. coli and Enterobacter, three times for Klebsiella,
2005−08.) CTX-M ESBLs were predominant, comprising 90% of ESBLs
in E. coli and 67% in Klebsiella but only 22% in Enterobacter in
2005−08. ESBL producers were commonly multiresistant, as previously
noted. In 2008, all ESBL-producers remained susceptible to imipenem,
meropenem and doripenem, although a few non-producers (1 Klebsiella,
3 Enterobacter) were non-susceptible to one or more of these agents. The
spread of multiresistant ESBL-producers did not explain all the changes
seen in antimicrobial resistance: among E. coli (but not other genera)
ciproﬂoxacin non-susceptibility in ESBL non-producers also increased
from 2001, and appears to have stabilized from 2007, standing at 12%
in 2008.
Conclusion: Prevalence of ESBLs in E. coli and Klebsiella, and
ciproﬂoxacin non-susceptibility in E. coli, rose rapidly in the early 2000s.
It has now stabilized, but at a level that demands continued vigilance
and care in the selection of empirical treatment.
ESBL production and ciproﬂoxacin non-susceptibility: % of isolates
from blood, 2001–2008
Year E. coli Klebsiella Enterobacter
N ESBL CIP N ESBL CIP N ESBL CIP
2001 245 0 8 233 6 10 180 6 13
2002 250 3 7 242 5 15 206 9 17
2003 248 2 11 245 8 9 217 6 16
2004 248 6 18 225 16 18 206 9 13
2005 247 7 17 237 13 16 213 15 14
2006 242 12 26 237 13 15 198 10 17
2007 248 9 24 227 12 18 204 9 17
2008 467 9 19 206 12 15 157 9 13
ESBL=% producing ESBL; CIP =% non-susceptible to ciproﬂoxacin
(MIC 1mg/L).
O136 Risk factors for intestinal carriage of Enterobacteriaceae
with extended-spectrum b-lactamase-producing phenotype
on a medical ward
M. Lupse °, M. Flonta, A. Moisuc, A. Seiceanu, M. Maricoiu,
S. Muresan, M. Horvath, S. Tomescu, A. Dicea (Cluj-Napoca, RO)
Background: Intestinal carriage is a reservoir for invasive infection with
ESBL producing Enterobacteriaceae (ESBL PE) and their dissemination.
The aim of the study is to establish the risk factors for intestinal carriage
in patients admitted on a medical ward with infectious and noninfectious
diseases.
Method: A prospective study conducted between 1st Aug and 31st Oct
2009 on patients hospitalized for more than one week. Patients were
screened on discharge (convenience sample). Rectal swabs were placed
in 1ml sterile 0.9% saline then inoculated on cultured media Chrom
ID ESBL Biomerieux. The results were conﬁrmed with double disc
diffusion assay according to CLSI. Univariate and multivariate analyses
were performed.
Results: 153 patients were screened (46% male, median age 53.8 years)
from which 129 patients (84%) were admitted for infectious diseases. 64
ESBL PE were isolated (carrier rate 41.83%). ESBL PE included: E. coli
(39), Klebsiella spp. (21), Proteus spp. (2), Serratia spp. (2). Variables
associated with ESBL PE carriage by univariate analysis: length of
stay (p = 0.03), length of antibiotic use (p = 0.02), use of ceftriaxone
(p< 0.01), use of ciproﬂoxacin (p = 0.003). In multivariate analysis, only
length of stay (p = 0.004) and use of ciproﬂoxacin (p = 0.001) were
independently associated with carriage of ESBL PE.
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Conclusions: ESBL PE carriage rate after hospitalization and treatment
in our medical ward is high. Length of stay and use of ciproﬂoxacin are
important risk factors for intestinal carriage with ESBL PE.
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O137 Risk factors of death among hospitalized patients with
tuberculosis: a report from Iran
P. Tabarsi °, P. Baghaei, M. Marjani, M. Shamai, F. Varahram,
D. Mansouri, M. Masjedi, A. Velayati (Tehran, IR)
Background: Although mortality levels have decreased there is still
signiﬁcant number of people, especially in Iran, expiring as a result
of TB infection. In this study we evaluate risk factors of death among
hospitalized patients with TB.
Method: The retrospective study was carried out at the National
Research Institute of Tuberculosis and Lung Disease (NRITLD) in
Tehran, Iran from May 2003 to Dec 2009. Patients with documented
pulmonary TB were included. A death case is considered as a case that
died during the treatment of TB from any causes. Data was gathered
from medical records and compared between two groups of patients
who died and the group who didn’t die during their treatment. These
variables include age, sex, nationality, history of smoking and opium,
HIV status, history of TB treatment, co-morbidity, symptoms and sign
of TB, cavitary lesion, and other demographic, clinical and radiological
factors. All data were entered into SPSS (Version 15.0). The Cox-
proportional hazard model was used for the signiﬁcant factors with
survival.
Results: In this study, 1897 tuberculosis patients were included. The
mean age was 50.18±21.13 years and 54±20 in all patients and in
death group respectively, a difference that was statistical signiﬁcant.
973 were male (51.3%).76.8% of the patients were Iranian and the
remaining 440 (23.2%) were from the neighboring countries. During
the hospitalization, 163 (8.6%) patients died. The mean duration of
admission was 34±36.8 days (Median = 22 days, Range 1–365). Totally
among whom HIV test was performed, 32 (22.2%) cases of the death
group and 82 (14.3%) of the control group were found to be HIV positive
that reach statistical signiﬁcance.
The mean duration of symptoms to admission was 8.27±16.79 months.
Notably, cough, dyspenea, and fever were more commonly seen in death
group (P< 0.05).
During the course of treatment, 231 (12.2%) developed drug-induced
hepatitis that 45 (19.5%) of the patients died (p< 0.05). In c2 analysis,
male sex, Iranian nationality, opium addiction, HIV positive status,
concomitant respiratory and immunosuppressive diseases and MDR-TB
were statistical signiﬁcant in death group.
In the stepwise Cox regression model, is showed that TB history,
smoking, co-morbidity, involvement of lung, cavitary lesion, Drugs
induced hepatitis, WBC< 4000 and >10000 and age >65 affected the
in-hospital mortality rate (Table 1).
Conclusion: Identiﬁng these risk factors may improve clinical outcome
of patients.
Table: Cox-proportional hazard model of factors
Multivariate logistic regression
Crude HR HR 95%CI
TB history 2.270 1.562 1.023–2.383
Smoking 0.538 0.621 0.443–0.871
Co-morbidity 0.326 0.424 0.295–0.610
Involvement of lung 0.899 0.498 0.311–0.798
Cavitary lesion 1.650 1.379 0.960–1.980
DIH 2.155 1.592 1.112–2.282
WBC 1.425 2.169 1.555–3.027
Age >65 1.896 1.688 1.165–2.445
O138 Mycobacterium in paediatric patients during a 2-year period
in a health district of Madrid, Spain
A´. Somodevilla °, D. Domingo, S. Agudo, B. Herna´ndez, M. Alonso,
M. Lopez-Brea (Madrid, ES)
Objective: The aim of this study is to describe the prevalence of
tuberculosis and non-tuberculosis mycobacteria isolates in paediatric
patients during a two year period (November 2007 to November 2009)
in a health district of Madrid (Spain).
Methods: Four hundred and ninety eight specimens from paediatric
patients were proceseed for mycobacterial study. All of them were pre-
pared for auramine stain and decontaminated by NaOH-N-acetylcysteine
method. When the specimen was a gastric acid, it was neutralizated
before with bicarbonate of sodium. After decontamination each specimen
was cultured in liquid and solid medium (MIGT and Coletsos,
respectively). If growth was detected a Zielh-Neelsen stain was done.
Accuprobe kit (Gen-Probe) was used to identiﬁcate Mycobacterium
tuberculosis Complex or Mycobacterium avium Complex strains.
Other Non Tuberculosis Mycobacteria (NTM) were identiﬁed by solid
hybridization using GenoType Mycobacterium kit (Hain Lifescience).
Results: Thirty two (6.42%) out of 498 specimens received were
positive: 17Mycobacterium tuberculosis Complex (53.13%), 9Mycobac-
terium abscessus (28.12%), 4 Mycobacterium avium Complex (12.5%)
and 2 Mycobacterium lentiﬂavum (6.25%).
They were obtained from different specimens from 22 patients:
– M. tuberculosis Complex: 14 gastric juice, 2 pleural liquid and 1
sputum.
– M. abscessus: 7 sputum, 2 bronchoalveolar lavage.
– M. avium Complex: 2 ﬁne needle aspiration biopsies (FNAB), 1 gastric
juice and 1 bronchoalveolar lavage.
– M. lentiﬂavum: 2 FNAB
Five out of 22 patients were cystic ﬁbrosis patients, in 4 of them
the microorganism isolated was M. abscessus. In the other one,
M. lentiﬂavum was recovered.
Conclusions: The most common specimens received were those of
the respiratory tract, where M. tuberculosis was the most prevalent
mycobacteria followed by M. abscessus. On the other hand in
FNAB specimens the species isolated were M. avium Complex, and
M. lentiﬂavum. M. abscessus is the most common mycobacteria isolated
in cystic ﬁbrosis patients in this population during this period.
O139 Seroprevalence of human immuno-deﬁciency virus infection
among patients diagnosed with sputum smear positive
pulmonary tuberculosis at an infectious diseases hospital,
Kano, Nigeria
Y. Mohammed ° (Kaduna, NG)
Objective: The main objective of the study is to estimate the HIV
seroprevalence among patients diagnosed with sputum smear positive
pulmonary tuberculosis (PTB).
Methods: Inorder to estimate the HIV seroprevalence one thousand
six hundred and ninety-two (1,692) males (1066) and females (626)
patients aged 15 years and above, with no previous TB treatment that
presented to the chest clinic with symptoms like cough, night sweats,
fever, weight loss, chest pain etc, and whose initial sputum smears
demonstrated acid fast bacilli (AFB) by direct smear sputum microscopy
using Ziehl-Nelseen (ZN) stain at least two specimens in line with WHO
recommendation. Each patient was offered conﬁdential HIV testing
accompanied by pre and post-test counseling accordingly. Those that
agreed to be screened for HIV antibodies had blood sample taken
for the test and performed according to the standard hospital practice
and followed guidelines developed by the National HIV Rapid Test
Algorithm using ELISA Test of Capillus, Genie 11 and Determine HIV
kit.
Results: The overall HIV prevalence was 38%, of that value, male,
accounted for 37% and females 41%. There was no statistical difference.
However, the prevalence is 48% in the age group 25−34years as
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compared to only 12% in the age group 55−64years which was
statistically different (P< 0.05). A higher proportion of females (42%)
than males 37% were HIV Seropositive, but the difference is not
statistically signiﬁcant (P> 0.05).
Conclusion: There is high Human Immunodeﬁciency Virus prevalence
(38%) among the studied patients with sputum smear positive pulmonary
tuberculosis. The link between HIV and TB is often well known but few
TB patients currently have the opportunity to know their HIV status and
the stigma attached to HIV may deter people with features of suspicious
of TB from seeking TB care.
O140 Different clinical isolates of Mycobacterium tuberculosis
induced distinctive pulmonary inﬂammation in mice
E. Soares °, C. Peres, A. Secatto, E. Garcia Soares, M. Palaci,
A. Kritski, C. Silva, L. Faccioli (Ribeirao Preto, Bauru, Espı´rito Santo,
Rio de Janeiro, BR)
Background: Mycobacterium tuberculosis (Mtb) is a virulent intracel-
lular pathogen that infects and persist in host macrophages, resulting
in granuloma formation and collagen deposition in the lung. The
mechanisms that confer resistance to Mtb or results in establishment
of disease are poor understood. Data from the literature suggest that
differences in Mtb virulence contribute to setting up of the disease.
In order clarify this aspect, our purpose is to investigate the immune
response and lung pathology in mice infected with Mtb obtained from
distinct clinical isolates. The isolates were recovered from patients with
noncavitary (SV 009) or extrapulmonary (SV 068) active tuberculosis.
Methods: Female Balb/c mice were infected intratracheally with 1×105
CFU/100mL of Mtb clinical isolates. Neutrophils and mononuclear cells
recruitment to the lung were accessed by bronchoalveolar lavage at 30
days post infection and lung histology were evaluated on 30 and 60 days
post infection.
Results: Mice infected with SV 068 showed 22% more neutrophils
(9×105/mL) and 70% more mononuclear cells (6×105/mL) recruited
to bronchoalveolar space 30 days post infection, when compared with
mice infected with SV 009, 5×105 mL and 4.5×105 mL respectively.
The histology analysis of lung tissue, demonstrated that animals infected
with SV 068 present greater number of foamy macrophages containing
aggregations of Mtb, especially at 60 days post infection. Also, in this
period, we observed the presence of more intense inﬁltrate of neutrophils
in perivascular and perialveolar spaces when compared with animals
infected with SV 009.
Partial Conclusion: Our preliminary ﬁndings suggest that the host
defense can vary accordingly to the type of clinical isolation, leading
to a correlation between the virulence and the source of infection.
O141 Infection of a knee joint with Mycobacterium avium in a
patient with sarcoidosis
J. Hahne °, T. von Stein, M. Militz, R. Werle, V. Bu¨hren (Murnau, DE)
Objective: Infections of osteoarticular tissue caused by Mycobacterium
avium are reported in the literature but are still rare. Mycobacterium
avium is found throughout the environment, the transmission is still
unknown. Patients show a variety of symptoms and the septic process is
insidious which is leading to a delay of diagnosis. Most patients reported
on were immunocompromised. Potential treatments are either surgery,
antituberculous drugs or both.
Method: We present a case of a 33 year old Caucasian male with a
Mycobacterium avium infection of the knee joint.
Results: In March 2009, a 33 year old Caucasian male with
previously documented sarcoidosis presented in a german university
hospital with pain and swelling in the right knee joint. The patient
underwent knee arthroscopy and consequetively developed purulent
knee arthritis and a lateral joint ﬁstula. Repetitive debridements were
performed. The histological examination of the resected tissues showed
granulamatous inﬂammation. Mycobacterium avium was conﬁrmed via
culture. In addition to surgery the patient was treated with ethambutol,
clarithromycin and rifabutin. The ﬁstula persited and therefore treatment
was changed to air dressing. At the request of the patient he was sent
to our specialist department for septic surgery. Repetitive debridements
were started. Tissue samples revealed Pseudomonas aerogenosa and
Staphylococcus haemolyticus. Tests for Mycobacterium avium were
positive. Because of superinfection with the listed bacteria ethambutol
was replaced by ciproﬂoxacin. The soft tissue quality improved. In
august 2009 a ALT ﬂap was transplanted. Postoperative progress was
uncomplicated − the patient was discharged in September 2009. We
recommended treatment with clarithromycin, ciproﬂoxacin and rifabutin
for another 7 months. Mobilisation at full weight bearing as pain
allowed was started at discharge. Deﬁnitive treatment options have to
be reevaluated 6 months after last surgery. A total knee replacement in
the case of negative microbiological tests is optional.
Conclusion: In immunocompromised patients with osteoarthritis the
infection with ATM (atypical Mycobacterium) should always be consid-
ered. Treatment should include both: surgery and antituberculous drugs.
Knowing the in vitro resistance of most ATM against antituberculous
drugs, it’s debatable whether the superinfection of other bacteria is
clinically relevant for the symptoms and should be treated with priority.
O142 Mycobacterium conceptionense (M. fortuitum group) catheter-
related bloodstream infection in an immunocompromised
patient − necessity for antibiotic treatment after removing
the central venous catheter? Review of literature
A. Mischnik °, D. Schobel, S. Zimmermann (Heidelberg, Baden-Baden,
DE)
Objective: Atypical Mycobacteria can cause disease in both healthy and
immunocompromised individuals. They can rarely cause disseminated
infections. Nevertheless infections in immunocompromised patients by
atypical mycobacteria are described.
Results: We report a case of a 54-year-old man with diffuse
large b-cell lymphoma (DLBCL) stadium III E B of the stomach,
proximal duodenum, axillary, inguinal and cervical lymph nodes
after six cycles R-CHOP 14 and one cycle R-DHAP chemotherapy
received via central venous catheter (CVC) who develops leucopenia
and anemia. Blood culture reveals Mycobacterium fortuitum. On
admission to our hospital several days later a blood sample reveals
leucocytosis (10.97×109 cells/litre), low hemoglobin level (9.8 g/dl)
and thrombocytosis (517×109 platelets/litre). The C-reactive protein
level was 43.9mg/l. The patient has no fever. Blood cultures taken
simultaneously peripherally and via CVC reveal both Mycobacterium
conceptionense (Mycobacterium fortuitum group). The CVC is removed,
but routine culture is negative for Mycobacteria. Because of a
sustained bacteraemia for more than ten days and an underlying
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immunocompromission antibiotic treatment with clarithromycin (500mg
twice daily) and amikacin (15mg/kg once daily) is done for two weeks in
accordance with the guidelines of the American Thoracic Society (ATS).
A repeat blood culture after therapy is sterile.
Conclusion: In literature there are only few descriptions of invasive
infections with rapidly growing Mycobacterium fortuitum. In a setting of
underlying immunocompromised disease we treat bloodstream infection,
advocate a duration of two weeks after having removed the catheter and
review literature for the necessity for antibiotic treatment.
O143 Human Mycobacterium bovis infection in Buenos Aires:
epidemiology, microbiology and clinical presentation
E. Cordova °, X. Gonzalo, A. Boschi, M. Lossa, M. Robles, S. Poggi
(Buenos Aires, AR)
Objectives: Describe the clinical, epidemiological, and microbiological
characteristics of a series of cases of M. bovis infection in humans
diagnosed in the Infectious Diseases ‘Francisco J. Mun˜iz’ Hospital,
Buenos Aires, Argentina.
Methods: Analytic and retrospective study of clinical, epidemiological
and laboratory ﬁndings of 39 patients with conﬁrmed diagnosis of
M. bovis infection (1996–2008).
Results: N=39. Male: 28/39 (72%). Age (median): 45 years. Previous
conditions: Diabetes 8/30 (27%), HIV(+) 8/37 (22%) (CD4 count
(median): 34 cells/mm3), malignancy 1/30 (3%). Domicile: Buenos Aires
city and Conurbano: 22/22 (100%).
Risk factor for M. bovis: 26/28 (93%); a) Occupational exposure: 17/26
(65%) (meat processing plant (n = 9); butcher’s shop (n = 4); tannery
(n = 2); handling meat for pets (n = 2)); b) Consumption of unpasteurized
milk 1/26 (4%); c) History of living in rural area: 8/26 (31%).
Clinical presentation: fever 16/25, malaise 14/25, weight loss 20/25,
night sweats 8/25, cough 21/25, expectoration 21/25, haemoptysis
7/25, dyspnea 7/25, headache 2/25. Pulmonary disease: 29/39 (74%),
extrapulmonary disease: 4/39 (10%); both: 6/39 (15%). Extrapulmonary
disease included: lymph nodes 5/10, skin 1/10, bone and joints 2/10,
renal 2/10, CNS 2/10. Comparing risk factor for M. bovis and pulmonary
disease: occupational 17/17 (100%) vs. non occupational 6/9 (67%)
(p = 0.03). Chest X-ray: cavities 10/26, miliary 2/26, pleural effusion
2/26, alveolar inﬁltrates 13/26. Mantoux test (+): 6/17 (35%). Outcomes:
died 5/22 (23%) (HIV(+) = 3/3) (p = 0.01). Microbiology results:
pulmonary specimens (sputum=35, BAL=2): Ziehl–Neelsen stain (ZN)
(+): 28/37 (77%); Lymph nodes (n = 5): ZN(+): 1/4 (25%). All samples
grew well in Stonebrink medium and neither in Lowenstein-Jensen.
Susceptibility: Pirazinamide (Z) resistance (natural): 39/39. Susceptibil-
ity to isoniazid (H)–rifampin (R)–ethambutol (E)–streptomycin: 27/29
(93%). R resistance: 1/29 (3%). Multidrug resistance (H+R): 1/29 (3%).
Empirical treatment (H−R−E−Z): 25/27 (93%). Follow up sputum (after
day 60): ZN(+): 3/9.
Conclusions: The most important risk factor was occupational exposure.
Pulmonary disease, indistinguishable from tuberculosis, was the most
frequent clinical presentation. A high proportion of the patients had
a compromised immune system with a high mortality among HIV(+)
patients. In contrast to what is commonly described the most likely route
of infection in our series was airborne transmission.
O144 Features of non-tuberculous mycobacterial pulmonary in-
fections in an eight-year cohort of non-HIV-infected patients
B.S. Davies, C.H. Roberts °, J. Klein, H.J. Milburn (Brighton, London,
UK)
Background: Non-tuberculous mycobacterial (NTM) pulmonary infec-
tions predominantly affect patients with advanced HIV and those with
chronic lung disease.. Data on the nature of infection, treatment course
and outcomes in the UK are sparse.
Objectives:
• To identify and characterise NTM pulmonary infections with slow
growing mycobacteria in non-HIV patients, diagnosed within a south
London teaching hospital between 2000 and 2007
• To assess underlying risk factors for infection
• To assess treatment given, incidence of side effects, treatment cure
and relapse rates
Methods: In this retrospective study 2000–2007, we examined
pulmonary NTM infections south London hospital. Cases were identiﬁed
through the microbiological database and case notes records. Inclusion
criteria were: culture positivity for Mycobacterium kansasii (MK),
Mycobacterium avium intracellulare (MAI), Mycobacterium xenopi
(MX) and Mycobacterium malmoense (MM); >18 years old; HIV
negative; meeting the ATS (American Thoracic Society) clinical criteria.
Radiological reports were made by a radiologist. Statistical analyses were
made on SPSS v15, using t tests and Mann Whitney U as appropriate.
Results: Of 211 patients identiﬁed with NTM isolates, 57 met inclusion
criteria. Males (76%) with a median age of 60.5 years predominated.
Predisposing factors were smoking (76.1%), alcohol (30.4%) and COPD
(39.1%). Radiologically, cavitation (63.6%) and pulmonary inﬁltrates
(31.8%) were common ﬁndings. 47 patients were treated, 10 not treated
and 5 died. The predominant organism was MK, 35 of 47 cases (74.5%).
Of the MK infections, there was a 100% cure rate with a 10% relapse rate
over a 3 year follow up period. Treatment courses differed from British
Thoracic Society (BTS) guidelines, most patients receiving triple therapy
of rifampicin, ethambutol and usually clarithromycin or ciproﬂoxacin
for >9 months. Side effects were common, occurring in 30% of treated
infections. The statistically signiﬁcant predictors of a poor outcome were
a low pre-treatment weight and absence of fever.
Conclusions: M. kansasii is the predominant NTM organism in London.
Optimal treatment regimens are unclear. In this study many patients
were treated with 3 agents, in counterpoint to BTS guidelines. However,
adding a third agent to the treatment regimen for MK did not appear to
reduce the relapse rate, but did increase the risk of side effects.








Median age (range) 58 (25−87) 7.5 (59−80) 0.081
Male sex 18 (72) 5 (62.5) 0.652
Median Pre-treatment weight (range) 60 47 0.046
Median weight difference, kg +1.4 −0.1 0.517
Symptoms & predisposing factors
Weight loss 11 (44) 5 (62.5) 0.394
Haemoptysis 4 (16) 3 (37.5) 0.304
Fever 2 (8) 0 0.022
Alcohol 7 (28) 2 (25) 0.876
Prior rnycobacterial disease 2 (25) 3 (12) 0.48
COPD 8 (32) 3 (37.5) 0.795
O145 Absence of non-tuberculous mycobacteria recovery in
sputum of cystic ﬁbrosis patients despite adequate
decontamination: a possible role of speciﬁc antimicrobial
therapy used in our centre
E. Andre °, J. Degraux, A. Simon, A. Ferroni, T.D. Huang (Brussels,
BE; Paris, FR)
Objectives: Non-tuberculous mycobacteria (NTM) were pathogens of
growing importance in non-paediatric cystic ﬁbrosis (CF) patients. In
our centre, the prevalence of NTM in these patients observed (0.5%)
during the last decade was markedly inferior to those reported in the
literature ranging from 6.5% to 24%. The aim of this study was to screen
for NTM in adult patients in our centre with 3 different decontamination
methods for mycobacterial cultures in order to determine whether the
choice of the decontamination technique of samples may have an impact
on their recovery in our centre.
Methods: Between January and June 2009, consecutive sputum samples
from adult patients with clinical suspicion of NTM infection (respiratory
function degradation without other microbiologic explanation) were
included in this study. 3 different decontamination protocols were
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used: N-acetyl-l-cysteine (NALC)-NaOH (DCT1), NALC-NaOH-oxalic
acid 5% (DCT2) and DTT-Chlorhexidine 1% (DCT3). Decontaminated
specimens were than cultured onto both solid Loewenstein-Jensen slants
(LJ; BioRad) and liquid MGIT (BD) culture. A sample was considered
NTM negative if no NTM isolate was recovered after a standard 42-day
incubation protocol.
Results: 36 sputum samples were collected from 26 adult patients during
the study period. The median age of patients was 26 years. 88% of
the patients received antimicrobial active against mycobacteria for more
than 24 months before sputum collection (61% of the patients had
ﬂuoroquinolones and 88% had macrolides). No NTM was detected in
the 36 specimens with none of the three decontamination techniques.
Conclusions: Long-term use of macrolides and ﬂuoroquinolones may be
an explanation for the absence of recovery of NTM in these CF patients.
Further studies in other CF centres prescribing similar antimicrobial
treatment regimens are warranted to support this observation.
O146 M. haemophilum outbreak among 9 Swiss women after
permanent make-up of the eyebrows
S.G. Giulieri °, M. Cavassini, T. Edney, M. O¨dman Jaques,
C. Voide, D. Guggisberg, C. Hammann, E. Musumeci, E. Masserey,
K. Jaton-Ogay (Lausanne, Neuchaˆtel, CH)
Objective: Between May and September 2009 9 patients were referred
to our infectious diseases outpatient clinic because of skin lesions and
suppurative lymphadenitis after permanent make-up of the eyebrows. We
present the clinical and microbiological characteristics of the patients and
the results of the outbreak investigation.
Methods: All but one patients had at least a lymph node ﬁne needle
aspiration, whereas skin biopsy of the eyebrow was performed only in
4 cases. Microscopic examination for mycobacteria, culture and broad-
range mycobacterial PCR (16 S rRNA) were performed. Diagnosis of
the ﬁrst case was established using broad-range mycobacterium PCR. As
PCR was positive for M. haemophilum, special culture was performed.
After notiﬁcation to the public health authorities, an investigation
was started and all possibly contaminated material was examined for
mycobacteria.
Results: All patients presented with an inﬂammatory lesion of the
eyebrow associated with ipsilateral lymphadenitis located within the
parotid gland. The lesions appeared 2−6 weeks after permanent make-
up of the eyebrows. Fine needle aspiration and skin biopsy of the
eyebrow were positive for mycobacteria in 8 and 1 case, respectively.
Microscopic examination showed acid-fast bacilli in 6 cases whereas
broad-range PCR was positive for M. haemophilum in 5 cases. Culture
was positive for 7 patients after 14–70 days (median 44 days) and
the microorganism was identiﬁed as M. haemophilum. All patients
were treated with various combinations of ciproﬂoxacin, clarithromycin
and either rifampin or rifabutin. Parotidectomy, local eyebrow excision
and partial neck dissection were performed in 3 cases. Three patients
were in complete remission following surgical intervention, one patient
was in partial remission after two months of conservative treatment.
The remaining 5 patients were stable after 2−6 weeks of antibiotic
therapy (still ongoing). Outbreak investigation showed that all make-
up procedures were performed by the same tattoo artist. PCR of the the
make-up ink was positive in 6 out of 19 samples for M. haemophilum,
cultures are still negative after 5 weeks.
Conclusions: We report the ﬁrst M. haemophilum outbreak after
permanent make-up due to contamination of the make-up ink. PCR
analysis of mycobacterial 16S rRNA is an effective tool for early
diagnosis and for appropriate selection of culture method. Optimal
management of the infection requires further studies.
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O147 Vaccination with Acinetobacter baumannii outer
membrane proteins elicits protective immunity against
multidrug-resistant and pan-resistant strains
M.J. McConnell °, J. Domı´nguez-Herrera, Y. Smani, R. Lo´pez-Rojas,
F. Docobo-Pe´rez, J. Pacho´n (Seville, ES)
Objective: Over the last two decades the incidence of hospital-associated
infections caused by multi-drug resistant Acinetobacter baumannii has
increased signiﬁcantly, requiring the development of novel approaches
for controlling this infection. The objective of the present study is
to develop a prophylactic vaccine for the prevention of A. baumannii
infection.
Methods: Outer membrane proteins (OMPs) were puriﬁed from
A. baumannii strain ATCC 19606, combined with an aluminium
adjuvant, and used to vaccinate C57BL/6 mice by intramuscular
injection. Levels of anti-OMP antibodies in serum were quantiﬁed by
ELISA, and the ability of serum to prevent bacterial adherence to the
A549 epithelial cell line was determined. Mice were challenged with the
ATCC 19606 strain and 2 clinical isolates using a disseminated sepsis
model, and the following parameters were measured: i) bacterial loads in
tissues, ii) serum levels of pro-inﬂammatory cytokines, and iii) mortality.
The ability of serum from vaccinated mice to protect naive mice from
infection by passive transfer was determined.
Results: Two doses of the vaccine three weeks apart elicited high
levels of OMP-speciﬁc antibodies which were able to block bacterial
adherence to A549 cells. At 12 hours post-challenge, vaccinated mice
had fewer bacteria than control mice in spleens (3.78 vs. 9.07 log10
cfu/g; p< 0.001), kidneys (3.50 vs. 8.33 log10 cfu/g; p< 0.001), and
lungs (3.73 vs. 8.95 log10 cfu/g, p< 0.001). Vaccinated mice had lower
serum levels of the pro-inﬂammatory cytokines IL-1b (2.0 vs. 396.1
pg/ml, p< 0.001), TNF-a (59.3 vs. 351.9 pg/ml; p = 0.002), and IL-6
(188.6 vs. 51141.3 pg/ml; p = 0.007) than control mice 12 hours post-
challenge. Vaccinated mice had increased survival over control mice
after challenge with the ATCC 19606 strain (100% vs. 0% survival;
p< 0.001), a multi-drug resistant clinical isolate (70% vs. 10% survival;
p = 0.007), and a panresistant clinical isolate (100% vs. 10% survival;
p< 0.001). Mice passively immunized with serum from vaccinated mice
3 hours prior to challenge were protected from infection, whereas control
mice receiving non-immune serum were unprotected (100% vs. 0%
survival; p = 0.003).
Conclusion: Immunization with an OMP-based vaccine protects against
infection with multi-drug resistant and panresistant A. baumannii
in a mouse model of disseminated sepsis. Passive immunization
with anti-OMP antibodies provides rapid protective immunity against
A. baumannii infection.
O148 Development of C5a peptidase and CspA based recombinant
polypeptides as vaccine components against group B
streptococci
N. Duplik °, I. Koroleva, A.N. Suvorov (Saint-Petersburg, RU)
Objectives: Group B streptococci (GBS) is a major cause of
pneumonia, sepsis, and meningitis in newborns and morbidity of
immunocompromised adults. It is known that C5a peptidase and CspA
allow GBS to evade phagocytosis by disrupting the C5a and several CXC
chemokines of the host. The aim of the current study was to construct
and investigate C5a-ase and CspA based recombinant polypeptides with
predominantly a helix structure and evaluate their immunogenicity.
Methods: Collection of GBS strains consisting of 75 GBS clinical
isolates from Russia, Sweden, China, USA and 10 reference strains
was analyzed. PCR generated DNA fragments from cspA and scpB
genes were cloned employing pQE expression vectors (Qiagen, USA).
Immunological assays: 1. Subcutaneous immunization of mice and
rabbits. 2. Opsonophagocytosis of GBS preliminary incubated with
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normal or immune sera with mouse peritoneal macrophages. 3.
Protection studies on immune mice intraperitoneally infected with GBS.
Results: All DNA samples from 85 GBS strains tested by PCR and
hybridization were found to carry cspA gene. Two portions of scpB
and two portions of cspA (pB1, pB3 and csp2, csp3) encoding for
a helical regions of C5a-ase and CspA were ampliﬁed and cloned.
Resultant proteins PB1, PB3 and CSP2, CSP3 (M.M. 12 kDa, 10 kDa
and 42 kDa, 12 kDa, respectively) were successfully expressed in E. coli
followed by puriﬁcation with Ni sepharose. All polypeptides under study
generated humoral immune response in mice and rabbits. The antisera
were examined for their opsonizing ability against GBS strains of six
different serotypes employing mouse peritoneal macrophages. The data
demonstrated signiﬁcant opsonizing effect of anti-PB1, anti-PB3, anti-
CSP3 immune sera over the control. Mice preliminary immunized with
the polypeptides were studied for development of GBS infection. As
result obvious GBS clearance from the spleens of mice immunized
with PB1, PB3 and CSP3 in comparison with control group was
determined. In contrast anti-CSP2 antibodies were found to possess
neither opsonizing ability nor protective activity in above mentioned
experiments.
Conclusion: 1. DNA from 85 GBS strains comprised cspA gene.
2. PB1, PB3 and CSP3 with high a helix structure displayed the
immunogenic and protective properties that allowed proposing them as
vaccine components against GBS.
O149 Novel combined multiple subunit vaccine protects against
extraintestinal pathogenic E. coli
A. Wieser °, S. Schubert (Munich, DE)
Objectives: Extraintestinal pathogenic E. coli (ExPEC) are frequent
causative agents of sepsis, neonatal meningitis and urinary tract
infections. They lead to signiﬁcant mortality and morbidity in humans
as well as live-stock and are a big burden for healthcare providers.
With fast rising antibiotic resistance rates among clinical ExPEC isolates
preventive vaccination against these pathogenic E. coli is greatly desired.
Methods: Based on genome analysis data and in vivo transcription
studies we selectively target virulence factors expressed during the course
of infection such as iron acquisition systems. Immunogenic regions as
well as the unknown three dimensional structure of these proteins were
analyzed in silico. MHCI and MHCII epitopes as well as proteasome
cleveage sites were also taken into account.
Based on this data two synthetic modular vaccine proteins were designed
each bearing eight epitope rich subfragments. For each a fully synthetic
gene was constructed and optimized regarding sequence and codon bias.
We used and evaluated two application routes in the mouse model. First
we used puriﬁed vaccine proteins for intranasal application. Second we
used a novel Salmonella based bacterial antigen delivery system which
is simply administered orally. As it translocates the vaccine directly into
the cytoplasm of immune cells in vivo, T-cellular response is greatly
enhanced.
Results: Speciﬁc immune responses were evaluated with IFN-g ELISpot,
ﬂow cytometry and sub-class sensitive antibody ELISA. Intranasally
immunized mice demonstrated massive increases of speciﬁc serum IgG
as well as vaginal ﬂuid IgA antibodies against the recombinant vaccine
protein as well as against puriﬁed full length virulence factors of ExPEC.
Expansion of vaccine speciﬁc IFN-g secreting T-cells could be proven
in both immunization routes. In the challenge model of peritonitis a
signiﬁcant reduction of bacterial load could be achieved in immunized
mice, demonstrating the ﬁrst successful combined T-cell vaccine against
ExPEC in the mouse model.
Conclusion: Combined T-cell and antibody stimulating vaccines
containing multiple epitopes are effective against ExPEC in the mouse.
Further evaluation is needed to elucidate the potential for use in humans.
O150 Dendritic cell vaccination generates protective responses
against inﬂuenza virus infection: a model explored for
effective vaccination of immunosuppressed cancer and stem
cell transplant patients
W. Decker, S. Li, R. Zabriskie, A. Machado, B. Gilbert, E.J. Shpall,
A. Safdar ° (Houston, US)
Introduction: We have recently demonstrated the ability to generate
robust, antigen-speciﬁc T-cell responses following priming of naı¨ve,
umbilical cord blood lymphocytes with recombinant inﬂuenza hemag-
glutinin (rHA) loaded dendritic cells (DC) (Safdar et al. Vaccine
2009). Toward the goal of validating this model in vivo, we have
developed a murine model of DC immunotherapy utilizing a Balb/c-
adapted A/New Caledonia H1N1 inﬂuenza virus. Here we demonstrate
that a single injection of rHA-loaded DCs can generate high antibody
titers and associated with protection against lethal inﬂuenzavirus
infection.
Methods: Balb/c-adapted A/New Caledonia was generated by 4 serial
passages of infected lung pools. Bone marrow stem cells derived from
Balb/c donors were incubated in GM-CSF and IL-4 for 6 days to generate
immature DCs. DCs were loaded with A/New Caledonia rHA protein
and then matured in a cocktail of GM-CSF, IL-4, IL-1b, TNF-a, IL-6,
and PGE2. Mature DCs were harvested after 24 hours and delivered at
a dose of 106 DC by subcutaneous (SC) or intraperitoneal (IP) routes.
Mice were bled 4 weeks after vaccination for serum HA-speciﬁc antibody
(Ab)titers by ELISA. Six weeks after vaccination, mice were challenged
with a 10xLD50 of Balb/c-adapted A/New Caledonia inﬂuenzavirus
administered intranasally. Efﬁcacy of the vaccine was determined by
survival.
Results: Four weeks after vaccination, 3 of 3 mice injected with DCs IP
had seroconverted with high titers apparent at 1:250 serum dilutions. In
contrast, only 1 of 3 mice injected SC demonstrated seroconversion and
only at a serum dilution of 1:25. None of the mice injected with control
DCs (not loaded with rHA) demonstrated rHA-speciﬁc seroconversion.
At six weeks post-vaccination, mice were challenged with a 10 x LD50
of Balb/c-adapted A/New Caledonia. On day 15 post-inoculation, the
four mice with HA-speciﬁc Ab titers were all alive with no signiﬁcant
changes in weight, appetite, or behavior, whereas the 4 mice with no
demonstrable HA-speciﬁc Ab titers had all died (p< 0.005).
Conclusions: The model demonstrates that robust HA-speciﬁc antibody
titers may be generated by a single injection of HA-loaded DCs, and
that such titers are protective against fulminant inﬂuenza infection. This
validation of in vitro data suggests that DC immunotherapy for the
prevention of inﬂuenza in immunosuppressed cancer patients might be
feasible and warrants further exploration of the technique.
O151 A novel DNA vaccine against toxoplasmosis induces
sporozoite speciﬁc protective immune response through
nonapoptotic cells
S. Gulce Iz °, M. Doskaya, A. Caner, A. Degirmenci, F. Rodriguez,
I. Deliloglu Gurhan, Y. Guruz (Izmir, TR; Barcelona, ES)
Objectives: Toxoplasma gondii is an obligate intracellular parasite
infecting all warm-blooded animals, including humans and causes
serious clinical presentations. There is no 100% effective drug to
treat toxoplasmosis. Development of a vaccine, which can prevent the
consequences of acute infection, is an attractive alternative.
Since 1990s, vaccination strategies against toxoplasmosis mainly used
DNA vaccine, puriﬁed recombinant proteins showed variable protection
because vaccine candidate antigens were almost always selected
randomly and targeted tachyzoite form which invades the host cell
abruptly and immediately embeds itself in a protective parasitophorous
vacuole which keeps away the host immune response.
Currently, there is substantial evidence about T. gondii oocysts (contains
sporozoites) as being the cause of water related outbreaks. After
classiﬁcation of T. gondii oocysts in category B bioterrorism agents
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as a water safety threat, the demand for a protective vaccine against
toxoplasmosis has increased.
The present study aims to generate ﬁrst time a DNA vaccine containing a
sporozoite speciﬁc surface antigen “SporoSAG” to block the sporozoites
as they are released from the oocysts in the intestine. To increase the
efﬁcacy of the vaccine, antigen speciﬁc-CD8 response inducing anti-
apoptotic Bcl-xL gene was inserted to the dual expression DNA vaccine.
Methods: During the construction of the dual expression DNA vaccine,
SporoSAG was inserted after CMV promoter and anti-apoptotic protein
Bcl-xL were inserted in frame with EGFP after IRES (pIRES2EGFP-
SporoSAG-Bcl-xL). In vitro transfection of BHK-21 cells was performed
to show the expression of SporoSAG and Bcl-xL. The functionality
of Bcl-xL was demonstrated by Casp3 ﬂow cytometry. Humoral and
cellular immune response (CD4/CD8, IFN-g) were analyzed from
sera and spleen cells of vaccinated BALB/c mice by western blot
and ﬂow cytometry using puriﬁed recombinant SporoSAG protein
(Figure 1).
Results and Conclusion: Western blot and ﬂuorescence microscopy
analyses of pIRES2EGFP-SporoSAG-Bcl-xL transfected BHK-21 cells
showed SporoSAG and Bcl-xL expression. Casp3 analyses rationalized
Bcl-xL expression that impedes apoptotic cell death. Analysis of
sera obtained from vaccinated mice showed anti-SporoSAG antibody
response compared to controls. Cellular immune response analyses
showed increased CD8 and IFN-g response compared to controls
indicative of protection against toxoplasmosis.
Figure 1.
O152 Assessment of a new DNA vaccine candidate against urinary
tract infection
J. Fallah Mehrabadi °, M. Hoseini Moghaddam, S. Najaﬁ,
N. Khoramabadi, M. Mahdavi (Tehran, Zanjan, IR)
Objective: Urinary Tract Infection (UTI) is one of the most common
infectious diseases and the major agent of UTI is Uropathogenic
Escherichia coli (UPEC). Most of the time, it has afﬁnity to attached
to the vaginal and urinary tract mucosa tissue. UPEC has intracellular
propagation, when do invasion of bladder epithelial cells. Therefore,
cellular immune response is so important in this case. In our research, a
genetic construct for inducing of cellular immune system was designed
and immune response of immunized mice was evaluated.
Materials and Methods: Chromosomal DNA extracted from E. coli
35218 as a positive type I pili strain and ﬁmH gene ampliﬁed by
using this template in PCR. The PCR product inserted to pBluescript
cloning vector and sequenced. Then, the ﬁmH gene sub cloned to
pVax eukaryotic expression vector. The recombinant vector sequenced
again. COS7 cell line transfected with a complex of pVax/ﬁmH and
ExGen 500 poly cationic polymer. Three groups of BALB/c mice
immunized with recombinant DNA construct. The ﬁrst group injected
intramuscularly (i.m) with two doses (100 mg for every injection during
two weeks) of puriﬁed pVax/ﬁmH. The second group injected with the
same amount of pVax vector and the third group injected with PBS as
negative control. All mice challenged, one week following the second
injection, with uropathogenic Escherichia coli strain 35218. Moreover,
lymphocytes isolated from spleen of immunized mice and cultured for
cytokines assay.
Results: The sequence of E. coli 35218 ﬁmH gene in our research
showed more than 97% identity to other ﬁmH sequence reports in
GenBank. Expression of ﬁmH gene in transfected COS7 was conﬁrmed
by RT-PCR. The result of challenge showed 100 times reduction of
E. coli colonization in bladder tissue of ﬁrst group mice. Additionally,
IFN-g titer got rise in ﬁrst group on compression with others groups.
Discussion: ﬁmH gene has a little variation among type I pili positive
strains but it has less variation on amino acid sequences. Hence, it
was detected more than 97% identity of E. coli 35218 ﬁmH sequence
with others. Expression of ﬁmH in pVax/ﬁmH cassette was conﬁrmed
by RT-PCR. Consequently, induction of cellular immune response was
showed by increasing of INF-g titration in immunized mice. So, DNA
vaccination has a potential candidate for limiting recurrent urinary tract
infection.
O153 Rabies neutralizing antibody in AIDS patients after rabies
post-exposure treatment with doubling the intramuscular
doses of conventional regimen and aluminium-adjuvanted
tetanus toxoid
T. Tantawichien °, W. Jaijaroensup, P. Khawplod, U. Thisyakorn,
V. Sitprija (Bangkok, TH)
HIV-infected patients with low CD4+ T lymphocyte had a poor Nab
response to conventional pre- and post-exposure rabies vaccination.
Our previous reports revealed that HIV-infected patients with CD4+
counts <200 /mL did not respond well to conventional intramuscular
(IM) post-exposure vaccination or multiple-site intradermal (ID)
vaccination.
We conducted a prospective study of the Nab response after doubling
the IM doses of WHO IM regimen (ESSEN) and aluminium-adjuvanted
tetanus toxoid (TT) in AIDS persons. Fifteen AIDS patients (age range,
30−46 years) without active opportunistic infections who presented with
possible or proven rabies exposure were enrolled. Four patients had
severe exposure (WHO category III). All patients had a history of AIDS-
related conditions such as opportunistic infections or CD4+ counts <200
/mL, Only 5 patients did not received antiretroviral therapy. All patients
were given the post-exposure rabies prophylaxis. They received doubling
the doses of IM regimen (2−2-2−2-2−0) with puriﬁed Vero cell rabies
vaccine (doubling the IM doses of vaccine in 1−1-1−1-1−0 ESSEN-IM
regimen) but one of the two rabies vaccines on day 0 was dissolved in
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0.5-mL dose of aluminium-adjuvanted TT. Blood samples were obtained
on days 0, 7, 14, 28, 90, 180 and 360 after vaccination for rabies
Nab. CD4+ counts were determined from all patients before vaccination.
Blood was drawn for determination of HIV-RNA level on days 0, 28,
and 90 after vaccination. There was no serious adverse reaction among
all patients treated. No death as a result of rabies during the next 1 year
was reported. Seven AIDS patients with CD4+ counts <100/mL (range,
1−99 /mL) had a poor or even undetectable Nab response. Eight AIDS
patients with higher CD4+ counts (>250 / mL) had good Nab responses
as our previous studies. We also observed that HIV-RNA level did not
increase signiﬁcantly after rabies vaccination.
Conclusion: At present, cleansing the wound, vigorous wound injection
with immunoglobulin, and determination of Nab response in AIDS
patients who had very low CD 4 + T lymphocyte count after post-
exposure rabies vaccination are the most important post-exposure
measures that can be offered to AIDS and moderately or severely rabies-
exposed patients.
O154 Safety of vaccination with 7-valent conjugated pneumococcal
vaccine among HIV-infected adult patients
C.L. Lu °, W.C. Liu, C.H. Wu, S.Y. Chang, C.C. Hung (Taipei City, TW)
Objectives: Patients with HIV infection have a higher incidence and
recurrence rates of invasive pneumococcal diseases compared with the
persons without HIV infection. An increasing number of clinical studies
are reported to evaluate the immunogenicity of 7-valent conjugated
pneumococcal vaccine (PCV) among elderly and transplant recipients,
but the data of safety of vaccination with PCV among HIV-infected
patients are sparse.
Methods: HIV-infected patients aged 18 years or greater were enrolled
for vaccination with PCV to prevent invasive pneumococcal diseases
in from October 2008 to October 2009. Two groups of patients were
assessed: group A, recipients of 2 doses of PCV given at a 1-month
interval and group B, recipients of 1 dose of PCV. Patients were further
stratiﬁed to 4 groups according to CD4+ count when primary PCV was
administered: group 1, CD4+ <200 cells/mL; group 2, CD4+, 200 to
349 cells/mL; group 3, CD4+, 350 to 499 cells/mL; and group 4, CD4+
500 cells/mL. All patients were given 1-week diary to record any
discomfort after vaccination. All statistical analyses are performed by
STATA statistical software.
Results: 407 HIV-infected patients were vaccinated with PCV during the
study period: 206 patients received two doses and 201 patients one dose.
After ﬁrst dose vaccination, 372 (91.1%) patients who returned their one-
week diary for recording side effects were assessed. Among these 372
HIV-infected patients, 124 (33.3%) patients reported discomfort after the
vaccination that included injection site soreness (22.85%), pain (8.60%),
redness (1.08%), swelling (1.62%), fever (1.62%), headache (1.88%),
fatigue (4.30%), cough (1.34%), rash (0.53%), rhinorrhea (0.27%),
sneezing (0.27%), and insomnia (0.27%). None of these patients reported
severe adverse events that prompted medical attention. The only factor
that was found to be associated with occurrence of side effects was high
nadir CD4 counts (P = 0.04) before vaccination. The associated factors
for injection site soreness, the most common side effect after vaccination,
included high nadir CD4 counts (P = 0.01) before vaccination and high
HIV viral load at vaccination (P = 0.01). None of the patients who
received two doses PCV reported aggravated discomfort after second
dose vaccination.
Conclusions: We conclude that vaccination with 7-valent PCV among
HIV-infected patients was generally safe and high nadir CD4 counts
before vaccination were associated with increased risk for injection side
reactions.
O155 Nasopharyngeal carriage of Streptococcus pneumoniae
non-vaccine serotypes among children attending day-care
centres in France: 1999–2008 after the introduction of the
7-Valent Pneumococcal Conjugate vaccine
B. Dunais, H. Carsenti °, M. Roussel-Delvallez, S. Onillon Chevrier,
P. Bruno, P. Touboul, M. Sabah, V. Loncle Provot, E. Bonnet, C. Pradier
(Nice, Lille, Paris, FR)
Objectives: S. pneumoniae (SP) carriage is monitored among children in
day care centers (DCCs) in France following implementation of 7-Valent
Pneumococcal Conjugate (Pn7) vaccination (2002) and interventions
promoting prudent antibiotic use (PAU).
Methods: Cross-sectional surveys were performed from January to
March 1999, 2002, 2004, 2006 and 2008 on a random sample of children
attending DCCs in two areas (Alpes Maritimes: area A and North: area
B). For each period, antibiotic susceptibility and serotype distribution
of NP SP isolates were recorded, as well as immunization status and
antibiotic use. A local intervention promoting PAU was conducted in
2000 and 2003, via academic detailing visits to general practitioners
and paediatricians( area A), and a national media campaign began in
2002(area A + B). Pn7 became available in 2002.
Results: SP carriage decreased in area A: 54% in 1999 to 45% in 2008
(p 0.01) and was stable in area B (46% to 42%) while the proportion
of SP with decreased susceptibility to penicillin (PDSP) fell from 63%
in 1999 to 42% in 2008 (p< 10−3) in area A and remained stable 72%
to 68% in area B. Antibiotic use dropped from 63% to 37% of children
(p< 10−3) in area A and from 66% to 53% in area B (p< 10−3). Overall
antibiotic susceptibility increased. Over 90% of the children had received
at least one vaccine dose in 2008 in area A and 86% in area B while
immunization rates were 37% and 30% respectively in 2004. A shift
from Pn7 serotypes 6B, 9V, 19F, 23F in 1999 to Pn7 vacccine related
6A, 19A, 23 non-F and non-vaccine types: 15 in 2008 was observed in
the two areas. Among PDSP, serotypes 6A, 19A and 15 accounted for
over 50% of strains in 2008 vs. 6% in 1999 (p< 10−5).
Conclusion: Children are now mostly colonized with vaccine-related
and non-vaccine strains with improved overall antibiotic susceptibility
after the introduction of pn7 vaccine; but PSDP isolates are now
mainly recruited among these. Inappropriate prescriptions threaten the
sustainability of vaccine-related beneﬁts through combined vaccine- and
antibiotic-driven selective pressure.
SP (%) PDSP (%)
Area A Area B Area A Area B
1999 2002 2004 2006 2008 1999 2002 2004 2006 2008 1999 2002 2004 2006 2008 1999 2002 2004 2006 2008
23F 30.9 18.5 9.3 1.8 0.0 25.6 27.6 10.2 2.7 0.0 48.5 22.3 14.9 0.0 0.0 34.5 31.3 12.7 2.4 0.0
6B 19.8 21.4 13.1 4.7 0.6 28.2 20.7 28.4 1.4 0.0 15.8 23.2 17.2 0.0 0.0 21.4 22.2 34.5 1.2 0.0
19F 11.7 15.0 19.1 9.4 3.1 8.5 13.8 19.3 11.0 8.0 5.9 14.3 17.2 18.6 6.1 7.1 16.2 23.6 17.1 11.9
14 11.7 16.8 7.7 4.1 0.6 8.5 12.9 10.2 1.4 1.1 16.8 23.2 16.1 5.1 1.5 9.5 15.2 16.4 2.4 1.7
9V 2.5 2.9 0.0 0.0 0.0 2.6 3.4 3.4 0.0 0.0 3.0 1.8 0.0 0.0 0.0 3.6 4.0 5.5 0.0 0.0
6A 5.6 8.7 17.5 10.5 9.4 0.9 1.7 14.8 10.3 8.0 1.0 3.6 6.9 11.9 12.1 1.2 1.0 0.0 4.9 3.4
19A 3.1 6.9 9.3 10.5 15.1 8.5 6.9 1.1 28.8 23.9 2.0 8.0 14.9 20.3 34.8 11.9 8.1 0.0 51.2 35.6
23 non-F 0.6 4.0 3.3 12.3 10.1 0.0 0.9 3.4 7.5 6.8 0.0 0.9 0.0 3.4 6.1 0.0 0.0 0.0 1.2 0.0
15 1.9 1.2 4.4 9.9 20.1 0.0 3.4 2.3 12.3 22.7 3.0 0.9 4.6 13.6 16.7 0.0 0.0 0.0 8.5 27.1
Others 11.7 3.5 16.4 31.6 37.7 17.1 7.8 4.5 18.5 27.3 4.0 1.8 8.0 22.0 19.7 10.7 2.0 7.3 6.1 15.3
O156 Pili distribution among invasive pneumococci in Portugal
after 7-valent conjugate vaccine
S.I. Aguiar °, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objective: Evaluate the distribution of the pilus islets among
Streptococcus pneumoniae recovered from invasive infections after
7-valent vaccine availability.
Methods: Two pilus-like structures (PI-1 and PI-2) have been recently
recognized in pneumococci. These have been implicated in virulence
and suggested as potential vaccine targets. However these pilus-like
structures are not universally distributed among pneumococcal strains.
We had previously demonstrated that carrying PI-1 was a clonal property
of S. pneumoniae and that only 27% of the invasive strains carried the
rlrA islet. Furthermore, 83% of these piliated strains expressed vaccine
serotypes. Similar ﬁndings were reported for the PI-2 islet which was
shown to be present in 16% of a convenience sample of strains. PI-2
positive clonal complexes were associated with serotypes 1, 2, 7F, 19A,
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and 19F. The introduction of the 7-valent conjugate vaccine (PCV7)
resulted in changes in serotype frequency that can also affect pili preva-
lence. To evaluate this effect we determined the presence of PI-1 and PI-2
among a collection of 475 invasive isolates recovered from children after
PCV7 introduction (2003–2008). The results were analyzed in terms of
pilus islet association with antibiotic resistance, serotype, pulsed-ﬁeld
gel electrophoretic proﬁle (PFGE) and multilocus sequence type.
Results: Overall, 46.7% of the strains presented one of the pilus islet.
As observed in previous studies serotype distribution analysis showed
a high correspondence between serotype and the presence and type of
pili (Wallace coefﬁcient, W= 0.85). This association was even higher
when considering pili and PFGE cluster (W= 0.98). The rlrA islet was
identiﬁed in 13% of the strains most of them expressing serotype 6B, 9V,
14, 19A and 19F. PI-2 islet was found to be present in 37% of the pneu-
mococcal strains and was identiﬁed mainly among serotypes 1 and 7F.
Conclusion: A decrease in the presence of the rlrA islet among invasive
pneumococcal strains was observed after PCV7 availability. This change
is associated with the decrease of vaccine serotypes since the majority of
the strains carrying PI-1 expressed vaccine serotypes. In contrast, PI-2
islet was more prevalent due to the predominance of serotypes 1 and
7F. Since most of the strains carrying pili presented serotypes that are
included either in current or future conjugate vaccine formulations, their
potential use in a vaccine would offer limited additional beneﬁts.
Epidemiology and control of C. difﬁcile
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O157 Final results of the ﬁrst pan-European Clostridium difﬁcile
infection survey
M.P. Bauer °, D.W. Notermans, B.H. van Benthem, J.S. Brazier,
M. Wilcox, M. Rupnik, D.L. Monnet, J.T. van Dissel, E.J. Kuijper
on behalf of the ECDIS Study Group
Objectives: To survey the incidence and demographic, clinical and
microbiological characteristics of Clostridium difﬁcile infection (CDI)
in hospitals in Europe.
Methods: We organised a network of 106 laboratories capable of
isolating C. difﬁcile strains in 34 European countries. In November
2008, 1−7 hospitals per country, depending on population size, tested
stool samples of patients aged >2 years who were suspected of CDI,
or who had developed diarrhoea after 3 days of hospital admission.
CDI was deﬁned by a positive enzyme immunoassay for C. difﬁcile
toxin A and/or B, a positive cytotoxicity test, or positive culture of a
toxigenic strain. Each hospital collected detailed clinical data of the ﬁrst
10 CDI cases, and sent stool isolates of C. difﬁcile for PCR-ribotyping
and characterization of toxin A, toxin B and binary toxin genes. After 3
months, follow-up clinical data were collected.
Results: CDI incidence varied across hospitals (mean: 5.5 per 10,000
patient-days per hospital; range: 0 to 36.3). Detailed information was
obtained on 509 patients and 395 isolates of these patients were available
for characterization. Sixty-two different PCR ribotypes were found,
among which 014 (15%), 001 (10%) and 078 (8%) were most prevalent.
The prevalence of PCR ribotype 027 was 5%. Most patients had the
previously identiﬁed risk proﬁle of an elderly patient with co-morbidity
and recent antibiotic use. At follow-up, 22% of patients had died and
in 40% of these deaths CDI played a role. In multivariate analysis, age
65 yrs, use of macrolides and infection by PCR ribotypes 015, 018 and
056 were signiﬁcantly associated with death to which CDI contributed.
Ceftazidime use and having recurrent CDI at inclusion were signiﬁcantly
associated with recurrences during follow-up.
Conclusion: In this pan-European, hospital-based study, the incidence of
healthcare-associated CDI varied widely between hospitals. The overall
and attributable mortality were high. Dominant PCR ribotypes were
014, 001 and 078, whereas 015, 018 and 056 were associated with a
complicated disease course. These data emphasise the importance of
multi-country surveillance and indeed that PCR ribotypes other than
027 are prevalent causes of CDI in Europe.
O158 Epidemiological and microbiological characteristics of
Clostridium difﬁcile infections, France, 2009: a national,
multicentre, prospective survey
B. Coignard °, M. He´bert, C. Eckert, D. Rahib, C. Tarnaud, S. He´nard,
D. Noe¨l, F. Barbut on behalf of the ICD-Raisin Study Group in
Saint-Maurice, France
Background: Following the emergence in 2006 of the PCR-ribotype
027 epidemic clone, surveillance of Clostridium difﬁcile infections
(CDI) in France was reinforced through the mandatory notiﬁcation of
severe cases or clusters in healthcare facilities (HCF). To complete this
strategy, the national public health surveillance institute (InVS) and
the C. difﬁcile national reference centre (NRC) launched a multicenter,
national, prospective survey in 2009.
Objectives: To assess CDI incidence in HCF and the geographical
distribution and characteristics of strains responsible for CDI.
Methods: From March to August 2009, voluntary HCF reported through
a web-based questionnaire the total number of new CDI patients by origin
and severity, admissions and patient-days (pd). ECDC case deﬁnitions
were used and data were stratiﬁed by type of wards: acute-care (AC) vs.
rehabilitation/long-term care (RLTC). HCF were asked to send to the
NRC strains isolated in March from patients diagnosed with a CDI for
characterisation and typing.
Results: 137 HCF participated in the epidemiological component of
the survey. On 1st November 2009, a complete dataset was sent by 85
(73%) of 117 HCF with AC wards and 72 (69%) of 105 HCF with RLTC
wards. In AC, 1,045 CDI-patients were reported; CDI incidence was 2.18
cases per 10,000 pd (1.05 case per 1,000 admissions). By origin, 686
(66%) cases were healthcare-associated (HA), 598 (87%) of which were
acquired in the reporting HCF; 294 (28%) community-associated (CA);
65 (6%) of unknown origin (UO). Among 734 CDI-patients diagnosed
in HCF actively following them up for a month, 100 (14%) were severe
cases and 25 (3%) died from their CDI. In RLTC, 251 CDI-patients were
reported; CDI incidence was 1.31 cases per 10,000 pd. By origin, 231
(92%) cases were HA, 204 (88%) of which were acquired in the reporting
HCF; 8 (3%) CA; 12 (5%) of UO. Among 186 CDI-patients diagnosed
in HCF actively following them up for a month, 4 (2%) were severe
cases and died from their CDI. Last, 237 C. difﬁcile strains were sent
by 54 HCF to the NRC; their characterisation and typing are underway.
Conclusions: Preliminary results from this survey conﬁrm that CDI
incidence in France is much lower than reported in other European
countries, and suggest that CDI are adequately controlled in French
HCF. However, the high proportion of CA cases reported in AC wards
suggests the need for further studies. Final results from this survey will
be presented in April.
O159 Prevalence of Clostridium difﬁcile in retail meat products in
north-eastern Italy
I. Drigo °, C. Bacchin, E. Tonon, E. Mazzolini, L. Bano, M. Bonci,
M. Favretti, M. Marcati, K. Rossetto, M. Cocchi, F. Agnoletti (Treviso, IT)
Recent studies conducted in Canada, United States and Sweden pointed
out that Clostridium difﬁcile spores are present in retail ground meat thus
suggesting that meat could act as food source of Clostridium difﬁcile for
human infections.
Objectives: The aim of this pilot study was to estimate the occurrence of
Clostridium difﬁcile in minced beef and pork at retail in North-Eastern
Italy.
Methods: The cross-sectional study was performed in February-March,
2008, in 150 retail outlets randomly sampled in 3 provinces of
North-Eastern Italy. Among those 3 provinces retailer’s sample size
was proportional to resident population. In each sampled retailer one
laboratory sample of minced beef and one of pork was randomly
collected. Each sample was microbiologically processed using the
Clostridium difﬁcile selective medium Cefoxitine Cycloserine Fructose
broth (added with Taurocolate). After 10 days of incubation broth
cultures were plated on blood agar base, horse blood red cells added
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(5% v/v), and tested by PCR for detection of Clostridium difﬁcile
DNA according to Penders (2005). The presence of toxins A and B
in the broth culture was evaluated by Techlab C.diff quik chek complete
kit (Techlab). A positive control (meat experimentally infected with
Clostridium difﬁcile spores) was carried out simultaneously with each
batch of the experimental samples.
Results: In total 300 (150 pork and 150 beef) samples were analyzed.
All samples were negative for Clostridium difﬁcile both at the
microbiological and PCR analysis. Search for Toxin A and B gave
negative result as well.
Conclusion: Although public health relevance of Clostridium difﬁcile
contaminated food is yet to be clariﬁed, these preliminary results
prompt to consider that ground beef and pork do not represent a risk
factor for human infection in North-East of Italy. Our ﬁndings are
supported by those of Von Abercron (2009), who found a low prevalence
(2%) of Clostridium difﬁcile contaminated ground meet in Sweden.
Differently Rodriguez-Palacios (2007) and Weese (2009) in Canada, and
Songer (2007) in United States reported 12−20% and 42%, respectively,
prevalence of Clostridium difﬁcile contaminated ground meat. These
apparently conﬂicting results may be due to different prevalence of
Clostridium difﬁcile at fatted calf and swine primary production or
to different hygiene both at slaughterhouse and at retail outlets. The
hypothesis should be further investigated.
O160 A review of the epidemiology, risk factors and strain
characteristics of Clostridium difﬁcile among hospitalized
patients: a pilot nested case–control study
P. Cleary °, C. Quigley, S. O’Brien, E. Bolton, N. Verlander, A. Guleri,
A. Dodgson, A. Fox, S. Maxwell, K. Braid (Liverpool, Manchester,
London, Blackpool, Stockport, UK)
Introduction: The study aimed to determine the outcomes, mortality and
morbidity from Clostridium difﬁcile infections (CDI) in the North West
of England, and to identify possible differences in risk factors between
ribotypes.
Methods: Multicentre case control study at three large hospitals in NW
England. Cases deﬁned as hospitalized patients with positive Clostridium
difﬁcile toxin in diarrhoeal stool samples. Controls randomly selected
from matched patients with negative stool samples, at a ratio of 1:1,
frequency matched by 10 year age band. Data was abstracted at case
note review. Stool samples from cases cultured and typed at regional
reference laboratory.
Results: Between Sept 9, 2007 and Sept 30, 2008, data on 296 cases
and 296 controls collected and analysed. Average age for controls and
cases was 77 years. 40.2%(119/296) of controls and 48.3%(143/296) of
cases were male. 48 (16%) controls and 97 (33%) cases died during the
study period. Of the samples typed, 27.7% were 001, 26.6% were 001
and 20.9% were 027.
In the overall logistic regression model, length of stay, transfer from
another NHS hospital, number of different antibiotics, number of days
of quinolone antibiotics, degree of comorbidity and number of days of
nitroimidazole antibiotics were identiﬁed as risk factors (see ﬁgure).
Reduction in odds of CDI with H2-blocker therapy was an interesting
ﬁnding.
On subgroup analysis the three main strains were all associated with
length of hospital stay and transfer from another NHS hospital. All were
associated with antibiotic use, especially quinolones. Only ribotype 001
was associated with cephalosporin use. PPI therapy was only a risk factor
for ribotype 106.
The 014/020, 078 and 027 ribotypes had the highest observed rates
of mortality and morbidity, but there were no signiﬁcant difference in
mortality or morbidity detected between different ribotype.
Discussion: This study did not ﬁnd any difference in mortality or
morbidity between different strains of Clostridium difﬁcile, but did
ﬁnd some differences in risk factors between ribotypes. An unexpected
association of H2-blocker therapy with a reduction in odds of CDAD
was observed.
This study has some limitations. Diagnosis of Clostridium difﬁcile
associated disease was based on toxin detection, which may not be
sensitive or speciﬁc. Details to be presented.
Figure. Multiple logistic regression model for all ribotypes.
O161 Stronger correlation between antibiotic consumption and
incidence of Clostridium difﬁcile determined by cultures
instead of faecal toxin only
D. Mertz °, R. Frei, H. Plagge, M. Battegay, U. Flu¨ckiger, A.F. Widmer
(Basel, CH)
Objectives: The diagnosis of Clostridium difﬁcile (C. difﬁcile) associated
diarrhoea is usually based on the detection of faecal toxin A/B, rather
than on stool cultures. Therefore, studies on the correlation between
the incidence of C. difﬁcile and antibiotic consumption were limited
to toxic strains in the past. The aim of this ecological study was to
analyse the association between unit-speciﬁc antibiotic consumption and
the incidence of toxigenic and non-toxigenic C. difﬁcile in hospitalised
patients.
Methods: Unit speciﬁc antibiotic consumption data and the incidence
of C. difﬁcile in 19 units over 5 years were analysed at the University
Hospital of Basel, Switzerland. Stool samples were tested for toxin A/B
and simultaneously cultured. In a second step, positive cultures were
tested for toxin production. In order to analyse speciﬁc antibiotics, unit
speciﬁc length of stay and antibiotics showing a signiﬁcant association
in univariate analysis were entered in a multiple linear regression model.
Results: Over 5 years, a total of 165 ﬁrst isolates of toxin producing
C. difﬁcile and 413 ﬁrst isolates of C. difﬁcile were detected. The
incidence of C. difﬁcile overall and of toxin producing C. difﬁcile was
0.39 and 0.15 per 1000 patient days, respectively.
The correlation (ﬁgure) is highly signiﬁcant in both analyses (p< 0.001),
but a higher correlation results when all C. difﬁcile strains are included
in the model (R = 0.80 vs. R = 0.63). In a multivariate analysis explaining
more than 80% of the variance of the incidence of C. difﬁcile (R2=0.82),
only piperacillin/tazobactam, trimethoprim/sulfamethoxazole, and the
aminoglycosides were found to be statistical signiﬁcant risk factors.
Conclusion: We show for the ﬁrst time, that the correlation between
antibiotic consumption and the C. difﬁcile incidence rates signiﬁcantly
improves, if detection is not limited to toxin producing strains. Overall
antibiotic pressure as a risk factor was previously underestimated due
to restriction to the toxin producing strains. Our results underline
the importance of the overall pressure of antibiotics that explains the
majority of the variance rather than the importance of a single group
of antimicrobial agents such as quinolones. Therefore, interventions to
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reduce the overall antibiotic consumption might be more successful in
controlling C. difﬁcile incidence than interventions focusing on certain
groups of antibiotics.
Figure. Correlation between unit-speciﬁc antibiotic consumption and
incidence of C. difﬁcile.
O162 Risk factors associated with Clostridium difﬁcile infection
in hospitalized patients with hospital-onset healthcare
facility-associated Clostridium difﬁcile infection
M.F. Emons °, B.H. Nathanson, H.T. Yu, T. Haidar, E. Alemao,
D. Gardiner, R.K. Spoeri (Beverly Hills, Longmeadow, Collegeville, US)
Objective: To assess risk factors associated with Clostridium difﬁcile
infection (CDI) in hospitalised patients with hospital-onset healthcare
facility-associated (HO-HCFA) CDI.
Methods: This retrospective analysis utilised data from April 1, 2005 to
December 31, 2008 within Cerner’s Health Facts® database. Qualifying
cases were adults with an inpatient encounter with a primary or
secondary diagnosis of pseudomembranous colitis (ICD-9-CM code:
008.45) AND a positive C. difﬁcile toxin test AND the ﬁrst positive
C. difﬁcile test (index event) was ordered more than 72 hours after
admission. Non-CDI controls were hospitalised for at least 72 hours with
no diagnosis of pseudomembranous colitis AND no C. difﬁcile culture
or toxin assays during the study period. Stepwise logistic regression
with bootstrapping and a Bayesian Information Criterion analysis were
used to identify variables with the strongest association with HO-HCFA
CDI. Logistic regression was used to quantify the variables’ effect on
HO-HCFA CDI. The area under the receiver operating characteristic
(AUROC) curve and Hosmer-Lemeshow (HL) statistic were used to
assess the model’s overall ﬁt.
Results: Among 34,261 inpatients, 1,454 met the study deﬁnition of
HO-HCFA CDI. A ﬁnal model of 26 variables (AUROC = 0.89, HL
statistic = 10.82, P = 0.21) is reported in the table. Factors most associated
with increasing the odds of CDI include evidence of impaired immune
function (odds ratio [OR] = 4.77; 95%CI, 3.73–6.10), an unknown
infection source (OR= 4.35; 95%CI, 2.92–6.46), and being admitted
from a skilled nursing facility (OR= 3.47; 95%CI, 2.39–4.92). The
antibiotic tigecycline was associated with lower risk of CDI (OR= 0.21;
95%CI: 0.06–0.76).
Conclusions: Impaired immune function, a high comorbidity burden,
advanced age, and the presence of other infections were seen as risk
factors for HO-HCFA CDI. Antibiotic therapy has been known to play a
central role in the pathogenesis of CDI but the observation of tigecycline
exposure’s protective effect is unexpected. Additional research is needed
to better understand the differential risks and beneﬁts of various broad
spectrum antibiotics among patients at risk for HO-HCFA CDI.





Evidence of impaired immune function 4.767 3.725–6.101 <0.001
Admitted from skilled nursing facility (referent = ER admission) 3.470 2.387–4.922 <0.001
Admitted from unknown location (referent = ER admission) 2.799 1.540–5.088 0.001
Gram-positive infection 1.801 1.531–2.118 <0.001
Age (per 10 year increase) 1.151 1.054–1.258 0.002
Charlson Comorbidity Index (per unit) 1.118 1.086–1.152 <0.001
Southern hospital location (referent =Northeast) 0.404 0.208–0.783 0.007
Hospital beds: 300 to 499 (referent = 500 or more beds) 0.357 0.160–0.795 0.012
Unknown race (referent =White) 0.118 0.032–0.438 0.003
Chronic conditions on or 12 months prior to hospital admission
Acute renal failure 2.663 2.246–3.158 <0.001
Cerebrovascular disease other than intracranial/intracerebral hemorrhage 2.391 1.624–3.519 <0.001
Heart failure 1.746 1.436–2.123 <0.001
Cardiac dysrhythmias 1.681 1.421–2.002 <0.001
Infection source
Other or unknown 4.347 2.924–6.464 <0.001
Respiratory 2.059 1.670–2.538 <0.001
Skin infection 2.052 1.766–2.384 <0.001
Device/implant/graft 1.935 1.444–2.593 <0.001
Gastrointestinal other than CDI 1.649 1.346–2.020 <0.001
Genitourinary 1.472 1.225–1.768 <0.001
Total number of systemic antibiotic (by drug class) received before index
event (referent = 0)
2 1.541 1.250–1.900 <0.001
3 1.821 1.418–2.338 <0.001
Use of medications before index event
Miscellaneous antibiotics 2.587 1.992–3.361 <0.001
Carbapenems 2.090 1.375–3.177 0.001
Third/fourth generation cephalosporins 1.640 1.449–1.857 <0.001
Proton pump inhibitors 1.608 1.342–1.927 <0.001
Tigecycline 0.212 0.059–0.758 0.010
ER: emergency room; CDI: Clostridium difﬁcile infection.
O163 Higher mortality of Clostridium difﬁcile possessing the genes
for the binary toxin in addition to the genes for toxin A and
toxin B
S. Bacci, K.E. Olsen °, J.N. Jensen, K. Mølbak (Copenhagen, DK)
Objectives: Clostridium difﬁcile PCR ribotype 027 may cause severe
disease with high mortality. Only a few studies have evaluated whether
the outcome of infection is associated with the toxin proﬁle and PCR
ribotypes of the infecting strain. Clostridium difﬁcile (CD) isolates
are referred for typing to the Danish National Reference Laboratory
according to the criteria for mandatory submission as part of the Danish
CD surveillance programme. Our aim was to assess the 30-day mortality
of infections caused by [1] unselected isolates not referred for typing and
the following groups of submitted and typed CD: [2] CD possessing the
genes for Toxin A, Toxin B and the binary toxin, PCR ribotype 027
(CD027); [3] CD possessing the genes for Toxin A, Toxin B and the
binary toxin, PCR ribotype non-027 (CD non-027); [4] CD possessing
only the genes for Toxin A and Toxin B (CD A and B).
Methods: Laboratory based registries and the Civil Registry with
demographic information on all people resident in Denmark including
the date of death were used to design a cohort study. Each patient was
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included only once in any of the four groups and only with the ﬁrst
episode of infection. Poisson regression was used to estimate the relative
risk of death within 30 days after infection.
Results: A total of 54/193 CD 027 (28%), 20/72 CD non-027 (28%),
36/212 CD A and B (17%), and 247/1822 unselected (14%) patients died
within 30 days after infection (log rank test, p< 0.001). The relative risk
of death in patients with the binary toxin (CD027 and CD non-027) was
1.8 (95%CI 1.2−2.7) compared to patients without the binary toxin (CD
A and B). In a multivariate analysis after adjustment for age, sex and
geographical region, the relative risk was 1.6 (95%CI 1.0−2.4).
Conclusion: An identical mortality was seen for patients with CD strains
possessing the binary toxin − irrespective of the PCR ribotype (CD027
or CD non-027). The mortality for patients with CD A and B strains was
signiﬁcantly lower than among patients with CD027 and CD non-027
but higher than among unselected patients. The results suggest that the
binary toxin either is a marker for more virulent CD strains or contributes
directly to the virulence of these strains.
Furthermore, the data conﬁrms that criteria used in the Danish CD
surveillance programme ensure molecular characterisation (genotypic
toxin proﬁling and PCR ribotyping) of the most virulent strains enabling
detection of emerging hyper virulent strains.
O164 Impact of different antibiotic treatment regimes for respi-
ratory tract infections on emergence of Clostridium difﬁcile
A.H. Bruns °, J.J. Oosterheert, E.J. Kuijper, A. Troelstra, A. Hoepelman
(Utrecht, Leiden, NL)
Background: It has been suggested that treatment of lower respiratory
tract infections (LRTI) with broad spectrum antibiotics and newer
ﬂuoroquinolones in particular, contributes to selection for Clostridium
difﬁcile (C. diff). We studied the prevalence of C. diff carriage, selection
for C. diff and development of C. diff infection (CDI) in patients (pts)
hospitalized and treated for LRTI and compared the different treatment
regimes.
Methods: Pts receiving antibiotic treatment for LRTI in one university
medical center and an afﬁliated teaching hospital were prospectively
followed for 30 days with careful monitoring of the development of
diarrhoea. Of all patients, stool samples collected on admission, day 5,
day 3 after discontinuation of antibiotics and day 30 were cultured for
C. diff using selective plates. Cultured isolates were further characterized
for toxin production and typed by PCR ribotyping. CDI was deﬁned as
the presence of diarrhoea and a positive faeces toxin test.
Results: Of 107 pts included, 45 (41.1%) pts were treated with
moxiﬂoxacin, 47 (43.9%) with b-lactam monotherapy and 15 (14.0%)
with b-lactam/macrolide combination therapy. The endemic rate of CDI
in the participating hospitals is 0.6/1000 pts a year. In total, during
the study period, C. diff was cultured in 18.7% (n = 20) of pts. 6
(30%) isolates were toxin positive. On admission, baseline prevalence
of C. diff carriage was 10.4% (n = 10). Of those, one patient had mild
CDI and persistent positive cultures for C. diff during the study period.
The overall acquisition rate of C. diff carriage after antibiotic treatment
for LRTI in our population was 10.3% (n = 11). Acquisition rates of
C. diff carriership were 11.1% (n = 5) in moxiﬂoxacin, 10.6% (n = 5) in
b-lactam and 6.7% (n = 1) in b-lactam/macrolide treated pts (p =NS).
Tests for faeces toxin production were negative in all pts who acquired
C. diff. No acquired CDI or relapse of previous CDI occurred during
the study period. Risk factors for C. diff carriership at any time were
intravenous antibiotic treatment >7 days (OR 3.89, 95%CI 1.3–11.8)
and hospitalization the past 3 months (OR 4.08, 95%CI 1.4–11.9).
Conclusions: In a setting with a low endemic rate, acquisition rates for
C. diff during antibiotic treatment for LRTI were 10% and did not lead
to CDI. Moxiﬂoxacin was not associated with increased acquisition rates
for C. diff as compared to other antibiotics classes prescribed for LRTI.
O165 Successful control of an outbreak of diarrhoea in a vascular
surgery unit caused by a high-level clindamycin-resistant
Clostridium difﬁcile PCR ribotype 106
L. Ratnayake °, J. McEwen, N. Henderson, D. Nathwani, G. Phillips,
D. Brown, J. Coia (Dundee, Glasgow, UK)
Objective: Description of an outbreak of Clostridium difﬁcile infection
(CDI) affecting nine patients in a vascular surgery ward over a 6 week
period in 2009 caused by a high level clindamycin resistant PCR ribotype
106 (clindamycin MIC > 256mg/L).
Methods: C. difﬁcile outbreak was suspected on the basis of three
cases within 30 days and departure from the normal pattern. A case of
CDI was deﬁned as a patient with diarrhoea, positive for C. difﬁcile
toxin and negative for other enteric pathogens. Cultures were sent
to Scottish Reference Laboratory (SSSCDRL) for PCR ribotyping,
antibiotic susceptibility testing and PCR detection of ermB.
Results: The ward has 24 beds (6 side rooms). The outbreak involved
9 patients: two diagnosed post discharge. The mean age of patients
was 73 years (range 38–90 years). Eight patients were male. All had
signiﬁcant underlying medical disorders and received clindamycin and
ciproﬂoxacin. This was in accordance with the approved and long
standing antibiotic policy of the unit. None of the cases had severe
complications of C. difﬁcile. All nine cases were typed as PCR ribotype
106 and they showed high level resistance to clindamycin suggesting
cross transmission on the ward. Five of these isolates were tested by
PCR for the presence of the ermB gene and no ampliﬁcation was
detected. This strain has rarely been isolated outwith this ward. The
outbreak was controlled successfully by closure of the ward with terminal
cleaning using a hypochlorite solution, reinforcement of infection control
precautions especially hand washing, stopping the use of ciproﬂoxacin
and clindamycin and the introduction of a new antibiotic policy. There
have been no new cases of C. difﬁcile for over 120 days since the last
outbreak case was diagnosed.
Conclusion: This report demonstrates that outbreaks of CDI can be
caused by C. difﬁcile PCR ribotypes other than 027. This outbreak
was caused by an unusual strain that displayed high level clindamycin
resistance, not mediated by ermB and belonged to PCR ribotype 106.
The outbreak was most likely associated with the use of clindamycin and
cross infection with spores in this environment. This report highlights
that implementation of strict infection control precautions, antimicrobial
stewardship and enhanced environmental cleaning are key components
in managing such an outbreak successfully. Interestingly the number of
MRSA acquisitions also dropped dramatically after these interventions.
O166 The value of real-time monitoring of the comprehensive
Clostridium difﬁcile infection containment programme and
impact of rise in clindamycin usage (daily deﬁned doses)
A. Guleri °, R. Palmer, K. Woodrow, N. Harper, M. Jagadeesan
(Blackpool, UK)
Background: Clindamycin (CD) has been widely reported in literature
to be associated with high risk for C. difﬁcile infection (CDI). High-
dose CD (daily deﬁned doses = DDD data) use for variety of clinical
indications has steadily increased in last 3-yrs in Blackpool Victoria
Hospital (large district hospital). A Clostridium difﬁcile infection
containment programme (CCDCP) was introduced with an aim to reduce
avoidable CDI, associated morbidity, mortality & costs and increase
quality of care and patient safety. The rates of CDI in trust have
declined since introduction of CCDCP. Real time monitoring through 2
multidisciplinary audits (Feb-Apr07 & Sep-Dec08), multicentre regional
health protection agency led nested case–control (296 each) study on
CDI and rootcause analysis of every case (Jan–Oct 2009). Findings(incl.
data on use of CD) from these have been used to inform and ﬁne tune
the program.
Methods: Data (2007–09) on rates of CDI; CD usage (in DDD); key
results of the three studies (as above). To be presented − CCDCP
package of interventions (eg. Strengthening infection control team,
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quinolones/3rd gen.cephalosporin restrictions; root cause analysis (RCA)
of every case; deep clean programme; PEAT audit; hand hygiene &
ban-the-bug campaign; revised antibiotic formulary; 5-day stop empiric
antibiotic policy;HCAI ward rounds; high-cost antibiotic rounds; revised
CDI guidance; integrated care pathway, etc).
Results: post-48 h CDI rates have reduced by 58% (0.47/1000 beddays
Apr-Oct09 & estimated v/s 1.13/1000 beddays 2007−08). Monthly
CD usage between 300–1500 DDD were reported. Nil (63 analysed
cases) & 1(59 analysed) case of CDI with previous exposure to CD
within 30-days were recorded in the two audits while the regional case
control study observed a 2%(cases) & 0.7%(controls) [p value 0.286
using Fisher’s exact test] for all ribotypes. RCA(Jan–Oct09) revealed
55% avoidable/probab avoidable CDI; non-compliance to formulary
and inappropriate, repeated or prolonged courses of antibiotics the
predominant association.
Conclusions: 80% of patients in the two audits were over 65yrs of age.
CCDCP includes a variety of interventions as a package. Post-48 h CDI
rates are declining. The results from the two whole health economy
CDIaudits, RCA and case control study were used to inform/modify
the program. New CDI action plan has been drafted to address current
challenges. High dose (600mg q6 h) CD use has steadily increased over
last 3-years while the three studies and RCA reveal minimal association.
Antibiotic resistance to the ribotypes awaited.
Azithromycin − new horizons (Symposium
supported by Teva)
S171 Azithromycin in the treatment of chronic bacterial prostatitis
V. Sˇkerk ° (Zagreb, HR)
Prostatitis is an inﬂammatory condition of the prostate that presents with
urethral symptoms, prostatic symptoms and sexual dysfunction. It is
diagnosed by clinical symptoms and signs, the microscopy of expressed
prostatic secretion (EPS) and culture of EPS and segmented urine
samples. Prostatitis is chronic when symptoms have been present for at
least 3 months. As a part of several scientiﬁc research projects we have
been prospectively investigating prostatitis syndrome at the Outpatient
Department of Urogenital Infections and Sexually Transmitted Diseases,
Dr Fran Mihaljevic University Hospital for Infectious Diseases, Zagreb,
Croatia, since March 1, 1999 and is still ongoing. We examined more
than 3450 patients over 18 years of age with symptoms of chronic
prostatitis and no evidence of lower genitourinary tract abnormalities.
Azithromycin fulﬁlls the criteria for the treatment of chronic prostatitis
and sexually transmitted infections − high efﬁcacy against the most
common bacterial agents of urogenital and sexually transmitted
infections, acceptable toxicity and tolerability, simple oral use, excellent
penetration through chronic inﬂammatory changed prostate capsule,
achieves high concentrations in prostatic tissue and slowly eliminates
for 4−8 weeks, has anti inﬂammatory and immunomodulatory effect,
and is active against bacterial bioﬁlm.
At total of 307 patients with chronic prostatitis caused by Chlamydia
trachomatis were treated with azithromycin in a total dose of 4.0, 4.5 or
6.0 g for 3−4 weeks. Eradication of Chlamydia trachomatis was achieved
in about 80%, with 70% of patients clinically cured. There were no
statistically signiﬁcant differences between these three dosage regimens.
A total of 82 patients with chronic prostatits caused by Ureaplasma
urealyticum were treated with azithromycin in a total dose of 4.5 g for 3
weeks. The eradication of Ureaplasma urealyticum was 85% and clinical
cure 76%.
Conclusion: azithromycin is an effective and safe antimicrobial drug for
the treatment of chronic prostatitis caused by Chlamydia trachomatis or
Ureaplasma urealyticum. It is recommended in a total dose of 4.5 g po.
during 3 weeks, administered for 3 days weekly in a dose 1x500mg po.
per day.
The results of recently published clinical studies on the treatment of
chronic bacterial prostatitis with combination therapy with ciproﬂoxacin
and azithromycin are impressive. We also have a limited, but positive
experience.
Azithromycin − new horizons (Symposium
supported by Teva)
S172 The role of azithromycin in the treatment of acute infectious
gastroenterocolitis
D. Vukelic (Zagreb, HR)
Acute infectious gastroenterocolitis is a common disease worldwide.
In most cases, gastroenterocolitis does not require antimicrobial
treatment as it is considered a self-limiting and mild disease of
short duration. However, antibiotic therapy is indicated in most severe
cases. HIV-positive or immunocompromised patients should also receive
antimicrobial treatment. In such cases, antibiotics could decrease the
duration of the disease, enable a faster recovery and shorten the carrier
state. Azithromycin proved effective in the treatment of acute infectious
gastroenterocolitis. Two studies involving US military personnel in
Thailand indicated that a single azithromycin dose (1 g) or a 3-day
regimen (500mg/day) were comparable or superior to ciproﬂoxacin
or levoﬂoxacin in empirical treatment of acute diarrhea. Efﬁcacy of
azithromycin in the treatment of traveler’s diarrhea in infants and children
has also been suggested.
Campylobacter enterocolitis is the most frequent form of acute bacterial
diarrhea affecting humans, particularly children and young adults.
We evaluated the efﬁcacy and tolerability of a single oral azithromycin
for the treatment of Campylobacter enterocolitis in children 12 years
of age, administered early in the course of the disease compared to a
standard 5-day erythromycin regimen or no antibiotic. Our study suggests
that a single azithromycin 30mg/kg administered early in the course of
Campylobacter enterocolitis in children 12 years of age effectively
eradicates the pathogen and accelerates clinical cure attainment and
that it is clinically superior to an early commenced 5-day erythromycin
regimen.
S173 Current and future issues in resistance of respiratory
pathogens: is the horizon still bright?
R. Kozlov (Smolensk, RU)
Respiratory tract infections (RTIs) continue to be the major causes
of morbidity and mortality worldwide. Lower respiratory tract infec-
tions (LRTIs), including CAP, were ranked third in a list of the 30 leading
causes of death worldwide in 1990. Out of all pathogens, S. pneumoniae,
H. inﬂuenzae, M. catarrhalis and “atypical” pathogens still remain to be
the most prevalent ones, independently on the country. Traditionally,
b-lactamase, modern macrolides and respiratory ﬂuoroqinolones (for
adults only) are drugs of choice for the therapy of RTIs. But antimicrobial
resistance among these pathogens continues to be the major challenge for
the physicians in all countries. A total of 2,449 S. pneumoniae from 23
cities of Central, North-Western, Southern, Privolgsk, Ural, Siberian and
Far-Eastern regions of Russia were studied from 1999 to 2009. b-lactams
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retained comparatively high in vitro activity against S. pneumoniae:
non-susceptibility to penicillin, amoxicillin/clavulanate and ceftriaxone/
cefotaxime was 9.7%, 0%, 1.8% in 1999–2003; 8.1%, 0.3%, 2%
in 2004–2005 and 14.5%, 0.6%, 4.4% in 2007–2009, respectively.
Resistance to macrolides (including azithromycin) was low and varied
from 2.0% to 8.2% in 1999–2003, 4.3% to 6.6% in 2004–2005
and 7.9−10% in 2007–2009 with no statistically signiﬁcant changes
over indicated period. Susceptibility to chloramphenicol varied from
89.4% to 94.1%. Resistance to tetracycline was high during 1999–
2009 (23.7–29.6%). Non-susceptibility to co-trimoxazole increased from
31.7% in 1999–2003 to 41.3% in 2007–2009 (p< 0.0001). Levoﬂoxacin
and moxiﬂoxacin retained high in vitro activity against S. pneumoniae.
Proportion of multiresistant S. pneumoniae did not exceed 12% in
studied period. Ampicillin resistance in Haemophilus inﬂuenzae was
5.4% with no resistance to amoxicillin/clavulanate. Resistance to
azithromycin wass found to be 1.5%. Moraxella catarrhalis seems to
be of low epidemiological importance in Russia, being isolated only
in rare cases from patients with otitis media and acute exacerbation
of chronic bronchitis with virtually all strains being b-lactamase
producers and retaining susceptibility to b-lactam/b-lactamase inhibitors.
In conclusion, all above three classes of antimicrobials retain their place
in treatment of RTIs.
S174 Clinical effectiveness of azithromycin in an era of multidrug
resistance: results of a prospective international, multicentre
observational study (SUPoRTI)
B. Barsˇic (Zagreb, HR)
Azithromycin after twenty years of extensive use is still one of the
most prescribed antibiotics in the treatment of bacterial, respiratory
tract infections. Multidrug resistance (MDR) is reported worldwide,
but clinical consequences of MDR still remain controversial. SuPoRTI
study was designed to evaluate efﬁcacy of a 3-day azithromycin therapy
in the treatment of respiratory tract infections in adults and children
and to compare results with early clinical trials. SuPoRTI study is a
multicenter, prospective non-comparative phase IV study, which included
550 patients with bacterial upper and lower respiratory tract infections.
Three countries and 26 centers participated in the study. Only outpatients
were included in the study. The trial included patients with acute
pharyngitis, sinusitis and otitis media as well as patients with acute
exacerbation of chronic bronchitis and mild to moderate community
acquired pneumonia. Azithromycin was administered orally. Clinical
effectiveness was assessed after the third or fourth visit and dynamic of
clinical scores was assessed throughout the study. We present the results
of effectiveness and safety of azithromycine obtained in this study.
Non-typeable Haemophilus inﬂuenzae,
the “unrevealed pathogen” (Symposium
supported by GlaxoSmithKline Biologicals)
S178 The role and pathogenicity of non-typeable Haemophilus
inﬂuenzae in invasive and mucosal respiratory diseases
A.W. Cripps °, D.C. Otczyk, M. Ravuru, W.P. Hausdorff (Gold Coast,
AU; Wavre, BE)
Non-typeable Haemophilus inﬂuenzae (NTHi) is a common commensal
of the human respiratory tract mucosa. It is a fastidious Gram-negative
coccobacillus that resides exclusively in the human host. To date,
NTHi infection has been accepted largely as opportunistic and to occur
particularly in cases in which the host’s immune status or physiological
barriers have been compromised, for example in acute exacerbations of
chronic obstructive pulmonary disease in adults and otitis media (OM)
in young children. However, there is increasing evidence that, despite the
absence of a polysaccharide capsule, NTHi causes signiﬁcant invasive
disease as well as mucosal respiratory infections in subjects without
predisposing risk factors. In both developed and developing countries,
NTHi may cause septicaemia and meningitis in children at a prevalence
at least equal to that due to a single, major Streptococcus pneumoniae
serotype. In developed countries, especially in the post H. inﬂuenzae
vaccine era, it is difﬁcult to estimate the current disease burden, although
some countries have suggested an increasing number of cases of invasive
disease reported in the literature. Maternal genitourinary tract infection
has been identiﬁed as a source of highly fatal, early onset neonatal
NTHi septicaemia. The most signiﬁcant mucosal infections known to be
caused by NTHi are OM, sinusitis and conjunctivitis. Approximately
one-third of the bacterial isolates from OM and sinusitis are NTHi.
In the post-PCV-7 era, a proportionate increase in the frequency of
recovery of NTHi from mucosal isolates has been demonstrated in
children and adults in the United States. Furthermore, several lines of
evidence suggests NTHi may also play an important role in paediatric
community acquired lower respiratory infections, especially in children
with recurrent and persistent bronchitis & pneumonia. Further studies
are warranted to understand the public health importance of NTHi, as a
pathogen.
This review suggests that NTHi, as a cause of invasive disease, has been
underestimated and that there is an important invasive disease burden.
NTHi appears to be more commonly responsible for mucosal respiratory
infections than previously recognized.
S179 Clinical implications related to NTHI: from treatment to
potential prevention
J. Van Eldere ° (Leuven, BE)
Guidelines on the treatment of respiratory tract infections (RTI) may
need to be re-evaluated considering the increasing importance of non-
typeable Haemophilus inﬂuenza (NTHI).
• Reports comparing the prevalence of bacterial pathogens in acute otitis
media and acute bacterial sinusitis in children prior to and after the
introduction of the 7-valent conjugated pneumococcal vaccine (PCV7)
show replacement of Streptococcus pneumoniae vaccine types with
non-vaccine types. They also show an increased prevalence of NTHi.
• Recent reports conﬁrm that NTHi are associated with recurrent and
protracted morbidity.
• There are signs that the b-lactamase-dependent b-lactam resistance in
NTHi is being replaced by a non-b-lactamase-dependent resistance
mechanism that may render the use of current ﬁrst-line treatment
antibiotics, such as amoxy-clavulanic acid and second-generation
cephalosporins, ineffective.
Worldwide, b-lactamase production accounts for the majority of
H. inﬂuenzae ampicillin resistance. Mutations in penicillin-binding
proteins are another b-lactam resistance mechanism. These H. inﬂuenzae
strains are called b-lactamase-negative, ampicillin-resistant or BLNAR.
BLNAR strains are less susceptible to ampicillin but also to amoxy-
clavulanate and to second- or third-generation cephalosporins.
BLNAR strains were, until now, rare and increases in minimum
inhibitory concentrations (MIC) were limited, making use of aminopeni-
cillins in high doses still warranted. This situation is changing. Most
notably, for example, BLNAR strains have increased signiﬁcantly in
Japan. Similarly, in some European countries (Spain and France), an
increasing prevalence of BLNAR is also seen. Some of these strains
have increased MIC values that make treatment with aminopenicillins or
second- or third-generation cephalosporins ineffective.
A further increase of BLNAR strains might challenge our current
guidelines for treatment of RTI that advocate use of amoxy-clavulanate
or second-generation cephalosporins as ﬁrst-line treatment options.
Based on the observed effects of PCV7, the possible clinical implications
of new vaccines should be explored.
S180 The need for surveillance: a call for action
M.P. Slack ° (Abingdon, UK)
In order to monitor the impact of Hib vaccination on the epidemiology of
invasive Haemophilus inﬂuenzae disease, an international collaboration
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was established in 1996. By 2006, 28 countries had responded and
provided national surveillance data on invasive H. inﬂuenzae.1 By 2000,
14 of these countries had incorporated the Hib conjugate vaccine into
their infant immunization schedules and routinely serotyped all clinical
H. inﬂuenzae isolates. A total of 10,081 H. inﬂuenzae infections were
reported between 2000 and 2006;2 of these, 2836 (28%) were due to Hib
and 4466 (44%) to non-typeable H. Inﬂuenza (NTHi). It was found that
the incidence of NTHi was almost twice that of Hib (0.28 versus 0.15
per 100,000 cases) and that both Hib and NTHi infections were more
common in infants and the elderly. Moreover, the incidence of NTHi
was much higher than Hib in the ﬁrst month of life (11.4 versus 1.2 per
100,000 cases) and infections were more likely to occur in the ﬁrst week
of life, suggesting vertically acquired infection. Overall, however, the
median age at disease was higher for NTHi infections than for Hib (58
years versus 5 years, p< 0.0001). NTHi infections were also associated
with: a higher case fatality ratio (CFR; 366/3172 [11.5%] versus 88/2005
[4.4%]; p< 0.0001), particularly among infants (17.4% versus 2.9%;
p< 0.0001); and a higher proportion of NTHi infections among women
of child-bearing age. In addition, one-third of reported meningitis cases
were due to NTHi. The CFRs for Hib and NTHi meningitis were similar
in EU-IBIS data (4.1% versus 4.2%) but in England and Wales, the CFR
was much higher for NTHi meningitis (17% versus 5%). The reasons
for this are unclear. In conclusion, there is a need for continued, large-
scale, clinico-epidemiological surveillance to collect data on clinical
presentations of NTHi, risk factors, management and NTHi-attributable
death.
Reference(s)
[1] www.euibis.org [Accessed December 14th 2009]
[2] Ladhani S, Slack MPE, Heath PT, von Gottberg A, Chandra M,
Ramsay ME; EU-IBIS participants. Emerg Infect Dis 2010 [ in
press].
Emerging trends in fungal infections
K182 Emerging trends in fungal infections
C. Lass-Flo¨rl ° (Innsbruck, AT)
The frequency and diversity of serious fungal infections does increase
and severely immunocompromised patients are particularly vulnerable
to infection from moulds and yeasts. Candida and Aspergillus species
are the predominant pathogens. Candida bloodstream infections are
associated with high morbidity and mortality in both neutropenic
and non-neutropenic critically ill patients. Risk factors associated
are diverse and include exposure to broad spectrum antimicrobial
agents, mucosal colonization, indwelling vascular catheters, surgery
and cancer chemotherapy. Differences in geographical epidemiology are
emerging, in particular regarding a shift towards non-albicans species.
This shift has been correlated with routine ﬂuconazole administration.
Aspergillus spp. can cause a wide spectrum of diseases in humans,
including allergy, superﬁcial infection, and invasive disease. Invasive
aspergillosis has emerged as a leading cause of morbidity and mortality
in immunocompromised patients. The most important species are
Aspergillus fumigatus followed by Aspergillus ﬂavus.
Contemporaneously, infections with rare molds are on rise. Zygomyzetes,
Trichosporon, Fusarium, Alternaria, Pseudallescheria and dematiaceous
fungi are recognized more frequently. The emergence of these organisms
is multifactorial and can be related to more intense immunosuppression,
the prolonged survival of patients, and the selective pressure of broad
spectrum antifungal agents used for prophylaxis or therapy. Among
these rare mould infections, the zygomycetes are the most commonly
encountered, and appear to be associated with the use of voriconazole.
Aspergillus terreus, a species that is resistant to amphotericin B, and
less frequently, A. ustus and A. lentulus, have been noted increasingly
as causes of invasive aspergillosis in some tertiary care centres.
Scedosporium with innate resistance to many antifungal agents have
emerged as major causes of disseminated infections, followed by
infections due to Fusarium species. Dematiaceous, or brown-black,
fungi, most often associated with chronic localised infections, are
now increasingly reported as a cause of disseminated infection in
immunosuppressed hosts.
Watchful surveillance, rapid detection of disease, adequate treatment
and effective control measures are highly warranted in the optimal
management of these difﬁcult to treat fungal infections.
Impact of the commensal ﬂora on health and
diseases
K183 Impact of the commensal ﬂora on health and diseases
L. Engstrand ° (Stockholm, SE)
Our adult bodies harbour approximately ten times more microbial cells
than human cells and their genomes (the microbiome) endow us with
physiological capacities that strongly inﬂuence our well-being. However,
our microbiome is largely unexplored and there is a great need to increase
our understanding of the interactions between our human and microbial
genomes. The sequencing of the human genome constituted a starting
point in the understanding of human biology at a global scale, yet today
there is a growing agreement that human health and disease cannot
be understood without considering the microbial communities. Now
when the human microbiome project has been launched a number of
international consortiums are starting up with efforts to explore the role
of the human microbiota in health and disease. Many lines of evidence
suggest a role for both commensal and transient microbes in the status
of human health as well as for the risk of contracting certain diseases.
During the last years molecular microbiology has revolutionized the
landscape of microbiology and will continue to do so by providing
new solutions for microbe identiﬁcation and characterization. Next-
generation sequencing has opened up new areas of research for people
in the ﬁeld of intestinal, skin, oral cavity and other microbiomics.
The high-throughput sequencing platforms we now have access to
will hopefully also help to increase our understanding of host-bacteria
interactions, immune maturation and mechanisms behind chronic disease
development. An interdisciplinary approach must be taken on comprising
medical, epidemiological, computational, and biotechnology expertise
focusing on understanding the human microbial communities and their
effect on human health. Application of different “omics”-methods and
computational systems biology methods to unique biobanks will be
required in order to map out the human microbiome as well as the
human cellular machinery interacting it.
ESBL-producing E. coli in the community
S185 How big is the threat in the outpatient setting?
N. Woodford ° (London, UK)
E. coli with CTX-M enzymes are globally the most prevalent ESBL
producers. They are often isolated from urines of patients attending
general practice, but there are few data to assess accurately the extent
of the community burden. The prevalence of ESBL producers in faeces
from healthy people is typically <5% in Europe. In a recent multicentre
study of non-hospitalized patients with infections, one third of the ESBL
producers (mainly E. coli) were from those with no recent health care
contact (Ben-Ami et al. Clin Infect Dis. 2009;49:682). In the UK, ESBL-
producing E. coli cause c. 2500 cases of bacteraemia p.a., and may be
estimated to cause c. 50,000 urinary tract infections p.a. Many belong to
the globally-disseminated O25:H4-ST131 uropathogenic clone and have
CTX-M-15 ESBL, though CTX-M-3 is equally common in this clone in
Belfast, a city where the ST131 clone is present in the faeces of 40%
of nursing home residents. CTX-M-15 ESBL is associated with IncFII
multi-resistance plasmids, while CTX-M-3 in Belfast is encoded on IncI1
plasmids. These plasmids cannot readily be lost even in the absence
of antibiotic selective pressure, since they encode multiple ‘addiction’
systems. Hence ESBL producers may serve as long-term community
reservoirs of resistance genes. Foreign travel may also be associated
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with gut colonization by ESBL-producing isolates, and the ESBL present
often reﬂects the type most prevalent in the countries visited. Food
remains an under-explored potential source for ESBL-producing E. coli.
Raw chicken has been sampled in the UK, with CTX-M group 2 and 8
ESBLs found in meat imported from South America; these types account
for <1% of ESBLs from clinical infections. There are currently no data
to suggest wide presence of CTX-M-15 ESBL in foodstuffs; it may be
found in E. coli from animals, but the strains are usually distinct from
the dominant human clinical types. ESBL producers are often multi-
resistant. Carbapenems are the drugs of choice for serious infections, but
resistance may emerge in strains with reduced permeability, as observed
in a UK nursing home resident who had no recent hospitalization
or carbapenem exposure. Carbapenemase-producing E. coli are rare,
although isolates with NDM-1 metallo-carbapenemase in addition to
CTX-M-15 and acquired AmpC enzymes give cause for concern lest
they become as prevalent as those with ‘traditional’ CTX-M-15 enzyme,
or follow them into the community setting.
S186 How does changing epidemiology alter our management and
prevention strategies?
J. Pitout ° (Calgary, CA)
Since 2000 Escherichia coli producing CTX-M enzymes (especially
CTX-M-15) have emerged worldwide as important causes of community-
onset urinary tract (UTIs) and blood stream infections due to
extended-spectrum b-lactamase (ESBL) producing bacteria. Molecular
epidemiology studies suggested that the sudden worldwide increase
of CTX-M-15-producing E. coli is mostly due to a single clone
named ST131 and that foreign travel to high-risk areas such as the
Indian subcontinent might play in part a role in spread of this clone
across different continents. The carbapenems are widely regarded as
the drugs of choice for the treatment of severe infections due to
ESBL-producing Enterobacteriaceae Empiric antibiotic coverage for
these resistant organisms should be considered in community patients
presenting with sepsis involving the urinary tract especially in patients
with certain risk factors such recent antibiotic use, residence in a long-
term care facility, recent hospitalization, males older than 65 years
and recent travel to a high-risk area. Failure to initiate appropriate
antibiotic therapy from the start appears to be responsible for higher
patient mortality. Studies from different parts of the world shows
that that up to 5 percent of the population in the community can
be rectally colonized by ESBL-producing Enterobacteriaceae but the
large scale introduction of these bacteria into the hospital setting has
not yet been demonstrated. However higher rates of colonization with
ESBL-producing Enterobacteriaceae are present in household contacts of
patients with infections caused by ESBL-producing Enterobacteriaceae,
residents from nursing homes or long-term care centers. Preventing the
spread of these bacteria and managing infections caused by ESBL-
producing E. coli from the community remain difﬁcult and controversial
issues.
The integrated diagnostic platform versus
the stand-alone microbiology laboratory
S188 The integrated diagnostic platform
J. Van Eldere ° (Leuven, BE)
Clinical microbiology is subject to rapid evolution due to the need
for rapid and more complex diagnostics, the increasing difﬁculty in
recruiting trained personnel as well at the medical as at the technical
level, the need for proven cost-efﬁciency and the increasing overhead
costs associated with quality control. On the other side, there are new
opportunities following the introduction of new techniques such as PCR,
MALDI-TOF and in particular the availability of automated inoculation
and plate reading systems to replace manual labour.
Reactions to these challenges differ, ranging from outsourcing to
non-hospital based specialized microbiology labs to various forms
of cooperation between smaller labs. This cooperation can exist in
centralizing a part of or almost all activity in a central hospital-based
lab or can be a network with a division of labor between collaborating
labs. All these solutions share one factor. By increasing size, they
seek to increase cost-efﬁciency and facilitate the introduction of new,
specialized and expensive techniques. Outsourcing is often rejected
because it risks reducing microbiology to a purely analytical activity
with little microbiologist-dependent added-value. Concentrating smaller
microbiology labs in one central lab or networking may not always
be possible for practical reasons and will again increase the distance
between clinical microbiologists and some of the microbiological tests.
A solution that can assure a sufﬁcient lab size even in medium-
sized hospitals without the need for collaboration with other labs or
outsourcing is integration of the microbiology lab with other pathology
labs such as clinical chemistry or clinical hematology. This kind
of integration can combine economy of scale with conserving the
microbiological activity within the hospital and thus the close link
between microbiology and infectious disease and infection control
specialists. Integration of laboratories in its simplest form can exist in
sharing of machines and lab space. It can also lead to an integration
of all diagnostic activity according to common workﬂows. An example
is an integrated unit for molecular testing performing all nucleic acid
based testing; microbiological, hematological but also human genetics or
forensic medicine. This integrated lab demands new ways of organizing
lab activity. Essential to the integrated lab is a separation of medical and
technical expertise and medical and organizational responsibility.
EBV, CMV and virus hepatitis in solid-organ
transplant recipients
S189 EBV and CMV-speciﬁc immunity
M.K. Brenner ° (Houston, US)
Following allogeneic stem cell transplantation, patients have profound
and prolonged immunosuppression. This is most severe after HLA
mismatched transplants that require extensive T cell depletion to prevent
graft-versus-host disease, and in recipients of cord blood transplants,
which contain few memory T-lymphocytes. The consequence is a high
morbidity and mortality from infection and disease relapse. We have been
developing two approaches to repopulate the immune system following
transplantation to reduce both types of risk. Our ﬁrst approach is to
isolate viral and fungal antigen reactive T lymphocytes from donor
blood and expand them ex vivo before infusing them into the stem
cell recipients. We have generated T lymphocytes that are speciﬁc
for common viruses such as Epstein–Barr virus, cytomegalovirus, and
adenovirus, and engineer them to expand efﬁciently in vivo. They have
proved effective at preventing and treating serious virus illness in the
target patient populations and we are now extending this approach to
the treatment of fungal disease. Our second approach is to remove
alloreactive T cells from donor PBM and infuse these depleted T cells
to produce broad immune reconstitution. As a further safety measure
to prevent GvHD from the infused cells, we incorporate a new suicide
gene composed of a modiﬁed caspase 9 that can be activated by a small
molecule drug. Early clinical results show high safety and efﬁcacy of
the approach.
We have also developed tumor-speciﬁc cytotoxic T lymphocytes, using
both native and chimeric receptors directed to tumor associated antigens.
We express the chimeric receptors in virus speciﬁc T lymphocytes, thus
gaining the beneﬁt of both an antiviral and an antitumor response from
the same infused T-cells. These approaches appear to be extremely cost
effective and to have a high margin of safety.
S190 Hepatitis E: monitoring and treatment
J. Izopet ° (Toulouse, FR)
Hepatitis E virus (HEV) infection is now considered as an emerging
infectious disease in industrialized countries. HEV genotypes 3 and 4
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are widely distributed in animals and there is growing evidence that
hepatitis E is a zoonotic disease transmitted directly or indirectly from
animals to humans. It has been shown recently that HEV can lead
to chronic infection in solid-organ transplant recipients. Liver ﬁbrosis
progression in this population can be very rapid, leading to liver cirrhosis
within a few years after infection.
Virological tools are crucial not only for diagnosis but also for
determining the incidence of HEV infections in solid-organ transplant
recipients. Although the sensitivity of EIA tests for detecting anti-
HEV antibodies among immunocompromised patients may be poor,
the performances of the anti-HEV IgM assays appear to be useful for
identifying a recent HEV infection. However, detection of HEV RNA in
blood and stools by PCR remains the gold standard.
In a prospective cohort of 38 solid organ transplant recipients with
acute hepatitis E, 58% developed a chronic infection. Two main HEV
genotypes were identiﬁed by sequencing the ORF2 region, genotype 3f
and 3c. The concentrations of HEV RNA in plasma at the acute phase
in patients who cleared the virus were similar to those who developed a
chronic infection. By contrast, the acute phase aminotransferase activities
were higher in the patients who cleared the virus.
When possible, reduction of immunosuppressive drugs targetting T-cells
in chronically infected patients must be considered as a ﬁrst-line
therapeutic option in order to obtain HEV RNA clearance. Recent data
also indicate that pegylated interferon and ribavirin induce biochemical
and virological responses in selected populations.
In conclusion, HEV infection must be considered in the differential
diagnosis of hepatitis in solid-organ transplant patients. Improved
information and prophylactic measures are needed to reduce the risk
of virus transmission and chronic liver disease.
Impact and cost-effectiveness of MRSA
screening
O195 Screening procedures have a signiﬁcant impact on incidence
densities of methicillin-resistant Staphylococcus aureus in
German intensive care units
A. Kohlenberg °, F. Schwab, C. Geffers, M. Behnke, P. Gastmeier
(Giessen, Berlin, DE)
Objectives: To evaluate the incidence densities (IDs) of methicillin-
resistant Staphylococcus aureus (MRSA) and screening and control
measures in intensive care units (ICUs) participating in the German
Nosocomial Infection Surveillance System (KISS).
Methods: The surveillance module for multidrug-resistant bacteria in
ICUs (MDR-KISS) collects data on all MRSA cases in participating
ICUs with the aim to provide a national reference and a tool for
monitoring and evaluation of infection control management. The median
IDs of MRSA cases per 1000 patient-days (pd) with the interquartile
range (IQR) are calculated for all MRSA cases and for the subcategories
of imported and ICU-acquired cases from the pooled data of all ICUs
as a reference for comparison with local MRSA IDs.
In 2008 a detailed questionnaire regarding ICU structure, microbiological
diagnostics, MRSA screening procedures, MRSA control measures,
infection control education and implementation of surveillance was
sent to all participating ICUs. The association between questionnaire
results and high MRSA IDs (>75% percentile) was evaluated by logistic
regression analysis.
Results: 186 ICUs with 298631 patients and 1064246 pd had submitted
data on 4730 MRSA cases for 2007–2008 and had completed the
questionnaire. Median MRSA IDs in these ICUs were 3.23 (IQR 1.19–
5.68), 2.05 (IQR 0.62–4.22) and 0.61 (IQR 0.14–1.35) per 1000 pd
for all cases, imported and ICU-acquired cases, respectively. Routine
screening for MRSA was performed in 142 (76.3%) ICUs, with
conventional MRSA detection methods used in 74 ICUs (39.8%), PCR-
based screening in 11 ICUs (5.9%) and both methods in 57 ICUs
(30.6%). The most relevant screening procedures and control measures
are shown in table 1. Of all variables derived from the questionnaire only
the variables general admission screening of all patients (odds ratio 8.2,
p< 0.001) and screening of admitted patients at regular intervals (odds
ratio 4.9, p< 0.001) were independently associated with high MRSA IDs.
Conclusion: Considerable differences exist in MRSA incidence densi-
ties, screening and control measures in German ICUs. MRSA screening
procedures have the most important impact on MRSA incidence
densities. ICUs decide to perform a general admission screening
probably because they have realized their MRSA problem.





Computerized MRSA alert system 134 (72.0)
Screening of known carriers 118 (63.4)
Screening of contact patients 113 (60.8)
Screening of high-risk patients 104 (55.9)
General admission screening of all patients 51 (27.4)
Screening of admitted patients at regular intervals 39 (21.0)
Isolation of MRSA carriers in single rooms 174 (93.5)
Decolonisation with mupirocin ointment/antiseptic washing 173 (93.0)
O196 How many patients do you need to screen for methicillin-
resistant Staphylococcus aureus to ﬁnd a positive? Results
from a screening programme in a UK teaching hospital
G. Jones °, J.K. Sutton, S. Aplin, D. Browning (Southampton, UK)
Objectives: Screening for methicillin-resistant Staphylococcus aureus
(MRSA) became mandatory in the UK for all elective and day case
admissions from April 2009 and will be mandatory for all emergency
admissions from April 2011. Data to assess the effectiveness of this
strategy at an individual hospital level are lacking. We analyzed our
screening programme data to determine the number needed to test (NNT)
to detect a colonised patient across a range of clinical specialties, and
develop a risk assessment strategy for MRSA screening.
Methods: MRSA screens of nose and groin were performed using
chromogenic agar, with additional sites such as wounds and catheters
included when present. In our hospital, MRSA screening data were
resolved prospectively to individual patient level as opposed to a
commonly utilized approximation using matched census (admission)
data. Screening data were mapped to a patient administration system
database containing relevant speciality codes. Mismatches where no
screening results existed for individual patients were investigated weekly
and included identiﬁcation of patients in speciﬁc categories excluded
from screening. Screening efﬁciency by specialty was fed back weekly to
clinical teams to drive improved performance. Rates of MRSA positivity
and NNT to detect a positive patient were determined for each specialty.
Results: For the 12 months from October 2008, the laboratory performed
>160,000 MRSA swabs on 51,855 individuals costing 600,000 Euros.
Screening efﬁciency for elective admissions improved from 60% to
99% (2228/2249) and for emergency admissions from 76% to 97%
(2996/3077). Overall, 1.2% of hospital admissions were MRSA positive,
with 1.6%, 0.7% and 0.6% being MRSA positive in emergency, elective
and day case cases respectively. The highest MRSA positivity rates were
seen in emergency cases in hepatology (4.3%), interventional radiology
(3.7%) and vascular surgery (3.3%). 1.5% of elective vascular surgery
patients were MRSA positive. The lowest MRSA positivity rate was
in day case orthopaedics where 1,006 patients were screened without
detecting a single positive patient. NNT to detect a positive ranged from
24 to >1,006 depending on clinical speciality and admission type.
Conclusions: Accurate data on results of MRSA screening can be
used to assess both risk for individual patient admissions and the cost
effectiveness of screening in speciﬁc patient groups, and to enhance the
efﬁciency of the screening process.
Impact and cost-effectiveness of MRSA screening S47
O197 Long-term control of endemic methicillin-resistant
Staphylococcus aureus in a tertiary centre: a segmented
regression analysis of a stepwise approach
J. Rodrı´guez-Ban˜o °, L. Garcı´a, E. Ramı´rez, C. Lupio´n, M.A. Muniain,
C. Velasco, J. Ga´lvez, M.D. del Toro, A. Milla´n, L. Lo´pez-Cerero,
A. Pascual (Seville, ES)
Objectives: We evaluated the long term efﬁcacy of several bundles of
control measures against endemic methicillin-resistant Staphylococcus
aureus (MRSA) in a 1000-bed tertiary hospital.
Methods: A cuasi-experimental study of interrupted time series was
performed. The outcome variables were hospital-wide bimonthly rates
(cases per 1,000 patient-days) of nosocomial colonisation/infection and
bacteraemia due to MRSA from January 2005 to December 2008.
The interventions were as follows: Intervention 1 (In1), implemented
in January 1997: contact precautions for MRSA patients detected by
clinical samples; intervention 2 (In2), implemented in January 1999:
active surveillance of MRSA colonisation of patients and healthcare
workers (HCW) in wards with ongoing MRSA transmission as suspected
by the analysis of clinical epidemiologic data; and intervention 3 (In3),
implemented in January 2001: active surveillance of readmitted patients
and patients admitted from other centers. For the analysis, segmented
regression was used. The following model was adjusted: Y = b0 + b1
x time + b2 x In1 + b3 x time after In1 + b4 x In2 + b5 x time after
In2 + b6 x In3 + b7 x time after In3 + e, where b1=baseline time trend,
b2=level change after In1, b3=trend change after In1, b4=level change
after In2, b5= trend change after In2, b6=level change after In3, and
b7=trend change after In3.
Results: The rate of colonisation/infection and bacteraemia in the
preintervention period (1995–1996) was 0.56 and 0.10, respectively.
Neither the level nor the trend chenged after In1. Rates were signiﬁcantly
reduced to 0.28 and 0.04 after In2, and to 0.07 and 0.02 after In3,
respectively, and were kept in those levels since 2008. There was
no signiﬁcant changes in the rate of bacteraemia due to methicllin-
susceptible S. aureus. The results cannot be explained by changes in the
case-mix or antibiotic consumption. The segmented regression model is
shown in the table.
Conclusion: Sustained control of endemic MRSA in tertiary centres is
possible by active screening of patients and HCW, contact precautions,
and control of high risk patients at hospital admission.
MRSA colonisation/infection MRSA bacteraemia
Coefﬁcient (95% Cl) P Coefﬁcient (95% Cl) P
b0 0.58 (0.49; 0.67) <0.001 0.10 (0.076; 0.12) <0.001
b1 −0.004 (−0.16; 0.008) 0.4 0.001 (−0.003; 0.004) 0.75
b2 0.03 (−0.08; 0.14) 0.5 −0.018 (−0.050; 0.014) 0.2
b3 0.001 (−0.016; 0.018) 0.8 0.002 (−0.003; 0.006) 0.4
b4 0.06 (−0.05; 0.18) 0.2 −0.05 (−0.08; −0.02) 0.002
b5 −0.04 (−0.06; −0.02) <0.001 −0.006 (−0.010; −0.001) 0.01
b6 0.07 (−0.01; 0.16) 0.04 0.002 (−0.022; 0.026) 0.8
b7 0.04 (0.03; 0.05) <0.001 0.003 (0.000; 0.006) 0.05
O198 Diagnostic yield and ﬁnancial consequences of anatomic sites
tested using rapid diagnostic tests for methicillin-resistant
Staphylococcus aureus
M.W. Wassenberg °, J. Kluytmans, A. Troelstra, M. Bonten on behalf
of the Dutch Rapid MRSA Diagnostics Study Group
Objectives: The Dutch MRSA screening strategy requires sampling
of multiple sites and with rapid diagnostic testing (RDT) conventional
cultures are mandatory as back up. We determined cost-effectiveness of
a less extensive screening regime using RDT without back up cultures
in a prospective multi-center study.
Methods: All patients at risk of MRSA colonization and fulﬁlling
the criteria for pre-emptive isolation in 14 hospitals between 12/05
and 06/08 were eligible. In addition to conventional cultures, BD
GeneOhmTM MRSA PCR (‘IDI’, BD Diagnostics) or the Xpert MRSA
assay (‘GeneXpert’, Cepheid) was performed directly on patient material.
In a nested cohort study the chromogenic agar MRSA-ID (bioMe´rieux)
was tested. Cost-efﬁcacy is determined assuming isolation measures
would have been based on single site testing of the nares without back
up cultures. Isolation of MRSA at any site tested using broth enrichment
culture was the gold standard.
Results: 1764 patients (mean 48 years, 56% male) were enrolled. 3.3%
carried MRSA: after hospitalization abroad 1.6% (20/1225), contact
with pigs 15.0% (29/193) and contact screening related to MRSA
positive patients 2.8% (8/289). The sensitivity of screening of the nares
using IDI PCR, GeneXpert and MRSA-ID was 69.2%, 56.3% and
61.5%, respectively with negative predictive values >98.4% for all tests.
Costs per patient tested were €56.62, €70.92 and €8.06 for IDI PCR,
GeneXpert PCR and MRSA-ID, respectively. Isolation days avoided
were 2.3%-5.2% higher with single site testing compared to multiple site
testing because of higher speciﬁcity (and lower sensitivity). Test costs
per isolation day avoided were €25.00, €34.48 and €4.91 for IDI PCR,
GeneXpert PCR and MRSA-ID respectively. As compared to “nares-
only” multiple site testing prevented respectively, 4 and 6 false negative
cases using IDI PCR (4/853, 0.5%) and GeneXpert PCR (6/911, 0.7%)
at the additional costs of respectively €148.55 and €161.78 per patient.
Chromogenic agar testing of multiple sites prevented 4 FN results (4/428,
0.9%) at no additional costs.
Conclusion: Although the recommended multiple site sampling strategy
has a higher sensitivity than “nares-only” screening without back up
cultures, our results demonstrate that in a low endemic setting the
beneﬁts of such a strategy are limited, and the costs are high. Financial
consequences of the missed MRSA patients have to be determined to
draw deﬁnite conclusions.
O199 Modelling the cost-effectiveness of screening and
decolonization in the control of methicillin-resistant
Staphylococcus aureus
J.V. Robotham °, N. Graves, B.D. Cookson, J. Wilson, A.G. Barnett,
J. Edgeworth, R. Batra, B.S. Cooper (London, UK; Brisbane, AU;
Bangkok, TH)
Objectives: To use transmission dynamic models to assess the cost-
effectiveness of deﬁned screening and decolonisation strategies in the
control of methicillin-resistant Staphylococcus aureus (MRSA).
Methods: We developed a dynamic transmission model of MRSA
in intensive care units (ICUs) to evaluate the effectiveness and
cost-effectiveness of screening and topical decolonisation (both nasal
ointment and body wash-based antiseptic protocol). The model was
parameterized using evidence from multiple sources (data, literature
and expert opinion) including full parameter uncertainty. Thirteen
strategies were compared, including decolonisation of all admissions,
decolonisation of patients identiﬁed as MRSA positive through screening
(comparing conventional cultures, chromogenic agars and polymerase
chain reaction (PCR)-based techniques) and targeting interventions
to high risk patients. Incremental costs and health beneﬁts of the
alternatives were evaluated under different settings of prevalence,
proportion of high risk patients and ICU size.
Results: Compared to a baseline strategy of decolonisation of clinical
infections only, all other strategies were cost-saving and gave increased
health beneﬁts. Decolonisation of all patients was the most cost effective
option, saving £60,000/quality adjusted life year (QALY) gained. For
screening, and decolonisation of identiﬁed MRSA positives, PCR had the
greatest ability to reduce MRSA transmission (giving a 94% reduction
in infections per 100 admissions, compared to 64% with conventional
culture). Including parameter uncertainty, the best decision depended on
the decision maker’s willingness to pay for health beneﬁts: at a value
of £20,000−30,000 per QALY, admission screening with PCR combined
with decolonisation of identiﬁed positives was the best strategy. However,
there was uncertainty in this decision, reﬂecting parameter uncertainty,
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and the expected value of perfect information on the parameters was
high (~£10,000).
Conclusion: With no microbial resistance to decolonisation agents, all
decolonisation strategies were cost-effective, particularly decolonisation
of MRSA positive admissions identiﬁed through PCR screens. These
models allow uncertainty in decision making to be quantiﬁed and
highlight parameters on which more information is needed to ensure
cost-effective decisions, in this case the probability of progressing from
colonisation to infection for decolonised and ‘un-decolonised’ patients.
Future high-throughput microbiology
laboratory
S204 I believe in mass-spectrometry
X. Nassif ° (Paris, FR)
MALDI-TOF mass spectrometry: a revolution in the identiﬁcation of
pathogens in clinical laboratories. In the management of bacterial
infections, identiﬁcation of the pathogen following growth remains
essential to propose as soon as possible the most appropriate treatment
before the availability of antibiotic susceptibility. The strategy for most
common pathogens requires Gram staining, the results of simple tests
such as determination of oxidase and catalase activity and appropriate
phenotypic tests using commercial identiﬁcation kits and/or automated
systems. A new proteomic strategy is progressively changing this
strategy by identifying bacterial or fungal species grown on plates
within minutes. Matrix assisted laser desorption ionisation time-of-
ﬂight mass spectrometry (MALDI-TOF-MS) of intact bacteria yield
reproducible spectrum depending upon strain or species. Using whole
viable bacteria we describe here the application of MALDI-TOF-MS
to the identiﬁcation of bacterial pathogens isolated in routine clinical
microbiology laboratories. Our aim was, once a primary isolate of a
bacterium has grown onto a plate, to identify spectral prints, in the
MALDI-TOF spectrum, that can be used to recognize the genus or
the species. MALDI-TOF-MS was performed using bacteria obtained
from one isolated colony. Over 400 clinically relevant bacterial species
were selected. For each of these species one or several references strain
was (were) selected to establish spectral prints. For each strain, only
peaks that were conserved in the spectra of all 10 isolated colonies and
with a relative intensity above 0.1 were retained, thus leading to a set
of 3 to 30 selected peaks per strain. For each group of pathogens the
database was validated using a set of isolates identiﬁed using mostly 16S
RNA sequencing. The use of this strategy to identify bacterial species
in clinical microbiology laboratories will be presented.
Climate change and parasitic infections in
Europe
S206 Expansion of leishmaniasis and other parasitic diseases in
Europe
B. Evenga˚rd ° (Umea˚, SE)
Objectives and Methods: To give an overview over climate change in
Europe with some regional examples and the knowledge we have on its
inﬂuence on the prevalence of parasitic infections with the use of review
of literature.
Results: The northern part of Europe, the Arctic will have three times
higher temperatures than the rest of the world due to climate change.
We have a lot to learn from what is happening in the circumpolar area
for adaptation strategies. Parasitic infections as Leishmania, Opistorchis,
Echinococcosis multilocularis and alveolaris are expanding along with
Giardia intestinalis as some examples. The impact will differ regionally.
Conclusion: Given the dynamis and the complexity of climate/sensitive
infectious disease, particularly those transmitted by mosquitos or rodents
Europe needs to develop and sustain surveillance and early warning
systems with a regional focus.
Food for thought: tackling the problem of
food-borne infection in the elderly
S209 The elderly patient as a sitting duck for food-borne
infections: causes and consequences
L. Medeiros ° (Columbus, US)
According to the United Nations, the world population of elderly will
surpass that of children under age 15 by the year 2045. Health resources
will shift with population growth; thus, measures to reduce health
cost through preventive care are prudent. Illnesses from food-borne
pathogens are avoidable if technologies are used to maximize safety
of food and water, populations are educated in self-care, and medical
therapies are advanced for early diagnosis and treatment. Since self-
care strategies require alteration of usual cultural and habitual behavior,
education efforts have limited success with the elderly. Why is it
difﬁcult to teach the elderly how to handle food safely and what are
the consequences for failure to heed professional advice? Medically,
when is a person elderly? When does the body begin senescence and
susceptibility to opportunistic infections increase? The aging immune
system is the primary reason for susceptibility to food-borne pathogens
in the elderly. Natural, senescent immunity is exacerbated by the immune
insufﬁciency of chronic disease and pharmacological therapies common
in the population. Immune insufﬁciency associated with malnutrition
becomes a causative factor as the physical and mental capacity of the
aging individual deteriorates. Poor hygiene, failure to handle and store
foods safely, and inability to distinguish between safe and tainted food
may all be consequences of diminished mental or general health. For
those in group housing, failure of care staff to heed food handling
guidance could affect the health of multiple residents due to wide-spread
exposure and immune insufﬁciency. Yet, acceptance of well-meaning
advice to change poor health habits is limited due to lack of trust in the
efﬁcacy of the information, information that is contrary to cultural and
traditional practices, or the failure to recognize and accept the decline of
physiological and mental health. The challenge to the health professional
that is providing food safety guidance is to recognize the social, health
and mental barriers that control the ability of the individual to act on
the advice. The goal is no food-borne illness in the world, but reality
is that when preventative care is no longer possible, palliative care must
take its place.
Paediatric infectious diseases
O215 Aetiology of community-acquired pneumonia in children
during the inﬂuenza A (H1N1) outbreak
L. Michelim °, J. Fracasso, P. Garrido, V. Buffon, L. Generosi,
P. Oliveira Filho (Caxias do Sul, BR)
Objective: In July 2009, a respiratory illness outbreak caused by
inﬂuenza A virus (H1N1–2009) was identiﬁed in Caxias do Sul, Brazil.
The aim of the study is to determine the impact of inﬂuenza A H1N1
2009 on the viral etiology of pneumonia among children admitted at
General Hospital of Caxias do Sul from July 01 to August 31, 2009.
Methods: Retrospective medical chart reviews on the pediatric
hospitalized patients diagnosed with acute respiratory infection between
July and August 2009. We evaluated demographic data, clinical and
laboratory ﬁndings. Nasopharyngeal aspirates for detection of respiratory
viruses were analyzed by indirect immunoﬂuorescence (IFI) and real-
time polymerase chain reaction (RT-PCR).
Results: A total of 53 children were hospitalized for severe acute
respiratory disease, according to the criteria established by the Health
Ministry of Brazil. Most patients were male (60.3%) and had less than
one year of age (35.8% with less than 6 months and 26.4% between 6
and 12 months). Comorbidities were identiﬁed in 9.4%. Fifteen patients
were referred for the intensive care unit, and one third of them required
mechanical ventilation. No deaths occurred. Six patients (11.3%) had
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conﬁrmed inﬂuenza A (H1N1) and in 27 children (50.9%) were identiﬁed
respiratory syncytial virus (RSV) as the etiologic agent of pneumonia.
Conclusion: As in previous years, respiratory syncytial virus has
remained as predominant agent in the etiology of viral pneumonia in
spite of the outbreak of inﬂuenza A (H1N1) experienced in 2009.
O216 Norovirus infection in hospitalized Australian children
A. Kesson °, N. Benwell, E. Elliott (Westmead, Sydney, AU)
Objective: Norovirus, previously the Norwalk agent, is a common cause
of acute gastroenteritis. We determined the incidence and relative impact
of norovirus in children with acute diarrhoea admitted to a tertiary
paediatric hospital in New South Wales, Australia.
Methods: Faecal samples were collected from children presenting to our
Hospital with episodes of acute diarrheal illness over a 12 month period
(2007). The viral pathogens, rotavirus and adenovirus were detected
using immunochromatography and norovirus was detected using enzyme
linked immunosorbent assay.
Results: During this 12 month period, faecal samples were collected
from 3962 children who presented with diarrhoea to our Hospital and
viral pathogens were detected in 294 of these children who required
hospital admission. 231 of 294 (78.5%) children with gastroenteritis
required a hospital stay of one week or less, median 1 day and 212
had a single viral stool pathogen detected of which 63 (30%) were
norovirus, 56 (26%) were adenovirus and 93 (44%) were rotavirus. Dual
viral infections were detected in 19 (8%). Norovirus infections most
commonly presented in spring (September-November, with an October
peak) in infants (age less than 12 months). Of the 63 patients with a
hospital stay greater than one week, 28 (44%) had norovirus infection,
16 were non-oncology patients who developed nosocomial infection after
admission for another condition. The 25 oncology patients were older
and had a longer hospital stay (median 11 days) than non-oncology
patients and 7 (28%) had nosocomial infection due to norovirus.
Conclusion: We have demonstrated the impact of community-acquired
norovirus gastroenteritis and the high frequency of nosocomial norovirus
infection in a tertiary paediatric hospital. With the advent of rotavirus
vaccination, norovirus may become the major viral pathogen causing
gastroenteritis in Australian children.
O217 Impact of rapid PCR detection of enteroviruses in spinal
ﬂuid in children with meningitis
K.M. Huizing °, C.M. Swanink, A.M. Landstra, A.A. van Zwet, P.A. van
Setten (Arnhem, NL)
Objectives: We hypothesized in this study that the use of a rapid PCR
on enteroviruses in spinal ﬂuid signiﬁcantly reduces the duration of
hospitalization, and use of antibiotics. We expected that these reductions
would lead to lowering of hospital costs.
Methods: The study group comprises children admitted to the hospital
from April 2009 until November 2009 with conﬁrmed enterovirus
meningitis. Since 2009 we performed the PCR on enteroviruses in spinal
ﬂuid in our hospital. The results are available within 3 hours. This
study group was compared to a historical control group that consisted of
children who were admitted in 2007 and 2008 with conﬁrmed enterovirus
meningitis. In the historical control group, results for enterovirus PCR
tests were available after 3 to 7 days. We analyzed both groups for clinical
and laboratory parameters, length of hospital stay, use of antibiotics and
estimated overall costs.
Results: The study group and historical control group were comparable
with respect to clinical and laboratory data. A signiﬁcant difference was
found between the groups in length of hospital stay (p< 0.0001). The
mean duration was 6.7 days in the 2007–2008 group (range 2.3–41.0
days) versus 1.8 days in the 2009 group (range 0.8–4.55 days). The mean
duration of use of antibiotics was also signiﬁcantly reduced (p< 0.0001)
from 4.48 days (range 1.3–12.8 days) to 0.75 days (range 0.1–1.5 days).
Overall costs were 2900 euro lower per patient in the 2009 group.
Conclusion: Our data show that in children with enterovirus meningitis
the use of a rapid PCR results in a signiﬁcant reduction of hospital
stay and duration of antibiotic treatment. Subsequently, it also leads to
an important reduction of hospital costs. The rapid enterovirus PCR
is an important diagnostic tool in daily management of children with
meningitis.
O218 Predictive model for diagnosis of neonatal sepsis
D. Husada °, P. Chanthavanich, K. Pengsaa, C. Sirivichayakul,
W. Chokejindachai, J. Kaewkungwal, U. Chotigeat, P. Suntarattiwong
(Surabaya, ID; Bangkok, TH)
Early diagnosis of neonatal sepsis is essential to prevent severe
complications and avoid unnecessary use of antibiotics.
Objective: To develop a predictive model for the diagnosis of neonatal
sepsis.
Methods: This case–control study was conducted in QSNICH, Bangkok.
Data were derived from the medical records of 45 sepsis and 135
non-sepsis neonates for early sepsis, and 52 sepsis and 156 non-sepsis
cases for late sepsis, during the period 1 October 2004−30 September
2007. Potential predictors consisted of risk factors, clinical conditions,
laboratory data, and treatment modalities. The models were developed
based on multiple logistic regression analysis.
Results: The incidence of early and late proven neonatal sepsis was 1.27
and 1.46%, respectively. For early neonatal sepsis, the equation and score
consisted of 5 variables: length of stay pre-sepsis, poor feeding, abnormal
oxygen saturation (<92%), thrombocytopenia (<150,000/mm3), and
leucopenia (<5000/mm3). For late neonatal sepsis, the model had 6
variables: poor feeding, abnormal heart rate (outside the range 100–180
x/min), abnormal temperature (outside the range 36–37.9ºC), abnormal
oxygen saturation, abnormal leucocytes(according to Manroe’s criteria by
age), and abnormal pH (outside the range 7.27–7.45). The area below
the ROC curve were 87.8 and 95.5% for early and late neonatal sepsis,
respectively. Validation used subsets of the original data-set, twice for
each model, and produced areas below the curve of 82.2 and 86.2%
(for the early group) and 96.3 and 93.6% (for the late group). For early
sepsis, score 1 had a sensitivity of 73.3% and speciﬁcity of 84.4%. For
late sepsis, score 2 had a sensitivity of 88.5% and speciﬁcity of 90.4%.
Conclusion: 2 predictive models were developed, one for proven early-
onset and another for proven late-onset neonatal sepsis. Derivation and
preliminary validation produced good results.
O219 Failure of oral colistin to prevent colonization with
extended-spectrum b-lactamase-producing enterobacteria in
newborns hospitalized at a neonatal intensive care unit
V. Strenger °, T. Gschliesser, G. Zarfel, G. Feierl, A.J. Grisold,
L. Masoud, B. Resch, W. Mu¨ller, B. Urlesberger (Graz, AT)
Objectives: Colonisation and infection with extended-spectrum
b-lactamase producing Enterobacteriaceae (ESBL-E.) is an emerging
problem at Neonatal Intensive Care Units (NICU). ESBL-E. often show
additional antimicrobial resistance. Colistin is reported to be effective in
treatment of infections with multiresistant enterobacteria as well as for
selective digestive decontamination (SDD).
Over the last years several outbreaks of ESBL-E. colonisation occurred
at our NICU.
Methods: For prophylaxis of necrotizing enterocolitis (NEC) all term
and preterm born neonates hospitalised at the NICU of the Medical
University of Graz routinely receive gentamicin orally (15mg/kg/d).
Patients are routinely screened at least twice a week for ESBL-E. in stool
specimens. ESBL-E. colonised patients subsequently are cohorted. From
May 2005 through September 2007, gentamicin was replaced by colistin
(8mg/kg/d) administered orally during ESBL-E. outbreak situations.
We retrospectively analysed all neonates colonised with ESBL-E. from
May 2005 through September 2007 regarding inﬂuence of colistin on
colonisation with ESBL-E.. Genetic relatedness of strains was assessed
by using repPCR-technique.
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Results: During the study period 3 ESBL-E. outbreaks were observed
and 30 (2.02%) out of 1488 neonates have been colonised with
ESBL producing Klebsiella pneumoniae (ESBL-Kp, n = 22) or Klebsiella
oxytoca (ESBL-Ko, n = 8). 12 out of 22 pts. colonised with ESBL-Kp
and 1 out of 8 pts. colonised with ESBL-Ko had received oral colistin
at time of colonisation with ESBL-E. Four different clones of ESBL-Kp
and 2 different clones of ESBL-Ko were isolated indicating occurrence
of patient-to-patient transmission.
Conclusion: Despite administration of Colistin during outbreaks of
ESBL-E. colonisation, additional colonisations (including patient-to-
patient transmission) were observed. Thus, oral colistin (8mg/kg/d) does
not prevent colonisation with ESBL-E. Further analyses are needed to
assess its usefulness for SDD.
Success stories about control of nosocomial
antimicrobial resistance − yes, we can!
S222 KPC control (Israel)
M.J. Schwaber ° (Tel Aviv, IL)
Containment of a nationwide outbreak of KPC-producing Klebsiella
pneumoniae via a centrally-coordinated public health intervention.
Background: Since 2006, Israeli hospitals have faced a clonal outbreak
of carbapenem-resistant Klebsiella pneumoniae, producing the serine
carbapenemase KPC-3. Locally-implemented infection control measures
in affected hospitals failed to contain spread. A nationwide intervention
was launched to contain the outbreak and introduce a strategy to
control future dissemination of antibiotic-resistant bacteria in healthcare
facilities.
Methods: In March 2007, the Ministry of Health issued guidelines
mandating physical separation of hospitalized carriers of carbapenem-
resistant Enterobacteriaceae (CRE) and dedicated stafﬁng, and appointed
a professional task force charged with containing the spread of the
epidemic strain. The task force paid site visits at acute care hospitals,
evaluated infection control policies and laboratory methods, supervised
adherence to the guidelines via daily census reports on carriers and their
conditions of isolation, provided regular feedback on performance to
hospital directors, and intervened additionally when necessary. During
2008, the intervention was extended to long-term care facilities, and in
June 2008 national guidelines for active surveillance were issued. The
primary outcome measure was the incidence of nosocomial CRE cases
diagnosed by clinical culture in acute care hospitals.
Results: By March 2007, over 1200 patients were affected in the nation’s
acute care hospitals. Prior to the nationwide intervention, the monthly
incidence of noscomial CRE climbed steadily, peaking at over 180 cases.
Crude 30-day mortality was >30%. With the intervention, the continuous
rise in incidence of CRE acquisition was halted, and by the end of the
14-month initial intervention period the number of new monthly cases
was reduced to 46. Following the introduction of active surveillance
guidelines, monthly incidence fell further, reaching a low of 24 as of
October 2009. A direct correlation was observed between compliance
with isolation guidelines and success in containment of in-hospital CRE
transmission.
Conclusions: A centrally-coordinated public health intervention has
succeeded in containing a nationwide outbreak of CRE in Israeli
hospitals after local infection control measures failed. The intervention
demonstrates the importance of strategic planning and national oversight
in combating antimicrobial resistance.
MALDI-TOF in clinical microbiology
S224 Microbiological identiﬁcation by routine use of MALDI-TOF
M. Drancourt ° (Marseille, FR)
The analysis of bacterial protein proﬁle obtained after matrix-
assisted laser desorption ionization time-of-ﬂight (MALDI-TOF) mass
spectrometry (MS) emerged over the past years as a new method
for the accurate identiﬁcation of bacterial isolates. MALDI-TOD-MS
protein proﬁling can be achieved within muinutes thus speeding the
identiﬁcation; it is a cheap technology including the decreasing cost
for mass spectrometers; protein proﬁles and issued identiﬁcations are
reproducible and robust; and new generation mass spectrometers are
smaller machines easily implanted within the laboratory. All these
parameters make MALDI-TOF MS the technology to be introduced
in any modern microbiology laboratory, including the point-of-care
laboratory.
Databases, the crucial part of the process, now comprise of most
of the bacterial species routinely encountered in the microbiology
laboratory. Despite the fact that some Gram-positive organisms remain
“MALDI-TOF resistant” in part because of underlying taxonomic
weaknesses and in part because of database weaknesses, MALDI-TOF is
deﬁnitely the ﬁrst line method for the routine identiﬁcation of bacterial
isolates in the 21 century, pushing biochemical proﬁling and even the
gram staining off the laboratory towards the museum of bacteriology.
S225 Bacterial typing
T. Hain ° (Giessen, DE)
Rapid identiﬁcation and typing of Listeria species by matrix-assisted
laser desorption ionization-time of ﬂight mass spectrometry. Listeria
monocytogenes is a food-borne pathogen that is the causative agent
of human listeriosis, an opportunistic infection that primarily infects
pregnant women and immunologically compromised individuals. Rapid,
accurate discrimination between Listeria strains is essential for appropri-
ate therapeutic management and timely intervention for infection control.
A rapid method involving matrix-assisted laser desorption ionization-
time of ﬂight mass spectrometry (MALDI-TOF MS) that shows promise
for identiﬁcation of Listeria species and typing and even allows for
differentiation at the level of clonal lineages among pathogenic strains of
L. monocytogenes is presented. A total of 146 strains of different Listeria
species and serotypes as well as clinical isolates were analyzed. The
method was compared with the pulsed-ﬁeld gel electrophoresis analysis
of 48 Listeria strains comprising L. monocytogenes strains isolated
from food-borne epidemics and sporadic cases, isolates representing
different serotypes, and a number of Listeria strains whose genomes have
been completely sequenced. Following a short inactivation/extraction
procedure, cell material from a bacterial colony was deposited on a
sample target, dried, overlaid with a matrix necessary for the MALDI
process, and analyzed by MALDI-TOF MS. This technique examines the
chemistry of major proteins, yielding proﬁle spectra consisting of a series
of peaks, a characteristic “ﬁngerprint” mainly derived from ribosomal
proteins. Specimens can be prepared in a few minutes from plate or liquid
cultures, and a spectrum can be obtained within 1 minute. Mass spectra
derived from Listeria isolates showed characteristic peaks, conserved at
both the species and lineage levels. MALDI-TOF MS ﬁngerprinting may
have potential for Listeria identiﬁcation and subtyping and may improve
infection control measures.
S226 MALDI-TOF-MS of surface-associated and stable
intracellular proteins for identiﬁcation and resistance
proﬁling of human pathogens
H.N. Shah ° (London, UK)
Microbial classiﬁcation and identiﬁcation is today based largely upon
comparative 16S rRNA sequencing analysis. There is, however, a desire
to retain a polyphasic approach as microorganisms are far too diverse
to be unequivocally delineated by a single method. Proteomics, in the
form SDS-PAGE, MLEE or IEF proﬁles, have had a long history
of applications and have shown excellent congruence with genomic
methods such as DNA-DNA reassociation. The arrival of MALDI-MS
and ESI-MS has made the study of the proteome so accessible that within
less than a decade platforms are now available for clinical applications.
Thus, the development of intact cell MALDI-TOF mass spectrometry is
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approaching maturity and its uptake by diagnostic laboratories has been
increasing steadily. Extensive databases eg AnagnosTec (>100,000 MS
spectra), negligible sample preparation and rapid analysis have been the
main reasons for its success. The peptides/proteins present in the MS
spectra are either surface-associated on intracellular ribosomal proteins,
consequently, at present, little information can be obtained using solely
this approach to gain information on antibiotic resistance patterns.
More in-depth analysis involving 1D, 2D and LC-MS-MS methods
are required. Using such approaches, new information on antibiotic
resistance mechanisms are becoming apparent and providing an excellent
tool to elucidate complex mechanisms where genomic analysis alone
cannot provide a solution.
S227 Yeast identiﬁcation
G. Haase ° (Aachen, DE)
Identiﬁcation of clinical yeasts is an important task in the mycological
laboratory especially in view of a rising number of patients with
respective opportunistic mycoses. Reliable species identiﬁcation can be
used as a ﬁrst guidance for initiation of an appropriate antifungal therapy.
Classical phenotypical identiﬁcation of yeasts is often tedious and needs
up to 3 days for optaining a reliable result. A further obstacle is the
limited databases of commercially available systems and test results with
variable outcome for a given species. Genetic identiﬁcation by in situ
hybridization or by sequence analysis is relative expensive in terms of
consumables per test.
After initial introduction of mass ﬁngerprinting for species identiﬁcation
of bacteria by Claydon et al. 1996 availability easy-to-handle instruments
and equiped with sophisticated analysis software facilitated use of this
technique also for identiﬁcation of yeasts in the last years.
Qian et al. (2008) described the use a ﬁxation step by using alcohol as
an essential prerequisite for obtaining improved mass signatures in case
of yeasts. In a comparative study Marklein et al. (2009) could show that
usage of a commercial MALD-TOF MS-based microbial identiﬁcation
system (MALDI BioTyper System, Bruker Daltonics) was superior to
a phenotypic based identiﬁcation system in case of clinical yeasts. We
could successfully demonstrate that addition of user deﬁned reference
spectra to this database facilitates a reliable discrimination of members
of the Candida parapsilosis clade. Von Bergen et al. (2009) used this
system for the otherwise difﬁcult-to-achieve identiﬁcation of potentially
pathogenic Prototheca spp., a group of algae with a yeast-like cultural
appearance. Of note, Marinach et al. (2009) demonstrate that MALDI
MS is capable to estimate Fluconazole resistance in case of C. albicans.
In conclusion, MALDI-TOF MS ﬁngerprinting turned out as a very
promissing tool for reliable and rapid (hands-on time <5 min)
identiﬁcation of clincal yeasts with low costs for consumables per
identiﬁcation (<1 €). This approch was not so much hampered by
inﬂuence of the morphology of the fungus and cultural conditions e.
g. culture media and minor changes in incubation temperature when
compared to MS-based identiﬁcation of hyphomycetes. So this technique
facilitates high through put and objective identiﬁcation of yeasts when
using a quality-checked database.
Infections in the elderly, new concepts
S228 HIV and aging
R. Cauda ° (Rome, IT)
Epidemiological data show that HIV-infected population is aging, mainly
as a result of prolonged survival due to potent antiretroviral regimens
that can successfully control viral replication, thus preventing AIDS-
related events, but also of a late diagnosis of HIV infection in older
patients. No speciﬁc guidelines have been developed for the clinical
management of older HIV-infected patients but clinicians must take
into account several factors that are peculiar of this population, like
the presence of co-morbidities, the pharmacokinetics characteristics of
the elderly, a possible higher incidence of drug-related toxicity and a
different response to antiretroviral therapy.
In older HIV-infected population, morbidity and mortality still remain
high as a consequence of an increased risk of non-AIDS related
conditions compared to age-matched HIV-seronegative subjects. These
conditions include cancers, neurocognitive disorders, cardiovascular,
liver, kidney and bone diseases. Many factors contribute to non AIDS-
related co-morbidities and they can be related to the population
characteristics (e.g. higher prevalence of traditional health-related risk
factors like diabetes, hypertension, hyperlipidemia and smoking), to
antiretroviral drugs (e.g. association between long term exposure to
protease inhibitors and higher risk of cardiovascular disease, tenofovir
exposure and renal or bone dysfunction) or to the HIV-infection itself
(e.g. association between age-related events and low CD4 cells count or
higher levels of inﬂammation markers found in HIV-positive patients).
The pharmacokinetic characteristics of the elderly are peculiar, with a
possible modiﬁcation of drug absorption, distribution and hepatic or
renal clearance that results in a high inter-individual pharmacokinetic
variability. Moreover, interactions between antiretrovirals and drugs
frequently prescribed for non HIV-related co-morbidities can further
contribute to this variability. As a consequence, plasma drug levels can
drop below effective concentrations promoting treatment failure or can
become high resulting in toxicity.
Many data shows that, despite a high rate of virological suppression
(usually attributed to high adherence to the therapy), older patients had a
signiﬁcantly slower CD4 cells count reconstitution than younger subjects.
The causes for such ﬁnding could be due to several factors like the late
diagnosis and treatment of HIV infection on the one hand, or the thymic
involution and immunosenescence during aging on the other hand. Many
studies indicated that suboptimal CD4 cells increase is associated to a
higher risk of non AIDS-associated morbidity and mortality (for cancer,
heart and liver disease) in this patient population.
In conclusion, as the prevalence of older HIV-infected patients is
increasingly growing, additional research is needed to fully understand
factors contributing to the peculiar evolution of HIV infection and
associated co-morbidities in this age group, in order to optimize the
clinical care of this population.
S230 Infectious disease outbreaks in nursing homes
M. Pujol ° (Hospitalet Llobregat, ES)
Advances in health care have conduced in developed countries to an
aging population. Long-term care facilities (LTCF) are institutions which
provide heath care to people unable to manage themselves in the
community. Most residents are elder and have multiple comorbidities.
Residents will stay at LTCF for months or years. Hence, comfort,
dignity and socialization are important issues. In order to control costs,
many post-acute patients who used to stay in acute care hospitals for
a long time, are now currently transferred to LTCF. This situation
has led to the necessity of invasive devices such as urinary and
vascular catheters and feeding tubes. This fact increases the incidence
of nosocomial infections, as does the one observed in hospitals. Several
signiﬁcant differences can be pointed out between hospitals and LTCF;
most notably the nurse-patient ratio, the availability of microbiological
cultures, laboratory and diagnostic equipment on site and the access
to costly antibiotics. In addition there are few LTCF with infection
control staff. Most of them lack of nosocomial infections surveillance
programs and also of antibiotic policy strategies. In general, rates of
colonization by multiresistant bacteria in residents of LTCF are higher
than those observed in hospitalized patients. For example, some studies
have shown that rates of methicillin resistant Staphylococcus aureus
(MRSA) carriage among LTCF residents can reach 50%, while in
hospitals are generally below 1−2%. Although it is possible to detect
outbreaks, MRSA infections in LTCF are sporadic, related to pressure
ulcers and generally less serious than those seen in hospitals. The
prevalence of multidrug resistant Gram-negative (MDR-GNB) bacteria
is also high among LTCF residents, particularly among those with
faecal incontinence and antibiotic exposure. MDR-GNB is frequently
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recovered from environmental samples and common areas providing
opportunities for person-to-person transmission. Clostridium difﬁcile
continues to be an increasing problem in LTCF. It is the most common
cause of non-epidemic acute diarrheal illness in LTCF. Outbreaks have
also been recognized, particularly related to antimicrobial consumption.
In conclusion, LTCF act as a reservoir of multi-resistant bacteria that
can cause sporadic infections as well as indolent outbreaks. A multilevel
approach, including antimicrobial policies and prevention transmission
measures are needed to limit the impact of this problem.
S231 Herpes zoster: is there a role for vaccination?
M. Rothberg ° (Springﬁeld, US)
Herpes Zoster (shingles) is caused by reactivation of the varicella zoster
virus. It is characterized acutely by a painful rash, and 10−20% of
patients experience prolonged pain (postherpetic neuralgia), which in
rare cases can last for years and be debilitating. Both the incidence and
severity of zoster increase with age. Treatment options for zoster and post
herpetic neuralgia are limited and costly. A shingles vaccine was licensed
in Europe and the United States in 2006 following the completion of
the Shingles Prevention Study, a randomized controlled trial of 38,546
healthy adults; vaccination decreased both the incidence and severity
of zoster over a median of 3 years. Primary efﬁcacy was measured
by a burden of illness score which combined incidence, duration and
severity of pain. The vaccine decreased burden of illness by 61%, but
the effects varied by age. Efﬁcacy in preventing acute zoster declined
with age at vaccination, and there was minimal efﬁcacy past age 80 years.
Vaccination reduced the incidence of post-herpetic neuralgia at all ages
by 66%. This was achieved by preventing acute zoster among patients
aged 60−69 years, and attenuating disease in patients aged 70 years.
Side effects were mild, but serious adverse events were more common
in the vaccination group (1.9 percent vs. 1.3 percent, P = 0.03). Debate
about the use of the vaccine revolves not around the effectiveness, but the
cost-effectiveness, as the vaccine is expensive (€136 per dose). Published
analyses have found incremental cost-effectiveness ratios ranging from
€18,500 to €76,500 per quality-adjusted life year. The vaccine appears
to be most cost-effective among 65- to 70-year-olds, as the incidence of
disease in this age group is high, but vaccine recipients are still able to
mount a satisfactory immune response. Despite recommendation by the
Centers for Disease Control that all adults aged 60 years receive the
shingles vaccine, uptake in the US has been slow. Barriers to vaccination
include difﬁculties with vaccine storage, variable insurance coverage, and
competing priorities for primary care doctors. Since licensure, the cost
of the vaccine has increased by 30%. Moreover, studies of willingness-
to-pay suggest that current vaccine pricing is not acceptable to patients.
In conclusion, the shingles vaccine appears to be effective in reducing
morbidity, but the cost is high and universal vaccination over age 60
years may not currently represent good value.
Rapid diagnosis and resistance testing in
mycobacteria
O233 Improved sensitivity of rapid detection of Mycobacterium
tuberculosis in clinical specimens by real-time PCR
I. Szpinda, A. Myhre, H. Hamsun, H. Grewal, T. Tønjum ° (Oslo,
Bergen, NO)
Objective: Our aim was to compare the use of DNA ampliﬁcation
by two polymerase chain reaction (PCR) tests for the detection
of Mycobacterium tuberculosis directly in human respiratory and
extrapulmonary specimens. For this purpose, the sensitivity and
speciﬁcity of culture and smear diagnostics as well as the Cobas
Amplicor PCR test and the Cobas TaqMan MTB real-time PCR test
were compared in a trial study.
Methods: The PCR assays employed was the Cobas Amplicor
M. tuberculosis test and the real-time PCR Cobas TaqMan MTB test
(Roche Diagnostics, Switzerland), which use the 16S rDNA as the
target template. Eight hundred and seventy-eight samples from 763
patients submitted to our clinical microbiology laboratory were processed
by enriched culture analysis, direct microscopy and PCR. Rifampicin
susceptibility testing was performed with culture-based MGIT assays
and rpo sequence analysis.
Results: Out of the 878 clinical specimens, 120 were from TB-positive
patients. In comparison with culture, the sensitivity of the real-time PCR
test Cobas TaqMan MTB test and the AmplicorM. tuberculosis test were
99.0% and 95.5% for smear-positive samples and 83.0 and 72.1% for
smear-negative samples, respectively. Interestingly, 15 specimens from
TB-positive patients were real-time PCR positive and Amplicor PCR
negative. These specimens included 8 airway samples and 7 extra-
pulmonary samples. A single TaqMan MTB test positive and culture
negative specimen was found. The speciﬁcity of the M. tuberculosis
PCR tests were challenged with DNAs and cultures from strains of
Mycobacterium ulcerans and M. marinum, which are the mycobacterial
species most closely related to the M. tuberculosis complex, resulting in
negative PCR test results. Less than 2% of the isolates were rifampic in
resistant, reﬂecting the low level of M. tuberculosis drug resistance in
Norway.
Conclusions: A comparison of two M. tuberculosis-speciﬁc PCR tests
was performed, and the sensitivity of the real-time PCR test Cobas
TaqMan MTB test was clearly superior to that of the Amplicor
M. tuberculosis PCR test. The improved sensitivity, rapidity and less
labour-intensive format of the Cobas TaqMan MTB test make this a
valuable tool in routine tuberculosis diagnostics.
O234 A high-throughput method for the simultaneous detection of
drug resistance and genotypic mutations in M. tuberculosis
isolates
I. Bergval °, A. Schuitema, P. Klatser, R. Anthony (Amsterdam, NL)
Objective: To make the genetic screening of tuberculosis (TB) isolates
suitable for low-income countries as well as endemic countries with
high prevalence/incidence of drug-resistant TB. The emerging epidemic
of drug-resistant TB calls for rapid diagnosis and early detection of
drug resistance. This allows immediate and appropriate treatment of
the patient and could thereby reduce the spread of multidrug-resistant
(MDR) or extensively drug resistant TB (XDR-TB).
We have recently developed an MTB-speciﬁc multiplex assay, based
on Multiplex Ligation-dependent Probe Ampliﬁcation (MLPA). This
method allows simultaneous detection of multiple dispersed DR
mutations and genotype-speciﬁc mutations in the Mycobacterium
tuberculosis (MTB) genome and has proved to be highly speciﬁc.
Method: The current read-out of MLPA is done by capillary
electrophoresis, a method that is expensive and time-consuming and
therefore difﬁcult to implement and sustain in low-income countries.
Recent developments in biotechnology have raised the opportunity to
transfer the assay to a liquid array. Current MLPA-probes were modiﬁed
to be compatible with such a system.
To cover the increasing prevalence of MDR- and XDR-TB isolates,
targets revealing resistance to several important second-line drugs (e.g.
ﬂuoroquinolones) were included in the MLPA assay, as well as additional
genotypic markers.
Results and Conclusion: The newly included MLPA-probes were
very speciﬁc for the targeted SNPs, allowing the detection of prevalent
second-line drug resistance mutations and a further delineation of MTB
complex members. The genotyping abilities of the MLPA assay were
additionally increased by the discovery of a new genotypic marker. There
will be an explosion of SNP discovery in the next years as data from
high throughput sequencing projects become available. Methods allowing
informative SNPs to be rapidly detected will then become increasingly
valuable.
Furthermore, we feel that the new analysis method for MLPA will
speciﬁcally be of added value in low-income countries with high
endemicity of DR-TB. The liquid array allows multi-parameter testing
and could provide a standard platform for several diagnostic and
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screening tests, which are traditionally performed by several different
methods. Therefore, MLPA combined with this detection system can
bring molecular typing of MTB clinical isolates closer to the patient
than is currently feasible.
O235 Application of the rapid detection system for M. tuberculosis
complex and rifampicin resistance Xpert MTB/RIF in
decontaminated respiratory specimens, non-respiratory
specimens and cultures
L. Deforges, J.M. Le Glaunec, N. Launay, R. Vergne, A. Minaret,
M. Marzouk, M. Marmiesse °, N. Finnstro¨m, P. Legrand (Creteil,
Maurens-Scopont, FR)
Objectives: GeneXpert (Cepheid) is an automated real-time PCR system
which is very easy to use and suitable for emergency use. The principle
of the Xpert MTB/RIF test, running on GeneXpert, is to detect
M. tuberculosis complex and mutations in the gene rpoB that cause
resistance to rifampicin. This is done directly from at minimum of 500
ml of a respiratory sample. After 15 min treatment of the sample all stages
of the sample preparation and PCR takes place within the instrument in
1 h30.
Some restrictions of use led us to validate this system on various types
of samples.
Methods: Respiratory samples were decontaminated with NACl/NaOH
and 500 ml of decontaminated product added to 1.5ml of lysis
buffer (provided with the Xpert product). For non-respiratory non-
decontaminated samples (CSF, pleural liquid and biopsies) the sample
volume was sometimes too low. In these cases distilled water was
added up to 500 ml before addition of lysis buffer. For solid culture
one colonie was resuspended in 500 ml of distilled water, for liquid
culture 500 ml of medium were centrifuged prior to addition of lysis
buffer. Fifteen decontaminated respiratory samples (PPD) and 24 non-
pulmonary samples (PNP) were tested in the Xpert MTB/RIF assay, solid
culture, Cobas TaqMan MTB test and cultures were tested with probes
from GenProbe for identiﬁcation.
Results: Twelve PPD of 15 were negative in Xpert MTB/RIF and the
COBAS TaqMan MTB Test. Culture was also negative for 10 of these. In
two samples atypical mycobacterium was isolated. 3 PPD were positive
in Xpert and COBAS and showed no mutations in rpoB. The culture
conﬁrmed M. tuberculosis sensitive to rifampicin in these 3 cases. 20
PNP of 24 were negative by both PCR techniques and culture. Four of
24 (1 CSF, 1 pleural, 2 lymph node biopsies) were positive by both
techniques and showed no mutations in the rpoB gene. The culture
conﬁrmed M. tuberculosis sensitive to rifampicin in these 4 cases. Nine
culture isolates tested were identiﬁed as M. tuberculosis by Xpert and
GenProbe. One isolate was determined resistant to rifampicin in Xpert.
This was conﬁrmed by susceptibility testing.
Conclusion: These preliminary results obtained on a limited number of
samples show a perfect match for Xpert MTB/RIF with conventional
laboratory tests irrespective of the nature of the sample tested.
O236 Evaluation of the GeneXpert® MTB/RIF assay for the
rapid detection of rifampicin resistance in Mycobacterium
tuberculosis isolates
C. Cavusog˘lu, A. Nazli ° (Izmir, TR)
Introduction: Mycobacterium tuberculosis is one of the most signiﬁcant
causes of death from an infectious agent. The incidence of pulmonary
tuberculosis in Turkey is nearly 27.9 per 100,000 populations. The
proportion of multidrug resistant tuberculosis among new cases is 2.9%
and among previously treated cases is 15.5%.
DNA sequencing studies demonstrate that 95% of rifampicin (RIF)-
resistant M. tuberculosis strains has a mutation within the 81-bp hotspot
region of the rpoB gene. The GeneXpert® MTB/RIF Assay (Cepheid,
Sunnyvale, California) is a novel real-time PCR-based method for the
diagnosis of tuberculosis and rapid detection of RIF-resistance in clinical
specimens. However, there is a limited data about the performance of the
GeneXpert® MTB/RIF Assay to detect different rpoB gene mutations.
Objectives: We aimed to determine the performance of the GeneXpert®
MTB/RIF Assay for detection of the mutation within the 81-bp hotspot
region of the rpoB gene in RIF-resistant M. tuberculosis isolates.
Methods: A total of 37 M. tuberculosis isolates (27 RIF-resistant, 10
RIF-susceptible), were included in the study. Drug susceptibility testing
for RIF had been previously performed with the proportional method on
7H10 medium due to the criteria of the CLSI. Mutations in the rpoB
gene for each isolate had also been determined by DNA sequencing.
Results: Thirteen different mutations (531-TTG, 526-CGC, 531-TGG,
526-TAC, 522-TGG, 516-TAC, 515-ATC, 533-CCG, 533-CCG, 526-
TGC, 516-GTC, 513-CCA, 490-CAT, and insertion of CGG between
514 and 515) were studied in 27 RIF-resistant M. tuberculosis isolates
(Table 1).
The GeneXpert® MTB/RIF was able to detect the mutation within the
81 bp of the rpoB gene in 26 of the 27 RIF-resistant strains. However,
one isolate had 490-CAT mutation outside the 81 bp of the rpoB gene
was identiﬁed as susceptible by GeneXpert® MTB/RIF. The assay also
correctly identiﬁed 10 RIF-susceptible isolates.
Conclusion: GeneXpert® MTB/RIF correctly identiﬁed RIF-resistance,
except one isolate which had a mutation outside the hot-spot region. In
conclusion, this assay can be useful for the prediction of RIF resistance
in clinical specimens and also for rapid screening of RIF resistant
M. tuberculosis isolates.
Table 1. Comparison of GeneXpert® MTB/RIF System with DNA
sequencing data of RIF-resistant isolates of M. tuberculosis (n= 27)
No. of isolates Nucleotide change(s) GeneXpert MTB/RIF result/
unbounded probe(s)
1 490 CAG to CAT S*
1 513 CAA to CCA R# (B)
1 514 515 ins. CGG R (B)
2 516 GAC to TAC R (B)
1 516 GAC to GTC R (B)
2 522 TCG to TGG R (C)
4 526 CAC to CGC R (D)
2 526 CAC to TAC R (D)
1 526 CAC to TGC R (D)
7 531 TCG to TTG R (E)
3 531 TCG to TGG R (E)
1 533 CTG to CCG R (E)
1 515 ATG to ATC R (B, E)
533 CTG to CCG
*Susceptible; #Resistant.
O237 Detection by genotype MTBDRsl test of complex resistance
mechanisms to second-line drugs and ethambutol in
multidrug-resistant strains of Mycobacterium tuberculosis
F. Brossier, N. Veziris, A. Aubry, V. Jarlier, W. Sougakoff ° (Paris, FR)
Objectives: The Genotype MTBDRsl test aims at rapid detection of
resistance to ethambutol, ﬂuoroquinolones and second line aminogly-
cosides (amikacin, kanamycin) and cyclic peptide (capreomycin) in
Mycobacterium tuberculosis (Mtb).
Methods: A set of 41 MDR (multidrug-resistant) and 8 XDR
(extensively drug-resistant) Mtb strains has been tested by MTBDRsl and
DNA sequencing of the resistance-determining regions in gyrA and gyrB
(ﬂuoroquinolones), rpsl (streptomycin), rrs and tlyA (aminoglycosides-
cyclic peptide) and embB (ethambutol).
Results: The values of sensitivity/speciﬁcity of the MTBDRsl test were
as follows: ﬂuoroquinolones 87/96%, amikacin 100/100%, kanamycin
77/100%, capreomycin 80/98% and ethambutol 57/92%. Analysis of the
discrepant results indicated that 3 FQ-resistant strains (including one
XDR) with mutations in gyrB were missed by MTBDRsl, and that one
FQ-susceptible strain, identiﬁed as resistant by MTBDRsl, had a double
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mutation T80A-A90G in GyrA not conferring resistance to FQ. Five
strains (including 2 XDR) without mutation in rrs were mono-resistant
to aminoglycosides or cyclic peptide and were missed by MTBDRsl.
Finally, 16/28 ethambutol-resistant strains had a mutation at codon 306
in embB while 2/24 ethambutol susceptible strains had such a mutation.
Conclusions: MTBDRsl efﬁciently detects the most common mutations
involved in resistance to ﬂuoroquinolones, aminoglycosides-cyclic
peptide and ethambutol and accurately assesses susceptibility to
amikacin. However, due to mutations not included in the test (particularly
in gyrB) or yet-uncharacterized resistance mechanisms (particularly
those related to ethambutol and to aminoglycosides-cyclic peptide mono-
resistance), the wild-type results yielded by the MTBDRsl test need
to be conﬁrmed by drug susceptibility testing when the prevalence of
resistance is high.
O238 Molecular diagnosis of tuberculous meningitis − a 4-year
experience
A. Mendes °, S. Almeida, S. Fernandes, K. Rodrigues, A. Santos,
H. Ramos (Oporto, PT)
Objectives: Tuberculous meningitis (TBM) is the most severe form
of extrapulmonary tuberculosis, with high mortality rates and serious
long-term consequences. Accurate and early diagnostic conﬁrmation is
essential in patient management. The purposes of this study was to,
retrospectively, evaluate the performance of a molecular test for the
detection of Mycobacterium tuberculosis complex in cerebrospinal ﬂuid
specimens (CSF), compared with culture and microscopy, and correlate
the results with clinical ﬁndings.
Methods: Between November 2005 and September 2009, 118 CSF
specimens were sent to the Molecular Biology Unit of Centro Hospitalar
do Porto, with requests for M. tuberculosis molecular detection (MTD,
GenProbe), with mycobacterial culture (MGITTM and Lowenstein-
Jensen) and microscopy examination performed in the Microbiology
laboratory. MTD test was performed as described by manufacturer, but
after mechanical cell lysis, nucleic acid puriﬁcation was carried out
in EZ1 BioRobot (Qiagen). Presence of ampliﬁcation inhibition was
veriﬁed in every sample. MTB diagnosis was based in laboratory results
and clinical criteria, such as patient response to anti-bacillary therapy.
Results: 118 samples from 107 patients were studied. Molecular
detection of M. tuberculosis complex was positive in 5 cases, which were
conﬁrmed by cultural methods. Microscopy revealed acid-fast bacilli
in one sample. MTB diagnosis (laboratory and clinical criteria) was
established in 17 cases, 12 being presumptive. All 17 patients showed
altered cytology with pleocytosis. Protein level was elevated in 16
samples (0.55–10.5 g/L). Compared with MTB diagnosis, MTD showed
a sensitivity value of 30%, speciﬁcity of 100%, positive predictive value
(PPV) of 100% and a negative predictive value (NPV) of 89%.
Conclusion: Our results suggest the potential role of molecular methods
in conﬁrming diagnosis of MTB, with short turnaround time results
(2.5 h), high PPV, and similar sensitivity as culture (30%). Results
must be interpreted in parallel with clinical ﬁndings and conventional
microbiology methods. The use of molecular tests should not exclude
a diagnosis of MTB (NPV-89%). More studies would help improve the
adequacy of these methods.
O239 Real-time PCR for broad detection of the Mycobacterium
tuberculosis complex and medically important atypical
mycobacteria
G. Abdeldaim °, R. Carl-Johan, E. Svensson, L. Kirsebom, J. Blomberg,
B. Herrmann (Uppsala, Gothenburg, SE)
Objectives: To determine the sequence of the rnpB gene, coding for the
ubiquitously present ribonuclease P RNA, and develop a real-time PCR
for detection of the Mycobacterium tuberculosis complex and atypical
mycobacteria.
Methods: The rnpB sequences of 17 Mycobacterium spp. were
determined. Based on obtained rnpB sequences, two quantitative real-
time PCRs for detection of the M. tuberculosis complex (Mytu PCR)
and atypical mycobacteria (Myat PCR) were developed and combined
into a single tube format. The analytical sensitivity of the PCR assay was
determined with serial dilutions of target DNA. The speciﬁcity of the
duplex PCR assay was tested with 21 mycobacteria species (55 strains),
and 35 bacteria species other than mycobacteria. The PCR assay was
evaluated on 10 samples from a quality control panel (QCMD) and on
442 clinical samples. The results were compared with the results of
culture, direct microscopic examination and the Roche Amplicor PCR.
Results: Obtained rnpB sequences showed hypervariable regions
enabling species speciﬁc identiﬁcation and PCR design. The ana-
lytical sensitivity for detection of the M. tuberculosis complex was
<50 copies/reaction, while for atypical mycobacteriae it was 500
copies/reaction. The assay was speciﬁc and did not detect any of 35
non-mycobacterial bacteria spp. The Mytu PCR speciﬁcally detected all
four species of the M. tuberculosis complex and the Myat PCR detected
all tested 17 atypical mycobacteria species, except 2 of 7 strains from
the M. avium complex.
The PCR assay correctly detected all 10 samples from QCMD quality
assurance panel. In analysis of 442 clinical specimens M. tuberculosis
was detected in 40 cases (9%) by Mytu PCR, in 38 cases (8%) by the
Roche PCR, in 46 cases (10%) by culture and in 23 (5%) cases by direct
microscopic examination. The atypical mycobacteriae were detected by
Myat PCR in 18 (4%) cases, in 11 (2%) by culture cases, and in 8 cases
(2%) by direct microscopic examination.
Conclusions: Sequence determination of the rnpB gene is useful for
Mycobacterium species identiﬁcation.
Our duplex real-time PCR was shown to detect strains from both
the M. tuberculosis complex and tested atypical mycobacteria strains.
The PCR assay has a broader detection range of mycobacteria than
commercial standard PCR method and has a sensitivity similar to culture.
O240 Molecular differentiation of Mycobacterium tuberculosis
complex members from non-tuberculous mycobacteria
M. Slany °, J. Svobodova, I. Pavlik (Brno, CZ)
Objective: Most mycobacterial infections are still caused by My-
cobacterium tuberculosis complex (MTC) members; however, infections
caused by non-tuberculous mycobacteria (NTM) are increasing, partic-
ularly among immunocompromised patients. NTM are ubiquitous in
the environment and are responsible for several diseases in humans
known as mycobacterioses. More than 128 mycobacterial species are
currently described. Conventional species-speciﬁc identiﬁcation and
proper patient management are delayed due to the slow-growing nature
of mycobacteria, their biochemical properties and antituberculotic drugs
sensitivity testing. We propose simple molecular based method using
multiplex PCR (mPCR) for rapid detection and differentiation of NTM
from MTC followed by sequence analysis used for NTM identiﬁcation.
Methods: In the frame of study were have analysed: 50 MTC
and 57 NTM isolates collected in 2009 in the Czech Republic; 14
non mycobacterial (non myco) reference strains. Bacterial supernatant
applied as DNA template for the mPCR reaction targeting rpoB gene
was used for detection and differentiation of isolates as MTC or NTM.
One amplicon of 235 bp from MTC members or a single amplicon of
136 bp from NTM are expected. NTM identiﬁcation was archieved by
DNA sequence analysis of the species-speciﬁc 16S rRNA gene region.
Results: The mPCR reaction with template DNA from mycobacteria
yielded the expected amplicons. We assume that proposed mPCR is
speciﬁc for mycobacteria because analysis of non myco strains resulted
in any amplicons. Detection limit for proposed mPCR was 50 copies
per reaction, which faciliated its use for analysis of DNA extracted
directly from clinical samples (sputa or biopsies). DNA sequencing of the
16S rRNA gene conﬁrmed the status of analysed bacterial isolates and
enabled precise isolate identiﬁcation to the species level. Different NTM
(Table 1) causing mycobacterial infections in humans were detected
using this approach.
Conclusion: The mPRC used in this study allowed rapid detection
and differentiation of primary cultures as MTC, NTM or non myco.
Speciﬁc NTM identiﬁcation is possible in second step by sequence
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analysis of 16S rRNA gene, thus helping in timely institution of speciﬁc
mycobacterial therapy.
This work was supported by grants No. MZE0002716202, NPV1B53009
and QH91240 from the Ministry of Agriculture of the Czech Republic.
Table 1. Bacterial classiﬁcation by multiplex PCR
Bacterial isolates1 No. of
isolates
Source2 MTC3 NTM3 Non
myco3
MTC 50 human 50 − −
Mycobacterium arupense 2 human − 2 −
M. avium subsp. avium 21 human − 21 −
M. a. subsp. hominissuis 2 human − 2 −
M. a. subsp. paratuberculosis 3 environment − 3 −
M. celatum 1 environment − 1 −
M. chelonae 1 human − 1 −
M. chitae 1 environment − 1 −
M. engboekii 3 environment − 3 −
M. gordonae 5 environment − 5 −
M. interjectum 2 environment − 1 −
M. intracellulare 1 human − 1 −
M. marinum 3 human − 3 −
M. nonchromogenicum 3 human − 3 −
M. peregrinum 6 environment − 6 −
M. raccae 1 environment 1 −
M. terrae 1 human − 1 −
M. xenopii 1 human − 1 −
Enterobacter cloacae 1 reference − − 1
Enterococcus faecalis 1 reference − − 1
Enterococcus faecium 1 reference − − 1
Escherichia coli 1 reference − − 1
Klebsiella pneumoniae 1 reference − − 1
Pasteurella multocida 1 reference − − 1
Staphylococcus aureus 1 reference − − 1
Staphylococcus epidermidis 1 reference − − 1
Staphylococcus haemolyticus 1 reference − − 1
Staphylococcus warneri 1 reference − − 1
Salmonella spp. 1 reference − − 1
Streptococcus anginosus 1 reference − − 1
Streptococcus pasteria 1 reference − − 1
Streptococcus dysagalactiae 1 reference − − 1
Total 121 50 57 14
MTC: M. tuberculosis complex; NTM: non tuberculous mycobacteria; non myco:
bacteria other than mycobacteria.
1Isolates differentiation conﬁrmed by sequence analysis. 2Clinical isolates obtained
by cultivation from human sputum or skin biopsies; environmental isolates were
obtained from water, soil, dust, bioﬁlm, organic remains and animal samples.
3Isolates classiﬁcation obtained from multiplex PCP.
O241 Surveillance of antibiotic resistance in leprosy by a new
molecular test, the GenoType® LepraeDR
E. Cambau °, L. Tejmar-Kolar, A. Chauffour-Nejevans, R. Roth Dit
Bettoni, V. Jarlier (Paris, FR; Nehren, DE)
Objectives: Although leprosy is treated by multidrug therapy since
1982, resistance to the ﬁrst-line drug (dapsone, rifampicin) is described
for 30 years and resistance to second-line drug as ﬂuoroquinolones
is described since 1997. Since Mycobacterium leprae is not growing
in vitro, its susceptibility testing (one year experiment in the mouse
footpad) is rarely done. Molecular methods are thus necessary to detect
antibiotic resistance in leprosy and are so far in house methods requiring
sequencing. Our aim was to provide a commercially based molecular test
able to detect for antibiotic resistance in leprosy.
Methods: M. leprae strains contained in biopsy skin samples were
studied for resistance to dapsone, rifampicin and oﬂoxacin by the
reference drug susceptibility method (the mouse footpad method). DNA
was extracted and regions involved in resistance to the three drugs
(rpoB gene for rifampicin, gyrA gene for oﬂoxacin and folP1 gene for
dapsone resistance) were ampliﬁed and sequenced. The new DNA strip
test, GenoType® LepraeDR, was applied blindly. Results were compared
to those obtained by the genotypic method (PCR sequencing) and the
phenotypic reference method (mouse footpad).
Results: Among the 91M. leprae strains, 14 were resistant to rifampicin,
18 were resistant to dapsone and 1 was resistant to oﬂoxacin. For
the resistant isolates, PCR sequencing was 100% concordant with the
mouse footpad test with mutation (numbering system of the M. leprae
genome) in rpoB (10 S456L, 2 S456M, 1 Q438V, 1 G432S), in folP1 (5
P55L, 3 P55R, 7 T53I, 2 T53A, 1 T53V) and gyrA (1 A90V). Results
obtained by the GenoType® LepraeDR test were 100% concordant
with the two reference methods. For the susceptible strains, there were
two discordances between the mouse footpad testing and the PCR
sequencing: PCR-sequencing showed in one strain a silent mutation
at codon 427 in rpoB and in a second strain a serine to cysteine
substitution at the same codon, which were both not associated to
rifampicin resistance. GenoType® Leprae DR showed a wild-type pattern
for rpoB for these two isolates.
Conclusion: Results obtained by the GenoType LepraeDR test were
100% concordant with the reference phenotypic susceptibility testing
and 98% with the genotype determined by PCR and sequencing. The test
is easy to perform and may be affordable in all laboratories, including
those in endemic countries.
O242 A novel real-time PCR assay for speciﬁc detection and
quantiﬁcation of Mycobacterium avium ssp. paratuberculosis
in milk with the inherent possibility of differentiation
between viable and dead cells
M. Dzieciol °, P. Volgger, J. Khol, W. Baumgartner, M. Wagner, I. Hein
(Vienna, AT)
Objectives: Mycobacterium avium subsp. paratuberculosis (MAP) is
known as the etiological agent of paratuberculosis (Johne’s disease)
in ruminants. Crohn’s disease is an inﬂammatory gastrointestinal tract
disease in humans, presenting with similar symptoms and pathological
changes in the gut as Johne’s disease in cattle. Therefore, it was suggested
that MAP could be one of the etiologic factors of the disease. The aim
of the present study was to develop a MAP-speciﬁc real-time PCR assay
providing the additional possibility of detecting viable MAP.
Methods: A real-time PCR assay based on ampliﬁcation of the speciﬁc
Mptb52.16 target was designed including an internal ampliﬁcation
control to identify false negative results. The detection limit was
established in artiﬁcially contaminated raw milk samples and the
optimized assay applied to 96 naturally contaminated raw milk samples.
The potential of the real-time PCR assay to detect viable MAP was
explored by assessing expression of the Mptb52.16 target in raw milk
samples and inoculated Dubos broth.
Results and Conclusions: The method showed 100% inclusivity and
exclusivity when testing 11 MAP strains, 22 non-MAP mycobacteria,
and 16 raw milk microﬂora strains. The detection limit in artiﬁcially
contaminated raw milk was 2.42×101 MAP cells/ml milk. In a survey
of naturally contaminated samples obtained from dairy herds with a
known history of paratuberculosis, 47.8% pre-milk and 51.9% main milk
samples tested positive. Real-time PCR-derived MAP-speciﬁc bacterial
cell equivalents (BCE) ranged from 1×100 to 5.1×102 BCE/51.44ml;
the majority of samples had less than one BCE per ml milk. Expression
of the chosen target was detected in artiﬁcially contaminated raw milk
as well as inoculated Dubos broth, thus conﬁrming the real-time PCR
assay’s potential to detect viable MAP cells.
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O243 Acquisition of cytomegalovirus speciﬁc immune response
during pre-emptive therapy protects high-risk solid organ
transplant patients from infection
O. BenMarzouk-Hidalgo °, J. Cisneros, E. Cordero, A. Martin-Pen˜a,
B. Sanchez, M. Gomez-Bravo, A. Gentil, E. Lage, P. Perez-Romero
(Seville, ES)
Objectives: The objective of this study is to determine whether the
activation of a cytomegalovirus (CMV)-speciﬁc T cell-mediated response
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during pre-emptive therapy controls further replication episodes without
valganciclovir administration in solid organ transplant (SOT) patients at
high risk for CMV infection.
Methods: SOT recipients at high risk for CMV infection, those
that are seronegative and receive a seropositive graft, were followed
for 18 months after transplantation. CMV viral loads (VL) were
determined by real-time PCR, and the CMV-speciﬁc immune response
was characterized by ﬂow cytometry by the detection of CD4+,
CD8+ and CD3+ T cells expressing CD69 and secreting IFN-g and
IL-2. Preemptive treatment was administered when VL reached 1,000
copies/ml. Once a CMV-speciﬁc immune response was detected no
treatment was administered and patients were closely monitored.
Results: Eleven patients with a median age of 53 years were included.
Between 2 and 7 weeks after transplantation, all patients experienced
CMV replication episodes that ranged from 787 to 1,432,217 copies/ml.
All of them were resolved after administration of valganciclovir. Between
weeks 10 and 20 post-transplantation a CMV-speciﬁc immune response
was detected in all patients. After this, 33 replication episodes were
detected, 32 of which (97%) were controled by the host immune system
without the administration of treatment (VL ranging from 10 to 31,317
copies/ml). Furthermore, although the number of positive PCR results
was similar before and after the acquisition of immunity, VL levels were
signiﬁcantly lower (p = 0.017) after immunity than before with median
values of 1,696 copies/ml and 20,110 copies/ml, respectively. From week
39 to week 51 all replication episodes were 1,000 copies/ml and no new
replication episodes were detected after week 51.
Analysis of the immune response demonstrated that IL-2 was secreted
from CD4+ T cells signiﬁcantly earlier than IFN-g (6 vs 8.5 weeks
post-transplant; p = 0.001). Aditionally, IFN-g was secreted from CD4+
T cells signiﬁcantly earlier than from CD8+ T cells (9 vs 12 weeks
post-transplant; p = 0.005).
Conclusion: Pre-emptive therapy promotes the acquisition of an early
immune response after transplantation in SOT patients at high risk
for CMV infection. We demonstrate that the immune response elicited
during pre-emptive therapy confers immunity to later CMV replication
events.
O244 Break-through HHV-6B infections during antiviral
prophylaxis after liver transplantation
I. Lautenschlager °, R. Loginov, T. Karlsson, K. Ho¨ckerstedt (Helsinki,
FI)
Objectives: Human herpesvirus-6 (HHV-6) activation, mostly of
the variant B, is common after liver transplantation. Most HHV-6
reactivations are asymptomatic, but symptoms such as encephalitis,
hepatitis or graft dysfunction have been described. The clinical
experience on antiviral therapy is very limited, but based on in vitro
studies, the current antiviral drugs effective against cytomegalovirus
(CMV), have also activity against HHV-6. However, ganciclovir is less
effective against HHV-6B than HHV-6A. The aim of our study was
to investigate the efﬁciency of antiviral prophylaxis, given to the CMV-
seronegative risk patients receiving the graft from the seropositive donor,
in preventing HHV-6B reactivation.
Methods: Of 232 consecutive adult liver transplant patients 36 belonging
to the CMV high risk group received valganciclovir (or ganciclovir)
prophylaxis up to 3 months after transplantation. The patients were
frequently monitored for CMV by real-time quantitative PCR and
HHV-6 reactivations were demonstrated by the antigenemia test in
PBMC by using indirect immunoperoxidase staining and monoclonal
antibodies against HHV-6B and HHV-6A. Intragraft HHV-6 infection
was demonstrated in liver biopsies by using the same antibodies and
immunostaining.
Results: During antiviral prophylaxis, no break-through CMV infections
were recorded. On the contrary, HHV-6 antigenemia was detected in
13/36 (36%) patients appearing mean 12 days (range 7−22 days) after
transplantation. All reactivations were caused by HHV-6B. In three cases
HHV-6 antigens were also detected in the transplant associated with graft
dysfunction.
Conclusions: HHV-6B reactivations were common during antiviral
prophylaxis after liver transplantation. At least in three cases also the
transplant was infected. Valganciclovir/ganciclovir prophylaxis did not
prevent HHV-6B infections in adult liver transplant patients.
O245 Diagnosis of polyomavirus-associated nephropathy in
renal-allograft recipients by real-time polymerase chain
reaction and urine cytology
Y.J. Chan °, Y.T. Lin, C.C. Loong, Y.H. Huang, D.M. Ho (Taipei, TW)
Objective: Polyomavirus-associated allograft nephropathy (PVAN)
frequently results in allograft dysfunction in renal transplant patients
in the era of powerful immunosuppressive agents. BK virus (BKV) is
the dominant causal agent whilst JC virus (JCV) accounts for the rest.
Although renal biopsy is considered as the diagnostic standard for PVAN,
a less invasive surrogate method is helpful. This study evaluated the
clinical utility of urinary decoy cells and urine and plasma BKV/JCV
real-time polymerase chain reaction (PCR) in the diagnosis of PVAN in
renal transplant recipients with allograft dysfunction.
Methods: In a retrospective analysis, 22 renal transplant patients with
allograft dysfunction and with renal biopsy results were evaluated. All
patients received real-time PCR assays for BKV and JCV for their
plasma and urine samples within one week of renal biopsy. The biopsy
results included 7 renal-allograft recipients with pathological diagnosis of
PVAN (5 BKV- and 2 JCV-associated) and 15 patients with pathological
diagnosis other than PVAN. Urine cytology was evaluated for decoy cells
within 1 week of renal biopsy in all patients.
Results: In the 7 PVAN patients, exclusive BKV viruria was detected
in all patients with BKV-associated PVAN and exclusive JCV viruria
was detected in 2 patients with JCV-associated PVAN. BKV viremia
exceeded the cut-off threshold value (104 copies/ml) was found in all
5 BKV-associated PVAN patients. JCV viremia was found in one JCV-
associated PVAN patient. The use of decoy cells as a marker of PVAN
had a sensitivity of 85.7% and negative predictive value of 93%. The
use of polyomavirus viruria in aiding the diagnosis of PVAN had a
sensitivity of 100% and negative predictive value of 100%. The use of
polyomavirus viremia in aiding the diagnosis of PVAN had a speciﬁcity
of 93.3% and positive predictive value of 85.7%.
Conclusions: BKV and JCV real-time PCR methods may help in the
diagnosis of PVAN among renal transplant patients. BKV viremia (>104
copies/ml) is highly associated with BKV nephropathy whilst the cut-off
value for JCV requires further investigation.
O246 Norovirus-related severe and chronic diarrhoea in renal
transplant adult recipients
D. Roos-Weil °, P. Pothier, F. Lanternier, M-F. Mamzer-Bruneel,
K. Ambert-Balay, R. Snanoudj, M. Lecuit, E. Thervet, C. Legendre,
O. Lortholary, J. Zuber (Paris, Dijon, FR)
Objectives: Noroviruses (NoV) and Sapoviruses (SpV) are two
separate genera in the Caliciviridae family. NoV are an increasingly
recognized cause of transient gastroenteritis in immunocompetent
individuals and have been recently implicated in chronic diarrhea in
immunocompromised patients. However, clinical and epidemiological
spectrum of Caliciviridae infections in renal transplant recipients is still
poorly deﬁned.
Methods: We undertook a single-center retrospective analysis of the
clinical and virologic features of Caliciviridae infection, diagnosed by
reverse transcription polymerase chain reaction (RT-PCR) from July
2008 to September 2009. Genotypes and variants were identiﬁed by
genome sequencing. Other infectious agents were ruled out.
Results: Eleven renal transplant adult recipients were identiﬁed as
having Caliciviridae infection, including 10 NoV and 1 SpV. All of
them were given an induction immunosuppressive therapy relayed by
a triple maintenance therapy. The median time from transplantation to
symptoms and from then to diagnosis were 21 months (range: 1−83)
and 30 days (range: 9–154), respectively. All patients had protracted
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diarrhea, requiring hospitalization and IV rehydration. Vomiting and
fever were present in 5 (45%) and 2 (18%) patients, respectively. All
but one experienced weight loss with an average loss of 4.5±2.2 kg,
8 (72%) of them presented with acute renal failure. Patient-to-patient
nosocomial transmission was very likely in two patients who shared
the same hospital room and in whom the same variant was identiﬁed.
All others had community-acquired-norovirus infection and one in the
context of a family outbreak. NoV genotypes found were GI-3, GII-2,
GII-4, GII-6 variants in 1, 1, 6 and 2 patients, respectively. Diarrhea was
lasting more than 4 weeks in 10 of them with a median duration of 56
days (range: 8–261). Strikingly, diarrhea resolved after mycophenolate
tapering or withdrawal in 5 (46%) and 4 (36%) patients, respectively.
All patients survived and none experienced a relapse of diarrhea with a
median follow-up of 5 months (range: 1−17).
Conclusion: NoV is a likely underestimated cause of severe and
chronic diarrhea in renal transplant recipients. This may delay
effective therapeutic intervention that mostly consists in reducing
immunosuppression. Prospective studies are warranted to assess the
correlation between immunosuppressive regimens, resolution of diarrhea
and virus clearance.
O247 Evolution of anelloviridae strains in serial blood and biopsy
samples from a renal transplant patient
P. Biagini °, B. Dussol, Y. Berland, P. de Micco (Marseille, FR)
Objectives: The Anelloviridae family is composed of multiple viral
species belonging to the prototype TT virus. Biology and implications
for host health of this intriguing viral family is still a matter to debate.
In order to better understand the evolution of anelloviridae strains in the
immunocompromised host, we performed a molecular analysis of serial
blood and biopsy samples from a kidney transplant recipient.
Methods: Viral DNA was extracted from plasma samples using the
High pure viral nucleic acid kit (Roche). Biopsy tissue samples were
pre-digested using proteinase K, and nucleic acids were further extracted
using the same approach. Rolling circle ampliﬁcation (RCA) using Phi29
DNA polymerase was performed on extracted materials in order to opti-
mise the detection of viral DNA. Anelloviridae detection was performed
using a highly conserved PCR system; ampliﬁed products were further
cloned and sequenced, and submitted to phylogenetic analyses.
Results: The evolution of viral strains detected in blood samples was
bimodal: 1) prior to kidney transplant (T-90 days to T0), the genetic
diversity exhibited by anelloviridae sequences was moderate; 2) on the
other hand, multiple variants were detected from T+15 to T+420 (end
of follow-up).
Regarding the biopsy samples, although the ﬁrst sample (T+11) was PCR
negative, an anelloviridae sequence was identiﬁed in the second sample
(T+170). Interestingly, this sequence was identical or nearly identical
to a cluster of sequences identiﬁed in the blood of the patient before
transplant.
Conclusion: This study suggests that a transplant is able to be
colonized by an anelloviridae strain identiﬁed previously in the blood
of the corresponding patient. It conﬁrms also that major changes
in anelloviridae dynamics occur in the blood of patients undergoing
immunosuppressive treatments. Precise analysis of biological and
molecular data collected in this study is exposed.
O248 Relationship of viral load Epstein–Barr virus as a marker
predictive lymphoproliferative disease after liver transplant
J. Hernandez, M. Nava, J. Casasola, J. Arellano, R. Farfan ° (Distrito
Federal, MX)
Background: Lymphoproliferative disease (ELPT) are a heterogeneous
group of lymphoid disorders that can develop in patients undergoing
solid organ transplantation. The incidence ranges between 2% adults
and 10% in children and reach a mortality rate between 40 and 70%.
The wide range of clinical presentations ranging from a mononucleosis
syndrome and lymphadenopathy, masses to multiple organ dysfunction.
The risks identiﬁed in pediatric patients post transplant are the early
ages, the use of Tacrolimus, a high viral load and a concomitant low
cellular immune response.
Objectives: To describe the relationship between EBV viral load as a
predictive marker for the presence of ELPT and clinical characteristics of
patients after transplantation of liver in the Hospital Infantil de Mexico
“Federico Gomez” in the period January 2005 to January 2008.
Methods: A descriptive, retrospective and observational study of a series
of cases.
Results: From January 2005 to January 2008, nine liver transplants
were performed, three were high risk by serology (EBV D-/ R +), of
which one ELPT development at 100 weeks post-transplant viral load of
1450 genomes / mL plasma. The time of reactivation of EBV infection
on average for the nine patients was 3.3 weeks after transplantation.
Seven patients belonged to age group <5 years (high risk by age). And
4 ELPT developed ELPT viral loads >800 genomes/mL of plasma.
Five of nine patients developed ELPT diagnosed by liver biopsy and
immunohistochemistry. All patients had elevated liver enzymes more
than 4 times its baseline, 2 patients had atypical lymphocytes in the
time of diagnosis and 3 ELPT monocytosis. Two patients had clinical
mononucleosis-like and 3 were asymptomatic at the time of diagnosis
of ELPT with viral loads of >900 genomes/mL. The patient number 9
ELPT present two events with added diagnosis of acute cellular rejection
by biopsy in his second event of ELPT and high viral loads.
Conclusions: Viral load >800 genomes/mL accompanied by elevation
in liver enzyme values of up to four or more times their normal levels
were related to the development of ELPT.
O249 Reduced IgG antibody avidity in organ transplant recipients
after varicella-zoster-virus vaccination
M. Prelog, J. Scho¨nlaub °, M. Zlamy, L. Zimmerhackl, R. Wu¨rzner
(Innsbruck, AT)
Objectives: Varicella-zoster virus (VZV) infection may cause signiﬁcant
morbidity and mortality in the immuno-compromised patient. VZV
vaccine induces both humoral and cellular immunity. However, there is
no clear correlation between IgG antibody titers and protection against
infection. Antibody protection is a function of both concentration and
afﬁnity (=chemical binding strength). Avidity is a measure of functional
afﬁnity. It has been suggested that studies of vaccine efﬁcacy should
incorporate analysis of avidity, since high avidity is a marker of memory
priming. The present study was designed in order to answer the question
as to whether solid organ transplant (SOT) recipients have a lower VZV
IgG antibody avidity, despite having protective IgG antibody levels after
vaccination, or not.
Methods: The serum samples of SOT recipients were evaluated for IgG
antibody levels against VZV and IgG antibody avidity. Twenty-eight pa-
tients were included in the study (20 had had liver transplantation, 3 heart
transplantation, 5 kidney transplantation) and had received a single dose
of Varivax (Aventis Pasteur, Lyon, France) prior to transplantation. The
control group consisted of 50 healthy children, 36 of whom had had clin-
ical and serological conﬁrmed varicella infection after wild-virus contact
and 14 of whom had varicella vaccination with a single dose of Varivax.
Results: Median IgG antibody levels were 800 U/ml in wild-virus
infected controls, 810 U/ml in vaccinated controls and 630 U/ml in SOT
recipients. Median relative avidity index (RAI) was 89% for wild-virus
infected controls, 94% for vaccinated controls and 82% for transplant
recipients (p = 0.01 compared to wild-virus infected controls, p = 0.002
compared to vaccinated controls).
Conclusions: In conclusion, IgG antibody avidity in SOT recipients
may serve as a substitute marker to evaluate humoral immunity
against VZV. This is of particular importance in the clinical setting of
exposure to VZV when considering VZV-speciﬁc immunglobulin and/or
acyclovir treatment in order to prevent clinical relevant re-infection and
varicella-caused complications as a result of exposure to VZV after
transplantation. However, the role of humoral protection against VZV
has to be evaluated in long-term follow-up, since also cellular immunity
may play a crucial role in defence against viral infections.
S58 20th ECCMID, Oral presentations
O250 Characteristics and timing of bloodstream infections
following orthotopic liver transplantation: a single-centre
experience
B. McGovern °, A. Gilleece, A. McCormick, S.F. FitzGerald, L. Fenelon,
K. Schaffer (Dublin, IE)
Aims: To analyse the characteristics of bloodstream infections (BSI)
occurring in orthotopic liver transplant (OLT) recipients in an Irish
tertiary care hospital during the 2 year period from July 1st 2007 to
June 30th 2009. To compare the ﬁndings with data from a previous time
period.
Methods: The incidence, timing, aetiology and microbiology of BSIs in
OLT recipients were obtained retrospectively. 124 OLTs were performed
from July 1st 2007 to June 30th 2009. Chart reviews were performed on
all patients who had positive blood cultures up to 12 weeks post-OLT.
Bacteraemia or fungaemia was considered to be signiﬁcant according to
the CDC criteria. Previous related literature was reviewed.
Results: Overall 21 BSIs were recorded with an incidence of 17 BSIs
per 100 patients transplanted. 75% of all BSIs occurred within the ﬁrst
two weeks post-OLT. The most frequent sources of BSI were abdominal
(52%) and intravascular catheters (32%). Gram-positive organisms were
the most frequent aetiological agents overall (43%). Gram-negative
organisms were the primary aetiological agents in the early post-
operative period (<1 week). In week one post-OLT, 73% (8/11) of BSIs
were due to Gram-negative organisms (85% abdominal source). Gram-
positive organisms predominated after the ﬁrst post-operative week,
causing 70% (7/10) of BSIs. Crude mortality of BSIs was 33%, being
highest in the early post-operative period. Among the Gram-positive
isolates, 8% were vancomycin-resistant enterococci and there was no
methicillin-resistant Staphylococcus aureus isolated. Among the Gram-
negative isolates, 70% were ESBLs and 30% were AmpC producers.
Overall the incidence of BSI at our transplant centre has decreased
between the two time periods. In the period 1995 to 2000, 91 OLTs were
performed with an incidence of 28 BSIs per 100 patients transplanted.
Gram-positive organisms were the most frequent causative agents during
this period (60%).
Conclusion: BSIs remain a major concern in OLT recipients. An
understanding of the aetiology of BSI post-OLT is important for empiric
antibiotic choice in the event of infectious complications post-surgery.
In an attempt to further reduce the incidence of BSI post-OLT we plan
to target IV catheter-related sepsis at our centre.
O251 Multi-resistant pathogens − a problem in nosocomial
bloodstream infections in patients with haematopoetic cell
transplantation? Evaluation of ONKO-KISS data
D. Luft, R. Babikir, H. Bertz, A.F. Widmer, W. Kern, M. Dettenkofer °
and the ONKO-KISS Study Group
Objectives: To assess the relevance of three multiresistant pathogens
(methicillin-resistant Staphylococcus aureus [MRSA], extended-spectrum
b-lactamase [ESBL] producing Escherichia coli, vancomycin-resistant
[VR] Enterococcus facium) in nosocomial bloodstream infection (BSI)
during neutropenia in adult patients undergoing hematopoetic cell
transplantation (HCT), data derived from the ongoing multicenter
surveillance project ONKO-KISS were evaluated. The project was
initiated by the German National Reference Centre for Surveillance of
Nosocomial Infections in 2000.
Methods: Nosocomial bloodstream infections are identiﬁed using
CDC deﬁnitions for laboratory-conﬁrmed BSI [for detailed information
see: CID 2005; 40: 926, or in German language: http://www.nrz-
hygiene.de/surveillance/onko.htm]. Data on BSI and pathogens detected
in blood cultures as well as key resistance patterns are reported to the
Reference Centre for Surveillance.
Results: From January 2004 up to June 2009 24 centers participated.
Altogether 6,303 patients with 93,026 neutropenic days were investi-
gated. 984 cases of nosocomial BSI were diagnosed and a total of 1101
pathogens were detected, of whom 37 belonged to the above mentioned
multiresistant pathogens (3.4%). 7 out of 22 S. aureus isolates were
MRSA (31.8%), 17 out of 174 E. coli isolates were ESBL-producers
(9.8%) and 13 out of 63 E. faecium isolates showed Vancomycin
resistance (20.6%). For details see Table.
Conclusion: The overall number of BSI involving multiresistant
pathogens in the ONKO-KISS patient group is rather low. Rates of
MRSA and VR E. faecium were varying in the observation period and
sometimes higher than the corresponding rates for Germany derived
from EARSS [European Antimicrobial Resistance Surveillance System;
www.rivm.nl/earss]. However, the low overall numbers must be taken
into account. ESBL producing E. coli were not seen before 2007 but
thereafter with a high percentage in comparison to EARSS data for 3rd
generation cephalosporin resistant E. coli.
Year MRSA/S. aureus
total no. (%)
ESBL producing E. coli/
E. coli total no. (%)
Vancomycin resistant E. faecium/




2004 2/7 (29%) 0/27 (0%) 2/6 (33%) 167
2005 0/3 (0%) 0/34 (0%) 8/18 (44%) 220
2006 3/5 (60%) 0/25 (0%) 2/9 (22%) 199
2007 1/4 (25%) 5/38 (13%) 0/9 (0%) 206
2008 0/2 (0%) 10/37 (27%) 1/18 (6%) 230
01−06 2009 1/1 (100%) 2/13 (15%) 0/3 (0%) 79
Total 7/22 (32%) 17/174 (10%) 13/63 (21%) 1101
O252 Quantiﬁcation of CMV DNA in plasma by real-time PCR
for management of allogenic stem cell transplant recipients
L. Carden˜oso, S. Agudo °, M.J. Moreno, S. Rodrigo, O. Mun˜oz,
V. Rivera, M. Lo´pez-Brea (Madrid, ES)
The objective was to evaluate a quantitative real time PCR in plasma
samples for monitoring active CMV infection in allogenic stem cell
transplant (allo-SCT) patients and try a new strategy for the initiation of
CMV preemptive therapy.
We studied 395 plasma samples obtained of 51 CMV infection episodes
from 32 allo SCT patients between January 2007 and February 2009.
29 out of 32 received one or more course of preemptive therapy
upon positive AG and/or TNAI-PCR results and 6 (19%) developed
CMV end-organ disease (4 colitis and 2 neumonitis). All patients were
monitored post-STC with antigenemia pp65 CINApool®, Argene (AG)
and conventional quantitative PCR, COBAS® Amplicor® CMV after
automatic extraction COBAS® Ampliprep® TNAI kit, Roche (TNAI-
PCR). A positive sample was deﬁned by AG 2/4×105 PMNs and/or
TNAI-PCR 600 copies/mL.All samples were retrospectively tested
using a real time PCR Afﬁgene® CMV trender after automatic DNA
extraction with NucliSENS® easyMAG®, bioMe´rieux (rt-PCR); data
lower than 57 copies/ml were considered as negative. An episode was
deﬁned as the period between the ﬁrst positive sample by antigenemia
and/or TNAI-PCR, until the ﬁrst negative sample by both techniques.
Plasma samples were positive in 28.3%, 30.6% and 46% by AG,
TNAI-PCR and rt-PCR, respectively. Rt-PCR detected 72% of AG
positive samples vs 60% by TNAI-PCR. AG was not evaluable in 30
samples (7.5%). Sixteen samples (53%) were positive by rt-PCR vs
7 (23%) by TNAI-PCR. 12% of samples were only positive by rt-
PCR. The range for rt-PCR was 63–2.77×104 copies/ml vs 608–2.7×104
copies/ml for TNAI-PCR. Episodes were detected in 46 (90%), 38 (82%)
and 41 (89%) by AG, TNAI-PCR and rt-PCR, respectively. Six episodes
(11.8%) were only detected by AG (all PCRs negative). Five episodes
(10.9%) were detected only by PCR assays. Thirty-four episodes out
of 51 episodes (66.7%) were detected by both PCR techniques, in 14
out of 34 (41.2%) were detected earlier by RT-PCR than TNAI-PCR
(median = 7 days), and in 5 (14.7%) TNAI-PCR was earlier than Rt-PCR
(median = 3 days). Concordance between PCRs assays was 79% (k = 0.6).
Strategy based on the quantiﬁcation of CMV DNA in plasma could be
established in >153 copies/Ml (curve ROC, graphic 1) for triggering the
initiation of CMV preemptive therapy in this clinical setting. Rt-PCR can
be introduced to allow the more sensitive, rapid, and accurate diagnosis
of CMV reactivation infection in SCT recipients, which allowed for
preemptive therapy to be administered as early as possible.
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Treatment of hospital-acquired candidaemia:
strategies, opinions and practice (Symposium
supported by Astellas)
S253 Treatment of hospital-acquired candidemia: strategies, opin-
ions and practice. A question-and-answer expert workshop
M. Ghannoum, O.A. Cornely, P. Mun˜oz, F. Saliba (Cleveland, US;
Cologne, DE; Madrid, ES; Villejuif, FR)
Invasive Candida infections occur in many different patient populations.
Critical care is widely acknowledged as an important predisposing
factor, with a third of candidaemia episodes occurring in the ICU.
This is chieﬂy because ICU patients are exposed to many of the risk
factors, which include compromises to natural barriers of infection;
Candida colonisation and alterations in normal ﬂora; and the presence
of debilitating diseases or immunosuppression, particularly neutropenia.
Invasive Candida infections also occur outside the ICU, as the cardinal
risk factors are present in a variety of patient types, including patients
undergoing major abdominal surgery; bone marrow and solid-organ
transplant patients; and patients undergoing cancer chemotherapy.
Although risk factors for invasive Candida infections are well
characterised, deﬁnitive diagnosis remains problematic due to the long
lead times associated with blood culture and histopathology. Targeted
treatment, i.e. selection of an antifungal agent tailored to a particular
Candida species with known antifungal susceptibility, is rarely possible
initially. Consequently, pre-emptive and empirical strategies, which make
use of the limited information available to guide treatment decisions, are
commonly employed.
Patients with invasive Candida infections are often severely ill prior to
developing a fungal infection. Therefore, rapid initiation of therapy is
vital, as the risk of mortality increases signiﬁcantly with any delay in
treatment. However, it is also important to consider carefully the choice
of agent, as differences exist in microbiological and clinical efﬁcacy.
Many cases of invasive Candida infections are caused by species that
are potentially resistant to older antifungals, particularly ﬂuconazole.
Therefore, if the causative agent is unknown, or is suspected to be a
ﬂuconazole-resistant species (i.e. C. glabrata or C. krusei), a broad-
spectrum antifungal agent should be selected ﬁrst-line, with recent
guidelines recommending echinocandins as the best overall choice.
Differences also exist between the echinocandins, particularly with
regard to their suitability for use in certain patient populations. Therefore,
careful assessment of individual cases is the optimal basis for selection
of therapy. Micafungin, which was evaluated in an extensive clinical
trial programme and has to date been administered in 600,000 patients
worldwide, is a recognised treatment option.
Blood, bone and bioﬁlm: improving outcomes
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S254 Management of catheter-related bacteraemia
P. Grossi ° (Varese, IT)
Intravascular catheters are indispensable in current medical practice.
However, they provide surfaces for microbial colonisation and bioﬁlm
formation and predispose patients to bacteraemia. Some of the most
common causative pathogens, such as coagulase-negative staphylococci
and Staphylococcus aureus, have adherence properties that are important
in the pathogenesis of catheter-related infections. The prevalence of
multidrug-resistant pathogens, the need for rapidly effective empiric
therapy to avoid complications and improve outcomes and the altered
pharmacokinetics of septic patients make bacteraemia a signiﬁcant
clinical challenge.
The Infectious Diseases Society of America (IDSA) recently published
updated guidelines for the management of catheter-related bacteraemia.
Catheter removal and prompt systemic antibiotic therapy are central
to both complicated and uncomplicated bacteraemia management. The
IDSA and other guidelines highlight ongoing clinical challenges, which
more recent antibiotics are helping to address. For example, clinical
evidence of reduced MRSA susceptibility to vancomycin has prompted
the IDSA to recommend daptomycin* in institutions where vancomycin
MICs >2mg/ml are common. Bacteraemia caused by vancomycin-
resistant enterococci is also of increasing concern. Therapeutic options
are limited and recent novel antibiotics may be helpful in these cases.
Haemodialysis patients have particular risk factors for catheter-
associated bacteraemia. Catheter removal may pose logistical problems;
however, failure or delay in removal increases the risk of haematogenous
spread. Compared with catheter retention, removal of S. aureus-infected
catheters is associated with a more rapid response to therapy and/or a
higher cure rate. Furthermore, success rates for catheter salvage using
adjunctive antibiotic lock therapy are lower for Gram-positive pathogens,
such as S. aureus, enterococci and Staphylococcus epidermidis, than for
Gram-negative infections. The IDSA provides dosage recommendations
for daptomycin and linezolid for dialysis patients.
This presentation will discuss these and other topical clinical challenges
in the management of catheter-related bacteraemia.
*Daptomycin is licensed in Europe for the treatment of complicated
skin and soft tissue infection (cSSTI), for S. aureus right-sided infective
endocarditis (RIE) and for S. aureus bacteraemia when associated with
cSSTI or RIE.
S255 Management of non-catheter-related bacteraemia
J.M. Miro´ ° (Barcelona, ES)
Patients with Gram-positive non-catheter-related bacteraemia are at high
risk of septic metastases, particularly in bones and joints (especially
if prostheses are present), the epidural space, intervertebral discs and
cardiac valves. The presentation of non-catheter-related bacteraemia
(which includes primary bloodstream infection [BSI] and bacteraemia
secondary to infections in other sites acquired either in the community
or in nosocomial settings) is heterogeneous and may require diagnosis
and treatment of infections in foci beyond the blood.
A dominant pathogen in both nosocomial and community-acquired
bacteraemia is Staphylococcus aureus, and S. aureus bacteraemia is
associated with a high frequency of complications, including infective
endocarditis (IE). Mortality is signiﬁcantly worse in patients with pri-
mary or secondary BSI compared with catheter-related bacteraemia and
also in those infected with MRSA vs MSSA. Furthermore, inappropriate
empiric treatment for patients with Gram-positive bacteraemia increases
mortality risk.
Treatment guidelines for bacteraemia are primarily based on speciﬁc
infection foci, such as IE and catheter-related infections. Empiric
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treatment for bacteraemia should take account of the likely pathogen
and local susceptibility patterns, in addition to presenting symptoms,
patients’ general heath status and medical history (including risk factors
for MDR involvement), comorbidities (e.g. renal impairment) and
concomitant medications. When the infection focus is not a vascular
catheter, management should also address the risk of complications,
particularly related to S. aureus, and the need for some patients to receive
prolonged therapy, potentially with initial hospital treatment followed by
continued antimicrobial therapy post-discharge.
Daptomycin* is one of the few antibiotics with efﬁcacy and safety in
the treatment of S. aureus bacteraemia, including that associated with
IE. Rapid bactericidal activity, including against bioﬁlms and stationary
phase bacteria, and the potential for outpatient treatment with the
once-daily 2-minute intravenous injection, are further characteristics of
daptomycin that may be useful for non-catheter-related bacteraemia.
*Daptomycin is licensed in Europe for the treatment of complicated
skin and soft tissue infection (cSSTI), for S. aureus right-sided infective
endocarditis (RIE) and for S. aureus bacteraemia when associated with
cSSTI or RIE.
S256 Continuous challenges in hospital-acquired deep-seated
infections: need for antibiotics with activity against bioﬁlm
A. Trampuz ° (Lausanne, CH)
Prosthetic joint infection (PJI) and osteomyelitis (OST) are difﬁcult
to eradicate and remain an ongoing challenge for treating physicians.
Until recently, prosthetic surgery was usually approached as either a
two-stage exchange, separated by a long interval (6−8 weeks), or life-
long antibiotic suppression therapy. The ﬁrst approach is associated
with prolonged hospitalisation and risks of secondary complications; the
second has a low probability of success. Antimicrobials effective against
slow-growing, stationary growth-phase and adherent microorganisms are
needed to eradicate bioﬁlm infections.
This presentation will discuss novel treatment concepts and their impact
on long-term outcomes and also recently updated treatment guidelines
for PJI and OST. The choice to retain or remove an implant depends on
the patient proﬁle: in speciﬁc groups, implant infections can be cured
by early debridement and long-term treatment with antibiotics that have
good bioﬁlm activity. Antimicrobial type, doses and duration of therapy
will be discussed. Potentially, newer antibiotics such as daptomycin*
may prove to be valuable options in implant-associated methicillin-
resistant staphylococcal and enterococcal infections. Treatment protocols
of phase II studies with daptomycin with or without rifampin in PJI and
OST will be reviewed as well as the use of higher doses of daptomycin.
Common pitfalls and reasons for treatment failure will be outlined.
Empiric antibiotic therapy should not be administered before microbi-
ological diagnostic conﬁrmation, which is difﬁcult when antibiotics are
administered for a draining wound overlying an implant. In addition,
the risk of development of antimicrobial resistance is high, particularly
for rifampin. Therefore, rifampin should be avoided if there is contact
between the body surface and the implant (e.g. open wounds, wound
dehiscence, ﬁstulae, vacuum-assisted closure foam or drainage). Other
common mistakes are insufﬁcient duration and/or dose of antibiotics and
switching from intravenous to oral agents with insufﬁcient bioavailability
or inactivity against bioﬁlms.
*Daptomycin is licensed in Europe for the treatment of complicated
skin and soft tissue infection (cSSTI) at a dose of 4mg/kg od and
for Staphylococcus aureus right-sided infective endocarditis (RIE) and
S. aureus bacteraemia when associated with cSSTI or RIE at a dose of
6mg/kg od.
Antimicrobial resistance: rising to the
challenge exploring new territories to ﬁght
microbial resistance (Symposium supported
by bioMe´rieux)
S257 Emerging resistance mechanisms: current status and future
risks
D. Livermore ° (London, UK)
Recent years have witnessed dramatic shifts in the prevalence and
nature of antibiotic resistance. Key changes include: (i) the rise
and, in some countries, subsequent decline of MRSA, also (ii) the
rise of quinolone and cephalosporin resistance in Enterobacteriaceae,
particularly E. coli and Klebsiella spp., with CTX-M ESBLs increasingly
the dominant source of the cephalosporin resistance, (iii) the proliferation
of A. baumannii with OXA carbapenemases and (iv) the ‘loss’ of
ﬂuoroquinolones against gonorrhoea, with resistance rates as high as
90% in China. Treatment shifts predicated on these problems are now
exerting their own selection pressure, favouring the spread of yet further
resistances. The greatest concern for hospital medicine is the emergence
of Enterobacteriaceae with acquired carbapenemases, including the IMP,
VIM, and NDM metallo-types, the class A enzyme KPC and the class D
enzyme, OXA-48. At present, Enterobacteriaceae with these enzymes
are proliferating in different parts of the world: NDM in India, OXA-
48 in Turkey, VIM in Greece and KPC in the US − but the stability
of this distribution is unpredictable, in view of migration and medical
tourism. In general, the IMP, VIM and NDM enzymes are spread by
plasmids, whilst accumulation of K. pneumoniae isolates with KPC
enzyme largely involves dissemination of the ST258 clone. ‘Loss’ of
the carbapenems against Enterobacteriaceae would be a public health
catastrophe, in view of the lack of alternative therapies for infections
due to multiresistant Gram-negative bacteria. A shift that should be of
greater concern than it is presently receiving is the erosion of the anti-
gonococcal activity of cephalosporins. Owing to changes to PBPs, porins
and efﬂux it is increasingly common to see N. gonorrhoeae isolates
with ceﬁxime and ceftriaxone MICs of 0.12−0.5mg/L, representing the
edge of treatability, again with a lack of convenient alterative therapies.
Future risks are harder to predict but potentially include transferable
resistance to new anti-Gram-positive agents, and it is notable here that
many soil streptomycetes can degrade daptomycin. Such organisms were
the sources of several other resistance genes that have spread to mobile
DNA and into clinical pathogens. But, as the saying goes, ‘Prediction is
very hard, especially when it concerns the future’ and only two things
are certain: that neither evolution nor resistance surprises have stopped
yet.
S259 Individual determinants of antibiotic prescription
J.C. Lucet ° (Paris, FR)
The use of antibiotics in the hospital setting is shaped by cultural and
behavioural aspects as well as by clinical situation and microbiological
considerations. An understanding of the determinants of antibiotic
prescription is critical to explain current patterns and to devise programs
to reduce inappropriate use. Physician behaviour is explained by such
factors as lack of information, marketing campaigns to increase use of
newer products and fear of adverse outcome with ineffective prescription.
Studies of antibiotic use patterns consistently demonstrate frequent
inappropriate prescribing and low adherence to antibiotic prescription
(ABP) guidelines, a factor likely to increase the emergence of resistant
organisms.
Behavioural aspects of the antibiotic prescription remain largely
unknown. We explored beliefs and perceptions associated with measured
knowledge about ABP in two French university hospitals.
Physicians in charge of ABP in inpatient hospital wards were asked
to participate. Volunteers completed in a same meeting (less than 1
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hour): (i) 4 case vignettes presenting infectious situations and exploring 4
aspects: whether hospitalization was needed, initiation and choice of AB,
re-evaluation at day 2−3, and treatment duration and (ii) a self-reported
questionnaire to collect data about their own belief and perception
regarding ABP. A global score (/20) was given, combining answers
to all 4 vignettes. Logistic regression identiﬁed variables independently
associated with answers to case vignettes above the median global score.
Of 393 eligible physicians, 206 (52%) agreed to participate: 114
senior and 92 junior physicians, comprising 100 medical physicians, 49
surgeons, 37 anesthesiologists/intensivists (AI) and 20 ER physicians.
The median global score was 11.4 (IQR, 8.9–14.3). In multivariate
analysis, being a surgeon (aOR, 0.14; 95%CI, 0.06–0.38, P< 0.0001),
AI (3.33, 1.28–9.08, 0.01), perceiving inappropriate ABP as risky for
the patient (3.17, 1.14–8.77, 0.03) and self-perception of ability to
comply with ABP guidelines (2.74, 1.35–5.57, 0.005) were signiﬁcantly
associated with measured knowledge above the median score.
The participation rate was reasonably high, suggesting awareness to
ABP in these hospitals. Case vignettes are a simple method to measure
knowledge regarding ABP, and identiﬁed surgeons as a job proﬁle for
enhanced education. At the individual level, strengthening the perception
of the risk of inappropriate ABP and self-ability to comply with
guidelines may contribute to better practice with ABP. Further studies
are needed to better delineate factors that can help to shape physician
behaviour in antibiotic prescribing.
S260 Contribution of procalcitonin for guidance of antibiotic
therapy in respiratory tract infections
P. Schuetz ° (Basel, CH)
Lower respiratory tract infections (LRTI) account for almost 10% of the
burden of morbidity and mortality in western countries1. LRTIs comprise
a continuum of different severities of infections ranging from typically
self limiting acute bronchitis, to more severe acute exacerbation of
chronic pulmonary disease (AECOPD) and to life-threatening bacterial
community-acquired pneumonia (CAP). Clinical signs and symptoms,
and traditional laboratory parameters are unreliable to distinguish viral
from bacterial LRTI. As a consequence, up to 75% of LRTI are treated
with antibiotics, despite their mainly viral origin leading ultimately to
emergence of bacterial resistance. To limit antibiotic overuse, rapid and
more accurate differentiation of clinically relevant bacterial LRTI from
other causes is key.
A novel approach to estimate the probability of a bacterial origin
of LRTIs is meas-urement of serum procalcitonin (PCT) levels. PCT
increases rapidly upon infection (3−6 hours) and decreases upon
recovery. PCT correlates with severity and has prognostic implications.
Its kinetics makes it a good marker for assessing the effectiveness of
treatment, which is a prerequisite for safe guidance of antibiotic therapy.
PCT levels can be used to guide antibiotic therapy in individual
patients as a surrogate biomarker. Antibiotic stewardship based on PCT
cut off ranges has successfully been implemented in patients with
LRTI in different clinical settings. Thereby, initiation or continuation
of antibiotics was more or less discouraged (<0.1 ug/L or <0.25
ug/L) or encouraged (>0.5 ug/L or >0.25 ug/L) (Figure 1). If PCT
values are increased and antibiotics therapy is initiated, repeated PCT
measurements are recommended and antibiotics can be discontinued
using the same cut-off ranges. This clinical algorithm was prospectively
tested in different intervention trials in the emergency room, in the
intensive care unit, in primary care and recently, this concept has been
externally validated in a large Swiss nation-wide multi centre trial
including over 1350 patients. Overall, PCT-guided antibiotic stewardship
reduced antibiotic prescription rate by 40−50% in patients with acute
bronchitis or AECOPD; in CAP, it reduced the initial prescription rate by
about 10%, but importantly shortened the duration of antibiotic therapy
by 65% with a similar outcome in patients with all severities. Similarly,
PCT guidance safely reduced antibiotic exposure by more than 75% in
primary care patients with upper and lower RTI9. Thereby, PCT guidance
signiﬁcantly reduced antibiotic-related side effects, especially diarrhoea
and nausea.
The septic syndrome is far too heterogeneous and complex to be reduced
to a single cut-off of any surrogate marker. Biomarker must always
be evaluated in the context of a careful clinical and microbiological
assessment. As the kinetics of biomarkers are of particular diagnostic and
prognostic interest, repeated measurements should always be performed,
especially if antibiotics are withheld.
Emerging bacterial resistance to antimicrobial agents calls for more
efﬁcient efforts to reduce the unnecessary use of antimicrobial agents
in self-limited and non-bacterial diseases. Embedded in a clinical
algorithm, PCT-guided antibiotic stewardship offers great potential to
safely and markedly reduce antibiotic exposure and antibiotic-associated
side effects.
Figure 1. Clinical algorithm for antibiotic guidance in LRTI.
ESBLs and AmpCs − understand the
mechanisms
S271 Current trends in epidemiology of ESBLs and acquired
AmpCs
J. Pitout ° (Calgary, CA)
Since 2000, Escherichia coli producing CTX-M enzymes (espe-
cially CTX-M-15), have emerged worldwide as important causes of
community-associated urinary tract (UTIs) and blood stream infections
due to extended-spectrum b-lactamase (ESBL) producing bacteria.
Molecular epidemiology studies suggested that the sudden worldwide
increase of multi-resistant CTX-M-producing E. coli (especially CTX-
M-15) is mostly due to a single clone named ST131 and that foreign
travel to high-risk areas such as the Indian subcontinent might play in
part a role in spread of this clone across different continents. Clone
ST131 that produce CTX-M ESBLs (i.e. most often CTX-M-15 but
also CTX-M-3 and CTX-M-14) is associated with IncFII and IncI1
multi-resistance plasmids and certain virulence factors such as malX,
ompT and usp. Community-associated acquisition and infections due
to enterobacteria with plasmid-mediated AmpC b-lactamases are a
relatively recent phenomenon and have been described in the UK, Canada
and USA. The spread of clones in the community setting have not
been described for enterobacteria that produce plasmid-mediated AmpC
b-lactamases. Empiric antibiotic coverage for these resistant organisms
should be considered in community patients presenting with sepsis
involving the urinary tract especially in patients with certain risk factors
such recent antibiotic use, residence in a long-term care facility, recent
hospitalization, males older than 65 years and recent travel to a high-
risk area. If this emerging public health threat is ignored, it is possible
that the medical community may be forced in the near future to use the
carbapenems as the ﬁrst choice for the empirical treatment of serious
infections associated with urinary tract infections originating from the
community.
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S273 The role of plasmids and bacterial clones in the spread of
ESBLs and acquired AmpCs
A. Carattoli ° (Rome, IT)
A multidisciplinary approach is currently applied to study the acquisition
and spread of antimicrobial resistance in clinically-relevant bacterial
pathogens: the established surveillance is implemented by molecular
characterization of the strains by genotyping, identiﬁcation of the
resistance gene types, virulotyping analysis and replicon typing of
the circulating plasmids. Multilocus sequence typing is also used
to document the international occurrence of successful, healthcare-
associated and community-acquired clones.
Many of these clones are often resistant to multiple antibiotics and
multidrug resistance is often encoded by extrachromosomal elements,
called plasmids. Plasmids evolve as an integral part of the bacterial
genome, providing resistance genes that can be easily exchanged among
bacteria of different origin and source, through the natural process of
conjugation.
Particular plasmid families are playing a major role in the diffusion of
ESBLs such as CTX-M, SHV, TEM and acquired AmpCs. For instance,
IncFII, IncA/C, IncL/M, IncN and IncI1 plasmids carrying ESBLs are
considered as “epidemic resistance plasmids”, being detected in resistant
bacteria of different origin and sources. The emergence of the CTX-
M-15 enzyme has been associated to the spread of the highly virulent
E. coli O25:H4-ST131 clone carrying plasmids belonging to the IncF
group. Other CTX-M variants have been ampliﬁed locally, such as
CTX-M-9 and CTX-M-14 in Portugal and Spain, CTX-M-3 in eastern
countries associated to speciﬁc plasmid families. TEM-52 and CTX-M-1
disseminated prevalently on IncI1 plasmids among E. coli of human and
animal origin. The identiﬁcation of KPC-2-positive IncN and ColE-like
plasmids in K. pneumoniae from USA and Colombia suggests that these
plasmids could contribute to the rapid spread of the gene. Acquired
AmpCs widely disseminated on IncA/C and IncI1 plasmids.
The occurrence of the particular epidemic plasmids seems tightly linked
to positive selection exerted by the antimicrobial use, incrementing their
prevalence compared to that observed in bacterial populations that are
not pre-selected for antimicrobial resistance.
Many questions remain unanswered about mechanisms driving the
successful dissemination of a speciﬁc plasmid type or a bacterial
clone. However, the recognition of successful clones and plasmids is an
essential ﬁrst step that may lead eventually to the design of intervention
strategies at preventing their spread.
S274 Mutational modiﬁcations of ESBL and AmpC activities
T. Palzkill ° (Houston, US)
The class A TEM-1 and SHV-1 b-lactamases are common plasmid-
encoded b-lactamases in Gram-negative bacteria. These enzymes
efﬁciently hydrolyze pencillins and many cephalosporins but are not
effective catalysts for extended-spectrum cephalosporins and thus do
not provide resistance against these drugs. However, variants of TEM-1
and SHV-1 that can hydrolyze extended spectrum cephalosporins have
evolved in clinical isolates over the last two decades, which has
limited treatment options. These evolved enzymes, termed extended-
spectrum b-lactamases (ESBLs), contain from one to ﬁve amino
acid substitutions that result in increased catalytic efﬁciency of the
enzymes for hydrolysis of extended spectrum cephalosporins. Site-
directed and random mutagenesis studies have revealed that the amino
acid substitutions commonly found in the evolved variants increase the
catalytic efﬁciency for hydrolysis of extended spectrum cephalosporins
and, in some cases, stabilize the evolved enzymes. The evolution of high
level resistance involves a process of mutational changes in the active
site that increase catalysis but often decrease protein stability. This, in
turn, leads to the acquisition of secondary mutations that increase the
in vivo half life of the enzyme. The interactions between amino acid
substitutions and the resultant impact on the evolution of ESBL activities
will be discussed.
AmpC b-lactamases are highly efﬁcient for hydrolysis of many
cephalosporins, however, they exhibit lower activity towards extended-
spectrum cephalosporins. Nevertheless, AmpC mediated resistance to
extended-spectrum cephalosporins can occur due to high levels of
enzyme production or through mutations in the enzyme that result in
increased hydrolysis of the drugs. Several amino acid substitutions as
well as small insertions and deletions in AmpC enzymes have been
reported to increase resistance to extended spectrum cephalosporins and
have been associated with increased hydrolysis of these antibiotics. The
mutational changes occur in regions in the vicinity of the active site and
may act by increasing access for the bulky oxyiminocephalosporins. In
addition, random mutagenesis experiments have revealed positions where
amino acid substitutions alter the substrate speciﬁcity of the enzyme. The
impact of amino acid substitutions on the evolution of extended spectrum
cephalosporin hydrolysis by AmpC enzymes will be discussed.
Non-tuberculous mycobacterial infections
S275 Non-tuberculous mycobacterial pulmonary infections
E. Tortoli ° (Florence, IT)
The lung can be easily affected by inhalation of aerosolized mycobacteria
and is by far the most frequent site of human mycobacteriosis.
In HIV-negative patients, the disease is undistinguishable from
tuberculosis and is characterized by very slow progression. The
manifestations range from absence of symptoms to cavitary disease,
and X-ray may reveal ﬁbrosis, upper lobe cavitation, nodular or
parenchymal opacity, and pleural thickening. The most affected are
elderly patients with predisposing pulmonary conditions (e.g. silicosis,
obstructive pulmonary disease, pneumoconiosis, previous tuberculosis,
bronchiectasis or cancer). The symptoms include cough, fever, weight
loss, weakness and respiratory insufﬁciency. The NTM most frequently
responsible for disease belong to the Mycobacterium avium complex; in
Europe, infections caused by Mycobacterium xenopi and, particularly in
northern countries, those caused by Mycobacterium malmoense are also
quite frequent whereas, in the USA, infections caused by Mycobacterium
kansasii are more prevalent.
In AIDS patients the radiographic picture is often normal or may reveal
mediastinal or hilar adenopathy, and the progression of disease is very
rapid. The most frequent symptoms are cough, fever and weight loss.
The patients have usually a CD4 lymphocyte count lower than 100/mL.
In recent years, the widespread use of highly active anti-retroviral
treatments has dramatically reduced the frequency of mycobacterial
diseases, including the pulmonary ones, in HIV-positive patients.
Recently pulmonary infections due to NTM have increasingly been
reported in patients with cystic ﬁbrosis.
Because of the high risk of contamination of the sputum by
environmental mycobacteria, it is estimated that less than 30% of the
isolations of NTM from the respiratory tract have clinical relevance.
The strict observance of the criteria of the American Thoracic Society
is essential for a correct diagnosis.
S276 Buruli ulcer disease: epidemiology, clinical manifestations,
diagnosis, treatment
F. Portaels °, D. Walsh, W. Meyers (Antwerp, BE; Bangkok, TH;
Washington, US)
Buruli ulcer (BU), caused by Mycobacterium ulcerans is the third
most common human mycobacteriosis worldwide after tuberculosis and
leprosy.
BU is endemic in rural wetlands of tropical countries of Africa, America,
Asia and Australia but remains uncommon in non-African countries.
A few cases have been reported in non-tropical areas. Incidence rates
vary greatly by continent, country, and in areas within a country. Known
incidence rates currently are highest in West Africa.
Children 15 years old or younger account for approximately 75% of
cases. Risk factors include tropical climate, exposure to stagnant water,
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unprotected water sources, hygiene, trauma to skin and HIV infection.
M. ulcerans disease presents a spectrum of forms related partly to patient
delay in admission to hospital. Estimated incubation periods range from
2 weeks to several years.
The nonulcerative forms represent the ﬁrst stages of the disease. Early
stages are often ignored by the patients and may sometimes heal
spontaneously.
The clinical diagnosis can be difﬁcult even for experienced health
professionals, hence the importance of microbiologic conﬁrmation.
Four laboratory tests are currently in use:
1. Direct smear of exudates from ulcerated lesions in situ, or ﬁne needle
aspirates (FNA) from nonulcerated lesions, or biopsy specimens
2. In vitro cultivation of M. ulcerans from exudates, FNA or biopsies.
3. Gel-based or quantitative real-time PCR targeting IS2404.
4. Histopathologic examination (important in both BU diagnosis and
differential diagnosis).
Numerous other infectious and noninfectious diseases and neoplasms are
diagnosed among clinically suspected cases of BU. Tropical phagedenic
ulcer is the most common diagnostic problem.
Options for therapy for BU are surgery, antibiotics, or combinations of
both. Antibiotic therapy for all forms is gaining acceptance. The World
Health Organization (WHO) recommends, if not contraindicated, the
directly observed use of at least an 8-week course of oral rifampin and
streptomycin by intramuscular injection. This antibiotic treatment may
also be combined with surgery. Other antibiotic regimens, especially
those administered completely orally, are under evaluation.
Severe ZN positive lesions (large ulcers and disseminated forms) should
receive speciﬁc antibiotherapy and should be surgically treated without
delay to avoid deterioration of lesions and possible bone dissemination.
S277 Non-tuberculous mycobacterial infections related to cosmetic
and medical procedures and acupuncture
A. Carbonne °, F. Brossier, I. Arnaud, I. Bougmiza, E. Cambau,
J.P. Meningaud, V. Jarlier, E. Caumes, P. Astagneau (Paris, FR)
Objectives: Mesotherapy is an increasing used technique involving
subcutaneous injections of minute quantity of various medical drugs for
cosmetic or rheumatism purposes. This practice was already reported to
be related to infection risk.
In January 2007, a general practitioner notiﬁed to the health authorities
and the regional centre for infection control a cluster of subcutaneous
infections due to non-tuberculosis Mycobacteria (NTM) following
mesotherapy. An epidemiological investigation was performed to
describe the outbreak, to identify the source and the mechanism of
contamination and to determine risk factors.
Methods: The case deﬁnition was based on typical clinical subcutaneous
lesion associated with positive specimens for NTM. An assessment
practice study was performed to determine potential risk factors to
be tested in a comparative epidemiological study. Data were collected
including schedules of outpatient visits, localisation of injections, and
type of injected products. Tap water of the medical examination room
was sampled for search of Mycobacteria. Mycobacterium chelonae
strains were compared using Pulsed Field Gel Electrophoresis (PFGE).
Results: Overall, 16 cases were identiﬁed among 105 outpatients (attack
rate: 15.2%), including 11 positive for Mycobacterium chelonae and
2 for M. fredericbergensen. M. chelonae was found in the tap water.
Assessment practice study identiﬁed inappropriate cleaning and rinsing
of the multiple injection device (automatic repetitive machine) using tap
water which was likely to be the source of NTM contamination. Indeed,
PFGE M. chelonae strains patterns were similar between patients and tap
water samples. In the univariate analysis, NTM infection incidence rate
was higher in patients having Monday or Thursday visits, being at the 2nd
rank during the session, having cosmetic purpose for weight loss or more
injections on abdomen, upper leg or hip. In the multivariate analysis,
being at the 2nd rank during the session(Odds ratio = 3.1 [1.0−9.6]) and
having a higher rate of visits on Monday or Thursday (Odds ratio = 9.7
[1.2–77.8]) remained the only independent risk factors of NTM infection.
Conclusion: This investigation highlights that failure in disinfection of
injecting material could generate severe infections with highly resistant
bacteria related to non regular medical cares. Efforts should focus on
control of hygiene practices in non hospital settings based on appropriate
guideline recommendations.
S278 Management of non-tuberculous mycobacterial lymphadenitis
in children
J. Amir ° (Petah Tiqwa, IL)
The spectrum of clinical manifestations caused by nontuberculous
mycobacteria (NTM) in immunocompetent individuals comprises three
major categories: lymphadenitis, pulmonary infections and skin/soft tis-
sue infections. Lymphadenitis due to NTM strikes mainly young children
whereas pulmonary and skin/soft tissue infections are common in adults.
The frequency of NTM lymphadenitis has increased over the past few
decades. Diagnosis is based on clinical presentation, PPD skin test and
bacterial isolation from nodal aspiration or incision. Mycobacterium
scrofulaceum was the most common cause in the 1970s, replaced by
M. avium-intracellulare complex (MAC) andM. haemophilum in last two
decades. Management options are surgery, antibiotics or “observation
only”. Complete excision of the infected lymph node has been considered
the optimal therapy by most researchers, however, it is associated with
various side effects such as unacceptable scarring with or without keloid
formation, wound breakdown, secondary staphylococcal infection and
facial nerve paresis. Most facial nerve damage is transient, although in
approximately 2% permanent palsy developed. Incision and drainage is
performed when the lesions are too large to be excised. Few retrospective
case series have demonstrated superiority of complete excision over
incision and drainage. Pharmacologic therapy with clarithromycin alone,
or combined with other antimycobacterial agents such as rifampicin,
rifabutin, or ethanbutol have been reported. On the other hand, there
are no controlled clinical trials showing the efﬁcacy of chemotherapy
versus placebo. Very few cases of “observation only” in children with
NTM lymphadenitis were reported in the past. A recently published
study described the natural history of 92 immunocompetent children
with cervical NTM lymphadenitis. In most cases, the skin over affected
lymph nodes underwent violaceous changes, with discharge of purulent
material for 3−8 weeks. Total resolution was achieved within 6 months
in 71% of the patients, and within 9−12 months in the remainder. No
complications were observed, and at 2 years follow-up, a skin-colored
ﬂat scar in the region of the drainage was noted.
In conclusion, The optimal therapy for this condition is still controversial.
Nevertheless, it seems that antibiotics are not very effective in treating
immunocompetent children. A randomized, controlled trial examining
surgical excision versus spontaneous healing is warranted.
Treatment and prophylaxis of malaria
S279 Why malaria prophylaxis sometimes fails?
V. Krcmery °, J. Sokolova, L. Seng Duong (Bratislava, Trnava, SK)
Reasons for antimalarial prophylaxis failure include:
i. poor adherence to antimalarial agents
ii. malabsorption of antimalarial drugs
iii. interactions with other medications
iv. adverse reaction leading to treatment interruptions
v. underdosing the patient
vi. in vitro resistance
In case of clinical failure standby treatment is recommended, if no health
infrastructure is available. Commonly used antimalarials for prophylaxis
in travelers include meﬂoquine or atovaquon-proguanil. In prophylaxis
failure therapy with artemisin based combination drugs (ACT) is
indicated. Special conditions exist for IPT (Intermittent Preventive
Treatment) in pregnant women in endemic areas and children. For long
term travelers/residents prophylaxis in hyperendemic areas is usually
ineffective.
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S282 Artemisinin resistance
H. Noedl ° (Vienna, AT)
Within the past 10 years virtually all malaria-endemic countries have
ofﬁcially adopted artemisinin-based combination therapies (ACTs) as
ﬁrst or second line therapy for the treatment of P. falciparum malaria.
Artemisinins have become the most essential class of antimalarials, their
impact comparable only to that of chloroquine in the mid 20th century.
Spreading artemisinin resistance could therefore have a devastating
impact on malaria control efforts throughout the malaria-endemic world.
In the current situation losing a single class of antimalarial drugs to
resistance may severely impact the ability of many countries to treat
falciparum malaria.
The concept of artemisinin resistance has been a contentious one for
many years, with some authorities suggesting that it was unlikely to
arise in the ﬁrst place. However, recent data indicate that the ﬁrst
cases of genuine artemisinin resistance have already emerged in western
Cambodia. We may already be losing artemisinins in selected parts of
the world.
Our data showing individual parasite isolates resistant to high doses of
artemisinins, prolonged parasite clearance times, and reduced in vitro
drug response indicate that this phenomenon is as yet limited to a
relatively small proportion of the parasite isolates and probably also
to a relatively small area in Southeast Asia.
Once it starts spreading, resistance to artemisinin derivatives, currently
the most essential antimalarial drugs, could very well be the most
devastating event in the history of malaria control in the 21st century.
Artemisinin-resistant malaria is a new emerging disease that will require
new treatment and control strategies to limit the impact and spread of
resistance to the rest of the malaria-endemic world.
Microbial colonization of respiratory tract:
does it always predict a nasty outcome?
S285 Clinical signiﬁcance of Pneumocystis colonization
A. Morris ° (Pittsburgh, US)
Pneumocystis pneumonia has long been recognized as a cause of
morbidity and mortality in immunocompromised populations, partic-
ularly those with human immunodeﬁciency virus (HIV) infection.
Pneumocystis colonization is deﬁned as detection of the organism or
its DNA without signs or symptoms of pneumonia. Sensitive molecular
techniques such as polymerase chain reaction are frequently utilized to
identify colonization. Accumulating evidence suggests that colonization
with Pneumocystis may be an important clinical phenomenon. The
clinical signiﬁcance of colonization is not yet fully understood, but it
may be important for several reasons. Colonized persons may be at risk
of developing Pneumocystis pneumonia. Even if colonized individuals do
not themselves develop Pneumocystis pneumonia, they might transmit
the organism to others. Exposure to Pneumocystis-colonized animals
leads to colonization of normal animals and to the development of
clinical disease in immunosuppressed animals. Colonization in persons
receiving long-term anti-Pneumocystis prophylaxis may also lead to the
development of mutations that have been associated with drug resistance.
Furthermore, Pneumocystis may play a role in progression of lung
diseases such as chronic obstructive pulmonary disease (COPD). The
presence of Pneumocystis in the lungs, even at low levels as seen in
colonization, produces inﬂammatory changes similar to those seen in
COPD, with increases in the numbers of neutrophils and cytotoxic CD8+
lymphocytes. Colonization with Pneumocystis has been demonstrated
in HIV-infected subjects, and HIV-infected smokers are particularly
susceptible to Pneumocystis colonization regardless of CD4 cell count
or use of Pneumocystis prophylaxis. Pneumocystis colonization is also
increased in non-HIV-infected patients with COPD and is directly related
to the severity of the disease. Models of Pneumocystis colonization
in mice with smoke exposure and in non-human primates infected
with an HIV/simian immunodeﬁciency virus chimera demonstrate the
development of COPD-like changes. These studies suggest that treatment
or prevention of Pneumocystis colonization in at-risk populations may
be a novel therapy for COPD.
Virus oncogenesis: mechanisms and clinical
aspects
S287 EBV-associated tumours
D.A. Thorley-Lawson ° (Boston, US)
Epstein–Barr virus is a human herpesvirus that is known to infect
and efﬁciently drive the activation and proliferation of resting B cells
in vitro. It achieves this through the expression of nine latent proteins.
However, in vivo EBV persists in a benign, dormant state in resting
memory B cells. The link between these two observations is that
in vivo EBV uses its latent proteins to activate newly infected cells
in lymphoid tissue so that the cells can then differentiate through
the germinal center to become resting memory cells. In doing so
the virus infected cells mimic the normal process whereby antigen
activated B cells become long term memory cells. At each stage of
the process EBV uses different combinations of latent proteins. If
at any stage the infected cell is unable to progress into the resting
memory state it is at risk of becoming a tumor expressing the pattern
of latent proteins characteristic of its particular stage of infection.
Thus EBV is associated with several human malignancies including
Burkitt’s lymphoma, Hodgkin’s disease, immunoblastic lymphoma,
nasopharyngeal carcinoma and gastric carcinoma. Each of these tumors
expresses a different pattern of latent proteins reﬂecting their origins
from speciﬁc stages of the viral life cycle. Recently it has been shown
that EBV also expresses ~40miRNAs in latently infected cells. miRNAs
are thought to play critical regulatory functions in normal and malignant
cells but the roles of the EBV miRNAs remain unclear. It is also unknown
if they are expressed in a tumor speciﬁc pattern like the latent proteins.
In this presentation I will:
1. Discuss the mechanism of how EBV establishes persistent infection
in memory B cells including recent evidence on how EBV usurps
the germinal center process to gain access to the memory B cell
compartment.
2. Detail how the model of EBV persistence explains the origin of the
EBV associated tumors especially the lymphomas.
3. Demonstrate tumor speciﬁc expression proﬁles of miRNAs and a
possible functional signiﬁcance of these expression patterns.
S290 Polyoma virus-associated tumours
J.M. Pipas ° (Pittsburgh, US)
Some polyomaviruses induce tumors in their natural hosts or in test
animals. Tumorigenesis by these viruses is effected by a number
of different mechanisms depending on the speciﬁc virus. Studies
with simian virus 40 have shown that this virus targets key cellular
regulatory proteins, in particular the tumor suppressors pRb and p53
to stimulate cell proliferation and to block cell death. Our laboratory
uses a combination of genetics, proteomics, gene expression arrays
and transgenic and knockout mice to understand how the action of
SV40 proteins on these cellular targets leads to tumorigenesis. This
talk will review this research and present a model for SV40-induced
transformation and tumorigenesis.
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Innate immunity to pathogens: from genes
to cells
O291 The role of staphylococcal Panton-Valentine leukocidin
during lung inﬂammation in vivo
A. Zivkovic °, O. Sharif, K. Stich, M. Biaggio, B. Doninger, I. Mesteri,
S. Knapp (Vienna, AT)
Objective: Panton-Valentine Leukocidin (PVL) positive Staphylococcus
aureus is an emerging pathogen associated with highly lethal necrotizing
pneumonia. PVL is a bi-component b-barrel pore-forming toxin that has
been shown to cause cell death in neutrophils. However, the precise
mechanisms leading to necrotizing pneumonia are not fully understood
and the role of PVL herein is controversial. We therefore aimed to
investigate the mechanism by which PVL might contribute to the
development of severe lung inﬂammation.
Methods: Recombinant PVL was generated and its cytotoxic properties
were veriﬁed by patch clamp and FACS. The inﬂammatory potential
of PVL was tested on alveolar macrophages using mciroarray proﬁling,
PCR and ELISA. Signaling pathways were investiagted using western
blots and electromobility shift assays. The in vivo role of PVl was then
studied in a murine pneumonitis model, in which lung tissue and lavage
ﬂuid was assessed for cell-inﬂux and cytokine/chemokine release.
Results: PVL rapidly induces pore formation and death of neutrophils.
In contrast, alveolar macrophages were found less sensitive to the toxic
effects and only succumbed after prolonged incubation. Microarray
assays performed 1 h after addition of PVL to alveolar macrophages
revealed the selective induction of 29 genes upon stimulation.
Bioinformatic analysis disclosed the upregulation of NFkB target genes.
These data were veriﬁed by PCR and on protein levels and suggest
that PVL selectively induces NFkB associated inﬂammation in vitro.
Inhibitor studies and gene reporter assays further conﬁrmed this ﬁnding.
Furthermore, PVL-induced lung inﬂammation in mice conﬁrmed the
inﬂammatory potential of PVL, as illustrated by a rapid inﬂux of
neutrophils and enhanced levels of pro-inﬂammatory cytokines and
chemokines within the pulmonary compartment.
Conclusions: Our data demonstrate that PVL, beside its pore-forming
properties on neutrophils, is able to strongly induce inﬂammation via
NFkB activation in alveolar macrophages, leading to pneumonitis in vivo.
O292 Serum IgG antibodies strongly augment lipoteichoic acid
induced immune activation in human peripheral blood
S. Sigel °, S. Bunk, D. Metzdorf, T. Hartung, S. Knapp, S. von Aulock
(Vienna, AT; Constance, DE)
Objective: Staphylococcus aureus (S. aureus) is an important human
pathogen that causes diverse diseases ranging from innocuous skin
infections to often fatal forms of sepsis. During the initial phase
of infection speciﬁc molecular patterns of S. aureus are recognized
by innate immune receptors of the host leading to the induction
of inﬂammatory responses. Among these patterns lipoteichoic acid
(LTA), a component of the Gram-positive cell wall, represents a potent
immunostimulatory molecule that is able to elicit cytokine release from
human peripheral blood in a TLR2/6 dependent manner. Since in contrast
to our data, LTA of a mutant S. aureus strain lacking lipoproteins
(delta lgt-LTA) has been described by other investigators to be
immunobiologically inactive, we investigated the functional requirements
for the delta lgt-LTA mediated activation of innate immune responses.
Methods: Using an ex vivo model based on human peripheral blood
cells the conditions and cofactors required for the recognition of delta
lgt-LTA by innate immune cells were investigated.
Results: In this study we demonstrate that delta lgt-LTA induced
immune activation critically depends on the immobilization of LTA
and the phagocytic activity of blood cells as well as the presence of
human serum components, which was also observed for LTA of the
respective wild type S. aureus (wt-LTA) albeit with a lower degree of
signiﬁcance. Under experimental conditions, conducive to optimal LTA
stimulation, we found no differences between the immunostimulatory
capacity of delta lgt LTA and wt-LTA arguing for a limited contribution
of possible lipoprotein contaminants to wt-LTA mediated immune
activation. Interestingly, we found that LTA speciﬁc IgG antibodies, here
detected in human sera at varying levels, can bind to immobilized delta
lgt-LTA and thereby strongly augment delta lgt-LTA mediated immune
activation in human peripheral blood.
Conclusion: Our results not only suggest a novel mechanism for delta
lgt-LTA mediated immune activation in human blood cells that involves
an opsonization-dependent uptake and recognition process of LTA but
also provide a conclusive explanation for the controversial ﬁndings
obtained in previous experiments comparing the immunostimulatory
capacity of delta lgt-LTA and wt-LTA.
O293 Hypoxia ampliﬁes inﬂammatory signalling in response to
Pseudomonas aeruginosa in pulmonary epithelial cells
B. Schaible °, C. Taylor, K. Schaffer (Dublin, IE)
Objectives: Cystic Fibrosis (CF) is an autosomal recessive disorder
with an incidence of 1 in 2500 in Caucasians. Pseudomonas aeruginosa
(P. aeruginosa) is the predominant bacterial pathogen in CF and grows
within a hypoxic bioﬁlm in the CF lung causing chronic infection and
associated inﬂammation. In this study we have investigated the effects
of hypoxia on the activity of the proinﬂammatory transcription factor
NF-kappaB in alveolar epithelial cells in response to stimulation with
P. aeruginosa.
Methods: A549 lung epithelial cells were incubated with heat inactivated
P. aeruginosa or speciﬁc TLR ligands (TLR2: Pam3CysSK4, TLR4:
LPS, TLR5: ﬂagellin) at 21% and 1% atmospheric oxygen. Activation
of NF-kappaB was determined by immunoblotting of nuclear of p65 (NF-
kappaB family member) and cytosolic Cox2 (target gene of NF-kappaB)
as well as by luciferase activity, wereby A549 cells were transfected with
a NRE-luciferase plasmid beforehand.
Results: Incubation of cells with heat inactivated P. aeruginosa clearly
increased nuclear p65 protein level and luciferase activity in a manner
that was profoundly ampliﬁed by either epithelial cell hypoxia or hypoxic
bacteria. Stimulation of innate immunity in alveolar epithelial cells is
largely mediated by three toll-like receptors (TLR2, TLR4 and TLR5).
Incubation of cells with toll-like receptor speciﬁc agonists, primarily
ﬂagellin for TLR5, increased NF-kappaB level in a manner which was
also ampliﬁed by hypoxia.
Conclusions: These data indicate that microenvironmental hypoxia is a
major determinant of the pulmonary epithelial inﬂammatory response
during P. aeruginosa infection. Further investigations of signaling
molecules participating in this response will reveal new targets for anti-
inﬂammatory therapy in Cystic Fibrosis.
This work is supported by grants from IRCSET Embark Initiative and
Science Foundation Ireland.
O294 Nalp3 and ASC are not required for caspase-1 mediated
antifungal host defence in disseminated candidiasis
F.L. van de Veerdonk ° (Nijmegen, NL)
Objectives: Contradictory data have been reported regarding the role
of the inﬂammasome in anti-Candida host defense. In order to address
these discrepancies, we investigated host defense against disseminated
candidiasis in knock-out mice defective in the various components of
the inﬂammasome.
Methods: Mice deﬁcient in caspase-1, ASC, Nalp3 or P2X7 were
infected intravenously with C. albicans. Survival, fungal outgrowth in the
organs, histology, and modulation of cytokine production were compared
in these mouse strains with the wild-type C57/Bl6 control mice. PBMCs
from healthy volunteers with or without reactive oxygen species (ROS)
inhibitor and PBMCs from patients with chronic granulomatous disease
(CGD) that are deﬁcient in ROS production were stimulated with
C. albicans.
Results: Caspase-1−/− mice and ASC−/− mice had a decreased survival
during disseminated candidiasis (50%) compared to the control mice
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(87%). Caspase-1−/− mice had a 100-fold increase in fungal loads in
the kidneys of the deﬁcient animals and showed preferential growth
of hyphae in the pyelum of the caspase-1−/− mice accompanied by
remarkbly little inﬂammation (Figure). In contrast, ASC−/− mice did
not have higher fungal loads, but they showed a signiﬁcantly stronger
inﬂammatory reaction in the kidneys. ASC−/−splenocytes showed a
higher TNF production after Candida stimulation. NLRP3−/− and
P2X7−/− did not display an increased susceptibility to disseminated
candidiasis. Local bioactive IL-1b and INFg in vivo was only affected in
the caspase-1−/− mice, but not in the ASC−/−, NLRP3−/− or P2X7−/−
animals. In addition, caspase-1 was constitutively active in ROS deﬁcient
monocytes and C. albicans induced IL-1b production was not reduced
in the absence of ROS.
Conclusions: Caspase-1-dependent processes are important in anti-
fungal host defense during Candida sepsis. In contrast to current
thinking, these process are not dependent on the inﬂammasome
components, ASC, NLRP3 and the ATP receptor P2X7. These data
conﬁrm previous studies in human monocytes showing that caspase-1
activation during Candida infection does not require pathogen-mediated
in ﬂammasome activation. ASC plays an important role in disseminated
candidiasis, but unexpectedly seems to have a different function in vivo,
speciﬁcally by regulating TNF production and local inﬂammation in
the organs. Finally, ROS did not play a critical role in inﬂammasome
activation and Candida-induced IL-1b production.
O295 Amphotericin B mediates killing in C. neoformans through
induction of oxidative burst rather than through pore
formation at the membrane
O. Zaragoza °, L. Scorzoni, F. Sangalli Leite, M.J. Gianinni,
J.L. Rodrı´guez-Tudela, M. Cuenca-Estrella (Majadahonda, Madrid,
ES; Araraquara, BR)
Objectives: Amphotericin B (AmB) is an antifungal drug widely used
for the treatment of fungal infections, such as cryptococcal meningitis,
which is caused by the encapsulated fungal pathogen Cryptococcus
neoformans. AmB binds to ergosterol and forms pores at the membrane,
resulting in cell death. However, other reports indicate that AmB also
acts as an oxidant. In this work we have studied the effect on AmB on
C. neoformans.
Methods: We have compared three viability methods: XTT assay,
prodium iodide staining, and colony forming units enumeration. XTT is
reduced in the mitochondria by living cells, producing a compound that
is quantiﬁed spetrophotometrically. Propidium iodide is a DNA-binding
ﬂuorescent compound that only penetrates in the cells once they lose the
membrane integrity. Finally, CFUs enumeration estimates the ability of
the cells to replicate and form viable colonies.
Results: While AmB inhibited the formation of colonies at concentra-
tions above 0.5−1mg/L, the cells did not become permeable to propidium
iodide in the same conditions, suggestin that AmB has other effects
on C. neoformans different than pore formation. When viability was
measured using the XTT assay, a correlation with the CFUs results was
observed, conﬁrming that AmB exerts its killing effect intracellularly.
However, we also observed a “paradoxical effect” in which cells treated
with high AmB concentrations (4−16mg/L) produced higher levels of
reduced XTT than cells treated with intermediate AmB concentrations
(0.25−1mg/L). Since this “paradoxical effect did not correlate with
CFUs appearance, we argued that it might reﬂect an induction of the
electron transfer in the mitochondria, as a consequence of an increased
oxidative burst induced by AmB. So we measured the amount of
reactive oxygen species (ROS) in the cells using dihydroﬂuorescein, a
compound that when is attacked by free radicals releases ﬂuorescence.
Our results demonstrated that AmB induced a strong release of ROS in
the cells, which correlates with the metabolic inactivation measured by
the XTT assay.
Conclusions: Although AmB can bind to ergosterol and produce pores
at the membrane, our results indicate that this antifungal drug induces
killing in C. neoformans mainly through an induction of a strong
oxidative burst. These ﬁndings conﬁrm that Am B has multiple effects on
the cells, which suggests an explanation for the low antifungal resistance
to this compound observed among clinical isolates.
O296 Characterization of class I-restricted epitopes of Trypanosoma
cruzi HSP70 protein recognized by Chagas’ disease patients
C. Maran˜o´n °, A. Egui Machado, B. Carrilero, M. Segovia, C. Thomas,
M.C. Lo´pez (Armilla, Murcia, ES)
Objectives: The protozoan parasite Trypanosoma cruzi is the aetiological
agent of Chagas disease or American trypanosomiasis, which affect
near 20 million people with severe consequences in terms of morbidity
and mortality. The host’s ability to generate a parasite-speciﬁc immune
response plays an essential role in the control of the evolution and the
severity of the disease. In particular, efﬁcient CD8+ T cell responses are
required for the immune control of the infection. Heat shock proteins
have been characterized as immunodominant CD8+ antigens in several
bacterial infections and tumours, but not still in parasitic diseases. The
aim of this work is to know whether T. cruzi HSP70 is processed and
presented to CD8+ T lymphocytes during natural infection.
Methods: Peptides containing HLA-A*0201-binding motifs were
selected using bioinformatics, and their binding afﬁnity were evaluated
using T2-binding assays. HSP70-immunized or T. cruzi infected C57BL-
A2/Kb transgenic mice were used to predict immunodominant epitopes
within the protein by cytotoxicity assays. The recognition of candidate
peptides by circulating lymphocytes from chagasic patients were assessed
through IFN-g secretion tests.
Results: Thirty peptides were selected as putative HLA-A*0201 binders
and synthesized. Of these, 16 candidates were selected and their
recognition was tested by splenocytes of C57BL-A2/Kb mice immunized
with HSP70 protein or, alternatively chronically infected with T. cruzi.
No signiﬁcative peptide recognition was observed in non-infected or non-
immunized animals, and two peptides were signiﬁcatively recognized by
both immunized and infected mice. When the recognition of these two
peptides by circulating lymphocytes of chagasic patients was tested by
IFN-g secretion assays, both peptides were well recognized by chagasic
patients in different stages of the disease.
Conclusion: The data above demonstrate that T. cruzi HSP70 is an
immunodominant CD8+ epitope, which is naturally processed and
presented during Chagas disease progression. CD8+ T cell response
against microbial HSP70 has been shown to be protective in other
infections like tuberculosis. Since currently no vaccine against Chagas
disease is available, the characterization of new parasite antigens
providing protective responses will be of great value in order to ﬁght
against T. cruzi infection.
O297 Differential induction of in vitro CD4+/CD8+ T-cell
responses by live vs. killed Leishmania major
M. Nateghi Rostami °, A. Khamesipour, A. Miramin Mohammadi,
E. Eskandari, A. Sarraf-Nejad, H. Keshavarz (Tehran, IR)
Objectives: Different clinical trials of killed Leishmania vaccines
showed a limited efﬁcacy compared to inoculation of live Leishmania
major (leishmanization=LZ) against cutaneous leishmaniasis (CL). The
reason for the discrepancy in efﬁcacy of live and killed vaccines is not yet
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known, in vivo and in vitro studies on T-cell function against live/killed
stimulatory effect might provide valuable information.
Methods: Nine leishmanin skin test (LST) positive donors with history
of self healing CL (HCL) and seven healthy LST negative donors
were included in this study. CD4+/CD8+/CD14+ cells were isolated
from peripheral blood. 5,6-carboxyﬂuoescein diacetate succinimidyl
ester (CFSE) labeled CD4+ or CD8+ lymphocytes were cultured in
the presence of 1:10 of mitomycin treated autologous monocytes
and 100 micro g/ml killed Leishmania lysate (KLL) or 2.5×105/ml
live Leishmania major (LLM). Cells were harvested after 7 days of
incubation at 37ºC and analysed for proliferation using ﬂow cytometry.
Culture supernatants were collected on day 3 for IL-5, IL-10, IL-13 and
IFN-g titration using sandwich ELISA method.
Results: In HCL volunteers, upon stimulation with KLL, the number of
proliferated CD4+ or CD8+ T cells (at division 4) was signiﬁcantly more
than unstimulated cells (P< 0.001) or LLM stimulated cells (P< 0.05)
or cells from controls (P< 0.05 for CD4+ and P< 0.001 for CD8+ cells).
Cells from HCL donors showed a signiﬁcantly higher IL-10 production
to LLM stimulation compared with KLL stimulation (P< 0.001 for
CD4+ and P< 0.0005 for CD8+ cells) or comparing controls (P< 0.05
for CD4+ and P< 0.001 for CD8+ cells). Stimulation of CD4+ T
cells with LLM (P< 0.001) or KLL (P< 0.05) induced a signiﬁcantly
higher IFN-g production compared to cells from controls, but LLM
induced signiﬁcantly more IFN-g than KLL (P< 0.05). On the CD8+
compartment, a signiﬁcantly higher IFN-g production was observed
when the cells were stimulated with LLM (P< 0.05).
Conclusion: While killed Leishmania induced more proliferation
response in puriﬁed T cells of HCL volunteers, live Leishmania
induced cytokine production in T cells without a signiﬁcant induction
of proliferation. The results from healed CL volunteers in this study
might be implicated in further investigations on T-cell function against
live/killed Leishmania vaccination in vivo.
O298 Genetic variants of dectin-1 and susceptibility to infections
with Candida spp.
T.S. Plantinga °, M.D. Johnson, W. van der Velden, D. Rosentul,
E.J. Giamarellos-Bourboulis, B. Ferwerda, P.B. Smith, B.D. Alexander,
L.A. Joosten, J. van der Meer, P. Donnelly, J.R. Perfect, N. Blijlevens,
B.J. Kullberg, M.G. Netea (Nijmegen, NL; Durham, US; Athens, GR)
Objectives: Systemic and oropharyngeal candidiasis represent a cause
of high morbidity especially in immunocompromised hosts, with risk
varying signiﬁcantly between individuals. Recognition of Candida
albicans is mediated through pattern recognition receptors such as the
b-glucan receptor dectin-1. We recently identiﬁed an early stopcodon
single nucleotide polymorphism (SNP) Y238X in dectin-1 that is
associated with the loss of b-glucan recognition (N Engl J Med.
2009;361:1760−7).
Methods:We assessed whether the presence of the dectin-1 Y238X SNP
was associated with an increased susceptibility to Candida infections
in several clinical settings: i. in 365 American and Dutch patients
with candidaemia compared to 351 non-infected American and Dutch
controls; ii. in 142 Dutch patients undergoing haematopoietic stem cell
transplantation (HSCT); and iii. in 170 Greek HIV-infected patients.
Results: Dectin-1 Y238X SNP was strongly correlated with Candida
colonization in HSCT patients: 34% of the individuals bearing the wild-
type allele were colonized with Candida, compared to 85% of the
individuals bearing the mutant allele (p< 0.005), necessitating more
frequent use of ﬂuconazole treatment (p< 0.01). Functional assays
demonstrated a loss-of-function phenotype of the SNP, as shown by
the decreased cytokine production by immune cells bearing this SNP.
In contrast, the dectin-1 Y238X SNP did not inﬂuence susceptibility
to candidaemia or that of oropharyngeal candidiasis in HIV-infected
patients.
Conclusions: The dectin-1 Y238X SNP is non-redundant for the
recognition of C. albicans, and inﬂuences mucosal Candida colonization.
In contrast, lack of functional dectin-1 is not accompanied by an
increased susceptibility to bloodstream Candida infections.
O299 Single nucleotide polymorphisms in the PTX3 gene do not
affect susceptibility to meningococcal disease but inﬂuence
plasma concentrations during meningococcal septic shock
T. Sprong °, E. Barbati, B. Bottazzi, A. Mantovani, L.B. Joosten, J. van
der Meer, M.G. Netea, M. van Deuren (Nijmegen, NL; Rozzano, IT)
Objectives: Meningococcal disease is an important cause of morbidity
and mortality world-wide. Pentraxin 3 (PTX3) is an important element
of the innate immune system. Experimentally, PTX3 binds meningococci
and activates complement and PTX3 is elevated in meningococcal
septic shock. This prompted us to evaluate the relevance of single
nucleotide polymorphisms (SNPs) in the gene for PTX3 in relation
to susceptibility to meningococcal disease, disease manifestation and
plasma concentrations of PTX3 during septic shock.
Methods: We studied a sample of 115 case-parent triads and
153 individual patients that had been admitted to the ICU with
meningococcal disease. From 21 patients PTX3 plasmaconcentrations
during meningococcal disease were determined using ELISA. PTX3
SNPs rs2305619 and rs3816527 were analysed using PCR.
Results: Minor allele frequencies were 0.468 (G) for rs2305619 and
0.451 (C) for rs3816527. Allele frequencies did not differ signiﬁcantly
from Hardy-Weinberg equilibrium. The SNPs rs2305619 and rs3816527
are in linkage disequilibrium.
TDT analysis showed no association of the SNPs rs2305619 and
rs3816527 in the gene for PTX3 with meningococcal disease. Also no
preferential transmission of these SNPs was found in the subgroups of
patients with meningitis, shock, shock and meningitis or bacteraemia.
Patients with meningitis had a somewhat higher prevalence of the
A allele in rs2305619 and the C allele in rs3816527, but this was
not signiﬁcant. In addition, no differences were found for number of
days spent in ICU or disease severity. During active meningococcal
infection, in patients with meningococcal septic shock, peak plasma
concentration of pentraxin 3 appeared to be dependent on PTX3
genotype. Patients homozygous for the A allele in rs2305619 had higher
peak plasma concentrations of PTX3 than other individuals (P = 0.05).
Instead, patients homozygous for the A allele in rs3816527, had lower
peak plasma concentrations than AC and CC individuals, this approached
signiﬁcance (P = 0.09) (Figure 1).
Conclusions: These ﬁndings indicate that in patients with septic shock
PTX3 plasmaconcentrations are in part dependent on PTX3 genotype for
the rs2305619 and rs3816527, but these SNPs do not affect susceptibility
to meningococcal disease.
Figure 1. Pentraxin 3 peak plasma concentrations during meningococcal
septic shock according to PTX3 genotype. Medians and interquartile
ranges are presented. P value by Mann–Whitney test.
O300 Mannose-binding lectin and tuberculosis infection: a
meta-analysis
J.T. Denholm, E.S. McBryde, D.P. Eisen ° (Parkville, AU)
Objective: Resistance to tuberculosis has been proposed as a mechanism
for selection for high rates of mannose-binding lectin (MBL) deﬁciency.
Mechanistically, low levels of this pattern recognition receptor may
lead to relatively lower degrees of phagocytosis of Mycobacterium
tuberculosis and protect against TB however evidence to date has been
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conﬂicting. We aimed to systematically review published literature on the
effect of MBL2 genotype and/or MBL levels in tuberculosis infection,
and perform meta-analysis considering its effect on susceptibility to
infection.
Methods: We performed a systematic literature review of Medline and
PubMed from 1966 to August 2009 to identify articles considering the
effect of MBL2 genotype and/or MBL levels on tuberculosis infection.
All human trials that included subjects with conﬁrmed tuberculosis
and either MBL serum levels or MBL2 genotypes were selected and
included in meta-analysis. The frequency of MBL2 structural gene
variants, referred to collectively as ‘O’ (wild type = ‘A’) was extracted
from the published data in each paper. While out of keeping with
contemporary knowledge, in this retrospective meta-analysis we have
had to deﬁne MBL deﬁcient genotypes as A/O or O/O. To consider
evidence of publication bias, we prepared funnel plots of the studies
included in the ﬁnal analysis. c2 tests were performed to assess the
degree of heterogeneity between trials, and both ﬁxed and random-effects
metaregression models ﬁtted.
Results: 17 trials relevant trials were identiﬁed. 13 studies, containing
a total of 1802 patients and 2199 controls, contained sufﬁcient data for
inclusion in meta-analysis of MBL2 genotype and tuberculosis infection.
Separate analyses were performed for HIV-positive and negative patients.
Overall, no signiﬁcant association could be demonstrated between MBL2
genotype and tuberculosis infection (OR for AA v AO/OO 0.95, 95%CI
0.77–1.17). 5 studies, containing a total of 436 patients with active
tuberculosis and 603 controls, had sufﬁcient data regarding serum MBL
levels. In these studies, serum MBL levels were shown to be consistently
elevated in the setting of tuberculosis infection, to a degree consistent
with the acute phase reaction.
Conclusions: This analysis suggests that neither MBL2 genotype nor
MBL serum levels signiﬁcantly affect susceptibility to tuberculosis
infection.
Serious Gram-positive infections: the need
for new treatment options (Symposium
supported by Astellas)
S301-S304 Serious Gram-positive infections: the need for new
treatment options
J. Garau, A. MacGowan, D. Nathwani, M. Niederman (Barcelona,
ES; Bristol, Dundee, UK; Mineola, US)
Serious Gram-positive infections are becoming increasingly difﬁcult
to treat because of the escalating incidence of multidrug-resistant
pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA).
In order to improve clinical outcomes and to select the most
appropriate therapy, it is essential to consider pharmacokinetic (PK) and
pharmacodynamic (PD) parameters, such as PD targets and their relation
to dosing and the use of PK parameters as measures of exposure. In
addition, AUC/MIC ratios should be used to predict clinical efﬁcacy,
and the relationship between MICs and dosing requirements should be
considered.
In patients with suspected multidrug-resistant infections, prompt
initiation of appropriate therapy is an important determinant of mortality.
In some European hospitals MRSA strains account for >40% of all
S. aureus isolates so it is crucial that the chosen therapy provides
appropriate coverage for MRSA. Current treatment guidelines for serious
Gram-positive infections, such as hospital-acquired pneumonia (HAP)
and complicated skin and soft tissue infections (cSSTIs), recommend
the use of vancomycin or linezolid for infections caused by MRSA.
However, the role of these agents in the treatment of serious Gram-
positive infections is still uncertain and there is currently an unmet need
for additional agents that are effective against serious Gram-positive
infections caused by both methicillin-susceptible S. aureus (MSSA) and
MRSA.
Telavancin is a rapidly bactericidal lipoglycopeptide with a novel dual
mode of action and a broad spectrum of activity against clinically
important Gram-positive pathogens, including MRSA. In phase 3 trials,
telavancin has demonstrated non-inferiority compared with vancomycin
for the treatment of cSSTIs and HAP (including ventilator-associated
pneumonia) caused by Gram-positive pathogens, including MSSA and
MRSA. These results suggest that telavancin would be a promising
addition to current therapeutic options in the management of serious
Gram-positive infections caused by MSSA and MRSA.
The medical and public health impact
of rapid molecular testing (Symposium
supported by Cepheid)
S308-S311 The medical and public health impact of rapid
molecular testing
M. Ieven, D. Goff, N. El Helali, J. Kluytmans (Antwerp, BE; Columbus,
US; Paris, FR; Breda, NL)
Despite notable advances in recent years, molecular diagnostics
applications for infectious disease detection have yet to reach their full
potential. Often performed in specialized laboratories far removed from
where patient care decisions are made, specimens usually spend more
time in transit than in actually being analyzed, and once samples do
arrive in the lab, further delays are incurred by obligatory dependence
on batch processing.
The chief limitations of current molecular diagnostic approaches are not
due to the underlying technology, but rather in how this technology
is implemented. Real-time PCR is perfectly capable of generating
results within a few minutes. However, the processes leading up to the
analytical steps are often unwieldy and performed in batches within
a high-complexity laboratory environment. Moreover, the requirement
for complex procedures ties the availability of molecular diagnostic test
results with the limited availability of highly trained personnel.
In many cases, medical value of a diagnostic result is tied directly to how
quickly results can be linked to patient management and/or treatment
decisions. Fortunately, technologies for nucleic acid detection are now
evolving in the direction of modern clinical chemistry analyzers, the
most successful of which allow for random access, high throughput,
and STAT testing capability. In addition, by virtue of the simplicity
afforded by integrated, automated sample processing, the technology is
fully capable of being decentralized in order to minimize the impact
of sample transport on turnaround time. This symposium will focus
on the “need for speed” in driving maximum medical impact for four
different areas relevant to molecular diagnostics − respiratory infections,
group B strep prophylaxis, blood cultures positive for staphylococci, and
pre-surgical prophylaxis.
Current and future management of fungal
infections (Symposium supported by Pﬁzer)
S312 Recent results with voriconazole prophylaxis
C. Kibbler ° (London, UK)
Objectives: Despite increasing understanding, the treatment and
prevention of invasive fungal infections (IFIs) remains a major challenge.
IFI is an important cause of complications and mortality among
hospitalised patients, especially among immunocompromised patients
in the haematology setting. The potential of voriconazole (VORI) as
primary and secondary prophylaxis for IFI has recently been evaluated in
clinical trials in patients with haematological disease having undergone
allogeneic transplantation.
Methods: In the primary prophylaxis study IMPROVIT (A), patients
12 years were randomised to receive oral VORI or oral itraconazole
(ITRA) from the day of transplantation, for 100–180 days; the primary
composite endpoint was success of prophylaxis at Day 180 (i.e. survival
without developing proven/probable IFI or discontinuing prophylaxis for
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>14 days during the ﬁrst 100 days). In the secondary prophylaxis study
VOSIFI (B), patients 18 years with proven/probable IFI in the previous
12 months received VORI 4mg/kg/12 hours IV or 200mg/12 hours PO
within 48 hours post-conditioning chemotherapy, for 100–150 days; the
primary endpoint was the incidence of proven/probable IFI during the
subsequent 12 months.
Results: In A, the success of prophylaxis was signiﬁcantly higher in
the VORI group (n = 234) compared with the ITRA group (n = 255) at
Days 100 (55% vs 41%; 95%CI: 6%, 24%; p = 0.0007) and 180 (49% vs
35%; 95%CI: 7%, 24%; p = 0.0004). Signiﬁcantly more patients treated
with VORI than ITRA (54% vs 40%; p = 0.0014) had sufﬁcient days
of prophylaxis (median: 97 vs 68 days). While the incidence of IFI
was low in both arms (VORI: 1.3%, ITRA: 2.4%), 3 patients receiving
ITRA developed IFI compared with none on treatment with VORI.
In B (n = 42), 3 cases of IFI occurred: 1 recurrent Candida albicans
candidaemia, 1 recurrent Scedosporium proliﬁcans fungaemia (fatal)
and 1 new case of zygomycosis, at Day 3, 16, and 66 after transplant,
respectively (incidence: 7%). The most common VORI-related adverse
events were hepatotoxicity, nausea, headache and hallucinations/visual
impairment (<15%). In A, there was no difference in 180-day survival
(85% in each treatment group); in B, 11 patients (24%) died (median:
136 days post-transplant) but only 1 from IFI.
Conclusion: Based on the results of these prophylaxis studies, VORI is
an effective and safe option for both primary and secondary prevention
of IFI after allogeneic transplantation.
Microorganisms as human carcinogens: a list
without an end
K317 Micro-organisms as human carcinogens: a list without an end
L. Gissmann ° (Heidelberg, DE)
The current estimation of the cancer cases that are related to infectious
events varies between 18 and 20% and there is evidence that this
number is still growing. Besides Helicobacter pylori and some parasites
there are mostly viruses for which a causative relation to malignant
diseases has been demonstrated. Establishing such a link depends on the
epidemiologic proﬁle of the disease and the putative causal infectious
agent as well as its biologic properties in experimental cell culture and
in vivo models. Often one of the classical Koch’s postulates (isolation
of the putative agent from the affected tissue) cannot be fulﬁlled and, in
some instances, not even traces of the microbe (i.e. its nucleic acid) can
consistently be found in the tumor. The reason might be that cancer is
the late and rare consequence of a chronic infection where replication of
the infectious agent does no longer take place and gene functions are not
required for maintenance of the tumor growth. Therefore a combination
of observational and experimental strategies has to be applied to collect
sufﬁcient evidence and to initiate attempts for preventive measures that
target the infectious agent such as development of vaccines. Examples
of classical and innovative approaches will be presented.
Reporting b-lactam susceptibility tests on
Enterobacteriaceae
S318 Pro − report in accordance with test results
J. Turnidge ° (North Adelaide, AU)
The emergence of extended-spectrum b-lactamases (ESBLs) in En-
terobacteriaceae (ENTB) in the 1980s began to alter the laboratory
approach to b-lactamase detection in Enterobacteriaceae. Prior to that
time, results for b-lactams were reported according to the test result,
and speciﬁc detection of acquired narrow spectrum b-lactamases such
as TEM-1 was not sought. With the arrival of ESBLs, detection and
conﬁrmation was considered very important, and the default position
arose that the presence of an ESBL in a test clinical strain, whatever the
MIC of the organism, required the reporting of the organism as resistant
to cephalosporins of all types. Many susceptibility testing methods
recommended the use of ESBL screening and conﬁrmation tests on a
routine basis. However, a number of issues have emerged routine use
over the years:
1. The problem of deﬁning an adequate number of substrates to ensure
sufﬁciently sensitive screening.
2. The lack of simple and reliable phenotypic methods to detect ESBLs
in species with inducible AmpC b-lactamases.
3. The failure of current ESBL detection methods to provide advice
on the interpretation of a positive screening test but a negative
conﬁrmation test, especially if the isolates are “susceptible”
to extended-spectrum cephalosporins using method-recommended
breakpoints.
4. Animal model data showing that the response to treatment of ENTB
(measured as in vivo killing) is correlated with the MIC of the strain,
and not the presence or absence of an ESBL.
A range of recent studies has suggested that failures of treatment
with extended-spectrum cephalosporins are likely when strains of
ENTB have MICs elevated above the wild-type. Further, application
of pharmacokinetic/pharmacodynamic principles to the most widely
recommended dosing schedules of cephalosporins have shown that the
susceptibility breakpoints recommended by many methods have been too
high. Lower breakpoints for injectable cephalosporins are now published
by CLSI and EUCAST, with recommendations to optionally conduct
speciﬁc ESBL tests, for instance if there is an epidemiological need.
These newer cephalosporin breakpoints put us in a position where almost
all ESBL-producing and plasmid-borne AmpC-producing ENTB will be
detected and reported as I or R with the new breakpoints, and speciﬁc
b-lactamase testing will not be required. This is appropriate for clinical
reports whose major purpose is to guide therapy in individual patients.
S319 Con − report in accordance with resistance mechanism
D. Livermore ° (London, UK)
It is argued that treatment outcomes, e.g. for ESBL producers, can
be predicted from MICs, irrespective of the resistance mechanism.
Proponents of this view contend that it is unnecessary for clinical
laboratories to edit susceptibility data on the basis of resistance
mechanisms and that these should only be sought, if at all, for purposes
of epidemiological surveillance.
Several outcome studies support this view (though others do not) and
it would have great merit in a perfect world where routine MICs
were rapidly and precisely determined for clinical isolates. The reality
is very different. MICs, if measured at all in clinical laboratories,
are determined, late, on a geometrical scale with four-fold run-to-run
variation tolerated for control strains. Often zone diameters are used as
a proxy for MICs and, as anyone who has ever run a multicentre disc-
based survey discovers, these are prone to disturbingly wide site-to-site
variation. In this imperfect reality an ESBL producer with a cefotaxime
MIC of 1mg/L (probably responsive to cefotaxime in vivo) cannot
be reliably distinguished from one with an MIC of 4mg/L (probably
not responsive) and it is simpler and safer to follow the precautionary
approach of seeking the ESBL and, if this is found, reporting the isolate
as resistant.
A further advantage of seeking mechanisms is that − using selective
primary culture media or chromogenic tests − they can be found by 24-h
post specimen, as against 48-h for a precise MIC. This differential, which
is only likely to increase with the coming of molecular methods to detect
resistance mechanisms, may be critical, allowing the association between
early effective therapy and reduced mortality in severely-ill patients.
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Antiretroviral therapy
O324 Longitudinal evaluation of lipoprotein-associated
phospholipase A2 as a cardiovascular disease-associated
biomarker in relation to abacavir therapy
J. Parra-Ruiz °, A. Pena-Monje, C. Tomas-Jimenez, V. Guillot, M. Alvarez,
J. Lopez-Bueno, F. Garcia-Garcia, J. Hernandez-Quero (Granada, ES)
Objectives: As there exists still some concern about the potential
relationship of Abacavir (ABC) and myocardial infarction (MI), and
some authors has postulated that the increase in the risk of MI
might be caused because of pro-inﬂammatory state, as increase and
decrease of the risk follows quickly the start and resume of ABC, we
decided to longitudinally evaluate Lipoprotein-associated phospholipase
A2 (Lp-PLA2), a widely accepted marker of vascular inﬂammation and
cardiovascular disease during ABC therapy in HIV patients due the lack
of accuracy of other markers as IL6, IL8, hs-CRP or TNFalfa.
Methods: Eleven consecutive HIV-positive patients starting ABC-
containing HAART were sampled at 0, 6 and 12 months after the start
of ABC. Eleven HIV-positive patients on ABC sparing HAART were
individually matched for other potential cardiovascular disease markers
as hypertension, sex, age, smoking status, cholesterol and diabetes, and
were sampled as controls.
Results: There were 4 women and 7 men in the cases matched against the
same proportion of males/females. Median age was 42 years old (32−54)
and 42 (30−54) for men in cases and control, respectively and 40 (35−46)
and 40 (33−46) for women in cases and controls respectively. Results
are depicted in Table 1. Values of LpPLA2 are expressed in ng/mL.
Mean values for every patient at any given time point were higher than
clinical cut points established in 2006 (low risk Lp-PLA2 <200 ng/mL).
Interestingly, there was an increase in mean LpPLA2 in all four groups 6
months after the change in HAART, followed by a decrease. At 6 months
there were no differences in men regarding ABC, but at 12 months there
were an increase in men taking ABC whereas there were a decrease in
men without ABC (p = 0.02). Women did not show any differences.
Conclusion: There is an increase in Lp-PLA2 during therapy with ABC
in men, but because there were no MI during the one year follow-up
among the two groups, the mean Lp-PLA2 values are more than 3 times
higher than clinical cut points and Lp-PLA2 seems to exhibit a “risk
threshold” we cannot rely on LpPLA2 as a cardiovascular marker in our
population.
Mean (range)
Start 6 months 12 months
Men
ABC 614.41 (483.1–812.3) 702.9 (582.3–860.9) 669.92 (497.3–835.94)
No ABC 653.74 (517.3–778.1) 693.6 (615.2–769.5) 620.8 (483.1–764.5)
Women
ABC 535.7 (450.9–661.6) 548.8 (480.9–670.2) 566.83 (483.8–685.94)
No ABC 644.6 (503.1–763.8) 646.4 (542.3–723.4) 652.72 (472.3–806.6)
O325 Effectiveness of tenofovir-abacavir containing HAART in
pretreated HIV-1 infected patients
A. Pen˜a-Monje, D. Vinuesa-Garcı´a, C. Tomas-Jimenez,
L. Mun˜oz-Medina, M. Alvarez, M.A. Martinez-Perez, F. Garcia-Garcia,
J. Parra-Ruiz °, J. Hernandez-Quero (Granada, ES)
Objectives: Although there has been an increase in available antiretrovi-
ral for pretreated patients, their high cost and short time since approved
make nucleoside reverse transcriptase inhibitors (NRTI) to be the most
widely used backbone. However, since pre treated patients usually
harbored mutations in reverse transcriptase, frequently tenofovir (TDF)
and abacavir (ABC) are the only NRTI available. Since there are no
reports about the combination of ABC and TDF, ans some concern about
drug-drug interaction, we made a retrospective review to establish the
effectiveness of ABC plus TDF as a NRTI backbone of HAART in
pretreated patients.
Methods: A single clinic retrospective study including all HIV-1
infected pretreated patients >18 years of age starting ABC-TDF
irrespective of their prior HAART. The effectiveness was evaluated in
an ITT analysis.
Results: Forty-six patients, 31 men (67%) with a mean age of 43 years
(28−65) and median CD4 cell count of 447 (75–1935). Mean HIV-1 viral
load was 29400 copies/mL (19–85600). Among the sample 12 patients
(26%) had undetectable viral load when starting the combination. Failure,
as deﬁned, occurred in 26 patients (57%), with 21 patients (46%) having
virological failure. The other 5 patients resumed therapy because side
effects to any of the drugs (4 patients) or lost to follow up (1 patient).
Among these 5 patients, 3 had undetectable HIV-1 viral load when
stopped therapy. Median duration of therapy for non-failure patient was
27 months (11−54) and 12 months (3−33) for patients who resumed
therapy. When stratiﬁed by viral load at the starting of therapy we found
that patients who had undetectable viral load had better chance to keep on
therapy than patients who started with detectable viral load 8/12 (66%)
vs 12/34 (35%), almost reaching statistical signiﬁcance (p = 0.061).
Conclusion: TDF-ABC backbone should not be routinely used in HIV
pre-treated patients. However, if the patient has undetectable viral load,
the combination might be used with a high chance of success at 96
weeks follow-up in an ITT analysis.
O326 Optimization of antiretroviral treatment of HIV-patients with
viral loads below 1,000 copies/mL based on genotyping data
J. Mier-Mota °, L. Lopez-Cortes, P. Viciana, P. Perez-Romero (Seville, ES)
Objectives: Despite the success of antiretroviral therapy (ART) in
the majority of patients, a percentage of patients receiving ART have
sustained low-level viremia with viral loads (VL) between 20 and 1,000
copies/mL. The objective of this study was to determine whether the
early optimization of the treatment based on the resistance pattern
determined in patients with VL below 1,000 copies/ml results in the
decrease of the VL to undetectable levels.
Methods: Our laboratory has developed a method for amplifying and
sequencing the protease and retrotranscriptase genes from the plasma of
patients with VL between 20 and 1,000 copies/mL. In this method HIV-
RNA is concentrated using RNA afﬁnity colums and is used as a template
for high ﬁdelity RT-PCR. The products are sequenced and mutations
determined and analyzed. Using this method we studied HIV patient
samples collected from September 2008 to September 2009. Genotyping
data were obtained for each patient and ART was modiﬁed according to
the resistance pattern and previous clinical history.
Results: Genotyping was determined for 37 patients that fullﬁlled the
requirements of sustained low-level viremia. Resistance mutations were
detected in 89% of the sequences. The most common mutations in the
protease were at positions 10 (40.5%), 71 (16.2%) and 90 (18.9%).
The most common mutations in the retrotranscriptase associated with
resistance to nucleoside analogs were at positions 67(27.1%), 184
(27.1%) and 215 (37.5%), while the most prevalent mutations associated
with resistance to non-nucleoside analogs were at positions 98 (10.4%),
100 (14.6%) and 103 (16.7%).
After genotyping, 17 patients received an optimized treatment regimen.
In 15 of these patients (88.2%) the VL became undetectable, in one
patient (5.9%) theVL decreased signiﬁcantly but not to undetectable
levels and in one patient (5.9%) the VL was undetermined. Of the 20
patients that did not undergo treatment change, in 4 patients (20%) the
VL decreased to undetectable levels, in 9 patients (45%) the VL remained
between 20 and 1000 copies/ml, in 3 patients (15%) the VL increased to
over 1,000 copies/mL and in 4 patients (20%) the VL was undetermined.
Conclusion: The developed method allows for genotyping of patients
with VL between 20 and 1,000 copies/mL. Treatment changes based on
these genotyping data have clinical signiﬁcance since the VL decreased
to undetectable levels in the majority of the patients who underwent
treatment change.
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O327 Lack of correlation between plasma residual viraemia and
total HIV-DNA in PBMCs of successfully treated patients
S. Parisi °, L. Sarmati, L. Dori, S. Andreis, A. Buonomini, M. Montano,
C. Boldrin, E. Nicastri, C. Andreoni, R. Scaggiante, V. Vullo, G. Palu`,
M. Andreoni (Padua, Rome, IT)
Objectives: The origin of residual viremia (RV) in HAART-treated HIV-
seropositive patients (pts) is unknown. Many investigators interpret RV
as the result of ongoing cycles of replication, others as the reactivation of
virus from latently infected cells. The aim of the study was to correlate
the level of HIV-RNA in plasma and level of HIV-DNA in PBMCs in a
cross-sectional analysis.
Methods: 195 HAART-treated pts who achieved virological suppression,
as deﬁned by two consecutive plasma HIV-RNA measurements <50
copies/ml, from at least 18 months were enrolled. On the basis of RV
values, the pts were subdivided in 4 groups: pts with undetectable plasma
RNA level (UL, <1 copy/ml), pts with low level (LL, >1−10 copies/ml),
pts with high level (HL, >10−50 copies/ml) and pts with viral blip (VB,
>50–400 copies/ml). RV was quantiﬁed by an ultra-ultrasensitive method
based on a modiﬁed Amplicor HIV-1 Monitor 1.5 (Roche Molecular
Systems, USA), with a detection limit of 1 copy/ml. To quantify the
total proviral HIV-DNA copy number in PBMC, the Real Time TaqMan
protocol published by J-P Viard was adapted, with a sensibility of 5
copies/106 PBMCs.
Results: 66 (33.8%) pts were UL, 63 (32.3%) were LL, 41 (21%)
were HL and 25 (12.8%) were VB. UL pts had highest number of
nadir CD4+cells compared to other groups (UL: 360 cells/ml, LL: 315
cells/ml, HL: 279 cells/ml and VB: 305 cells/ul; mean values). Not
signiﬁcant difference was detected in CD4 cell count in the four groups
of pts (698, 764, 680 and 691 cell/ul, respectively; mean values). Twenty
two patients had undetectable level of proviral DNA in PBMCs (10 UL,
2 LL, 9 HL and 1 VB). The 12 patients with undetectable proviral DNA
but detectable residual viremia had a median of 22 copies of HIV-RNA
copies/ml (range 12−81 copies/ml). Finally, 11 out of 31 (35.5%) pts
with more than 1,000 copies of HIV-DNA/106 PBMCs had undetectable
level of RV.
Conclusion: A lack of correlation between HIV proviral DNA and
residual viremia levels in a cohort of virological long term suppressed
pts was demonstrated. This study conﬁrms the complex origin of RV
and the need to evaluate the relevance of the impact of the new potent
drugs, such as Integrase Inhibitors and CCR5 Inhibitors, on episomal
viral DNA, on RV and on the long term treatment success.
O328 Prevalence of secondary drug-resistant mutations to
antiretroviral drugs in Iranian HIV-infected patients
A. Ramezani, R. Hamkar, W. McFarland, A. Aghakhani, M. Banifazl °,
M. Foroughi, M. Mohraz (Tehran, IR; San Francisco, US)
Objective: Several studies have reported increasing number of
therapeutic failures with antiretroviral drugs in HIV infected patients.
The emergence of viral resistant strains is a major problem for the
medical management of infected individuals. In this study we aimed
to determine the prevalence of secondary antiretroviral resistance-
associated mutations in Iranian HIV infected patients.
Methods: A total of 40 HIV infected patients under antiretroviral drug
treatment were enrolled in this study. All of the patients were received
antiretroviral treatment for at least 1 year. One protease inhibitor (PI)
or one nonnucleoside transcriptase inhibitor (NNRTI) in combination
with 2 nucleoside transcriptase inhibitors (NRTI) are considered for
antiretroviral therapy.
The HIV pol region including viral protease and reverse transcriptase
genes were ampliﬁed and sequenced for determining genotype, subtype
and antiretroviral resistance-associated mutations.
Results: Sequencing of the samples revealed that 40% of strains
belonged to subtype B, 20% subtype A, 35% were A/D and 5%
were CRF01-AE recombinants. Drug resistance-associated mutations
identiﬁed more common in subtype A/D recombinant. Virus samples
from 30% of participants showing no drug resistance mutation and 70%
of them carried 2 drug resistance mutations. Dual-class drug-resistant
virus (NRTI and NNRTI) was present in 22% of participants, and 43%
had virus with triple-class drug resistance.
The prevalence of NRTI mutations was 77% with M184V and V118I
present in 55% and 48% of samples respectively. The prevalence of
NNRTI mutations was 66% which P225H mutations were present in
30% of study specimens. The prevalence of PIs mutations was 44%.
Major PIs mutation L90M was seen in 45% and minor protease inhibitor
mutation A71V was detected in 50% of samples. The other major PIs
mutations were V32I, L33F, M46I, I54V, V86T, and I84V.
The highest frequency of resistance to PIs was related to nelﬁnavir (60%,
high level resistance) and saquinavir (60%, intermediate resistance).
For NNRTI, the frequencies of resistant isolates were 56% to nevirapine,
44% to delavirdine and 44% to efavirenz, and for NRTI was 56%, high
level resistance to lamivudine.
Conclusions: Our study showed a high prevalence of secondary
resistance mutations in Iranian HIV infected patients. Continued
surveillance of resistance patterns is warranted to guide therapeutic
approaches as selection of second-line regimens in Iran.
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O329 Performance of interferon-gamma CSF tests in the diagnosis
of TB meningitis in children
O.A. Caliman-Sturdza °, D. Mihalache, C. Petrovici (Iasi, RO)
Objectives: We investigated whether a rapid diagnosis of TB meningitis
at children can be established by interferon-gamma blood and
cerebrospinal ﬂuid tests in routine clinical practice and assess the level
of agreement with classic laboratory methods.
Methods: The patients have been separated in two groups: ﬁrst group,
where the diagnosis of TB meningitis has been conﬁrmed by positive
culture from CSF and efﬁcacy of treatment; second group with non-TB
meningitis. We performed QuantiFERON-TB Gold in Tube (QFT-G) in
blood and CSF at all patients.
Results: From a total of 46 children enrolled, 21 cases has been
diagnosed with TB meningitis and 25 patient was in the control group;
B:F = 18:10; mean of age was 9.75 (age range 6 months to 17 years). The
symptoms and physical examination at the admission may suggest TB
meningitis: fever, headache, vomiting and neck stiffness at 17 patients,
cranial nerve palsies at 2 patients, hemi paresis at 3, altered mental status
at 13 and seizures at 6 subjects.
TST was positive at 13 patients in the ﬁrst group and at 6 in the second.
The CSF analyses were suggestive for TB at 16 patients: pleocytosis
300 elements/ml, high CSF protein level and low CSF glucose. All
patients had negative smear and only 7 (33.3%) had positive culture.
The mean time interval required for QFT-G results was 48 hours and
for cultures was 25.6 days. In the ﬁrst group, the results of QFT-G
in blood samples were: 15 (71.4%) subjects had QFT-G positive, 5
(23.8%) had QFT-G negative and one indeterminate (4.7%). In CSF,
16 (76.2%) patients had positive results, 3 (14.3%) had negative and 2
(9.5%) indeterminate. In group of non TB meningitis, 23 (92%) patients
had negative results in blood and 2 (8%) positive; in CSF, 19 (76%)
subjects had negative results and 6 (24%) indeterminate. The sensitivity
of QFT-G in CSF was 84.2% and 75% in blood; speciﬁcity 100% in CSF
and 92% in blood; the positive predictive value of QFT-G was 100% in
CSF and 88.2% in blood; negative predictive value was 86.3% in CSF
and 82.1% in blood. The sensitivity of TST was 61.9% and speciﬁcity
76%. The sensitivity of the culture from CSF was only 33.3%. The
sensitivity and speciﬁcity of QFT-G was higher than TST and culture
and better in CSF than in blood.
Conclusions: The determination of g-interferon in serum and CSF
is useful diagnostic marker of tuberculosis who could improve the
management of TB meningitis, by a rapid diagnosis and an early
treatment initiation.
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O330 Sensitivity, speciﬁcity and inter-test agreement of
interferon-gamma release assays for the diagnosis of latent
tuberculosis infection in HIV-infected individuals with
advanced immunodeﬁciency
C. Ni Cheallaigh °, J. Grace, I. Fitzgerald, G. Singh, S. O’Dea,
N. Gibbons, T. Rogers, J. Keane, S. Clarke, C. Bergin (Dublin, IE)
Objective: Treatment of latent tuberculosis (LTBI) in HIV+ patients
reduces the incidence of TB. Interferon-gamma release assays (IGRAs)
may be more speciﬁc in diagnosing LTBI than the tuberculin skin test,
but their sensitivity at lower CD4 counts has not been established. We
studied the effect of CD4 count on IGRA results.
Methods: T-SPOT.TB® ELISPOT assays, incorporating ESAT-6 and
CFP-10, and Quantiferon 3G® ELISA assays, incorporating ESAT-6,
CFP-10 and TB7.7, were performed in HIV+ patients with CD4
counts <250×106/L (n = 72, median CD4 count = 124×106/L) and
HIV+ controls with CD4 >250×106/L (n = 160, median CD4 count
= 460×106/L). Active TB was excluded in all patients. ELISA and
ELISPOT responses were related to patient characteristics.
Results: ELISA responses were positive in 21% (n = 15) of patients with
CD4< 250×106/L and 31% (n = 49) of those with CD4> 250×106/L,
(difference of 10%, 95%CI −2–22%, p = 0.15). ELISPOT responses were
positive among 8% (n = 5) of patients with CD4< 250×106/L and 15%
(n = 22) of those with CD4 >250×106/L, (difference of 7%, 95%CI
−2–16%, p = 0.13). However; when multivariate regression analysis was
used to adjust for LTBI risk factors such as origin from countries of
high TB prevalence, ELISA and ELISPOT results were independent of
CD4 count.
Migration from countries with a high prevalence of TB (COHP) was
associated with positive results on multivariate analysis: in those from
COHP the OR for positive ELISA was 2.7 (95%CI 1.5−5), p = 0.03;
and OR for positive ELISPOT was 4.0 (95%CI 1.6−10), p = 0.003.
Injection drug use, incarceration and homelessness were not associated
with positive results. Signiﬁcantly, 17% (7/41) of individuals with no
risk factor for LTBI had a positive ELISA, and 5% (2/41) had a positive
ELISPOT.
30% (70/232) of patients had one or more positive IGRA result, of whom
only 32% (21/70) were positive on both tests. Agreement between the
two IGRAs was moderate, Cohen’s kappa = 0.37. There was no associa-
tion between inter-test agreement and CD4 count. Origin from a COHP
was associated with a higher level of agreement between positive tests.
Conclusions: ELISA and ELISPOT responses were independent of CD4
count. Disagreement between the tests is frequent, and not related to CD4
count. Discordant results are more common in patients with lower pre-
test probability of LTBI and, given the high rate of positive results in
those with no risk factor for LTBI, may represent false positive results.
O331 Clinical experience with Tspot.TB™ for diagnosis of
tuberculosis in HIV-negative and HIV-positive patients
L. Turtle °, T. Kemp, J. Darroch, N. Beeching, M.B. Beadsworth
(Liverpool, UK)
Aims: IFN-g release assays (IGRA) had principally been developed for
the diagnosis of latent tuberculosis infection (LTBI) and appear more
sensitive and speciﬁc than than tuberculin skin testing. IGRAs may
also offer an attractive option for assisting in diagnosis of active TB.
Several studies have been published comparing IGRAs with conventional
diagnosis. As part of on-going assessment of TB diagnostic approaches
we assessed the reliability of IGRA within our cohort at the regional
Tropical and Infectious Diseases Unit (TIDU).
Methods: All patients who underwent Tspot TB testing within the TIDU,
since testing was introduced in Jan 2008, were included. Comparison was
made with M. tuberculosis culture and with a ﬁnal diagnosis of TB (the
administration of a full course of TB therapy). The comparison was also
performed separately for both HIV+ and HIV− patients.
Results: 73 Tspot.TB tests were performed on 72 patients; 32% of
patients (n = 23) were HIV+, 8 were not HIV tested. 76% of patients
(n = 55) had mycobacterial culture results available (36%, n = 20 HIV+).
94% of patients (n = 68) had data on the administration of TB therapy;
35% (n = 24) received TB therapy (7 HIV+). The kappa coefﬁcient for
agreement between Tspot TB and culture of M. tuberculosis for all
patients was 0.42 (standard error (SE) 0.13); the kappa value for receipt
of TB therapy was 0.47 (SE 0.12). For HIV+ patients (n = 23) the kappa
value compared with culture was 0.38 (SE 0.22) and for TB therapy was
0.27 (SE 0.2). For HIV- and untested patients (n = 46) the kappa value
for culture was 0.43 (SE 0.16) and the kappa value for TB therapy was
0.56 (SE 0.15). The sensitivity of Tspot.TB in all patients compared with
culture was 69.2% (95%CI 57–81.4), speciﬁcity 78.6% (95%CI 67.8–
89.4), positive predictive value 50% (95%CI 36.8–63.2) and negative
predictive value 89.2% (95%CI 81–97.4). Compared with receipt of TB
therapy in all patients the sensitivity of Tspot TB was 58.3% (95%CI
45.3–71.3) and speciﬁcity 86.7% (95%CI 77.7–95.7). Further analysis
will be presented.
Conclusion: The performance of IGRA (Tspot TB) in our everyday
clinical use, compared with other published studies is poorer for both
HIV positive and negative patients. This indicates the need for further
prospective studies to be undertaken before recommending IGRA as a
diagnostic tool in active TB.
O332 Usefulness of interferon-gamma release assays for latent tu-
berculosis screening in patients candidate for TNF-a therapy
I. Sauzullo °, F. Mengoni, R. Scrivo, G. Valesini, C. Potenza, N. Skroza,
M. Lichtner, R. Marocco, V. Belvisi, V. Vullo, C. Mastroianni (Rome,
Terracina, Latina, IT)
Objectives: Reactivation of Mycobacterium tuberculosis infection is
a major complication of anti-tumor necrosis factor (TNF-a treatment.
Thus, screening for latent tuberculosis infection (LTBI) is mandatory
before starting anti-TNF therapy. The TST has 2 main disadvantages:
the low speciﬁcity with false positive results in BCG vaccinated subjects
and lower sensitivity in presence of immunosuppressive therapy resulting
in false negative results. Diagnosis of LTBI may beneﬁt from new
interferon-gamma release assays (IGRA). The aim of this study was to
investigate the performance of QuantiFERON-TB Gold In Tube (QFT-
GIT) assay and its agreement with TST in the screening of LTBI in
patients with an immune-mediated inﬂammatory diseases candidate for
anti-TNF therapy.
Methods:We consecutively enrolled 215 patients affected by rheumatoid
arthritis (n = 77), psoriatic arthritis (n = 38), psoriasis (n = 64), ankylosing
spondylitis (n = 8), Crohn’s disease (n = 22), and Behcet’s disease
(n = 6) were enrolled. Screening included: clinical evaluation, chest
X-ray, TST and QFT-GIT. 106 patients were on corticosteroid and/or
immunosuppressive drugs and 20 were BCG-vaccinated.
Results: Of the 215 patients, 34 (15.8%) had a positive, 152 (70.6%) a
negative, and 29 (13.4%) had an indeterminate QFT-GIT result. In 122
(65.5%) patients the TST and QFT-GIT were both negative, in 30 (16%)
patients both the tests were positive, while 34 (18%) had discrepant
results between TST and QFT-GIT. Agreement between two tests was
81.7% (k = 0.53). A diagnosis of LTBI was considered in 38 cases
(17.6%). By univariate analysis, we observed an association between
BCG vaccination and discordant QFT-GIT-/TST+ (OR= 6; 95%CI: 2.3–
37.1; p< 0.001) and between the immunosuppressive therapy and an
indeterminate QFT-GIT tests (OR= 2.79; 95%CI: 1.06−7.6; p< 0.02).
No association between the immunosuppressive therapy and discordant
QFT-GIT+/TST− (OR= 0.16; 95%CI: 0.01−1.8; p< 0.09) was found.
Conclusion: Our results show that QFT-GIT may be helpful for
screening LTBI in patients candidates for anti-TNF-a therapy not only
to conﬁrm positive TST results but also to discriminate false-negative
TST results as a consequence of previous long-term immunosuppressive
treatments. The performance of QFT-GIT seems to not be affected by
immunosuppression in our patients. IGRA appears to offer a better
chance than TST for monitoring TB infection during anti-TNF-a therapy.
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O333 Diagnosis of tuberculosis infection in patients awaiting
transplantation
S. Casas, L. Mun˜oz °, A. Andreu, R. Moure, J. Castellote, M. Arnan,
M.R. Guerra, L. Gonzalez, F. Alcaide, A. Rafecas, R. Duarte, T. Peralta,
M. Santin (L’Hospitalet de Llobregat, ES)
Objectives: To compare the tuberculin skin test (TST) with the
QuantiFERON® TB Gold-in Tube (QFT-GIT) for the diagnosis of
tuberculosis infection (TBI) in patients prior to transplantation.
Methods: A prospective, cross-sectional study of the patients evaluated
for liver and haematopoietic progenitor transplantation in a teaching
hospital in Spain, from July 2008 to September 2009. Simultaneous
QFT-GIT and two steps TST were performed.
Results: 92 patients were screened for TBI, 69 (75%) candidates to
liver transplantation (LT) and 23 (25%) to haematopoietic progenitor
transplantation (HPT). Sixty (65.2%) were men, mean age of 55 years.
Fifty two (56.2%) presented some risk factor for TBI and 23 (25%) had
BCG-vaccination. In the LT group, 67 (97.1%) patients were diagnosed
with cirrhosis with a mean MELD score of 13.8. In the HPT group,
21 (91.3%) patients had received chemotherapy, at least, in the previous
6 months. Thirty eight (41.3%) patients had a positive TST (35 with
the 1st TST and only 3 with the 2nd one), and also 38 (41.3%) had a
positive QFT-GIT. Among LT patients, there were 31 (44.9%) positive
TST and 31 (44.9%) positive QFT-GIT results, and among HPT patients
7 (30.4%) positive TST and 7 (30.4%) positive QFT-GIT results. In the
LT group, a MELD score >18 (OR 0.09, CI95% 0.02–0.55; p = 0.01)
and albumin <30 (OR 0.23, CI95% 0.07–0.82; p = 0.02) were associated
with a lower likelihood of positive TST but not with QFT-GIT results.
Discordant results were observed in 11 QFT-GIT+/TST− patients and
in 11 QFT-GIT−/TST+. QFT1-GIT+/TST− results were associated with
MELD score >18 (9.8, CI95% 1.6−62; p = 0.02). There were only 3
(3.3%) indeterminate QFT-GIT results.
Conclusions: QFT-GIT and TST are both feasible tests for diagnosing
TBI in patients considered for LT and HPT. Higher MELD score and
hypoalbuminemia were associated with a lower likelihood of positive
TST, but not with QFT-GIT.
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O334 Epstein–Barr virus gene expression patterns in paediatric
liver transplant recipients
B. Kasztelewicz °, I. Jankowska, J. Pawlowska, P. Kalicinski,
K. Dzierzanowska-Fangrat (Warsaw, PL)
Objectives: Determination of EBV gene expression patterns in
association with EBV DNA load monitoring might be more informative
and effective tool in monitoring EBV infection in immunosuppressed
patients, allowing earlier detection of EBV related lymphoproliferations
and therapeutic intervention in time. The aim of this study was to analyse
latent and lytic EBV transcript levels, in relation to EBV DNA load in
peripheral blood lymphocytes in immunosuppressed paediatric patients
after liver transplantation (LTx).
Methods: Thirty patients after LTx were included in this study.
Mean±SD age at LTx was 24.1±30 months. Mean follow-up was 36.2
months (range 4.7–122.8 months). Multiple blood samples prospectively
collected at different time points during post-transplant checkups were
used for EBV load measurement and viral gene expression analysis.
Quantitative analysis of latent (EBNA1, EBNA2, LMP1, LMP2) and
lytic (BZLF1) gene expression was performed in 75 samples by two-step
RT real-time PCR. The B95−8 cell line was used as a calibrator, and the
expression level of EBV genes was normalized to the expression levels
of the endogenous control (HMBS gene). Simultaneously EBV DNA
load was monitored using quantitative real-time PCR method.
Results: In children after LTx several distinct patterns of EBV gene
expression were identiﬁed. Majority of samples (53/75, 71%) showed
latency 2 proﬁle (LMP1±LMP2 expression), in 10 samples (13%)
latency 3 was found (EBNA2 + other latent transcripts), whereas
latency 0 (LMP2 only expression) was detected in 8 samples (11%).
Additionally, in 4 samples from 4 children lytic infection (BZLF1
expression) was identiﬁed. In three cases it was accompanied by a
simultaneous presence of latent transcripts. In most children (12/16)
in whom multiple blood samples were analysed EBV gene expression
patterns varied over time. Similarly, expression level of particular EBV
genes varied over time up to 5-log fold in individual patients. EBV
latency pattern was not associated with the EBV DNA level. Similarly,
the appearance of lytic infection (detectable BZLF1 expression) did not
lead to a signiﬁcant increase of EBV copy number. However, viral load
correlated signiﬁcantly (p< 0.05) with the LMP1 and LMP2 expression
levels (both r = 0.29), but not with EBNA1 or EBNA2 transcript levels.
Conclusion: The activity of LMP1 and LMP2 genes may inﬂuence EBV
DNA load in immunosuppressed paediatric patients.
O335 Prevalence of papillomavirus in HIV-positive patients
M. Lorenzo, M.P. Romero-Gomez ° (Madrid, ES)
Objective: The aim of the present study was to determine the
prevalence and genotype distribution of concurrent anogenital human
papillomavirus (HPV) infection in male patients infected with the human
immunodeﬁciency virus (HIV), using polymerase chain reaction and
reverse hybridization.
Methods: HPV testing was performed on anal cytology specimens
collected from 65 HIV-seropositive men from January to October 2009.
Results of de anal cytology also were collected.
Anal samples were collected by a trained nurse and cytological
specimens were prepared using a liquid based collection method
(ThinPrep).
The samples were loaded onto the EasyMAG system (bioMe´rieux,
Durham, NC) and DNA extractions were made according to the
manufacturer’s protocol. The genotyping was performed with a new
technological platform using a low density Microarray CLART®
Papillomavirus 2 (Genomica, Spain). All samples were analyzed for the
presence of the following HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72,
73, 81, 82, 83, 84, 85 and 89.
Results: HPV DNA was detected in 58 (89.2% of samples). The most
frequently detected HPV types were HPV 53 (29.2% of the positive
samples), HPV 16 (24.6%), HPV 33 (24.6%), HPV 51 (23%), HPV 58
(21.5%), HPV 59 (18.5%) and HPV 68 (16.9%). We found only seven
patients with one genotype infection of HPVs.
Twenty nine patients (44.6%) with normal anal cytology had high and
low risk HPV. In six patients we found high risk HPV and abnormal
cytology [3 patients had low-grade squamous intraepithelial lesion
(LSIL), 2 patients with grade I anal intraepithelial neoplasia (AIN-I)
and 1 patient with atypical squamous cells of undetermined signiﬁcance
(ASCUS)].
Conclusions: A wide variety of HPV genotypes was detected, and co-
infection with multiple genotypes was common in ours patients.
HPV screening in HIV-positive patients even in cases of normal anal
cytology can be useful for detecting those patient with risk to develop
cancer.
O336 Natural polymorphism of UL23 thymidine kinase and UL30
DNA polymerase among herpes simplex virus type 1 and 2
strains
S. Burrel, C. Deback, B. Le Labousse, F. Conan, H. Agut,
D. Boutolleau ° (Paris, FR)
Objectives: Genotypic detection of herpes simplex virus (HSV)
resistance to antivirals is based on thymidine kinase (UL23) and
DNA polymerase (UL30) gene sequencing. The interpretation of results
requires distinguishing resistance mutations from natural interstrain
sequence variations. The objective of this work was to assess extensively
the natural polymorphism of pUL23 and pUL30 among HSV strains.
Methods: Three laboratory strains (KOS, G-HSV-2, MH2) and 54
clinical isolates (27 HSV-1 and 27 HSV-2) were studied. Forty strains
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were collected from patients who had not received any previous anti-HSV
treatment, and 14 strains exhibited acyclovir and foscarnet phenotypic
susceptibility using a plaque reduction assay. The entire open reading
frame of UL23 and UL30 genes was sequenced. Nucleotide and amino
acid sequences were compared with that of reference strains from
Genbank: accession numbers X14112 (HSV-1 strain 17) and Z86099
(HSV2 strain HG52).
Results: The interstrain identity of UL23 gene ranged from 99.3%
to 100% at the nucleotide level in the 57 HSV strains investigated.
There were 19 and 11 variant nucleotides for HSV-1 and HSV-2 strains,
respectively. Overall, 19 amino acid changes were identiﬁed for HSV-1
strains and 7 amino acid changes for HSV-2 strains (that is, 5.1% and
1.9% of the total codons of the protein, respectively). The analysis of
UL30 gene showed >99.5% interstrain identity among all HSV strains.
Surprisingly, in HSV-1 strains, 113 variant nucleotides were evidenced,
of which 72% produced silent mutations, whereas in HSV-2 strains, only
28 were evidenced, of which 32% produced silent mutations. Thirty and
18 amino acid changes distributed across UL30 DNA polymerase were
described for HSV-1 and HSV-2 strains, respectively, corresponding to
2.4% and 1.3% of the total codons of the protein. Of note, one HSV-2
isolate harboured a deletion at codons 1106–1111 in the C-terminal
region of pUL30. For both viral proteins, 71 out of 74 amino acid
changes identiﬁed lied within nonconserved regions.
Conclusion: Our results show that UL23 thymidine kinase and UL30
DNA polymerase are highly conserved among HSV strains, with
a weaker variability for HSV-2 strains. Beside previously described
mutations, a number of previously undescribed natural variations were
identiﬁed. This work provides the natural polymorphism map of pUL23
and pUL30 among both HSV-1 and HSV-2 strains that will be helpful
for HSV genotypic antiviral resistance testing.
O337 Detection of human bocavirus and human metapneumovirus
by real-time PCR in children with respiratory tract
infections during four successive winter periods in Belgium
D. Ursi °, Y. Santiago Cores, K. Bergs, M. Michiels, H. Goossens,
M. Ieven (Edegem, BE)
Objectives: To examine the prevalence of two recently discovered
viruses, human metapneumovirus (hMPV) and human bocavirus (hBoV)
in respiratory specimens of a pediatric population during 4 successive
winter periods (2005–2008) by real-time PCR.
Methods: Nucleic acids were extracted from nasopharyngeal aspirates
with a Nuclisens easyMAG platform (Biome´rieux). A suspension
of Phocine Herpes virus and Phocine distemper virus was added
as an extraction/inhibition control to each sample before extraction.
Ampliﬁcations were performed on a Lightcycler 480 (Roche). For hMPV
a separate cDNA synthesis step was included before ampliﬁcation.
The hMPV primers and probe sequence were from Maertzdorf et
al.(2004) JCM 42, 981−6. These target the most conserved regions of the
nucleoprotein gene of the virus. The hBoV primers and probe sequence
target the most conserved regions of the non structural sequence of the
virus. Our study included 234 nasopharyngeal samples collected from
paediatric patients with symptoms of respiratory tract disease without
known cause, collected on UZA between 2005 and 2008.
Results: Only samples with a satisfactory ampliﬁcation of the
extraction/inhibition control were taken into consideration. Twenty-six
of 230 samples (11%) were found positive for hMPV, 42 of 226 samples
(18%) were found positive for hBoV and 7 of 219 samples (3%) were
found positive for both viruses. Both viruses were found during the 4
successive winterperiods, with an incidence ranging from 6% in 2006
to 15% in 2007 for hMPV and from 9% in 2006 to 29% in 2005 for
hBoV. When looking at the age distribution, hMPV was found with a
prevalence of 9% in children under 1 year, 19% in children between 1
and 2 years, both 14% in children between 2 and 3 and between 3 and
4 and 7% in children older than 4. For hBoV, the prevalence was 13%
in children under 1 year, 32% in children between 1 and 2 years, 7% in
children between 2 and 3, 38% in children between 3 and 4 and 11.6%
in children older than 4. For both viruses, there was no clear pattern of
seasonal distribution.
Conclusions: Both hMPV and hBoV were found in each of the 4
successive winterperiods examined between 2005 and 2008 in Belgium
in a signiﬁcant number of children presenting with respiratory tract
infections. Although prevalent in all age categories, higher prevalences
were found for both viruses in children under 4 years of age. For both
viruses, there was no clear pattern of seasonal distribution.
O338 Phylogenetic analysis of human bocavirus isolated from chil-
dren with acute respiratory illness and gastroenteritis in Iran
S.A. Nadji °, L. Poos-Ashkan, R. Yaghoobi, R. Nategh (Tehran, Jahrom,
Shiraz, IR)
Objectives: Human Bocavirus (hBoV) was ﬁrst discovered in 2005.
Based on phylogenetic analysis and genomic organization, hBoV has
been classiﬁed to Parvoviridae family. hBoV is prevalent in children
worldwide and seems to be associated with respiratory tract illness and
acute gastroenteritis. One to three slightly different genetic lineages have
been reported among hBoV isolated worldwide. The aim of present
study is to determine the prevalence of hBoV and analysis of hBoV
phylogeny in children suffering from acute respiratory tract illness and
acute gastroenteritis in NRITLD, Iran.
Methods: Clinical samples were collected from 180 patients (17y/o)
including 50 exacerbated asthma cases, 83 cases with respiratory tract
illness and 47 gastroenteritis cases between 2006 and 2008. The
specimens were immediately transported in cold box to the virology
laboratory at Virology Research Center, treated and stored at −70ºC
until use. For screening, nested PCR were performed using primers in
NS-1 coding region. 10 positive samples were subjected to sequencing
for VP1/VP2 gene junction. Phylogenetic and molecular evolutionary
analyses were conducted using MEGA version 3.1.
Results: The hBoV was detected in a range of 6% to 12.8% in
different clinical presentations. Most hBoVs were detected in children
less than 3 years of age and in cold seasons. Statistical differences
were observed in age group and seasonal distribution of hBoV in
asthma exacerbation cases (P = 0.031) and gastroenteritis (P = 0.024),
respectively. However, there was high nucleotide identity (99.18%-100%)
between all hBoV sequences, the phylogenetic analysis resulted in 3
genetic groups (Figure 1). 14 of the 864 nucleotide positions were
variable, when compared to Swedish reference strain (accession number
NC_007455), with 10 transitions (71.4%) and 4 transversions (28.67%).
At the amino acid level, there was 98.46–100% sequence identity among
isolates and only two changes were found at codon 152 (S→T) and
codon 207 (V→M).
Figure 1.
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Conclusion: This study is the ﬁrst research of phylogenetic analysis
of hBoV isolated from children with acute respiratory tract illness and
gastroenteritis in Iran. Phylogenetic analysis based on VP1/ VP2 gene
junction showed the existence of 3 different genetic groups among hBoV
isolates that co-circulate in Iranian population. hBoV from Iran was
distributed among all three groups and showed that hBoV is highly
conserved and there is no speciﬁc-geographical variation.
Community-acquired MRSA and MSSA
O339 Clonal composition and antimicrobial resistance of Panton-
Valentine leukocidin-positive Staphylococcus aureus in Wales
N. Bome-Mannathoko, M. Wootton, L.G. Harris, R. Howe, D. Mack °
(Swansea, Cardiff, UK)
Objectives: Panton-Valentine Leukocidin (PVL)-positive S. aureus
typically cause skin/soft-tissue abscesses, haemorrhagic pneumonia and
necrotising fasciitis. Wide dissemination of PVL-positive CA-MRSA
clones, i.e. USA300 and USA400, requires continuous surveillance.
We investigated the molecular epidemiology and antibiotic resistance
of PVL-positive S. aureus obtained at two institutions in Wales.
Methods: Two cohorts of PVL-positive S. aureus were studied: i.
19/560 (3.4%) consecutive wound isolates from NPHS Microbiology
Swansea PVL-positive by PCR (ABMU); ii. PVL-positive S. aureus
strains submitted to Specialist Antimicrobial Chemotherapy Unit, NPHS
Microbiology Cardiff (SACU; n = 61), using mecA, PVL, and arginine
catabolic mobile element (ACME) PCR, pulsed-ﬁeld gel electrophoresis
(PFGE), spa-, and SCCmec-typing. Susceptibility testing was performed
using BD Phoenix.
Results: mecA prevalence was signiﬁcantly different between ABMU
2/19 (10.5%) and SACU 35/61 (57.4%) strains (p< 0.001). ABMU
MRSA strains exhibited t019-MRSA-IVd and t437-MRSA-V genotypes.
The majority of ABMU strains were diverse MSSA containing 3
strains each of spa-types t021 and t314 (15.8%) and the new spa-
type t4791. The SACU cohort comprised a predominant clone (n = 16;
26.2%) t008-MRSA-IVa, conﬁrmed as USA300–0114 by PFGE and
presence of ACME. Other clones included: t044-MRSA-IVc (n = 5;
8.2%); t002-MRSA-IVc (n = 3; 4.9%) and t127-MRSA-IVa (n = 2; 3.3%).
Two new spa-types were encountered (1 MRSA, 1 MSSA, assignment
pending). Resistant strains (n = 80): oxacillin 45%, gentamicin 5%,
tobramycin 36%, erythromycin 28%, clindamycin 1%, tetracycline
18%, trimethoprim 64%, TMP-SMZ 18%, ciproﬂoxacin 5%, fusidic
acid 10%. D-test revealed 36% inducible clindamycin resistant (CR),
5% constitutive CR, and 59% clindamycin sensitive strains in 22
erythromycin resistant strains. Signiﬁcant differences were seen for
SACU/ABMU cohort strains for oxacillin 57%/5%, gentamicin 2%/16%,
and tetracycline 10%/42% (p< 0.05).
Conclusions: There was a striking difference of antibiotic resistance
and clonal composition of the two cohorts. USA300–0114 was the
most prevalent clone in the SACU cohort and other globally distributed
clones were also represented. None of these clones were found in the
unselected ABMU cohort. While molecular epidemiologic analysis of
strains submitted to referral units provides valuable information, this
needs conﬁrmation by investigation of unselected isolates from the same
area.
O340 Frequency of PVL-positive community-associated MRSA
and livestock-associated MRSA among patients in Belgian
acute-care hospitals
S. Vandendriessche °, O. Denis, M. Hallin, A. Deplano, C. Nonhoff, R. De
Ryck, R. De Mendonc¸a, M.J. Struelens (Anderlecht, BE; Stockholm, SE)
Objectives: Healthcare-associated strains of methicillin-resistant Staphy-
lococcus aureus (HA-MRSA) are endemic in Belgian hospitals for two
decades. Recently, PVL-positive community-associated MRSA (CA-
MRSA) and livestock-associated MRSA ST398 strains (LA-MRSA)
have been identiﬁed in Belgium. We determined the relative frequency
of MRSA strains by genotype in patients in acute-care hospitals as part
of an ongoing surveillance program since 1995.
Methods: All hospitals were invited to collect three consecutive, non-
duplicate MRSA isolates from hospitalised patients in 2005 and 2008
(ﬁve isolates in 2003). MRSA were conﬁrmed by PCR for nuc and mecA
genes and genotyped by spa- and SCCmec-type. MLST was performed
on a subset of strains (n = 20).
Results: Of MRSA isolates from 315 patients in 109 hospitals, 53%
were detected on admission or 48 hours after admission, compared
to 36% in 2005 and 2003. Five PVL-positive strains (1.6%) of ST80-
SCCmec IV (n = 4) and ST5-SCCmec IV (n = 1) were detected. PVL-
positive MRSA represented 1.2% and 0.2% of MRSA from hospitalised
patients in surveys of 2005 and 2003, respectively. Two patients with
LA-MRSA ST398 (0.6%), showing spa-type t011, were identiﬁed. LA-
MRSA isolates were found in 0.9% and 0.4% of MRSA in 2005 and
2003, respectively.
Conclusion: The proportion of patients with MRSA that are imported in
hospitals was over ﬁfty percent in Belgium in 2008. However, LA-MRSA
and PVL-positive MRSA strains only represent a small proportion (<3%)
of the burden of MRSA strains in this patient population in 2008. The
frequency of PVL-positive MRSA and LA-MRSA has remained stable
since their ﬁrst detection in 2003.
Table 1: Distribution of MRSA during surveys in 2003, 2005 and 2008
2003 (n = 518) 2005 (n = 327) 2008 (n = 315)
HA-MRSA
B2-ST45-SCCmec IV: 48.5% ST45-SCCmec IV: 47.1% ST45-SCCmec IV: 39.7%
A20-ST8-SCCmec IV: 18.7% ST8-SCCmec IV: 22.6% ST8-SCCmec IV: 30.5%
C1-ST5-SCCmec II: 13% ST5-SCCmec II: 12.5% ST5-SCCmec II: 12.1%
G10-ST5-SCCmec II: 5.2% ST5-SCCmec IV: 4.3% ST5-SCCmec IV: 6.3%
C3-ST5-SCCmec IV: 2.3% ST22-SCCmec IV: 3.7%
L1-ST22-SCCmec IV: 1.9%
Total: 79.1% Total: 90.2% Total: 88.6%
PVL-positive CA-MRSA
J-ST30-SCCmec IV (n = 1) ST80-SCCmec IV (n = 2) ST80-SCCmec IV (n = 4)
ST30-SCCmec IV (n = 2) ST5-SCCmec IV (n = 1)
48 h (n = 1) 48 h (n = 2), no data (n = 2) 48 h (n = 3), >48 h (n = 2)
Total: 0.2% Total: 1.2% Total: 1.6%
LA-MRSA
ST398 (n = 2) ST398 (n = 3) ST398 (n = 2)
48 h (n = 1), >48 h (n = 1) 48 h (n = 1), >48 h (n = 2) 48 h (n = 1), >48 h (n = 1)
Total: 0.4% Total: 0.9% Total: 0.6%
O341 Association of PVL with staphylococcal pyogenic skin
infections
A.M. Kearns °, M. Ganner, I. McCormick Smith, C. Perry,
B.D. Cookson, M.J. Ellington (London, UK)
Objectives: Whilst the role of PVL in staphylococcal disease remains
contentious, the association of PVL-positive S. aureus (PVL-SA) with
recurrent skin and soft tissue infections is compelling. Following
the introduction of initiatives for enhanced ascertainment of PVL-
related disease in England, we sought to investigate the clinical and
epidemiological features of pyogenic skin infections cause by PVL-
positive versus PVL-negative S. aureus.
Methods: Isolates of S. aureus submitted referred to the national
Staphylococcus Reference Unit (SRU) recovered from pyogenic skin
infections (boils, abscesses, carbuncles etc) from patients throughout
England, Wales and Northern Ireland during 2008 were included for
study. Isolates were characterised by toxin gene proﬁling (including
PVL), mecA testing and DNA ﬁngerprinting by pulsed-ﬁeld gel
electrophoresis. Patient demographic data and clinical features including
the site of the lesion(s) and recurrence of infection were analysed.
Results: During 2008, a total of 1230 isolates of S. aureus from pyogenic
skin infections were submitted to the SRU for characterisation. Of these,
835 were MSSA and 395 were MRSA (68 and 32% respectively).
Patients were aged 0 to 95y (median 30y); the male:female ratio was
1:1.
A total of 800 (65%) isolates were PVL-positive; the majority of which
(523; 65%) were MSSA. Comparison of cases according to PVL status
showed PVL-SA were recovered from younger cohorts (median 26y)
and were commonly associated with buttock, thigh and/or axilla lesions
(50% cases). In contrast, PVL-negative SA were associated with older
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individuals (median 38y) with lesions from a wide range of body
sites, the commonest sites being breast or back (11% each). Recurrent
infections were more apparent among the PVL group (30 vs 20% cases).
A multiplicity of strains/lineages was identiﬁed. Of 10 different clones of
PVL-MRSA identiﬁed, 3 lineages (USA300, European and South West
Paciﬁc clones) predominated.
Conclusion: PVL-SA from pyogenic skin infections predominantly
occurred in younger individuals, most commonly affecting the buttocks
and/or axillae; a third of infections were recurrent. These data have
important implications for recognising, diagnosing and managing such
infections in the community.
O342 Staphylococcus aureus skin and mucosa infections in primary
healthcare in Denmark: a 12-year population-based study
M. Dalager-Pedersen °, M. Søgaard, M. Mølvadgaard,
H.C. Schønheyder (Aalborg, DK)
Objectives: A rise in community onset S. aureus infections has been
observed in several European countries. The objective of this study was
to ascertain trends of S. aureus infections in primary health care in
Denmark.
Methods: We conducted the study within the North Denmark Region
(pop. 495,000 inhabitants) 1996 though 2008. We retrieved information
on bacteriological specimens collected from skin and mucosal surfaces
by general practitioners and practicing specialists. We further obtained
data on redeemed dicloxacillin prescriptions which is the preferred anti-
staphylococcal penicillin in Denmark. Our unit of observation was a
specimen, S. aureus isolate or prescription with no similar record within
the previous year. According to this deﬁnition we limited the study to
the years 1997–2008. By use of direct standardization, we computed
annual age- and gender standardized rates of bacteriological specimens,
S. aureus isolates and prescriptions of dicloxacillin per 100,000 person-
years (pyr).
Results: A total of 108.758 specimens were obtained of which 42.778
(39%) yielded S. aureus. The rate of specimens doubled during the study
period reaching 2399 per 100,000 pyr in 2008. The rate of S. aureus
isolates increased until 2003 and remained fairly stable thereafter (842
per 100,000 pyr in 2008). Among children 0−14 years old, the rate of
S. aureus isolates increased steeply from 1997 to 2002 followed by a
gradual decrease thereafter (peak 145 per 100,000 pyr in 2002). The
most prominent trend observed 1997 to 2002 was a 7-fold rise in rate
of specimens from impetigo patients (peak rate 217 per 100,000 person-
years in 2002). After 2002, the falling rate of impetigo specimens was
counterbalanced by an increased number of specimens from wounds in
adult and elderly patients. A total of 156.462 dicloxacillin prescriptions
were identiﬁed, and the rate of prescriptions increased 2.5 times during
the study period reaching a level of 3700 per 100,000 pyr in 2007–2008.
Conclusion: The rising incidence of bacteriological cultures and anti-
staphylococcal antibiotic prescriptions indicate an increasing attention
to S. aureus infections in primary health care in Denmark. National
campaigns for prudent use of antibiotics may have been an incentive
to perform more bacteriological cultures. Impetigo, especially among
children, contributed to the rising trend but in recent years there has
been a further increase of S. aureus isolates from other sources and age
groups.
O343 Concomitant prevalence of community- and healthcare-
associated MRSA among residents and staff of long-term
care facilities in northern Israel
M.J. Schwaber °, S. Masarwa, S. Navon-Venezia, Y. Kandlik,
I. Chmelnitsky, G. Smollan, R. Glick, G. Neria, Y. Carmeli (Tel Aviv,
Safed, IL)
Background: Long-term care facilities (LTCFs) are important reservoirs
of MRSA. We determined the prevalence and molecular characteristics
of MRSA among residents and staff of LTCFs in northern Israel.
Methods: Nasal swabs were obtained from residents and staff at 6
LTCFs during February-May 2009. MRSA was identiﬁed via growth
on CHROMagar™ MRSA plates, and coagulase production. Deﬁni-
tive identiﬁcation and antibiotic susceptibilities were determined by
VITEK® 2. Genetic relatedness of strains was determined by spa-typing,
multi-locus sequence typing (MLST) and pulsed-ﬁeld gel electrophoresis
(PFGE). SCCmec typing was performed via multiplex PCR, and the
Panton-Valentine leukocidin (pvl) gene was tested for by PCR.
Results: A total of 191 residents (30% male, median age 85) and 132
staff members (20% male, median age 49) were screened. MRSA was
isolated in 14% of residents and in 11% of staff members. The major
MRSA strain carried among residents (24/27 isolates, 89%) in 5 of the 6
institutions was a healthcare-associated (HA-) MRSA strain: ST5, t002,
SCCmec type II. This HA-MRSA strain was also carried among staff
(5/14 isolates, 36%) in 2 of these institutions. HA-MRSA (ST5, t002,
un-typable SCCmec) was found as well among staff (2/14 isolates, 14%)
in an additional institution in which no residents were MRSA carriers.
An additional MRSA strain prevalent among staff (3 institutions, 6/14
isolates, 43%) was a community-associated (CA-) MRSA strain: ST8,
t008, with an un-typable SCCmec in 5 of 6 isolates grown. This CA-
MRSA strain was detected in only one resident (1/27 isolates, 4%), from
an institution in which this strain was found among 4 of its staff members
(Table). All MRSA isolates lacked the pvl gene.
Conclusions: MRSA is highly prevalent among residents and staff in
LTCFs in northern Israel. Contrary to a priori assumptions, molecular
analysis revealed little connection between MRSA among staff and that
among residents, arguing against transmission between them. The MRSA
strain ST8, t008, with a CA-MRSA phenotype, was prevalent among
staff but rare among patients.
Table MRSA details from long-term care facilities in Northern Israel
Status No. Screened Antibiotic susceptibility proﬁle MRSA molecular characterization
No. Positive MRSA
(%)
Spa type MLST SCC mec
Facility A
Residents 15 15 3 (20) 3 GENSCIPRCLIR ERYR 13 t002 ST5 II
Staff 9 9 0 (0)
Facility B
Residents 11 11 2 (18) 2 GENS/RCIPRCLIRERYR 2 t002 ST5 II
Staff 9 9 0 (0)
Facility C














Residents 12 12 0 (0)
Staff 14 14 2 (14) 2 GENRCIPRCLISERYS 2 t002 ST5 Un-typable
Facility E








Staff 12 12 4 (33) 4 GENSCIPRCLISERYS 4 t008 ST8 Un-typable
Facility F
Residents 125 125 13 (10) 13 GENSCIPRCLIRERYR 14 t002 ST5 II













Residents 192 191 27 (14%)
Staff 135 132 14 (11%)
GEN, gentamicin; CIP, ciproﬂoxacin; CLI, clindamycin; ERY, erythromycin.
Antifungal resistance and molecular
mycology
O344 Azole-resistant environmental aspergilli and Aspergillus
terreus in Denmark, Austria and Spain
K. Mortensen °, E. Mellado, C. Lass-Flo¨rl, J.L. Tudela, M. Arendrup
(Copenhagen, DK; Madrid, ES; Innsbruck, AT)
Objectives: To investigate if azole resistant aspergilli and A. terreus
are present in the environment and in commercial compost in Denmark
(DK), Austria (A) and Spain (ES).
Methods: Soil samples were collected from the surroundings of the main
hospitals in Copenhagen (CPH) (27), Innsbruck (25) and Madrid (31),
ﬂowerbeds in an amusement park in the centre of Copenhagen (23) and
ﬁnally from compost bags purchased in DK (26), A (25) and ES (28).
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Two grams of soil/compost were suspended in 5ml 0.2 M NaCl-
1% Tween and 100 ml plated on Sabouraud agar and 50 ml on each
of 4 RPMI-1640−2% glucose agars containing itraconazole (4mg/l),
voriconazole (1mg/l), posaconazole (0.5mg/l) and no antifungal, respec-
tively, and incubated at 37ºC. Identiﬁcation of aspergilli was based on
standard micro- and macro-morphological criteria. Aspergillus isolates
which grew on the azole containing agars underwent susceptibility
testing using EUCAST E.DEF 9.1 microdilution method for itraconazole,
posaconazole and voriconazole and b-tubulin sequencing unless they
were able to grow at 48ºC. The promoter and entire coding sequence of
the cyp51A gene were sequenced for azole resistant isolates.
Results: From a total of 185 samples A. fumigatus was recovered in
139 (DK: 50/76, 66%; A: 49/50, 98%; ES: 40/59, 68%), A. niger in
36 (DK: 4/76, 5%; A: 5/50, 10%; ES: 27/59, 46%), A. terreus in seven
(DK: 0/76; A: 7/50, 14%; ES: 0/59), A. nidulans in four (DK: 1/76,
1%; A: 0/50; ES: 3/59, 5%), A. ﬂavus in three (DK: 2/76, 3%; A:
0/50; ES: 1/59, 2%), A. lentulus (ES: 1) and A. spp (ES: 2, molecular
identiﬁcation pending). A total of four A. fumigatus isolates (three
from the amusement park in CPH and one from surroundings of CPH
University Hospital (CPHUH)) displayed elevated MICs to itraconazole
(>4mg/l), posaconazole (0.5−4mg/l) and voriconazole (4− >4mg/l).
All harboured the TR-L98H resistance mechanism. Additionally, one
A. nidulans and one A. niger with elevated itraconazole MICs of 4mg/l
and 2mg/l, respectively, were recovered from CPHUH.
Conclusion: Multi-azole resistant A. fumigatus is present in the
environment in DK. The resistance mechanism is identical to that of
environmental isolates in the Netherlands. In ES and A only Aspergillus
species with intrinsic resistance to either azoles or amphotericin B were
found. No link to commercial compost could be detected. Resistant
aspergilli should be considered in aspergillosis, even in antifungal drug-
naı¨ve patients.
O345 Impact of CYP51A mutations associated with azole-
resistance on in vitro growth rates and in vivo virulence of
clinical Aspergillus fumigatus isolates
E. Mavridou °, J. Meletiadis, M. Arendrup, W.J. Melchers, J.W. Mouton,
P. Verweij (Nijmegen, NL; Athens, GR; Copenhagen, DK)
Objectives: The emergence of multi-drug resistant Aspergillus fumigatus
(AF) causing invasive aspergillosis has raised the question of whether the
evolution of azole-resistance has an impact on virulence and therefore
on clinical outcome. The aim of this study was to determine whether
acquired azole resistance in fungi through mutations in CYP51A or other
unknown genes comes with a cost in ﬁtness.
Methods: The virulence study included a) 8 multi-azole resistant AF
clinical isolates with different mutations in the CYP51A gene (3 strains
with TR/L98H, 1 each with M220I, M220V, M220K, G54W, G138C) b)
3 wild-type azole susceptible (WT) strains as reference and c) 2 isogenic
isolates with no CYP51A mutations (1 susceptible and 1 resistant
strain) which were serially recovered from a single patient pre- and
post-antifungal treatment. Microsatellite-typing method and CSP-method
were performed to verify the genetic relationship of the 2 isolates.
Susceptibility testing was performed based on the CLSI-M38A method.
RT-PCR was performed to determine the CYP51A expression. In vitro
growth rates were determined using a previously described kinetic system
(Meletiadis et al JCM 2001) and deﬁned as the incubation time needed to
reach a hyphal growth of 70 microm. In vivo virulence was determined
based on the 15-day mortality in each of 52 groups of 572 outbred
i.v infected CD-1 mice (11 mice/group × 13 AF strains × 4 different
CFU inocula).
Results: There was a marked reduction of virulence of the post-treatment
azole-resistant isogenic isolate 2 (0% 15-day mortality) compared to
a) the reference WT groups (57.6% average mortality, p< 0.05) b)
the CYP51A groups (47.72% average mortality, p< 0.05) and c) the
pre-treatment azole susceptible isolate 1 (90.91% mortality, p< 0.05).
There was no difference (p< 0.05) in virulence for all CYP51A mutants
compared to the WTs. The in vitro growth rates of the AF CYP51A
mutants were not different compared to those of the AF WT control but it
was signiﬁcantly reduced when compared to the resistant isolate 2. Linear
correlation was found between in vitro growth rates-and in vivo virulence
(R2 0.99, slope 2.28, p< 0.001). Moreover, Cyp51A elevated RNA levels
implicate a-demethylase in an important role in azole resistance but not
in virulence.
Discussion: Acquired antifungal resistance can lead to dramatic decrease
of virulence of AF. However, CYP51A mutations associated with
acquired azole resistance did not affect AF virulence.
O346 Infections due to Candida spp. with reduced susceptibility
to caspofungin in France
E. Dannaoui, M. Desnos-Ollivier, D. Garcia-Hermoso, D. Raoux,
D. Hoinard, F. Dromer, O. Lortholary ° for the French Mycoses Study
Group
Objectives: Resistance to caspofungin in Candida spp. is rare with less
than 25 cases reported so far in the literature. We thus analyzed the
characteristics of infections due to isolates with reduced susceptibility
to caspofungin collected at the French Natl Reference Center (NRCMA)
between 2004 and 2009.
Methods: All Candida spp. received at the NRCMA are routinely
tested for their susceptibility to caspofungin in AM3 medium using the
EUCAST method. Those with caspofungin MIC > 0.5 mg/ml (Desnos-
Ollivier AAC 2008, 52:3092), were analyzed by sequencing the hot-
spot regions of the FKS genes. Initial isolates were also analyzed
when available and serial isolates were genotyped using polymorphic
microsatellite markers. All medical charts of patients harbouring such
isolates were reviewed.
Results: For the 14 episodes involving isolates with reduced suscep-
tibility to caspofungin, patients (sex ratio M:F = 10:4, mean age: 44y)
were diagnosed with candidemia (n = 8), other invasive infections (n = 4)
and oropharyngeal candidiasis (n = 2). Underlying diseases were hemato-
logical malignancies (n = 6), solid organ transplant (n = 2), HIV infection
(n = 1), and other conditions (n = 5). Candida species were 7 C. albicans,
6 C. glabrata, and 1 C. krusei. All 14 isolates have been recovered after
the patient was treated with caspofungin for a duration ranging from
10 days to several months. All had mutation in FKS genes. Among 10
patients for whom a previous isolate was available, paired isolates shared
identical genotypes. Furthermore, for each pair, the isolate recovered be-
fore caspofungin treatment had higher susceptibility (MIC< 0.25 mg/ml)
to caspofungin than the second ones, and had wild-type FKS genes.
Conclusions: Caspofungin resistance in Candida spp. was always
associated with prior exposure to the drug in severely ill patients. Further
analysis should uncover if other factors such as treatment’s duration
inﬂuence its occurrence. Invasive infections due to various species
of Candida spp. with acquired reduced susceptibility to caspofungin
deserve attention.
O347 Innovative multiplex diagnostics for Candida spp. using
MLPA
G. Dingemans °, R. Boesten, C. Klaassen, M. Reijans, J. Meis,
T. Boekhout, G. Simons (Maastricht, Utrecht, Nijmegen, NL)
Objective: Candida yeasts are the fourth most common source of
nosocomial bloodstream infections. Especially during the last decade,
the prevalence of opportunistic Candida infections has increased and
has become a serious threat to high risk patients.
To date, most molecular diagnostic tools are based on ribosomal
regions. Although broadly applied, these target genes have difﬁculties
discriminating closely related species, causing misidentiﬁcation and
underestimation of polymicrobial infections. This results in an urgent
need of high discriminatory and accurate detection methods for clinical
purposes using novel probes.
The aim of this project is to improve molecular diagnostics of yeast-
related infections.
Methods: A novel DNA based diagnostic system using Multiplex
Ligation-dependent Probe Ampliﬁcation (MLPA) technology serves as
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our platform for molecular diagnostics using newly developed diagnostic
probes.
A Candida-MLPA assay containing probes for C. albicans, C. dublin-
iensis, C. krusei, C. tropicalis, C. parapsilosis, C. glabrata, C. guillier-
mondii, and C. lusitaniae has been developed.
Results: The speciﬁcity of the assay was validated on 50 Candida/non-
Candida spp. from CBS Fungal Biodiversity Centre. In addition, 95
clinical isolates were screened with the MLPA assay and the results
were compared with AFLP proﬁles. In case of any discordance the
identity of the strain was established by sequencing the ITS region.
Furthermore, the total screening encompassed phylogenetically related
species, including 31 Candida spp., 4 Pichia spp. and S. cerevisiae.
The Candida-MLPA assay showed a 100% concordance with the ITS
sequences. The analytical sensitivity of the Candida-MLPA assay was
established on 100 fg gDNA, which represents less than two yeast cells.
Conclusions: We demonstrated that an assay based upon the MLPA
technology was able to identify 8 Candida spp. in one reaction. Multiple
infections, up to 7 species in one sample, could be identiﬁed. Due to
the nature of the MLPA technology highly complex assays are possible
providing room for additional probes like a generic Candida probe or
probes for other emerging species.
The speciﬁcity and sensitivity of this multiparameter assay shows great
potential for a fast and comprehensive screening approach for clinically
relevant Candida spp. in a diagnostic setting.
O348 Evaluation of publicly available sequence information in the
NCBI nr/nt database to identify fungi isolated from clinical
samples
C.D. Burnham °, E.J. Duncavage, G.P. Morris, R. Collins, W.M. Dunne
Jr. (Saint Louis, Salt Lake City, US)
Objectives: Deﬁning the speciﬁc etiology of a fungal infection is critical
to selection of appropriate antifungal therapy. Morphologic identiﬁcation
of fungi can take days to weeks and requires an experienced mycologist.
Sequence based identiﬁcation of fungi could expedite identiﬁcation but
it has been estimated that up to 20% of fungal sequences deposited in
NCBI are incorrect. A reliable database of clinically relevant fungal
sequences is critical for advancing molecular diagnosis of fungal
infections. The purpose of this study was to compare morphologic
identiﬁcation to sequence identiﬁcation of fungi isolated from clinical
samples.
Methods: Fungi isolated from clinical samples at Barnes-Jewish
Hospital and St. Louis Children’s Hospital were identiﬁed based on
morphological and/or biochemical characteristics. DNA was extracted
from the fungi using the BD GeneOhm kit with a 5 min lysis followed by
heating at 95 C for 15 min. The ITS1−5.8s rRNA-ITS2 region from 133
isolates was ampliﬁed and PCR products were bi-directionally sequenced
on an ABI 3130. Trimmed sequences were then aligned with sequences
in the NCBI nr/nt database using BLAST. Filamentous fungi and yeast
from 33 genera and 55 species were included in the study.
Results: For 64 of the 133 isolates sequenced, the morphological
identiﬁcation matched the sequence based identiﬁcation. Morphologic
and sequence based identiﬁcation were disparate in 38 cases. For 31 of
the isolates, the sequence-based identiﬁcation was equivocal; that is, the
morphologic identiﬁcation was found in the top ten “hits” in the sequence
database, but the morphologic identiﬁcation was not the ﬁrst choice or
there were other choices that were equal probability matches. Sequence
identiﬁcation performed well for most yeast species, and for some
ﬁlamentous fungi, such as Aspergillus, Scedosporium and Fusarium spp.
Sequence identiﬁcation was not as accurate for identiﬁcation of
dermatophytes, Zygomycetes, and dematiaceous moulds.
Conclusions: Use of the NCBI sequence database for identiﬁcation
of clinical isolates of fungi may result in incorrect identiﬁcation and
administration of appropriate antifungal therapy. Once our data have
been compiled into a database of fungal sequences, we will conduct
challenge experiments for the identiﬁcation of clinical isolates.
Legionella
S349 Population genetics, phylogeny and genomics
C. Buchrieser ° (Paris, FR)
Legionella pneumophila is a human pathogen that was recognized
only about 30 years ago. It is the causative agent of Legionnaires’
disease, a severe pneumonia that is transmitted through inhalation of
aerosols of contaminated water. Shortly after its discovery, the ability
of Legionella to multiply intracellularly in fresh water protozoa was
discovered. This long lasting co-evolution between the eukaryotic host
and Legionella has led to the selection of a panoply of virulence factors,
which allow to exploit important cellular processes during infection.
Compelling evidence for the importance of protozoa in the evolution of
this bacterium comes from analysis of complete genome sequences. A
key feature of the L. pneumophila genomes is the presence of a high
number and wide variety of eukaryotic like proteins and protein domains
probably acquired through horizontal gene transfer and/or convergent
evolution. In the last years several different typing methods aiming
in investigating the molecular epidemiology of L. pneumophila have
been developed. Furthermore, the access to whole genome sequences of
several L. pneumophila strains allowed to apply large scale comparative
genomics studies using DNA arrays. A higher genetic diversity among
environmental isolates with respect to clinical isolates and the presence
of speciﬁc clones of L. pneumophila overrepresented in human disease
or causing legionellosis world wide, were identiﬁed. Recently we applied
new generation sequencing to further investigate the evolutionary history
and population structure of the worldwide distributed epidemic and
endemic clone L. pneumophila Paris as well as the newly emerging
clone Lorraine.
S350 Cell microbiology
C.R. Roy ° (New Haven, US)
We are interested in the dialogue between intracellular pathogens and
eukaryotic host cells. To better understand how pathogens communicate
with the host we have been studying bacterial proteins that function in
the manipulation of host cellular processes. This lecture will describe
proteins produced by the intracellular pathogen Legionella pneumophila
that are delivered into eukaryotic cells by a specialized “type IV”
secretion system. These bacterial proteins function to prevent fusion of
lysosomes with vacuoles containing L. pneumophila and promote fusion
of the pathogen-occupied vacuole with endoplasmic reticulum-derived
vesicles. Several of these bacterial proteins modulate the activity of
small GTP-binding proteins belonging to the ARF and Rab families.
The biochemical activities of these bacterial effector proteins and their
speciﬁcity for host targets will be discussed.
Travel medicine: an emerging ﬁeld of
infectious diseases
K352 Travel medicine: an emerging ﬁeld of infectious diseases
P. Parola °, P. Gautret, P. Schlagenhauf (Marseille, FR; Zurich, CH)
Some 80 million individuals from industrialized nations travel to the
developing world each year and it is estimated that more than 200
million people now reside outside their country of birth. In recent
years, growth in international travel has been estimated at approximately
6% per year, and European travellers represent the vast majority of
international travellers. Travel medicine focus on protecting the health
of the individual and protecting the wider community in which that
individual lives, works or travels. Initially derived from infectious
diseases and tropical medicine, the specialty now encompasses primary
care, migrant medicine, occupational medicine, wilderness medicine, as
well as international health.
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Travelers can spread new and reemerging infectious diseases that initially
appear in developing countries, and act as ideal sentinels for the
early detection of these diseases. Over the past decade, the global
public health community has been facing the challenges brought on by
the emergence and rapid worldwide spread of novel inﬂuenza strains,
SARS, chikungunya virus, and drug-resistant tuberculosis amongst
other pathogens. Modern transportation and the growth of tourism,
immigration, and business travel were factors that contributed to
dissemination of these high impact pathogens.
Specialized travel/tropical medicine clinics in Europe are ideally situated
to effectively detect emerging infections and to track ongoing trends
in travel-related illness and emerging agents in collaboration with
laboratories of microbiology. Over the past decade, both global and
regional provider-based surveillance networks have emerged that have
provided, for the ﬁrst time, systematic and robust data that deﬁne the
spectrum of illness and the places of exposure to the most signiﬁcant
health risks that face travelers.
Infection control: zero tolerance?
S354 Zero tolerance: an impossible task
W. Graninger ° (Vienna, AT)
With a declining arsenal of antibiotics to treat infections, it was
increasingly clear that the traditional orientation toward control of HAIs
(hospital acquired infections) needed to shift to one where preventing
the occurrence was the priority throughout the institution.
There has to be a global capacity for the political, ﬁnancial,
managerial, and technical support needed for worldwide initiatives.
These considerations were all addressed when diseases like smallpox,
polio, measles, dracunculiasis, lymphatic ﬁlariasis, onchocerciasis,
Chagas disease, and Hansen disease were targeted for eradication. This
model doesn’t exactly work for HAIs, because we deal with many
different organisms and types of infections, humans are not the only
reservoir, many of the organisms are normal ﬂora, and relatively limited
scientiﬁc and operational resources have actually been dedicated to
preventing HAIs.
New technologies and procedures, more virulent pathogens and increas-
ing resistance will continue to challenge the healthcare community in its
efforts reduce HAIs.
If one looks theoretically at all of the infections that occur, one could
divide them up into two main groups; some that are preventable and
some that are not. The ones that are preventable are preventable through
the implementation of practices, behaviors and procedures, and following
a very strict clinical pathway. Others are not probably preventable, and
that is the irreducible amount.
The ‘getting to zero’ movement is the product of three forces: the
expansion of external pressures on infection control programs, the
intrusion of suboptimal evidence, and the convergence of quality
improvement and infection control. The ‘zero’ obsession has a number of
worrisome, unintended consequences. It sets up unrealistic expectations
on the part of the public and healthcare administrators, leading to
unreasonable demands on infection control programs. It fosters a punitive
culture, since someone must be at fault for causing infections. It
separates infection control from safety and quality, when infection
control concerns trump other important safety issues. It has shifted the
development of interventions away from an approach based on local risk
assessment to the promotion of a one-size-ﬁts-all approach. Healthcare
workers and hospital epidemiologists have become demoralized when
the expectations for getting to zero persist but the elusive zero has not
been attained.
The concept of “targeting zero HAIs” is controversial, because many
people believe it sets unrealistic or impossible expectations that all HAIs
are preventable and that any HAI that may occur was due to an error
or a broken process. Targeting ‘zero’ is problematic, because it does not
address the variation in the risk of HAIs in different patient populations
or settings, it does not address the denominator or time frame that
is necessary to understand rates of infection, and it inherently seems
scientiﬁcally unrealistic.
“Getting to zero” is a sound bite that misleads the public and is not
helpful to hospital epidemiologists. The “zero” approach to HAIs is
rigid, dishonest, and anti-intellectual, and it dives a culture of blame.
MRSA screening: what else to know
S355 Light and shadow of new tests
M.J. Struelens ° (Stockholm, SE)
Healthcare associated staphylococcal infection represents a major health
and economic burden world wide. The in vitro diagnostic industry has
in recent years invested signiﬁcantly to develop and market advanced
SA/MRSA screening tests for clinical and public health decision
support in healthcare facilities. Successful technology innovation meets
longstanding medical needs of timely detection of SA/MRSA carriers
to accelerate control of transmission. The purpose of SA/MRSA
screening is two-fold: (1) to adapt individual therapeutic and prophylactic
treatment regimens and (2) to isolate and decolonise carriers early on to
reduce secondary nosocomial transmission. Novel screening tests include
enhanced culture-based methods and molecular-based DNA detection
methods. Signiﬁcant enhancement of culture based MRSA screening has
been achieved with marketing of new generation of selective, cefoxitin-
containing chromogenic agar media. The best performing media provide
MRSA detection within 16 to 48 h post sampling with variable sensitivity
(ranging 50−99%) and good to excellent speciﬁcity (>95%). A more
sophisticated, semi-automated system of luminescent growth detection
in selective liquid media proved insufﬁciently sensitive in clinical trials.
Several PCR systems are commercially available for MRSA screening.
PCR assay time varies from 75 min to 6 h. Analytical complexity
ranges from multi-step manual procedure of sample preparation, DNA
extraction, ampliﬁcation and hybridisation to fully automated systems
with minimal sample preparation. Diagnostic accuracy of PCR tests
varies according to test, test version, sample site and reference method
used as gold standard with sensitivity range of 70–100% and speciﬁcity
range of 90−99%. Impact of rapid MRSA screening on transmission
control effectiveness depends on many contextual factors, including
workﬂow integration and clinical turn-around time, case-mix and type
of care, MRSA incidence and prevalence, infection control policy,
compliance with infection control measures and intervention study
design. Cost-effectiveness evaluation should carefully examine these
parameters for each test before routine implementation.
The threat of a new inﬂuenza A pandemic
S358 A “One Health” approach to inﬂuenza virus infections to
support public health
I. Capua ° (Legnaro, IT)
The emergence and spread of the 2009 pandemic H1N1 virus (H1N1
2009) from the animal reservoir raises questions on the future approach
to inﬂuenzavirus infections. We have evidence demonstrating that
inﬂuenzavirus genes migrate across continents and animal species, and
assemble themselves in combinations which are a threat to animal and
human health, resulting in panzootics like H5N1 or pandemics like H1N1
2009. The latter contains a unique combination of genes from three
species and two hemispheres. In a globalized environment, mapping
gene movement across species and national borders and identifying
mutations and gene constellations with pandemic potential or virulence
determinants is essential to enact prevention and control strategies at
a global level. This is in line with, and possibly the best example of,
the ‘One Health’ vision: a multidisciplinary collaborative approach to
improve the health of humans, animals and the environment endorsed
by the UN Food & Agriculture Organisation, the World Organisation for
Animal Health (OIE) and the World Health Organisation.
Vast improvements in capacity building have been achieved as a result
of the H5N1 global crisis. Thousands of viral isolates with zoonotic
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potential have been obtained through surveillance efforts, although
the genetic information has not been exploited fully. In addition, the
circulation of inﬂuenzaviruses in certain species including dogs, pigs
and horses has been neglected.
Time has come to invest in a novel approach to inﬂuenzavirus infections,
abandoning preﬁxed compartments linked to geographical origin or
species of isolation, and analyse the inﬂuenza gene pool as one entity.
We propose capitalising on existing achievements and investments to
develop an international network and a permanent observatory which will
improve our understanding of the dynamics of the inﬂuenzavirus gene
pool in animals and humans. This will generate essential information to
support both public and animal health.
The “One Flu” initiative would result in international synergies, bridging
gaps between medical and veterinary scientists, permanent monitoring
of virus evolution and epidemiology and the best exploitation of
investments in capacity building. Above all it could be a challenge and
opportunity to implement the “One Health” vision, and possibly act as
a model for other emerging zoonotic diseases.
Antimicrobial activity against carpabenem
resistant Gram-negative bacteria
O359 In vitro activity of antimicrobials in combination against
clinical strains of extreme drug-resistant Acinetobacter bau-
mannii to all antibiotics including polymyxin B in Singapore
T.P. Lim °, W. Lee, S. Sasikala, L.Y. Hsu, T.H. Koh, T.T. Tan, A.L. Kwa
(Singapore, SG)
Objectives: We have used polymyxins since 1990s in Singapore. Emer-
gence of extreme-drug resistant(XDR) Acinetobacter baumannii(AB)
infection resistant to all available antibiotics including polymyxins have
ﬁnally occurred. Combination therapy may be the only viable option
until new antibiotics become available. We assess the in vitro activity
of various antimicrobials and elucidate the most effective combination
therapy against these XDR AB.
Methods: Five XDR AB strains from 4 different patients (1 with
haematological malignancy and 3 with severe burns injuires) were
identiﬁed, after weeks of polymyxins therapy. MICs were determined
according to a modiﬁed CLSI broth-dilution method. Time-kill studies
(TKS) were performed with approximately 105 CFU/ml at baseline with
the maximum, clinically achievable, unbound concentration (mg/L) of
PB (2), (R)rifampicin (2), (M)meropenem (64), (C)cefepime (200) and
(T)tigecycline (2) alone and in combination against these 5 isolates.
Results: All isolates were resistant to all antibiotics including PB
(MICs 16–128mg/L). In TKS, CP provided a killing effect of >99%
(>2 log kill) from baseline inoculum at 24 h for all 5 strains. CM & MR
exhibited killing effect of >99% from baseline inoculum at 24 h for 4
strains. MP exhibited killing effect of >99% from baseline inoculum
at 24 h for 3 strains. CR, TM & PR exhibited killing effect of >99%
from baseline inoculum at 24 h for 2, 1, & 1 strains, respectively. Four
strains had 3 or more antibiotic combinations that provided killing effect
of >99% from baseline inoculum at 24 h, while 1 strain had only 1
antibiotic combination that was effective.
Conclusions: Clinical isolates of AB resistant to PB is also resistant to
all major antibiotic classes with no compromise in bioﬁtness; in contrary
to previous reports that illustrate PB resistant AB with a substantial
deﬁcit in bioﬁtness in vitro. We had shown that CP, CM, MR, MP may
be potential antibiotic combinations as pre-emptive therapy for XDR AB
infections and the effective combinations were strain speciﬁc. Our study
warrants further investigations.
O360 In vitro antibacterial activity of ceftazidime in combination
with the b-lactamase inhibitor NXL104
P. Levasseur °, C. Miossec, A.M. Girard, L. Lavallade, M. Black,
D. Shlaes, J. Pace, K. Coleman (Romainville, FR; Connecticut,
Philadelphia, US)
Objective: NXL104 is a novel b-lactamase inhibitor that has been shown
in vitro and in vivo to inhibit both class A and class C b-lactamases; it
is currently in phase 2 of clinical development in combination with
ceftazidime (CAZ). The objective of the study was to evaluate the
antibacterial activity of CAZ/NXL104 combination against characterized
Enterobacteriaceae species.
Methods: Activity of CAZ/NXL104 combination was tested on 222
strains of Enterobacteriaceae representing most clinical species. The
panel included 49.5% CAZ-resistant isolates, most with characterized
b-lactamases. Minimal Inhibitory Concentrations (MIC) were determined
with NXL104 at ﬁxed ratios of 1:1 to 16:1, or at ﬁxed concentrations of
2, 4, and 8mg/mL.
Results: CAZ/NXL104 combinations were active against all isolates and
had signiﬁcantly lower MICs than CAZ alone, cefotaxime, ceftriaxone,
cefepime, or piperacillin/tazobactam (MIC90s >128mg/mL). MIC50s
and MIC90s for CAZ with ﬁxed concentrations of NXL104 were
0.125−0.5 and 1−4mg/mL, respectively, and 1−2 and 4−16mg/mL,
respectively, with ﬁxed ratios. Potentiation of CAZ by NXL104 was
generally 16 to 512-fold for TEM, SHV, CTX-M or KPC producers.
Against KPC producers, NXL104 reduced CAZ MICs from >128 to
0.25−8mg/mL. Potentiation of 8 to 512-fold was observed against
AmpC enzyme producers.
Conclusion: The CAZ/NXL104 combination exhibits a broad spectrum
activity against resistant Enterobacteriaceae isolates, and represents an
important next-generation of b-lactam/b-lactamase inhibitor combina-
tion.
O361 Activities of tigecycline in combination with colistin
or meropenem against KPC carbapenemase-producing
Enterobacteriaceae by time-kill analysis
S. Pournaras, E. Neou, A. Poulou °, G. Vrioni, A. Tsakris (Larissa,
Serres, Athens, GR)
Objectives: Enterobacteriaceae producing KPC carbapenemases cause
hospital infections often associated with therapeutic failures and
increased mortality. The treatment of these infections usually requires
the use of tigecycline or colistin as a last-resort drug. The objective of
this study was to test the in vitro activity of tigecycline against KPC-
producing Enterobacteriaceae.
Methods: The KPC-producing isolates comprised four Klebsiella
pneumoniae, two Escherichia coli, one Enterobacter cloacae and one
Serratia marcescens. The K. pneumoniae and E. coli isolates were
randomly selected among those representing different clonal types. MICs
were obtained using the macrodilution method in fresh Mueller–Hinton
broth (MHB), before performing time-kill assays by inoculating 5x105
CFU/mL of the test organisms in 3ml MHB. E. coli ATCC 25922
was used as control. Antibiotics (tigecycline, colistin and meropenem
as single agents and in combinations) were added at concentrations 1x
and 2x the MIC for each isolate. Aliquots were removed at times 0, 2 h,
4 h, 6 h, 8 h, 16 h and 24 h post-inoculation, serially diluted and plated
on MH agar plates for enumeration of viable colonies. Each time-kill
experiment was performed twice. As bactericidal activity was deﬁned a
3 log10 CFU/mL reduction in viable cells with respect to the original
inoculum.
Results: Macrodilution MIC values were 0.25 to 2mg/L for tigecycline,
0.5 to 1mg/L for colistin and 2 to 16mg/L for meropenem. In time-
kill assays, tigecycline and meropenem as single agents were mostly
bacteriostatic for the ﬁrst 6−8 hours of incubation with bacterial
regrowth to follow, while colistin alone was ineffective. The tigecycline
plus colistin combination was in most cases bactericidal after 4 to
8 h of incubation and in some cases also synergistic compared with
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tigecycline alone, although bacterial regrowth was observed after 8 to
16 h. The tigecycline plus meropenem combination was in most cases
also bactericidal after 4 to 6 h of incubation and thereafter regrowth was
observed.
Conclusion: The results of the present study indicate that tigecycline
alone could be a therapeutic option for infections due to multidrug
resistant KPC producers when bacteriostatic activity is adequate or in
combination with colistin or meropenem when bactericidal activity is
necessary. Additional in vivo tests may be warranted to fully assess the
killing kinetics of tigecycline against KPC producers when the immune
system is competent.
O362 Activity of temocillin against carbapenem-resistant clinical
Enterobacteriaceae
S. Mushtaq, M. Warner, J-C. Zhang, S. Maharjan, M. Doumith,
N. Woodford °, D. Livermore (London, UK)
Objectives: Until recently, carbapenems retained near-universal activity
against Enterobacteriaceae but resistance is now emerging, mediated
either by combinations of ESBL or AmpC enzyme and porin loss or
by carbapenemases. The prevalent emerging carbapenemases vary by
country: KPC enzymes in the USA and Israel, OXA-48 in Turkey,
VIM in southern Europe and NDM in Italy. The UK sees small
numbers of isolates with each of these types, some imported, some
representing domestic spread. Most are multiresistant. We examined
their susceptibility to temocillin a 6-a-methoxy derivative of ticarcillin,
notable for stability to ESBLs and AmpC.
Methods: The 81 isolates tested isolates variously had KPC (n = 10),
SME-1 (1), IMP (13), VIM (5), NDM (17) or OXA-48 (19 carbapen-
emases or had combinations of impermeability with an AmpC enzyme
or ESBL (16); they included 52 Klebsiella spp., 18 Enterobacter spp., 6
E. coli and 5 others. Transformants and transconjugants were prepared
in E. coli DH5-a and J62−1, respectively. Carbapenemase genes were
identiﬁed by PCR and sequencing; MICs were measured by CLSI agar
dilution.
Results: MICs for isolates with KPC carbapenemases were from
16−64mg/L (geom. mean 40mg/L) and introduction of a KPC+ plasmid
into E. coli only raised the MIC from 8 to 16mg/L; by contrast MICs for
isolates with metallo-b-lactamases were >128mg/L in 22/36 cases, and
introduction of plasmids coding NDN carbapenemase (the commonest
MBL in the UK) into E. coli DH5a raised the temocillin MIC from 4
to >64mg/L. Temocillin MICs for isolates with OXA-48 enzyme were
>128mg/L in 18/19 cases, and the MIC shift on transformation of E. coli
DH5-a was from 4 to >128mg/L. Temocillin MICs for isolates with
combinations of porin loss and AmpC or an ESBL were from 8 to
128mg/L (geom. mean 25mg/L).
Conclusion: If the dosage can be raised from the present 2 g bds,
temocillin may be a therapeutic option in some infections due to
Enterobacteriaceae with KPC carbapenemases or combination of AmpC
or ESBL and porin loss, not against those with OXA-48 or metallo-
carbapenemases.
O363 Interactions mediating the positioning of mercapto-
phosphonate inhibitors in the active site of
metallo-b-lactamases
P. Lassaux, H. Delbru¨ck, M. Gulea, M. Kupper, K. Hoffmann,
M. Galleni, C. Bebrone ° (Lie`ge, BE; Aachen, DE; Caen, FR)
Objective: Metallo-b-lactamases (MBL) represent an emerging problem
due to their capacity to hydrolyze almost all b-lactam antibiotics,
including last generation cephalosporins and carbapenems. Due to the
presence of two chelating functions (sulfanyl and phosphonato), the mer-
captophosphonic acids (phosphorous analogues of mercaptocarboxylic
acids) are potential candidates for MBL inhibitors.
Methods: The inhibitory effect of 14 mercapto-phosphonate derivatives
against representatives of the three subclasses of MBLs (VIM-4 (B1),
CphA (B2) and L1 (B3)) was previously reported [1]. Here, in order
to determine the interactions mediating the positioning of the inhibitors
in the active site of each enzyme, crystallographic and docking studies
were performed with 10a and 18, both inhibitors being active against the
three subclasses.
Results: The crystallographic structure of the CphA-10a and CphA-18
indicated that the sulphur atom of 10a and the phosphonato group of
18 interact with the zinc ion respectively. Molecular modelling on the
VIM-4 (B1) and FEZ-1 (B3) enzymes with 10a and 18 also brought to
light different binding modes depending on the enzyme and the inhibitor,
consistent with the crystallographic structures.
Conclusions: The investigation of mercapto-phosphonate derivatives
as MBL inhibitor has allowed us to ﬁnd potent inhibitors active on
representative members of all the three MBL subclasses. Moreover, on
the basis of structural and modelling data, the inhibitory strength of these
compounds will be improved further.
Reference(s)
[1] Lassaux P., Hamel M., Gulea M., Mercuri P., Horsfall L.,
Bebrone C., Gaumont A-C., Fre`re J., Galleni M. Mercapto-
phosphonate compounds as broad-spectrum inhibitors of the metallo-
b-lactamases, Abstract number: 1732_295, ECSMID 2007.
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O364 Hormographiella aspergillata: an emerging mould in acute
leukaemia patients?
A. Conen °, M. Weisser, D. Hohler, R. Frei, M. Stern (Aarau, Basel, CH)
Objectives: Invasive fungal infections (IFI) are a major cause of mor-
bidity and mortality in hematological patients. The emergence of non-
Aspergillus molds has been observed in recent years. Hormographiella
aspergillata is a Basidiomycete and has previously been implicated in
human infections rarely. We describe 3 cases of IFI with H. aspergillata
occurring within one year on the hematological ward at the University
Hospital Basel.
Methods: Patients were hospitalized in single rooms with special high-
efﬁciency particle air ﬁlters. Surveillance fungal cultures of air ﬁlters
were carried out regularly. No primary mold prophylaxis was performed.
Screening for mold infections was performed by twice weekly measuring
serum galactomannan and weekly pulmonary CT scans. Sabouraud agar
was inoculated for fungal cultures. The identiﬁcation of H. aspergillata
by culture was molecularly conﬁrmed. Susceptibility testing was
performed by Etest.
Table 1. Minimal inhibitory concentrations of antifungals against
Hormographiella aspergillata patients isolates
Compound Case 1 Case 2 Case 3
Amphotericin B not done 0.5mg/l 0.5mg/l
Caspofungin not done 2mg/l >32 mg/l
Voriconazole not done 0.125mg/l 0.25mg/l
Fluconazole not done not done >256mg/l
Posaconazole not done not done not interpretable
Results: In one year, 3 cases of pulmonary IFI with H. aspergillata in
leukemic patients, undergoing prolonged periods of severe neutropenia,
were found. One patient (case 1) also had cerebral and ocular
involvement in autopsy. This patient had positive blood cultures with
H. aspergillata. In all patients pulmonary CT showed inﬁltrates,
bronchoalveolar lavage performed failed however to identify the
causative microorganism and serial serum galactomannan measurements
remained negative. In contrast, specimens collected by VATS grew
H. aspergillata in both patients where it was performed (cases
2+3). In vitro susceptibility testing was done in 2 cases (Table 1).
Treatment consisted of caspofungin in one patient (case 1), after severe
hepatotoxicity due to azoles, and of second generation azoles in the
others. An evaluation of the in vivo efﬁcacy of antifungal treatment in
this series is difﬁcult. All patients died, one due to the disseminated
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IFI (treated with caspofungin), 2 due to progression of the underlying
hematological disease and allogeneic transplant related complications.
Conclusions: Despite the accumulation of 3 cases of an unusual IFI
with H. aspergillata, no hospital source was detected. Due to the rarity
of cases reported there is no established treatment for H. aspergillata.
Standardized antifungal susceptibility testing of ﬁlamentous fungi has
been established only recently and breakpoints with proven clinical
relevance have yet to be identiﬁed. Voriconazole might be a valuable
treatment option.
O365 How to improve microbial documentation in febrile
neutropenia? Impact of implementing an automat in the
ward and addition of DNaemia detection
C. Pautas °, Y. Hicheri, S. Bastuji-Garin, C. Corbel, S. Bretagne,
L. Gregoire, E. Sbidian, S. Maury, C. Cordonnier, E. Cambau (Creteil,
Paris, FR)
Objectives: Febrile neutropenia (FN) is the most frequent complication
of high-dose chemotherapy-induced neutropenia. Only 30% of FN
episodes are microbiologically documented by routine procedures,
mainly by blood cultures (BC). We wondered whether shortening the
time before incubation could improve this ﬁgure. In addition, we
searched microbial DNA by the Septifast® test.
Methods: Adult patients were eligible at their 1st FN episode if they
were neutropenic (PMN< 0.5×109/L), febrile (38º3 or twice 38º
within 8 h), and had a central venous catheter (CVC). At onset of
fever, we collected 4 BC bottles (2 aerobic and 2 anaerobic)sampled
through the CVC. They were immediately incubated in the ward
(BacT/Alert3D®). Septifast was performed on 1.5ml of blood sampled
at the same time. In parallel, 2 standard BCs (1 aerobic and 1 anaerobic
bottles) were routinely sampled (1 CVC and 1 peripheral) and sent to
the laboratory for incubation. Each patient was assessed for microbial
documentation in the blood, either BC positivity or DNA detection; and
the time elapsed between blood sampling and documentation, when
this latter was positive. Pairwise analyses were performed using the
McNemar test for documentation rate and the Wilcoxon signed-rank
test for times for positivity.
Results: 120 consecutive FN episodes were included from Feb 2008 to
Mar 2009: 97 (80%) acute leukemia/myelodysplasia, 26 (17%) lymphoid
malignancies and 4 (3%) others with 18 (15%) episodes in allogeneic
and 16 (13%) in autologous stem cell transplantation. The rate of BC
positivity was 30% (36 episodes) in the study process and 28.3% (34
episodes) in the routine process (McNemar’s c2 = 0.67, p = 0.41). In
the microbiologically documented episodes, the time elapsed between
incubation and positivity was signiﬁcantly shorter for the BC bottles
incubated in the ward (median rank: 12 h25 min [7 h55−25 h37]) than
for the routine BC bottles (median rank: 13 h03 min [9 h31−43 h33])
(p = 0.002). The Septifast test was positive in 9 episodes (7.5%) that
were positive also by the BC testing. In 8 additional episodes, the
Septifast® test showed low DNA content out of the threshold, which
was nevertheless concordant with positives BCs.
Conclusion: Immediate incubation of blood cultures in the ward and
detection of DNaemia with the Septifast test did not improve the rate of
microbial documentation for FN episodes when compared to BC routine
process. However, it reduced the time to positivity.
O366 Aetiology of eye infections in hospitalized ophthalmological
patients
M.M. Wroblewska °, G. Broniek (Warsaw, PL)
Objectives: Ophthalmological patients are prone to nosocomial infec-
tions due to advanced age and common underlying medical conditions.
Eye infections caused by multi-drug resistant (MDR) pathogens may
further contribute to loss of vision in already visually disabled persons.
Antimicrobial therapy is often difﬁcult due to unsatisfactory penetration
of many agents into the eye. Empiric therapy should be based on data
comprising most prevalent pathogens, including MDR pathogens.
Methods: Specimens for bacteriological and fungal culture were
obtained from patients hospitalized in ophthalmological hospital (2005–
2009). Samples were cultured and isolates identiﬁed according to
standard microbiological techniques.
Results: In total 1662 specimens were cultured, including swabs from
conjunctiva, cornea, throat, nose, wounds and cornea conservation
medium. The samples yielded 328 isolates, comprising 293 strains of
bacteria and 7 strains of yeast-like fungi. Among bacteria predominated
staphylococci − 197/293 (67.23%), followed by enteric rods − 36/293
(12.29%), non-fermenting rods − 20/293 (6.87%) and streptococci −
19 (6.48%). Among alarm pathogens there were methicillin-resistant
S. aureus (MRSA) strains (4/50, 8.00%), high-level aminoglycoside
resistant (HLAR) strains of enterococci (1/8, 12.50%), extended-
spectrum b-lactamase producing − ESBL(+) enteric rods (2/36, 5.56%)
and ESBL(+) Gram-negative nonfermenting rods (4/20, 20.00%).
Methicillin-resistant coagulase-negative staphylococci (MRCNS) com-
prised 28/147 (19.05%) strains. Among all cultured microbial isolates
there were 7/300 (2.33%) strains of fungi. Predominated Candida
parapsilosis (4/7 strains), followed by C. albicans (2/7) and C. glabrata
(1/7).
Conclusion: In ophthalmological specimens predominated Gram-
positive cocci, mainly staphylococci. The presence of MRCNS (19%)
may be important in therapy of bioﬁlm-associated implant infections. In
this study there was a high percentage (20%) of ESBL(+) Gram-negative
nonfermenting rods. Among yeast-like fungi Candida parapsilosis
was more often isolated than C. albicans. This is clinically relevant
as C. parapsilosis tends to form a bioﬁlm on artiﬁcial materials,
increasingly used in ophthalmic surgery.
O367 Prognosis of human listeriosis is directly associated with the
severity of the underlying disease
M. Ferna´ndez Guerrero °, R. Torres Perea, B. Mancebo, J. Jusdado,
M. Go´rgolas (Madrid, ES)
Objectives: To determine the incidence, manifestations, outcome and
risk factors for mortality of a series of adult patients with listeriosis.
Methods: Retrospective review of medical records of adult patients with
isolation of Listeria monocytogenes from blood, CSF or other sterile ﬂuid
during a period of 15 years in two hospitals in Madrid.
Results: Sixty four patients were assessed. The mean age was 58.8
years (from 20 to 85) without differences in distribution by genders.
The prevalence of infection was 0.5 cases per 100.000 inhabitants year.
Seventy per cent of patients had a chronic underlying disease: cirrhosis
of the liver (30%), hematologic neoplasms (25%), chronic debilitating
conditions (23%), collagen vascular disease (13%) and solid neoplasms
(11%) were the most common underlying conditions. Only 1 pregnant
woman was seen. Primary bacteremia (56%) and meningoencephalitis
(44%) were the most common presentations. In addition, 10 patients
developed focal infeccio´n such as bacterial peritonitis (4), endocarditis
(3) and brain abscesses (3). Although most infections were community-
acquired, 17 episodes (26%) developed within the hospital after more
than 72 h of admission. Nosocomial outbreaks were not detected.
Ampicillin (34%) alone or in combination with gentamicin (44%) and
cotrimoxazol (16%) were the antimicrobial regimens most frequently
used. We did not ﬁnd differences in the mortality rate among patients
on monotherapy (32%) and combined therapy (35%). Cotrimoxazol was
successfully used in 9 out of 10 patients treated. Nineteen patients (39%)
died within 30-days of diagnosis. Mortality was signiﬁcantly higher in
patients with hematologic or solid neoplasms than in those with cirrhosis
or other underlying debilitating disorders (64% vs 36%, p< 0.05). All
the patients without comorbidities survived the infection.
Conclusions: Human listeriosis is a severe disease still producing high
mortality particularly in immunocompromised hosts with hematologic
and solid neoplasms and other debilitating conditions. Despite synergistic
in vitro activity, the combination of ampicillin plus gentamicin did not
determined survival beneﬁts. Cotrimoxazol may be a useful alternative
for the antimicrobial therapy of human listeriosis.
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O368 Campylobacter sp. bacteraemia in Taiwan, 1999–2008
C.Y. Chuang °, Y.T. Huang, C.H. Liao, P.I. Lee, P.R. Hsueh (Taipei
City, TW)
Objectives: Bacteremia caused by Campylobacter species is rarely
described in Asia. We investigated the bacteriology and clinical
presentation of Campylobacter bacteremia in Taiwan.
Methods: There were 28 episodes of Campylobacter spp. bacteremia
in 28 patients occurred from January 1999 to December 2008 in
National Taiwan University Hospital. All the 28 isolates were identiﬁed
by conventional phenotypic methods and later conﬁrmed by using
previously described multiplex PCR (cadF, hipO and asp gene detection)
and 16S RNA gene sequencing up to 900 base pairs. Medical records
were reviewed in 24 patients.
Results: The most common species is C. coli (N = 17[60.7%]) followed
by C. fetus and C. jejuni (N = 6[35.2%] and N= 5[29.4%]; respectively).
One isolate was identiﬁed as C. coli by multiplex PCR which is not
consistent with the result of 16S RNA gene sequencing (C. jejuni
strain SWUN0713; accession number: gb GQ479815.1). Of the 24 cases
with available medical records, 17 patients were male with a median
age of 45.7 (range of age was from 7.75 to 80.67 years old). The
main underlying conditions were hemato-oncological disease (41.67%)
followed by hepatic decompensation (37.5%), renal insufﬁciency
(33.3%) and liver cirrhosis(25%). There were 7 patients (29.17%) were
in usage of steroid. The most common clinical manifestations were intra-
abdominal infection (54.16%), primary bacteremia(10 patients, 41.67%),
and cellulitis (4.1%). The mean Pitts bacteremic score was 1.58 (range
from score 0 to score 9). There were 6 patients’ systolic blood pressure
were below 90mmHg(25%). And consciousness change were noted in
8 patients (33.33%). Leucocytosis were noted in 12 patients(50%), and
the mean value of white blood cell counts were 11,065.5/ul (Range was
from 4,050/ul to 21,340/ul). And the mean value of c-reactive protein
was 6.56mg/dl. Third generation antibiotics was the most commonly
used empirical treatment regimen (50%) and Amoxicillin/clavunalic acid
was 20.83%. The mean hospitalization stay was 12.96 days. All cause
mortality at 14 days was 4.16% (N= 1) and 16.67% (N= 4) at 30 days.
Conclusions: Campylobacter coli is the leading species causing invasive
Campylobacteriosis in immunocompromised patients in Taiwan.
Experimental treatments in animal models
O369 Antifungal drugs improve survival by immunomodulation
rather than by reduction of fungal burden in experimental
cerebral aspergillosis
I. Ullmann, R. Strahm, S.L. Leib, S. Zimmerli ° (Berne, CH)
Objectives: To evaluate the antifungal and immunomodulatory effects
of antifungal drugs we used a lethal model of cerebral aspergillosis in
non-immunosuppressed infant rats.
Methods: Eleven-day-old male Wistar rats were infected by intracister-
nal injection of 7.17 log10 colony-forming units of Aspergillus fumigatus
conidia. Treatment started 22 h after infection and was given for 10d.
Regimens were (i) caspofungin (CAS) 1mg/kg/d i.p. qd, (ii) liposomal
amphotericin B (L-AmB) 5mg/kg/d i.p. qd, (iii) both drugs combined at
the same dose, and (iv) voriconazole (VCZ) starting at 15mg/kg bid and
increasing the dose to compensate for auto induction of metabolism. In
survival experiments censored at 11d brains were examined at the time of
death. To monitor cerebral disease progression, animals were sacriﬁced
2, 3, 5, and 11d after infection. Brain homogenates were analyzed by
quantitative fungal culture, a ﬂow-cytometry based assay for cytokine
quantiﬁcation, and ELISA for galactomannan (GM) detection. Animals
with symptoms of severe disease were sacriﬁced for ethical reasons.
Results:
1. Survival experiments [Fig. A]: Compared to controls (4.4±2.7d),
survival times were signiﬁcantly increased by treatment with CAS
alone (10.3±1.7d; p< 0.0001) and combined with L-AmB (9.3±2.8d;
p< 0.0001) as well as VCZ (10.1±2.2d; p< 0.0001). In contrast,
survival time of animals treated with L-AmB alone (4.3±3.1d) was
not different from untreated controls.
2. Fungal culture: The cerebral fungal burden declined over time in
all animals including untreated ones. Interestingly, there was no
signiﬁcant difference between controls and treated animals.
3. GM: GM peaked later than the CFU counts in all treatment groups
except L-AmB. There were no signiﬁcant differences in GM indices
regarding treatment and time.
4. Cytokines: At 2d after infection both IFN-g and TNF-a [Fig. B]
levels were signiﬁcantly higher in animals treated with L-AmB
alone (135.8±93.9pg/mg and 25.8±22.2pg/mg) compared to
CAS (24.1±20.8pg/mg and 6.3±8.4pg/mg; p< 0.001), and VCZ
(13.8±8.0pg/mg and 2.0±1.9pg/mg; p< 0.001). No differences were
found for IL-1a and IL-10. IL-6 was undetectable in most animals
but elevated in severe disease.
Conclusion: In this lethal model of cerebral aspergillosis mortality is
not determined by the antifungal drug’s effect on cerebral fungal burden
but by its modulation of the host’s immune response.
O370 Receptor for advanced glycation end-products is protective
during murine tuberculosis
M.A.D. van Zoelen °, C.W. Wieland, G. van der Windt, J.M. Braun-Pater,
S. Florquin, P.P. Nawroth, A. Bierhaus, T. van der Poll (Utrecht,
Amsterdam, NL; Heidelberg, DE)
Objective: The development of active tuberculosis after infection with
Mycobacterium (M.) tuberculosis is almost invariably caused by a
persistent or transient state of relative immunodeﬁciency. Multidrug-
resistant strains are on the rise and the frequent occurrence of co-
infection with the human immunodeﬁciency virus makes the treatment
and outcome of tuberculosis even more worrisome. The receptor for
advanced glycation end products (RAGE) is a promiscuous receptor that
is involved in pulmonary inﬂammation and infection. We here aimed to
investigate the role of RAGE in tuberculosis.
Methods: RAGE deﬁcient (RAGE−/−) and normal wild-type (Wt) mice
were intranasally inoculated with live virulent M. tuberculosis.
Results:While lungs of infected Wt mice expressed RAGE, in particular
on endothelium, M. tuberculosis pneumonia was associated with an
enhanced expression of pulmonary RAGE. Lung inﬂammation was
increased in RAGE−/− mice, as indicated by histopathology, percentage
of inﬂamed area, lung weight and cytokine and chemokine levels. In
addition, lung lymphocyte and neutrophil numbers were increased in the
RAGE−/− mice. RAGE−/− mice displayed higher mycobacterial loads
in the lungs after 3 weeks of infection, while they showed similar loads
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in the liver at 3 and 6 weeks. Finally, RAGE−/− mice displayed body
weight loss and a worsened M. tuberculosis induced mortality (Figure).
Conclusion: These data suggest that RAGE plays a beneﬁcial role in
the host response to pulmonary tuberculosis.
O371 Imipenem or meropenem plus clavulanate combination
improves survival of mice infected with M. tuberculosis
N. Veziris °, C. Truffot, J. Mainardi, V. Jarlier (Paris, FR)
Background: Due to the emergence of extensively drug resistant
strains (XDR) of M. tuberculosis, new antituberculous agents are
desperately needed. Although b-lactam antibiotics are not considered
as antituberculous drugs, it has been recently shown in vitro that the
combination of meropenem and clavulanate has synergic activity against
M. tuberculosis.
Objectives: We wished to evaluate in the murine model of tuberculosis
the activity of penems alone and combined with clavulanate against
M. tuberculosis.
Methods: Swiss mice were infected intravenously with 3.105 M. tu-
berculosis H37Rv and treated the day after inoculation for 4 weeks.
Treatment groups consisted of 10 mice. The test groups were treated with
clavulanate (100mg/kg) alone, imipenem (100mg/kg) and meropenem
(100mg/kg) alone or combined with clavulanate whereas a positive
control group was treated with isoniazid (25mg/kg) and a negative
control group was held without treatment. At the end of treatment,
surviving mice were sacriﬁced and lungs harvested. Treatment efﬁcacy
was assessed on survival rate, spleen weights and lung CFU counts.
Results: at the end of the 4 weeks, the mortality rates were the following:
untreated 60%, isoniazid 0%, clavulanate 30%, imipenem 10%,
meropenem 30%, imipenem+clavulanate 0%, meropenem+clavulanate
0%. The combination of imipenem or meropenem plus clavulanate
signiﬁcantly improved survival (p = 0.01 vs untreated mice). On the
other hand, imipenem and meropenem combined with clavulanate
did not prevent splenomegaly (591 and 573mg) whereas isoniazid
did (304mg) (p> 0.05). Among groups of mice with 100% survival,
only isoniazid reduced lung CFU counts (−1.2 log10 CFU vs D0),
the penem+clavulanate combinations did not prevent bacterial growth
(+0.9 to 1.4 log10 CFU vs D0).
Conclusion: although less active than isoniazid, the combinations of
imipenem or meropenem and clavulanate improve survival of mice
infected with M. tuberculosis and should be further evaluated.
O372 Evaluation of the efﬁcacy of anti-staphylococcal human
therapies in a severe PVL pneumonia model
D. Croisier-Bertin °, C. Badiou, S. Rousseau, D. Hayez, S. Mahy, G. Lina,
F. Vandenesch, J. Etienne, P. Bret, P. Chavanet (Dijon, Lyon, Paris, FR)
Objectives: Many strains of S. aureus harbour the Panton Valentine
Leukotoxin (PVL) phage and can cause severe necrotising pneumonia in
young immunocompetent patients. In vitro studies showed that some anti-
staphylococcal drugs can induce or inhibit the PVL production. Animal
models are needed to evaluate new treatment strategies in such infections.
We compared the efﬁcacy of 4 antibiotic human therapies in a severe
model of PVL necrotizing pneumonia in rabbits.
Methods: 2 isogenic and fully-susceptible S. aureus strains were used to
induce pneumonia: RN6390 PVL− and LUG855 PVL+. Animals were
randomized to no treatment (controls) or to a 48 h IV human equivalent
dosage of either vancomycin (VA continuous perfusion Css=30mg/l),
cloxacillin (CLOX 2g/6 h), clindamycin (CLI 600mg/8 h) or linezolid
(LZO, 600mg/12 h). Serum levels were measured by microbiological
assay or HPLC, pharmacokinetic data were obtained, and evaluation of
efﬁcacy was based on bacterial counts in lungs (mean±SD) and the
residual quantity of PVL (mg/residual CFU).
Results: Several inocula were tested to perfect this model. Here are the
results for an inoculum of 8.5 log CFU/mL (table).
Controls: The mortality rate (60−66%) and bacterial content in controls
were the same between PVL− and PVL+ groups.
Bacterial reduction: No signiﬁcant efﬁcacy was obtained with VA. LZO,
CLOX and CLI were highly efﬁcacious against both strains with a
complete sterilization of lungs and spleen for CLOX and CLI (CLOX =
CLI > LZO > VA).
Early mortality: VA did not reduce the mortality rate. 0% of early
mortality was obtained with CLOX and CLI. LZO slightly reduced the
mortality rate (CLOX = CLI > LZO > VA).
PVL assessment: VA and CLOX did not reduce the residual PVL quantity
signiﬁcantly. LZO reduced by half the PVL quantity. CLI was strongly
effective on pulmonary PVL reduction (CLI > LZO > CLOX > VA).
Conclusion: No difference was noted in both control groups PVL−
or PVL+ in terms of pathogenic effect (mortality, CFU, macroscopic
score . . . ) probably due to other virulence factors. VA was slightly
efﬁcacious in this model. CLOX was strongly bactericidal contrasting
with the persisting production of PVL. LZO and CLI reduced the PVL
production and the residual bacterial content in this model. Other studies
are under way to evaluate the impact of such strategies in a MRSA-PVL
model.













Control 8.75±0.59 66% − 8.07±1.30 60% 0.266±0.504
VA 8.05±0.58 75% − 6.36±2.45 50% 0.177±0.267
CLOX 1±0 0% − 1±0 0% 0.164±0.120
LZO 3.05±1.32 50% − 4.02±1.80 50% 0.042±0.024
CLI 1±0 0% − 1±0 0% 0±0
O373 The colonizing ability of E. coli strains isolated from
patients with inﬂammatory bowel disease
S. Schjørring °, A.M. Petersen, S.C. Gerstrøm, K. Krogfelt
(Copenhagen, DK)
Objectives: E. coli strains of the phylogenetic group B2 were isolated
more frequently from patients with IBD compared to healthy controls.
Furthermore, B2 strains with ExPEC genes were found more frequently
among IBD patients with active disease compared to patients with
inactive disease. It is of great interest to further characterise those strains.
The objective was to investigate the colonising traits of B2 E. coli strains
isolated from patients with IBD in a gastrointestinal animal model.
Methods: Two B2 E. coli strains from IBD patients and one E. coli
isolate from a healthy person were investigated. Strains were also
compared to the probiotic E. coli Nissle 1917 and to the laboratory
E. coli MG1655. Growth rate was determined in vitro. The adhesion
capacity was assessed in the human epithelial intestine cell line (Int-407).
The colonising ability was tested by colonisation of the large intestine
of streptomycin treated mice. Different colonisation, competition and
inoculation procedures were tested in this model.
Results: Both IBD strains had increased growth rate compared to the
E. coli from the healthy person and the E. coli Nissle strain. Likewise, the
IBD strains had an increased adhesion capacity in the cell adhesion assay.
In the animal model all strains were able to colonise the gastrointestinal
tract in high levels when inoculated alone. In competition with the
probiotic Nissle strain both IBD strains co-colonised, though to a log
higher (in CFU/g faeces) than Nissle, when inoculated in equal high
levels. When E. coli Nissle was inoculated in high levels compared to
IBD strain in low levels the strains also co-colonised at the end of the
experiment. The E. coli strain from the healthy person also co-colonised
with E. coli Nissle in intestine of the mice, but stabilised at a log lower
than Nissle strain, when inoculated in equal high levels and two logs
lower when inoculated at a lower level than E. coli Nissle.
Conclusion: IBD strains had increased growth rates and adhesion
abilities compared to E. coli isolated from a healthy person and E. coli
Nissle. Furthermore, E. coli from IBD patients had an increased ability
to co-colonise with the probiotic E. coli Nissle strain.
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New antibacterial agents
O374 MUT056399, a new drug candidate against S. aureus: PK
parameters and safety
S. Escaich °, C. Soulama, F. Moreau, V. Gerusz, L. Durant (Paris,
Romainville, FR)
Background: MUT056399 is a novel antistaphylococcal agent targeting
the essential enzyme FabI. We present here its key properties:
in vivo efﬁcacy, preclinical pharmacokinetics and safety, ﬁnally the
pharmacology data of phase I.
Methods: Standard procedures were used for evaluation of PK
parameters. Preclinical safety sudies were conducted on mice, rat and
dogs in GLP conditions. In vivo assays were performed using the mice
models of septicaemia and thigh infection using methicillin-susceptible
and non susceptible S. aureus (MSSA and MRSA). Linezolid and
vancomycin were used as comparators.
In Phase I, ascending doses of MUT056399 formulated in HPBCD were
administrated to healthy volunteers by iv infusions.
Results: PK studies in 3 species indicated that MUT056399 given iv
was rapidly cleared from the blood (T1/2 =3−5 h). The MUT056399
molecule was well distributed among tissues without accumulation.
In the thigh infection model with MRSA strains, after a single sc
administration the mean static dose was 143mg/kg/d in neutropenic mice
and 45mg/kg/d in immunocompetent mice.
In the mouse septicaemia model using a single sc administration
of MUT056399, the mean ED50 against MSSA ATCC 29213, was
21.6mg/kg/day, against MRSA strains the mean ED50 was 31mg/kg/day
and 49.6mg/kg/day for a GISA strain.
In GLP safety studies in rats and dogs MUT56 399 did not affect CV,
CNS or respiratory functions.
In Phase I, the administration of a single intra venous doses from 10mg/d
to 1.2mg /d was safe.
Conclusion: MUT056399 is a novel highly potent antistaphylococcal
agent with a clean safety proﬁle. These properties support MUT056399
as a very promising candidate for a novel drug to treat severe
staphylococcal infections.
O375 Efﬁcacy of two novel antimicrobials, BC-3781 and BC-3205,
in a murine MRSA-pneumonia model
W.W. Wicha, Z. Ivezic-Schoenfeld, R. Novak ° (Vienna, AT)
Background: BC-3781 and BC-3205 are two new antimicrobial agents
of the pleuromutilin class, which are both in an early stage of
clinical development for intravenous and/or oral treatment of skin and
skin structure infections (SSSI) and community-acquired pneumonia
(CAP). BC-3781 and BC-3205 exhibit excellent antimicrobial activity
against a range of relevant bacteria frequently identiﬁed in SSSI and
CAP including methicillin-resistant Staphylococcus aureus (MRSA).
Invasive severe infections caused by MRSA, particularly those involving
persistent bacteraemia and necrotizing pneumonia are associated with
high mortality. Since treatment with currently available antibiotics is
often unsatisfactory novel antibacterials with improved efﬁcacy against
severe MRSA infections are urgently needed.
Methods: Murine pulmonary infections caused by MRSA were
established in neutropenic female BALB/c mice. Mice were grouped
(n = 6) and subcutaneous therapy using BC-3781, BC-3205, linezolid
or vancomycin started 2 h post infection (1.5×107) with a single dose
and continued for two days with a bid dosing regimen. Lungs of mice
were dissected on day 3 after start of infection. The bacterial burden
in pulmonary tissues was determined using standard plating techniques.
Untreated animals died on day 2. An Emax dose response model was
used to obtain the bacteriostatic dose levels and the maximum killing
potency of all tested compounds.
Results: BC-3781 and BC-3205 showed excellent efﬁcacy with a
reduction of 3−4 log10 CFU/lung being achieved with doses of
160mg/kg BC-3205 and BC-3781, respectively. For the same reduction
of viable MRSA in lungs a dose of 240mg/kg/day linezolid was required.
The maximum killing potency of vancomycin was only ~1.3 log10
CFU/lung at a dose of 480mg. BC-3781 and BC-3205 ensured 100%
survival already at daily doses greater than 20 and 40mg/kg, respectively.
Doses of >60mg/kg/day linezolid and >240mg/kg/day vancomycin,
were needed for 100% survival.
Conclusions: Both compounds, BC-3205 and BC-3781, demonstrated
excellent efﬁcacy in a murine pulmonary infection caused by MRSA.
Both compounds, BC-3781 and BC-3205, showed superior efﬁcacy
compared to the standard of care antibiotics linezolid and vancomycin.
O376 BAL30072, a new sulfactam with excellent in vitro
and in vivo activity against Escherichia coli producing
extended-spectrum b-lactamases
S. Navon-Venezia °, O. Hermesh, B. Kuzmenko, M. Page, Y. Carmeli
(Tel Aviv, IL; Basel, CH)
Objectives: BAL30072 is a novel siderophore monocyclic b-lactam
belonging to the sulfactams. We evaluated the in vitro antimicrobial
activity of this compound against a panel of Escherichia coli clinical
isolates and studied its efﬁcacy against peritonitis and sepsis in mice
caused by an ESBL-producing strain of E. coli.
Methods: The antimicrobial activity of BAL30072 was tested against 39
strains (20 wild type and 19 ESBL-producers). MICs were determined
using agar dilution on Mueller-Hinton agar supplemented with 2, 2’
bipyridyl to induce iron transport. In vivo efﬁcacy was evaluated against
a CTX-M-15-like-producing E. coli strain using a lethal peritonitis
sepsis model in neutropenic ICR mice. Survival was monitored for
seven days after infection. E. coli inocula ranged from 2.5×106 to
5.0×106 cfu/mouse (2−5 X LD50) and BAL30072 was administered
intraperitoneally 3 times daily for 3 days (doses of 100mg/kg down to
12.5mg/kg) following infection. Saline was administered to the untreated
control group and meropenem was administered to the treated control
group.
Results: MIC50/MIC90 of BAL30072 for wild type, and ESBL-
producing E. coli were 0.125/0.5, and <0.0625/1mg/L, respectively
(ranges <0.0625−1 and <0.0625–256mg/L, respectively). The MIC of
BAL30072 against the ESBL-E. coli used in the mouse model was
<0.0625mg/L. In vivo experiments in mice infected intraperitoneally
with various E. coli inocula showed that, at doses from 100mg/kg down
to 12.5mg/kg, BAL30072 conferred protection similar to meropenem
(90–100% survival). Survival in the placebo group was 0−33%.
Conclusion: BAL30072 is an effective antibacterial agent against
clinical isolates of E. coli, including ESBL-producing strains. It is highly
effective treatment against infection caused by ESBL-producing E. coli
as demonstrated in mice peritonitis-sepsis model.
O377 Activity of ACHN-490 and other aminoglycosides vs.
carbapenem-resistant Enterobacteriaceae isolated in the
United Kingdom
S. Mushtaq, M. Warner, J-C. Zhang, S. Maharjan, M. Doumith,
N. Woodford, D. Livermore ° (London, UK)
Objectives: ACHN-490 is a novel sisomicin derivative stable to nearly all
aminoglycoside-modifying enzymes. We compared its activity with that
of other aminoglycosides vs. clinical Enterobacteriaceae representing the
diversity of carbapenem resistance types now emerging in the UK. Most
were multiresistant.
Methods: The 81 isolates comprised those with the Class A
carbapenemases KPC (n = 10) or SME-1 (1); Class B enzymes, IMP
(13), VIM (5) and NDM (17) and the Class D enzyme, OXA-48 (19)
or with combinations of impermeability plus an AmpC or ESBL (16).
They included 52 Klebsiella spp., 18 Enterobacter spp., 6 E. coli and
5 others. Carbapenemase genes were identiﬁed by PCR and sequencing
as were those encoding the 16S rRNA methylases ArmA and RmtA-C.
MICs were measured by CLSI agar dilution.
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Results: ACHN-490 was active against all 64 non-NDM+ isolates at
<2mg/L, with 95% of MICs between 0.06 and 0.5mg/L. Isepamicin
was active at 8mg/L against 62 of these 64 whereas 35%, 61% and
19% were resistant to gentamicin at 4mg/L, tobramycin at 4mg/L
and amikacin at 16mg/L, respectively. Among the 17 isolates with
the NDM-1 enzyme − many from patients with prior medical contact
on the Indian subcontinent − 16 harboured armA or rmtC and were
resistant to ACHN-490 and to all other human-use aminoglycosides
at >32mg/L; armA and rmtC were absent from the sole ACHN-490-
susceptible NDM-1-positive strain. Apramycin, a veterinary analogue,
was active at 4−8mg/L against (i) control strains, (ii) the NDM-1-
positive isolates with armA or rmtC and (iii) all other strains except
a Serratia with SME-1 enzyme (MIC > 128mg/L).
Conclusion: ACHN-490 had potent activity vs. all the carbapenem-
resistant isolates screened except those with combinations of NDM-1
enzyme and ArmA or RmtC rRNA methylases; the international
prevalence of these enzymes needs urgent surveillance. Evasion of ArmA
and RmtC by apramycin is striking and may facilitate future human drug
development.
O378 Novel antimicrobial agent NI02 displays potent activity
against a range of pathogenic bacteria
S.K. Sandiford °, M. Upton (Manchester, UK)
Objectives: The ever increasing resistance of pathogenic bacteria
towards the current arsenal of antimicrobial therapeutics emphasizes
the urgent requirement for development of novel agents. It is currently
estimated over 80% of clinical infections are also bioﬁlm associated,
therefore, agents that are effective against multiply resistant, bioﬁlm
forming would be extremely advantageous. The aim of the current study
was to assess the effect of novel antimicrobial agent (NI02) against a
range of pathogenic bacteria and against a clinical isolate Staphylococcus
epidermidis that displays methicillin resistance and a bioﬁlm phenotype.
Methods: The deferred antagonism method was used to assess the range
of activity of NI02 against a selection of pathogenic Gram-positive
and Gram-negative bacteria. The traditional bioﬁlm forming assay was
also employed using preparations of NI02 with an inhibitory activity of
>2560 AU/ml to coat microtitre wells and also to treat mature (48 hour)
bioﬁlms.
Results: The deferred antagonism assay showed NI02 to have
good activity against a range of Gram-positive pathogens including
vancomycin resistant enterococci, methicillin resistant Staphylococcus
aureus, Streptococcus pneumoniae, Streptococcus pyogenes, Listeria
sp., Bacillus subtillis and Bacillus cereus and Gram-negative isolate
Moraxella catarrhalis. NI02 also showed good activity against Staphy-
lococcus epidermidis bioﬁlms as coating microtitre plate wells resulted
in complete inhibition of bioﬁlm development and treatment of mature
bioﬁlms resulted in a signiﬁcant reduction in bioﬁlm density (P 0.001).
Conclusion: The results obtained in the current study demonstrate the
broad-spectrum activity of antimicrobial agent NI02 against a range of
pathogenic bacteria and the ability of the inhibitor to prevent and disrupt
bioﬁlms.
Carbapenemases other than KPCs: MBL
and OXAs
S380 Current epidemiology of MBL-producing Gram-negative
non-fermenters and Enterobacteriaceae
M. Edelstein ° (Smolensk, RU)
Gram-negative bacteria producing acquired metallo-b-lactamases
(MBLs) represent one of the greatest challenges for modern antimicro-
bial therapy. MBL producers commonly exhibit resistance not only to
a broad-spectrum of b-lactams but also to a variety of non-b-lactam
agents owing to association of MBL genes with those affecting
different groups of antibiotics. The IMP and VIM enzymes are the
most common acquired MBLs. These enzymes were ﬁrst reported
in Japan and Europe but are now broadly disseminated in many
countries of all populated continents. Production of acquired MBLs
is most often observed in P. aeruginosa, with VIM-2 being the most
ubiquitous enzyme, and less frequently in Acinetobacter spp. and in
Enterobacteriaceae, mainly in Klebsiella pneumoniae and Enterobacter
cloacae, with VIM-1 or VIM-4 being the most typical variants in the
latter species. MBLs of other genetic groups were either identiﬁed in
isolates causing sporadic infections and local outbreaks (e.g. GIM-1,
SIM-1, KHM-1, AIM-1) or as endemic types in some geographic
areas (e.g. SPM-1 in Latin America). However, the recent reports of
the international importation of SPM-1 from Brazil to Switzerland
and of NDM-1 from India to the UK provide continuing evidence
of the increasing complexity of MBL epidemiology. The prevalence
of MBL-producers varies signiﬁcantly among different countries and
their epidemiology now ranges from sporadic monoclonal outbreaks
to polyclonal endemicity. Furthermore, MBL-producing strains are no
longer conﬁned to nosocomial environment but are being identiﬁed
also in residents of long-term-care facilities and even in patients with
community-acquired infections. The association of MBL genes with
mobile genetic platforms (e.g. Tn402-like transposons in the case of
blaVIM genes), broad host range plasmids and highly epidemic clones
(e.g. P. aeruginosa clonal complexes CC235 and CC111) were apparently
implicated in the rapid spread of these important resistance determinants.
S381 Natural and acquired CHDLs: biochemical properties,
expression, and impact on resistance
L. Poirel ° (Le Kremlin Bicetre, FR)
Class D b-lactamase-mediated resistance to b-lactams has been
increasingly reported during the last decade. Those enzymes also known
as oxacillinases or OXAs are widely distributed among Gram negatives.
They do usually possess a narrow spectrum b-lactam hydrolysis proﬁle,
but some of them do possess the ability to hydrolyse carbapenems, even
at a low level. They have been named Carbapenem-Hydrolysing class D
b-Lactamases, or CHDLs.
CHDLs are known to be intrinsic in some Gram negative rods, including
Acinetobacter baumannii (OXA-51-like enzymes) and Pseudomonas
aeruginosa (OXA-50-like enzymes), but usually play a minor role in
the natural resistance phenotypes. Besides those naturally-occurring
CHDLs, others have been identiﬁed as acquired. They have been
mostly identiﬁed in Acinetobacter spp. (mostly in A. baumannii),
and belong to four distinct groups according to their amino acid
sequences, namely the OXA-23, OXA-40, OXA-58, and OXA-143
groups. The genes encoding those CHDLs in A. baumannii are
either plasmid- or chromosome-encoded. Interestingly, the blaOXA-
23 progenitor was shown to be Acinetobacter radioresistens, a non-
pathogenic and environmental species.
Despite their weak ability to hydrolyse carbapenems, those CHDLs
are responsible for high level resistance to those compounds when
their expression is associated with other mechanisms such as efﬂux
overepression, penicillin-binding protein modiﬁcations, or porin loss.
Another CHDL, OXA-48, distantly related from those CHDLs identiﬁed
in A. baumannii, has been identiﬁed in several enterobacterial species,
and mostly in Klebsiella pneumoniae. The blaOXA-48 gene which has
been found to originate from Shewanella spp. is plasmid-mediated,
increasingly reported in different countries, and responsible for resistance
to carbapenems when associated with permeability deffects.
Acquired CHDL encoding genes have been mostly identiﬁed in
association with insertion sequences that are either responsible for their
expression and their acquisition. In particular, both the blaOXA-48
and blaOXA-23 genes have been identiﬁed inside composite integron
structures (IS1999- and ISAba1-made, respectively).
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S382 Molecular epidemiology of carbapenem-resistant
Acinetobacter baumannii: genes, plasmids and clones
N. Woodford ° (London, UK)
Carbapenems (excluding ertapenem) are treatments of choice for
infections caused by multi-resistant A. baumannii so the emergence
of carbapenem resistance is a serious problem. As with other
Gram-negative species, carbapenem resistance has been attributed to
multiple mechanisms, including reduced permeability through loss of
outer membrane proteins, altered penicillin-binding proteins and over-
expression of weakly carbapenem-hydrolyzing b-lactamases, but the
major mechanism is carbapenemase production. Diverse carbapenemases
have been reported in A. baumannii, differing in their regional
prevalence: isolates with IMP or VIM metallo-enzymes are globally
scattered; those with SIM-1 are associated particularly with the Far
East, while NDM-1 has been observed only rarely. OXA class D
enzymes are the dominant carbapenemases in A. baumannii, with 5
phylogenetically distinct groups identiﬁed. OXA-51-like enzymes are
intrinsic to the species, and are only associated with carbapenem
resistance when up-regulated by an adjacent insertion sequence, usually
ISAba1. By contrast, OXA-23-like, OXA-40-like, OXA-58-like and
OXA-143 carbapenemases have all been acquired via horizontal gene
spread. These enzymes usually confer clinically signiﬁcant carbapenem
resistance, although the MICs for individual isolates are inﬂuenced
by the particular gene present, its copy number, and presence of
accessory mechanisms (e.g. loss of the CarO porin). The blaOXA
genes may be located on the chromosome, as part of large resistance
islands, or on plasmids. Local outbreaks of carbapenem-resistant
A. baumannii typically include a predominant strain, and strains from
epidemiologically unlinked sites may show sufﬁcient similarity to be
regarded as the same clone. There are two dominant carbapenem-
resistant clones in the UK, ‘OXA-23 clone 1’ has OXA-23 enzyme,
and the ‘South-east clone’ has ISAba1-up-regulated OXA-83 enzyme;
both have affected >50 hospitals and belong to sequence group 1 (based
on ompA, csuE and blaOXA-51-like alleles), which is European clone
II. In other countries there may be greater evidence for horizontal gene
spread in addition to strain spread, as observed for OXA-72 (an OXA-
40-like enzyme) in a Taiwanese hospital. There are few therapeutic
options for infections caused by carbapenem-resistant strains other than
a polymyxin or glycylcycline and effective infection control remains
essential to control their spread and impact.
Tuberculosis at the cutting edge
S383 New insights into host–pathogen responses in TB
A. Lalvani ° (London, UK)
Host–pathogen interactions determine the outcomes M. tuberculosis
infection by inﬂuencing key control points in the natural history of
infection, including progression from latent infection to active disease
and the clinical spectrum of active disease itself.
Our understanding of the natural history and epidemiology of
tuberculosis infection are based on two key century-old tools, the
tuberculin skin test and chest radiography. The advent of new, more
accurate markers of infection presents an opportunity to re-evaluate
our conventional understanding of the host–pathogen relationship
in tuberculosis, including the natural history and epidemiology of
tuberculosis infection.
The application of interferon-gamma release assays in epidemiologically
well-deﬁned tuberculosis outbreaks and longitudinal cohorts points
towards a new class of host–pathogen interaction in a subset of
tuberculosis contacts that likely involves a transient, self-resolving
infection. This entity was not previously appreciated and has signiﬁcant
implications for our understanding of the host–pathogen interaction in
tuberculosis infection which will be discussed. T cell-based testing for
tuberculosis infection has also uncovered a role for BCG vaccine in
preventing infection despite M. tuberculosis exposure. The implications
of this phenomenon for the design and evaluation of new tuberculosis
vaccines, as well from tuberculosis control, will be discussed.
Newer biomarkers, measuring multiple facets of the host response to
tuberculosis infection and disease, have recently been developed and may
enable discrimination between the several stages in the natural history
of tuberculosis infection, eg differentiating between active and latent
tuberculosis infection. These new types of biomarkers will be reviewed
as well as the the new insights they could provide for our understanding
of the host–pathogen equilibrium in tuberculosis infection.
S385 Genomics and therapeutics
S. Cole ° (Lausanne, CH)
New medicines for tuberculosis (NM4TB): Tuberculosis (TB) is one of
the oldest infectious diseases known to man and has infected one third of
the world’s population. As a result, someone dies from the disease every
15 seconds and over 20 million more people will lose their lives to TB in
the next decade. Although directly observed short course chemotherapy
(DOTS) is available to treat the disease, this treatment is old, slow
and inefﬁcient by the current standards of the pharmaceutical industry.
Furthermore, the efﬁcacy of the DOTS programme has been severely
compromised in certain regions by the emergence of multidrug- and
extensively drug-resistant strains of Mycobacterium tuberculosis. This
new menace is of particular concern to Europe and the countries of the
former Soviet Union.
In an integrated approach to discover new TB drugs, we have been
pursuing a new class of antimycobacterial compounds known as
the benzothiazinones (1,3-benzothiazin-4-ones, BTZs). The BTZ kill
M. tuberculosis in vitro, ex vivo, and in mouse models of TB and
are exceptionally potent. Using genetics and biochemistry, we identiﬁed
the enzyme decaprenylphosphoryl-b-D-ribose 2’-epimerase as a major
BTZ target. The inhibition of this critical enzyme activity abolishes the
formation of decaprenylphosphoryl arabinose, a key precursor that is
required for the synthesis of the cell-wall arabinans, thereby provoking
cell lysis and bacterial death. The most advanced compound, BTZ043,
which is currently in the late preclinical stage, is a candidate for inclusion
in combination therapies for both drug-sensitive and extensively drug-
resistant TB.
Use of epidemiological methods in making
rational treatment decisions in infectious
diseases
S389 From case reports to causality: how can we quantify
rare adverse events, how should they be considered in the
treatment decisions?
R. Platt ° (Boston, US)
Rare adverse events after drugs, vaccines, and other therapeutic agents
are usually identiﬁed after the product is licensed and in widespread
use. Historically, surveillance for these has relied on case reports.
While case reports have identiﬁed many important problems, they have
drawbacks, including unknown sensitivity for detecting events of interest
and inability to provide the quantitative estimates of risk that are needed
to make informed decisions about the balance of beneﬁts and risk.
Quantitative information about risks and also about beneﬁts is becoming
increasingly available through the secondary use of electronic health
data − both electronic medical records and administrative data −
collected during the routine delivery of health care. Among the earliest
examples is the U.S. Centers for Disease Control’s Vaccine Safety
Datalink, which performs both active, near real-time, surveillance for
vaccine-associated adverse events, and retrospective epidemiological
studies. These methods are being modiﬁed to work in groups of health
plans with tens of millions of members, and to address the sequelae of
exposures to drugs as well as vaccines. An important feature of these
methods is that they require minimal sharing of conﬁdential personal
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information, because there is no need to create large pooled datasets in
order to identify signals of adverse events.
The presentation will illustrate these issues using the current experience
evaluating the safety of the H1N1 inﬂuenza vaccine and others. It
will also address the U.S. Food and Drug Administration’s plan to
create a Sentinel Network, which will use information from electronic
medical records covering 100 million people to perform routine safety
evaluation of marketed medical products. Additional considerations
regarding assessment of beneﬁt will be addressed.
MRSA bacteraemia and endocarditis −
treatment considerations
S392 Pharmacodynamics of anti-staphylococcal antibiotics −
implications for clinical management
M. Rybak ° (Detroit, US)
MRSA bacteremia and endocarditis represent some of the most
challenging and difﬁcult infections to overcome with antibiotics.
Understanding the relationships between antibiotic pharmacokinetics and
pharmacodynamics, target organism, site of infection and the potential
for resistance development is key for successful patient outcome.
Optimizing therapy exploits the speciﬁc antibiotic pharmacodynamic
parameter that best predicts in vivo efﬁcacy. For example, in the case
of b-lactams, improving the time above the MIC for the targeted
pathogen may be accomplished by prolonging the infusion time or
utilizing continuous infusion administration. For aminoglycosides, use of
high-dose once-daily therapy should increase the Cmax/MIC. Recently,
based on the need to improve the performance of vancomycin, higher
troughs have been recommended. Higher troughs are needed in order
to achieve a higher AUC/MIC ratio which is thought to be important
for serious infections like complicated bacteremia, infective endocarditis
and pneumonia. Additional factors that affect antibiotic performance
include the ability to reach the site of infection (barriers to penetration)
and conditions at the site of infection such as pH, protein binding
and inoculum. This lecture will discuss speciﬁc antibiotic PK/PD
characteristics, conditions at the site of infection that diminish antibiotic
activity and opportunity to improve performance.
Surveillance of ESBL
O395 Massive emergence of multidrug-resistant Enterobacteriaceae
in blood culture isolates of children in Ghana
F. Huenger °, A. Agyekum, B. Nkrumah, S. Ekuban, N. Sarpong,
N.G. Schwarz, H. Schu¨tt-Gerowitt, J. May, Y. Adu-Sarkodie (Dortmund,
DE; Kumasi, GH; Hamburg, Cologne, DE)
Objective: To evaluate the prevalence of antimicrobial resistance in
Enterobacteriaceae isolated from blood cultures of children in rural
Ghana.
Methods: Between October 2007 and June 2009 blood cultures were
collected from children admitted to the Agogo Presbytarian Hospital
located in the rural area of the Ashanti − Akim North District
with a population of about 135,000. Peds Plus™ bottles and the
BacTec™ 9050 system were used and detected strains were identiﬁed
by Gram staining, selective subcultures, biochemical testing and speciﬁc
agglutination tests. Minimum inhibitory concentration (MIC) of isolated
Enterobacteriaceae and production of extended-spectrum-b-lactamases
(ESBL) was determined by the Etest™ method.
Results: In this study isolated Enterobacteriaceae (n = 178) were non-
typhoid Salmonella enterica (NTS) (113), Salmonella Typhi (39),
Escherichia coli (15) Klebsiella sp. (9), Shigella boydii (1) and
Enterobacter sp. (1).
NTS were highly resistant to ampicillin (80.5%), cotrimoxazole (82.3%),
chloramphenicol (83.2%), and tetracycline (10.6%). No strain was
resistant to ciproﬂoxacin, but one strain had reduced susceptibility to
ceftriaxone. The majority of S. Typhi strains were also resistant to ampi-
cillin (69.2%), cotrimoxazole (60.0%), chloramphenicol (66.7%), and
tetracycline (60.0%), but all were completely susceptible to ciproﬂoxacin
and ceftriaxone. All E. coli isolates were resistant to ampicillin and
20% produced ESBL. Resistance to cotrimoxacole (93.3%), tetracycline
(86.7%), chloramphenicol (53.3%) and ciproﬂoxacin (26.7%) was
frequently detected. All Klebsiella strains were resistant to ampicillin and
tetracycline and 77.8% produced ESBL. Only one strain was susceptible
to cotrimoxazole, 77.8% were resistant to chloramphenicol and one third
to ciproﬂoxacin. The Enterobacter strain procuced ESBL and was only
susceptible to ciproﬂoxacin. The Shigella boydii isolate was susceptible
to ceftriaxone and ciproﬂoxacin.
Conclusion: The study indicates that the majority of Enterobacteriaceae
causing bacteraemia in children in the study area are resistant to the
majority of local available antibiotics. Moreover this massive emergence
of multidrug-resistant Enterobacteriaceae and ESBL producing E. coli
and Klebsiella strains in clinical isolates indicates a serious medical and
economic burden for African healthcare systems. Surveillance programs
and prevention strategies have to be established to face this challenge.
O396 Molecular analysis of extended-spectrum b-lactamase
dissemination in Escherichia coli within families
L. Lo´pez-Cerero °, P. Egea, M. Navarro, L. Serrano, J. Rodrı´guez-Ban˜o,
A´. Pascual (Seville, ES)
Objectives: The means of transmission of ESBL-producing E. coli
(ESBLEC) isolates in the community are poorly understood. We
previously reported that the prevalence of faecal carriage with ESBLEC
was higher in relatives of patients with urinary tract infections (UTI)
caused by these organisms.in 54 households The aim of this study was
to analyse the molecular relationship of the ESBLEC within families
settings and the plasmids identiﬁed.
Methods: We studied 72 ESBL-producing E. coli isolates (34 CTX-
M-14, 31 SHV-12, 3 CTX-M-9, 3 CTX-M-15 and 1 CTX-M-32) from
19 families of patients with UTI caused by ESBLEC where at least
other faecal carrier within the family was identiﬁed (19 patients with
UTI and 23 relatives). All isolates were evaluated by XbaI PFGE; the
molecular the relatedness was determined by the UPG method using the
Dice similarity index on Fingerprinting 3.0. Phylogenetic groups were
assigned by multiplex PCR. Transfers of bla genes were carried out by
conjugations experiments and transformation by electroporation into J53
and DH10 E. coli, respectively. Plasmids were compared by size using S1
nuclease digestion and by the patterns resulted of southern hybridation of
HindIII-digested plasmid DNAs from transformants or transconjugants.
Results: A total of 44 different PFGE patterns were identiﬁed distributed
among phylogenetic groups A (23%), B1 (34%), D (32%) and B2 (11%).
Nine relatives (39%) from 7 families (37%) carried the same pulsotype
and ESBL than the patient with UTI in their family. In 10 families
(53%), the isolates from different members yielded different pulsotypes
harbouring the same enzyme; among them, the ESBL was located in
similar RFLP plasmidic patterns in 5 families (3 with CTX-M14 and 2
with SHV-12). The CTX-M14 bla gene hybridazed with a single 20 kb
hybridation band in 9 plasmids, whereas SHV-12 bla gene was located
in fragments with different sizes in 13 plasmids.
Conclusions: Common source or horizontal transmission of the same
ESBL-producing strain or plasmid was found in 63% of the families with
ESBL-producers carriers. The acquisition of different clones producing
different ESBL enzymes by members of the same household was less
frequent in our study, but denote other routes of spread in the community.
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O397 High frequency of faecal colonization with ESBL-producing
Enterobacteriaceae among Swedish persons after travelling
outside the Scandinavian countries
A˚. O¨stholm Balkhed, M. Ta¨rnberg, L. Nilsson, H. Hanberger,
M. Nilsson, L. Lindvall, A. Johansson, A. Ha¨llgren ° Travel Study
Group of Southeast Sweden
Objectives: Risk factors for acquisition of ESBL-producing Enterobac-
teriaceae (ESBL-PE) in a low endemic country like Sweden are not
well understood. Previous studies have shown that travel might increase
the risk. The aim was to study weather travel to countries outside
Scandinavia increases the risk to be colonised by ESBL-PE.
Methods: From Sept 1, 2008 to March 31, 2009 persons attending
vaccination clinics in southeast Sweden planning to travel outside
Scandinavia for <3 months, were asked to participate. Faecal samples
and questionnaires were collected before and after travel. Faecal samples
were cultured on chromogenic media: chromID ESBL (bioMe´rieux) and
chromogenic UTI-medium (Oxoid) with discs containing cefotaxime,
ceftazidime, cefepime, piperacillin/tazobactam, meropenem and line-
zolid. Isolates with suspected ESBL-phenotype were subcultured and
conﬁrmed according to the methods of the extended ESBL deﬁnition
suggested by the Swedish Reference group for Antibiotics (SRGA)
(www.srga.org).
Results: Of 262 enrolled persons, 231 submitted faecal samples and
questionnaires before and after travel and were included for analysis.
Before and after travel, 9 (4%) and 73 (32%) persons were colonised
by ESBL-PE, respectively. No KPC were found. E. coli was the most
commonly found species. Gender, age, use of oral cholera vaccination or
antibiotics and duration of travel were similar among persons acquiring
ESBL-PE during travel (travel associated (TA)-carriers, n = 69) and
persons never colonised by ESBL-PE (non-carriers, n = 154). TA-carriers
more often reported diahorrea (54%) or other abdominal symptoms
(25%) during travel, compared to non-carriers (38% and 13%). Business
was a more common cause for travelling among TA-carriers (12%) than
non-carriers(6%), whereas TA-carriers more often reported travelling as
“backpackers”, 16% vs. 8%. The frequencies of TA-carriers after travel
to the most visited countries (>10 travellers/country) were: India 82%,
Egypt 57%, Peru 36%, Thailand 37%, South Africa 27% and Tanzania
24%, respectively.
Conclusions: Travel increases the risk of faecal colonisation by ESBL-
PE. Acquisition of ESBL-PE during travel is associated with abdominal
symptoms such as diahorrea.
O398 Comparative epidemiology of faecal carriage of extended-
spectrum b-lactamase-producing enterobacteria in 2
hospitals specialized in liver diseases in Egypt and in France
S. Defasque, N. Fam, F. Bert, V. Leﬂon-Guibout, A. El Ray,
M. El-Ghannam, M. El Deen Attia, M. Omar, S. El Din, D. Valla,
M. Nicolas-Chanoine ° (Clichy, FR; Cairo, EG)
Objectives: Extended-spectrum b-lactamase (ESBL) is a worldwide
public health problem. Few data are available on ESBL in Egypt.
The aim of this study was to compare the fecal carriage of
ESBL-producing enterobacteria (ESBL-E) in patients admitted to the
hepatology department of 2 hospitals specialized in liver diseases,
Theodor. Bilharz Research Institute (TBRI) in Cairo (Egypt) and Beaujon
hospital (Bj) in Clichy (France).
Methods: All patients admitted during May-June 2009 for more than
24 h in the hepatology department in TBRI and in Bj were screened
at admission with a rectal swab for detection of ESBL-E digestive
carriage. CTX-M groups were identiﬁed by PCR and TEM and SHV
derivatives with the check point system. Phylogenetic groups of E. coli
were determined by multiplex PCR and clone ST131 by PCR of
gene pabB.The following demographic and clinical data were collected:
gender, age, previous hospitalizations, underlying diseases and ascites.
Results: During the study period, the prevalence of patients with
ESBL-E was 77.6% (45/58) in TBRI and 6.5% (13/199) in Bj. A
previous hospitalization was more common (p = 0.003) in Bj patients
(93%) than in TBRI patients (45%). The 2 populations also differed with
regard to the underlying diseases (p = 0.0003). We studied 49 ESBL-E
from TBRI and 14 from Bj because 4 and 1 patients, respectively, had
2 ESBL-E. Of the 49 ESBL-E of TBRI, 90%, 8% and 2% were E. coli,
K. pneumoniae, and E. cloacae, respectively. Of the 14 ESBL-E from
Bj, 72%, 14%, 7% and 7% were E. coli, E. cloacae, K. pneumoniae and
K. oxytoca, respectively. The species distribution did not differ between
the 2 countries. In TBRI, 59%, 29% and 12% of ESBL were enzymes of
groups CTX-M-1, CTX-M-9 and SHV, respectively, whereas in Bj, 79%,
14% and 7% were of groups CTX-M-1, TEM and SHV, respectively. No
signiﬁcant difference was observed for enzymes of groups CTX-M-1 and
SHV. Of the 44 TBRI E. coli, 59% belonged to phylogenetic group A,
27% to D, 7% to B1 and 7% to B2 whereas of the 10 Bj E. coli,
40% belonged to A, 40% to B1 and 20% to D. ESBL-E of group B1
were signiﬁcantly higher in Bj than in TBRI (p = 0.04). The 3 TBRI B2
isolates belonged to clone ST131.
Conclusions: The prevalence of patients with ESBL-E fecal carriage
was very high in TBRI. More than 50% of these patients did not have a
previous hospitalisation, suggesting a very high prevalence of ESBL-E
in t the community in Egypt.
O399 Risk of acquiring multidrug-resistant Gram-negative bacilli
from prior room occupants
S. Nseir °, C. Blazejewski, R. Lubret, A. Durocher (Lille, FR)
Objectives: Two recent studies identiﬁed admission to a room previously
occupied by a methicillin-resistant Staphylococcus aureus (MRSA) or a
vancomycin-resistant enterococci patient as an independent risk factor
for acquisition of these bacteria. The aim of our study was to determine
whether admission to an ICU room previously occupied by a multidrug-
resistant Gram negative bacilli (MDRGNB) carrier increase the risk of
acquiring these bacteria by subsequent patients.
Methods: Prospective observational cohort study performed in a 30-bed
ICU during a 1-year period. All patients hospitalized >48 h were eligible.
Patients with MDRGNB at ICU admission were excluded. MDRGNB
were deﬁned as MDR Pseudomonas aeruginosa (resistant to imipenem
or to ceftazidime), Acinetobacter baumannii, and extended spectrum
b-lactamase (ESBL) producing GNB. All patients were hospitalized in
single rooms. The infection control policy included isolation techniques,
routine screening of MDR bacteria (MDRGNB and MRSA), written
antibiotic treatment protocol, and continuous surveillance of nosocomial
infections. Isolation techniques were used for all patients at ICU
admission, until receipt of screening results. In addition, these techniques
were used for patients with MDR bacteria, and for all immunosuppressed
patients. Routine screening of MDR bacteria (nasal, and anal swabs;
and tracheal aspirate in intubated patients) was performed for all
patients at ICU admission and weekly thereafter. Risk factors for
MDR P. aeruginosa, A. baumannii, and ESBL were determined using
univariate and multivariate analysis.
Results: 511 consecutive patients were included. 82 (16%) patients
acquired a MDR P. aeruginosa, 57 (11%) an A. baumannii, and
50 (9%) an ESBL GNB. Independent risk factors for ICU-acquired
P. aeruginosa were prior occupant colonized with P. aeruginosa
(OR[95%CI]=2.3[1.2−4.3], p = 0.012), surgery (1.9[1.1−3.6], p = 0.024),
and prior piperacillin/tazobactam use (1.2[1.1−1.3], p = 0.040). In-
dependent risk factors for ICU-acquired A. baumannii were prior
occupant colonized with A. baumannii (4.2[2−8.8], p< 0.001), and
mechanical ventilation (9.3[1.1−83], p = 0.045). Independent risk factors
for ICU-acquired ESBL were tracheostomy (2.6[1.1−6.5], p = 0.049), and
sedation(6.6[1.1−40], p = 0.041.
Conclusion: Admission to an ICU room previously occupied by a MDR
P. aeruginosa or an A. baumannii carrier is an independent risk factor
for acquisition of these microorganisms by subsequent room occupants.
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O400 Intestinal colonization with Gram-negative bacteria and
subsequent ICU-acquired bacteraemia during selective
digestive decontamination
E.A.N. Oostdijk °, M. Bonten (Utrecht, NL)
Objectives: In a recent study (NEJM 2009;360:20) selective digestive
decontamination (SDD) was, compared to Selective Oropharyngeal
Decontamination (SOD), associated with a signiﬁcant reduction in ICU-
acquired bacteremia caused by Gram-negative bacteria (GNB). The
difference between SDD and SOD is intestinal tract decontamination
and standard 4 days of cefotaxim during SDD (and not during SOD).
We hypothesized that intestinal colonization with GNB was associated
with subsequent ICU-acquired GNB bacteremia in patients receiving
SDD.
Methods: Retrospective cohort study in a tertiary care ICU in the
Netherlands, including all patients that had received SDD between Sept
2008 and Sept 2009. Rectal carriage with GNB was determined twice
weekly during ICU-stay. For each patient-day the status of intestinal GNB
colonization was determined, creating patient-days with and without
intestinal GNB colonization. Incidence densities of ICU-acquired GNB
bacteremia were calculated for 1,000 patient-days with and without
intestinal GNB colonization.
Results: 730 patients (7762 patients-days at risk) were included and
650 (89%) had >1 episode of rectal GNB colonization during ICU-stay.
23 patients (3.2%) had >1 episode of ICU-acquired GNB bacteremia.
Incidences of ICU-acquired GNB bacteremia were 6.1 and 1.9 per
1,000 patient days for the periods with and without intestinal GNB
colonization [relative risk 3.78 (95%CI 1.66–8.61)]. The median onset
of ICU-acquired bacteremia with and without intestinal GNB was 12
(IQR 37.5) and 8.5 (IQR 14.3) respectively (p = 0.4); 3 and 2 ICU-
acquired bacteremias occurred within the ﬁrst 4 days after ICU-
admission. 10 (43%) Episodes of bacteremia were preceded by rectal
colonization with the same species, being most frequently Serratia spp
(n = 3) and Pseudomonas aeruginosa (n = 3). 3 patients had already lost
rectal carriage at the time of bacteremia with the same species.
Conclusion: Intestinal colonization with GNB during SDD is associated
with an almost 4-fold risk of developing GNB bacteremia. 78% of ICU-
acquired bacteremia occurred after day 4, indicating that this association
seems not to be inﬂuenced by cefotaxime use.
O401 Characterization of CTX-M15-producing Klebsiella
pneumoniae associated with an outbreak in a neonatal
intensive care unit. A follow-up study shows long-term faecal
colonization and transmission to family members
I.H. Lo¨hr °, S. Rettedal, K. Øymar, A. Sundsfjord, O. Nata˚s (Stavanger,
Tromsø, NO)
Objective: Molecular characterization of a multiresistant extended-
spectrum blactamase (ESBL)-producing Klebsiella pneumoniae-strain
associated with an outbreak in a neonatal intensive care unit (NICU) at
Stavanger University Hospital, Norway. Evaluate long term colonization
in affected newborns and transmission to family members.
Methods: Rectal/fecal samples were cultured on modiﬁed MacConkey
agar and on chrom ID ESBL-plates (bioMe´rieux). Susceptibility testing
was performed by disk diffusion and Etest. ESBL-production was
conﬁrmed by double disk approximation test. blactamase-genes were
detected by PCR and typed by DNA sequencing. Clonal relatedness
was examined by PFGE. A follow-up study has been initiated. Monthly
rectal/fecal samples are collected from the newborns and their families.
Results: The outbreak was disclosed Jan 30th 2009 after identiﬁcation
of multiresistant K. pneumoniae in clinical samples from three
patients. Subseqently, 58 children were found to be colonized with
ESBL-producing K. pneumoniae after screening all patients in the
NICU (26/27 colonized) and children discharged from the NICU or
maternity ward during Nov 2008 to Jan 2009 (28/500 colonized).
After cohorting and strengthened infection control measures another
four children (4/89) at the NICU were colonized during Feb to April.
Only one patient had a severe clinical infection (septicaemia) and
recovered successfully after treatment with meropenem. All isolates
(n = 58) expressed resistance to aztreonam, 3rd and 4th generation
cephalosporins, clavulanic acid synergy as well as co-resistance
to aminoglycocides, trimethoprim-sulfamethoxazole and nitrofurantoin.
CTX-M-type (group1) was conﬁrmed by PCR and DNA sequencing. All
isolates examined (n = 17) displayed an indistinguishable Xba1-PFGE-
pattern. 49 colonized children and 80 family members were included in
the follow-up study. After nine months of follow-up, 45 children (92%)
are still colonized. Transmission to 16 family members (20%) has been
detected.
Conclusions: This is the ﬁrst major hospital outbreak caused by ESBL-
producing Enterobacteriaceae in Norway. The outbreak onset was about
two months before the ESBL-producing K. pneumoniae-strain was
identiﬁed. A subclinical outbreak like this is difﬁcult to detect unless
patients are regularly screened. Long time carriage in newborns is a
possible reservoar for the spread of ESBL-producing bacteria in hospitals
and in the community.
O402 Duration of extended-spectrum b-lactamases colonization
during hospitalization and after discharge
M. Leverstein-van Hall °, J. Muilwijk (Bilthoven, NL)
Objectives: Infection control practices on extended spectrum
b-lactamase (ESBL) include barrier precautions and ﬂagging of carriers.
The Dutch guidelines on infection control of ESBLs recommend to
perform twice-weekly surveillance cultures and to end the precautions
if 2 consecutive cultures are negative. The cost-effectiveness of these
cultures is dependent on the proportion of pts that remain positive. These
data are, however not available. In addition, carriers should be ﬂagged.
However, there are little data on the duration of ESBL colonization and
therefore recommendations for the duration of ﬂagging are lacking. The
aim of this study was 1) to determine the duration of ESBL colonization,
both hospital and community acquired and 2) to determine the proportion
of pts that remain positive during hospitalisation.
Methods: In the 2008 database of the national antimicrobial resistance
surveillance system (ISIS-AR) each pt with a positive culture with either
Escherichia coli (EC) or Klebsiella pneumoniae (KP) (intermediate)
resistant (I/R) to third generation cephalosporines (CEPH) and at least
one follow up culture with an EC or KP were identiﬁed. For each
pt the time period was determined between the ﬁrst ESBL positive
and ﬁrst negative culture. The primary end point was July 31st, 2009.
The duration of colonisation was estimated by Kaplan–Meier survival
analysis, in which all pts without a last negative culture were censored.
Figure. Days to 3rd gen. cephalosporin susceptible isolate.
Results: In 2008, 1139 pts had a positive culture with an isolate I/R to
CEPH (ESBL conﬁrmation test positive in 81% of pts). 926 pts had an
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ESBL positive follow-up culture. The median colonisation time was 192
days (95%CI 172–216), the ﬁrst quartile 56 days (95%CI 41−69) and
the third quartile 365 days (95%CI 334–391) (Figure).
For 575 pts the ﬁrst positive isolate was cultured during admission. Of
the 470 with a follow up culture the proportion of pts with a positive
isolate after week 1 was 63% and after week 2 58%.
Conclusions: At least 75% of pts remain ESBL positive for at least
2 months and 25% of the pts is still carrier after one year. This
implicates that ﬂagging should be continued until screening cultures at
(re-) admission are shown to be negative.
At least 60% of the patients remain ESBL positive during hospitalisation.
Since the real percentage is likely higher due to interference of
antimicrobial therapy with culture results, the advice to perform 2-weekly
surveillance cultures should be reconsidered.
O403 Individual risk factors for colonization with carbapenem-
resistant Klebsiella pneumoniae among residents in post-
acute-care facilities in Israel: a matched case–control study
D. Ben-David °, S. Masarwa, S. Navon-Venezia, G. Smollan,
H. Mishali, I. Fridental, B. Rubinovitch, Y. Carmeli, M.J. Schwaber
for the PACF CRKP working group
Background: Since 2006, a nationwide outbreak of carbapenem-
resistant Klebsiella pneumoniae (CRKP) has been reported in acute-
care hospitals in Israel. In a point-prevalence study in post-acute-care
facilities (PACFs), we previously identiﬁed type of ward, prolonged
length of stay (LOS) and infection control policies as ecological factors
associated with CRKP colonization. It is important to distinguish
between ecological and individual-level risk factors in order to direct
interventions appropriately. Here we extended our analysis to assess
individual risk factors for colonization among residents without history
of CRKP carriage.
Methods: A point-prevalence study was conducted in 12 PACFs. Rectal
swabs were obtained from residents without a history of CRKP carriage
in 33 wards. Suspicious colonies growing on CHROMagar™ KPC plates
were speciated and tested for carbapenem susceptibilities by VITEK® 2,
supplemented by Etest®. We used a nested, matched case–control study
design to assess individual risk factors for colonization. Cases were
deﬁned as patients with positive rectal screening. Controls were selected
from patients with negative rectal screening, matched to cases by
ward. Patient data collected from medical records included demographic
characteristics, comorbid conditions, presence of skin lesions, presence
of invasive devices, antibiotic exposure, number of colonized roommates,
and PACF LOS.
Results: Of 1004 residents without history of CRKP, colonization was
detected in 119 (12%). Covariates entered into the matched multivariable
model included: Norton score, antibiotic exposure during the past 3
months, skin lesions, receipt of amoxicillin–clavulanate during the past
month and colonization with other resistant pathogens. Independent risk
factors for CRKP colonization were: antibiotic exposure during the past
3 months (OR 1.6, 95%CI 1.03−2.6, p = 0.04) and colonization with
other resistant pathogens (OR 1.6, 95%CI 1.06−2.6, p = 0.03).
Conclusion: This nested, matched case–control study identiﬁed an
important modiﬁable risk factor for CRKP colonization not identiﬁed in
the ecological analysis: antibiotic exposure. Antibiotic control programs
may have an important role in decreasing the burden of CRKP in PACFs.
O404 Seasonal and ascending trends in the incidence of
extended-spectrum b-lactamase-producing E. coli and
Klebsiella sp. in two German university hospitals
K. Kaier °, U. Frank, A. Conrad, E. Meyer (Freiburg, Berlin, DE)
Objectives: In the present study, the incidence of extended spectrum
{b}-lactamase (ESBL) producing strains were analysed for general
trends and seasonality.
Methods: Monthly data on ESBL producing strains were collected
retrospectively at two large university hospitals in the Southwest and
Northeast Germany. For the analysis we focussed on E. coli, Klebsiella
pneumoniae and Klebsiella oxytoca for consistency both between the two
settings and during the study periods. Multivariate time-series analyses
were carried out to explain variations in the monthly incidence densities
of ESBL cases (E. coli- and/or Klebsiella-related ESBL cases per 1000
patient days) in the two settings (Berlin and Freiburg). For the ﬁnal
models, we were able to incorporate variables for the ascending linear
trends and other variables representing the average monthly temperature.
Results: Our models show that in general all the incidences of ESBL
cases show an increasing trend. In addition, all incidences of ESBL cases
responds positively to the average temperature, meaning that in summer
when the temperature is high more ESBL cases were detected than during
winter months (See Figure for details). The study methodology was also
applied to the incidences of MRSA in the two settings, but an association
with the average temperature could not be detected.
Conclusions: In the present study, we afﬁrmed that ESBL-producing
E. coli and K. pneumoniae are an emerging problem in German hospitals.
Furthermore, we demonstrated that the monthly incidence of ESBL
strains is highly correlated with the mean monthly temperature, a fact
which should be considered in experimental studies as an additional
parameter inﬂuencing the incidence of ESBL.
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O405 Candidaemia in 536 intensive care units, 2001–2008
E. Meyer °, F. Schwab, P. Gastmeier, C. Geffers (Berlin, DE)
Background: We analyzed the epidemiology and secular trends in
candidemia within a network of 536 German ICUs reporting data to
the German Surveillance System for Nosocomial Infections.
Methods: CDC standard deﬁnitions were used for diagnosis of
nosocomial laboratory conﬁrmed primary blood stream infection (BSI).
Incidences were calculated by BSI per 100 patients, incidence densities
by nosocomial BSI per 1000 patient days and per 1000 central venous
catheter (CVC)-days.
Results: 536 ICUs submitted data of 1,942,745 patients, 6,881,170
patient-days and 4,740,019 CVC. Fungi were isolated in 492 of the
6,608 positive BSIs. Of them, 335 BSIs were associated with C. albicans
and 325 were CVC-associated (97%). C. albicans ranked ﬁfth in the
most frequent isolated pathogens in BSIs. The mean CVC-associated
BSI rate with C. albicans stayed stable over time with 0.06 per 1000
CVC-days and it was 0.02 for non-albicans Candida (2006–2008). For
monomicrobial C. albicans BSIs, the mean time from ICU-admission to
onset of infection was 14 days. Crude ICU-mortality of all pathogens
was highest for C. albicans with 19%. Primary BSI differed by type of
ICU or hospital and was highest in university hospitals as well as in
paediatric, surgical and cardiothoracic ICUs.
Conclusion: In critically ill patients C. albicans versus non-albicans
Candida remained the predominant species in our network of 536 ICUs
and ranked ﬁfth of the top pathogens causing primary BSI with a crude
mortality of 19%. The mean incidence of primary candidemia with 0.06
C. albicans BSI/1000 CVC-days remained unchanged over an eight year
period.
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O406 Incidence of candidaemia and antifungal sensitivity in
critically ill patients
M. Mascellino °, A. Oliva, C. Gallinelli, R. Nicosia, F. Chiarini (Rome,
IT)
Introduction: The incidence of invasive candidaemia is increasing all
over the world, mainly in critically ill and immunocompromised patients.
A shift to non-albicans species and a growing resistance to the common
antifungal have been noticed over the last years.
Objectives: Aim of our study was to analyze the different Candida
species isolated from bloodstream infections and the related antifungal
susceptibility pattern over a three year period at Policlinico Umberto I
of Rome.
Methods: 7574 blood cultures were analyzed from 2007 to 2009
by both automated and manual methods. Candida species isolates
were identiﬁed using chromogenic culture media and by API system
(Bio-Merieux). VITEK-2 cards were used to perform the antifungal
agents sensitivity to the following drugs: ﬂucytosine, amphotericin B,
ﬂuconazole, itraconazole, voriconazole. To determine the susceptibility
or resistance patterns, CLSI breakpoints were used.
Results: The overall incidence of invasive candidaemia during the three
years under study was 4.75% with a marked increase from 2007 to 2009
(3.85% to 7.5%). The species isolated were the following: C. albicans
37.6%, non-albicans species 62.4% (C. krusei 30.2%, C. glabrata 21.7%,
C. parapsilosis 5.6%, C. tropicalis 3.8%, C. lusitaniae 1.1%). We
observed that the detection of C. albicans raised from 7.1% in 2007
to 55.5% in 2009, whereas C. krusei, C. parapsilosis and C. tropicalis
incidence decreased over the three year period. C. glabrata isolation
was almost the same during the whole period (28.6% in 2007, 22.2%
in 2009). As far as C. albicans is concerned, we noticed an increase of
resistance to amphotericin B (from 0% in 2007 to 6.6% in 2009) and
voriconazole (from 0% in 2007 to 13.4% in 2009). C. krusei showed
a raising resistance to amphotericin B, ﬂuconazole, itraconazole and
voriconazole (from 0% to 40%, from 25% to 80%, from 25% to 50%,
from 0% to 20%, respectively). In C. glabrata a marked increased of
resistance to all the antifungal agents was observed. All the isolates of
C. parapsilosis were resistant to voriconazole; in contrast, C. tropicalis
was susceptible to all antimycotic agents.
Conclusions: Our study conﬁrms the high incidence of candidaemia in
the setting of critically ill patients. C. albicans resulted to be the most
prevalent species. The overall rate of resistance increased over the study
period in all the Candida strains under consideration.
O407 Low prevalence of azole-resistant isolates causing fungaemia
in patients admitted to intensive care units
J. Guinea °, P. Mun˜oz, P. Escribano, B. Padilla, M. Giannella,
M. Rodrı´guez-Cre´ixems, T. Pela´ez, E. Bouza (Madrid, ES)
Objectives: The widespread use of azoles may be responsible for an
increasing number of episodes of fungemia caused by ﬂuconazole-
resistant isolates. We previously showed that, during 2000–2006, only
3.5% of fungemia episodes occurring in patients admitted to intensive
care units (ICUs) were caused by a ﬂuconazole-resistant isolate. In the
present study, we assess the proportion of episodes of fungemia caused
by azole-resistant strains in patients recently admitted to ICUs (2007 to
2009).
Methods: From February 2007 to June 2009, we recorded 80 episodes
of fungemia in 78 patients admitted to the ICUs of a tertiary
hospital in Madrid, Spain. The distribution of episodes by ICU was
as follows: general, 41.2%; neonatology, 32.5%; major heart surgery,
21.3%; and paediatric, 5%. We selected only 1 isolate per episode (83
isolates; 3 patients were co-infected by 2 different species). Antifungal
susceptibility to ﬂuconazole and voriconazole was determined using the
CLSI M27-A3 microdilution procedure.
Results: The 80 fungemia episodes were caused by C. albicans
(n = 32; 40%), C. parapsilosis (n = 27; 33.8%), C. glabrata (n = 9;
11.2%), C. tropicalis (n = 6; 7.5%), C. albicans + C. parapsilosis (n = 3;
3.8%), Arxula adeninivorans (n = 1; 1.2%), Rhodotorula mucilaginosa
(n = 1; 1.2%), and Trichosporon inkin (n = 1; 1.2%). The antifungal
susceptibility (MIC50/MIC90/MIC range [mg/ml]) of the isolates was
0.25/4/0.125−>128 for ﬂuconazole and 0.015/0.125/0.015−4 for
voriconazole. According to the CLSI M27-A3 breakpoints, the isolates
were classiﬁed as susceptible, (96.2%) and resistant (3.8%) to ﬂucona-
zole and as susceptible (97.4%), susceptible–dose-dependent (1.3%), and
resistant (1.3%) to voriconazole. Three patients had fungemia caused by
ﬂuconazole-resistant isolates. The isolates were voriconazole-resistant
(C. glabrata), voriconazole-susceptible–dose-dependent (A. adeninivo-
rans), or voriconazole-susceptible (R. mucilaginosa). The 3 patients were
admitted to the general ICU (C. glabrata and A. adeninivorans) and the
major heart surgery ICU (R. mucilaginosa) and only one had recently
received ﬂuconazole. Outcome was favourable in 2/3 patients.
Conclusions: Fungemia caused by ﬂuconazole-resistant isolates oc-
curred only in adult ICUs. Only 3.7% of cases of fungemia were caused
by azole-resistant isolates, and this proportion has not increased recently
in our hospital. J. Guinea (CP09/00055) is contracted by FIS.
O408 Evaluation of the risk for invasive candidiasis in intensive
care patients after cardiothoracic surgery
C. Kratzer °, S. Tobudic, A. Schiferer, H. Fischer, A. Lassnigg,
W. Graninger, E. Presterl (Vienna, AT)
Objectives: To improve the diagnostic procedures for invasive Candida
infections in critically ill patients after cardiothoracic surgery, a
prospective surveillance study was performed at our cardiothoracic
intensive care unit (ICU) of the Medical University of Vienna.
Methods: Patients admitted to the cardiothoracic ICU for at least 4 days
between December 2006 and December 2008 were enrolled into the
study. Two times weekly surveillance cultures (n = 4718) for superﬁcial
sites were analyzed for the presence of Candida. To determine the
risk for invasive candidiasis, the following data were assessed: age,
sex, Simpliﬁed Acute Physiology Score SAPS II, the European System
for Cardiac Operative Risk Evaluation (EuroSCORE), length of ICU
stay and hospital stay, type and duration of cardiothoracic procedure,
number of redo surgeries, additional gastrointestinal (GIT) surgery,
parenteral nutrition, severe Candida colonization, bacteremia, severe
sepsis, leukocytosis or leucopenia and the highest Sequential Organ
Failure Assessment (SOFA) Score.
Results: A total of 198 patients were included into the study, 10
ICU patients (5%) developed invasive Candida infections. Age, gender,
SAPS II and euroSCORE of patients, the type and duration of
cardiothoracic procedures and parenteral nutrition were no signiﬁcant
risk factors in our study population. In all invasive Candida infection
patients severe Candida colonization (p< 0.001), leukocytosis >14G/l
or leukopenia <4G/l (p = 0.03) and a SOFA score >8 (p = 0.002) were
found. The risk for invasive Candida infections in cardiothoracic ICU
patients was calculated using the following determinants: severe Candida
colonization, leukocytosis or leucopenia, highest SOFA score >8, redo
surgical procedures >2 and additional GIT surgery.
Conclusion: Cardiothoracic ICU patients are at risk for invasive Candida
infections at the presence of severe Candida colonization, leukocytosis
or leucopenia, a SOFA score >8, additional GIT surgery and when
undergoing multiple cardiothoracic interventions >3.
O409 Functional IL-10 and IL-12B polymorphisms are associated
with persistent Candida spp. bloodstream infection
M.D. Johnson °, T.S. Plantinga, W.K. Scott, E. van de Vosse, D.R. Velez
Edwards, P.B. Smith, B.D. Alexander, J.C. Yang, G. Laird, M. Oosting,
J. van der Meer, J.T. van Dissel, B.J. Kullberg, M.G. Netea, J.R. Perfect
(Durham, US; Nijmegen, NL; Miami, US; Leiden, NL; Denver, US)
Objectives: Candida bloodstream infections cause signiﬁcant morbidity
and mortality in hospitalized patients. While clinical and microbiologic
factors affecting prognosis have been identiﬁed, the impact of immune
responses, mediated by cytokines, on outcomes of infection remains to
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be studied. The present study assessed the role of genetic variation
in cytokine genes on susceptibility and/or clinical outcomes of
candidaemia.
Methods: Single nucleotide polymorphisms (SNPs) in six cytokine
genes (IFN-g, IL-10, IL-12B, IL-18, IL-1B, IL-8) and one cytokine
receptor gene (IL-12RB) were genotyped and analyzed with logistic
regression in 365 patients with candidaemia and 351 non-infected
controls. In addition, the presence of these SNPs and measured
concentrations of pro-inﬂammatory cytokines were further analyzed for
association with persistent fungemia (5 days of positive blood cultures)
in 325 Americans with candidaemia. Other variables were assessed
including type of Candida spp. identiﬁed, total parenteral nutrition
(TPN), dialysis dependence, malignancy, immunocompromised state,
renal/liver failure. Variables with p< 0.10 on univariate analysis were
further analyzed using multivariable logistic regression.
Results: None of the SNPs examined were associated with susceptibility
to candidaemia. Mean age of candidaemia patients was 55 years (±21.3),
with 44% female, 32% African American, 58% immunocompromised,
31% active malignancy, 10% neutropenic, 43% recent surgery, 21%
receiving total parenteral nutrition (TPN), 12% dialysis, 25% liver
disease, and 49% ICU residence. The following species were identiﬁed:
C. albicans (43%), C. glabrata (27%), C. parapsilosis (17%),
C. tropicalis (12%), C. krusei (3%), >1 Candida species (6%). Overall,
persistent fungemia occurred in 15% of cases. In the multivariable model,
persistent candidaemia was signiﬁcantly associated with (OR, [95%CI]):
TPN (2.69 [1.28–5.62]), dialysis dependence (3.45 [1.36–8.74]), IL10
rs1800896 (3.07 [1.31–7.12]) and IL12B rs41292470 (4.34 [1.38–13.8]).
In addition, signiﬁcantly lower pro-inﬂammatory cytokine concentrations
were measured in serum from patients with persistent fungemia.
Conclusions: SNPs in IL-10 and IL12B were associated with persistent
fungemia in candidaemia patients, which also associated with low serum
concentrations of pro-inﬂammatory cytokines. This may provide insights
for future targeted management strategies for patients with this high
mortality condition.
O410 An echinocandin vs. a comparator antifungal in Candida
bloodstream infections: a meta-analysis
Y. Golan °, D. Harrison, K. Fahrbach (Boston, US)
Objective: Mortality from Candida bloodstream infections (CBSI)
is high if not treated adequately. In recent clinical trials of CBSI,
treatment with an echinocandin resulted in higher success rates. However,
superiority has not been demonstrated. Given similarities in trial design
and deﬁnitions, data from these trials can be combined in a metaanalysis.
We compared the efﬁcacy, measured as global clinical success at the end
of intravenous therapy, of an echinocandin vs. a comparator AF agent in
the treatment of CBSI.
Methods: We used standard metaanalysis methodology and a random
effect model. We conducted a literature search to identify all randomized,
controlled, trials (RCTs), assessing the efﬁcacy of an echinocandin
(caspofungin, micafungin, anidulafungin) in CSBI. To evaluate whether
the comparator (ﬂuconazole or amphotericin preparations) success rates
were consistent with previously published data, we conducted an
additional literature search of all RCTs in which these agents were
evaluated. Articles were reviewed independently by 2 reviewers. The
corresponding authors and sponsors were approached for additional data.
Results: 8 RCTs were included: 3 comparing an echinocandin to
comparator antifungal (CAF), 1 comparing two echinocandins, and
4 comparing amphotericin preparations to ﬂuconazole. The summary
odds ratio for global success was 1.58 (95%CI 1.07–3.54) in favor of
echinocandin therapy. The removal of a high-recruiting center that had
a high anidulafungin response-rate had an insigniﬁcant impact on the
results (OR 0. 1.46 95%CI 1.10–1.94). Global success rates observed
in all included RCTs of ﬂuconazole (5 treatment arms), amphotericin
(4 arms) and the echinocandins (5 arms) were 62%, 73%, and 83%,
respectively. In the echinocandin trials, success rates observed in the CAF
arms were consistent with prior published trials. In an additional analysis
that included only CBSI caused by C. albicans, echinocandin therapy
resulted in higher success rate vs the CAF (74%; 95%CI 69−78% vs
59%; 95%CI 51−66%).
Conclusions: In patients with CBSI, as compared to amphotericin
preparations or ﬂuconazole, echinocandin therapy is associated with
higher global success rates. This better effect is maintained when
restricting the analysis to C. albicans, suggesting that effectiveness
differences may be unrelated to the level of ﬂuconazole susceptibility.
O411 Candidaemia in neonatal intensive care unit, Malaysia: a
success story
A.R. Zaidah °, M. Zeehaida, H. Habsah, W.M. Zahiruddin, S. Suraiya,
R. Noraida, H. Van Rostenberghe (Kelantan, MY)
Objectives: Neonates in intensive care units were susceptible of
having blood stream infections because of invasive procedures and
underdeveloped immune system. Prolonged hospitalization and broad
spectrum antibiotics further risk the development of candidemia. This
report was written to share the success story in controlling the
candidemia after a major outbreak in 2004 by adopting strict infection
control practice, in which indirectly resulted in the reduction of
candidemia in our neonatal intensive care unit (NICU).
Methods: This is a retrospective laboratory based analysis study from
January 2001 to August 2009. Spectrum and distribution of Candida
isolated from blood cultures taken from the NICU at Hospital Universiti
Sains Malaysia before and after a major outbreak in 2004 was analyzed.
The prevalence of candidemia before and after outbreak was compared
and the trends of Candida spp. were determined. Candida spp. was
identiﬁed using standard microbiological tests and a commercialized
identiﬁcation system, API-32C system.
Results: Altogether, 413 Candida were isolated during the study
period. Generally, there was a signiﬁcant reduction in the prevalence of
candidemia after 2004 for both Candida albicans and non-albicans. The
reduction was sustained for the past ﬁve years. Candida parapsilosis
(40%) was the predominant species isolated followed by Candida
albicans (24.8%), Candida glabrata (15.2%) and Candida tropicalis
(12.4%).
Conclusion: Adherence to strict infection control practice is important
to control candidemia. Candida parapsilosis was the major species
implicated in candidemia among our neonates.
O412 Is there any factor prompting early central venous catheters
removal from cancer patients with candidaemia?
E. Velasco °, R. Portugal (Rio de Janeiro, BR)
Background: Few studies have addressed the timing of CVC removal
as a prognostic factor of mortality in cancer patients with candidemia.
Objective: To evaluated the clinical factors associated with early central
venous catheter removal in cancer patients with candidemia who survived
>3 days after the index blood culture.
Methods: This is a retrospective analysis from a candidemia study
conducted between January 2001 and June 2005 at an oncology cancer
center in Brazil. Eligible patients were those whose catheters were
eventually removed. We excluded patients who died within 72 h after
the candidemia onset or had catheters in place for 48 h. Early catheter
removal was deﬁned as those catheters withdrawn 72 h after the onset
of candidemia.
Results: We enrolled 164 patients with a 10.4% overall mortality
rate. Multivariate analysis revealed the temporary nontunneled central
venous catheter type (OR, 5.06; 95%CI 2.16–11.83) as the only variable
independently associated with early removal. Among the 82 episodes not
catheter related, 52 catheters (63%) were removed at doctor’s discretion
due to the urgency for cancer treatment continuance. Most of these
removal (n = 46) occurred within 3 days of the index blood culture. No
differences in the overall mortality rates were seen among patients with
early or delayed catheters removal (P> 0.05). Nevertheless, stratiﬁed
analysis showed a survival beneﬁt (P = 0.04) of early removal in the
subgroup of patients with performance Karnofsky score >60.
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Conclusion: This study showed short-term nontunneled central venous
catheter type as the only factor associated with early catheter removal.
There were a high proportion of removed catheters with the purpose of
not interrupting the underlying cancer treatment. Overall, early catheter
removal did not have a beneﬁcial impact on mortality. Nevertheless,
the observed favorable survival beneﬁt of early over late catheter
removal in the subgroup of patients without signiﬁcant medical illnesses
merits further investigation. Clinical trials enrolling sufﬁcient number
of homogeneous patients are necessary to analyze the impact of central
venous catheter management on the outcome of cancer patients with
candidemia.
Strategies to stay one step ahead of bacteria
(Symposium supported by Janssen-Cilag)
S413 The bacterial challenge: time to react
J. Garau ° (Barcelona, ES)
The changing pattern of antimicrobial resistance presents a challenge
which needs to be met on many fronts. This, combined with the lack of
development of new antimicrobials, necessitates a review of current treat-
ment strategies. Strategies which will be discussed in this symposium
will include the beneﬁts of appropriate empirical antimicrobial treatment
for serious infections, and more rational ways of administration (higher
doses and varying infusion times) of some antimicrobials. Resistance
development is well monitored in Europe, with resources such as
the European Antimicrobial Resistance Surveillance System (EARSS),
and additional country and local surveillance (e.g. PEG-surveillance in
Germany, Austria and Switzerland). Data will be presented on resistance
proﬁles and evolution rates within the intensive care unit, where the
challenge is to contain and prevent the spread of resistance. These
data are critical for the rational choice of adequate empirical antibiotic
treatment which will not lead to failure. This can be achieved using
broad-spectrum, potent agents, which are least likely to select for
resistance, before changing to a more targeted therapy (de-escalation)
once susceptibilities have been determined. These methods allow us
to use our limited armamentarium effectively. If this approach is
not followed, the risk of failure and increased mortality associated
with initial inadequate antibiotic treatment, the emergence of resistant
strains while on therapy, and their subsequent spread to others, are the
main consequences. The number of new antibiotics to treat multidrug-
resistant pathogens in the pipeline are too few, particularly those against
Gram-negative bacteria and those with new mechanisms of action.
New strategies are needed to close the gap between the burden of
infections due to multidrug-resistant bacteria and the development of
new antibiotics.
S414 Optimizing b-lactams by reducing resistance development
D. Livermore ° (London, UK)
The development of resistance to antibiotics has long been a thorn in
the side of the infectious disease physician. Dr Livermore will discuss
current resistance issues from a microbiological perspective. The concept
of potency and how it relates to minimal inhibitory concentrations
(MICs) and breakpoints will be covered, with particular reference to
carbapenems and Pseudomonas aeruginosa, where simple mutations
leading to loss of the ‘carbapenem-speciﬁc’ porin OprD can confer
frank resistance to imipenem whereas resistance to meropenem or
doripenem additionally requires some upregulation of efﬂux. For reasons
that remain obscure, these latter combinations of mechanism usually
have a lesser effect on doripenem MICs than those of meropenem. In
these circumstances there is potential for the dosing of carbapenems
to affect the likelihood of resistance development, though any practical
signiﬁcance remains to be conﬁrmed in clinical studies, particularly for
the meropenem / doripenem comparison.
In contrast to P. aeruginosa, carbapenem-resistance in Acinetobacter spp.
is due to OXA-carbapenemases. Some low-level producers may remain
marginally susceptible to imipenem (not meropenem or doripenem)
but there seems little general scope to overcome resistance by dosage
adjustment for any of the compounds. Among Enterobacteriaceae,
carbapenem resistance can arise either via combinations of porin loss
together with production of extended-spectrum or AmpC-lactamases or
via the production of true carbapenemases. The former mechanism,
mostly seen in Klebsiella or Enterobacter spp. affects ertapenem more
than any other analogue and this compound therefore seems most likely
to act as a selector; the true carbapenemases − including IMP, VIM and
NDM (New Delhi Metallo) zinc-enzymes as well as the KPC and OXA-
48 serine types affect all carbapenems, and it seems unlikely that any
could be overcome by dosage adjustment, though some might, in the
future, be overcome by carbapenem/inhibitor combinations.
S416 Optimizing b-lactam antibiotics by maximizing PK/PD
F. Pea ° (Udine, IT)
Consideration of pharmacokinetic (PK) and pharmacodynamic (PD)
principles can be useful to optimise dosing of b-lactam antibiotics.
b-lactams have time-dependent action, with time above the minimal
inhibitory concentration (MIC) critical for maximum efﬁcacy. PK/PD
data can be used in Monte Carlo simulations to predict probabilities of
obtaining an exposure target for a given dose. Evidence from Monte
Carlo simulations, animal models and clinical studies have led to real-
world recommendations, such as using extended infusions and other
strategies to maximise efﬁciency of b-lactams. Prolonged and continuous
infusions can give better efﬁcacy, can lower the likelihood of resistance
developing through higher trough levels and eliminate or at least reduce
the need to increase the dose. b-lactam antibiotics that can be dosed via
continuous/prolonged infusions include penicillins, cephalosporins and
carbapenems. However, data should be assessed for each antimicrobial.
For example, doripenem exhibits linear pharmacokinetics and does not
accumulate with repeated dosing over 7 days, which supports its use
as a prolonged infusion. Dr Pea will compare differences between
carbapenems and classic b-lactams. Dosing strategies for different
carbapenems will be discussed, including their stability and safety
proﬁles. Practical considerations for prolonged infusions include having
knowledge of the relationship of serum levels to target organ levels for
different antimicrobials and an awareness of differences in PK and PD
parameters among diverse patient groups. Dr Pea will conclude with a
discussion on which particular patient populations, such as those with
Pseudomonas infection, may beneﬁt most from continuous infusions.
He will also discuss the effect of different comorbidities, such as use
in patients with severe sepsis or septic shock and with renal failure
or glomerular hyperﬁltration, and how their pathophysiology can affect
drug levels.
S417 Novel b-lactams: what makes them different?
T. Welte ° (Hanover, DE)
Dr Welte will discuss b-lactams which are newly approved and in
late-stage development from a clinical perspective. Discussion will
include summaries of in vivo data including pivotal clinical studies,
recent meta-analysis, such as activity studies against Pseudomonas and
Acinetobacter, and new clinical data on carbapenems, such as doripenem
data dosed at 1 g. The use of intravenous antibiotics for patients
with renal failure will be discussed, including considerations when
using hemoﬁltration and continuous renal replacement therapy (CRRT).
Comparative safety data will be presented for the carbapenems and
recent health economic and hospital utilization datasets will also be
discussed. Dr Welte will illustrate his talk with examples, particularly
of patients who have failed therapy, with reasons for failure, which can
be complex. Techniques and approaches to minimise the possibility of
treatment failure will be discussed, such as appropriate initial empiric
treatment and prolonged infusion. The presentation will conclude with a
brief review of b-lactams currently in the pipeline including ceftobiprole,
ceftaroline, and faropenem.
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Cytomegalovirus infection: strategies,
recommendations and future solutions
(Symposium supported by DiaSorin)
S422 Epidemiology of human cytomegalovirus with focus on
mother/child transmission
G. Jahn ° (Tubingen, DE)
Human cytomegalovirus (HCMV) affects 30–100% of adults worldwide
depending on geography and lifestyle by the age of 40 years. Two
possible sources of sexual transmission of HCMV are virus in the female
cervix and in semen of men. The frequency of HCMV infection in adults
correlates with the number of sexual partners and sexual experience.
This b-herpesvirus is the virus most commonly transmitted to the fetus
before birth, occurring in 0.3−2% of all live births. Another even
much more frequent transmission route of mother-child is breastfeeding.
The local viral reactivation of the HCMV antibody positive mothers
during lactation is highly frequent and self limited and follows unimodal
kinetics. The vertical transmission rate from mother to child is about
40%. Also horizontal HCMV transmission from newborns and young
children to their mothers or other individuals taken care of those infants
happens. Children may shed the virus in saliva and urine for months
or years, but the relative portion of this kind of horizontal transmission
from children to children or from children to adults is unknown. Also
the horizontal transmission among adults, besides sexual intercourse,
is not well descript, but unlikely. In medical care, HCMV can be
transmitted by blood products or organ transplantation. As with all other
herpesviruses, HCMV has the ability to establish latent/silent infection
in the host after primary infection. Activation from silent infection can
occur under immunosuppression, during pregnancy and during lactation.
Individuals can be infected with multiple strains, meaning secondary
infection as exogenous reinfection or endogenous reactivation may occur.
HCMV disease with various symptoms can result from either primary or
secondary infection, also in primary infection disease is more severe and
more frequent. The outcome of congenital HCMV infection is variable.
About 10−15% of infected newborns exhibit clinical symptoms at birth
such as CNS sequelae with hearing loss, cognitive impairment and
cerebral palsy. Remarkably from 85−90% of HCMV infected newborns
who are asymptomatic at birth will later develop hearing loss in about
15%. In both symptomatic and clinical asymptomatic newborns, sequelae
often are not apparent in the ﬁrst months or years of life. That all is an
urgent need for speciﬁc HCMV diagnostic procedures and interpretations
for pregnant women and newborns to guide the solid management of
fetal/infant infection.
Contemporary challenges in b-lactamase
inhibition
S435 Inhibition of KPC b-lactamase
J. Spencer ° (Bristol, UK)
The growth of antimicrobial resistance, and in particular the proliferation
of ESBL-producing Enterobacteriaceae, means that carbapenems are
increasingly front line therapy for nosocomial infections. In consequence
numerous carbapenem-hydrolysing b-lactamases have emerged and
begun to disseminate across geographic and species boundaries. Several
class A carbapenemases have now been described. Of these the KPC
enzymes are of the most immediate clinical relevance. Growing numbers
of reports indicate the presence of KPC variants in Enterobacteriaceae,
notably from the Eastern United States and Israel but also in China and
a number of South American and European countries. KPC-expressing
isolates frequently contain additional b-lactamases as well as other
resistance determinants, severely limiting treatment options and affecting
patient outcomes.
Although class A carbapenemases have been extensively studied, the
molecular basis for this activity has remained obscure in light of
their close structural resemblance to other class A enzymes. It is now
established that the acylenzyme formed when carbapenems react with
class A b-lactamases such as TEM or SHV can adopt two conformations,
and that associated tautomerisation ultimately results in inhibition.
However, equivalent studies are yet to be reported for the species formed
when carbapenems associate with class A carbapenemases. Using X-ray
crystallography we have now studied the interactions of the carbapenem
meropenem with a model class A carbapenemase (SFC-1 from Serratia
fonticola) in which we have used directed mutagenesis to trap the
substrate and acylenzyme complexes. These structures show that SFC-1
binds carbapenems in a single well deﬁned orientation where, in contrast
to carbapenem-inhibited enzymes like SHV, the b-lactam amide nitrogen
remains close to the active site Ser-130. We propose that this model
represents productive binding of substrate and is likely to apply to other
class A carbapenemases, including KPC enzymes.
One approach to combatting carbapenemase-producing organisms is to
combine b-lactams with an appropriate b-lactamase inhibitor. However,
available b-lactamase-inhibitor combinations are variably effective
against carbapenemase producers. Accordingly, a number of b-lactamase
inhibitors under development have been tested against KPC and other
class A carbapenemases. Recent results in this area will be reviewed.
S437 Designing class C inhibitors
M. Page ° (Basel, CH)
Many Gram-negative bacteria, especially Pseudomonas aeruginosa,
Acinetobacter baumannii and Enterobacteriaceae, including Enter-
obacter, Citrobacter and Serratia species, possess chromosomally
encoded Class C b-lactamases (AmpC) that are important determinants
of resistance towards a broad range of b-lactam antibiotics. Even
carbapenems lose activity when confronted with class C lactamases
if the organism also has restricted outer membrane permeability. For
example, loss of the OprD outer membrane porin of P. aeruginosa,
which is essential for the rapid entry of imipenem into the periplasm,
will lead to high-level resistance if a class C b-lactamase is expressed.
In the last decades, a number of AmpC enzymes have been mobilized
on plasmids or other genetic elements and have spread to organisms
such as Escherichia coli and Klebsiella pneumoniae that did not usually
express AmpC. Carbapenem-resistant strains of K. pneumoniae that have
altered porin expression and a plasmid-encoded AmpC b-lactamase have
been reported from several countries. In general, class C lactamases
are not well inhibited by the clinically available b-lactamase inhibitors
clavulanic acid, sulbactam and tazobactam. Insights into the mechanism
of class C b-lactamases have aided the rational design of speciﬁc
inhibitors for this group of enzymes that also have the potential to
been optimized for penetration of the outer membrane of P. aeruginosa.
This presentation will review the fundamental steps in the mechanism
of class C b-lactamases and how this knowledge can be applied to the
design of novel inhibitors.
S438 OXA carbapenemases and their inhibition
M. Galleni ° (Lie`ge, BE)
The catalytic efﬁciency of the class D b-lactamase depends critically on
an unusual carboxylated lysine as the general base residue for both the
enzyme acylation and deacylation steps of catalysis. Different class D
b-lactamase’s X-ray structures indicate that the active site Lys-70 is
surrounded by a hydrophobic core comprising residues such as Val-
117, Phe-120 and Trp-154. Evidence is presented that the interaction
between the indole group of Trp154 and the carboxylated lysine is
essential for the stability of the post-translationally modiﬁed Lys70.
Substitution of Trp154 by Gly, Ala or Phe yielded non carboxylated
enzymes which displayed poor catalytic efﬁciencies and reduced stability
when compared to the wild type OXA-10. A comparison of the three
dimensional structures of the different proteins also indicated that the
Trp154 mutations did not modify the overall structures of OXA-10 but
induced an increased ﬂexibility of the omega-loop in the active site.
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Finally, the deacylation impaired W154A mutant was used to determine
the structure of the acyl-enzyme complex with benzylpenicillin. Stopped-
ﬂow and quenched-ﬂow experiments indicate that the deacylation step
is clearly rate limiting for the OXA-10 b-lactamase. The observation of
acyl-enzyme complex with the K70C mutant by X-ray crystallography
also suggests that the deacylation step is rate limiting but the acylation
step is also affected for the lysine mutants. Indeed, the values of
the acylation constants (k2) are clearly lower than with the wild-type
enzyme. The catalytic efﬁcencies of the V117T mutant decrease for all
substrates tested. The structure of the V117T OXA-10 mutant indicates
that the Lys-70 is partially carboxylated at pH 8.0 in monomer A whereas
monomer B contains a non-carboxylated Lys-70. This conﬁrms that
the valine residue in the hydrophobic core is important to promote the
carboxylation of the Lys-70.
It has been reported that class D b-lactamases are inhibited by chloride
ions. Interestingly, in we could show that the inhibiton is due to the
replacement of the side chain carboxylate group of the modiﬁed lysine
by chloride ion.
Finally, the structural modiﬁcations induced also the apparition of a
detectable carbapenemase activity in OXA variants.
Finally, the deep analysis of structure-function relationship for class D




S441 Pathogenicity: what does question the role of PVL?
A. Norrby-Teglund ° (Stockholm, SE)
Community-acquired methicillin-resistant Staphylococcus aureus (CA-
MRSA) has emerged as a major health problem world-wide. CA-MRSA
is a frequent cause of skin and soft-tissue infections, and has also been
reported to cause rapidly progressing life-threatening infections with un-
usually severe pathology, including necrotizing pneumonia, severe sepsis
and necrotizing fasciitis. A large number of epidemiological and clinical
studies have established a strong association between these severe CA-
MRSA infections and strains harbouring the pore-forming toxin Panton-
Valentine Leukocidin (PVL). Although compelling, epidemiological data
alone is insufﬁcient to establish a role of PVL in disease pathogenesis.
However, this issue has been addressed in a large number of studies
utilizing different experimental systems including PVL-deﬁcient mutants
and various in vivo models. The results of these studies have been highly
conﬂicting, and consequently, this topic is a matter of great debate in
the staphylococcal ﬁeld. The current progress toward understanding the
enhanced virulence potential of CA-MRSA with special emphasis on
PVL, but also including other relevant staphylococcal virulence factors,
will be summarized and discussed during this talk.
S442 Epidemiology and epidemicity of CA-MRSA pneumonia
G. French ° (London, UK)
Healthcare-associated MRSA (HA-MRSA) infection is now widespread
throughout the world. Recently, new strains of community-associated
MRSA (CA-MRSA) have emerged that affect people with no history of
healthcare contact. These are community strains of MSSA that have ac-
quired mecA. They are generally more virulent than HA-MRSA and can
cause primary infection in healthy people, including children. CA-MRSA
often possess genes encoding the putative virulence factor Panton-
Valentine Leukocidin (PVL). CA-MRSA clones can be deﬁned by
multilocus sequence (ST) and SCCmec type. CA-MRSA have appeared
in most countries of the world. They are common in the USA and much
less common, but increasing, elsewhere. There are many different clones
whose distribution differs geographically. Some are particularly success-
ful. USA300 (ST8-IV PVL+) has replaced USA400 (ST1-IV PVL+) as
the commonest type in the USA. The ‘European clone’ (ST80-IV PVL+)
is common in Europe and the ‘South West Paciﬁc’ clone (ST30-IV
PVL+) in the Far East and South America. In Europe there is great clonal
diversity and new types are continually being reported, including the pig-
associated ST398 strain (usually PVL−) that is common in Denmark
and the Netherlands but now spreading elsewhere. Although new CA-
MRSA clones continue to appear, successful older ones are being
introduced into new geographical areas by travellers and immigrants.
CA-MRSA pneumonia is uncommon worldwide but increasing. It may
follow inﬂuenza in previously healthy people and may cause fatal
necrotizing disease, usually associated with PVL-producing CA-MRSA.
PVL-positive staphylococci produce necrotizing pneumonia in animal
experiments but the role of PVL in human disease is still under debate.
Although PVL+ USA300 is the most frequent strain causing pneumonia,
this may be because it is common; it remains to be seen whether other
types of CA-MRSA, including PVL− strains, also have this ability. With
the continuing spread of CA-MRSA and the on-going inﬂuenza pan-
demic, we can expect the incidence of severe CA-MRSA pneumonia to
increase. HA-MRSA pneumonia in ventilated patients is well recognised
and has a poor prognosis. CA-MRSA is now spreading in hospitals and
becoming increasingly multi-drug resistant (MDR). Physicians should be
aware of the threat of hospital-acquired pneumonia with virulent, PVL-
producing MDR CA-MRSA and national and international organisations
should provide appropriate surveillance systems for CA-MRSA.
Preventing catheter-related infection: light
and shadow
S453 Evidence-based practice to reduce CVC-related infections
W. Zingg ° (Geneva, CH)
Many patients require a central venous catheter or an arterial line.
Although indispensable and of beneﬁt, vascular access devices pose a
potential risk of complications due to central line-associated bloodstream
infections (CLABSI). The risk for CLABSI varies between 1 to 7
episodes or more per 1000 catheter-days depending on ward-type,
institution and socio-economic status of the country.
Most successful CLABSI prevention strategies are multimodal and
include a combination of effective single intervention measures. Some
measures are “procedural”, such as using maximal sterile barrier
precautions at catheter insertion, avoiding the femoral site, strict hand
hygiene and applying a non-touch technique for catheter handling,
opening hubs on antiseptic-impregnated pads, change of tubing only
when indicated, and avoiding unnecessary access to the system.
Furthermore, any indication for a central line insertion must be
justiﬁed and catheters should be removed as soon as possible. Other
intervention measures are more “technical”, such as chlorhexidine-
containing products for skin antisepsis, chlorhexidine dressings at
the catheter insertion site, impregnated catheters with antibiotics or
chlorhexidine and silver-sulfadiazine, access devices coated with silver
particles, and closed infusion systems. A promising approach in CLABSI
prevention is the use of lock-solutions consisting of taurolidine-citrate,
ethanol, EDTA or citrate/methylene-blue/paraben.
Although there is evidence that some intervention combinations or
bundles are effective, no speciﬁc combination should be considered
superior to another. However, effort, complexity and costs may limit the
possibility to apply all measures together. Even more important, infection
prevention measures, and especially procedures, are of no use if they are
not respected in daily practice. Most episodes of CLABSI are identiﬁed
in the intensive care unit where care is complex. In such an environment,
attention may be drawn away from infection control measures. Thus,
infection control measures must be simple and easy to integrate into daily
practice. Furthermore, it is indispensable to promote an infection control
culture among nurses and physicians to ensure that prevention measures
are observed under stress conditions. Although technical devices may be
of help in stress situations, the failure to adopt a safety culture cannot
be replaced by the use of impregnated catheters, chlorhexidine dressings
or lock solutions.
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S454 Antimicrobials against bioﬁlm-based catheter-related
infections: new perspectives
G. Donelli ° (Rome, IT)
Antimicrobials against bioﬁlm-based catheter-related infections: new
perspectives. In the last decades, different strategies have been developed
to prevent microbial colonization of intravascular catheters through
surface adsorption or incorporation in the device polymer matrix of
antibiotic/antifungal agents. However, the currently available medicated
catheters have shown to inhibit microbial bioﬁlm formation for relatively
short periods, mainly due to the massive release of the loaded
antimicrobial agents in the ﬁrst 24 h followed by a slow release at
sub-inhibitory concentrations until drug exhaustion, this phenomenon
involving the risk of emergence of antibiotic-resistant strains. To
overcome these limitations, we focused our research efforts in developing
different experimental approaches to prevent microbial colonization of
central venous catheters based on the adsorption of antimicrobial agents
to synthesized and properly functionalized polyurethanes with the aim
to control drug adsorption and release. Firstly, we have impregnated
appropriately functionalized polyurethanes with two antibiotics with
different mechanisms of action, rifampicin and cefamandole nafate,
along with pore forming agents such as albumin and polyethylene glycol.
This in vitro model exhibited a good polymer/antibiotic afﬁnity and the
ability to obtain a controlled release of large amounts of antimicrobials
for up to 23 days. These results suggest that the entrapping of antibiotic
molecules and pore-formers in properly functionalized polyurethanes
may represent a promising approach to prevent catheter colonization
and onset of bacterial resistance. Other antibioﬁlm strategies we are
dealing with concern: i) the development of antimicrobial polymers by
the use of polyurethanes able to coordinate metal ions (Ag+, Zn2+, etc);
ii) the exploiting of the bioﬁlm matrix-degrading enzyme, Dispersin
B, to allow a better penetration of antibiotics through the microbial
bioﬁlm, thus improving their activity; iii) the development of a magnetic
nanoparticles-based targeting system to ﬁght catheter-related infections
by an in situ, on demand, antimicrobial treatment.
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S455 Fever in travellers from India and south-eastern Asia
N. Beeching ° (Liverpool, UK)
This presentation will focus on the changing epidemiology of fevers
imported from this region reﬂected in travel infection databases, and use
brief vignettes to highlight important clinical diagnostic and management
issues. As in all travellers, a detailed travel, exposure and immunisation
history is essential, combined with knowledge of patient comorbidities
that may predispose to acquiring certain infections. In general, malaria
is less likely to be the cause of fever than other infections, contrasting
strongly with the differential diagnosis in travellers arriving from Africa.
However, recent increases in malaria transmission in tourist areas such
as Goa remind us of the need to maintain a high index of suspicion and
continually to review pretravel advice on prevention. The emergence of
artemesinin resistance in the Thai-Myanmar border area is a concern for
the future.
In most recently returned travellers, arbovirus infections such as dengue
and chikungunya are common causes of fever and can be conﬁrmed
using molecular techniques in the ﬁrst week of illness and serological
tests thereafter. Importation of scrub typhus is less common than is tick
typhus in travellers from Africa. Leptopirosis is associated with fresh
water activities popular with tourists in South East Asia, such as white
water rafting and “tubing”, but imported schistosomiasis from this area
is rare. Eosinophilia is more likely to be due to other enteric or systemic
helminth or ﬂuke infections.
Enteric fevers are common in travellers from the Indian subcontinent,
with recent predominance of paratyphoid A, which is often resistant
to ﬂuoroquinolones and multidrug resistant to other ﬁrst line agents.
Empirical treatment while awaiting culture results and resistance data
should avoid such agents and include a third generation cefalosporin
and/or azithromycin. Antimicrobial resistance is common in infections
imported from this area, including extended spectrum b-lactamase
producing Gram negative bacteria, and multidrug resistant tuberculosis.
Respiratory infections are common in any traveller, and inﬂuenza has
been demonstrated to be the most frequent vaccine preventable infection
acquired by tourists in South East Asia. Recent experience with SARS
and ongoing concerns in the region about avian inﬂuenza remind us
of the continued risk in this region of the emergence of novel virus
infections spread by the respiratory route.
S456 Fever in travellers from South America
E. Gotuzzo ° (Lima, PE)
In a study performed by Geo Sentinel and published recently, it was
found that, among North Americans, fever after a travel to South
America is not very common and that it includes malaria, salmonellosis,
dengue, etc.
It is important to make geographic distinctions:
1. In Mexico: amebiasis, hepatic abscess and typhoid fever should
always be included.
2. In Central America: typhoid fever and dengue are the main causes
of fever. Histoplasmosis and toxoplasmosis have been detected in
immunosuppressed patients.
3. In South America: Malaria by P. falciparum and P. vivax are frequent
causes of fever. Since 1991, the frequency of typhoid has decreased
with more than 90%. The strains of S. typhi continue to be sensitive to
chloramphenicol, ampicilline and ﬂuoroquinolones. By contrast with
Asia, multidrug resistant strains have not been detected.
Dengue and enteric hepatitis are frequent causes of fever. In Peru,
brucellosis (as well as in Mexico and Venezuela) and bartonellosis should
be considered as important diseases.
Occasionally, regional mycoses such as histoplasmosis (exposure to
caves) and paracoccidioidomycosis are seen.
S458 Computer-assisted diagnosis of fever in travellers
J. Van den Ende ° (Antwerp, BE)
Kabisa, a computer based tutorial for tropical medicine, has been
developed since 1992, the ﬁrst version in foxpro, the second in C++,
the third in MS Access XP, and the last in Delphi. (Van den Ende et al.
1997a) For developing countries it is a didactic tool that challenges the
student with cases electronically assembled from a randomly generated
disease and randomly chosen related presenting symptoms. The student
should ﬁnd the diagnosis with a set of disease characteristics, available
in the context of a hospital in developing countries. The logical engine is
based upon both pattern recognition and Bayesian logic. For a Western
context the programme offers also an expert system for imported fever,
based on a prospectively generated database of over 2000 patients.
The expert module is innovative with the suggestion of new tests based
on the data already provided by the user. In this suggestion, a threshold
driven logic is followed: (Pauker & Kassirer 1980) for the highest ranked
diagnosis strong excluders are asked for, once this diagnosis is worked
out less probable hypotheses are examined also. Ranking of suggested
tests takes into account power, feasibility, risk and cost.
During the session, real examples will be played and the application of
the logic shown. If wanted, detailed explanation of the programming can
be given. Participants are invited to bring their laptop; the program will
be installed and distributed for free.
Reference(s)
[1] Pauker, S. G. & Kassirer, J. P. 1980, “The threshold approach to
clinical decision making”, New England Journal of Medicine, vol.
302, no. 20, pp. 1109–1117.
[2] Van den Ende, J., Blot, K., Kestens, L., Van-Gompel, A., & Van-den-
Enden, E. 1997a, “Kabisa: an interactive computer-assisted training
program for tropical diseases”, Med. Educ., vol. 31, no. 3, pp. 202–
209.
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Reducing hospital-acquired infections. What
is new?
O459 Hospital resources and capabilities in dealing with highly
infectious diseases: EuroNHID data from a survey of 44
isolation facilities in 14 European countries
S. Schilling, H. Brodt, R. Gottschalk, B. Bannister, P. Brouqui,
F.M. Fusco °, H.C. Maltezou, G. Thomson, V. Puro, G. Ippolito for
the EuroNHID (European Network for Highly Infectious Diseases)
Study Group
Objective: Highly Infectious Diseases (HIDs, e.g. Viral Haemorrhagic
Fevers and SARS) are life-threatening, human-to-human transmissible
diseases that may cause Public Health emergencies, requiring special
procedures for their containment. To review isolation hospital resources,
the European Network for Highly Infectious Diseases project conducted,
through a speciﬁcally developed checklist, a survey in the facilities
designed to deal with HIDs. These data from 44 facilities in 14 European
Countries are described.
Methods: The checklist, including 10 items and 44 questions, was
developed through a “networking strategy”: a project partner with
speciﬁc expertise sent drafts for comments and amendments. Final
agreement had been reached during a meeting involving all partners.
Facilities to be surveyed were selected by national authorities, and are
those planned for giving care to patients affected by HIDs. In site surveys
were conducted from March to November 2009.
Results: Totally, 481 hospital beds in 350 rooms are available, and in 185
of them it is possible to give intensive care. These facilities are mainly
recently built/renovated (70% after 2000). Most of surveyed facilities use
these beds routinely, while in 10 isolation facilities they are reserved to
HIDs only. Among technical issues, about 90% of facilities are equipped
with anterooms, negative pressure inside the isolation area, and high-
efﬁciency ﬁltration of exhausting air. Availability of other technical
features (autoclave, sealing of the room, use of adequate material,
communication systems, negative pressure indicators, self-closing doors)
varies among countries. Four facilities have a BSL-4 laboratory in the
same centre/city, while BSL-3 laboratories are available in the same
centre/city for 36 facilities. In 60% of facilities, staff is speciﬁcally
trained, including physicians and nurses with Infectious Diseases and
Intensive Care background.
Conclusion: According to preliminary data analysis, generally the
hospital resources in isolation are adequate, despite the fact that different
levels of preparedness among different countries are still present, in
particular in the ﬁeld of intensive care capabilities and availability of
trained staff. These data will represent a valuable tool both for surveyed
facilities, in order to identify their strengths and weaknesses, and for
European authorities, providing an “on-the-ﬁeld” evaluation of European
hospitals’ capabilities in dealing with HIDs.
O460 Effects of selective digestive and selective oropharyngeal
decontamination on bacteraemia and respiratory tract
colonization with highly resistant micro-organisms
A.M. De Smet °, J. Kluytmans, H. Blok, M. Bonten, M. Bootsma
(Amsterdam, Breda, Utrecht, NL)
Background: Selective Digestive tract Decontamination (SDD) and
Selective Oropharyngeal Decontamination (SOD) were associated with
improved day-28 survival in intensive care patients, but the effects
on infections and respiratory tract colonization with Highly-Resistant
Microorganisms (HRMO) are unknown.
Methods: SDD, SOD and standard care (SC), during periods of six
months each, were evaluated in an open clustered group-randomized
cross-over study in 13 ICUs, with the order of interventions randomized
per center. SOD consisted of four times daily topical application
of tobramycin, colistin and amphotericin B in the oropharynx. SDD
consisted of SOD and topical application of the same antibiotics in the
stomach and four days of intravenous cefotaxime. Cultures of respiratory
tract were obtained twice weekly during SDD and SOD, and on clinical
indication only during SC. HRMO were deﬁned according to Dutch
guidelines. All blood and respiratory tract culture results were evaluated.
Results: 5,927 patients were available for analysis: 1,989 (SC), 1,904
(SOD) and 2,034 (SDD). Compared to SC, odds ratios (OR) for ICU-
acquired bacteremia were 0.48 (95%CI 0.38–0.60) during SDD 0.66
(95%CI 0.53–0.82) during SOD. OR for ICU-acquired bacteremia
caused by HRMO during SDD were 0.41 (95%CI 0.18–0.94) as
compared to SC, which corresponds to a rate reduction of 59%, an
absolute risk reduction (ARR) of 0.6% and a number needed to treat
(NNT) of 170. As compared to SOD, the OR for SDD was 0.37 (95%CI
0.16–0.85), which corresponds to a rate reduction of 63%, an ARR of
0.7% and a NNT of 145. ICU-acquired colonization of Gram negative
bacteria was highest among patients receiving SC. ORs for acquiring
HRMO colonization, as compared to SC, were 0.58 (0.43–0.78) and
0.65 (0.49–0.87) for SDD and SOD respectively, corresponding to 38%
and 32% rate reductions, 5.5% and 4.6% ARR and with NNT of 18
and 22, respectively. Acquired colonization with cefotaxime-resistant or
colistin-resistant pathogens was lowest during SDD.
Conclusions: As compared to SC, ICU-acquired bacteremia and
respiratory tract colonization with HRMO were 48% and 59% lower
during SDD and acquired respiratory tract colonization with HRMO
was 38% lower during SOD.
O461 Prevention of catheter-related bacteraemia with a daily
ethanol-lock in haematology patients with tunnelled
catheters. Randomized placebo-controlled trial
B.J. Rijnders °, L. Slobbe (Rotterdam, NL)
Objective: Catheter-related bacteraemia (CRB) results in signiﬁcant
attributable morbidity and mortality. In this randomized double-blinded
placebo-controlled trial, we study the efﬁcacy and safety of a daily
ethanol-lock on prevention of CRB in patients with a tunnelled central
venous catheter (CVC).
Methods: From 2005 until 2008, each CVC lumen of adult haematology
patients was locked for 15 minutes per day with either 70%-ethanol or
placebo, following which the lock-solution was ﬂushed through. As a pri-
mary endpoint, rates of endoluminal CRB in each group were compared.
Results: The catheter-based ITT-analysis was based on 376 patients,
accounting for 448 catheter episodes and 27,745 catheter days. For
ethanol-locks, the incidence of CRB per 1000 days of CVC-use was
0.70 compared to 1.19 in patients allocated to placebo (incidence rate
ratio 0.59; p = 0.19). In patients who classiﬁed for endoluminal CRB
according to the strictest deﬁnition (positive hub culture and concurrent
bacterial strain detected in blood) a 3.6-fold, but not statistically
signiﬁcant reduction of CRB was observed for patients receiving ethanol
(2/226 versus 7/222; p = 0.103). No life-threatening adverse events were
observed. More patients receiving ethanol discontinued lock therapy
(11/226 versus 1/222; p = 0.006) or continued with decreased lock
frequency (10/226 versus 0/222; p = 0.002), due to subjective discomfort,
especially facial ﬂushing and drowsiness.
Conclusion: In this study, the use of ethanol-locks non-signiﬁcantly
reduced the incidence of endoluminal CRB. However, further studies
are needed as the overall low incidence of endoluminal precludes
deﬁnite conclusions. Alternative sources of bacteraemia, like microbial
translocation during mucositis or exoluminal CRB may have been more
important in this patient population.
O462 Different strokes: a co-relational modelling study of common
(community and acute hospital) HCAI reduction targets,
variable dynamics and antibiotic prescribing
I. Maitland °, R. Kato, M. Ibeto, M. Qulaghassi, A. Guleri (Blackpool,
UK)
Objectives: Reducing healthcare associated infections (HCAI) in
hospitals & community has been priority for department of health (DH).
Blackpool Victoria Hospital, large district acute hospital covers
Reducing hospital-acquired infections. What is new? S99
Blackpool PCT & North Lancashire PCT. DH conferred HCAI
innovation technology award 2009 for most innovative use of technology
(MRSA PCR) to signiﬁcantly reduce MRSA. The comprehensive
HCAI containment program (CHCP) including multiple interventions
was introduced in BVH in 2008 with successful reductions: MRSA
bacteraemia 78%, C. difﬁcile infections (CDI) 45%; ESBL 25% and gly-
copeptide usage 32%. Antibiotic stewardship (AS) is a key area. Revised
separate formularies for hospital and primary care (with restrictions on
quinolones & 3rd gen cephalosporin) introduced. HCAI rates (CA &
HA) are jointly submitted. We present a co-relational study from audit
on GP antibiotic prescribing, comparative reductions in HCAI and new
whole health economy (joint primary care–hospital) initiatives.
Methods: Data from audit (initial Aug08 & ﬁnal Aug09) on antibiotic
prescribing in a large GP surgery in North Lancashire [e.g. Compliance
to formulary, choice/dose/duration/appropriate, etc); data on HCAI
(pre48 h & post48 h) were analysed.
Results: The audit revealed 64.4% prescriptions had adequate indication;
Recommended antibiotic was prescribed in 53.4% (321/601) &
70.9% (73/103) cases in the initial & ﬁnal audit resp. The ﬁnal audit
revealed 37.9% (36/103) carried correct dose & duration of antibiotic
while 61.2% (60/103) had only correct dose.
HCAI rates (Apr08–Sep09): CA-CDI reduced by 25% (Apr–Sep09 v/s
Apr–Sep08) while HA-CDI reduced by 37%. CA-MRSA bacteraemia
increased by 33.3% while HA-MRSA reduced by 50%. CDI-RCA
across PCT & hospital (Jan–Oct09) reveal non-compliance with
formulary, repeated & extended courses of antibiotics/susceptible
(>65 yrs) population is the single predominant cause of ‘avoidable/
probably-avoidable’ CDI.
Conclusions: HCAI travel freely between community & hospital.
There is variation in the dynamics & resources of PCT & hospital
ICTs. However, the key to a successful joint HCAI programme is
team working & complimenting expertise, joint initiatives & real-time
monitoring of the CHCP to align it to meet new challenges.
Data reﬂect only 37.9% of compliance to both accurate dose
and duration. We recommend additional microbiologist & antibiotic
pharmacist input, raising awareness about HCAI, infection control &
antibiotic stewardship is required to improve GP prescribing.
O463 Decontamination of sink wastes and traps is associated with
a reduction in Gram-negative sepsis in a neonatal intensive
care unit
S. Knowles °, M. Matheson, M. Walsh (Dublin, IE)
Objectives: To compare the incidence of nosocomial Gram-negative
sepsis in a neonatal intensive care unit (NICU) before and after the
introduction of quarterly dismantling, cleaning and disinfection of sink
wastes and traps.
Methods: Prospective surveillance of all late-onset (neonate >72 hours
of age) nosocomial Gram-negative sepsis in the NICU over a 40 month
period from July 2006 to October 2009. Gram negative bacteria isolated
from blood or cerebrospinal ﬂuid were included. Sepsis rates during 24
months before the introduction of quarterly cleaning and disinfection
of sink wastes and traps in July 2008 were compared with the 16
months following. Patient demographic information collected includes
sex, gestation, birth weight, multiple birth, day of onset of sepsis and
outcome. Data from environment screening of sink faucets and drains
are documented.
Results: Twenty one episodes of sepsis occurred in 21 neonates during
the period from July 2006 to June 2008. There was 1 meningitis
(E. coli), 1 meningitis and bacteraemia (Enterobacter species) and
19 bacteraemia’s (6 E. coli, 4 Klebsiella pneumoniae, 7 Enterobacter
species, 1 Proteus mirabilis and 1 Pseudomonas aeruginosa). After
introduction of quarterly cleaning and disinfection of sink wastes and
traps 3 episodes of sepsis have occurred in 3 neonates during the 16
months from July 2008 to October 2009. These were 3 bacteraemia’s (2
Klebsiella species and 1 Acinetobacter species). Before introduction of
this practice, there were an average of 10.5 episodes of Gram-negative
sepsis per annum compared to 2.25 per annum currently (p< 0.01).
Conclusions: No signiﬁcant infrastructural work took place during this
40 month period. There was no signiﬁcant change in medical, nursing,
hygiene or infection control stafﬁng numbers. The antibiotic policy
remained unchanged. The number of admissions to the NICU was stable
(1239 in 2006; 1215 in 2007 and 1232 in 2008), although the percentage
of neonates <1500g birth weight increased from 99 (8%) in 2006 to 137
(11.3%) in 2007 and 154 (12.5%) in 2008. The reduction in the rate
of Gram-negative sepsis as very low birth weight admissions increased
was unexpected. Methods to reduce Gram-negative sepsis are complex
and multifactorial infection control measures are required. Nonetheless,
we found quarterly dismantling, cleaning and disinfection of sink wastes
and traps was associated with a reduction in Gram-negative sepsis.
O464 Hand hygiene compliance in 13 European intensive care units
L. Derde °, C. Brun-Buisson, M. Bonten on behalf of the MOSAR
research consortium
Objective: To quantify hand hygiene compliance (HHC) and its
determinants in 13 European intensive care units (ICUs).
Methods: Between May 2008 and September 2009 15.223 hand hygiene
opportunities were observed in ICUs in France (n = 3), Greece (n = 2),
Italy (n = 1), Latvia (n = 1), Luxemburg (n = 1), Portugal (n = 2), Slovenia
(n = 2) and Spain (n = 1). Observations were performed by trained
research nurses at random dates, times and bed spaces during 6 months
using a standardized protocol derived from the WHO “5 moments”
method. No feedback of results or training of staff was allowed. A
standardized test was used to assess inter-observer variation.
Results: The mean bed occupancy rate was 85% (58−99%) and ICUs
had on average 13.11 (9−21) beds, with 61% of patients being ventilated
(43−81%). The average nurse-to-patient ratio (per occupied bed) was
0.52 (0.34–0.91). HHC rates varied from 7% to 88% (mean: 48%).
Nurses’ HHC was higher than physicians’ HHC (mean: 51 vs 39%)
in all but two centers. Auxiliary nurses and other healthcare workers
had intermediate HHC (42% and 44%, respectively).
When separated per indication category (i.e. hand hygiene before and
after actions that require hand hygiene), HHC was higher in the latter
group (43 vs 57%, p = 0.003).
45% of missed hand hygiene opportunities involved the use of gloves,
mainly before performing an aseptic task or after possible body ﬂuid
contact. Gloves were used in 47% of opportunities missed by nurses
compared to 30% for physicians (p = 0.005). No relationship between
HHC and nurse stafﬁng hours (correlation 0.049) or bed occupancy rate
(correlation −0.314) could be demonstrated. In a standardized written
test-scenario of 41 items, inter-observer variation was low, with a mean
HHC scored of 31% (SD 7.18) compared to 29% in the referent test
(p = 0.250). Preliminary data of 10 of the ICUs suggest that a hand
hygiene improvement program (HHIP; WHO method) improves HHC
signiﬁcantly.
Conclusions: In these 13 ICUs, HHC varied from 7% to 88%. In general
nurses had higher HHC rates than physicians. No correlation between
nurse stafﬁng hours or bed occupancy and HHC could be demonstrated.
Preliminary data suggest that HHC was improved with a HHIP program
(WHO method).
S100 20th ECCMID, Oral presentations
O465 A survey examining promotion of hand hygiene in healthcare
through campaigns and programmes coordinated at a
national/sub-national level
E. Mathai °, B. Allegranzi, C. Kilpatrick, S. Bagheri Nejad,
W. Graafmans, D. Pittet (Geneva, CH)
Objective: The WHO First Global Patient Safety Challenge “Clean
Care is Safer Care” (CCiSC) recognises the importance of nationally
coordinated activities in achieving its goal of reducing healthcare-
associated infection (HAI) through improved hand hygiene in healthcare.
A baseline survey of existing hand hygiene national/sub-national
initiatives was conducted in 2007 and repeated in early 2009 to assess
current status and to generate information on factors contributing to their
success.
Methods: Campaigns and programmes promoting hand hygiene in
healthcare were identiﬁed through WHO regional ofﬁces and experts
in the ﬁeld. An online survey using a structured questionnaire was
conducted during March-April 2009.
Results: In 2009, 38/38 campaigns/programmes identiﬁed (18/20 in
2007) completed the survey. Of the 38, 29 were active national/sub-
national level initiatives from all WHO regions, except for Africa; 21
(72.4%) were initiated after the launch of CCiSC in October 2005.
The main targets of hand hygiene promotion were general, district and
university hospitals, with increasing coverage of long-term care facilities
and primary care. The scope varied from awareness raising to well
scaled-up activities with ongoing evaluation. Most activities (20/29)
obtained funding from multiple sources with governments among the
main funders; governments were responsible for initiating 25/29 (86.2%)
campaigns/programmes. Through the 2009 survey, the facilitator role
played by CCiSC in initiating activities and the support with tools and
recommendations emerged very clearly. Barriers were identiﬁed, but the
perceived signiﬁcance of speciﬁc barriers varied considerably. Those
related to commitment (priority and support) and resource availability
were important across all regions. A range of indicators to measure the
impact of the initiative was reported with process indicators being more
common.
Conclusion: Hand hygiene is being promoted in healthcare in
several countries at national/sub-national level with clear objectives,
strategies and governmental support. Such embedding through policies
and resource allocation is important for sustainability. Actions to
improve commitment from different stakeholders are needed. Indicators
for measuring impact need to be more uniform and more widely
implemented. Further actions to initiate coordinated activities across the
world, including countries with limited resources, are required.
O466 Effect of a multifaceted intervention on adherence to hand hy-
giene among healthcare workers: a cluster randomized trial
D. Mertz °, N. Dafoe, S. Walter, K. Brazil, M. Loeb (Hamilton, CA)
Objectives: Compliance with hand hygiene among health care workers
(HCWs) is widely felt to be a key factor in reducing the spread of
nosocomial infections. The objective of this study was to evaluate the
impact of a multi-faceted intervention to increase adherence of hand
hygiene among healthcare workers (HCWs) and assess the effect on
the incidence of nosocomial methicillin-resistant Staphylococcus aureus
(MRSA).
Methods: A cluster randomised controlled trial was conducted from
June 2007 to May 2008 in 30 units of three tertiary care hospitals in
Hamilton, Ontario, Canada. Study units included eight medical, four
general surgery and eight intensive care units. Following a three month
baseline period of data collection, 15 units were randomly assigned to the
intervention arm (performance feedback, small group teaching seminars,
posters) and 15 to usual practice. Hand hygiene was observed during
randomly selected ﬁfteen-minute periods on each unit and the incidence
of MRSA measured using surveillance specimens.
Results: 3812 (48.2%) of 7901 opportunities for hand hygiene in the
intervention group resulted in adherence compared to 3205 (42.6%) of
7526 opportunities in the control group (P< 0.001). However, there was a
signiﬁcant increase of adherence compared to baseline adherence (15.4%
in the control and 16.2% in the intervention group) for both groups
(Figure). There was no reduction in the incidence of nosocomial MRSA
in the intervention group.
Conclusion: Among HCWs in Ontario tertiary care hospitals, adherence
to hand hygiene signiﬁcantly increased with a multi-faceted intervention.
Moreover, there was a marked increase in adherence to hand hygiene
in both study groups. No resulting difference in MRSA rates between
patients in the two study groups could be observed.
Figure. Mean adherence rates to hand hygiene in the control and
intervention group.
O467 Glove use in infection control − is this a signiﬁcant barrier
to hand hygiene compliance?
C. Fuller, J. Savage, S. Besser, S.P. Stone ° (London, UK)
Objectives: WHO guidelines stipulate that gloves are required for
speciﬁc clinical procedures, but warn that they are not a substitute for
disinfecting or cleaning hands. It has been suggested previously that
wearing gloves could be a barrier to good hand hygiene compliance but
the literature is divided as to whether healthcare workers (HCWs) are less
likely to clean their hands when wearing gloves. We carried out a large
multicentre study to determine whether wearing gloves was associated
with poorer hand hygiene compliance.
Methods: 232 hours of observations (7020 observations) were carried
out on 15 Intensive Therapy Units (ITUs) and 41 Acute Care of the
Elderly/General Medical (ACE/GM) wards in 20 hospitals in England &
Wales, whilst conducting a randomised controlled trial of an intervention
to improve hand hygiene compliance (FIT trial N0256159318, NRR
website). Glove use was not part of the intervention. Hand hygiene
moments & behaviours were recorded using a rigorously standardised
hand hygiene observation tool (the HHOT), and noting whether the
HCW was using gloves or not. Compliance with & without gloves was
compared overall & for different hand hygiene moments.
Results: Of the 7020 observations, 1729 (25%) were associated with
glove use in both ITUs and ACE/GM wards. Gloves were used in
78% of high risk hand hygiene moments (aseptic technique, body ﬂuid
exposure) and in 16% of low risk moments (before & after patient
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contact, after environmental contact). Overall hand hygiene compliance
was lower when wearing gloves (42.6%) than when not wearing gloves
(51.2%). The odds of HCWs cleaning their hands were less when gloves
were worn (OR= 0.71; [CI 95% 0.61–0.82]). This was true for all hand
hygiene moments. On ACE/GM wards there was a greater difference in
overall compliance (35.3% with gloves v 49.5% without; OR= 0.56 [CI
95% 0.45, 0.69]) than on ITUs (50.1% v 54.9%).
Conclusions: This large study found that glove use was associated with
worse hand hygiene compliance, and may present a barrier to HH.
Modelling studies suggest that small increments in compliance may
result in large reductions in transmission of organisms. It is therefore,
possible that interventions to reduce unnecessary glove use & ensure
appropriate compliance before & after glove use could have a signiﬁcant
effect on spread of infection. Further work examining the predictors of
glove usage & associated hand hygiene by HCWs may be warranted to
guide such interventions.
O468 Achieving sustained improvement in hospital hygienic
cleaning using peer-group benchmarking
P. Carling °, B. Dick, E. Eck (Boston, Toledo, Passadena, US)
Objectives: Ongoing contamination of surfaces in the “patient zone”
(Pittet 2007) has become increasingly recognized as playing a role
in the transmission of major healthcare-associated pathogens. Over
the past ﬁve years an indirect monitoring system has been used to
improve environmental hygiene related to discharge cleaning in almost
100 hospitals. In view of these results, we undertook a prospective
evaluation of a multi-hospital benchmarking program to further analyze
this approach for improving the thoroughness of disinfection cleaning
(TDC) at discharge.
Methods: The TDC of fourteen high touch objects was evaluated
using a ﬂuorescent dye based targeting method in two hospital systems
consisting of 12 hospitals (Group A) and 7 hospitals (Group B)
administratively related within each group but geographically and
functionally independent institutions. A three phase intervention was
utilized as previously described (ICHE 2008; 29: 1035−41). TDC scores
were provided to the environmental services administration at each
hospital and on a regular basis as part of system-wide quality assurance
reviews for each system. At each meeting TDC scores were reviewed and
the most effective programmatic and educational interventions shared.
Results: As noted in the Figure, pre-intervention (Phase I) TDC
scores averaged 39% (95%CI 27.4 to 50.1) in group A hospitals
and 53% (95%CI 33.1 to 72.8) in group B hospitals. Following
education alone (Phase II), scores in both hospital groups improved
with group A hospitals improving to 70.1% and group B hospitals to
68%. Subsequently (Phase III) and as a result of serial feedback and
peer group benchmarking (F/Us), overall TDC continued to improve in
group A hospitals to 88% and group B hospitals to 77%. As noted in
theFigure, high levels of improvement were documented for sustained
periods of time (to date, 6 to 16 months).
Conclusions: (1) Phase I of the study disclosed previously unsuspected
differences in TDC despite the existence of similar cleaning policies in
all hospitals. (2) Group benchmarking of TDC scores favorably impacted
additional improvement in cleaning. (3) The ongoing transparency
engendered by the system-wide programs has made it possible to sustain
gains for up to 18 months. (4) The development of a patient-safety
oriented, non-punitive environment as well as individual hospital and
system-wide leadership support were recognized as critical components
of the success of the program.
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O469 The ESAC point prevalence survey: antimicrobial
prescribing in 2 age groups of elderly patients from 49
hospitals in 28 European countries in 2008
B. Amadeo °, P. Zarb, G. Gavazzi, A. Muller, V. Vankerckhoven, P. Davey,
H. Goossens on behalf of the ESAC Hospital Care sub-project Group
Objectives: As ageing population raises fast, elderly aged above 65 years
are usually considered as a one group in literature. However, if infections
are more frequent and more severe in the elderly, they also have speciﬁc
features related to different subgroups of the elderly patients. This study
aimed to identify and to assess the variability of antimicrobial (AM) use
between 2 age groups of elderly patients.
Methods: Data were extracted from 49 hospitals of the European
Surveillance of Antimicrobial Consumption (ESAC) Point Prevalence
Survey carried out during a maximum of 2 weeks from May to June in
28 European countries in 2008. The survey included all inpatients wards
and collected information on the treated patients with indications and
diagnoses. The analyses were restricted to patients above 65 years which
were divided into 2 age year groups (G1: [65−75[; G2: 75).
Results: Data for treated patients were obtained for 1,579 patients in G1
and 2,132 patients in G2. Among all the treated patients, G2 received less
AM combination (G1: 33%; G2: 24%) and parenteral AM (G1: 65%;
G2: 57%). The top three AM classes prescribed were similar in both
groups and corresponded to combinations of penicillins with b-lactamase
inhibitors (G1: 18%; G2: 24%), ﬂuoroquinolones (G1: 12%; G2: 14%)
and third-generation cephalosporins (6% for both groups). Infections
represented 74% and 83% of all indications in G1 and G2, respectively.
Respiratory tract infections were the commonest infections in both
groups (G1: 29%; G2: 33%) followed by skin-soft-tissues-and-bone-
joint infections in G1 (18%) and urinary tract infections in G2 (23%).
The proportion of surgical prophylaxis was lower in the oldest patients
(G1: 69%; G2: 66%). The >1 day duration of surgical prophylaxis was
54% in both groups. The prescribed doses for 5 parenteral AM, i.e.
benzylpenicillin, gentamicin, cefuroxime, piperacillin–tazobactam, and
vancomycin were higher in G1 whilst amoxycillin and cefazolin were
higher in G2.
Conclusion: The results of this study showed differences between the 2
elderly age groups, particularly in the proportion of AM combination,
parenteral use, and infection site. It became clear that in line with
the improved quality of life of the elderly population in industrialized
countries, the treatment of G1 is more comparable to that of younger
adults. Importantly, future analyses on AM use should take several age
groups of the elderly population into consideration.
O470 The European Surveillance of Antimicrobial Consumption:
point prevalence survey of antimicrobial prescriptions in 270
European nursing homes
B. Jans °, K. Latour, E. Broex, A. Muller, V. Vankerckhoven,
R. Stroobants, H. Goossens on behalf of the European Surveillance of
Antimicrobial Consumption (ESAC) Nursing Homes subproject group
Objectives: Facing the treat of antimicrobial resistance in healthcare
settings, optimising the use of antibiotics (AB) in the nursing home (NH)
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population is an important priority of quality of care. However, data on
AB-use in European (EU) NHs are scarce. The European Surveillance
of Antimicrobial Consumption (ESAC) NH sub-project team, funded by
the European Centre for Disease Prevention and Control, carried out a
methodology in order to measure and describe AB prescriptions among
residents living in EU NH.
Methods: In April 2009, a PPS was carried out in 301 NH in 19 EU
countries. Inclusion criteria for residents were to be present in the NH for
at least 24 hours and to receive systemic AB on the day of the PPS. Data
were obtained from nursing notes, medication administration records
and staff in relation to AB prescribing, characteristics, risk factors and
determinants at NH- and at resident level.
Results: Data were available for 17 countries and 270 NH (29.360 NH-
beds). The mean number of beds by NH was 108 (20–621 beds). Among
27.614 eligible residents, 1740 (median 5.9%, 0−30%) received an AB
on the PPS-day. In 20 NH no residents received AB. In the total NH-
population 4% (0−57%) had an urinary catheter, and of these, 17%
received an AB. Wounds were present in 10% of the population (0−75%)
and AB were prescribed in 15% of them. Vascular catheters were
uncommon (0.78%) but 36% of this sub-population used an AB. Among
residents with AB, 24% had a recent hospital stay. In total 1757 AB
molecules were used. AB were administered orally in 90%, parenteral
in 9% and nasal (decolonisation MRSA) in 1%. 53% of all treatments
concerned urinary tract (prophylactic: 55%) and 29% the respiratory
tract (empirical: 92%). 51% of all prescribed regimens were empirical
treatments (RTI: 53%, UTI: 23%), 32% was prophylactic (UTI: 89%,
RTI: 5%) and 16% was for a documented infection (UTI: 72%). The
prevalence of AB use was signiﬁcantly lower in NH with regular training
of prescribers (p = 0.02), with written guidelines for appropriate AB-use
(p = 0.01) or with a NH therapeutic formulary (p = 0.0002) compared to
NH without these tools.
Conclusion: Strong differences in AB-prevalence and device-use were
observed in EU NH. Both micro (case-mix)- and macro determinants
(cultural differences) partially contribute to these differences. The high
proportion of AB-use for urinary tract, especially the important part of
uroprophylaxis, was surprising and needs to be explored.
O471 Impact of medical care and coordination on antibiotic policy
and consumption: data of the European Surveillance of An-
timicrobial Consumption (ESAC) nursing home subproject
K. Latour °, E. Broex, A. Muller, N. Drapier, V. Vankerckhoven,
R. Stroobants, H. Goossens, B. Jans on behalf of the European
Surveillance of Antimicrobial Consumption (ESAC) Nursing Home
subproject group
Objectives: The aim was to explore medical care and coordination in
European nursing homes (NH) and their effect on antibiotic (AB) policy
and use.
Methods: The European Surveillance of Antimicrobial Consumption
(ESAC) NH subproject explored the medical care and coordination and
AB policies by using a standardised questionnaire which had to be
completed by participating European NHs.
Results: The questionnaire was completed by 270 NHs in 16 European
countries. Medical care was provided by personal general practitioners
(GP), by an employed medical staff or by both in 67.3%, 20.3% and
12.4% of the NH, respectively (n = 266). A NH working with GPs was
visited by a median of 26.3 personal GPs per 100 NH beds (min.0.3-
max.96.6 per 100 beds) while in other NHs the medical staff consisted
of a median of 2 physicians (min.1-max.14). A coordinating physician
(CP) of medical care was assigned in 68.4% of the NHs (n = 256). The
most reported tasks of the CPs were to develop an infection prevention
policy (77.7%), to train nursing staff (76.0%), and to develop medical
care strategies (70.9%). The presence of a CP in a NH did not result in a
signiﬁcant lower number of AB prescriptions compared to NHs without
a CP (median AB prevalence 5.78% vs. 5.71%; p = 0.46). However,
NHs where the CP developed an infection prevention policy showed
a signiﬁcant lower rate of AB use in comparison to NHs where the
CP did not have this speciﬁc task (median 5.2% vs. 8.7%; p = 0.0097).
Furthermore, the presence of a CP led to a signiﬁcant higher availability
of a restrictive AB list compared to NHs without an assigned CP (median
17.4% vs. 6.3%; p = 0.018).
Private institutions were more likely to work with GPs than public
NHs (59.2% vs. 40.8%), which in their turn had a greater tendency
(84.9% vs.15.1%) to work with an employed medical staff (p< 0.001).
Working with visiting GPs in the NH made it more difﬁcult to develop
a restrictive AB list compared to NHs with a medical staff (5.6%
vs. 43.1%; p< 0.001). However, the number of visiting GPs per 100
beds did not signiﬁcantly inﬂuence (categorical variable: <20, 20−40,
>40 GPs/100 beds; median 5.06%, 6.19% and 6.67%, respectively) the
prevalence of AB use (p = 0.15).
Conclusion: Although an impact of an appointed CP in the NH on the
prevalence of AB use could not be demonstrated, his role in developing
a restrictive AB list and infection prevention policy was clearly shown
in our survey.
O472 The European Surveillance of Antimicrobial Consumption
(ESAC) survey of wound prevalence and antibiotic use in
270 European nursing homes in 2009
E. Broex °, K. Latour, A. Muller, N. Drapier, V. Vankerckhoven,
R. Stroobants, H. Goossens, B. Jans on behalf of the ESAC Nursing
Homes Subproject group
Objectives: To deﬁne wound prevalence, its determinants and its relation
with antibiotic (AB) use in European nursing homes (NHs).
Methods: A point prevalence study, on AB use, characteristics of
residents and characteristics of the NH was conducted in European NHs
in 2009.
Results: Results from 270 NHs in 16 European countries are available.
A median of 9.7% (11.7% mean) of all NH residents (n = 26,063)
was diagnosed with an undeﬁned wound. Among residents treated with
ABs (n = 1734), 24% had a wound. However, when considering wound-
and AB prevalence (dichotomized above and below the median) at
institutional level there was no signiﬁcant relation (p = 0.19). Of the
AB using residents 2.5% was treated (i.e. prophylactic, empirical or
documented) for a wound infection (WI). Among AB using residents
with wounds 7% was treated for a WI. Remarkable is that 1.5% of the
residents reported not to have wounds was treated for a WI. Of the AB
treated NH residents that were admitted to a hospital within the last
three months, 35% had a wound. Of those without hospital admission,
20% had a wound (p< 0.0001). Escherichia coli accounted for 47% of
the microorganisms (MOs) detected among residents without a wound, in
contrast to only 24% (p = 0.0002) for residents with a wound. Methicillin-
resistant Staphylococcus aureus was found among 15% of residents with
a wound, and 4% of those without (p = 0.00015).
Residents with a wound received more often empirical (55%) or
documented AB treatments (22%) than residents without a wound (49%,
p = 0.045 and 15%, p = 0.0012, respectively). Prophylactic ABs were
used less for patients with (22%) than for those without wounds (36%,
p< 0.0001). Residents with in contrast to those without wounds received
more often combinations of penicillins and b-lactamase inhibitors
(J01CR, 21% vs. 13%, respectively, p< 0.0001) and cephalosporins
(J01D, 13% vs. 7%, p = 0.012). On the contrary, residents with wounds
received other antimicrobials (J01X) signiﬁcantly less (18% vs.31%,
p< 0.0001). Finally, residents with compared to those without wounds
received less often oral ABs (83% vs. 93%, respectively, p< 0.0001) but
signiﬁcantly more often parenteral ABs (15% vs. 7%, p< 0.0001).
Conclusion: The presence of wounds does not seem to signiﬁcantly
inﬂuence AB prevalence. However, there is a relation between the
presence of a wound and recent hospital admission, registered MOs,
AB indication, type of AB and route of administration.
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O473 Antibacterials for systemic use in Belgian hospitals
S. Vaerenberg, E. Hendrickx, B. Catry ° for the Belgian Antibiotic
Policy Coordinating Committee
Objectives: The aim of the present study is to explore differences in
antimicrobial consumption in Belgian hospitals including differences
between ward types. This report was restricted to antibacterials for
systemic use (WHO-ATC classiﬁcation J01C).
Methods: Belgian hospitals were invited to report their antimicrobial
use to the federal Scientiﬁc Institute of Public Health (IPH), which was
responsible for the data collection, conversion into deﬁned daily doses
(DDD), analysis and feed back. The data collected were split up for
non-pediatric and pediatric wards. There is also an optional reporting of
intensive care wards and hematology-oncology wards.
Results: The overall results are shown in Table 1. The optional reporting
was highly variable over different unit types (range of unit types:8−44).
The median antibacterial use per bed-day was more than twice as high in
ICU compared to NPD (1150 vs. 456 DDD/1000 bed-days for 2006 and
1209 vs. 536 DDD/1000 bed-days for 2007). The median antibacterial
use in HAO (787 DDD/1000 bed-days in 2006, 943 DDD/1000 bed-days
in 2007) was situated in between the use on NPD and HAO. For 2007,
a big increase in variation in ICU was observed.
Conclusion: Overall incidence of antimicrobial use slightly increased
during the observation period, possibly biased by the different number
of participating hospitals in the second year of observation. The
methodology allows a close trend follow up, with the possibility to
compare the consumption between different unit types over time. From
2008 onwards, participation is obliged for the majority of Belgian
hospitals.
Table 1. Hospital use expressed as DDD/1000 bed-days (subgroup J01)
2006 (n = 28) 2007 (n = 55)
Class ATC Mean Range Mean Range
Beta-lactam antibacterials, penicillins J01C 234 168–375 253 100–380
Other beta-lactam antibacterials J01D 109 39–175 114 17–244
Quinolone antibacterials J01M 65 8–102 67 7–115
Other antibacterials J01X 35 12−61 37 10−81
Macrolides, lincosamides and streptogramins J01F 23 8−38 25 7−64
Aminoglycoside antibacterials J01G 14 1−38 14 1−55
Sulfonamides and trimethoprim J01E 8 1−22 9 1−29
Tetracyclines J01A 3 0−13 3 0−44
Amphenicols J01B 0 0−1 0 0−3
Total 492 344–694 524 242–792
O474 Increased antibiotic use in Swedish intensive care units,
1999–2008
M. Edstro¨m °, H. Gill, G. Fransson, J. Struwe, S. Walther, H. Hanberger
on behalf of the ICU-Strama and the Swedish ICU registry
The ICU-Strama programme was developed ten years ago and used for
regular audit of antibiotic use, antibiotic resistance and infection control
procedures in Swedish ICUs. It is a joint project between the ICU-Strama
and the Swedish Intensive Care Registry. A central component has been a
web-based application which includes a system for automatic feed-back.
The purpose of this report is to increase awareness of the usefulness
of the programme and provide a ten year trend analysis of antibiotic
consumption.
Material and Methods: The data on antibiotic consumption based on
the anatomical therapeutic chemical (ATC) classiﬁcation system were
collected from 64 Swedish ICUs and entered into the database using
the web application. Antibiotic consumption was expressed as deﬁned
daily doses (DDD) per 1,000 occupied bed day (DDD1000). We used the
annually updated DDD calculated by the WHO Collaborating Centre for
Drug Statistics Methodology as the average maintenance dose per day in
adults for the main indication of the drug(http://www.whocc.no/atcddd).
Data were analysed using the non-parametric test for trend across ordered
groups and Spearman’s rank correlation using STATA/SE 9.2(StataCorp
LP, College Station, TX, USA) and SPSS version 11.5 (SPSS Inc.,
Chicago, IL, USA). Statistical signiﬁcance was assumed if P< 0.05.
Results: The median antibiotic consumption increased from 1,256
DDD1000 1999 to 1,434 DDD1000 2008 (p< 0.001). Antibiotic
consumption varied widely between different units during 2008, ranging
between 696 and 2,722 DDD1000 with a median of 1,434 DDD1000.
Trend analyses of usage of different classes of antibiotics were
performed and showed increased carbapenem, triazole and piperacillin–
tazobactam consumption (p< 0.001). There was no signiﬁcant change in
consumption of cephalosporins for the ten year period but a trend towards
decreased consumption the last two years. No signiﬁcant correlation
between antibiotic consumption and standardised mortality rate was
shown.
Conclusion: The high antibiotic consumption concurs with ﬁgures
from European and US ICUs in general, but like a few ICUs in our
programme, relatively low antibiotic consumption has been reported
from Switzerland. The lower antibiotic consumption suggests that it is
possible to reduce antibiotic consumption in the critically ill, but it has
to be accompanied with a quality control system to make sure that it
does not compromise patient outcomes.
O475 Developing a database to facilitate the assessment of
antimicrobial consumption in an acute tertiary hospital
L.W. Hoo °, T. Kyaw Tun, D. Solanki, S. Foley (Dublin, IE)
Background: Monitoring antimicrobial consumption trends is part of
an effective systematic surveillance programme to prevent and control
healthcare-associated infection and antimicrobial resistance. Expressing
antimicrobial consumption data in the World Health Organization-
recommended measurement unit − Deﬁned Daily Dose (DDD) per 100
bed-days, is important for benchmarking purposes. This is also a part-
fulﬁlment of the national guidelines of antimicrobial stewardship for
hospitals in Ireland.
Objectives: To achieve this aim, the following have been carried
out: (1) a national survey on the opinions of pharmacists on data
collecting for antimicrobial consumption in hospitals, (2) development
of an antimicrobial consumption database (2005–2008), expressed in
DDD/100 bed-days, for hospital-wide and individual group of speciality
wards/units, (3) evaluation of the antimicrobial consumption trends
obtained from the database.
Methods: The original data presented in ‘unit dose’ is obtained from
the Hospital’s information database called the Diver SolutionTM, which
can interface with Microsoft® Excel 2007. The aggregate in-hospital
consumption data that includes both issues from and returns to pharmacy
from 2005 to 2008 were collected. The ABC Calc. (version 3.1,
2006) was adapted in an Excel worksheet to create the antimicrobial
consumption database, converting consumption data from ‘unit-dose’ to
DDD/100 bed-days.
Results: The survey found a variation in the method of data collecting for
antimicrobial consumption among hospitals. The lack of an appropriate
pharmacy information technology and inadequate education and training
on antimicrobial consumption data collection and reporting are some
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of the main issues of concern. Results from the evaluation of the
consumption trends demonstrate the need to monitor hospital-wide
and individual speciality wards/units separately. Limitations of the
ATC/DDD system have been identiﬁed and taken into consideration
when interpreting the results.
Conclusion: Variation exists in the methods of collecting and reporting
for antimicrobial consumption. The study has shown that setting up
of antimicrobial consumption databases expressed in DDD/100 bed-
days can be done at a local level. An antimicrobial consumption
database should be available in all hospitals to facilitate the close
monitoring of antimicrobial consumption, frequent feedback reporting
to the prescribers and also to supplement the surveillance of microbial
resistance.
O476 Antibiotic prescribing in outpatients: hospital and seasonal
variations in Ujjain, Madhya Pradesh, India
A. Pathak °, K. Mahadik, S. Dhaneria, G. Marrone, C. Lundborg
on behalf of APRIAM Group
Objective: To explore seasonal patterns of antibiotic prescribing for
selected infectious disease complaints for children up-to 5 years and
adults (>18 years) reporting to out patient clinics of two hospitals in
Ujjain.
Methods: This was cross sectional study; during 15 months period from
15th November 2007 to 15th February 2009. It covered 4 seasons,
2 winters, one summer and one rainy season. First consultations of
all patients for suspected infectious aetiology at outpatients of two
hospitals (one for proﬁt and other academic) were included. A diagnosis
prescribing form was ﬁlled by the treating consultant for each patient
irrespective of whether an antibiotic was prescribed or not. An average of
70% of available consultants participated. Each prescribed antibiotic was
coded according to the WHO Collaborating Centre for Drug Statistics
Methodology, ATC classiﬁcation index with DDDs 2009. All DDDs were
calculated/1000 patients/diagnosis (DDD/TPD). Stata 10.0 was used for
appropriate statistical tests.
Table. Number of patients per diagnosis, prescription rate with
commonest prescribed antibiotic groups with Deﬁned Daily Doses/










URTI† 728 38.6 Quinolones 435.8
Levoﬂoxacin 264
Ear discharge 105 96.2 Co-amoxiclav 152.7
Pneumonia 422 89.4 Quinolones 1889
Levoﬂoxacin 1597.8
Vaginal discharge 1361 72.2 Metronidazole 11632.5
Doxycycline 9183
Quinolones 434.2
UTI‡ 647 96.1 Quinolones 3647.2
Metronidazole 2893
Diarrhoea 525 53 Imidazole group 713
Co-trimoxazole 587.6 DUs/TPD
Dysentery 69 97.1 Quinolones 2118.6
Imidazole group 863
SSTI* 575 92.4 Co-trimoxazole 4032.5 DUs/TPD
Quinolones 1873.4
†URTI: Upper respiratory tract infection; ‡UTI: Urinary tract infection; *SSTI: Skin
and soft tissue infections.
Results: Out of a total of 5,733 patients antibiotics were prescribed in
3,732 (66.3%). These prescriptions contained 1−3 antibiotics, with a
mean of 1.28 antibiotics per prescription. Indications were respiratory
tract infections (32.2%), vaginal discharge (26.3%), urinary tract infec-
tions (16.3%), skin and soft tissue infections (15%), diarrhoea (9.2%) and
prophylaxis (1%). Quinolones were the commonest group prescribed.
Antibiotic prescribing was 37% less in academic hospital (P< 0.001).
Prescribing peaked in rainy season with 70% of patients prescribed
antibiotics. The independent predictors of antibiotic prescribing were
seasons (2nd winter > 1st winter), facility (for proﬁt > academic),
age groups (adults > children), education level (illiterate > more
educated), productive cough at presentation, ear discharge, pneumonia
and dysentery. The number of patients per diagnosis, prescription rate
with commonest prescribed antibiotic group with DDDs/ TPD per group
is shown in table.
Conclusions: Statistically signiﬁcant association between antibiotic
prescribing and seasons, for proﬁt hospital, age groups, education level,
symptom of productive cough at presentation, ear discharge, pneumonia
and dysentery was found. High use of quinolones is a cause of concern.
O477 Systemic antifungal therapy in European hospitals. Data
from the ESAC point prevalence surveys 2008 and 2009
P. Zarb °, B. Amadeo, A. Muller, V. Vankerckhoven, P. Davey,
H. Goossens on behalf of the ESAC Hospital Care sub-project group
Objectives: To determine the variability of antifungal treatment in
European hospitals and to identify targets for quality improvement in
antifungal prescribing.
Methods: The European Surveillance of Antimicrobial Consumption
(ESAC) Point Prevalence Survey (ESAC-PPS) was carried out during a
maximum of two weeks in 50 European hospitals in 2008 and in 134
hospitals in 2009. A web-based application was developed for online data
entry by the hospitals. Antimycotic prescriptions were recorded using
the WHO ATC classiﬁcation including ‘antimycotics for systemic use’
(J02) and terbinaﬁne (D01BA02). Demographic data on treated patients,
indications, and diagnoses were collected.
Results: From a total of over 85,000 admitted patients, 25,201 (29%)
received antimicrobials. Patients receiving antifungals amounted to 1,309
(3.8% of all antimicrobials) receiving a total of 3,125 therapies (mean
2.4, range 1−7). Dual therapy was used in 487 (37%) patients, and triple
therapy in 24% of patients. The most commonly prescribed antifungal
was ﬂuconazole, accounting for 60% of all antifungal therapy followed
by caspofungin (10%). The most frequently used antifungal-antibacterial
combinations included ﬂuconazole plus either a quinolone or a b-lactam,
mainly for medical prophylaxis. The proportion of parenteral use within
the total antimycotic prescriptions was 47%. The oral route accounted for
60% of ﬂuconazole prescriptions. In 38% of cases the site of infection
was undeﬁned whilst the most common sites were respiratory (20%),
gastro-intestinal (16%) and ENT (4%). The medical specialty accounted
for the majority (69%) of antifungal use. Hospital acquired infections
represented 46% of all the indications followed by medical prophylaxis
at 30%.
Conclusion: These ESAC-PPS results showed minimal variation in
treatment for fungal infections. This was mainly observed in the
predominance of ﬂuconazole. However, high use of ﬂuconazole can
increase the prevalence of other fungi, e.g., Candida glabrata, and
therefore increase the need for newer antifungals which are active
against inherently resistant pathogens. Ongoing surveillance will enhance
efforts to limit the extent of antifungal use and resistance. Antifungal
prophylaxis in the immunocompromised host needs further exploration.
ESAC-PPS methodology is the right tool for such analysis.
O478 European Surveillance of Antimicrobial Consumption:
outpatient systemic antiviral use in Europe
N. Adriaenssens °, S. Coenen, A. Muller, V. Vankerckhoven,
H. Goossens on behalf of the ESAC Study Group
Objectives: To assess the total outpatient systemic antiviral use in
Europe and to identify the antiviral substances most commonly used
before the outbreak of the A/H1N1 pandemic as a historical reference.
Methods: The European Surveillance of Antimicrobial Consumption
(ESAC; www.esac.ua.ac.be) project, now funded by the European
Centre for Disease Prevention and Control (ECDC; agreement number
2007/001), continues to collect data on antimicrobial consumption
for all Member States, candidate countries and European Free Trade
Association-European Economic Area countries using the anatomical
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therapeutic chemical (ATC) classiﬁcation and the deﬁned daily dose
(DDD) measurement unit. For 2007, data on outpatient use of all
antivirals for systemic use (ATC J05), aggregated at the level of the
active substance, was collected and use was expressed in DDD (WHO
ATC/DDD, version 2008) per 1000 inhabitants per day (DID).
Results: Total outpatient systemic antiviral use in 2007 in 11 European
countries varied by a factor of 6.9 between the country with the highest
(1.5 DID in the Netherlands) and the country with the lowest (0.2 DID in
Finland) use. In most countries substances to treat HIV infection (ATC
J05AE, J05AF01−07, J05AF09, J05AG, J05AR, J05AX02, J05AX05
and J05AX07−09) represented more than 50% of the total outpatient
systemic antiviral use. In Finland, Denmark, Italy and Luxembourg
nucleosides and nucleotides excluding reverse transcriptase inhibitors
(ATC J05AB) represented more than 80% of the total outpatient antiviral
use. The use of neuraminidase inhibitors (ATC J05AH) was the highest
in Austria (0.02 DID) and varied from 3.42% in Denmark to no use
reported in Belgium.
Conclusion: Our study demonstrates a variation of outpatient systemic
antiviral use in Europe as striking as that of outpatient systemic
antibiotic, antimycotic and antifungal use. More in-depth data on
outpatient systemic viral use from more countries are needed to explain
this variation. The ESAC data facilitate auditing of antiviral prescribing
and evaluation of the implementation of guidelines and public health
policies e.g. those related to A/H1N1.
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O479 Emergence and spread of GES-type-expressing Acinetobacter
baumannii in Belgian hospitals
P. Bogaerts °, C. Berhin, H. Rodriguez-Villalobos, A. Guisset,
A. Deplano, T.D. Huang, B. Lissoir, R. Cartuyvels, A. de Moreau,
Y. Glupczynski (Yvoir, Brussels, Gilly, Hasselt, BE)
Objectives: Worldwide emergence and spread of multidrug resistant
A. baumannii (AB) is a matter of concern. We studied the microbiologic,
epidemiological and molecular characteristics of GES-like producing AB
isolates (GPAB) recovered from 5 different Belgian hospitals.
Methods: Antibiotic susceptibilities were determined by agar disk
diffusion, VITEK2, and Etest MIC determination. ESBL, carbapenemase
coding genes and their genetic environment were analyzed by PCR-
sequencing. OXA-51 and ADC-like coding genes were also characterized
and the isolates were typed by PFGE. b-lactamase activities were
analyzed by IEF.
Results: Between april 2009 and September 2009, 9 patients with
GPAB isolates were identiﬁed in 5 Belgian hospitals. Isolates were
recovered upon admission from wound infection, and one empyema.
Index patients (pts) were transferred from Turkey (n = 2), Egypt (n = 2)
and Gaza Strip (n = 1). One pt was at the origin of a nosocomial
outbreak (n = 4 pts) in a burn unit requiring the closure of the unit
for outbreak control. Overall 3 pts dead but no attributable mortality to
GPAB was observed. Not common origin could be established between
the index pts of the 5 hospitals neither by epidemiological data nor PFGE
analysis. Phenotypic resistance proﬁle was difﬁcult to distinguish from
OXA-carbapenemase producing-AB. All isolates showed multiresistance
including carbapenem (MICs to imipenem and meropenem ranging from
12 to >32mg/L). Doripenem showed better activity with MICs from 3
to 32mg/L. Only colistin remained susceptible in all isolates. Three
different alleles (blaGES-11 from Turkey, Gaza and Egypt; blaGES-12
from Egypt and a new blaGES-14 from Turkey) were detected as part
of an identical Class I integron including also aac6′Ib and dfrA7. No
other ESBL or carbapenemase genes were detected except OXA-51-like
which was present in each isolate but not downstream to ISAba1. By
IEF, a band inhibited by clavulanic acid and corresponding to GES was
visualized at pI of about 6.
Conclusion: AB harboring blaGES-11 and blaGES-12 alleles were
detected recently in France and in UK but were not yet reported
elsewhere. The blaGES-14 variant is reported here for the ﬁrst time
in a pan-resistant AB isolate. This event further highlights the potential
of acquisition of resistance genes by AB and the risk of travel import of
multi-resistant bacteria with the possible subsequent inter/intra-hospital
spread in acute care hospitals.
O480 Resistance in agents of hospital-acquired respiratory
infection in the United Kingdom and Ireland, 2008–2009
R. Reynolds °, I. Morrissey, R. Hope on behalf of BSAC Working
Party on Resistance Surveillance
Objective: Hospital-acquired respiratory infections are an important
source of morbidity, are associated with substantial mortality, and are
caused by a wide range of pathogens potentially harbouring diverse
antimicrobial resistance mechanisms. The BSAC Respiratory Resistance
Surveillance Programme now monitors these infections.
Methods: Isolates obtained more than 48 hours after hospital admission
(H48) were considered to be hospital-acquired. In 2008/09, 22
laboratories in the UK and Ireland sent up to 13 H48 lower respiratory
isolates each of S. aureus and Pseudomonas and 50 Enterobacteriaceae
for central MIC testing by BSAC methods. Preliminary results for
isolates tested up to October 2009 were compared with those for H48
blood isolates from the similar 2008 BSAC Bacteraemia Resistance
Surveillance Programme.
Organism Source N % non-susceptible
(>48 hours after
hospitalization)
CIP CTX ERY GEN TET
MRSA LRTI 77 96 − 82 4 9
blood 72 92 − 75 6 7
MSSA LRTI 94 20 − 22 1 1
blood 159 18 − 18 3 4
E. coli LRTI 285 26 15 − 12 −
blood 217 22 12 − 11 −
Klebsiella LRTI 209 14 15 − 9 −
blood 117 19 18 − 10 −
Enterobacter LRTI 156 15 41 − 7 −
blood 107 16 35 − 9 −
Results: MRSA were more prevalent in H48 respiratory S. aureus
(77/171, 45%) than in H48 blood S. aureus (72/231, 31%), but had
a similar non-susceptibility proﬁle. Of 796 H48 respiratory Enterobac-
teriaceae, 37% were E. coli, 28% Klebsiella, 20% Enterobacter and
14% other genera, compared with estimates of 59%, 18%, 9% and
14% respectively among H48 blood isolates (combined data, BSAC
and HPA voluntary surveillance system 2008). Thus, Klebsiella and
especially Enterobacter were more common, and E. coli less common, in
respiratory compared with blood infections. Non-susceptibility proﬁles
were similar for respiratory and blood isolates. Non-susceptibility rates
among 169 H48 respiratory P. aeruginosa were modest and comparable
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with those of 125 H48 blood isolates for ceftazidime (3 vs. 4%),
gentamicin (5 vs. 6%) and piperacillin–tazobactam (8 vs. 10%), but
clearly higher for imipenem (21 vs. 5%) and perhaps also ciproﬂoxacin
(24 vs. 14%, but with many MICs close to the breakpoint).
Conclusion: Resistance rates in hospital-acquired lower respiratory
isolates are broadly similar to those in bacteraemia, but may differ
substantially in some cases. More data and analysis are needed to
clarify the inﬂuence of factors such as patient age and treating speciality
on these apparent differences in resistance between respiratory and
blood isolates. Direct surveillance of resistance in speciﬁc infections
is preferable to extrapolation from data obtained in bacteraemia, when
possible.
O481 Antimicrobial resistance among invasive Streptococcus
pyogenes isolates in Portugal
A. Friaes °, M. Ramirez, J. Melo-Cristino (Lisbon, PT)
Objectives: Although S. pyogenes is universally susceptible to penicillin,
in the treatment of complicated Group A Streptococci (GAS) infections
such as necrotizing fasciitis or STSS, the association of penicillin with
clindamycin has been advocated. Resistance to the latter has been
described in GAS, associated with resistance to macrolides. The aim
of this work was to evaluate the resistance of GAS invasive isolates to
several antimicrobial agents and to further characterize the macrolide
resistance isolates.
Methods: A total of 306 invasive GAS isolates recovered in
Portugal during 2000–2008 were tested for susceptibility to penicillin,
vancomycin, erythromycin, tetracycline, levoﬂoxacin, chloramphenicol,
clindamycin, quinupristin-dalfopristin, and linezolid by disk diffusion.
Intermediate susceptibilities were conﬁrmed by MIC determination using
E-test strips. Resistance genotypes were determined by PCR.
Results: All the 306 GAS isolates were susceptible to penicillin,
vancomycin, chloramphenicol, quinupristin-dalfopristin, and linezolid,
and only two (0.7%) presented reduced susceptibility to levoﬂoxacin
(MIC = 3 and 4 ug/ml). A total of 32 isolates (10.5%) were resistant
to erythromycin. Of these, 20 were also constitutively resistant to
clindamycin (cMLSB phenotype, 62.5%), whereas 12 presented the M
phenotype (37.5%). The cMLSB phenotype was associated with the
presence of the erm(B) gene, whereas the M phenotype was associated
with mef(A). Non-susceptibility to tetracycline was found in 42 isolates
(13.7%), of which 8 also expressed the cMLSB phenotype and 1 the M
phenotype.
Conclusion: Erythromycin resistance among invasive GAS isolates in
Portugal did not vary signiﬁcantly during 2000–2008, contrarily to what
has been reported for isolates causing pharyngitis, whose macrolide
resistance decreased from 1999 to 2006. The macrolide resistance
observed in this study for invasive GAS isolates (10.5%) is in line with
reports from other countries, as well as with the overall rate reported for
pharyngitis isolates in Portugal during 2004–2006 (13.2%).
O482 Effect of ertapenem on susceptibility of imipenem to
Pseudomonas aeruginosa six years later
D. Goff °, J. Mangino (Columbus, US)
Objectives: There is continued concern that ertapenem (E) will
negatively effect imipenem (I) susceptibility to Pseudomonas aeruginosa
(PA). Our purpose is to monitor E effect on (I) susceptibility to PA
from 2003–2008. Other antipseudomonals on the formulary, piperacillin/
tazobactam (P/T), cefepime (C), and tobramycin (T), were also
examined.
Methods: Antibiotic susceptibilities to I, P/T, C, and T were determined
by microdilution MIC using Microscan panels. E was not on Microscan
panels until 2007, so Etest was used prior to 2007. Change in I
susceptibility was analyzed using Mantel-Haenszel c2 test for linear
trend. A Poisson model was used to estimate change in carbapenem
deﬁned daily doses/1000 patient days (DDD) over time. A rate ratio
(RR) was calculated to compare carbapenem usage between 2003 and
2008 with a 95% conﬁdence interval.
Results: P. aeruginosa susceptibility to I, PT, C, and T remained
the same over 5 years and improved in year 6. An overall c2 test
(p = 0.010) indicated a difference in percentages over time. The Mantel-
Haenszel test for linear trend (p = 0.004) indicated an increasing trend
in percentages over time. 91% ESBL K. pneumoniae and 100% ESBL
E. coli and K. oxytoca isolates tested to E were susceptible MIC< 2. Total
carbapenem use had signiﬁcantly increased from 2002 (28DDD/1000PD)
to 2008 (42.4DDD/1000PD) RR= 1.08 (95%CI, 1.01–1.15, p = 0.017).
E was 13−44% of all carbapenem use; the increase was signiﬁcant
RR=1.24 (95%CI, 1.06–1.47, p = 0.006).
Conclusion: The use of ertapenem did not negatively effect the
susceptibilities of imipenem, P/T, C, or T to PA. P. aeruginosa
susceptibility to imipenem, PT, C and T remained the same or improved
over these 6 years.
Organism Susceptibility (No. of organisms tested)
2003 2004 2005 2006 2007 2008
K. pneumoniae 99% 99% 99% 99% 99% 100%
(537) (542) (703) (718) (699) (694)
Kp. ESBL 95% 100% 99% 100% 100% 99%
(40) (29) (135) (132) (150) (85)
E. coli 100% 100% 100% 100% 100% 100%
(1026) (1047) (1451) (1833) (1801) (1653)
Ec. ESBL 100% 100% 100% 100% 100% 100%
(11) (21) (19) (21) (36) (62)
E. cloacae 98% 98% 99% 97% 100% 100%
(211) (187) (260) (321) (339) (296)
S. marcescens 98% 98% 99% 100% 100% 98%
(115) (138) (191) (197) (181) (206)
P. aeruginosa 71% 71% 70% 72% 72% 77%
(741) (819) (923) (1174) (1229) (1020)
O483 Growing role of community-acquired MRSA infections in the
United States: a 10-year trend of replacement and expansion
R.M. Mera °, J. Suaya, H.A. Madsen, C.S. Hogea, E. Lu, C. Acosta
(Durham, Philadelphia, Upper Providence, US)
Objectives: To describe the role of Community-Acquired (CA) MRSA
in inpatient and outpatient staphylococcus aureus infections over a 10
year period in the US.
Methods: The study used the TSN Network® surveillance database
(Euroﬁns Medinet) for the period 1998 to 2007. The database
contains information on isolate source, setting (ambulatory or hospital),
geographic region, and demographic characteristics such as gender
and age. Identical CLSI breakpoints were used for all the time
points. CA-MRSA phenotype was deﬁned by a resistance proﬁle
that includes the absence of gentamicin/cotrimoxazole resistance, and
the absence of ciproﬂoxacin/ clindamycin/ erythromycin co-resistance.
Using multivariate logistic regression, we computed adjusted phenotype
prevalences and odds ratios (OR) with 95% conﬁdence intervals (CI).
Results: The study consisted of 824,307 S. aureus isolates. MRSA
prevalence continuously increased over the 10 year period from 32.7%
in 1998 to 53.8% in 2007 (OR 2.4, 95%CI 2.3−2.5). CA-MRSA
represented an increasing proportion of MRSA from 22.3% in 1998
to 66.1% in 2007 (OR 6.7, 95%CI 6.5−6.9). Changes in CA-MRSA
prevalence were observed for all age-groups, isolate sources, inpatient or
outpatient settings, and across all geographic regions of the US. However,
a comparatively larger statistically signiﬁcant temporal increase of CA-
MRSA occurred in children and young adults as compared to the elderly,
and in abscess and wound isolates when compared to blood and sputum.
By 2007, 81.5% of all MRSA isolates were categorized as CA-MRSA
among children, while CA-MRSA represented 48.9% of MRSA isolates
from the elderly. In 2007, out of all MRSA, CA-MRSA represented
85.7% of all abscess, 75.4% of wound, 43.6% of blood and 30.4% of
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sputum isolates, as well as 84.5% of outpatient and 40.8% of inpatient
isolates.
Conclusion: In the study period, MRSA isolates have become a growing
proportion of all S. aureus isolates. The majority of the growth of
MRSA share of S. aureus infections is explained by CA-MRSA, which
has not only proportionally expanded but also replaced HA-MRSA.
These changes occurred principally among abscess and wound isolates,
children and young adults, but with a lesser degree also among other
isolate sources and age groups. Four out of ﬁve isolates in the outpatient
setting now possess the CA-MRSA phenotype. These ﬁndings may have
preventive and therapeutic implications in the management of S. aureus
infections.
O484 Resistance of staphylococci isolated from infected hip
arthroplasties in Norway
O. Lutro °, H. Langvatn, J. Schrama, G. Hallan, H. Dale, B. Espehaug,
H. Sjursen, L. Engesæter (Bergen, NO)
Objectives: Antibiotic prophylaxis is commonly used during prosthesis
surgery both systemically and locally in cement. We have examined
bacterial ﬁndings from specimens taken during revision due to deep
infection reported to the Norwegian Arthroplasty Register (NAR). Sus-
ceptibility to aminoglycosides (gentamicin, tobramycin and netilmicin)
and blactamase-stable penicillins (meticillin, oxacillin and cloxacillin
(the methicillin-group) is presented. These antibiotics are the most
commonly used in prophylaxis and in treatment of prosthetic joint
infections (PJI).
Methods: We collected bacterial ﬁndings from operations reported as
revisions for infection to NAR. The information was collected from
notes from the ten hospitals in Norway that reported most revisions for
infection from 1987 to 2007. In this period 730 revisions were reported to
NAR from these ten hospitals. The total number of reported revisions was
1443 from all Norwegian hospitals. In this study we included operations
with one or more positive sample. The bacteria were tested against
different antibiotics at different hospitals and in different time periods.
We used the c2 test for linear trend to evaluate changes in distribution
of sensitive, intermediate and resistant (S, I, R) bacteria over time. We
excluded the ﬁrst ﬁve-year period due to low number of cases compared
to the latter three ﬁve-year periods (5 vs. 31, 38 and 70, respectively).
Results: The most frequent bacteria isolated were coagulase-negative
staphylococci (CoNS) (37%), and S. aureus (SA) (17%). Overall 153
operations with CoNS and 74 with SA were found.
Among CoNS 53% of the bacteria were resistant to aminoglycosides.
The proportion of resistance increased from 35% in 1993–1997 to 43%
in 1998–2002, and to 55% in 2003–2007 (p = 0.1). The overall resistance
of CoNS to the meticillin-group (MRSE) was 62%. We found that 45%
were MRSE in 1993–1997. The proportion increased to 50% in 1998–
2002 and to 76% in 2003–2007(p = 0.002).
All S. aureus were sensitive both to aminoglycosides and to the
methicillin-group.
Conclusion: The proportion of MRSE was increasing with time in the
present study. There was also a tendency to increased resistance to
aminoglycosides among CoNS. No MRSA was found.
This study shows that the development of antibiotic resistance is an
increasingly important challenge in the management of PJI.
O485 Increasing in vitro antibiotic resistance against Pseudomonas
aeruginosa isolates from patients in the intensive care unit
over the last two years
S. Baka °, A. Lykas, A. Panopoulou, I. Patikas, A. Spathi, I. Tsouma,
S. Demeridou, E. Kouskouni (Athens, GR)
Objectives: Pseudomonas aeruginosa is considered a “high-risk”
pathogen responsible for severe intensive care unit (ICU) − acquired
infections. In an era of increasing resistance, nosocomial infections
caused by P. aeruginosa are very common despite the application of
preventive measures in ICU leading to prolonged hospital stay, increased
morbidity, mortality and treatment cost. Very often, in the last years,
clinicians are left with very few antimicrobials as therapeutic options.
Therefore, we aimed to study the susceptibility proﬁle of P. aeruginosa
clinical isolates against an extended panel of antibiotics in the last 2
years.
Methods: Beginning January 2008 to October 2009 all strains of
P. aeruginosa isolated from surgical patients in the ICU were studied. In
order to identify aerobic microorganisms we inoculated the specimens
on blood agar, MacConkey, Mannitol Salt and Sabouraud Dextrose agar,
and then incubated the plates at 37º C for 24 hours, whereas anaerobic
cultures were carried out on Wilkins-Chalgren agar at 37º C for 48
hours. The identiﬁcation of isolated strains and their susceptibility test
to antibiotics using an extended panel of antibiotics were carried out with
the automated system VITEK 2 (bioMe´rieux, Marcy l’Etoile, France).
Results: A total of 52 isolates from 21 patients in 2008 and 49 isolates
from 19 patients in 2009 were studied. An increased resistance in all
antimicrobials studied (except for colistin), was observed. The most
active antimicrobials against P. aeruginosa isolates during 2008 and 2009
were piperacillin with 15% and 32% resistance, respectively, piperacillin/
tazobactam 8% and 17%, gentamicin 21% and 50%, amikacin 18%
and 43%, tobramycin 18% and 47%, ceftazidime 29% and 46%, and
ciproﬂoxacin 26% and 49%, respectively. Thirty-six percent of the
isolates were resistant to imipenem in 2008 and 37% in 2009 while
for meropenem the resistance was 31% and 40%, respectively, and for
tigecycline 36% and 58%, respectively. Finally, colistin was the least
resistant among all antimicrobials tested (9% in 2008 and 2% in 2009).
Conclusion: The development of resistance must be carefully monitored
in hospitals. Due to an increased use of tigecycline in our ICU,
an emerging resistance to this new and promising antimicrobial
was observed. Colistin maintained signiﬁcant in vitro activity against
P. aeruginosa isolates and should be considered in critically ill patients
with difﬁcult-to-treat infections.
O486 Surveillance of drug resistance of Mycobacterium tuberculosis
patterns in clinical sputum samples
C.D. Kalunga °, M. Tembo (Lusaka, ZM)
Introduction: Testing for ﬁrst line anti tuberculosis drugs formed the
back bone of the study based on routine drug susceptibility testing since
these drugs are widely used in the world and tested for in rounds of
proﬁciency testing among reference laboratories. Therefore the need to
determine the susceptibility and resistance patterns of Mycobacterium
tuberculosis in 641clinical samples for diagnosis and from retreatment
samples in the period between 2000 and 2009.
Objective: To determine the drug resistance patterns for Mycobacterium
tuberculosis in clinical samples.
Methodology: This was a retrospective descriptive study conducted
at chest diseases laboratory. 641 Tuberculosis positive cultures by
proportion methods. Data of the drug resistance survey conducted during
this period was excluded.
Results: The total number of strains examined was 641, showing drug
resistance to one, more drugs in Mycobacterium tuberculosis strains.
Total resistant strains 228 (31.7%), Mono resistance to Streptomycin
54 (8.4%), Isoniazid 23 (3.5%), Rifampicin 7 (1.09%), Ethambutol
4 (0.04%). Resistance to two drugs Rifampicin and Isoniazid 41 (6.3%),
Streptomycin and Isoniazid 11 (1.7%), Streptomycin and Rifampin
12 (1.8%), Isoniazid and Ethambutol 3 (0.46%). Resistance to three
drugs Streptomycin + Isoniazid + Rifampicin 11 (1.7%), Isoni-
azid +Rifampicin +Ethambutol 3 (0.46%), Streptomycin + Isoniazid +
Ethambutol 1 (0.15%) and resistance to all four drugs included
15 (2.3%).
Discussion: The trend seen in the study period shows that proportions
of resistance to Rifampcin and Isoniazid was increasing suggestive of
secondary drug resistance.
The resistance to streptomycin was high at 8.4%. Isoniazid resistance
trend was at 3.5%. Ethambutol 0.04%.
Conclusion: out of 641 positive cultures tested for drug susceptibility,
228 were resistant to one, two, three and four drugs. Multi drug
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resistance (6.3%) showed a rising trend and threatening to be a problem.
Streptomycin resistance was highest (8.4%) may be because it is used
for treatment of other infections. Mono resistance to Isoniazid (5.1%)
was in rising proportions due to its use in preventive administration.
Resistance to Rifampicin (1.09%), Ethambutol at 0.47% respectively.
O487 Four major drug-resistant mycobacterial strains isolated
between 2001–2008 in Konya, Turkey
I. Tuncer, H. Turk Dagi, G. Solgun, S. Yuksekkaya, O. Akkaya,
U. Arslan °, D. Findik (Konya, TR)
Objectives: In our study, we aimed to detect the presence of
M. tuberculosis with the BACTEC 460TB system (2001–2006) and the
BACTEC MGIT 960 (Mycobacteria Growth Indicato¨r Tubes, Becton-
Dickenson) system (2007–2008) in clinical samples containing suspected
pulmonary and extrapulmonary tuberculosis and also to determine the
resistance of the isolated M. tuberculosis strains against four major
antimicrobial drugs. The study period was between 2001 and 2008.
Methods: From 2001 to 2006, antimicrobial susceptibility tests to
isoniazid (INH), streptomycin (SM), ethambutol (EMB) and rifampin
(RIF) on 635 Mycobacterial strains were performed using the
radiometric BACTEC 460TB system. From 2007 to 2008, antimicrobial
susceptibility tests on 270 Mycobacterial strains were performed with
the BACTEC MGIT 960 SIRE kit.
Results: Of the 1039 M.tbc spp., antibiotic susceptibility tests were
performed on 905. We observed that 84.8% (767/905) were susceptible
to all 4 antibiotics, 15.2% (138/767) were resistant to at least one of the 4
antibiotics. Mono resistance rates to INH, SM, RIF, and EMB were 4.4,
1.3, 0.6 and 0.4, respectively. Total monodrug resistance was observed
in 6.7% of 905 the Mycobacterial isolates. Resistance to two drugs was
observed in 48 (5.3%) isolates, to three drugs in 24 (2.7%) isolates and
to four drugs in 5 (0.5%) isolates. The prevalence of MDR (Multidrug
Resistance) in 905 Mycobacterial isolates was 4% (36/905).
Conclusions: According to these results it could be concluded that, drug
resistance which requires immediate solution, continues to be a major
problem in our region.
Figure. The annual numbers of culture-positive specimens, the number
of susceptibility tested cultures, the number of cultures suceptible to four
drugs tested, the number of cultures resistant to at least one drug from
2001 to 2008.
O488 Antimicrobial resistance in Chinese Clostridium difﬁcile
strains
H. Huang, A. Weintraub, H. Fang, S. Wu, Y. Zhang, C.E. Nord °
(Stockholm, SE; Shanghai, CN)
Objectives: Clostridium difﬁcile infection is the leading cause of
nosocomial diarrhea. The emergence and spread of resistance in
C. difﬁcile are complicating the treatment and prevention. The purpose
of the present study was to investigate the antimicrobial susceptibility
patterns and resistance mechanisms of Chinese C. difﬁcile strains.
Methods: 110 toxigenic C. difﬁcile isolates collected between December
2008 and May 2009 at Fudan University Hospital Huashan were
analyzed for their antibiotic susceptibility patterns using the agar dilution
method. The heteroresistance to metronidazole in fresh isolates were
detected by disc diffusion and Etest methods. Resistance molecular
basis was investigated using polymerase chain reaction (PCR) and DNA
sequencing.
Results: 16 different PCR ribotypes were identiﬁed with a dominant
clone 017 accounting for 37.3% of the isolates, followed by 001
and H. Ribotype 027 was not found but one isolate belonged to
ribotype 078. All the isolates were susceptible to vancomycin and
piperacillin/tazobactam. However, 18 of 78 (23.1%) isolates were
found to be transient heteroresistant to metronidazole. Resistance to
moxiﬂoxacin, ciproﬂoxacin, levoﬂoxacin, erythromycin, clindamycin,
tetracycline, rifampin, rifaximin and fusidic acid was found in 61.8%,
100%, 66.4%, 85.3%, 88.1%, 62.7%, 29.1%, 29.1% and 8.2% of the
isolates, respectively. The isolates of common PCR ribotypes were more
resistant than the uncommon ribotypes. The prevalence of resistance
genes and mutations among the resistant isolates was as follows:
ermB, 69.1%; tetM, 97.1%; gyrA mutation, 63.2%; gyrB mutation, 4.4%;
gyrA and gyrB mutation, 32.4%, rpoB mutation, 100%, respectively. The
fusA mutation was only found in one isolate with minimum inhibitory
concentration (MIC) of 4mg/L.
Conclusions: Many C. difﬁcile isolates now show an alarming pattern of
resistance to the antimicrobial agents used in China. Isolates of common
PCR ribotypes are more resistant than uncommon ribotypes, especially
the dominant strain 017. Most of the resistance mechanisms which have
been identiﬁed in C. difﬁcile are similar to those in other Gram-positive
bacteria.
Molecular architecture and antigenic
structure of ﬂaviviruses
K494 Molecular architecture and antigenic structure of ﬂaviviruses
F. Heinz °, K. Stiasny, H. Holzmann, S. Kiermayr (Vienna, AT)
The genus Flavivirus in the family Flaviviridae comprises about
70 different virus species, many of which are arthropod-borne and
transmitted to their vertebrate hosts by mosquitoes or ticks. Among
those, the most important human pathogens are yellow fever virus,
dengue viruses types 1 to 4, Japanese encephalitis virus, West Nile virus
and tick-borne encephalitis virus. Depending on speciﬁc and different
natural host systems, these viruses differ with respect to their areas of
geographical distribution but − at least in some instances − have the
potential to emerge as new pathogens in previously non-endemic regions.
Flaviviruses are positive-stranded RNA viruses that have a lipid envelope
and only three structural proteins, designated C (capsid), M (membrane)
and E (envelope). Non-infectious, immature particles − containing a
precursor of the M protein (prM) − are formed intracellularly and the
proteolytic cleavage of prM by the cellular protease furin generates
mature and infectious virions shortly before their release from infected
cells.
With respect to their structure, ﬂaviviruses are among the best-studied
enveloped viruses. The atomic structures of E proteins of several
ﬂaviviruses have been determined using X-ray crystallography, and
the architectures of both immature and mature virions are known
from cryo-electron microscopic studies. Through the combination of
structural and immunological investigations, we have gained a detailed
understanding of the effects of antibody-binding to the virus and its
different antigens. This includes the deﬁnition of virus neutralization
and antibody-mediated enhancement (ADE) of infectivity at a molecular
level. The latter phenomenon has been proposed to play an important
role in the immunopathology of severe forms of dengue virus infections
(hemorrhagic dengue fever and dengue shock syndrome) in the course
of sequential infections with different dengue serotypes. All of these
structural insights have also shed new light on the different degrees
of cross-reactivity between ﬂaviviruses, including the existence of
cryptic epitopes that are recognized by broadly ﬂavivirus cross-reactive
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antibodies without leading to neutralization. The current picture of
antibody interactions with ﬂaviviruses will be presented in the context
of their biological signiﬁcance.
Treatment of invasive aspergillosis:
pharmacokinetics vs. resistance
S496 Clinical impact of azole resistance
P. Verweij ° (Nijmegen, NL)
The class of the azoles have become the most prominent class of
compounds for the management of invasive aspergillosis. The clinically
licensed triazoles with activity against Aspergillus include itraconazole,
voriconazole and posaconazole. The azoles are also the only drugs that
can be administered orally. The azoles interact with the biosynthesis
of ergosterol, which is an important component of the fungal cell
membrane. Intrinsic resistance to azoles has been documented for
A. calidoustus, but the vast majority of species are susceptible in vitro.
Recently, Aspergillus species with acquired resistance to azoles have
been reported, especially in A. fumigatus. It appears that resistance may
develop during azole therapy, especially in patients with chronic therapy
including patients with chronic infection and aspergilloma. Another route
of resistance development may be exposure of Aspergillus to azole
fungicides that are used in our environment. Patients would then inhale
azole-resistant conidia and develop azole-resistant aspergillosis. The
consequence of this route of transmission is that azole-resistant disease
may occur in patients without previous exposure to azole compounds.
Azole resistance is commonly due to mutations in the Cyp51A-gene and
is associated with different phenotypes. Isolates may be resistant to a
single azole compound, but more commonly a cross-resistant phenotype
is observed. Several cases of azole-resistant aspergillosis have been
reported and commonly these patients failed to respond to azole therapy.
Azole-resistant A. fumigatus isolates remain virulent and are capable
of causing invasive disease in patients at risk. The efﬁcacy of azole
compounds against azole-resistant isolates, with different resistance
mechanisms, has been investigated in experimental models of invasive
aspergillosis. These indicate that the minimal inhibitory concentration
has major impact on the efﬁcacy of the azole. Elevated MICs are
associated with loss of efﬁcacy of the azole compounds in vivo. The use
of azoles should be avoided in patients with azole-resistant aspergillosis,
if possible. Alternative agents such as lipid-formulations of amphotericin
B or caspofungin appear to retain their efﬁcacy against azole-resistant
isolates. A signiﬁcant problem is the early diagnosis of azole-resistance
as in the majority of cases an isolate is not obtained and, if an isolate
is cultured, in vitro susceptibility testing causes delay in treatment with
effective agents.
Living in the ideal CM/ID world
S497 Searching for an ideal clinical microbiologist − ID perspective
J. van der Meer ° (Nijmegen, NL)
Infectious diseases in our time pose a tremendous challenge to the
medical community. We are confronted with emerging infectious
diseases, increasing antimicrobial resistance, stagnant development
of new antibiotics, poor quality of antimicrobial prescribing, poor
compliance with hospital hygiene, a revolution in microbiology,
increasing numbers of immuno-compromised and frail patients, and
upcoming immunotherapeutic possibilities. To cope with these problems
in a successful way, synergy between clinical microbiologists and
clinicians with infectious disease expertise is needed more than ever.
In my view, the proﬁle of the ideal microbiologist is that of a well-
trained physician who received a specialty training which encompasses
laboratory skills (microbiology, molecular biology), practical training in
clinical infectious diseases, epidemiology and public health, hygiene,
research and communication.
In the ideal setting, there is close partnership with the ID physicians
and there is complementarity, optimal collaboration, mutual recognition
and trust. In daily practice, however, obstacles may be encountered, such
as competence, mistrust, ego and other psychological factors, ﬁnances,
time and organizational constraints. Such hurdles should be recognized
and dealt with.
S498 Searching for an ideal infectious diseases specialist −
CM perspective
A. Tambic Andrasevic ° (Zagreb, HR)
The nature of infectious diseases (ID) has changed signiﬁcantly over
the past decades. Many ID have successfully been eradicated through
vaccination and the course of some infections has changed due to
improved standard of life. On the other hand, changes in life style
and longer life expectancy have promoted the emergence and spread
of new ID. In spite of rigorous attempts to control hospital care
associated infections these infections are becoming a growing problem
in modern medicine. The appearance of multiply resistant organisms
and the shortage of new antibiotics in the pipeline have placed further
demands on developing expertise in the difﬁcult ﬁeld of antibiotic
stewardship. Therefore, the profession of an ID doctor in the 21st
century is a very complex one. He or she should have good skills and
knowledge in recognizing traditional infectious diseases even those that
are believed to be eradicated or not frequent in the area of practice.
However, over the past decades infectious diseases with typical clinical
presentation and a well deﬁned pathogen have been to a signiﬁcant extent
replaced by infections whose symptoms overlap with the symptoms
of the underlying diseases in the same patient or can not be easily
differentiated from other causes of systemic inﬂammatory response
syndrome. Therefore an ID doctor has to have good communication
skills in dealing with other colleagues of different specialties and should
be used to work in a team, appreciating different skills brought by
different disciplines. From a clinical microbiologist point of view an ideal
infectious disease specialist should recognize that the ﬁeld of clinical
microbiology (CM) has undergone the same transformation from mostly
research and public health oriented microbiology towards microbiology
at the patient bedside. In many patients only individual approach and
team work will produce satisfactory diagnosis and treatment of infection.
The fact that skills and competencies of modern ID and CM doctors
overlap to a greater extent than with other specialties makes a solid
ground for a close collaboration and partnership between these two
professions. This is important in the ﬁeld of clinical practice as well as
in the ﬁeld of research. There is a growing number of literature related
to infectious diseases and anyone involved in the management of such
patients should have a basic knowledge in research methodology and be
competent in practicing evidence based medicine.
Nocardia infections
S500 Clinical infection and treatment
P.R. Hsueh ° (Taipei City, TW)
Nocardiosis is an uncommon bacterial infection with a wide variety
of clinical manifestations in immunocompetent and immunocom-
promised patients. The number of cases reported in the literature
is increasing. This might be due to an absolute increase in the
number of immunocompromised patients but also to improvement
in laboratory techniques to detect nocardiosis. Host resistance to
nocardial infection depends on neutrophils in early lesions and then
the cell-mediated immune response. The most common predisposing
factors to opportunistic nocardia infections are long-term steroid usage,
chronic obstructive pulmonary disease, neoplastic disease, and human
immunodeﬁciency virus infection. Clinical manifestations of nocardiosis
range from cutaneous infections caused by traumatic inoculation in
normal hosts to severe pulmonary and central nervous system diseases in
immunocompromised hosts. The genus of Nocardia is rapidly expanding
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and the species distribution varies with different geographical locations.
Previous studies also emphasized the importance of determining the
species of Nocardia, because different species and isolates vary in
their antimicrobial susceptibility patterns. Sulphonamides have been
used in the treatment of nocardiosis since the 1940s and are still
the drugs of choice and the most common antimicrobials used
to treat these infections. Sulphonamide monotherapy, however, was
associated with mortality rates of almost 50% for patients with central
venous system (CNS) nocardial infections. In addition, patients with
non-CNS infections who had overwhelming or disseminated disease
had a high mortality rate when treated with sulphonamides alone.
However, currently available therapeutic alternatives are scarce and only
comprise amoxicillin/clavulanate, carbapenems (imipenem, meropenem,
doripenem, and ertapenem) and amikacin. Resistance to previously
administered drugs, the toxicity and intolerance of the antimicrobials
and even therapeutic failure necessitate the search for alternative agents.
Results from in vitro studies suggest that nemonoxacin (TG-873870),
a non-ﬂuorinated quinolone, linezolid and tigecycline show promise as
alternatives for the treatment of nocardiosis. Further clinical trials are
needed to clarify their role in the treatment of these infections.
Novel inﬂuenza A (H1N1)
O501 Efﬁcacy and safety of oseltamivir-zanamivir combination
compared to each monotherapy for seasonal inﬂuenza: a
randomized, double-blinded, placebo-controlled trial
C. Charlois-Ou °, V. Enouf, A. Mosnier, T. Blanchon,
M. Bouscambert-Duchamp, A. Tibi, F. Mentre´, C. Leport, B. Lina,
X. Duval (Paris, Bron, FR)
Objective: Evaluation of oseltamir-zanamivir combination efﬁcacy and
tolerance is of interest given the (H1N1) 2009 virus pandemic.
Methods: A randomized, placebo controlled, double blind study was
conducted during the 2009 seasonal Inﬂuenza epidemic to evaluate
oseltamivir-zanamivir combination. Adults with inﬂuenza like illness for
less than 36 hours and a positive Inﬂuenza A rapid test diagnosis were
randomized to oseltamivir 75mg orally twice daily plus zanamivir 10mg
by inhalation twice daily (OZ), oseltamivir plus inhaled placebo (O) or
zanamivir plus oral placebo (Z). Virological success was deﬁned by a
nasal viral load (RT-PCR) J2 <200 copies genome equivalents (cgeq) /
ml. Clinical response was assessed by time to allevation as symptoms.
Results: Overall 541 patients were included (OZ, n = 173; O, n = 192; Z,
n = 176). In the intention-to-treat analysis conducted in the 447 patients
with conﬁrmed Inﬂuenza A, the virological response was 46%, 59%,
and 34% in OZ, O and Z arms (p = 0.025, p = 0.028 for OZ/O and OZ/Z
comparisons). Mean viral load decrease D0-D2 was 2.14, 2.49, and 1.68
log10 cgeq /mL (p = 0.060, p = 0.016 for OZ/O and OZ/Z comparisons).
The time of disappearance of symptoms were 4, 3, 4 days (p = 0.030,
p = 0.77 for OZ/O and OZ / Z) The combination was well tolerated.
Conclusions: Monotherapy of oseltamivir remains the ﬁrst line antiviral
strategy for the ongoing Inﬂuenza pandemic. The lesser effect of the
oseltamivir-zanamivir combination should be further investigated.
O502 Effectiveness and safety of neuraminidase inhibitors
in reducing inﬂuenza complications: a meta-analysis of
randomized controlled trials
M. Falagas, P. Koletsi, E. Vouloumanou, P. Rafailidis °, A. Kapaskelis,
J. Rello (Athens, GR; Tarragona, ES)
Objective: Several studies provide evidence that neuraminidase in-
hibitors can reduce the duration of inﬂuenza symptoms. Yet, data
regarding their effectiveness in reducing inﬂuenza complications are
scarce.
Methods: We evaluated the effectiveness of neuraminidase inhibitors in
reducing inﬂuenza complications and mortality of patients with seasonal
inﬂuenza, by performing a meta-analysis of randomized controlled
trials (RCTs) retrieved from PubMed, Cochrane and Scopus databases,
comparing neuraminidase inhibitors with placebo.
Results: Eleven RCTs (10 double-blinded. 1 with an open-label design)
were included; 8 involved adults and adolescents. In total, 5315 patients
were included; 3491 (65.7%) with conﬁrmed infection. Total inﬂuenza-
related complications occurred signiﬁcantly less likely in otherwise
healthy patients with conﬁrmed infection treated with antivirals versus
placebo [7 RCTs, 2621 patients, OR (odds ratio)=0.71, 95% conﬁdence
interval (CI)=0.58–0.87]. This ﬁnding was more pronounced in high-
risk patients (4 RCTs, 475 patients, OR= 0.26, 95%CI=0.15–0.47),
compared with otherwise healthy patients (p< 0.01). In the comparisons
regarding other respiratory complications, a trend in favour of antivirals
was observed. Regarding acute otitis media speciﬁcally, a signiﬁcant
difference was observed. Signiﬁcantly fewer antibiotics were also
administered in patients with conﬁrmed infection treated with antivirals
versus placebo (6 RCTs, 1921 patients, OR= 0.77, 95%CI=0.62–0.96).
No differences were found in the comparisons regarding the safety
outcomes of our meta-analysis. Mortality data were scarcely reported.
No deaths were reported in the respective trials.
Conclusions: Neuraminidase inhibitors appear to be effective in
reducing total inﬂuenza-related complications both in otherwise healthy
with conﬁrmed infection and high-risk patients. They also reduce
additional antibiotic consumption.
O503 Clinical characteristics of inﬂuenza A H1N1–2009 outbreak
at a public university hospital in the north-eastern region
of Rio Grande do Sul, Brazil
L. Michelim °, J. Fracasso, P. Garrido, V. Buffon, D. Zeni,
C. Barcarollo, V. Mari (Caxias do Sul, BR)
Objectives: In July 2009, a respiratory illness outbreak caused by
inﬂuenza A virus (H1N1–2009) was identiﬁed in Caxias do Sul, Brazil.
The aim of this work is to describe the clinical and epidemiologic
characteristics of hospitalized patients at a public university hospital for
viral pneumonia who had laboratory conﬁrmed H1N1–2009 infection.
Methods: Retrospective medical chart reviews on the hospitalized
patients between July and August 2009. H1N1–2009 infection was
conﬁrmed in specimens with the use of a real-time reverse-transcriptase–
polymerase-chain-reaction assay.
Results: From July 1 through August 30, 2009, a total of 40 cases of
conﬁrmed H1N1–2009 pneumonia were identiﬁed among 124 patients
hospitalized for acute respiratory illness at the Caxias do Sul General
Hospital. More than half of the 40 patients were between 20 and 49 years
of age, and only 10 had preexisting medical conditions. All patients had
fever, cough, dyspnea or respiratory distress, increased serum lactate
dehydrogenase levels and lymphopenia. Thirty-seven patients required
mechanical ventilation, and ﬁve died.
Conclusions:In 2009, our region had the coldest winter season in many
years. Inﬂuenza infections are common cause of respiratory diseases in
our city, but on this year there was an increase of visits to doctors for
inﬂuenza-like-illness and also ﬂu-related hospitalizations. Comparisons
with seasonal inﬂuenza suggest that pandemic inﬂuenza A (H1N1–
2009) disproportionately affects younger ages and causes generally mild
disease, but during the outbreak we noticed that H1N1–2009 infection
had caused severe pneumonia and death in many previously young to
middle-aged healthy persons.
O504 Hospitalized cancer patients with severe infections due to
the novel inﬂuenza A (H1N1) in Brazil
E. Velasco °, J. Salluh, V.M. Gonc¸alves, V. Oliveira, T. Moreno,
S. Rocco (Rio de Janeiro, BR)
Background: The novel inﬂuenza A (H1N1) pandemia exposes im-
munocompromised cancer patients under chemotherapy to an increased
risk of mortality.
Objective: To describe clinical characteristics, treatment, and outcome
of cancer patients with 2009 Inﬂuenza A (H1N1) infection.
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Methods: A descriptive study of hospitalized cancer patients at an
Oncology Cancer Center in Brazil between July 8 and September 1,
2009 who were tested positive for the 2009 H1N1 virus with the use of
a RT-PCR assay and/or a direct ﬂuorescence antibody staining.
Results: As of 1 September, 24 cases were tested positive for inﬂuenza
virus infection. Median age was 14.5 years (2−69 years). Underlying
cancer diagnoses were: acute leukemia, 7 (29%); solid tumors, 6 (25%);
lymphoma, 6 (25%); multiple myeloma, 3 (12%) and chronic leukemia,
2 (8%). All patients had fever and acute respiratory symptoms. Previous
chemotherapy (79%), neutropenia (50%) and history of steroids therapy
(37%) were commonly present. No patients had laboratory-documented
bacterial infections at the illness onset, however all received antibacterial
agents at presentation. Seventeen patients developed bilateral pulmonary
inﬁltrates and severe hypoxemia was present in 15 cases (88.2%). Of
these, 11 underwent mechanical ventilation. Twenty-two patients were
treated with oseltamivir and, in 37.5% of them a double dose was
prescribed. Median time from admission to antiviral therapy start was
5 days (range: 0−20 days). Antiviral therapy was started within 48 h of
symptoms in only 10 patients (22%). Main reasons for therapy delay
were the lack of speciﬁcity symptoms in neutropenic patients and the
initial difﬁculty to obtain antiviral drugs. Five patients died (21%), and
two of them never received oseltamivir. In the other 3 cases, the therapy
was only started 8, 9 and 15 days after hospital admission.
Conclusions: This study presents a series of cancer patients with H1N1
virus infection with an elevated mortality. We observed a high number
of cases in young patients. Considering the clinical data, a nosocomial
transmission cannot be ruled-out. Our data shows a possible association
of mortality with a lack or a delay of antiviral therapy initiation. A
faster availability of antiviral medication for therapy and prophylaxis
and vaccination programs should be reinforced among cancer patients,
close contacts and healthcare workers.
O505 Epidemiology of severe paediatric patients with novel
inﬂuenza A (H1N1) in Korea
S.Y. Shin °, J.H. Kim, H.S. Kim, Y.A. Kang, H.G. Lee, J.S. Kim,
W.K. Kim (Seoul, KR)
Objectives: Since the ﬁrst outbreak of novel inﬂuenza A (H1N1) in May
2009, the virus has been spread throughout local communities. More
than 4,000 diagnosed cases are being reported daily as of November
2009. One of the major infection routes is the educational institutions,
so children and teenagers have very high risk of viral exposure. Recently,
mass outbreaks were reported from 870 schools within one week.
Korea Centers for Disease Control and Prevention (KCDC) is operating
nationwide monitoring system for severe hospitalization cases. The
objective of this study is to highlight demographics, infection risk factors
and clinical courses.
Methods: Novel inﬂuenza A (H1N1) patients who were hospitalized
in intensive care unit or had pneumonia in needs of intubation were
categorized as severe pediatric patients. Between June and October, total
of 22 cases under the age of 18 were identiﬁed as severe patients. After
the medical chart review, we had an interview with the doctor in charge.
All the patients were laboratory-conﬁrmed novel inﬂuenza A (H1N1)
virus infection by means of real-time polymerase chain reaction. Based
on the Advisory Committee on Immunization Practices, the patients
with high-risk medical conditions were deﬁned as having higher risk
for inﬂuenza complications.
Result: Among the reported 22 severe cases, 15 were male and 7 were
female. Ages ranged from 2 months to 18 years old (median 7, standard
deviation 5.4). Fourteen patients (63%) had high-risk medical conditions
such as 1) age less than 59 months (6 cases), 2) chronic respiratory
disease (3 asthma cases), 3) neuro-developmental disorder (3 cases), 4)
congenital heart disease (1 case) and 5) leukemia (1 case). Total of 7
patients have expired. Patients took anti-viral agent (Tamiﬂu®) average
2 days after onset. Thirteen patients received ventilator care, 7 did not
and 2 were unsure. Viral pneumonia was the most common complication
(17 cases, 77%) and 3 patients exacerbated into acute respiratory distress
syndrome. Initial symptoms were fever and cough (18 cases, 81% each).
There were 11 leukocytosis, 3 leucopenia and 3 thrombocytopenia cases
on complete blood count.
Conclusions: Half of patients with high-risk medical conditions have
expired. Considering current situations, we need to maintain high-risk
medical conditions category and to have continuous tracking for severe
pediatric patients with novel inﬂuenza A (H1N1).
Table 1. Characteristics or status of Korean pediatric patients with
inﬂuenza A(H1N1), June–October 2009





0−23 months 1 4.5
24−59 months 5 22.7





Ages under 59 months 6 27.2
Neurodevelopmental condition 3 13.6
Chronic pulmonary condition 3 13.6




2 days after illness onset 15 68.1
>2 days after illness onset 5 22.7
Nosocomial pneumonia
O506 Ventilator-associated pneumonia rates in 12 intensive care
units between 1995 and 2006, Lyon, France
P.B. Sow °, D. Lutringer-Magnin, T. Be´net, D. Baratin, P. Vanhems
(Lyon, FR)
Objective: The aim of this study was to describe trends of ventilator
acquired pneumonia (VAP) incidence in 12 intensive care units (ICU)
by taking into account of individual major risk factors of VAP.
Methods: A prospective surveillance in 12 ICUs participating in the
national nosocomial infection surveillance network in South-East France
between 1995 and 2006 was done. The VAP was deﬁned base on clinical,
radiological and bacteriological ﬁndings, according to the national
protocol. Yearly incidences of VAP were described. The risk of VAP
by time was modelled using a Cox proportional hazard model with the
year of admission in ICU as the main exposure. The tested covariates
were age, gender, and SAPSII.
Table l. Characteristics, incidences and risks of ventilator associated
pneumonia in 12 intensive care units included in a surveillance program
network, 1995–2006, Lyon, France
Year of
participation
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Total
No. of patients 250 506 524 726 1678 1135 1191 1669 1552 1451 1539 1622 13843
No. of ICUs 2 3 3 4 10 9 9 10 9 10 9 9 87





























































Adjusted HR* 1.00 1.09 0.47 0.34 0.53 0.75 0.70 0.87 0.95 0.62 0.97 0.96
(95%CI)a (0.8-1.4) (0.3-0.6) (0.2-0.5) (0.4-0.7) (0.6-0.9) (0.6-0.9) (0.7-1.0) (0.8-1.1) (0.5-0.7) (0.8-1.1) (0.8-1.1)
*SAPS II: Simpliﬁed acute physiology score II; VAP: ventilator acquired pneumonia, HR: hazard ratio adjusted on age, sex and SAPS II.
aComparisons with year 1995, CI: conﬁdence interval, SD: Standard deviation.
Results: Overall 13,843 patients were included, counting for 131,585
patient-days. A total of 1,936 VAP were observed. The mean incidence
was 16.4/1 000 patient-days. The mean age was 56 years (Standard
deviation = 32), and the mean SAPSII was 43 (Sd =19). Variations over
time were observed for VAP incidence (P< 0.001), age (P< 0.001), and
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SAPSII (P< 0.001), signiﬁcant by the Pearson khi square test. After
multivariate analysis, VAP risk per year decreased between years 1996
to 1998, increased continuously until 2001 and stabilized between 2002
and 2006, compared to 1995 (global Hazard Ratio=0.96; 95%CI [0.81–
1.14]).
Conclusion: Despite of an increase of risk factors as age and SAPSII
scores of ICU patients by time, we observed that the adjusted VAP
risk between 2002 and 2006 were stable. These results should be a
consequence of the implementation of speciﬁc prevention measures
related to ICUs practitioners.
O507 Attributable mortality of ventilator-associated pneumonia:
a meta-analysis
M. Agraﬁotis, I. Siempos, T. Ntaidou, M. Falagas ° (Athens, GR)
Objective: To investigate whether ventilator-associated pneumonia
(VAP) is a true cause of mortality in the intensive care unit (ICU) setting.
Methods: We performed a meta-analysis of available data obtained
through search of PubMed and relevant bibliographies without time
restrictions. A conservative DerSimonian-Laird random effects model
was employed to calculate pooled odds ratios (OR) and 95% conﬁdence
intervals (CIs).
Results: Out of 968 retrieved reports, 44 papers fulﬁlled our inclusion
criteria. Presence, as opposed to absence, of VAP was associated with
higher mortality in the ICU setting (OR: 1.96, 95%CI: [1.26, 3.04]). This
result persisted when matched case control studies (OR 1.73, 95%CI:
[1.23, 2.45]) or studies in which VAP was microbiologically conﬁrmed
in all patients (OR: 2.20, 95%CI: [1.01, 4.81]) were evaluated separately.
VAP was still associated with higher mortality when the impact of
immunosuppresion was controlled (OR: 1.74, 95%CI: [0.95, 3.16]); a
ﬁnding that did not reach statistical signiﬁcance. Though, presence of
VAP was not associated with higher mortality in the subgroup analysis of
studies including patients who received appropriate initial antimicrobial
treatment (OR 1.64 [0.68, 3.96]).
Conclusion: Presence, compared to absence, of VAP seems to be
associated with higher mortality in critically ill patients. Appropriateness
of initial antimicrobial treatment in such patients may moderate this
association.
O508 Impact of antiseptic based oral care on rates of
ventilator-associated pneumonia in intensive care unit
patients: a meta-analysis
K. Van de Vyver, S. Labeau, N. Brusselaers, D. Vogelaers, S. Blot °
(Ghent, BE)
Objective: Ventilator-associated pneumonia (VAP) is the most frequent
nosocomial infection in the intensive care unit. Reducing inoculums of
oral pathogenic microorganisms by adequate oral care could prevent VAP.
Methods: A systematic review of the literature concerning oral
decontamination with chlorhexidine or povidone-iodine on intubated
patients, and subsequent meta-analysis evaluating the effects of oral
decontamination on the incidence of VAP was performed. Relevant
articles were searched for in electronic databases as PubMed, CINAHL,
Web of Science and CENTRAL and supplemented by manual searches
of reference lists. Only randomized controlled trials evaluating the effect
of oral care with use of chlorhexidine or povidone-iodine vs. oral care
without use of an antiseptic on the incidence of VAP in adult intubated
patients were included. Data were extracted as dichotomous variables.
Data analysis was performed using RevMan 5.0. Statistical analysis was
conducted according the Mantel-Haenszel model to obtain the relative
risk (RR) and 95% conﬁdence interval (CI). Heterogeneity was assessed
using the Chi-2 test.
Results: Eleven studies were included in the analysis (n patients =
1971) of which 9 that investigated the effect of oral care with use
of chlorhexidine (n patients = 1862) and 2 that assessed the effect of
oral care with use of povidone-iodine (n patients = 109). The use of
an antisepticum resulted in a signiﬁcant reduction of the incidence of
VAP with a RR of 0.63 (95%CI 0.50–0.81; p = 0.0002). These results
are valid for chlorhexidine (RR 0.68; 95%CI 0.53–0.88; p = 0.004) and
povidone-iodine (RR 0.38; 95%CI 0.19–0.75; p = 0.005). Among studies
important differences exists concerning concentrations of the antiseptic
used, frequency of oral care, and study methodology and diagnostic
criteria for VAP. Clinical heterogeneity was conﬁrmed statistically and
was moderate (c2 = 43%; p = 0.08) for the trials using chlorhexidine and
high (c2 = 66%; p = 0.09) for those assessing povidone-iodine. Subgroup
analyses revealed most beneﬁcial effects with concentrations of 0.12%
and 2% chlorhexidine and 10% povidone-iodine, and in a population of
cardiac surgery patients.
Conclusions: This analysis shows that oral decontamination with an
antiseptic reduces the incidence of VAP signiﬁcantly. Both chlorhexidine
and povidone-iodine show this effect. However, further research is
needed to make recommendations about the concentration and frequency
of application.
O509 Efﬁcacy of panobacumab, an IgM monoclonal antibody,
in hospital-acquired pneumonia caused by Pseudomonas
aeruginosa
P.F. Laterre °, Q. Lu, A. Dugard, P. Eggimann, E. Mercier,
E.J. Giamarellos-Bourboulis, V.C. Gafner, H. Lazar, M. Tamm
(Brussels, BE; Paris, Limoges, FR; Lausanne, CH; Tours, FR; Athens,
GR; Berne, Basel, CH)
Objectives: Despite adequate antibiotic therapy Hospital Acquired
Pneumonia (HAP) and Ventilator Associated Pneumonia (VAP) caused
by P. aeruginosa are of the most common and deadliest nosocomial
infections. Panobacumab, a fully human IgM/kappa monoclonal antibody
targeting P. aeruginosa serotype O11, was evaluated as a new therapeutic
modality for treatment of VAP/HAP.
Methods: Patients with HAP caused by P. aeruginosa O11 were enrolled
in a Phase IIa open trial to be treated with Panobacumab 1.2mg/kg (days
1, 4, 7) in addition to standard antibiotic therapy.
Results: 17 patients, (23−83 years) with VAP (n = 14) or HAP (n = 3)
were treated with Panobacumab. Thirteen patients (completers) received
3 infusions and 4 patients (non-completers) received 1 infusion. The
study drug was safe and well tolerated. Panobacumab revealed a
pharmacokinetic proﬁle similar to a native IgM. Panobacumab could
be detected in BAL samples collected after treatment indicating the
antibody to reach the inﬂamed lung tissue. Clinically the initial mean
CPIS and APACHEII score were 8.53 (7−11) and 18.2 (6−33) with an
expected mortality of 29.6%. The overall observed mortality within 30
days after starting treatment was 17.6%. Despite an APACHEII score
of 18.5 and expected mortality of 30.6% all completers survived within
the ﬁrst 30 days while non-completers showed a survival rate of 25%.
Resolution of pneumonia was achieved by 9 out of 13 completers in
9.9±4.3 days (mean±SD) including two patients which were initially
inadequately treated. An early administration of the antibody seems
to correlate positively with the resolution of pneumonia. The mean
Cmax after the third dose of Panobacumab was higher in patients with
resolution than in those with continuation of pneumonia (34.8 versus
28.5mg/L) as well as in those with eradication of P. aeruginosa versus
those with continuation (37.3 versus 27.7mg/L).
Conclusions: A survival of 100% was observed in patients that
completed the full treatment cycle with 3 doses of Panobacumab
indicating efﬁcacy of the antibody treatment. Early administration of
Panobacumab and high Cmax levels seem to correlate positively with the
resolution of pneumonia and eradication of P. aeruginosa. The current
data is promising and warrant further trials with Panobacumab.
O510 Tigecycline in the treatment of multidrug-resistant
Acinetobacter baumannii pneumonia
M.S. Tasbakan, H. Pullukcu, O. Sipahi °, M. Tasbakan, S. Aydemir,
F. Bacakoglu (Izmir, TR)
Objectives: Nosocomial infections by multidrug-resistant (MDR)
A. baumannii are important causes of mortality in intensive care units
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(ICU). The treatment choices are limited. The aim of this study was to
evaluate the efﬁcacy of tigecyline in MDR A. baumannii pneumonia.
Method: This study was performed at a tertiary-care educational
university hospital with an active respiratory diseases ward with
100 beds, 8 of which are in ICU. We retrospectively evaluated the
outcome of adult (>18 years old) patients with culture proven MDR
A. baumannii pneumoniae treated with tigecycline between January
2009 and November 2009. Demographic, clinical and laboratory data,
predisposing factors, as well as information on response to treatment
and outcome were obtained from each patient’s hospital records.
Results: There were a total of 34 cases (18 male, mean age 66.79±14.84
years) fulﬁlling our inclusion criteria. On the admission 17 cases were
diagnosed as community-acquired pneumonia and 12 were diagnosed as
chronic obstructive lung disease. 27 cases (79.4%) had comorbidities
and the most common comorbidity was atherosclerotic heart disease
(8 cases) followed by diabetes mellitus (5 cases), cerebrovascular
disease (5 cases), respectively. When A. baumannii was isolated
from respiratory samples 19 were considered as ventilator-associated
pneumonia and 15 were considered as hospital-acquired pneumonia.
All isolates were sensitive to tigecycline, whereas all were resistant to
piperacillin/tazobactam and ceftazidime, 74%, 56%, 41% and 24% were
resistant to imipenem, cefoperazone/sulbactam, amikacin and netilmicin,
respectively. Tigecycline was used for a mean duration of 9.6±5.2 days.
Microbiologic eradication (on day 3 and 7) was observed in 21 cases
(61.8%). Tigecycline was combined with cefoperazone/sulbactam in 12
cases, with netilmicin in 6 cases and with amikacin in 3 cases. Nine of
21 cases with microbiologic eradication were lost whereas mortality was
100% in the other 13 cases (p = 0.0006). Mortality and microbiologic
eradication rates were not different in combination vs monotherapy
(p > 0.05). Mortal cases were elder than the survivors (71.1±12.6
vs 58.9±15.9, p = 0.02). Toxicity developed only in one case as liver
toxicity.
Conclusion: Our ﬁndings show that microbiologic eradication rate
of tigecycline in MDR A. baumannii is not very low. However this
microbiologic eradication rate did not result in good clinical results in
terms of mortality probably due to comorbidities.
Daptomycin − clinical experience
O511 Daptomycin for the treatment of infective endocarditis:
results from European Cubicin® Outcomes Registry and
Experience (EU-CORE)
P. Dohmen °, A. Guleri, N. Petrosillo, R. Utili, V. Gonza´lez Sanz,
R.A. Seaton, V.J. Gonza´lez-Ramallo, R. Hetzer, M. Heep, H.J. Thurston,
R.L. Chaves (Berlin, DE; Lancashire, UK; Rome, Naples, IT; Zaragoza,
ES; Glasgow, UK; Madrid, ES; Basel, CH)
Objective: Randomized controlled trials are scarce in endocarditis and
might not be representative for the general patient population. The aim
of this registry was to describe the clinical experience with Daptomycin
(DAP) for the treatment of infective endocarditis (IE) in Europe. DAP
is approved in Europe for the treatment of right-sided endocarditis due
to S. aureus at a dose of 6mg/kg once daily.
Methods: In this multi-centre, retrospective, non-interventional registry,
the outcome data were collected in patients (pts) who were diagnosed
with native or prosthetic valve IE and treated with at least one dose
of DAP. Clinical outcomes were assessed at the end of DAP treatment
by the investigators using standard deﬁnitions (cured, improved, failure,
non-evaluable). Success was deﬁned as the sum of cured or improved
outcome rates.
Results: Of the total 2581 pts in the EU-CORE registry from Jan 2006 to
Aug 2009, 276 pts (68% male and 53% 65 years of age) had IE. A total
of 117 (42%) pts received DAP in an ICU, congestive heart failure was
present in 31 (11%) pts and cardiac arrhythmias in 59 (21%) pts. Right
sided endocarditis was observed in 66 (24%) pts, left sided endocarditis
in 191 (69%) pts, and right plus left sided endocarditis in 19 (7%) pts,
respectively. The most common primary pathogen was S. aureus (n = 73,
26%), of which 25 were reported as MRSA. 180 (66%) pts received
concomitant antibiotic therapy, most commonly aminoglycosides (71,
26%) or carbapenems (46, 17%). The majority of pts received DAP
doses of 6mg/kg (62%) or higher (21%). The clinical outcome per IE
type were:
Right sided endocarditis, success 92%, failure 5%, non-evaluable (NE)
3%;
Left sided endocarditis, success 76%, failure 9%, NE 14%;
Right plus left sided endocarditis, success 89%, NE 11%.
The proportion of pts with low Creatinine clearance (<30mL/min)
improved from 17% (46/276) initially to 13% (35/276) at the end of
DAP treatment. Serious AEs were reported in 34 (12%) pts and 20 (7%)
pts discontinued the study drug due to AEs.
Conclusions: Daptomycin appears effective and well tolerated against a
variety of clinical presentations of infective endocarditis. Success rates
and adverse event proﬁle, including renal safety were comparable to
those observed in the pivotal trials. Further clinical studies on infective
endocarditis e.g. on the impact of DAP at higher doses might be
warranted.
O512 High-dose daptomycin for infective endocarditis
R. Kullar °, S. Davis, C. Crank, J. Segreti, S. Cosgrove, J. Zhao,
D. Levine, M. Rybak (Detroit, Chicago, Baltimore, US)
Objective: Infective endocarditis (IE) is a serious infection associated
with high morbidity and mortality. IE due to methicillin-resistant
Staphylococcus aureus (MRSA) and enterococci including vancomycin-
resistant strains (VRE) has been associated with high failure rates.
Daptomycin (DAP) has activity against both MRSA and VRE strains. We
evaluated the safety and efﬁcacy of high-dose (HD) DAP (8mg/kg/day)
for MRSA and VRE IE.
Methods: Consecutive patients treated with HD DAP for 72 h,
excluding dialysis, were retrospectively reviewed at 4 academic medical
centres. This subset analysis included all patients with IE deﬁned
by modiﬁed Duke criteria. Charts were reviewed for demographics,
comorbidities, antimicrobial therapy, microbiologic cultures, clinical




Median (range) or n (%)
Left-sided endocarditis (LIE)
(n = 20)
Median (range) or n (%)
Primary Organism
MRSA 19 (82.6%) 12 (60.0%)
VRE 1 (4.3%) 4 (20.0%)
No organism isolated 3 (13.0%) 4 (20.0%)
Clinical and Microbiological Outcomes
Duration of bacteraemia (days)
MRSA (n = 31) 6 (1−30) 12 (6−18)
VRE (n = 5) 1 12 (1−12)
Duration of fever (days) 4.5 (1−21) 8 (0−21)
Duration of leukocytosis (days) 10 (1−44) 11.5 (1−44)
Duration in ICU (days) 8.5 (0−13) 12 (1−79)
Duration of HD DAP (days) 8 (3−27) 12.5 (3−48)
Length of stay (days) 17 (8−57) 25 (10−91)
Median dose of HD DAP (mg/kg/day) 9.7 (8.0–11.4) 9.9 (8.0–12.1)
Clinical success
MRSA (n = 31) 13 (81.3%) 9 (90.0%)
VRE (n = 5) 1 (100%) 3 (75.0%)
Clinical failure
MRSA (n = 31) 3 (18.8%) 1 (10.0%)
VRE (n = 5) 0 (0%) 1 (25.0%)
Microbiological eradication 19 (86.4%) 19 (95.0%)
Organism persisted 3 (13.6%) 1 (5.0%)
Safety
EOT CPK <150 IU/L 20 (87.0%) 17 (85.0%)
Results: 45 patients were identiﬁed. Baseline characteristics: Median age
53 years (range 24−93), APACHE II 7 (0−28), 57.8% hospitalization
1 year, 22.2% MRSA infection 1 year, 57.8% injection drug use,
28.9% diabetes, 22.2% renal disease. 23 (51.1%) patients had right-
sided IE (RIE), 20 (44.4%) patients had left-sided IE (LIE), and 2
(4.4%) patients had both RIE and LIE. Characteristics and outcomes
of patients with RIE or LIE are presented in Table 1. The median days
of bacteraemia, as determined from clinical cultures, for MRSA RIE and
LIE were 6 days (1−30) and 12 days (6−18), respectively. Overall clinical
cure and microbiological eradication was 76.1% and 86.4%, respectively.
The median dose of HD DAP for RIE vs. LIE were 9.7mg/kg/day (8.0–
11.4) vs. 9.9mg/kg/day (8.0–12.1), respectively. Safety: 87% patients had
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end-of-therapy (EOT) creatinine phosphokinase (CPK) levels <150 IU/L
(15–452). No patients were discontinued from therapy due to myopathy
or any other adverse events.
Conclusion: Efﬁcacy and safety of HD DAP were favourable in a cohort
of pts with IE. Further studies with a larger cohort are warranted.
O513 Evaluation of safety and tolerability of daptomycin in the
treatment of osteomyelitis: results from a European Registry
R.A. Seaton °, P. Gargalianos-Kakolyris, K. Malizos, F. Romero-Candau,
A. Carretta, J. Herna´ndez-Quero, M. Militz, S. Reus Ban˜uls, G. Riccio,
M. Heep, H.J. Thurston, R.L. Chaves (Glasgow, UK; Athens, Larissa,
GR; Seville, ES; Bari, IT; Granada, ES; Murnau, DE; Alicante, ES;
Pietra Ligure, IT; Basel, CH)
Objectives: Osteomyelitis (OM) is a complicated and diverse disease and
long term efﬁcacy and safety of an antibiotic is an important determinant
in selecting the optimal therapy. This is the ﬁrst report of a large series
of OM cases treated with daptomycin (DAP) across many countries in
Europe.
Methods: Data were collected as part of the European CUBICIN® Out-
comes Registry and Experience (EU-CORE) program, a retrospective,
non-interventional, observational, multicenter study designed to describe
the clinical use of DAP. All patients (pts) who had a diagnosis of OM
were selected from the database. Pts who were treated with at least one
dose of DAP and for whom any safety parameter was assessed were
included in safety population. Efﬁcacy population was a subset of the
safety population where clinical outcome (cure, improved, failure, or
non-evaluable) was assessed by the investigators. Pts enrolled from Jan
2006 to Aug 2009 were included.
Results: Of 2581 pts enrolled 161 (58.4% male, 42% 65 years) were
diagnosed with OM. 90 (56%) cases of OM were non-prosthetic device
related, 50 (31%) were permanent prosthetic device related, 21 (13%)
were temporary prosthetic device related. For 103 pts (64%) primary
pathogens have been reported. S. aureus (45/103) was the most frequent
species, with MRSA (n = 19) as signiﬁcant subset. Coagulase-negative
Staphylococci (41/103) ranked second. Most pts received DAP doses
6mg/kg (76%). Median duration of DAP outpt therapy was 29 days
(range: 4−82), and inpt therapy was 14 (range: 1–246). Overall clinical
success (cured or improved) was seen in 73% (118/161) of pts and failure
in 9% (14/161). 18% of pts were non-evaluable (29/161). In subgroup
analyses, clinical success was observed in 72% (65/90) of pts without
devices, 72% (36/50) of pts with permanent devices and 81% (17/21)
of pts with temporary prosthetic devices. Serum creatine phosphokinase
(CPK) values were reported in 68% (109/161) of pts during DAP therapy.
In 86% of pts (94/109) CPK levels remained within normal range.
Discontinuation of DAP due to treatment failure was reported for 2
pts (1%) only. Serious AEs were reported in 3% (5/161) of pts. AEs
leading to study drug discontinuation were reported in 5% (8/161).
Conclusion: DAP at doses 6mg/kg once daily was the most frequent
dose regimen used for osteomyelitis in Europe. DAP was well-tolerated
also for longer treatment duration. These promising results warrant
conﬁrmation in additional studies.
O514 Daptomycin versus vancomycin for methicillin-resistant
Staphylococcus aureus bacteraemia with reduced in vitro
susceptibility to vancomycin
P. Osaki Kiyan, C. Moore, M. Perri, N. Haque, S. Donabedian,
M. Zervos ° (Detroit, US)
Background: Poor outcomes in MRSA bacteremia have been associated
with reduced in vitro susceptibility to vancomycin, yet still within the
susceptible range. Data for alternative management in these cases is
lacking, particularly with daptomycin (DAP).
Methods: We conducted a case–control study evaluating treatment with
VAN or DAP for MRSA-B with a VAN MIC of 1.5 or 2 ug/mL. Patients
were matched 2:1 by risk level of source, APACHE-II score at onset of
infection and age. Respiratory infections were excluded. Failure was a
composite of: 30-day mortality, microbiologic failure (positive cultures
>10 d from index culture) and/or recurrence of MRSA-B within 30 days
of end of tx.
Results: DAP treated patients (n 37) were compared to VAN treated
patients (n 74). VAN MIC was 1.5 (46 v 85%) and 2.0 (54 v 15%),
p< 0.01. Source of infection was similar between groups including
endocarditis (27 v 24%), skin (38 v 32%), catheter (19 v 19%), device (8
v 11%) and other (8 v 14%). Age, comorbidities, APACHE II score (14 v
14) and requirement of ICU admission (24 vs 21%) was similar between
groups, p> 0.05. Immunosuppression (24 v 7%) was more common in
the DAP group, p< 0.05. Factors signiﬁcantly associated with failure;
ICU at onset of infection, nursing home residence, CV disease, DM, and
ARF, p< 0.05. IVDA was signiﬁcantly associated with cure, p< 0.05.
Factors associated with 30 day mortality; Caucasian race, ICU at onset of
infection, NH residence, ARF, p< 0.05. Hemodialysis was signiﬁcantly
associated with survival, p< 0.05. VAN MIC by Etest had no association
with failure or mortality. There was a trend toward less failure (14 v
28%) and lower 30-day mortality (3 v 16%) in the DAP group, p = 0.06.
Failure by source of infection was; endocarditis (10 v 39%), skin (14
v 17%), catheter (14 v 14%), device (33 v 75%) and other (0 v 20%).
Mortality by source of infection was; endocarditis (0 v 28%), skin (7 v
8%), catheter (0 v 14%), device (0 v 13%) and other (0 v 20%).
Conclusion: Between groups, baseline comorbidities, risk level of source
and APACHE-II scores were similar, although immunosuppresion and
isolates with VAN MIC=2 were greater in the DAP group. This study
shows that DAP may be associated with better outcome of infection
as compared to VAN, and trended toward lower 30-day mortality,






Age (Mean, SD) 50 (13) 51(15) 0.68
Male gender 65% 65% 1.00




APACHE-II (mean, SD) 14 (7) 14 (7) 0.86
ICU at onset of infection 24% 21% 0.68
Cardiovascular disease 38% 37% 0.89
Diabetes mellitus 35% 39% 0.68
Acute renal failure 30% 23% 0.44
Hemodialysis 24% 24% 1.00
Liver disease 41% 28% 0.20
Malignancy 3% 10% 0.27
Immunosuppression 24% 7% 0.01
Nursing home resident 5% 14% 0.33




Vancomycin MIC (m g/mL) Etest <0.01
1.5 46% 85%
2.0 54% 15%
O515 Daptomycin against highly resistant Enterococcus faecium
invasive infections
C. Rosin °, C. Bernsmeier, J.M. Entenza, P. Moreillon, R. Frei,
M. Weisser, U. Flu¨ckiger (Basel, Lausanne, CH)
Objective: Treatment recommendations for invasive enterococcal
infections advocate synergistic combinations such as ampicillin plus
gentamicin. In case of resistance to one or even both of the drugs,
vancomycin therapy is proposed, albeit it is poorly bactericidal. The
Swiss surveillance program reports resistance of Enterococcus faecium
to aminopenicillin and high-level gentamicin to be as high as 82% and
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49%, respectively (www.anresis.ch). This leaves the clinician with a
therapeutic conundrum since no established therapeutic regimen exists.
Daptomycin is approved for complicated skin and soft tissue infections
with Gram-positive bacteria and showed efﬁcacy against E. faecium in
the experimental endocarditis model.
Methods: We report a case series of 11 patients with severe E. faecium
infections treated with daptomycin at the University Hospital Basel
between 2007 and 2009. All strains were resistant to ampicillin
(MIC> 8mg/l), but susceptible to vancomycin. 7/11 strains were also
highly resistant to gentamicin (MIC> 500mg/l).
Results: All patients were treated with multiple broad-spectrum
antibiotics prior to isolation of E. faecium and had severe underlying
diseases: Five had haematological malignancies, two had repeated
episodes of cholangiosepsis, two suffered from severe atherosclerosis
after multiple vascular surgical procedures, one had undergone liver
transplantation and one had colon cancer. Foci were mainly blood
stream infections or cholangitis. The reasons for daptomycin treatment
were renal failure (n = 3), vancomycin failure (n = 4) despite vancomycin
susceptibility (MIC 4mg/l), outpatient parenteral therapy (n = 2) and
uncontrolled infection (n = 2).
With one isolate from a patient with persistent bacteremia, in vitro kill-
curves were performed, showing a bactericidal effect of daptomycin (loss
of >3 log/CFU/24 h with 2mg/l and 10mg/l of the drug). In contrast,
10mg/l of vancomycin was bacteriostatic. Daptomycin was used in a
dose of 6mg/kg/d. 7 patients recovered, 4 patients died. Death was
related to uncontrollable infection in only one case, the other deaths
were attributable to the underlying diseases.
Conclusion: Our case series suggests that salvage therapy with
daptomycin was likely to be efﬁcient in 7/11 patients with refractory
invasive infections due to multi-resistant E. faecium. Thus, daptomycin
might be a safe option in such cases.
PK/PD approaches in Gram-negative
infections
O516 Pharmacokinetic evaluation of intravenous colistin following
two different dose regimens in multidrug-resistant infections
M. Cusato °, R. Imberti, P. Villani, L. Carnevale, G. Iotti, G. Accetta,
M. Langer, M. Regazzi (Pavia, Milan, IT)
Objectives: Infections caused by multidrug-resistant Gram-negative
bacteria are a growing clinical problem and are associated with
signiﬁcant morbidity and mortality. We evaluated colistin concentrations
at steady-state in plasma samples and bronchoalveolar lavage (BAL) of
critically ill patients admitted to our ICU.
Methods: Nineteen patients (16M, 3F) aged 20−70 years and affected
with ventilator-associated pneumonia were enrolled. Six patients received
1 million IU of colistin methanesulphonate (CMS) intravenously every
6 hours; thirteen patients received 2 million IU every 8 hours for
at least 2 days. Blood samples were collected from each patient at
baseline (predose) and at time intervals after the end of CMS infusion.
BAL was performed in all patients at 2 hours post-infusion. Colistin
plasma and bronchoalveolar concentrations were measured using a
selective and sensitive high performance liquid chromatography assay
with ﬂuorescence detector. Pharmacokinetic parameters were determined
by non-compartmental analysis using Innaphase Kinetica™ 4.0 software.
Results: Patients receiving 1M IU/6 h had mean [±SD] Cmax and
Cmin plasma concentrations at the steady-state of 1.57 [±0.57] and
1.10 [±0.43] mg/ml, respectively. Mean [±SD] AUC(0−6 h), t1/2 and
Vd were 6.40 [±2.32] mg·h/ml, 8.36 [±4.94] h, and 220.46 [±76.61]
L/h, respectively. Patients receiving 2M IU/8 h had mean [±SD] plasma
Cmax and Cmin levels at steady-state of 2.21 [±1.08] and 0.98
[±0.70] mg/ml, respectively. Mean [±SD] AUC(0−8 h), t1/2 and Vd
were 11.54 [±6.20] mg·h/ml, 5.87 [±2.56] h, and 143.24 [±116.47]
L/h, respectively. Cmax/MIC and AUC(0−24 h) /MIC ratios (MIC = 2
mg/ml) were 0.79 [±0.28] and 12.79 [±4.65], 1.1 [±0.54] and 17.30
[±9.30], after administration of 1M IU and 2M IU, respectively.
Colistin was undetectable in BAL under both regimens. A complete
eradication of bacteria was observed in 12/13 of our patients with the
2M IU/8 h dosing schedule.
Conclusions: In critically ill patients, the 2M IU/8 h dose regimen
provided higher Cmax and AUC than the 1M IU/6 h schedule: this
may be a therapeutic advantage because the AUC/MIC and Cmax/MIC
ratios are strongly associated with efﬁcacy. Further studies are needed
to provide important clinical answers, from individualising treatment to
optimising dosage and reducing adverse effects.
O517 Pharmacokinetic/pharmacodynamic modelling of
polymyxin B, rifampicin and tigecycline against pandrug-
resistant Acinetobacter baumannii in an in vitro model
T.P. Lim, W. Lee, S. Sasikala, T.Y. Tan, L.Y. Hsu, T.T. Tan, A.L. Kwa °
(Singapore, SG)
Objective: Outbreaks of pandrug-resistant (PDR) Acinetobacter bau-
mannii (AB) have emerged in Singapore. Combination therapy is often
the remaining viable option until new antibiotics are available. While
polymyxin B (P) may remain a viable treatment option, heteroresistance
has become a major problem. We evaluate the efﬁcacy of P, rifampicin
(R) and tigecycline (T) combined against PDR AB isolated from our
local hospitals.
Methods: PDR AB isolates from all public hospitals in Singapore were
collected from 2006−07. MICs were determined according to a modiﬁed
CLSI broth-dilution method. Time-kill studies (TKS) were then per-
formed with the maximum, clinically achievable, unbound concentration
(mg/L) of P (2), R (2) and T (2) alone and in combination against the
PDR AB isolates. A hollow-ﬁber infection model (HFIM) was used to
validate our quantitative assessment of combined killing against 2 iso-
lates (selected based on the unique genotype that represents the PDR AB
population). Resistance selection of the 2 isolates against P alone in the
HFIM were quantiﬁed using drug-free and selective (P at 3x MIC) media.
Results: Among 361 non-repeat AB isolates screened, 29 PDR AB
isolates found were susceptible to P (MICs 1−2mg/L) and resistant to all
antibiotic classes whereas R MICs ranged from 2−16mg/L. In TKS, P, R
and T alone was bacteriostatic with regrowth by 24 h in all isolates. P+R,
P+T and R+T achieved >99% kill from baseline in 15/29, 14/29 and 8/29
isolates with no regrowth at 24 h. These assessments were consistent with
observation in HFIM studies where we observe bacterial killing up to
120 h with P+R. Pharmacokinetic validation of the HFIM studies were
satisfactory. Minimal killing of the 2 isolates was seen when exposed
to P alone. Regrowth was seen at 24 h due to selective amplication of
resistant sub-population(s) on P supplemented plates. Repeat MIC testing
of the resistant isolates conﬁrms P resistance (MICs 32–128mg/L).
Conclusions: We have shown that our PDR AB has the propensity
to exhibit heteroresistance and combination therapy with P is needed.
P+R may be a potential antibiotic combination as therapy for PDR
AB infections. The in vivo relevance of our results warrants further
investigations.
O518 Pharmacodynamic evaluation of the intracellular activity
of tobramycin, doripenem, levoﬂoxacin, and colistin towards
Pseudomonas aeruginosa after phagocytosis by human
THP-1 macrophages
J. Buyck °, P.M. Tulkens, F. Van Bambeke (Brussels, BE)
Objectives: P. aeruginosa (Pa) is capable of invading epithelial and
phagocytic cells (Mol. Biol. Cell 2005; 16: 2577−85), which may play an
important role in the initiation and persistence of the infection process.
As no data is available about antibiotic activity against intracellular P.a.,
we have developed a 24-h infection model using THP-1 cells, a human
cell line known to be permissive for infection by several important human
pathogens. This model has now been used to test for the activity of 4
antibiotics representative of 4 classes of drugs used in clinics to treat
pseudomonal infections.
Methods: Phagocytosis of bacteria (opsonized with human serum) was
allowed for 2 h (bacteria/macrophage ratio: 10), extracellular bacteria
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were eliminated by washing and incubation for 60 min with gentamicin
at 50 x MIC, and Infected cells (5−7×105 CFU/mg cell prot.) incubated
with antibiotics (0.01 to 100×MIC). Activity against bacteria in broth
(1×106 CFU/ml) was determined in parallel (same conc. span). Activity
was expressed as change from the initial inoculum after 24 h, and the
data used for ﬁtting a concentration-response curve (Hill equation) and
for calculation of the Emax and Cstatic pharmacodynamic parameters
(AAC 2006; 50: 841−51).
Results: The table shows that while TOB and DOR were cidal in
broth (Emax≈−3 log CFU), their intracellular maximal efﬁcacy was
markedly reduced (less negative Emax) towards intracell. Pa. LVX was
also affected but to a lesser extent. CST, bacteriostatic against extracell.
bacteria, also showed decreased intracellular efﬁcacy. In addition, CST
and TOB showed a 6 to 9 fold decrease of relative potency (higher
Cstatic) when comparing intracell. and extracell. bacteria.
Conclusions: The model shows that, as for other intracell. bacteria,
antibiotics are considerably less active and, for 2 classes, less potent,
against intracellular forms compared to bacteria in broth, irrespective of
their mode of action. This may contribute to the difﬁculty of eradicating
P. aeruginosa in vivo.
Antibiotic MICa Extracellular Intracellular
(mg/L) Emaxb Cstatic
c R2 Emaxb Cstatic
c R2
Tobramycin (TOB) 0.5 −2.85±0.31 0.86 0.92 −1.22±0.22 7.93 0.95
Doripenem (DOR) 0.5 −3.19±0.28 0.30 0.86 −0.21±0.2 0.59 0.61
Levoﬂoxacin (LVX) 1−2 −3.17±0.36 0.15 0.69 −2.40±0.21 0.38 0.86
Colistin (CST) 2 −1.52±0.11 3.34 0.99 −0.20±0.17 18.84 0.93
aDetermined by microdilution in MH broth; bmaximum decrease in log CFU compared to initial inoculum for
an inﬁnitely high concentration in antibiotic; cconcentration (in mg/L) resulting in no apparent bacterial growth
(number of CFU identical to the original inoculum), as determined by graphical intrapolation.
O519 Population pharmacokinetics and pharmacokinetic–
pharmacodynamic metrics for delaﬂoxacin
C. Rubino, E. Burak, S. Bhavnani, A. Forrest, P. Ambrose ° (Latham,
New Haven, US)
Objectives: To develop a population pharmacokinetic (PK) model for
delaﬂoxacin (DFX) and use that model to estimate pharmacokinetic–
pharmacodynamic (PK-PD) indices in Phase 2 patients treated for
complicated skin and skin structure infections (cSSSI).
Methods: Data from 3 Phase 1 studies (1 single dose, two multiple
dose) and 1 Phase 2, cSSSI study were pooled to develop a population
pharmacokinetic model. All doses were administered by IV infusion;
doses ranged from 50 to 600mg. The Phase 2 study employed doses
of 300 or 450mg BID. Intensive PK sampling was employed in all
Phase 1 studies while Phase 2 patients contributed 4−5 samples at
steady-state over one dosing interval. Population PK modeling was
performed using Monte Carlo Parametric Expectation Maximization as
implemented in S-ADAPT 1.5.6. Two and 3 compartment models were
explored using linear and/or nonlinear elimination. Steady-state AUC
and Cmax estimates were calculated using individual PK parameter
estimates for Phase 2 patients and indexed to observed pathogen MICs
to calculate PK-PD indices. Previous animal studies have indicated that
free-drug AUC:MIC ratios (fAUC:MIC) of 9.3 and 14.3 are associated
with net bacterial stasis and 1-log10 CFU reduction, respectively, for
Staphylococcus aureus.
Results: The ﬁnal analysis dataset included 103 subjects (86 from
Phase 1, 17 from Phase 2) and 2273 plasma concentrations. A 2
compartment model with a mix of linear and nonlinear elimination pro-
vided the most robust ﬁt to the data (r2 = 0.965, observed=1.02*ﬁtted −
0.032). All parameters were estimated with excellent precision; inter-
individual variability in the parameters that deﬁne clearance (linear
clearance, intrinsic clearance, and Michaelis-Menten constant) ranged
from 24−70%. Twelve patients had requisite MIC data to calculate a
PK-PD index, all fAUCss:MIC estimates were above 100 (range: 108–
3754); all 12 patients were classiﬁed as clinical and microbiological
cures. The median (min − max) fCmax:MIC ratio was 191 (18.8–565).
Seven patients had MRSA as their primary pathogen; MIC values were
universally low (0.004–0.06).
Conclusions: Development of a population PK model allowed for the
estimation of drug exposure in a Phase 2 cSSSI study using relatively
sparse PK sampling. Based on PK-PD indices from the Phase 2 study,
300 and 450mg (BID) clinical doses were appropriate for the treatment
of cSSSI. Results also support coverage of MIC values up to 1.0 mcg/mL.
O520 Pharmacokinetics and penetration of ciproﬂoxacin into
bronchial secretions of critically ill patients with chronic
obstructive pulmonary disease
P. Kontou °, K. Chatzika, G. Pitsiou, A. Boutou, P. Argyropoulou,
I. Kioumis (Thessaloniki, GR)
Objective: Ciproﬂoxacin (CIP) is one of the antibiotics of choice for
the treatment of severe exacerbations of Chronic Obstructive Pulmonary
Disease (COPD). Antibiotic penetration into the site of infection is
critical for obtaining an optimal clinical outcome. Since in COPD
patients the infection develops within the airway lumen, it is important
to know the drug concentrations that are achieved in bronchial secretions
(BS). The purpose of this study was to evaluate CIP’s pharmacokinetic
(PK) proﬁle in plasma and penetration into BS of mechanically ventilated
COPD patients, when administered at the currently recommended dose
of 1200mg per day.
Methods: Ninenteen critically ill COPD patients received a 1-hour
infusion of 400mg CIP q8 h. They all had a respiratory infection as
well as risk factors for Ps. aeruginosa and they were intubated. Serial
blood and BS samples were obtained at steady state. Concentrations were
determined by a validated HPLC assay. Penetration ratio was calculated
by dividing the 24 h area under the curve (AUC0−24) of BS by the
AUC0−24 of plasma. The pharmacodynamic (PD) parameters for CIP
were also calculated.
Results: Mean±SD values for volume of distribution, clearance, half-
life and AUC0→24 were 174.31±85.42 L, 27.32±9.53 L/h, 5.5±2.34 h
and 47.58±18.07, respectively. The mean peak (Cmax) and trough levels
in plasma were 5.32±1.76 and 1.05±0.59mg/L respectively. In BS,
a mean Cmax of 3.11±1.27mg/L was achieved in 3±1.03 hours and
the penetration ratio was 1.17±0.61. Thirteen patients demonstrated
penetration equal to or even more than 100%. The PD target of
AUC0→24/MIC 125 in plasma, that has been shown to be predictive
of efﬁcacy for Gram-negative infections, was attained in all patients
and in the majority of them (74%) at MICs of 0.125 and 0.25 mg/ml
respectively but in only 3 patients and in none at higher MICs (0.5 and
1 mg/ml). Slightly better results were obtained for the PD threshold of
Cmax/MIC 10.
Conclusions: CIP exhibits excellent penetration into BS. There is
wide interindividual variability in its PK parameters in critically ill
COPD patients and inadequate PD exposure against bacteria with
MICs 0.5 mg/ml. Our data conﬁrm the need for combination therapy
against pathogens with high MICs such as Ps. aeruginosa, as well
as the institution of therapeutic drug monitoring for individualizing
antimicrobial dosing in order to optimize the efﬁcacy of antibiotic
therapy in the ICU.
Bioﬁlm infections − diagnostic, prophylactic
and therapeutic methods
S521 Diagnosis of bioﬁlm infections
T. Bjarnsholt ° (Copenhagen, DK)
The initial problem or challenge with all infections is to identify the
infecting organisms and the focus of the infection. This is usually not
a problem for acute infections since the bacteria are readily obtained
by swapping or sampling the infected area. For chronic infections it is
usually more problematic. An exception is cystic ﬁbrosis (CF) in which
the easy accessible purulent sputum coughed up by the patients on a
regular basis harbor the bacteria. For the other chronic infections routine
sampling has been either using a swab, a scrape or a biopsy, however all
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might fail to sample the bacteria. In a chronic wound the swab will only
collect bacteria on the surface not the bacteria embedded in the wound
bed. On the other hand, since the bacteria are very heterogeneously
distributed chances are that a biopsy fails to contain any bacteria. Also
for implant and catheter related infection diagnosing the bacteria prove
difﬁcult. Five to 10 years ago the bacteria on these surfaces and bioﬁlm
in general were considered unculturable. Here the problem is surface
adherence, the bacteria simply attach extremely well to the surface of
the foreign bodies. It is not that they are unculturable, they have to be
released from the surface, and vigorously vortexing or even mechanical
scraping is not enough. The implant or catheter has to be treated with
ultra sound (sonication) to release the bacteria.
The problems of diagnosing the bacteria in these chronic infections are
far from solved. Today bacteria can be detected by: culturing, PCR,
microscopy or diagnostic imaging. Each method has its advantages and
limitations. For culturing, the problem is to collect the bacteria, either
next to the surface, which is sampled, or from the catheter or implant.
PCR will detect even tiny amounts of available DNA or RNA available
in the sample. Additionally, just because a bacterium is present does
not necessarily indicate that it contributes to the pathogenesis of the
infection. Microscopy such as Gram-staining or ﬂuorescence in situ
hybridization (FISH) enables direct visualization of the infecting bacteria
and the surrounding tissue and inﬂammatory cells. Again the bacteria
need to be present in the collected sample, which means many biopsies
need to be analyzed for a correct diagnostics of e.g. a wound. On the
other hand if only a few bacteria are present they might be very hard
and statistically impossible to observe using traditional staining such as
Gram.
S523 Antibiotic therapy of bioﬁlm-forming group A streptococcal
infections
L. Baldassarri ° (Rome, IT)
Streptococcus pyogenes (group A streptococcus, GAS) is responsible
for a diverse range of clinical manifestations, from mild skin/soft
tissue infections and pharyngitis to more serious manifestations, such
as bacteremia, cellulitis, puerperal sepsis, meningitis, pneumonia, and
necrotizing fasciitis.
The drug of choice for streptococcal infections treatment still remains
penicillin. In fact, the ability of penicillin and its related antibiotics
(e.g., amoxicillin) to kill group A streptococci has not changed in
more than 50 years and, to date, there has never been a report on a
group A streptococcus resistant to this class of antibiotics. On the other
hand, macrolide resistance has been showing an increasing trend, with
resistance rates which vary considerably in different countries, reaching
up to almost 30% in some part of Europe.
Effective treatment is of utmost importance, even for streptococcal
pharyngitis, as it is primarily aimed at preventing non-suppurative and
suppurative complications and decreasing infectivity.
Even if not frequently, S. pyogenes infections may fail to respond to
antibiotic therapy leading to persistent throat carriage and recurrent
infections. Such failures cannot always be explained with the occurrence
of antibiotic resistance determinants. It was ﬁrst suggested that
erythromycin-resistant S. pyogenes may escape antimicrobial treatment
and the host immune response through invasion of epithelial cells. Later,
as GAS have recently been shown to be able to form bioﬁlm, and being
such character known to provide organisms with an improved antibiotic
resistance besides supporting colonization and persistence, bioﬁlm has
been suggested as possibly responsible for unexplained treatment failures
and recurrences due to susceptible microorganisms.
Preliminary data have shown that bioﬁlm may be produced, and/or up-
regulated, in S. pyogenes in response to either antibiotic treatment, other
therapeutic molecules or environmental stimuli. In particular, subMIC
antibiotic concentrations appear to stimulate bioﬁlm formation; such
phenomenon is being observed with increasing frequency for a number
of microorganisms, both for bioﬁlm and other virulence factors. The
latest ﬁndings on what it is known on bioﬁlm produced by S. pyogenes,
its possible role in the pathogenesis of streptococcal infections, and on
the interactions between antibiotics and other therapeutic molecules and
streptococcal bioﬁlm, will be examined.
S524 Diagnosis and treatment of Aspergillus bioﬁlms
C. Williams ° (Glasgow, UK)
Aspergillus fumigatus causes infections in both immunocompromised
hosts and patients with chronic lung infections.
The initial establishment of A. fumigatus infections involves the
germination of conidia and subsequent hyphal invasion of the lung
tissues. Histology and microscopic examination of bronchopulmonary
lavage samples reveals the presence of numerous A. fumigatus hyphae
in the form of a complex mesh like structure, similar to other fungal
bioﬁlms.
We have developed an in vitro model of an Aspergilus fumigatus bioﬁlm.
This model possesses the classical elements of bioﬁlm growth, namely
multicellularity, matrix production and sessile resistance and shows has
distinct developmental phases both genotypically and phenotypically.
I will discuss the in vitro antifungal activity of voriconazole,
amphotericin B and caspofungin and how this model may relate to the
use of antifungals in the clinic. Also how a better understanding of the
biology of Aspergillus fumigatus in vitro may lead to a different approach
to diagnosis of invasive fungal infection.
Challenges and solutions for determining
pharmacokinetics of antimicrobials in the
human body
S525 Imaging and microdosing − how do they ﬁt for antimicrobial
agents?
O. Langer ° (Vienna, AT)
Most drugs exert their effects not within the plasma compartment, but
in deﬁned target tissues into which drugs have to distribute from the
central compartment. Unfortunately, a complete and lasting equilibration
between blood and tissue cannot always be taken for granted. Drug
distribution processes may be characterized by a high intertissue- and
intersubject variability and target site drug levels may substantially differ
from corresponding plasma levels. Suboptimal target site concentrations
may have important clinical implications, as it is a potential explanation
for therapeutic failures. In particular for antimicrobial agents knowledge
of drug tissue distribution is of primal importance as tissue drug
exposure has been shown to be directly related to outcome of therapy.
Therefore, determination of drug tissue penetration plays an important
role in antimicrobial drug development. Positron emission tomography
(PET) is nuclear imaging method, which can be used to study the
tissue distribution of drugs labeled with positron-emitting radionuclides,
such as carbon-11 or ﬂuorine-18, non-invasively. These types of studies
have been termed PET-microdosing studies, as the amount of drug
administered in a PET study is usually less than 100 microgram. Due to
low administered drug doses, the potential toxicological risk to human
subjects is very limited. Consequently regulatory authorities require
reduced preclinical safety testing as compared to conventional phase 1
studies. In the present talk, recent applications of PET-microdosing in
antimicrobial drug development will be reviewed.
S527 PK modelling: obtaining PK proﬁles despite sparse sampling
J.B. Bulitta °, A. Bingo¨lbali, C. Landersdorfer (Albany, US)
Objectives: Tissue penetration studies pose a signiﬁcant challenge
for pharmacokinetic/pharmacodynamic (PK/PD) modelling, especially
if only one tissue sample can be obtained per patient. We sought
to systematically evaluate the ability of various optimized and non-
optimized clinical trial designs to determine the rate and extent of tissue
penetration and their between subject variability (BSV).
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Methods: Monte Carlo simulations with a 2-compartment model
were performed in Berkeley Madonna to simulate plasma and tissue
concentrations of 1000 patients for intravenous moxiﬂoxacin as
an example drug. Simulation scenario A assumed that the tissue
concentration is proportional to the concentration in the peripheral
compartment. For scenario B, rate and extent of tissue penetration
were estimated and tissue volume ﬁxed to a small value. Population
optimal sampling times were determined in WinPOPT (V1.2). For 12
sampling schedules, 100 datasets of 48 patients were drawn randomly
and analyzed by the MC-PEM algorithm in S-ADAPT V1.56 using the
true model (2400 population PK analyses in total). Bias and precision of
mean population PK parameters and variances representing BSV were
calculated.
Results: Except for designs that sampled both plasma and tissue at the
same time in all patients, in scenario A bias was <8% and precision
<19% for population means and bias was generally <25% and precision
<30% for BSV for all PK parameters. For scenario B and designs with
5 optimized plasma sampling times and one tissue sample per patient:
(1) Designs with all tissue samples at the same time showed bias up to
48% for extent of tissue penetration and up to 78% for rate of tissue
penetration. (2) A design with random tissue sampling times had bias
<7% and precision <21% for all population means. (3) A design with
four groups (each: n = 12) of patients each sampled at one optimized
tissue sampling time achieved bias <3% and precision <13% for all
population means and bias <18% and precision <33% for all BSV
estimates.
Conclusions: Tissue samples should be obtained at multiple optimized
time points to determine the rate and extent of penetration, even if only
one tissue sample per patient can be obtained. Designs with serial plasma
samples at population optimal times were beneﬁcial. Designs with one
plasma and one tissue sample per patient all at the same time performed
poorly and beneﬁtted from a full Bayesian approach for PK analysis.
S528 Role of pharmacokinetics in early stages of antimicrobial
development
U. Theuretzbacher ° (Vienna, AT)
The importance of diligent pharmacokinetic (PK) proﬁling in the early
drug research and development stages to reduce late attrition rate has
been increasingly recognized over the last decade and major advances
have been made. Based on the results of ADME screening (absorption,
distribution, metabolism, and excretion) during the lead optimization
phase, relevant predictive information on the pharmacokinetic behavior
of a preclinical candidate is typically obtained in two or three animal
species before administration to humans. The preclinical PK assessment
provides the input for in vitro and in vivo PK/PD (pharmacodynamic)
models that evaluate exposure-effect relationships. Such PK/PD models
are powerful tools for dose selection for the clinical phases of drug
development. If phase 1 PK data are available, population based PK/PD
models support effectively dose selection for late stage clinical trials.
Moreover, a PK/PD guided approach can provide decision support for
susceptibility breakpoints as well as strategies to mitigate resistance
development. Recent late stage clinical failures illustrate the importance
of understanding the impact of PKs such as protein binding and
concentrations at infection sites and incorporating them early into
adequate PK/PD evaluations.
Management of infections caused by viruses
in haematopoietic stem cell recipients
S531 Epstein–Barr virus infections
J.M. Middeldorp ° (Amsterdam, NL)
Epstein–Barr virus (EBV) infection in immune suppressed transplant
recipients is a frequent and potential life-threatening complication.
EBV causes B-cell lymphoproliferative disorders, collectively named
PTLD, which may lead to malignant lymphoma if left untreated. The
incidence, clinical appearance and severity of PTLD may be quite
variable, requiring appropriate risk-stratiﬁcation at onset and accurate
and standardized diagnostic monitoring approaches in the post-transplant
period aiming at early identiﬁcation of EBV involvement and distinction
from rejection and other (infectious) complications.
The biology and pathogenesis underlying PTLD in solid organ (SOT)
and stem cell transplant (SCT) recipients has different features, with
implications for diagnosis and treatment. Primary infection in the SOT
and nearly all (re)active EBV infections in SCT pose the highest risk
for fatal complications. A distinction should be made between early and
late-onset PTLD, the former being directly EBV driven and frequently
reversible by simple therapeutic intervention. The latter should be seen as
a consequence of misdiagnosed early EBV-driven B-cell ampliﬁcation,
allowing additional genetic defects to accumulate, thereby increasing the
malignant phenotype, which frequently require more severe intervention
strategies, including chemotherapy.
Early PTLD can be recognized by dynamic increases of EBV-DNA load
in blood over relatively short time intervals. In SOT this EBV load
is usually cell associated, whereas in SCT both cell and plasma DNA
loads are observed. Whole blood may be a preferred well standardized
sample for diagnostic monitoring. Dependent on the type of transplant,
therapeutic intervention may vary from a (mild-moderate) reduction
of immunosuppressive treatment (IST), via use of Rituximab (rtX) to
infusion of ex vivo activated EBV-reactive T-cells. A persistent decrease
of EBV-DNA load may be taken as a sign of therapeutic efﬁcacy, and
monitoring EBV-reactive T-cells by tetramer FACS or ELISPOT tests
may provide information on patient’s immune capacity to conquer EBV-
driven B-cell proliferation and restore EBV latency on the long term.
Treatment failure is indicated by persistent increases of EBV-DNA over
time, and should be taken as sign for more drastic intervention.
During early PTLD EBV-infected cells frequently disseminate via the
circulation, and thus becomes easily detectable, whereas late PTLD may
be conﬁned to tissue with little circulating cells. EBV transcription
proﬁling has revealed differences EBV gene expression in biopsy
material and circulating EBV-carrying cells in patients with early
PTLD, suggesting transcription regulation in affected lymphoid tissues.
Furthermore analysis of EBV gene expression in PTLD lesions at
the single cell level, reveals heterogeneous EBV gene expression,
reﬂecting more complex underlying pathogenic events rather than simple
proliferation of latency-III (growth program) expressing B-cells.
Infrequent measuring of EBV DNA loads is not considered a proper
diagnostic approach, because mere EBV DNA levels may vary between
patients. These generally have no clinical implication when being stable
over time. It is suggested that frequent (weekly) measurement of changes
in EBV-DNA load at early times post-transplant using sensitive and
standardized techniques, coupled to appropriate and timely EBV load-
guided therapeutic intervention may reduce and even prevent PTLD in
the transplant setting.
S532 Adenovirus infections
A. Heim ° (Hanover, DE)
Human Adenoviruses (HAdV) are a highly genetically divergent group
of DNA viruses consisting of seven species with 54 types. A few of
these HAdV types (1, 2, 5 and 31) are clearly associated with infections
of immunosuppressed patients as for example haematopoietic stem cell
recipients. These HAdV types are not typical opportunistic agents but
also cause less severe diseases in immunocompetent patients.
HAdV can persist for several months to years after an acute infection
even in immunocompetent hosts and are more prevalent in children
than in adults. Complications due to HAdV in haematopoetic stem
cell recipients may originate from HAdV persistence and de novo
infections. Due to HAdV persistence, diagnosis of HAdV disease
cannot be made by mere detection of HAdV DNA. In case of organ
related HAdV diseases, diagnosis is feasible by HAdV detection at the
putative infection site, e.g. in case of cystitis by HAdV detection in
urine. HAdV infection can also lead to potentially fatal disseminated
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HAdV disease. Main risk factors are young age, lymphopenia, T cell
depletion and high dosage of immunosuppressive drugs. Diagnosis of
the disseminated HAdV disease has been simpliﬁed by HAdV load
testing in peripheral blood samples using quantitative HAdV PCR.
High virus loads (>1e6 genome equivalents/ml) were clearly associated
with disseminated disease whereas low virus loads (<1e4 genome
equivalents/ml) can be observed in case of HAdV latency. However,
a precise threshold HAdV load value has not yet been determined.
Disseminated disease may be predicted in case of rapidly rising HAdV
loads in blood.
Pathophysiology of HAdV disseminated disease includes massive virus
replication in affected organs as for example the liver which may
be infected by interaction of HAdV capsids with clotting factor X.
Furthermore binding of HAdV capsids to platelets, formation of immune
complexes with preformed HAdV speciﬁc antibodies as well as induction
of cytokines may contribute to the pathophysiology of disseminated
HAdV disease.
An antiviral treatment for HAdV disease has not yet been established.
Cidofovir may have beneﬁcial effects if applicated early but may
fail if applicated in case of very high virus loads. HAdV speciﬁc
T-lymphocytes seem to be a promising therapeutic approach because risk
of disseminated HAdV disease is clearly associated with lymphopenia.
However, HAdV speciﬁc T lymphocytes must be prepared before onset
of disease in order to be available in time.
What do we expect from MALDI-TOF?
O533 Elaborate MALDI-TOF MS-based identiﬁcation of
micro-organisms: the Saramis concept
M. Welker °, M. Erhard (Potsdam, DE)
Identiﬁcation of microbial isolates by MALDI-TOF MS of whole cells
gains more and more acceptance in clinical microbiology. The reliability
of this technology depends largely on the reference database and the
algorithm for spectral comparison. Most simply, a sample’s spectrum
is directly compared to spectra of reference strains and as a result
a rated list of matches is provided. A more elaborate approach is
realized in the (Spectral Archive and Microbial Identiﬁcation System
(SARAMIS). SARAMIS uses a comprehensive database of mass spectral
data of reference strains for automated identiﬁcation. Two types of
spectral data are contained in the database: so called SuperSpectra for
fully automated ﬁrst-line identiﬁcation (including result transmission)
and Reference Spectra for semi-automated second-line identiﬁcation.
The concept of SuperSpectra has been developed in consideration
of the natural, intra-speciﬁc diversity encountered in all microbial
species. This diversity is also reﬂected in mass spectral ﬁngerprints
of individual isolates as variations in peak patterns, which complicates
the selection of appropriate reference data. To compute SuperSpectra,
spectral ﬁngerprints of a number of 10−20 isolates of a species are
searched for conserved mass signals that are summarized in a consensus
spectrum. In a second step, each mass in the consensus spectrum is
compared to the entire reference database to establish its speciﬁcity at
different taxonomic levels. By doing so, mass signals can be selected
that are speciﬁc at a desired taxonomic level, e.g., species-speciﬁc. By
excluding masses from the consensus spectra that are speciﬁc only at
higher taxonomic levels, the pattern of the remaining masses is highly
speciﬁc. This makes random matches highly improbable, practically
excluding false identiﬁcations. The SARAMIS database contains at
present 2700 SuperSpectra, representing 900 microbial species. Since
SuperSpectra by deﬁnition represent typical isolates of a species (not to
be confused with type strains), a certain percentage of isolates of a given
species will not be captured in automated routine analysis. In this case,
the second-line identiﬁcation starts that applies a direct comparison to all
35,000+ Reference Spectra in the database (representing 1500 species).
By this two-step approach basically all clinically, most veterinary and,
increasingly, environmental isolates can be reliably identiﬁed by a largely
automated procedure.
O534 MALDI-TOF MS for identiﬁcation of routine bacterial
isolates in a clinical microbiological laboratory
T. Jensen °, B. Gahrn-Hansen (Odense, DK)
Objectives: To compare identiﬁcation of routine bacterial isolates using
the SARAMIS identiﬁcation system and conventional methods.
Methods: Consecutive bacterial isolates from urine- and bloodcul-
tures were identiﬁed using conventional biochemical methods or
VITEK II. All isolates were subsequently identiﬁed using MALDI-TOF
(AXIMA@SARAMIS®). Discrepant isolates will be further identiﬁed
by means of 16S RNA sequencing.
Results: A total of 3,695 isolates (1,095 from blood, 2,600 from urine)
were included. 71.8% of the isolates showed fully agreement on species-
level, for another 9.7% fully agreement on genus-level was achieved.
15.7% of the isolates could not be identiﬁed by MALDI-TOF using the
95% identiﬁcation-score.
In 2.8% of the isolates, the two methods gave different identiﬁcation.
These isolates are currently subject to further characterization by 16S
RNA sequencing.
Conclusion: MALDI-TOF (AXIMA@SARAMIS®) gives a fast and
reliable identiﬁcation of commonly encountered bacterial isolates
in a clinical microbiology laboratory but has certain limitations.
Enterobacteriaceae (apart from Shigella), Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, Haemophilus inﬂuenza, Staphylococcus,
Enterococcus faecalis and E. faecium could usually be identﬁed to
species level. Anaerobes and streptococci were often unidentiﬁed.
O535 Fundamental improved sample preparation technique for
direct and fast analysis of positive blood cultures
T. Maier, B. Wegemann, S. Schubert °, M. Kostrzewa (Bremen, Munich,
DE)
Objectives: Automated blood cultivation of patients with suspicion
for sepsis is a routine clinical approach. Fast and accurate species
identiﬁcation of microorganisms after signalling of growth is of
fundamental interest. Currently, the identiﬁcation takes up to two
days because of the necessity for sub-cultivation and biochemical
identiﬁcation. The presented simple protocol has the potential to shorten
the identiﬁcation time to minutes.
Methods: Blood cultures spiked with bacteria or yeast were used for
method establishment, inoculated blood cultures and routine samples to
optimize and validate the protocol. 1ml of a blood culture was mixed
with 200ml of lysis solution followed by vortexing and centrifugation.
Thereby, blood cells were disrupted but bacteria and yeast survived.
Supernatant was removed and the pellet carefully suspended in wash
solution. After centrifugation supernatant was removed and bacteria
from the pellet were transferred to a MALDI target directly or after a
short extraction procedure. Species ID was achieved by measurement
in a MALDI-TOF MS mass spectrometer followed by analysis with
the MALDI Biotyper software. The method was optimized by varying
volumes and ratios of blood culture liquid and lysis solution.
Results: Positive blood cultures showed an average cell density of
about 107 cfu/ml and a high number of blood cells. The presented
protocol was able to remove blood cells extensively without signiﬁcant
loss of microorganisms. Therefore, resulting MALDI-TOF spectra
were of high quality. Different bacterial species (enterobacteria,
Gram negative non-fermenting bacteria, staphylococci, enterococci,
streptococci, Haemophilus sp.) could be identiﬁed with the procedure,
reliably. Also yeasts which could not be detected with previously
published protocols were identiﬁed. In some cases an identiﬁcation was
possible even 1−2 h before blood cultures were ﬂagged positive by the
automate, showing the high sensitivity of the method. Mixed cultures in
most cases lead to non-identiﬁcation or observation of only one species.
Work on bioinformatic algorithms will improve this.
Conclusion: The new protocol for species identiﬁcation from positive
blood cultures could be demonstrated as a very fast and accurate
alternative to classical methods. Identiﬁcation time is shortened from
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days to minutes for the majority of samples, thereby enabling quicker
adoption of antibiotic therapy.
O536 MALDI-TOF MS for direct bacterial identiﬁcation from
positive blood culture pellets
G. Prod’hom °, A. Bizzini, C. Durussel, J. Bille, G. Greub (Lausanne, CH)
Objectives: Blood cultures are the best approach to establish the
etiology of bloodstream infections. Rapid identiﬁcation of etiological
agent of such severe infections is pivotal to guide antimicrobial
therapy. The matrix-assisted laser desorption/ionization time-of-ﬂight
mass spectrometry (MALDI-TOF MS) allows the identiﬁcation at the
species level in few minutes of bacteria by measuring molecular masses
of proteins from whole bacterial extracts. We applied a simple procedure
for lysing erythrocytes from positive blood cultures and prepared a
bacterial pellet for MALDI-TOF MS analysis.
Methods: Pellets from positive blood culture vials detected by Bactec
9240 (Becton Dickinson) were prepared by using an ammonium chloride
lysing solution and centrifugation steps. Pellets were then analyzed by
MALDI-TOF either by direct deposition on the target plate or after a
formic acid:acetonitrile extraction step.
Mass spectra were acquired using the Microﬂex MALDI-TOF MS
(Bruker Daltonics). The identiﬁcation was considered as valid at the
species level when the score value was >2, as valid at the genus level
when the score value was >1.7 and <2 and as not valid when the score
was <1.7. The identiﬁcations obtained with MALDI-TOF MS analysis
were compared with biochemical identiﬁcation.
Results: 122 monobacterial positive blood vials from 76 patients
were analyzed. 96 (78.7%) bacterial identiﬁcations were obtained by
MALDI-TOF MS analysis, of which 69 (56.6% of 122) exhibited a
score value >2 and 27 (22.1%) a score value >1.7 and <2. Regardless
of the score value, 95 (98.95%) of the 96 bacterial identiﬁcation
obtained with MALDI-TOF MS were correct at the species level and
1 correct at the genus level only. In 26 (21.3%) of cases, no reliable
identiﬁcation was obtained (score value <1.7). 21/26 bacteria (80.8%)
were Gram positive, mainly streptococci (n = 13) and coagulase-negative
staphylococci (n = 5). Most unidentiﬁed streptococci were Streptococcus
pneumoniae. Among the 5 Gram negative bacteria with a score <1.7,
4 were of encapsulated species (2 Klebsiella pneumoniae and 2
Haemophilus inﬂuenzae).
Conclusion: The use of an ammonium chloride-driven hemolysis before
analyzing directly positive blood cultures by MALDI-TOF MS is a
very promising new method allowing fast, accurate and inexpensive
identiﬁcation of the etiological agents of life-threatening bloodstream
infections.
O537 Direct identiﬁcation and rapid antimicrobial susceptibility
testing of bacteria from positive blood culture bottles by
using MALDI-TOF MS and Phoenix rapid AST cards
T. Adam °, C. Gro¨ger, U. Go¨bel (Berlin, DE)
Objectives: Early and appropriate antimicrobial therapy critically
determines the outcome of bloodstream infections. Rapid identiﬁcation
(ID) and antimicrobial susceptibility testing (AST) is, hence, mandatory
to adjust empirical antimicrobial therapy instituted during the ﬁrst
two hours after onset of symptoms. To reduce the turnaround time
(TAT) aliquots from positive blood culture bottles (BC) were subjected
to differential centrifugation and gel separation using BD Vacutainer
SST II tubes. The preparations were used for direct identiﬁcation by
MALDI-TOF mass spectrometry (MS). In addition, we are optimizing a
protocol for rapid AST using the Phoenix BD system.
Methods: Blood cultures were drawn from septic patients and incubated
using the Bactec BD blood culture device. In the rapid arm aliquots from
consecutive positive BC bottles were processed for direct identiﬁcation
by Mass Spectrometry using the MALDI Biotyper (Bruker) system.
Controls were processed according to standard procedures, inoculation
of solid media and subsequent ID and AST using the MALDI Biotyper
or the Vitek 2 system (bioMe´rieux), respectively. In case of discrepant
ID results isolates were subjected to 16S rRNA gene sequencing..
Results: So far, we have tested 115 positive BCs. Direct MALDI
TOF analysis resulted in 76 (66%) species identiﬁcations showing no
discrepant results when compared with identiﬁcation of colonies grown
from these BCs. In 9 BCs more than 1 isolate could be grown on
plates. Thus, in 73% of monoinfectious BCs MALDI TOF can reveal
the etiologic agent in less than 1 h.
Conclusion: As compared to conventional procedures the combined use
of MALDI-TOF MS and rapid AST may signiﬁcantly reduce the TAT
in diagnosis of blood stream infections..
O538 Speeding up identiﬁcation of bacteria from urine by the use
of an Alifax HB&L Uroquattro incubator followed by Maldi
Biotyper identiﬁcation
M. Kostrzewa, C. Boogen, J. Maier, U. Weller ° (Bremen, Cologne, DE)
Objectives: Direct identiﬁcation of bacteria from infected urine by
the MALDI-Biotyper (MBT) has been shown previously. To enable
quantiﬁcation as well as identiﬁcation, which is necessary for routine
diagnostic we have tested the combination of an automated quantiﬁcation
system, the Uroquattro (ALIFAX HB&L), with the MALDI-TOF
workﬂow.
Methods: For this proof of concept study, 161 urine samples from
routine were analysed in parallel.
For the novel combined workﬂow, a 500 ml aliquot was transferred
into a 2ml HB&L tube with nutrient broth and stirrer, placed into the
Uroquattro instrument for 3 h at 37ºC and the CFU value was read.
Turbidity of the vials is monitored and bacterial count is calculated.
After incubation, 500 ml aliquots from the positive vials were pipetted
onto a 100 ml Ficoll-Paque Plus cushion and centrifuged (5 min at 15000
g in a 1.5ml Eppendorf cup). Supernatant was discarded and part of the
pellet transferred onto a MALDI target, air dried, overlayed with matrix
solution (HCCA), again air dried and subjected to identiﬁcation by mass
spectrometry using the MBT system. This approach was compared to our
standard workﬂow: plating the urine on 2 Petri dishes in a quantitative
way, MBT identiﬁcation of colonies after over night incubation at 37ºC.
Results: A bacterial count above 10E4 CFU was obtained for 77 of
the 161 samples. These patients where considered to have a bacterial
infection. The bacterial count was identical to a large extend with
both methods. However, MBT identiﬁcation was only possible in 63
of the samples incubated in the HB&L. Here, the results matched those
of the standard protocol. This was due to the presence of more than
one pathogen (as shown by the standard workup) which the current
identiﬁcation software of the MBT can not resolve.
Conclusion: This protocol enables reliable bacterial identiﬁcation
together with a bacterial count in few more than 3 hours in cases
of mono-bacterial infection using the standard protocol of the HB&L.
Ongoing improvement to the MBT identiﬁcation algorithms will resolve
the problem of poly-bacterial infections. Further extension of this
approach to usually sterile body ﬂuids, tracheal secretions and pleural
aspirates also here may lead to a dramatic reduction in turnaround time
of microbiological labs for identiﬁcation and subsequent AST-testing.
O539 Standardized method for fungal identiﬁcation using liquid
culturing and MALDI-TOF MS proﬁling
T. Maier, V. Bo¨ttcher, M. Kostrzewa ° (Bremen, DE)
Objectives: MALDI-TOF ﬁngerprint analysis became a valuable tool
for microorganism identiﬁcation and classiﬁcation, recently. While for
bacteria and yeasts simple and robust approaches for sample preparation
have been reported, leading to reproducible results with low impact of
cultivation conditions and growth state, the situation for ﬁlamentous
fungi keeps more complicated. In particular, sample preparation of
molds with rigid cell walls is more challenging and the ﬁngerprint
spectra derived from spores and mycel show signiﬁcant differences.
Also ﬁngerprint spectra seem to be dependent on cultivation media.
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We present a novel approach for sample preparation of fungi prior
to MALDI-TOF MS improving reproducibility and quality of spectra,
signiﬁcantly.
Methods: Fungal species (e.g. Aspergillus spp., Fusarium spp.)
harvested from solid media were grown over night in liquid medium.
Subsequently, cell material was harvested by centrifugation, and washed
with water. The pellet was dried well and extracted using 35% formic
acid/50% acetonitrile. 1ml of the extract was spotted onto a MALDI
target, dried on air, and overlaid with HCCA matrix. Mass spectra
were acquired in the linear mode, mass range 2000 to 20000 Da,
using a microﬂex MALDI-TOF mass spectrometer (Bruker Daltonik
GmbH, Bremen). Spectra were analysed using the ﬂexAnalysis software,
reference libraries were created and bioinformatic analyses were
performed with the MALDI Biotyper 2.0 software (Bruker Daltonik).
Results: Culture in liquid medium has lead to mycelia without spores
and thereby largely homogenous cell material. These samples facilitated
a successful protein extraction by a simple, short standardised method.
Mass spectra generated based on the novel sample preparation method
were reproducible and contained many characteristic peaks, thereby
leading to a signiﬁcantly improved identiﬁcation security. Further, the
higher quality of spectra increased the differentiation power of the
method and could highlight subspecies differences. A core database
of 50 ﬁlamentous species has been established and used for ﬁrst
comparative studies. Technical and biological replicates could be
identiﬁed successfully as well as isolates not included in the database.
Reproducibility of results obtained with different mass spectrometers
could be demonstrated.
Conclusions: The presented approach may lead to signiﬁcant improve-
ment of fungal identiﬁcation in clinical or other routine applications.
O540 Diagnosing fungal infections by mass spectrometry
J. Nedved, M. Kuzma, M. Strohalm, K. Lemr, M. Sulc, M. Volny, P. Novak,
J. Pol, V. Havlicek °, E. Barreto-Bergter, M. Hajduch, J.M. Holopainen
(Prague, CZ; Rio de Janeiro, BR; Olomouc, CZ; Helsinki, FI)
Objectives and Method: Mass spectrometry is presented as a modern
analytical tool for fungal strain typing and diagnosing fungal infections.
Results: Qualitative and quantitative proteomics approaches are docu-
mented on various Aspergillus strains: virulence protein factors present
on fungal spores are identiﬁed by peptide mapping, peptide- and de
novo-sequencing. Quantitative proteomics is addressed by NOVA-Q
in house-developed software improving the precision of results in
samples labeled by SILAC. Metabonomics approach is illustrated by
the detection of minor macrolide antibiotics produced by Streptomyces
strains. Peptidomics is represented by tracking non-ribosomal cyclic
peptides and depsipeptides produced by Beauveria, Paecilomyces and
Pseudallescheria genera. Peptide proﬁles are used as chemotaxonomic
tools. Patented unique non-ribosomal lasso-peptide structures are
reported as extremely speciﬁc fungal markers. Glycomics and lipidomics
armory is illustrated by hexosylceramide analysis in Scedosporium by
Fourier-transform ion cyclotron resonance mass spectrometry. Clinical
samples (tissues, whole blood) handling by advanced ambient ionization
techniques is reported with special focus to lipids in brain, eye bulb and
lungs (murine, porcine). The fungal infections in plants is addressed by
DAPPI mass imaging.
Conclusion: The current advances in mass spectrometry will lay the
experimental foundation for modern sensitive diagnostic tools. We
predict that particularly mass imaging of tissues infected by molds will
lead to discovery of speciﬁc fungal biomarkers.
O541 Comparative evaluation of MALDI Biotyper system, manual
biochemical tests and BD Phoenix™ automated microbiology
system for species identiﬁcation of staphylococci
A. Borovskaya °, M. Sukhorukova, A. Nikulin, E. Ilina, S. Zhukova,
M. Edelstein, T. Maier, M. Kostrzewa, V. Govorun (Moscow, Smolensk,
RU; Bremen, DE)
Objectives: S. aureus and several species of coagulase-negative
staphylococci are common human pathogens. Therefore, comprehensive
and accurate identiﬁcation of Staphylococcus species is of great
importance. Several ID methods based on conventional physiological or
biochemical characterization are commercially available in manual and
automated formats. The presented study aimed to examine the accuracies
of manual identiﬁcation tests, BD PhoenixTM system and MALDI
Biotyper system for the discrimination of Staphylococcus species.
Methods: A total of 301 clinical isolates of staphylococci were studied.
For conventional species identiﬁcation, manual or semi automated
biochemical identiﬁcation systems (bioMe´rieux, France) were used. All
isolates were also identiﬁed by PhoenixTM automated microbiology
system (BD Diagnostic Systems, USA) as well as by MALDI Biotyper
technique (Bruker Daltonik GmbH, Germany) which is based on
ﬁngerprinting of mass spectra acquired from fresh bacterial cultures.
16S rRNA gene sequencing was performed as conﬁrmatory approach
for discordant cases.
Results: Clinical isolates from 31 regions of the Russian Federation were
investigated including 101 isolates presumably identiﬁed by conventional
microbiological methods as coagulase-negative staphylococci and 200
isolates reported as S. aureus. A discordance between conventional
methods of identiﬁcation and the other tested technologies was found
in 9 (2.9%) cases for MALDI Biotyper technique, and in 29 (9.6%)
ones for BD PhoenixTM automated system. Discordant results of ID
using the Biotyper and Phoenix were obtained for 24 (8.0%) isolates.
Unambiguous species ID was achieved by MALDI Biotyper technique
and PhoenixTM automated system in 292 (97.0%) and 277 (92.0%) cases,
respectively. Likewise, 8 (3.8%) and 21 (7.0%) isolates, respectively,
were identiﬁed at the genus level only. Two isolates (0.7%) did not
belong to the Staphylococcus genus according to both approaches. The
discrepant cases were analyzed by 16S rRNA gene sequencing which
conﬁrmed the beneﬁts of MALDI Biotyper ID results in most of the
cases.
Conclusion: The MALDI Biotyper technique was superior to the
manual and automated (BD Phoenix) biochemical tests for the species
identiﬁcation of staphylococci.
O542 Comparison of MALDI-TOF MS, the Vitek 2 Anaerobic
card and BD BBL Crystal Anaerobe ID kit for identiﬁcation
of anaerobic bacteria
A. Ingebretsen °, M.Z. Pino, J.V. Bjørnholt (Oslo, NO)
Objective: Compare MALDI-TOF mass spectrometry (MS) with
established automated identiﬁcation systems for anaerobic bacteria. All
methods were compared to 16s rDNA sequencing.
Methods: 66 isolates from our routine diagnostic laboratory cultured on
non-selective media to secure pure culture, aged no more than 24−48
hours, underwent Gram staining, catalase testing and spot indole if
requested by the identiﬁcation method. Otherwise standard procedures
as speciﬁed by manufacturer were followed for VITEK 2 Anaerobic and
Corynebacteria identiﬁcation with VITEK 2 and the BD BBL Crystal
Anaerobe ID kit with the BBL autoreader. For sequencing of the 16s
rRNA gene, DNA was extracted using the Prepman Ultra protocol
(Applied Biosciences) and thereafter performed according to standard
procedure using an ABI 3730 sequencer and the BLASTn search tool.
Identiﬁcation of the microorganisms by MS was performed using the
Microﬂex MALDI-TOF mass spectrometer (Bruker Daltonik GmbH)
with the Biotyper 2.0 software. Preparation of the bacteria was performed
using the ethanol/formic acid extraction procedure according to the
manufacturer (Bruker Daltonik GmbH). All bacteria were analyzed in
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duplicates. The Biotyper 2.0 software generates a list of species matches
ranked by a log score value. In this study we accepted the score value
of 1.7 and higher if the duplicates matched each other.
Results:36 different anaerobic species were identiﬁed. Proportion of
isolates identiﬁed correctly according to species group compared to 16s
rDNA sequencing are presented in table 1. Generally MALDI-TOF MS
performed better than the 2 automated systems, although short comings
were present for some species. Of the two automated systems the
VITEK2 Anaerobic and Corynebacteria identiﬁcation card performed
marginally better than the BD BBL CrystalTM Anaerobe ID kit.
Conclusion: The automated systems for anaerobic identiﬁcation show
limited performances. Although the MALDI-TOF MS performed better,
signiﬁcant shortcomings are also present. The latter could be explained
by database limitations of the MALDI Biotyper 2.0 software, i.e. several
subspecies of Fusobacterium nucleatum have been described but are
not included. At present time 16s rDNA sequencing remains the gold
standard but may be somewhat replaced by MALDI TOF MS in the
near future depending on further development of the database. The 2
automated identiﬁcation systems can be used in adjunction to more
conventional identiﬁcation.
Table 1. Proportion of anaerobic isolates correctly identiﬁed by
MALDI-TOF mass spectrometry, BD BBL Crystal™ Anaerobe ID kit
and the VITEK® 2 Anaerobic and Corynebacteria identiﬁcation card







Actinomyces spp. 5/5 3/5 0/5 2/5
Bacterioides spp. 8/8 7/8 2/8 2/8
Clostridium spp. 16/16 13/16 9/16 10/16
Corynebacterium spp. 7/7 3/6 2/6 2/6
Fusobacterium spp. 10/10 6/10 3/10 4/10
Prevotella spp. 5/5 4/5 2/5 3/5
Propionibacterium spp. 10/10 10/10 6/10 10/10
Other 5/5 2/5 3/5 4/5
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O543 Eco-epidemiology and complete genome comparison of bat
SARS coronavirus in China reveal bats as reservoir for
frequent recombination
K. Li °, S.K. Lau, Y. Huang, H. Tse, M. Wang, G.K. Choi, H. Xu, R. Guo,
K.H. Chan, B. Zheng, P.C. Woo, K.Y. Yuen (Hong Kong, Guangzhou, CN)
Objective: Despite the identiﬁcation of SARS-CoV-like viruses in
horseshoe bats in China, the evolutionary and possible recombination
origin of SARS-CoV remains undetermined. To better deﬁne the
epidemiology and evolution of bat-SARS-CoV in China and their role
as recombination origin of SARS-CoV in civet, a four-year study on
coronaviruses in Chinese horseshoe bats in Hong Kong and Guangdong
province of southern China was conducted.
Methods: Respiratory and alimentary samples were collected from
1401 Chinese horseshoe bats captured in Hong Kong and Guangdong
province of southern China over a four-year period and were detected for
coronaviruses by reverse-transcriptase polymerase chain reaction. Five
hundred and eleven bats from Hong Kong were also tagged to study the
migration pattern of bats and viral persistence. The complete genomes of
10 strains of bat-SARS-CoV obtained at different time were sequenced
and compared to the previously characterized genomes.
Results: Bat-SARS-CoV was detected in alimentary specimens from
130 (9.3%) bats, with peak activity during spring. Bats carrying the
viruses appeared healthy, with viral clearance occurring between two
weeks to four months. Tagging exercise showed that migration distances
of Chinese horseshoe bats in Hong Kong range from 1.86 to 17 km.
Complete genome sequencing of 10 strains of bat-SARS-CoV revealed
frequent recombination between different strains, especially among the
bat viruses in China. Recombination was detected between bat-SARS-
CoV Rp3 from Guangxi and Rf1 from Hubei in the possible generation
of civet SARS-CoV SZ3, with breakpoint at nsp16/spike region.
Conclusion: Bat-SARS-CoV causes acute, self-limiting infection in
horseshoe bats which serve as reservoir for recombination between virus
strains from different geographical locations within reachable foraging
range. Civet SARS-CoV is likely a recombinant virus arising from
bat-SARS-CoV strains closely related to Rp3 and Rf1. Such frequent
recombination in these animals may have accounted for the cross-species
transmission and emergence of SARS.
O544 Epidemiology and control of Q fever in the Netherlands,
2007–2009
P.M. Schneeberger °, B. Schimmer, F. Dijkstra, A. Rietveld,
D.W. Notermans, M. Wegdam-Blans, Y. van Duynhoven, B.J. Rotterdam,
P. Vellema, H.J. Roest, C. Wijkmans, W. van der Hoek (Den Bosch,
Bilthoven, Veldhoven, Deventer, Lelystad, NL)
Objectives: Q fever is caused by Coxiella burnetii. Sheep and goats are
frequently described as the source. Humans are usually infected through
inhalation and half of the infected show symptoms. Before 2007, Q fever
was a rare disease in the Netherlands. Since 2005, Q fever emerged
in small ruminants and subsequently in 2007 in the human population
leading to the largest Q fever outbreak recorded up to date.
Methods: Analysis of data from public health facilities, regional
laboratories, the Animal Health Service and the National Institute for
Public Health and the Environment to describe the Q fever outbreak
occurring in the Netherlands.
Results: In the spring of 2007, Q fever occurred in a village in the
province of Noord Brabant with 168 cases. In 2008 and 2009 increasingly
larger outbreaks occurred in an increasingly wider area. By November
2009, more than 3000 cases have been notiﬁed. Six patients have
died. The number of chronic cases is not known. So far, contact with
hay/manure and a house location close to an infected dairy goat farm
have been identiﬁed as important risk factors for human Q fever. In the
affected area dairy goat farming is common and goat density per square
kilometre is the highest in the Netherlands. Since 2005 and preceding
the human outbreaks, abortion waves caused by C. burnetii have been
noticed on 27 dairy goat farms and 2 dairy sheep farms in the regions
where most of the human cases occurred. Sampling of incriminated
farms, animals and surroundings resulted in detection of C. burnetii.
Preliminary MLVA analysis points at spreading of a single clone in
goats, however the presence of this clone is not yet widely conﬁrmed in
humans. Control measures including mandatory veterinary notiﬁcation as
well as hygiene measures during spread of manure, lambing season and
mass vaccination of goats and sheep are being implemented. Preliminary
results of the monitoring of vaccination indicate a decrease of the
abortion rate in the vaccinated groups to zero and a drop in bulkmilk
levels of C. burnetii DNA.
Conclusion: The Q fever outbreak starting in 2007 in the Netherlands
is still on going. It is mainly restricted to the south of the country in an
area with intense dairy goat farming. However the epidemic has been
expanding to other areas in 2009. The effect of control measures is still
to be awaited. Epidemiological data point towards the intensive dairy
goat farming as the main source of the outbreak.
O545 Evaluation of a diagnostic algorithm for acute Q-fever in
an outbreak setting
M.M. Jager °, G. Weers-Pothoff, M. Hermans, J.J.A. Schellekens,
J.C. Meekelenkamp, P.M. Schneeberger, P.C. Wever (’s-Hertogenbosch,
NL)
Objectives: An outbreak of Q-fever with over 3300 notiﬁed cases is
ongoing in the Netherlands. Since 2007, immunoﬂuorescence assay (IFA)
has been the cornerstone of Q-fever serology in our hospital. IFA,
however, is time-consuming and subject to inter-observer variability.
Furthermore, the lag phase in antibody response to Coxiella burnetii
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renders serology less suitable for diagnosing early disease. Alternative
diagnostic approaches include an ELISA for IgM phase II antibodies
as screening assay (M II screen). In addition, IS1111 PCR on serum
samples is capable of diagnosing acute Q-fever before antibodies appear.
In 2009, we introduced a diagnostic algorithm (ﬁgure) for acute Q-fever
with the M II screen as initial step. Subsequently, IFA and/or PCR were
performed depending on outcome of M II screen, date of onset of disease
and inpatient or outpatient setting. When diagnostics were inconclusive
a 14-day follow-up serum sample was requested. Here, we evaluated the
value of the algorithm in an outbreak setting.
Methods: We retrospectively evaluated outcome of Q-fever diagnostics
according to the new algorithm in all patients referred between May 15th
and 31st, 2009, with date of onset of disease unknown or <3 months.
Results: In the 17-day period, 825 patients were tested. The diagnosis
acute Q-fever was made in 256 patients (31%) − in 197 patients on
the ﬁrst serum sample, in 59 patients on the 14-day follow-up serum
sample. A negative M II screen was obtained in 669/825 ﬁrst serum
samples resulting in reduction of IFAs performed by more than 80%.
Ninety-two M II screen negative patients were diagnosed with acute
Q-fever by positive PCR. Cross-reactivity was documented in 4% of
patients with a positive M II screen. Almost 50% of physicians did not
list date of onset of disease. Requested follow-up serum samples were
not received from 306 patients leading to inconclusive outcomes.
Conclusion: Introduction of the M II screen signiﬁcantly reduced the
number of IFAs performed, while introduction of PCR allowed for
diagnosis of acute Q-fever in a substantial number of seronegative
patients. Pitfalls to the presented algorithm are the poor communication
by many physicians of the ﬁrst day of disease, which is a critical
component in the algorithm, and the suboptimal response to requests
for follow-up serum samples implying that cases of acute Q-fever might
have been missed.
O546 Mortality burden of Clostridium difﬁcile-associated disease
in adults: an under-recognized crisis
T. Eckmanns ° (Berlin, DE)
Objectives: In response to the increase of Clostridium difﬁcile associated
disease (CDAD) and the emergence of Clostridium difﬁcile ribotype
027 in Germany in 2007, the Robert Koch Institute (RKI) implemented
nationwide notiﬁcation of severe cases of CDAD, starting from
November 2007.
Methods: We used ﬁrst years surveillance data to assess the population
burden of CDAD by calculating years of life lost (YLL) for infections
with Clostridium difﬁcile. In addition, data from the national surveillance
system were used to assess YLL for the most common gastrointestinal
pathogens which are notiﬁable in Germany, i.e., Campylobacter spp.,
Salmonella spp., rotavirus, and norovirus. All fatal cases associated
with these pathogens from 2004–2007 were included. For CDAD, we
included fatal cases from 01/01/2008–31/12/2008. WHO life expectancy
table (West Label 26) without discount and age-weighting was used to
calculate sex-weighted YLL for 19 age groups with a cut-off at age 85+
years.
Results: A total of 419 cases of severe CDAD, including 224 fatalities,
were reported to the RKI. Age dependent YLL are shown in ﬁgure
1. Overall, CDAD constitutes 66% of all YLL among the included
gastrointestinal diseases.
Conclusions: Substantial underreporting of severe and fatal CDAD
should be expected, since reporting is physician-based so far. With
steeply increasing case numbers in Germany, our result is alarming. YLL
from CDAD is an important measure of population burden and should
be considers when allocating public health resources. To determine
trends in occurrence of more toxigenic strains and their impact in the
community and in the hospital setting, continued surveillance for CDAD
is compulsory on an international scale.
Reference(s)
[1] Kleinkauf N, Weiss B, Jansen A, Eckmanns T, Bornhofen B,
Ku¨ehnen E, Weil HP, Michels H. Conﬁrmed cases and report of
clusters of severe infections due to Clostridium difﬁcile PCR ribotype
027 in Germany. Euro Surveill. 2007;12:E071115.2.
[2] Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium
difﬁcile surveillance trends, Saxony, Germany. Emerg Infect Dis.
2008;14:691−2.
Figure 1. YLL for gastrointestinal infections in Germany.
O547 Proposition of an algorithm for the toxigenic C. difﬁcile
diagnosis
M.A. Orellana °, A. Alcolea, L. Barrado, F. Chaves, M.J. Babiano,
J. Rodriguez (Madrid, ES)
Objectives: To evaluate a new test that detect C. difﬁcile −enzyme
glutamate dehydrogenase antigen (GDH) and toxin A/B in one step using
the culture, like reference method; and to propose an algorithm for the
routine diagnosis of CDAD.
Methods: CDAD study was performed to 970 stool samples of patients
more than 1 year old, between February and October 2009. It was
studied:
– Detection of GDH and Toxin A/B by ICT Techlab® C.diff Quick chek
Complete (Inverness Medical)
– Culture on CLO plates (Biomerieux).
When GDH(+), toxin(−) and culture(+): direct toxin detection from
culture was performed. When GDH(+), toxin(−) and culture(−): spore
selection by alcohol treatment was performed and cultured on CLO
plates.
Results: The 90.2% of samples were (−) to GDH, toxin and culture
(875); and the 3.4% (33) (+) to those parameters. The 4.8% (47)
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were GDH(+), toxin(−) and culture(+), being the 48.9% (23/47) of
those samples toxin(+) when direct toxin detection from culture was
performed. The 1.3% (13) were GDH(+), toxin(−) and culture(−),
recovering by alcohol treatment the 46.1% (6/13) of those samples, being
the 15.4% (2/13) toxin(+). The 0.1% (1) was GDH(+), toxin(+) and
culture(−); and the 0.1% (1) GDH(−), toxin(−) and culture(+).
The prevalence of toxigenic CD was 6.1%. The S, E, VPp and VPn of
GDH compared to culture were: 98.7%, 97.9%, 81.6% and 99.8%.
The algorithm purpose is:
GDH(−)/toxin(−): not CD
GDH(+)/toxin(+): toxigenic CD
GDH(+)/toxin(−): culture. If culture(+): direct toxin from culture. If
toxin(+): toxigenic CD; if (−): non toxigenic CD. If culture(−): alcohol
treatment. If culture(+): toxin. If toxin(+): toxigenic CD; if (−) non
toxigenic CD. If culture(−): not CD.
Conclusions: This test is reliable, sensitive and speciﬁc for detect CD
from stool. The detection of direct toxin from culture allowed to recover
the 48.9% of GDH(+)/toxin(−) samples, increasing the prevalence of
toxigenic-CD from 3.4% to 5.8% and with alcohol treatment to 6.1%.
This algorithm allows to exclude CD without additional tests when
GDH is (−) (90.2% of samples). In 93.6% of samples the results can be
obtain in less than 2 hours.
O548 Risk factors and outcome of Clostridium difﬁcile infection due
to the four predominant PCR-ribotypes in the Netherlands
A. Goorhuis °, C. van Kinschot, C. Harmanus, B.H. van Benthem,
D.W. Notermans, E.J. Kuijper (Leiden, Bilthoven, NL)
Background: Clostridium difﬁcile infection (CDI) due to hypervirulent
PCR-ribotypes (types) have been well described. Little is known about
other frequently encountered types.
Methods: We studied risk factors and clinical characteristics of the four
predominant types in The Netherlands, as observed by The National
Reference laboratory at the Leiden University Medical Center, from May
2005 until October 2008.
Results: Among 2047 isolates, the four predominant types were 001
(n = 162; 8% of all isolates), 014 (n = 217; 11%), 027 (n = 305; 15%)
and 078 (n = 205; 10%). Patients with types 014 and 078 were younger
(age <65 years 39% and 35%, respectively) than patients with types 001
and 027 (26% and 22%, respectively). Type 027 patients less frequently
had community associated (CA) CDI than patients with any of the 3 other
types (8% vs. 19−25%). Use of clindamycin was a speciﬁc risk factor
for type 001, when compared the other types (31% vs. 6−7%). Type 078
patients with complicated CDI were younger (<60 years) than patients
with types 001, 014 and 027 (19%, vs. 0%, 9% and 11%, respectively).
Attributable mortality for types 001, 014, 027 and 078 was 0%, 0%, 3%
and 2%, respectively. Patients with type 027 most often had a recurrence
>8 weeks after the ﬁrst infection (10% vs. 3−4% for the 3 other types).
Conclusions: Risk factors for and the clinical course of CDI vary and
depend on the involved type. The antibiotics associated with the highest
risk of acquisition of CDI relate to the speciﬁc type.
O549 Crimean-Congo haemorrhagic fever, ticks and base measures
H. Gedik ° (C¸anakkale, TR)
Crimean-Congo haemorrhagic fever (CCHF) is a viral haemorrhagic
fever of the Nairovirus, in the Bunyaviridae family of viruses. CCHF
virus possesses a negative-sense RNA genome consisting of three RNA
segments: the large (L), medium (M), and small (S) segments. For
an arthropod-borne virus, the genomic plasticity of CCHF virus is
surprisingly high. It seems likely that genetic reassortment may primarily
occur during coinfection of ticks due to the transient nature of vertebrate
infections relative to the long-term persistent virus infections seen in
ticks and their obligate need to obtain blood meals at metamorphic
junctures. Substantially, movement of genetic lineages of CCHF virus,
particularly over greater distances and between regions not linked by
livestock trade, likely also involves migratory animals or birds that
are either infected or are carrying virus-infected ticks. Consequently,
however migratory birds those mediate genetic lineages of CCHF exist
critical point for CCHF struggle such as avian inﬂuenza, ticks should
be targeted at ﬁrst. Especially, ﬁelds with high risk should be out of
order for pasturing and disinfected with repellent medicines. Acaricide
treatment of livestock in CCHFV endemic areas is effective in reducing
the population of infected ticks.
O550 Risk factors and pathological correlations in severe courses
of hantavirus infections in Germany
E. Krautkramer, S. Grouls, P. Schnitzler °, M. Zeier (Heidelberg, DE)
Objectives: Hantavirus infections show a high variability in the
intensity of symptoms depending on the hantavirus strain, but also
individual differences were observed. Gender- and patient-speciﬁc
differences in susceptibility and severity of infectious diseases, especially
for hantaviruses, have often been discussed. Therefore, we analyzed
epidemiologic and clinical data to identify risk factors for severity.
Methods: Hantavirus-infected patients (18 men and 4 women)
hospitalized in the Department of Nephrology from 2002 through
2008 were included. The diagnosis was conﬁrmed by detection of
circulating anti-hantavirus IgG- and IgM-antibodies. Demographic data,
underlying diseases, biopsy, cardiac, ultrasound and laboratory ﬁndings
were recorded.
Results: The men-to-women ratio for diagnosed hantavirus infections in
Germany is 2.6:1. The higher incidence of infection in men seems to be
caused by the way of transmission and corresponds with other rodent-
borne zoonoses. Gender or pre-existing conditions did not inﬂuence
the clinical presentation. Thrombocytopenia precedes organ failure and
severe courses were associated with lower platelet levels. Platelet levels
are therefore predictive for severe organ failure and, already early after
the onset of ﬁrst symptoms, a useful marker for identifying patients at
risk for severe disease.
Conclusion: Gender or pre-existing conditions did not inﬂuence the
clinical presentation in hantavirus infected patients, however severe
courses might be predicted for patients with low platelet levels.
O551 Epidemiology and molecular characterization of West Nile
virus infection in north-eastern Italy
L. Barzon °, E. Franchin, L. Squarzon, E. Lavezzo, S. Toppo,
T. Martello, S. Bressan, S. Pagni, M. Cattai, A. Piazza, M. Pacenti,
R. Cusinato, G. Palu` (Padua, IT)
Objectives: In Italy, an equine outbreak of West Nile virus (WNV)
infection was reported in 1998 in Tuscany region. The virus re-emerged
in 2008 with the occurrence of equine and human cases of WNV
neuroinvasive infection in Veneto and Emilia Romagna regions. Aim of
the study was to report WNV surveillance activity performed in Veneto
region in 2008–2009 and to investigate WNV strains circulating in Italy.
Methods: Since September 2008, our Centre performed surveillance of
WNV disease by the following diagnostic tests: WNV-RNA detection
in plasma and CSF, WNV isolation in Vero cell cultures, detection
of WNV IgM and IgG by ELISA followed by PRNT conﬁrmation.
A seroepidemiology survey in at risk population resident in Rovigo
province was also performed.
Results: Five cases (4 identiﬁed retrospectively) of WNV meningoen-
cephalitis and 1 of WNV fever were identiﬁed in August-September
2008 and other 6 cases of WNV neuroinvasive disease were identiﬁed in
August-September 2009; 11 cases were resident in Rovigo province and
1 in the border area between Venice and Rovigo provinces. The estimated
incidence of WNV encephalitis in Rovigo province was 2.5 cases per
100,000 population, while WNV seroprevalence was about 0.7%. For
the ﬁrst time in Italy, WNV was isolated from a NAT-positive blood
donation done in Rovigo. Whole genome sequence analysis showed the
new isolate was phylogenetically related to the Italy-1998 equine isolate
and to other recently isolated European strains, with acquisition of new
aminoacid mutations, including NS3-Thr249Pro. Molecular modelling
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of the effect of this mutation predicted a higher stability of the NS3
protein at high temperatures, such as in avian hosts.
Conclusion: Since 2008, an outbreak of WNV infection, characterised
by the occurrence of cases of severe meningoencephalitis, is ongoing in
north-eastern Italy. Genome sequencing of WNV isolates and molecular
modelling has provided insight into the mechanism of WNV re-
emergence in Italy, since the virus has acquired the Thr249Pro change
in WNV-NS3 helicase, a trait associated with avian virulence, rapid
geographic diffusion, and human outbreaks.
O552 Human babesiosis: an emerging zoonosis also in Italy?
Preliminary serological data
S. Gabrielli °, P. Calderini, A. Iori, M.P. Tampieri, M. Pietrobelli,
G. Cancrini (Rome, Rieti, Bologna, Padua, IT)
Objective: Aim of this study was to investigate on the seroprevalence
of babesioses in people resident/working in areas where some Babesia
species have been detected in the animals [1−4].
Methods: Blood samples (n = 687) from clinically healthy people
(foresters, veterinarian, breeders, residents) living in at risk areas of
Northern and Central Italy were collected. Sera obtained were tested for
the presence of speciﬁc IgG by using the indirect immunoﬂuorescent
assay on sale for B. bovis, B. canis, B. equi and B. microti (opportunely
adapted), and the western blot by us recently designed for B. divergens.
Results: A total of 21 out of the 240 (8.75%) sera so far analysed
proved reactive: 2/32 (6.2%) to B. bovis, 2/64 (3.1%) to B. equi, and 4/64
(10.4%) to B. microti. Sera tested for B. canis (n = 32) and B. divergens
(n = 153) proved negative. No cross-reactions were evidenced.
Conclusions: Our preliminary immunological ﬁndings on Italian human
population suggest a possible high seroprevalence of babesial infections,
greater than to date suspected, that have to be conﬁrmed by the more
extensive serological trials programmed. The unexpected high circulation
of antibodies to B. microti out of the United States conﬁrms the recent
report of an autochthonous case of human babesiosis due to B. microti
from Europe [5]. However, it requires to be studied in depth, by the
molecular analysis of the corresponding coagula in some cases available,
which may allow not only the conclusive identiﬁcation of the species
involved, but also its genetic relationship with the clustering strains.
Reference(s)
[1] Pietrobelli M, Cancrini G, Moretti A, Tampieri MP. Animal
babesiosis: an emerging zoonosis also in Italy? Parassitologia 2007;
49:33−8.
[2] Cassini R, Zanutto S, Frangipane di Regalbono A, Gabrielli et al.
Canine piroplasmosis in Italy: epidemiological aspects in vertebrate
and invertebrate hosts. Vet Parasitol 2009; 165: 30−5.
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O553 First description of carbapenem non-susceptible
K. pneumoniae isolates from Germany harbouring the
OXA-48 carbapenemase
M. Kaase °, L. Esmann, N. Wu¨ppenhorst, F. Szabados, S. Gatermann
(Bochum, DE)
Objectives: Multidrug resistance in Enterobacteriaceae is of utmost
clinical importance since no new antibiotics with activity against
gramnegative bacteria will be introduced in the next ﬁve years. OXA-
48 carbapenemases have been described as an emerging resistance
mechanism recently.
Methods: Susceptibility testing was performed by Vitek 2 and Etest.
Carbapenemase production was detected by a microbiological assay
employing cell-free extracts and parallel testing of the effects of selective
b-lactamase inhibitors. In addition a modiﬁed Hodge test was performed.
PCRs for known carbapenemase gens followed by sequencing were
performed. The number of b-lactamases was determined by isoelectric
focusing. A pulsed-ﬁeld gel electrophoresis (PFGE) was performed and
Plasmid transfer by transformation was tried.
Results: Four non-copy K. pneumoniae isolates from an universital
hospital in Freiburg (Southern Germany) were tested because of elevated
MICs in Vitek 2. The modiﬁed hodge test was positive in all isolates
and the micorbiological assay demonstrated a carbapenemase activity
which was not inhibited by EDTA, clavulanic acid, cloxacillin or
3-aminophenylboronic acid. Imipenem MICs varied between 1mg/L
and >32mg/L, meropenem MICs were in the range of 0.38mg/L til
>32mg/L. PCRs for KPC, VIM, IMP and GES were negative, whereas
PCRs and subsequent sequencing showed the presence of OXA-48.
Transformation of an OXA-48 harbouring succeeded; no resistance to
non-b-lactam antibiotics was co-transferred. PFGE band patterns were
related in all four isolates. By isoelectric focusing two b-lactamases with
a pI of 5.4 and 7.2, respectively, were found.
Conclusion: This is the ﬁrst description of OXA-48 in K. pneumoniae
isolates from Germany. Some strains showed carbapenem MICs in
the susceptible range, highlighting the difﬁculties in detection of this
resistance mechanism.
O554 Multidrug-resistant Klebsiella oxytoca carrying blaIMP-8
associated to OXY-hyperproduction isolated in an intensive
care unit from a community Spanish hospital
M.C. Conejo °, M.C. Domı´nguez, L. Lo´pez-Cerero, L. Serrano,
J. Rodrı´guez-Ban˜o, A. Pascual (Seville, Osuna, ES)
Objective: To study the antimicrobial resistance mechanisms of broad-
spectrum cephalosporin-resistant Klebsiella oxytoca strains with reduced
susceptibility to carbapenems isolated in an intensive care unit from a
200-bed community hospital.
Methods: Nine K. oxytoca isolates recovered from clinical (4) and
surveillance (5) cultures during a 3-month period were studied.
Susceptibility testing was performed by broth microdilution and disc
diffusion (CLSI). Phenotypic b-lactamase characterisation included
screening and conﬁrmatory test for ESBL, modiﬁed Hodge test for
suspected carbapenemase production (CLSI), and isoelectrofocusing
(IEF). b-lactamase genes were analyzed by PCR and sequencing. The
clonal relationship among isolates was determined by PFGE with XbaI
and cluster analysis was conducted by using UPGM with tolerance 1%.
Results: All isolates were intermediate or resistant to b-lactams
(amoxicillin–clavulanate, piperacillin–tazobactam, cefoxitin, cefotaxime,
ceftazidime, cefepime, and aztreonam), quinolones, trimethoprim-
sulphamethoxazole, tobramycin and tigecycline. Susceptibility was
retained only to gentamicin, amikacin, colistin, and carbapenems (MIC
of imipenem: 2mg/L; MIC range of meropenem: 0.5−1mg/L; MIC range
of ertapenem: 1−2mg/L). The nine isolates showed a negative double
disc test for ESBL detection and a positive modiﬁed Hodge test for
carbapenemase detection. IEF showed two bands per strain, one with pI
slightly higher than 6.5 and another with pI of 8.2. All isolates showed an
indistinguishable proﬁle by PFGE (100% similarity). The gene encoding
the metallo-b-lactamase IMP-8 was found in all isolates. In addition, all
strains presented a G-to-A transition at position 5 of the −10 hexamer
of the blaOXY promoter, which has been associated to an increased
amount of b-lactamase produced (OXY-hyperproduction), explaining the
resistance to aztreonam displayed by all strains.
Conclusion: An outbreak caused by multi-drug resistant K. oxytoca
in ICU patients from a community hospital was microbiologically
characterised. This is the ﬁrst report on IMP-8-producing K. oxytoca
in Spain.
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O555 Multifocal detection of KPC-producing Klebsiella
pneumoniae in Italian hospitals
M.M. D’Andrea, T. Giani, G. Brigante, L. Santoriello, G. Ortisi,
P. Casella, G. Riccio, G. Gesu, F. Luzzaro, G.M. Rossolini ° (Siena,
Lecco, Savona, Milan, IT)
Background: Worldwide emergence and spreading of Klebsiella
pneumoniae carbapenemases (KPCs) is a matter of clinical concern.
In Italy, a single KPC-producing K. pneumoniae isolate was reported
until now (Florence University Hospital, October 2008). Here we
report the multifocal detection of KPC-positive nosocomial isolates of
Klebsiella pneumoniae obtained from inpatients admitted to different
Italian hospitals during 2009.
Methods: Antimicrobial susceptibility was evaluated using the VITEK2
system (bioMe´rieux, Marcy l’Etoile, France) and conﬁrmed by the
Etest method (bioMe´rieux). Synergy tests based on EDTA and boronic
acid were performed to screen for different carbapenem resistance
mechanisms. Carbapenemase production was ﬁrst studied by the
modiﬁed Hodge test and then conﬁrmed by PCR using primers speciﬁc
for the detection of blaKPC-type alleles. Molecular typing was also
performed to assess clonal relationship.
Results: From May to October 2009, KPC-producing Klebsiella
pneumoniae isolates were detected in 5 Hospitals located in Northern
Italy. Isolates showed a multidrug-resistant phenotype, including (in
addition to b-lactams), ﬂuoroquinolones, amikacin, tobramycin, and
trimethoprim-sulfamethoxazole. MICs of ertapenem, imipenem, and
meropenem were 8mg/L. Susceptibility was retained only for
gentamicin, colistin, and tigecycline. Molecular typing showed the
occurrence of few clones, although most of strains were clonally
related. Epidemiological analysis revealed that two patients had been
transferred among hospitals causing inter-hospitals transmission. Intra-
hospital diffusion was also observed.
Conclusions: Following the ﬁrst case reported in 2008, KPC-producing
K. pneumoniae strains appear to be emerging in Italian hospitals.
Due to the ability to rapidly spread, the multifocal detection of these
strains is a ﬁnding of major concern. Monitoring and epidemiologic
surveillance are therefore needed. From a therapeutic point of view,
KPC-producing K. pneumoniae represent a new challenge for physicians
and microbiologists. Based on in vitro results, colistin and tigecycline
could represent therapeutic options for treating infections caused by these
MDR pathogens.
O556 First outbreak of Klebsiella pneumoniae producing KPC-2
in France
G. Cuzon °, T. Naas, N. Fortineau, A. Babics, I. Boytchev, F. Gayral,
P. Nordmann (Le Kremlin Bicetre, FR)
Objectives: KPC-producing K. pneumoniae (KPC-Kp) are increasingly
reported worldwide, mostly in the USA, Israel and Greece, and
are associated with higher patient mortality. We report here the
ﬁrst nosocomial dissemination of KPC-Kp isolates mediated by a
contaminated duodenoscope.
Methods: KPC-Kp isolates were characterized by standard biochemical
methods, by susceptibility testing, by PFGE, plasmid analysis, MLST-
and transposon Tn4401-typing. Antibiotic resistance genes were sought
by PCR and sequencing.
Results: A 85-year old patient with bladder cancer, (hospital K-Bicetre,
France) admitted for severe gastro-intestinal bleeding, underwent
endoscopy to stop bleeding. Five days later, he was screened positive
for KPC-Kp, resistant to all available antibiotics except gentamicin and
colistin. Despite increased awareness and reinforced hygiene precautions,
MDR screening of hospitalized patients in the same surgical unit
identifed two KPC-Kp(+) patients. Concommitantly, a patient from a
neighbouring hospital that underwent endoscopy at the same gastro-
enterology ward was diagnosed KPC-Kp positive. These patients had
endoscopy on separate days (two weeks apart) but with the same
endoscope. Bacterial cultures from this endoscope revealed KPC-Kp.
Retrospective analysis of all the patients that had gastroscopy with the
same endoscope, identiﬁed a Greek patient with KPC-Kp feacal carriage
that was directly transferred from the hospital of Chania (Crete, Greece)
two months earlier. Since this patient, 17 patients, being mostly from
regional hospitals and out-patients, underwent gastroscopy with the same
endoscope. Out of 10 patients that could be screened, 6 were KPC-
positive and 2 got infected (one bacteriemia and one bilioma) with KPC-
Kp.
Conclusion: Although the risk of endoscopy-related infection is
low, changes of endoscope reprocessing by replacing glutaraldehyde
decontamination bath by automated per-acetic acid washers (to prevent
Creutzfeldt-Jacob), may have been deleterious to this endoscope. This
report identiﬁed he spread of a panresistant enterobacterial isolate in our
hospital, and at a regional level in Paris.
O557 First detection in Europe of plasmid-mediated
ﬂuoroquinolone resistance qnrD determinant
R. Koncan °, A. Mazzariol, B. Kocsis, R. Fontana, P. Lanzafame,
M. Rassu, G. Cornaglia (Verona, Trento, Vicenza, IT)
Objectives: To investigate the presence of the newly-described plasmid-
mediated determinants of quinolone resistance qnrC and qnrD among
Enterobacteriaceae isolated in the North-East of Italy.
Materials and Methods: We collected 756 non-replicate Enterobacte-
riaceae, isolated during 2007 and 2008 in ﬁve different microbiology
laboratories in the North-East of Italy and selected for being non-
susceptible to ﬂuoroquinolones and/or resistant to third-generation
cephalosporins, qnrC and qnrD were determined by PCR and sequencing.
Results: No qnrC gene was detected, but ﬁve strains (0.66% of the total)
presented a qnrD gene. They included four Proteus mirabilis and one
M. morganii.
No ESBL could be found in either Proteus mirabilis or Morganella
morganii. No combination of qnrD with other plasmid-mediated
determinant of quinolone resistance was found. All qnrD genes were
cloned by heat-shock in E. coli DH5a. They were all located in a
conjugative plasmid, which was transferred into the E. coli J53 host strain
and selected with 100 mg/ml of Na-azide and 0.5 mg/ml of ciproﬂoxacin.
The ciproﬂoxacin resistance of the qnrD-producing clinical isolates
carrying the plasmid-mediated determinants widely ranged between
0.06 and 256mg/L.
Conclusions: QnrD genes have so far been reported only from China,
detected for the ﬁrst time in Salmonella enterica and, subsequently, in
E. coli, and Klebsiella pneumoniae. This is the ﬁrst report of the qnrD
gene in Europe, as well as the ﬁrst detection of this gene in isolates of
the tribe Proteeae (namely P. mirabilis and M. morganii). This is also
the ﬁrst time that any qnr determinant is found in M. morganii.
O558 Occurrence of PMQR determinants and ESBL in clinical
Enterobacteriaceae isolates from an Algerian hospital
N. Ramdani-Bouguessa, V. Manageiro °, E. Ferreira, D. Louro,
M. Tazir, M. Canic¸a (Algiers, DZ; Lisbon, PT)
Objectives: b-lactams and ﬂuroquinolones are the most commonly
prescribed antibiotic classes. The aim of this study was to characterize
the mechanisms of resistance to those antibiotics in Enterobacteriaceae
clinical isolates from an Algerian hospital.
Methods: Sixty-one Enterobacteriaceae strains collected between
January to June 2005 in CHU Mustapha Bacha, Algeria, were included
in this study: 33 K. pneumoniae, 7 S. marcescens, 6 Enterobacter spp.,
6 Proteus spp., 3 C. kooseri, 2 S. typhimurium, 2 M. morganii and 1
P. rettgeri. MICs were determined by microdilution broth method. PCR
and sequencing were used to screen and identify bla genes (blaTEM,
blaSHV, blaOXA, blaCTX-M and plasmid-mediated ampC) and as
well as plasmid-mediated quinolone resistance (PMQR) genes (qnrA,
qnrB, qnrC, qnrD, qnrS, qepA and aac(6′)Ib-cr). Linkage of blaCTX-M
with ISECp1, IS26 and IS903 insertion sequences was investigated by
PCR. Biochemical characterization was performed by isoelectrofocusing.
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Genetic relatedness among strains was analyzed by pulsed-ﬁeld gel
electrophoresis.
Results: The prevalence of extended-spectrum b-lactamases (ESBL)
CTX-M was 45/61 (74%) with 28 CTX-M-15, 16 CTX-M-3 and 1 CTX-
M-14 b-lactamases. Other b-lactamase families were also identiﬁed,
such as CMY-2 (n = 1), TEM-type (n = 60) and SHV-type (n = 35). IEF
conﬁrmed strains as ESBL producers. The association of blaCTX-M
genes with other bla genes in the same isolate, namely blaTEM-1 or
blaSHV-1, was observed. Multidrug resistance was presented especially
with aminoglycosides family (72%). PMQR genes were detected only in
4 quinolone non-susceptible isolates: 3 K. pneumoniae strains had the
aac(6′)-Ib-cr gene and 1 M. morganii strain had the recently described
QnrD determinant. PFGE analysis revealed a high clonal heterogeneity
(>80% similarity) among K. pneumoniae strains (23 unique proﬁle types
forming 6 clusters), S. marcescens (5 unique proﬁles types distributed by
2 clusters), and 2 S. typhimurium strains belonging to the same cluster.
Conclusions: This study revealed the ﬁrst report of a qnrD gene
from an Algerian Hospital. Our work conﬁrms also the geographic
spread in Algeria of CTX-M-type b-lactamases, mainly CTX-M-15,
and suggests the horizontal transfer of blaCTX-M genes, mediated by
mobile elements. Given the emergence of quinolone resistance strains
and the dissemination of ESBLs, their continuous spread would have a
distressing development.
O559 16S rRNA methylase containing Enterobacteriaceae in
the SENTRY Asia-Paciﬁc region frequently harbour
plasmid-mediated quinolone resistance and CTX-M types
J.M. Bell °, P. Andersson, R. Jones, J. Turnidge (North Adelaide, AU;
North Liberty, US)
Objectives: 16S rRNA methylases and plasmid-mediated quinolone
resistance (PMQR) genes have recently emerged as important resistance
mechanisms to aminoglycosides and ﬂuoroquinolones respectively. We
examined all 16S rRNA methylase containing Enterobacteriaceae from
the Asia-Paciﬁc region (2007–2008) for the presence of PMQR and
CTX-M-types, which are already known as a world-wide problem.
Methods: Enterobacteriaceae collected from 10 countries as part of
the SENTRY Antimicrobial Surveillance Program during 2007–2008
showing elevated aminoglycoside resistance (amikacin MIC 64mg/L,
and gentamicin and tobramycin 16mg/L) were tested for the 16S rRNA
methylase genes (armA, rmtB, and rmtC) by real-time PCR. Isolates
positive for 16S rRNA methylase genes were also screened for presence
of PMQR genes (qnrA, qnrB, qnrS, aac(6′)Ib-cr, qepA), and CTX-M
encoding genes, using real-time PCR.
Results: 16S rRNA encoding genes were detected in 209 of 4,161
isolates from 5 countries: China (107, 6.9%); India (71, 10.5%);
Hong Kong (3, 1.5%); Korea (17, 6.1%), Taiwan (11, 5.0%), among
9 species. armA was found in 136 strains and rmtB in 60 strains;
each were observed in all 5 countries. rmtC carrying isolates (n = 13)
were only from India, observed in 5 species, where previously only
described in Proteus mirabilis. 91.4% of all 16S rRNA methylase
containing isolates also had either PMQR genes: qnr (n = 79, 38%);
aac(6′)Ib-cr (n = 66, 32%); qepA (n = 20, 10%), or CTX-M genes
(n = 158, 76%). qepA was found in India and China, exclusively
with rmtB and predominantly in Escherichia coli. Multiple PMQR
resistance mechanisms was surprisingly frequent, with 32 (15.3%)
isolates containing two PMQR genes, predominantly qnr in combination
with aac(6′)Ib-cr. Close to 50% of all 16S rRNA methylase containing
isolates also harboured a PMQR gene in combination with CTX-M types.
Conclusion: These results highlight the increasing problem of multiple-
drug resistance among clinical isolates in the Asia-Paciﬁc region, and
the importance of vigilant surveillance programs to monitor emerging
resistance trends.
O560 Molecular characterization of multidrug-resistant strains of
Salmonella infantis isolated in Italy from human, animals
and environment
C. Lucarelli °, S. Owczarek, M. Staffolani, S. Fisichella, I. Luzzi,
A.M. Dionisi (Rome, Macerata, IT)
Objective: Salmonella infantis represents the third serovar isolated in
human infections in Europe, with the majority of strains susceptible to
drugs. In Italy, since 2004, it is the fourth serovar isolated, and during
2005–2006 multidrug resistant strains emerged in a region of central
Italy. In particular strains with R-type ACSSuTKmSxt were isolated in
human, environment and food of animal origin.
The aim of this work was to evaluate the clonal origin of multiresistant
S. Infantis strains isolated from different sources; in addition with the
purpose to analyze the molecular basis of antibiotic resistance, resistance
gene cassettes were identiﬁed and their localization investigated.
Methods: Seventy-two S. infantis strains, isolated between 2002–2008,
both susceptible or resistant to antimicrobial drugs, were tested by Pulsed
Field Gel Electrophoresis (PFGE) according to Pulse-net protocol.
Cluster analysis of PFGE proﬁles was performed using Bionumerics
software. Strains with R-type ACSSuTKmSxt have been tested by PCR
for the presence of the following gene cassettes: blaTEM, tetA-B-C-G,
sul2, strA-B and class 1 integron. Conjugation experiments have been
performed in order to establish the location of resistance genes. Plasmids
from parental and transconjugant strains were assigned to incompatibility
group by PCR-based replicon typing (PBRT).
Results: Cluster analysis performed on PFGE proﬁles showed a main
cluster (genetic similarity >90%) including 49 strains, of which 27 with
R-type ACSSuTKmSxt.
All the 27 strains showed the following resistance genes: blaTEM,
tetB, strA-B, sul2, conferring resistance to ampicillin, tetracycline,
streptomycin and sulphonamides. In addition they harbour a class
1 integron of 2.2 Kb, including folA, catB3, aadA4, sul1 gene
cassettes, which confer resistance to trimethoprim, chloramphenicol,
streptomycin/spectinomicyn and sulphonamides. Conjugation experi-
ments showed a unique plasmid harbouring all the resistance genes and
belonging to HI1 incompatibility group.
Conclusion: Molecular typing by PFGE and the identiﬁcation of a
plasmid harbouring the resistance gene cassettes demonstrated the
circulation of a cluster of S. Infantis, R-type ACSSuTKmSxt, during
2005–2006 in a region of central Italy. The presence of a plasmid
conferring multidrug resistance could have facilitated the spread of this
clone through the environment, food and human.
O561 Multidrug resistance in Salmonella isolates recovered from
different food sources in Colombia
M. Martins °, M. Karczmarczyk, M. McCusker, S. Mattar, L. Amaral,
S. Fanning (Lisbon, PT; Dublin, IE; Cordoba, CO)
Objectives: Salmonella enterica is the most common etiological agent
of food borne salmonellosis worldwide. Ciproﬂoxacin is the antibiotic of
choice for the treatment of these infections. Until date, ﬂuoroquinolone
resistance remains uncommon in this bacterium. However, the incidence
of nalidixic acid resistance is increasing with isolates showing decreased
susceptibility to ﬂuoroquinolones. We have screened a large collection
of Salmonella strains to determine the incidence of multi-drug resistance
(MDR) and to further characterize the genotypic and phenotypic
mechanisms that contribute to this MDR.
Methods: From 2002–2009, 93 Salmonella strains from Colombian
foods and exotic animals were obtained from the University of Cordoba
(Colombia). The serovar and the susceptibility proﬁle of each strain were
determined. Antibiotics representative of 8 different classes were tested
and strains that demonstrated resistance to nalidixic acid (NA) were
further characterized. PCR was performed to determine the presence of
qnr genes. Additionally, efﬂux activity was evaluated by the EtBr-agar
cartwheel method. Ex vivo studies were conducted to assess potential
differences on the infection and adherence ability of the isolates.
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Results: The most predominant serovars in these isolates were: Uganda
(n = 19), Anatum (n = 14), Newport (n = 11) and Braenderup (n = 10);
although in total 19 different serovars were obtained. Thirteen isolates
were resistant to NA (and/or other antibiotics). Four strains showed
increased efﬂux activity when compared with the controls. This was
further conﬁrmed by determining the minimum inhibitory concentration
of NA in the presence of the efﬂux pump inhibitor: phenylalanine-
arginine-b-napthylamide (PAbN). Resistance to quinolones was con-
ﬁrmed by PCR through the identiﬁcation of the qnrB19 gene that confers
low-level resistance to this class of antibiotics. Ex vivo assays were useful
to clarify the infection and adherence potential of the isolates.
Conclusion: In this study, a large collection of Salmonella isolates
obtained from food and exotic animals were resistant to NA and/or
other class of antibiotics. These isolates showed different serovars and
increased efﬂux activity along with the presence of the qnrB19 gene.
The ex vivo assays contributed to clarify the infection and adherence
potential of the isolates. These data highlight the importance of intrinsic
and acquired mechanisms of MDR in Salmonella.
O562 Increasing prevalence and population dynamics of MBL-
producing Pseudomonas aeruginosa in Russian hospitals
E. Skleenova °, J. D’Souza, O. Shevchenko, M. Edelstein, R. Kozlov
on behalf of the ROSNET Study Group
Objectives: To determine the trends in the prevalence and population
genetic structure of MBL-producing P. aeruginosa in Russian hospitals
over the period of 2002–2007.
Materials and Methods: A total of 1,840 consecutive non-duplicate
nosocomial P. aeruginosa isolates collected in 48 hospitals of 31 cities
of Russia as part of two national surveillance studies in 2002–2004
(n = 1,053) and in 2006–2007 (n = 787) were tested for MBL production
using EDTA-double-disk synergy test and PCR assays for blaVIM and
blaIMP genes. All MBL-producing isolates were typed by automated
ﬂuorescent MLVA; selected isolates of different MLVA clusters were
typed by MLST. Structures of class 1 integrons carrying MBL-gene
cassettes were analyzed using Taq I restriction endonuclease digestion
of PCR fragments generated using outward primers internal to blaVIM
or blaIMP genes and primers to 5′ (intI1) and 3′ (qacEdelta1 or tniC)
conserved integron sequences. The obtained PCR-RFLP proﬁles were
compared to those of the known integrons.
Results: A total of 48 (4.6%) and 158 (20.1%) isolates collected,
respectively, in 2002–2004 and in 2006–2007 were found to produce
MBLs. During the ﬁrst and second study periods MBL producers were
identiﬁed correspondingly in 3 of 21 and 12 of 26 cities surveyed.
By MLVA analysis, all MBL-positive isolates were distributed into two
genetic clusters: the predominant one encompassing 23 related MLVA
types and corresponding to sequence type (ST) 235 and a minor one
comprised of 6 related MLVA types and corresponding to ST234. Isolates
of the predominant genetic cluster carried 4 different MBL-integrons
whose RFLP proﬁles matched those of the known integrons harboring
blaVIM-2 (GenBank acc. nos. DQ522233 (n = 190), DQ522234 (n = 1),
DQ522235 (n = 3)) and blaIMP-1 (DQ522237 (n = 3)). Isolates of
the minor genetic cluster carried the blaVIM-2-containing integron
(GenBank acc. no. DQ522236; n = 9). VIM-2-producing isolates of the
two genetic groups have concomitantly increased in prevalence (ST235:
from 4.5% to 18.1%; ST234: from 0.1% to 1.0%) and geographic
distribution between the two study periods.
Conclusion: A dramatic increase in the prevalence of MBL-producing
P. aeruginosa in Russian hospitals between the periods of 2002–2007 to
2006–2007 was noted owing mainly to a clonal spread.
Community-acquired pneumonia
O563 Usefulness of sputum Gram stain and culture for S. pneu-
moniae and Haemophilus spp. in the aetiologic diagnosis of
community-acquired lower respiratory tract infections and
predictive value of serum PCT levels for these bacterial LRTI
M. Ieven °, C. Lammens, A. Vanderstraeten, K. Loens, T. Verheij,
P. Little, H. Goossens and the GRACE study team
Objectives: To evaluate (1) the usefulness of sputum Gram stain and
culture when applied routinely in the etiologic diagnosis of Community-
acquired Lower Respiratory Tract Infections (CA-LRTI) in the GRACE
study and (2) to correlate sputum culture results with PCT values in
serum.
Methods: From 10/2007 through 05/2008, 711 adult patients with
LRTI in the community were included during the ﬁrst winter in a
3 year prospective study in 11 primary care centers in 8 European
countries. Sputum and serum specimens were collected before possible
antibiotic therapy was started. Sputa were sent to the local laboratory
and processed immediately; sera were stored at −70ºC until shipment to
the central lab. Quality of sputa was scored according to the number of
leucocytes (WBC) and squamous epithelial cells: specimens with ratios
of WBC/epithelial cells >1 were deﬁned as good quality sputa. Gram
stain and culture were performed according to a standardized protocol.
Culture was considered diagnostic when S. pneumoniae or Haemophilus
spp were isolated as a predominant microorganism.
Kryptor based procalcitonin (PCT) assay (BRAHMS) was performed
according to the manufacturer’s instructions: interpretation of PCT values
in relation with bacterial infection was done according to Christ-Crain
(Lancet 2004).
Results: Of 711 patients included, 538 (75%) produced sputum: 254
(47.2%) were of good quality. A total of 117/538 (21.7%) of sputa
were culture positive: 80 (14.9%) and 37 (6.9%) were positive for
Haemophilus spp. and for S. pneumoniae respectively. 59/80 (73.8%)
of Haemophilus spp and 25/37 (67.6%) all S. pneumoniae positives
were from good quality sputa respectively. A predominant morphotype
in Gram stain was observed in 53/80 of Haemophilus spp and in 33/37
of S. pneumoniae positive sputa resulting in sensitivities of 66.3% and
89.2% respectively.
In 69/80 (86.3%) and in 35/37 (94.6%) of Haemophilus spp. and
S. pneumoniae positive sputa respectively, PCT values were <0.1mg/L
and 0.1–0.25mg/L indicating respectively absence of bacterial infection
or bacterial infection unlikely.
Conclusion: In GRACE, a good quality sputum was obtained from
a considerable number of patients presenting with LRTI and culture
of these specimens had a good diagnostic yield. Gram stain is more
sensitive for the detection of pneumococcal CA-LRTI compared to the
detection of Haemophilus spp. PCT was found insensitive to predict
bacterial infections and guide antibiotic use.
O564 Correlation of the bacterial aetiology with initial
procalcitonin levels and duration of antibiotic therapy in
lower respiratory tract infections
E. Ku¨nzli, K. Woitzek °, F. Dusemund, P. Schuetz, B. Mu¨ller, W. Albrich
for the ProHOSP Study Group
Objectives: Procalcitonin (PCT) has been established as a reliable and
efﬁcient marker for the differentiation between viral and bacterial lower
respiratory tract infections (LRTI) and to guide antibiotic therapy. There
is conﬂicting data about a correlation of higher PCT levels with Gram-
negative bacteraemia. In the current analysis we correlate the bacterial
aetiology with initial PCT-levels and the duration of antibiotic therapy
in LRTI.
Methods: Initial PCT levels of patients hospitalized with LRTIs as part
of the Swiss multicenter randomized controlled ProHOSP Study were
correlated with the identiﬁed bacterial aetiology and total antibiotic
duration in survivors. PCT was measured using the highly sensitive
Community-acquired pneumonia S129
Kryptor® (BRAHMS) assay. Bacteria were identiﬁed using standard
microbiological cultures from blood and sputum and urinary antigen
tests for pneumococcal and legionella (Binax®). Statistical analysis
was performed using Mann–Whitney U-Test and Spearman correlation
coefﬁcient.
Results: The current analysis includes 388 patients with LRTIs (age
70.5 + 16.7 years) from 2 of the 6 ProHOSP hospitals. Streptococcus
pneumoniae (45; 23 of those bacteraemic) was the most common known
aetiology, followed by legionella (8), and Enterobacteriaceae (5). Other
Gram-positive organisms were identiﬁed in 12, other Gram-negative
organisms in 6 and in 306 patients no causative organisms could be
detected. LRTI caused by legionella and Enterobacteriaceae showed
similar initial PCT values (median 1.46, p = 0.31; and 4.09, p = 0.80,
respectively) as pneumococcal infections. PCT values were higher for
pneumococcal LRTI (median 9.10mg/L) than for other Gram-negative
organisms (PCT median 0.30, p = 0.04), other Gram-positive organisms
(PCT median 0.40, p = 0.01) and if no organisms were identiﬁed (PCT
median 0.25, p< 0.001). Total antibiotic treatment duration was guided
according to PCT kinetics based on predeﬁned cut-off ranges.
Conclusion: Initial PCT values differed according to the aetiology
of LRTIs with more virulent organisms including pneumococci being
associated with higher levels. Considerable overlap in mean PCT values
precluded prediction of the aetiology based on PCT values alone.
However, combining knowledge of initial PCT values and causative
organisms might predict the required antibiotic duration. At the meeting,
we will present the data of the entire 1359 patients of all 6 ProHOSP
hospitals.
O565 Clinical features and outcomes of community-acquired
pneumonia due to Haemophilus inﬂuenzae
D. Viasus, C. Garcia-Vidal °, J. Adamuz, R. Verdaguer, F. Gudiol,
J. Carratala` (Barcelona, ES)
Objective: We sought to determine the clinical features, outcome,
and risk factors of community-acquired pneumonia (CAP) caused by
Haemophilus inﬂuenzae.
Methods: Observational analysis of a prospective cohort of nonseverely
immunosuppressed adults with CAP requiring hospitalization from 1995
through 2008.
Results: Of 3421 consecutive CAP episodes, 192 (5.6%) were caused
by H. inﬂuenzae. The diagnosis was established with the use of one or
more of the following methods: sputum Gram stain and culture (178),
blood culture (23), transthoracic needle aspiration specimen culture (5)
and pleural ﬂuid culture (1). b-lactamase production was detected in 25
(13%) of H. inﬂuenzae isolates. Patients with CAP due to H. inﬂuenzae
were older (69.7 vs 65.9 years; p = 0.016), more often male (75% vs 68%;
p = 0.033), had more commonly chronic obstructive pulmonary disease
(COPD) (52% vs 26%; p 0.001), smoking history (67% vs 56%;
p = 0.001) and were more frequently classiﬁed into high-risk pneumonia
severity index (PSI) classes (group IV-V) (69% vs 57%; p = 0.001)
than the remaining patients. They also had received more frequently
prior corticosteroid therapy (10% vs 6%; p =.039) and pneumococcal
vaccine (<5 years) (24% vs 15%; p = 0.001). Previous hospitalization
(<1 year) for pneumonia was more common among patients with
CAP due to H. inﬂuenzae (13% vs 7%; p = 0.002). Conversely, they
were less likely to had pleural effusion (12% vs 18%; p = 0.049) and
empyema (1% vs 4.3%; p = 0.028). No signiﬁcant differences were found
regarding time to clinical stability, length of hospital stay, and ICU
admission. Early (0.5% vs 2.3%; p=.1) and 30-day mortality rates (4.7%
vs 7.8%; p=.11) did not differ signiﬁcantly between groups. Multivariate
analysis identiﬁed COPD (OR= 2.5, 95%CI 1.8–3.5) and high-risk PSI
classes (OR= 1.4, 95%CI 1.02–2.17) as independent risk factors for
H. inﬂuenzae pneumonia.
Conclusions: CAP caused by H. inﬂuenzae occurs mainly in patients
with COPD classiﬁed into high-risk PSI classes and is associated with
signiﬁcant morbidity and mortality.
O566 Clinical prediction score for community-acquired Legionella
pneumonia
Ø. Simonsen °, J. Ringstad (Fredrikstad, NO)
Objectives: Legionnaires’ disease (LD) is an underdiagnosed
community-acquired pneumonia (CAP) with high mortality. Although
urinary antigen testing has facilitated the microbiological diagnosis
during the acute-phase, only 52 of 99 microbiologically veriﬁed LD-
cases from a large outbreak in our region in 2005 tested positive.
Previous attempts to design a clinical score have yielded conﬂicting
results. The aim of our study was to assess clinical and biochemical
predictors of Legionella pneumonia using outbreak patients.
Methods: All patients with CAP referred to the regional hospital during
a period of ﬁve weeks in May/June 2005 were included in the study. A
clinical protocol was initiated during an early phase of the outbreak.
Clinical and laboratory data on entry from patients with Legionella
pneumonia and non-Legionella pneumonia were compared.
Results: Complete data sets were present for 91 and 90 patients
in the LD-group and non-LD group, respectively. In multivariate
logistic regression Legionella pneumonia was associated independently
with high levels of C-reactive protein (OR 1.009, 95%CI 1.005–
1.013), presence of muscle pain (OR 2.8, 95%CI 1.4–5.9), low serum
sodium concentration (OR 0.91, 95%CI 0.84–0.98), and high body
temperature (OR 1.45, 95%CI 1.00–2.11). The continuous variables
were dichotomized according to the optimal cut-off value. A simple
predictive score was derived by assigning one point for each variable
(CRP> 175mg/L, presence of muscle pain, serum sodium <134mmol/L,
temperature >38.5 centigrades) resulting in a maximum of 4 points. The
area under the receiver operator characteristic of the combined score was
0.85 (95%CI 0.79–0.90), which was better than each parameter alone.
The median predictive score was higher in the Legionella group (2 (IQR
2–3) vs. 1 (IQR 1–2), p< 0.001). The sensitivity and speciﬁcity of a
score of 3 points was 65% and 92%, respectively, with corresponding
values of 86% and 66% for a score of 2 points. In the subgroup of LD
patients with negative Legionella urinary antigen test (n = 45), a score
of 3 points and 2 points yielded nearly unaltered sensitivity of 67%
and 82%, respectively.
Conclusion: A simple score including four routine clinical and
biochemical parameters can be used to predict Legionella as aetiological
agent of pneumonia, including patients with a negative urinary antigen
test. This score will be validated in an upcoming prospective CAP-study.
O567 Inﬂuence of antibiotic ﬁrst-dose timing on clinical outcomes
in patients with community-acquired pneumonia
S. Luque °, S. Grau, M. Marin-Casino, N. Berenguer, O. Ferra´ndez,
M. Espona, M.L. Sorli, J.P. Horcajada, E. Salas (Barcelona, ES)
Objectives: Databased studies have demonstrated the beneﬁts of an
early antibiotic treatment in community-acquired pneumonia (CAP) but
results from recent experiences have been less consistent. The objective
was to study differences in clinical outcomes between those patients
who received antibiotics within 4 h (early antibiotic treatment (ET))
of hospital admission and those who received them after 4 h (delayed
antibiotic treatment (DT)).
Methods: Prospective study including consecutively all patients
diagnosed with CAP and treated with ceftriaxone from July 2006 until-
February 2007. Main outcome measures: demographics, pneumonia
severity index (PSI), length of hospital stay (LOS), length of antibiotic
treatment (LOT), time to clinical stability (TCS) (measured as signs
and symptoms resolution) 30-day-mortality and 6-month-mortality. In
statistical analysis, “U” Mann–Whitney test for dichotomic variables and
Fischer exact test for continuous variables were employed. A value of
p< 0.05 was considered statistically signiﬁcant.
Results: total patients: 118. Data comparing early ET versus DT are
showed in table1.
Conclusions: Only differences in LOS were observed after comparing
ET versus DT. Mean LOS was 2.5 days shorter with antibiotic
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administration within 4 hours than with later administration. Timing was
not associated with LOT, TCS or short- and long-term mortality.





Age (years) 70.6 (95%CI 66.1–75.1) 71.9 (95%CI 68.1–75.8) 0.523
Male (%) 35 (74.5%) 45 (63.4%) 0.207
PSI class I 3 (64%) 4 (5.6%) 0.900
PSI class II 1 (2.1%) 2 (2.8%)
PSI class III 7 (14.9%) 14 (19.7%)
PSI class IV 20 (42.6%) 24 (33.8%)
PSI class V 16 (34.0%) 27 (38.0%)
LOS (days) 12.0 (95%CI: 9.9–14.1) 14.5 (95%CI 12.0–17.0) 0.041
LOT (days) 11.3 (95%CI: 10.0–12.6) 11.6 (95%CI 10.2–13.0) 0.978
TCS (days) 11.5 (95%CI: 8.6–14.5) 11.5 (95%CI 9.8–13.1) 0.286
30-day mortality 5 (10.6%) 7 (9.9%) 0.891
6-month-mortality 7 (14.9%) 11 (15.5%) 0.929
O568 FOCUS 2: randomized, double-blinded, multicentre phase 3
study of the efﬁcacy and safety of ceftaroline vs. ceftriaxone
in community-acquired bacterial pneumonia
P. Eckburg °, H.D. Friedland, J. Lee, L. Llorens, I. Critchley, D. Thye
(Oakland, US)
Objectives: Community-acquired bacterial pneumonia (CABP) is a ma-
jor cause of morbidity and mortality. Streptococcus pneumoniae remains
the most common pathogen and there are growing concerns about
the rising incidence of resistant or highly virulent pathogens, such as
multidrug-resistant S. pneumoniae (MDRSP) and community-acquired
methicillin-resistant Staphylococcus aureus (MRSA). Ceftaroline (CPT),
a novel, parenteral, broad-spectrum cephalosporin with bactericidal
activity against common Gram-positive organisms, including MDRSP
and MRSA, as well as common Gram-negative pathogens, was evaluated
for the treatment of CABP (Clinical Trials ID NCT00509106).
Methods: Hospitalized adult patients from 84 centres in 14 countries
with moderate to severe CABP (PORT Risk Class III or IV) requiring
intravenous therapy received CPT 600mg q12 h or ceftriaxone (CRO)1
g q24 h for 5 to 7 days (randomized 1:1). Clinical and microbiological
responses and adverse events (AEs) were assessed. The primary objective
was to determine non-inferiority (pre-speciﬁed CI margin of −10%)
in clinical cure rate of CPT compared with CRO at the test-of-cure
visit (8 to 15 days post-therapy) in the clinically evaluable (CE)
and modiﬁed intent-to-treat efﬁcacy (MITTE) populations. Secondary
objectives included evaluation of clinical cure in the microbiologically
evaluable (ME) and microbiological modiﬁed intent-to-treat efﬁcacy
(mMITTE) populations.







CE 82.1 (193/235) 77.2 (166/215) 4.9 (−2.5, 12.5)
MITTE 81.3 (235/289) 75.5 (206/273) 5.9 (−1.0, 12.7)
ME 81.2 (69/85) 75.0 (57/76) 6.2 (−6.7, 19.2)
mMITTE 80.0 (72/90) 75.0 (66/88) 5.0 (−7.4, 17.4)
Streptococcus pneumoniae 83.3 (35/42) 70.0 (28/40)
Staphylococcus aureus 66.7 (10/15) 56.3 (9/16)
CE= clinically evaluable; CI = conﬁdence interval; ME=microbiologically evalu-
able; MITTE=modiﬁed intent-to-treat efﬁcacy; mMITTE=microbiological modi-
ﬁed intent-to-treat efﬁcacy.
Results: Of 622 treated patients, 315 received CPT and 307 received
CRO. Baseline characteristics (MITTE) were comparable between
groups (mean age 60.6 vs 62.0 years and male sex 60.6% vs 64.1%
for CPT and CRO respectively). Clinical cure rates are shown in the
Table. Both CPT and CRO were well tolerated; most common AEs for
CPT were diarrhoea (3.8% vs 2.9% for CRO), headache (3.5% vs 1.6%),
and insomnia (3.2% vs 2.6%). AEs led to study drug discontinuation in
5.1% and 4.2% of patients treated with CPT and CRO, respectively.
Conclusions: CPT demonstrated non-inferiority to ceftriaxone in
treating patients hospitalized with moderate to severe CABP in the CE
and MITTE study populations of FOCUS 2. Clinical cure rates in the
2 co-primary populations and in patients with a conﬁrmed bacterial
infection were numerically higher for CPT compared with CRO. CPT
had high clinical cure rates and was well tolerated, with a safety proﬁle
similar to ceftriaxone. CPT has the potential to be an effective, well-
tolerated treatment option for CABP.
O569 Pneumococcal bacteraemia serotypes and immunization
status in a district general hospital in the United Kingdom
J. Seddon °, R. Vancheeswaran, D. Mack (London, UK)
Objective: Invasive pneumococcal disease (IPD) is a major cause
of morbidity and mortality in the United Kingdom. The 23-valent
pneumococcal polysaccharide vaccine (PPV) has been recommended
for all adults 65 years and over and younger adults with chronic
medical conditions or immunosuppression since 2005. The 7-valent
pneumococcal conjugate vaccine (PCV7) was introduced into the routine
childhood immunization program in September 2006. We aimed to look
at pneumococcal bacteraemia serotypes and PCV immunization history
in our district general hospital population.
Methods: Patients who had pneumococcal bacteraemia between October
2008 and April 2009 were identiﬁed retrospectively. Isolates were sent
to the United Kingdom Health Protection Agency reference laboratory
for serotyping. Clinical details were acquired via case note review.
Immunization status was obtained from general practitioners.
Results: We identiﬁed 29 adults with pneumococcal bacteraemia and
obtained clinical details for 28. There were 18 patients for whom PPV is
currently recommended. Of these seven (47%) had been immunized, of
whom two (29%) died; eight had no history of immunization, of whom
two (25%) died. For three cases immunization history was not obtained.
The total mortality for this group of 18 was 28%. Pneumococcal serotype
results were available for 23 patients. Of these, six patients had received
PPV, of whom four (66%) acquired infections with serotypes covered by
PPV. Of the ten patients who had not received PPV, nine had serotypes
covered by PPV. In total, 5 isolates (22%) were not covered by PPV or
PCV7, and 14 isolates (61%) were covered by PPV but not PCV7. The
total number of isolates covered by PPV was 18 (78%) (Table 1).
Conclusion: In this small study, we observed a high rate of mortality
in patients for whom PPV is recommended which was similar in
those who had (29%) and had not (25%) received PPV. Uptake of
vaccine where recommended was sub-optimal (39%). We observed four
cases of apparent failure of the PPV vaccine to protect against IPD
with pneumococcal serotypes covered by PPV. This is in keeping with
observations that PPV is incompletely protective against IPD. Of the
23 isolates serotyped, 14 (61%) were covered by PPV but not PCV7.
As serotypes may spread from the paediatric to the adult population,
these may represent serotype-replacement following the introduction of
PCV7. Promotion of vaccine uptake and ongoing serotype monitoring is
warranted.
Table 1: Immunization status and pneumococcal serotypes
Immunized Number Serotypes covered by immunizations
Not covered PPV and PCV7 PPV only PPV total (%)
Yes 6 2 1 3 4 (66)
No 10 1 1 8 9 (90)
Unknown 7 2 2 3 5 (71)
Total (%) 23 5 (22) 4 (17) 14 (61) 18 (78)
O570 Pneumococcal community-acquired pneumonia, serotype
distribution and potential vaccine coverage in the Netherlands
S. Huijts °, A. van der Ende, M. Bonten (Utrecht, Amsterdam, NL)
Objectives: We evaluated distribution of serotypes among adults
with pneumococcal Community Acquired Pneumonia (CAP) in the
Netherlands in order to determine potential vaccine coverage.
Community-acquired pneumonia S131
Methods: In a prospective, observational study in 22 Dutch hospitals,
patients (18years) admitted to the ER with a clinically suspected CAP
were included between January 2008 and March 2009. Recent hospi-
talization (<2 wks), stay in long-term care facilities, known bronchial
obstruction or a history of post-obstructive pneumonia, primary or
metastatic lung cancer, AIDS/ PCP/ TBC and unconsciousness were
exclusion criteria. History taking, physical examination, biochemical and
hematological blood testing, blood- and sputum cultures and BINAX
pneumococcal urinary antigen testing were performed in all patients.
All pneumococcal bacteremia isolates were serotyped (at the Netherlands
Reference Laboratory Amsterdam). Pneumococcal CAP was deﬁned on
the presence of clinical criteria for CAP, radiographic conﬁrmation by
a radiologist and isolation of S. pneumoniae from blood or sputum (if
dominant ﬂora) or positive antigen testing in urine.
Results: Of 1631 included patients, 1115 had radiographically conﬁrmed
CAP and 210 (18.8%) had pneumococcal CAP, diagnosed on isolation
of S. pneumoniae from blood culture (n = 82, 7.3% of all bloodcultures),
sputum culture (n = 24), or positive urinary antigen test (n = 151). 75
bacteremia isolates were serotyped. Serotypes 14 (n = 9), 1, 7F, 19A and
22F (n = 8) were most common. Potential vaccine coverage was 28%
for the 7-valent, 67% for the 13-valent pneumococcal conjugate vaccine
(PCV) and 93% for 23-valent polysaccharide vaccine (PS).
Conclusion: Based on bacteremia isolates vaccine coverage would be
67% with 13-valent pneumococcal conjugate vaccine that is currently
investigated in a double-blind placebo-controlled trial in the Netherlands.
Figure 1. Serotype distribution and potential vaccine coverage.
O571 Serotype-speciﬁc mortality risk among patients with invasive
pneumococcal disease: Swedish population-based study
P. Naucler °, J. Darenberg, A˚. O¨rtqvist, B. Henriques Normark
(Stockholm, SE)
Objectives: To investigate pneumococcal serotype-speciﬁc mortality risk
correlated to the serotype invasive disease potential among patients with
invasive pneumococcal disease (IPD).
Methods: In Sweden it is mandatory to report IPD and isolates are
collected for serotyping and molecular typing. Of 4195 episodes of IPD
among adults reported between Jan 2007 to Oct 2009 a total of 3692
isolates were serotyped (88%). A questionnaire study was performed to
obtain clinical and socio-demographic information about patients with
serotyped IPD [obtained for 1657/3692 patients (45%)]. In a preliminary
analysis of the 1657 patients we assessed the absolute serotype-speciﬁc
30-day mortality risks and relative risks using regression modeling on
group level according to previously deﬁned invasive disease potential
[high (serotypes 1 and 7), medium (serotypes 4, 9, 14 and 18) and low
(serotypes 3, 6A, 6B, 8, 15, 19, 33 and 38) and for individual serotypes.
Risk estimates were adjusted for potential confounders.
Results: Pneumococcal serotype prevalence ranged from 0.05% for
serotype 5 to 13.4% for serotype 14 and was stable over the
observed period. Absolute mortality risk was highest for serotypes
with low invasive disease potential (12.8%) followed by serotypes with
medium- (8.6%) and high (4.9%) invasive disease potential. Serotypes
with low invasive disease potential were associated with increased
mortality risk in unadjusted but not adjusted analyses [relative risks
2.62 (95%CI 1.38–5.00) and 1.61 (95%CI 0.84–3.09) respectively] and
a test for trend according to invasive disease potential was signiﬁcant
in unadjusted (p-value: 0.001) but not adjusted (p-value: 0.10) analyses.
Patients infected with serotypes of lower invasive disease potential were
older, more likely to be diagnosed with meningitis, suffer from chronic
disease and immunosuppression (all p-values <0.003). Serotype 3, 6B,
11A, 14, 18C, 19F and 23F were associated with increased mortality
risk in crude analyses but only serotype 6B and 11A were associated
with increased mortality risk in adjusted analyses.
Conclusion: In this large population-based study host risk factors
appeared to be the strongest determinants of both risk of infection with
serotypes according to invasive disease potential as well as mortality
outcome.
O572 Role of atypical pathogens in hospitalized adults with
community-acquired pneumonia
S. Ratchina, E. Shal, R. Kozlov °, O. Kretchikova, N. Ivanchik,
I. Ustjuzhanin, S. Yatsyshina, T. Astakhova, T. Kondratieva, Ya. Beykin,
L. Besedina (Smolensk, Moscow, Ekaterinburg, RU)
Background: CAP can be caused by a broad spectrum of bacterial
pathogens. Appropriate antimicrobial therapy is based on knowledge of
common causative agents. Incidence of atypical causative agents of CAP
may interfere in treatment choice.
Objectives: To investigate the frequency of atypical pathogens in
hospitalized adults with CAP in Smolensk region.
Methods: A prospective study on adult patients with CAP in various
Smolensk city hospitals was performed in 2007. Pretreatment respiratory
specimens were obtained for routine culture and DNA based polymerase
chain reaction (PCR) for the detection of Legionella pneumophila (L.p.),
Mycoplasma pneumoniae (M.p.) and Chlamydophila pneumoniae (C.p.).
Acute phase and reconvalescent serum samples were collected for the
detection of speciﬁc IgM and IgG antibodies of L.p., M.p., C.p. by
ELISA in accordance with manufacturer’s manual [1]. Multiple logistic
regression analysis was used to identify independent risk factors (age,
CAP severity, presence of complications, signiﬁcant comorbidities, etc.)
of infection with atypical pathogens.
Results: Overall, 295 patients aged from 18 to 87 years, mean age
43.0±19.9 years, 80.7% males, were enrolled. PCR was positive in
57/295 (19.3%) of cases: M.p. − 47/295 (14.9%), C.p. − 5/295 (1.7%),
L.p. − 5/295 (1.7%) and M.p. with C.p. − 3/295 (1%). Causative agents
were revealed by routine culture in 78/295 (26.4%) of cases. Both PCR
and serological tests were performed in 112/295 (38%) of patients.
The results coincided in 44/112 (39.3%) of cases; 24/26 (92.3%) of
PCR positive cases were conﬁrmed by serologic tests, serology yielded
positive results for 18/109 (16.6%), 29/110 (26.4%) and 50/91 (54.9%)
PCR negative L.p., C.p. and M.p. samples. Absence of complications
and serious comorbidities were only independent variables predicting
the high risk of M.p. and M.p. +C.p. infection.
Conclusions: Atypical bacteria (especially M.p.) are rather common
causative agents of CAP in hospitalized adults in Smolensk region. The
risk of M.p. and/or C.p. infection is increased in uncomplicated CAP
cases and patients without serious concomitant diseases. ELISA doesn’t
seem to be a reliable test for identiﬁcation of atypical bacterial pathogens.
Reference(s)
[1] Sero MPTM IgM, Sero MPTM IgG, Sero CPTM IgM and Sero CPTM
IgG, Savyon Diagnostics; Legionella pneumophila Serogroup 1
ELISA IgM and IgG, Vircell, s.1.
